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Abstract 
Antiretroviral therapy (ART) has transformed HIV infection from a death sentence into a 
chronic condition. In sub-Saharan Africa, the area most affected by this disease, availability of 
ART has increased dramatically over the last few years. Nevertheless, many people are still not 
receiving ART either because they are not aware of being HIV-positive or because they struggle 
to access ART or to engage in HIV care. It is fundamental to take decisions which maximise the 
health benefits with the limited resources available. 
When I was writing this thesis, there were countless discussions regarding whether the 
recommendation on when to start ART had to be modified to a CD4 count threshold higher 
than 350 cells/μL, given the compelling evidence that ART reduces substantially the risk of 
transmission in heterosexual serodifferent couples. In this thesis I evaluated the effectiveness 
and cost-effectiveness of alternative ways of increasing the number of adults receiving ART in 
South Africa: increasing the CD4 count threshold at which a person is eligible to be initiated on 
ART, or maintaining the eligibility criteria to CD4 count below 350 cells/μL but expanding the 
number of people who are diagnosed and engaged in care. In particular, I focused on the 
impact these two alternatives would have on the development and transmission of resistance. 
To inform the model on the extent to which NNRTI resistance mutations are present in people 
who have interrupted NNRTI, I conducted an analysis using data from the UK resistance 
database. In addition, since I found that the most cost-effective strategy was to expand the 
number of people engaged in HIV care without modifying the CD4 threshold at which a person 
is eligible to receive ART, I evaluated at which steps in the current leaky cascade of HIV care it 
was most cost-effective to intervene. 
Finally, as new evidence regarding the accuracy and acceptability of HIV self-testing came up, I 
decided to evaluate the cost-effectiveness of introducing HIV self-testing in a setting such as 
Zimbabwe.  
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1. Introduction 
1.1. Aim of the thesis 
The aim of this thesis is to evaluate the impact on human immunodeficiency virus (HIV) 
incidence and on patterns of resistance of different public health actions involving HIV testing 
and antiretroviral therapy (ART) in the South Africa and Zimbabwe adult epidemic, using a 
development of the Synthesis model, which is an individual based-stochastic model of the 
transmission and progression of HIV.  
The interventions that will be assessed are: 
 expansion of access to HIV treatment and care 
 modification of the eligibility criteria for ART initiation 
 improvement in different steps of the cascade of care  
 introduction of HIV self-testing (ST) 
Other mathematical models have addressed some of these questions, but most have not 
taking into account the role played by adherence to ART and the acquisition and transmission 
of drug resistant mutations. Particular focus will be given in this thesis to the impact on 
development of viral resistance through use of interventions, because there is growing 
concern that expansion of ART could lead to the spread of drug resistant virus. 
In addition, I aim to estimate the persistence of non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) resistance mutations after interrupting or stopping ART which contained an NNRTI. 
This parameter is particular important in settings with a high number of people lost to follow-
up (LTFU), such as South Africa (1;2). To address this question, data from the UK CHIC and UK 
resistance database will be used. Although these data are from the UK and not from Southern 
Africa there is no reason to believe that this parameter should be different and there is paucity 
of resistance data from South Africa. 
 
 
1.2. Overview of the thesis 
Chapter 1 provides a background on HIV natural history and virology and the effects of ART. 
The reason to review and describe all these aspects of HIV is that there is lots of understanding 
of the processes regarding the transmission and progression of HIV and the impact of ART on 
the progression and where possible they are included in the Synthesis model.  
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In Chapter 2 the HIV epidemics in South Africa and Zimbabwe are described. 
 
Chapter 3 presents the Synthesis transmission model in detail and the method used to 
calibrate it to the HIV epidemic in South Africa and Zimbabwe. 
 
In Chapter 4 I discuss the evidence and current recommendations for initiating ART and 
present the findings from the assessment of the impact on HIV incidence of expanding access 
to care and eligibility criteria for ART initiation in South Africa. In addition, the impact on HIV 
incidence and cost-effectiveness data are compared to results from other mathematical 
models which addressed the same question. 
 
Chapter 5 focuses on evaluating the impact on the levels of drug-resistance of expanding 
diagnosis, retention in care and modifying the eligibility criteria for ART initiation in South 
Africa. 
 
In Chapter 6 I estimate the persistence of NNRTI resistance mutations after interrupting or 
stopping ART which contained an NNRTI, using data from the UK CHIC and UK resistance 
database.  
 
In Chapter 7 I evaluate the cost-effectiveness of improvements in different steps in the 
cascade of care in South Africa. This chapter focuses on understanding which steps in the 
cascade of care among HIV testing, linkage to care, retention in pre-ART care, retention on ART 
and switch to second-line, have most influence on HIV incidence, deaths and costs, and hence 
which is more cost-effective to improve. 
 
Chapter 8 contains analysis of the effectiveness and cost-effectiveness of introducing ST in 
another sub-Saharan African setting, Zimbabwe.  
 
Chapter 9 summarizes the findings and conclusions from each of the chapters and discusses 
the overall limitations and implications of these results.  
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1.3. Description and mechanism of HIV virus 
HIV is a lenti-virus (in Latin “lenti” means slow) because of the long interval between initial 
infection and the onset of serious symptoms. It belongs to a larger group of viruses known as 
retroviruses (3-5), which are composed of ribonucleic acid (RNA) instead of deoxyribonucleic 
acid (DNA) (6). These viruses have an enzyme, called reverse transcriptase (RT), which confers 
to them the unique property of transcribing viral RNA into DNA after entering a cell. The 
retroviral DNA can then integrate into the chromosomal DNA of the host cell, where it cannot 
be eradicated without killing the host cell (6).   
 
There are two different strains of HIV: HIV-1 and HIV-2 (7). They are not closely related to each 
other and within these two types there are a variety of subgroups, some of which have 
considerable genetic diversity (3). HIV-1, characterized by higher rates of infectiousness (8) and 
faster progression, is the predominant form of the virus worldwide while HIV-2 is confined to 
areas in West-central Africa and India (7;9;10), for this reason I will focus only on HIV-1 and I 
will use the term HIV to refer to HIV-1. HIV-1 can be classified into four groups: the "major" 
group M, the "outlier" group O and two new groups, N and P (9;11;12). Group M is the most 
common and widely spread accounting for more than 90% of cases globally (9). Within group 
M there are at least eleven genetically distinct subtypes of HIV-1 circulating in the world: A1, 
A2, B, C, D, F1, F2, G, H, J and K (13).   The main HIV-1 subtypes circulating among heterosexual 
population in southern Africa and India is subtype C accounting for over 48% of worldwide 
infections, while in the Americas, Australia, Japan and Western Europe the predominant 
subtype is B (7;14;15) (see Figure 1.1).   
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Figure 1.1. Global distribution of HIV-1 subtypes and recombinants [12]. 
 
 
 
In order for the virus to enter the cell, the presence on the cell surface of CD4 receptors and 
certain co-receptors is required (16). CD4 receptors are molecules expressed predominantly on 
the surface of helper T cell lymphocytes and macrophages, which are particular types of white 
blood cells. The main HIV co-receptors, CCR5 and CXCR4 (17), are differentially expressed in 
subpopulations of CD4-expressing cells and are highly expressed in T lymphocytes, 
thymocytes, macrophages and dendritic cells. For these reasons the main target cells of the 
HIV virus are CD4+ T cell and macrophages (7;17;18). Some HIV-1 strains have a preference for 
T-cells (T cell tropic strain): they use the CXCR4 co-receptor and fail to replicate in 
macrophages. While others replicate in macrophages and primary T cells (Macrophage (M)-
tropic strain), using the CCR5 co-receptor (7). Although CXCR4-using viruses are generally more 
pathogenic than CCR5-using viruses, most viruses transmitted from one person to another use 
CCR5, even when infected persons have both viral types circulating in the blood. 
 
The replication of HIV-1 is a multistage process (18) (see Figure 1.2 at page 32 (19)).  The first 
step in the process of viral replication is “attachment”. When an HIV virion approaches a target 
cell, the surface glycoprotein gp120 binds to the CD4 receptor of the host cell (18).  The 
binding between the CD4 receptor and gp120 promotes further binding between the virion 
and co-receptor, which leads to a conformational change in gp120. At this point, 
Figure not available due to copyright restrictions 
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transmembrane molecules gp41 facilitate the fusion between the viral envelope and the 
membrane of the target cell. This second step is usually referred to as “fusion”. The viral core 
enters the host cell and breaks open (“uncoating”) releasing in the cytoplasm two copies of 
single-stranded RNA and three essential replication enzymes:  integrase, protease and reverse 
transcriptase. Once the enzyme RT enters the cell it begins transcribing single strands of viral 
RNA into double-stranded DNA using endogenous cellular nucleotides (“reverse 
transcription”). The resulting DNA is transferred into the cell nucleus, where the enzyme 
integrase facilitates its “integration” into the host cell genome (7). The host cell genome now 
contains the genetic information of HIV. Once viral DNA has integrated into the cell it can 
remain dormant and may go undetected by the immune system for many years (20;21). Major 
reservoirs of infection are formed in compartments outside of the blood: lymphoreticular 
tissues (gut associated lymphoid tissues), central nervous system (CNS) and genital tract. These 
immune cells are latently infected, so they do not produce virus but if these cells are 
activated, they can start producing virus. This has complicated attempts to eradicate HIV (22). 
This activation of the cell induces “transcription” of the proviral DNA (division of the two 
strands of DNA) into a new strand of viral RNA called messenger RNA. The messenger RNA 
migrates into the cytoplasm (“nuclear export”) where building blocks for a new virus are 
synthetized by translation of the information contained in the messenger RNA. Some of the 
protein building blocks need to be processed into functional form by the enzyme protease. 
These core proteins assemble with the two viral RNA strands to form the capsid (“assembly”). 
These immature virus particles bud from the surface of infected cells acquiring a new envelope 
of host cell membrane proteins (“budding”) and float off into the bloodstream. 
To become infectious these viral particles need to undergo “maturation”, a process involving 
systematic cleavage of Gag polyproteins by the activity of the protease. After maturation, the 
virus is ready to infect other cells.  It is estimated that a single cell can produce thousands of 
infectious HIV particles every day (5). 
 
CD4+ T cells are of particular importance because they are involved in activating and 
coordinating other white blood cells (macrophages and dendritic cells) when some pathogens 
are present. By doing this, HIV damages the whole immune system: decreases the number of 
macrophages and of natural killer cell and leads to malfunctioning of CD8 cells, which are 
designed to find infected cells and destroy them, and also of B cells, whose function is to 
identify which cells are infected and which ones are not and to produce antibodies.  
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Figure 1.2. HIV-1 viral life cycle (23) 
 
  
Figure not available due to copyright restrictions 
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1.4. HIV transmission 
HIV can be transmitted through blood, semen, cervico-vaginal and anal secretions and breast 
milk (24;25). The rate of transmission differs significantly by route of exposure. 
The routes through which infection can take place are: via sexual intercourse (either vaginal, 
anal or potentially oral (26)), via blood, through the sharing of contaminated needles or 
syringes (27) or transfusions of contaminated blood (28) and from a mother to her baby during 
pregnancy, childbirth or through breastfeeding (24). The risk of an individual becoming 
infected with HIV is largely dependent on the levels of the virus present in the infected 
individual (29-31). Figure 1.3 illustrates the variation in the risk of transmission across the 
different types of exposure, which are described in more detail in the following sections. 
 
Figure 1.3. Per contact probability of HIV transmission (32) 
 
 
 
 
 
 
 
1.4.1. Sexual transmission  
Worldwide, the most common route of HIV transmission is by sexual intercourse (29). The risk 
of HIV infection through this route is dependent on many factors (26;33;34) such as the sexual 
partner’s gender, the type of sex act, HIV-RNA viral load (VL) levels, the stage of infection, 
genetic susceptibility such as having a delta-32 mutation in the CCR5 gene so that this receptor 
is either not expressed (if homozygous) or expressed at lower density (if heterozygous), the 
presence of ulcerative sexually transmitted infections (STIs) (i.e. Herpes simplex virus-2, HSV-
Figure not available due to copyright restrictions 
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2), sexual practices which breach mucosal integrity and of course use of preventive methods 
such as condoms and circumcision, which will be discussed in section 1.10.   
 
1.4.1.1. Role of HIV-RNA levels on risk of transmission  
The strongest factor associated with the risk of sexual transmission of HIV is the VL of the 
infected partner, which reflects the volume of virus circulating in the body. The first large 
epidemiological study to estimate the risk of transmission by VL levels in the source partner 
was the Rakai study, published in 2000 by Quinn et al. (31).  They found that the mean serum 
VL level was significantly higher among HIV-positive subjects whose partners became infected 
with HIV than among those whose partners remained HIV uninfected. There was a significant 
dose response effect between risk of transmission and the serum VL of the index case: the rate 
of transmissions ranged from 0 in the 51 couples where the index partner had VL of 1500 
copies/mL or below up to 23/100 person-years (PYs) among couples where the HIV-positive 
partner had VL of 50,000 copies/mL or more. Subsequently other studies have confirmed this 
finding (35;36). Fraser and colleagues re-analysed the data from the Zambian cohort (35) and 
estimated the rate of transmission per 100 PYs within a stable long-term serodifferent 
relationship by set-point VL (see section 1.5.1) (37). These estimates are respectively 2/100 PYs 
for VL of 1,000 copies/mL, 13.2 for a VL of 10,000 copies/mL, 27.9 for a VL of 100,000 
copies/mL up to 31.3 for a VL of 1,000,000 copies/mL. It has been established that this effect is 
independent of other recognized predictors of HIV transmission, such as history of any 
unprotected sex, sex, HSV-2 seropositivity and circumcision of the HIV uninfected partner (38).  
 
1.4.1.2. Role of stage of infection on risk of transmission 
Another factor that has a major effect on the risk of transmission is stage of infection 
(described in section 1.5). Since the early days of HIV research, models and longitudinal studies 
suggested that the rate of heterosexual HIV transmission per coital act was higher during the 
first months since infection (referred to as primary HIV infection [PHI]), lower during the 
asymptomatic period and higher again in the last years before death. This is likely to be mainly 
due to the high VL observed in the earliest and latest period of HIV infection (39-41). Using the 
data from the Rakai study, Wawer et al. estimated the rate of HIV transmission per coital-act 
by stage of infection (42). During the first 5 months since seroconversion (SC, see section 1.5.1) 
is 0.0082/coital act, corresponding to 1 transmission in 122 sexual acts, 8-10 times higher than 
during the asymptomatic infection (between 6-15 months it is 0.0015, corresponding to 1 
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transmission in 667 acts) and then it increases again during the two years before death of the 
HIV-infected partner: 0.0028/coital act, corresponding to 1 in 357. The data on the primary 
and asymptomatic phase were based on a small number of serodifferent couples (n=23), and 
individuals were tested only every 10 months, therefore the date of SC and death were 
approximated as halfway through the interval. In 2008 Hollingsworth et al. (43) re-analysed 
these data, attempting to discount coital acts that happened after transmission occurred and 
assessing the rate of transmission as a function of time since the partnership was first 
observed, rather than per coital act. They estimated that the transmission rate per 100 PYs 
was: 276 in the first 3 months since infection, 10.6 during the asymptomatic phase and during 
the last years before death respectively, 76 (95% CI: 41.3, 128) between 19 and 10 months 
before deaths and 0 during the last 10 months before death, due to the limited sexual contact 
because of unhealthy condition of the infected partner. Mathematical models have estimated 
that PHI could contribute between 9 and 39% of HIV infections (33;43), while the late stage 
between 20 to 27% of HIV infections (43). Evidence of the crucial role of the acute infection 
also comes from phylogenetic studies, which estimated comparable contributions (44).  
It seems that VL may not explain all of the increased risk of transmission seen during the first 
months since SC (37;43;45). Additional factors include presence of other STIs, which will be 
discussed in more detail in section 1.4.1.3, potentially higher susceptibility in newly exposed 
HIV-negative partners and more infectious virus present during PHI (46). The high variability in 
susceptibility across individuals means that the most susceptible individuals are likely to get 
infected during the first exposure period, while other less susceptible partners are unlikely to 
get infected at all. The latter factor relates to the fact that there is some evidence that 
patterns of amino acids in the viral envelope could be favoured at transmission and be present 
during PHI but waning over time (46). In addition to the highest rate of HIV transmission per 
sex act, during PHI people are less likely to know their HIV status and are therefore less likely 
to use condoms (47;48). The important role that acute infection plays is generally agreed, 
although the relative contribution of PHI varies considerably according to the stage of the 
epidemic and the structure of sexual contact networks. 
The advanced stage of the disease is also characterized by a high rate of transmission per 
sexual contact due to the rising VL, but the contribution of this phase is believed to be smaller. 
This is likely because individuals in the late stage of HIV infection report less sexual intercourse 
and have fewer partners, and only a minority of HIV-infected partners remain serodifferent by 
this stage. It is not clear that the advanced stage is a risk factor for transmission independently 
of VL.  
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1.4.1.3. Role of STIs on risk of transmission 
An increased risk of HIV transmission can also be seen with increased levels of VL in genital 
secretions (49).  Concentration of HIV in semen and in the genital and rectal compartments is 
likely to be the most important determinant of sexual HIV transmission; nevertheless most of 
the studies considered levels of VL in plasma. Inter-current symptomatic and asymptomatic 
STIs can lead to a transient increase in VL in the genital compartment, especially those causing 
genital ulcer disease (GUD) (50) and this increases the risk of HIV transmission (51). HSV-2 
represents the most frequent cause of genital ulceration worldwide, with an estimated 
prevalence between 60% and 90% among people living with HIV (52). In people co-infected 
with HIV and HSV-2, reactivation of HSV-2 has been associated with raised levels of VL in blood 
and genital tracts (53-55). In particular in a meta-analysis of observation studies the risk of HIV 
transmission was estimated to be 5.3 times higher in people with history of GUD, compared to 
couples where both members never had STIs (56). A previous meta-analysis had estimated this 
factor would increase susceptibility by 2.8 times for females and by 4.4 in men (57), while a 
study on high risk group had estimated a much bigger effect: an increase in the risk of 
transmission per act of 10-50 times for male-to-female (M-to-F) and between 50 and 300 
times for female-to-male (F-to-M) (58). For these reasons it is thought to contribute 
significantly to the on-going HIV epidemic (53;59). 
 
1.4.1.4. Role of sex route and gender on risk of transmission 
Risk of transmission following exposure differs also by sex route and sex. A meta-analysis of 
observational studies estimated the heterosexual risk of HIV infection per sexual act in high 
and low income countries (56). In high income countries it was 0.0004 (1 in 2500) for F-to-M 
and 0.0008 (1 in 1250) for M-to-F, while in low income countries, in the absence of commercial 
sex exposure it was 0.0038 for F-to-M and 0.0030 for M-to-F (56). In multivariate analysis in 
high income countries, the M-to-F risk of transmission was 80% higher than F-to-M (although 
not statistically significant), while the relative risk (RR) for the same comparison in low income 
countries was close to 1, indicating no difference. In addition, the risk of transmission for F-to-
M in low income countries was significantly higher (3.3 times) that in high income countries. It 
is worth mentioning that estimates from low income countries were much more 
heterogeneous than from high income countries, likely indicative of poorer quality studies, 
higher heterogeneity of risk factors or underreporting of number of condom-less sex acts, 
which is more common among women than men (60). In Fideli et al. where it was assessed 
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whether the transmissions were epidemiologically linked (35) the association between VL and 
risk of transmission was much stronger for F-to-M than for M-to-F. In addition, when 
restricting to transmissions which occurred in couples who did not report receptive anal 
intercourse, GUD and commercial sex or to the asymptomatic phase the risk of M-to-F and 
combined transmission (0.0007 per act) was similar to the risk of M-to-F transmission in high 
income countries. This seems to suggest that this is the average per-vaginal-sex-act 
transmission risk in absence of cofactors, during the asymptomatic phase. 
The risk of transmission per M-to-F condom-less receptive anal intercourse (CLRAI) act is 
estimated to be much higher: 0.017 per sex act (1 transmission in 59 sex acts) (56), but this is 
based on very few studies (41;61). A meta-analysis focusing on HIV transmission risk through 
anal intercourse (62) found a similar estimate for CLRAI (0.014 per sex act) and no significant 
difference between the risk for male-to-male and M-to-F. Per-act estimates for condom-less 
insertive anal intercourse (CLIAI) on treatment are not available. The risk of transmission per 
partner per CLIAI is 0.217, compared to 0.404 for CLRAI (62). The PARTNER study following 
heterosexual and same sex serodifferent couples who reported condom-less sex, has so far 
observed zero linked HIV transmissions among couples where the HIV-positive was on ART 
with suppressed VL (63). However the upper limit of the confidence interval (CI) for the rate of 
HIV transmission per 100 PYs was up to a maximum of 4, for the practice of CLRAI in men who 
have sex with men (MSM), due to the lower number of PYs accumulated so far. 
In sub-Saharan Africa most of HIV transmissions are attributable to heterosexual sex, but 
epidemics among MSM have also been identified (64;65).  
 
1.4.2. Role of genetic mutation (delta-32) on risk of transmission 
Certain genetic mutations can also reduce the risk for acquisition of HIV infection, even within 
the context of on-going high sexual risk behaviours with HIV-positive partners. CCR5 
(chemokine receptor 5) is a chemokine receptor which is used by the HIV virus to enter the cell 
(see section 1.3). Individuals who are homozygous (and to a lesser extent heterozygous) for a 
32-base-pair deletion (delta-32 mutation) in the CCR5 reading frame are highly protected from 
HIV infection (34;66), because of the lower level of expression of this receptor on the cell 
surface, making cell infection and hence HIV acquisition risk lower. This mutation is more 
prevalent in caucasian populations, with prevalence around 10% (67). 
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1.4.3. Transmission via blood contact 
HIV can also be transmitted via blood and blood products, either through blood transfusion 
(28), re-using and sharing of syringes and needles (68) or by contact with infected blood (often 
referred to as occupational exposure) (69). Transmission via blood is the most efficient mode 
of transmission. For blood transfusion recipients, the transmission probability per exposure 
event is estimated to be between 90 and 100% (28;70). While the HIV acquisition risk for 
occupational exposures in terms of needle stick injury is estimated at 1 in 300 per exposure 
(69;71) and at 1 in 900 after mucus membrane exposure (72).  
The most common source of transmission via blood is through the reusing or sharing of 
syringes and needles among people who inject drugs (68). Incidence rates of transmission have 
been estimated up to levels between 10 and 50/100 PYs in people who inject drugs in many 
populations around the world (73).  
In the early stages of the epidemic when blood products were not screened for HIV, a number 
of people, patients needing organ or tissue replacement and people with haemophilia 
requiring Factor VIII replacement, a blood coagulant, became infected through exposure to 
infected blood products (74). Since 1985, blood products have been routinely screened for HIV 
in the USA, Canada, Europe and other high income countries (5). In most recent years some 
low and middle-income countries (LMIC) including South Africa, Botswana, Zimbabwe and 
Zambia have reported screening in a quality assured manner 100% of donated blood units (75). 
 
1.4.4. Mother-to-child transmission  
HIV can also be transmitted from mother to child (vertical transmission) either in utero during 
pregnancy, at birth or through breastfeeding (24;76-79). From the start of the HIV epidemic, it 
was clear that vertical transmission from mother to child was a major source of new HIV 
infections and still, in 2011, 330,000 new HIV infections occurred in children (80), mainly due 
to mother-to-child transmission (MTCT). The rate of MTCT, in the absence of any 
interventions, is around 15-45% (81-83), with higher rates seen amongst mothers who become 
HIV-positive during their pregnancy (84).   
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1.5. Pathogenesis of HIV infection 
The HIV disease progression can be classified in different stages. Both, the World Health 
Organization (WHO) and the Centers for Disease Control and Prevention (CDC), have 
developed classification systems for the stages of HIV disease and its progression to AIDS. 
Table 1.1 summarizes the details of the two classification systems. The main difference is that 
the CDC system assesses the severity of HIV disease progression by CD4 count and HIV-specific 
conditions, while the WHO system does not require CD4 count measurements and allows 
healthcare workers with varying levels of expertise and training to diagnose Acquired Immune 
Deficiency Syndrome (AIDS) (85). This is especially useful in resource constrained settings, 
where CD4 count measurements are not always routinely available. 
 
Table 1.1. Stages of HIV infection for adolescents and adults 
WHO classification (86) CDC stage 
classifications (87)  
Clinical symptoms  
1. Asymptomatic (HIV 
infection)  
A. Asymptomatic  
(HIV infection)  
No AIDS-defining condition (ADC) and 
either CD4+ T-lymphocyte count of >500 
cells/μL or CD4+ T-lymphocyte 
percentage of total lymphocytes of >29  
2. Mild (HIV infection)  B. Symptomatic  
 
No ADC and either CD4+ T-lymphocyte 
count of 200-499 cells/μL or CD4+ T-
lymphocyte percentage of total 
lymphocytes of 14-28.  
3. Advanced (advanced 
HIV disease)  
4. Severe AIDS C. AIDS  ADC or CD4+ T-lymphocyte count < 200 
cells/μL  
ADC: Acquired Immune Deficiency Syndrome defining condition; AIDS: Acquired Immune Deficiency Syndrome; 
CDC: Centers for Disease Control and Prevention; WHO: World Health Organization;  
 
1.5.1. Primary HIV infection 
The first phase of HIV infection which lasts between 9 to 12 weeks since infection (43;88) is 
usually called primary HIV infection or acute infection. It is characterized by high levels of VL in 
the blood stream (89-91) up to > 6 log copies/mL (5).  
 
During this period, within a few weeks of HIV infection, HIV antibodies develop and become 
detectable using standard antibody tests (see section 1.7). This is called seroconversion. At this 
point in time VL levels are on average 4.7 log copies/mL (92) and the CD4 cell count between 
500 and 700 cells/μL (92;93). CD4 levels at SC tend to be 30 to 50 cells higher in women than in 
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men (93;94), and this reflects the fact that in HIV-uninfected people it has been observed that 
women tend to have between 60 and 100 CD4 cells/μL more than men (95). 
SC is accompanied in most  individuals (70-80%) by mild flu-like symptoms for 7-10 days (25), 
which can include fever, sweats, malaise, lethargy, nausea, headache, sore throat, skin rash, 
lymphadenopathy, splenomegaly, myalgia, arthritis, diarrhoea or thrombocytopenia (89;96). 
Some more severe symptoms can occur rarely such as gastrointestinal haemorrhage, 
encephalopathy, pneumonitis, or rhabdomyolysis linked to acute renal failure.  
During this phase and for the first 6-10 months after SC, VL levels decline relatively sharp (0.53 
log copies/mL per year) (92) to achieve what is referred to as VL set-point (97) (see Figure 1.4). 
This is accompanied by a gradual decline in CD4 cell count; although an initial dramatic 
depletion of CD4+ T cells (25) (See Figure 1.4) occasionally occurs followed by an increase to 
levels below the pre-infection level (25). Most individuals enter a relatively asymptomatic 
stage (91;96).  
 
Figure 1.4 Typical course of HIV infection 
 
 
 
 
 
 
 
 
 
 
1.5.2. Clinical latency and advanced HIV infection 
The phase called “clinical latency” or “chronic HIV infection” includes two stages: the 
“asymptomatic” and the “symptomatic” phase (see Table 1.2). Based on the CDC classification, 
people are considered in the asymptomatic stage if their CD4 is above 500 cells/μL and they do 
not have an ADC and in the symptomatic stage if their CD4 is between 200 and 500 cells/μL, 
Figure not available due to copyright restrictions 
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they have not experienced an ADC, but they present with symptoms that either are 
attributable to HIV infection or indicate a defect in cell-mediated immunity or are considered 
to have a clinical course or management complicated by HIV infection.  The “symptomatic” 
phase in the WHO classification is divided into “Mild” (clinical stage 2) and “Advanced” (clinical 
stage 3) and the conditions which characterize these two stages are listed in Table 1.2. 
 
Table 1.2. WHO Clinical Staging of HIV/AIDS for Adults and Adolescents (86) 
 
 
 
Figure not available due to copyright restrictions 
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There is a sharp decline in VL in the first months from SC, after the initial peak, with the level 
falling to an average of around 4 log copies/mL, but with a high level of variation between 
individuals, from below 50 copies/mL to above 100,000 copies/mL. Thereafter VL slowly 
increases on average with a rate of increase between 0.08 and 0.11 log copies/mL per year 
(92;98;99), so that at two, five, and ten years following SC VL levels are on average 4.0, 4.3 and 
4.8 log copies/mL (92). The VL is very variable, not only within a person over time but also 
between persons, of the magnitude of thousands of times (100).  
 
This persistent viral replication leads to a progressive deterioration of the immune system: the 
CD4+ T cell count in the asymptomatic phase on average decreases moderately (see Figure 1.4 
at page 40): between -1.2 (93) (in MSM, 25 years old at SC in the post-1996 era ) and -1.7 
cells/μL per year on the square root scale) (92), but the rate of decline is highly variable 
between individuals and dependent among other things on the current VL. This translates into 
median times to respectively CD4 below 500, 350 and 200 cells/μL of 1.2 years, between 4 and 
4.2 years and between 7.6 and 7.9 years (93;101). Once the CD4 count drops below 500 
cells/μL half the immune reserve has been severely depleted (5).  
 
As VL increases and CD4 cell count falls, the risk of developing AIDS related illness and of dying 
increases. An AIDS diagnosis, also referred to as WHO clinical stage 4, is defined as the 
occurrence of one of a number of different opportunistic infections (OIs) listed in Table 1.2 
(86) (see Table 1.1 at page 39). Most AIDS events occur when CD4 cell count reaches levels 
below 200 cells/μL. Nevertheless, some events, such as tuberculosis (TB) and severe bacterial 
disease, which are the most frequent causes of HIV-related morbidity in Africa, can occur in 
individuals at any CD4 cell count. In adults, the average time between infection and 
development of AIDS is between 7.7 and 11 years (102;103). Among people infected at a 
young age (25-29 years) between 13% and 20% develops AIDS (excluding Kaposi's sarcoma) by 
5 years (103;104), 46% by 10 years (103;104) and 88% by 20 years (104). In cohorts from sub-
Saharan Africa faster progression to AIDS has been observed compared to cohorts of non-
African Europeans, nevertheless this was mainly due to pulmonary and disseminated TB (105).  
 
The average survival time after an AIDS diagnosis has been estimated to be between 15 (100) 
and 19 months (43), but it is very variable depending on the population studied, on the AIDS-
defining events and on the number of ADCs. In the absence of ART, it ranges from 3 months to 
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2 years in South Africa (106) and Europe (107), 7 months in Thailand (108) and 9.2 months in 
Uganda (109). In Europe, the ADCs with the shortest survival from diagnosis are progressive 
multifocal leukoencephalopathy (2 months) and malignant lymphoma (5 months), while those 
with the longest median survival are Kaposi's sarcoma and extra-pulmonary TB (17 and 22 
months respectively) (107). In South Africa survival from AIDS diagnosis varies from less than 3 
months from a diagnosis of encephalopathy and wasting to more than 2 years from a diagnosis 
of extra-pulmonary TB and herpes simplex virus infection (106). This relationship between type 
of ADC and survival is most marked in patients with CD4 above 50 cells/μL (106) and having a 
second ADC diagnosed decreases survival time by between 1.5 and 2-fold (110).  The type of 
ADC differs by setting, in particular in sub-Saharan Africa the most common are TB (around 
30%) and HIV wasting syndrome (around 15%), while in Europe among person of non-African 
origin, Pneumocystis pneumonia (PCP) and Kaposi's sarcoma (around 15-20% each) are most 
common (105). On the contrary, in people living in Europe of African origin the most prevalent 
ADC is TB with over 60% of case of which almost two thirds are extra-pulmonary TB (105).  
 
Overall, survival of people infected with HIV from SC who are untreated varies between 7.9 
and 12.5 years, depending on age at infection, in Europe, North America and Australia (103). 
Among people aged 25-29 years at SC, respectively 90% and 60% survived at 5 and 10 years 
(103). Similar estimates have been found in developing countries: an analysis including people 
from community-based studies in East Africa, South Africa (miners), Thailand and Haiti found 
median survival among people aged 25 to 29 years ranging from 7.5 years in Thailand to 11.6 
years among miners in South Africa (111). Studies in Uganda estimated median survival 
between 8.7 and 9.7 years (112;113), while studies in workers in Ethiopia and Tanzania 
estimated median survival between 9.1 and 13.7 years (114;115). The specific causes of 
mortality among HIV-infected patients also vary by country. In South Africa, the causes of 
death for HIV-infected patients have been examined among a group of HIV-infected miners. In 
this population TB was the leading cause of death in both HIV-positive (47%) and negative men 
(26%) who died from natural causes. Despite a great increase in the mortality rate from natural 
causes with duration of HIV infection, the pattern of disease changed minimally, suggesting 
that the speed of progression does not affect which type of disease can affect these people 
(116). 
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1.6. Predictors of disease progression 
In the absence of ART, the main predictors of progression to AIDS and death are VL, CD4 cell 
count, age and PCP prophylaxis, although many others have been investigated with conflicting 
evidence. Figure 1.5 illustrates the relationship between these factors.  
 
1.6.1. Role of viral load and CD4 in predicting disease progression 
The single best predictor of long-term progression to AIDS (117;118) and death is the amount 
of VL circulating in the plasma, as it predicts the rate of decline in CD4 cell count (117).  In fact, 
higher VL is associated with a faster rate of CD4 cell count decline (119;120) and disease 
progression (117;121;122). In particular, the CD4 slopes are estimated to be between 1.5 and 
1.9 steeper for people with the highest compared with the lowest VL quartile (123).  
One of the first studies to evaluate the capacity of plasma VL to predict progression found that 
the percentage of patients who progressed to AIDS within 6 years varied from 5.4% if their VL 
was 500 copies/mL or less, to 80% if the VL was more than 30,000 copies/mL; the percentage 
who died of AIDS ranged from 0.9 in those with VL of 500 copies/mL or less up to 69.5% in 
those with VL above 30,000 copies/mL. Nevertheless the use of CD4 measurements, in 
addition to VL, improves the capacity of predicting these outcomes (117;118). VL is usually 
considered a good long-term (5-10 years) marker of risk of clinical progression (117;124-127), 
while CD4 cell count is a much better predictor of short-term risk of disease progression 
(126;128-131).  
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Figure 1.5. Main factors determining progression of HIV in absence of antiretroviral 
treatment 
 
AIDS: Acquired Immune Deficiency Syndrome; PCP: Pneumocystis cariniii Pneumonia; 
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1.6.2. Factors affecting CD4 cell counts 
Even in healthy individuals, several factors can influence CD4 cell count levels, including sex 
and age, genetic factors, such as HLA type, factors such as parasitic, respiratory, 
gastrointestinal co-morbidities and acute infections (132), conditions such as fatigue, stress 
and exercise, drug use and even time of the day (133-135).  In HIV uninfected individuals CD4 
count can vary between 500 and 1600 cells/μL (7;95;136) and natural daily variability is large 
(134;137).  
Among HIV-infected populations, few studies have assessed the depletion of CD4 cells in 
African countries (138-140) and very few have directly compared estimates from low and high 
income countries (105;114;141-143). Some have found a lower CD4 cell count at SC 
(105;114;141;143) in African populations and slower CD4 decline over time 
(105;114;142;144;145). This does not seem to depend on income level of country of residence 
because studies that have compared people living in high income countries of African origin 
and not found a significantly lower CD4 decline in those of African-descent (on the square root 
scale -0.04/year) compared to people of non-African origin (-0.07/year) (105;142;146). Part of 
this effect seems to be explained by HIV subtype, with subtype C being characterized by a 
slower decline compared to B (142;146). Nevertheless, this ethnicity effect remains even when 
adjusting for subtype (146;147), therefore the most likely explanation is a genetic cause. 
Although, the CD4 cell count is significantly lower at SC in people of black ethnicity, due to 
slower CD4 cell loss, by approximately 2.5 years since SC the CD4 levels are the same as those 
of caucasian ethnicity (105). 
 
Older age at SC is associated with steeper CD4 count slopes (93;94;123;138;148), although 
some smaller studies failed to find this effect (149;150).  
 
Other factors seem to be associated with CD4 cell count decline, but the evidence is less clear. 
Presence of a clinically recognized SC illness is associated with steeper slope (94). Risk group 
(93) also seems to be related to CD4 depletion, with people infected through heterosexual sex 
and people who inject drugs experiencing a slower CD4 count decline compared to individuals 
infected through homosexual sex (93;94;151). Some studies found a faster CD4 decline for 
women (152;153), but studies with a bigger sample size and a more accurate date of SC did not 
find any evidence of this (93;94;154).  In addition, several studies have attempted to 
determine whether the virulence of HIV-1 has increased over the course of the epidemic, but 
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the results are conflicting with some suggesting that HIV-1 virulence is decreasing (155-158), 
stable (159-164) and some that it is increasing (165)(166-169) over time and more recently a 
study hypothesised virulence increased and then reached a plateau (170). 
 
1.6.3. Effect of demographic factors on risk of AIDS and death 
In the absence of ART, age at SC is the major predictor of development of AIDS (148;171) and 
death (172) after time since SC and therefore VL and CD4 count. In developed countries it has 
been estimated that the median time to developing AIDS in the absence of ART ranges from 
7.7 years for people aged 45-54 years at SC up to 11 years for those aged 15-24 years and the 
survival time from around 8 years in the older group up to 12.5 years for those aged 15-24 
years (103). An almost linear increase in mortality rate as age increases has been found as well 
in studies from South Africa (173;174) and Uganda (112;113). In South Africa, death rates in 
HIV-infected people vary from below 50/1,000 PYs in people aged less than 20 years up to 
150/1,000 PYs in people aged 50 years or more (174). 
 
Many studies investigated whether there was a difference in survival between sexes, given the 
lower CD4 cell counts in women, but no significant difference has been found between sex 
(112;174;175) nor among exposure categories (103). The only exception is Kaposi's sarcoma 
with higher incidence in those infected through sex between men (103) and cervical cancer, an 
ADC that can only occur in women.  
 
Despite the slower rate of CD4 depletion observed in African people, the risk of developing 
AIDS is higher in people of African origin, especially if living in sub-Saharan Africa (105). Shorter 
survival has been observed in people with subtypes D, and AD recombinant or multiple 
infections compared with subtype A. Non-A subtypes had a median survival time of 7.5 years, 
whereas over 90% of those infected with subtype A survive more than 7 years from SC (112). 
 
1.6.4. Effect of co-infections on AIDS and mortality 
Co-infections, such as with hepatitis C virus (HCV), hepatitis B virus (HBV), which share 
transmission routes with HIV and endemic illnesses, including malaria and diarrheal diseases, 
which HIV people are more susceptible to (176-180), could potentially have an impact on HIV 
progression.  
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Findings are conflicting regarding the role of HBV and HCV on the course of HIV disease. Early 
studies found faster progression to AIDS among HBV-antibody-positive people (181), but this 
has not been confirmed by studies conducted in the early ART era (182) or more recently 
(183). On the contrary for HCV, early studies failed to detect any relationship between HCV 
infection and HIV progression (184-188), but some studies have observed faster HIV 
progression in people co-infected with HCV (189;189-191). A meta-analysis published in 2009 
(192) concluded that HCV co-infection did not increase mortality among patients with HIV 
infection before the introduction of ART, but that since the introduction of ART, people co-
infected with HIV and HCV, compared with HIV infection alone, have increased risk of 
mortality, but not of developing AIDS. A more recent study from China has even found that 
HCV co-infection seems to be associated with slower disease progression in the absence of 
ART (193). Co-infection with GB virus C (GBV-C, or hepatitis G virus) was associated with 
improved survival in the pre-ART era but modern ART has eradicated this advantage (194).  
People co-infected with malaria and diarrheal diseases tend to have higher HIV viral loads, of 
the order of 0.25 log higher copies/mL (195-197) and more rapid disease progression than 
people infected only with HIV (198;199). A recent randomized controlled trial (RCT) 
demonstrated that providing people with water filters and insecticide-treated bed nets 
significantly reduce the likelihood of diarrhoea and malaria and is associated with a slower HIV 
progression (200). 
 
1.6.5. Effect of co-trimoxazole on AIDS and mortality 
Prophylaxis with co-trimoxazole (CTX), a combination of two antibiotics (Trimethoprim and 
sulfamethoxazole), is recommended in adults with HIV and WHO clinical stage 2, 3 and 4 and if 
CD4 measurements are available in all those with CD4<350 cells/μL (201). Irrespective of CD4 
cell counts, in patients with clinical stage 2 or 3 of the WHO classification (202) or with 
pulmonary TB at any CD4 level (203) it reduces the rates of mortality, up to half (203), and 
substantially those of severe events (202). Even in areas with high rates of bacterial resistance 
to CTX, CTX prophylaxis is effective in reducing mortality by around 50%, rates of malaria by 
around 70% and diarrhoea by 35%. 
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1.7. Tests to detect HIV 
1.7.1. HIV testing 
A reproducible laboratory test able to detect HIV antibody was developed in 1984 (204). It 
became available in 1985, but it was mainly used to confirm the diagnosis of symptomatic 
people and to screen blood products (see section 1.4.3). The first type of HIV test widely 
employed to screen for HIV is the enzyme-linked immunosorbent assay. This test is 
characterized by high sensitivity but has to be conducted in a laboratory; it takes at least few 
hours to be processed and is quite expensive. Rapid, point-of-care (POC) tests, which do not 
require laboratory equipment nor specialized laboratory staff and produce a result usually in 
less than 40 minutes became available in the late 1990s (205). 
These tests are all antibody tests and therefore are unable to detect HIV infection if the HIV 
infection is recent, because the antibodies take some time to develop (usually up to around 3 
months or more). The time from infection to when the test is able to detect the HIV infection is 
usually referred to as the “window-period”. 
Fourth generation tests, able to detect antibodies and p24 antigens with a much shorter 
window period (11 days-1 month) are now available, mainly in high income countries. They are 
generally extremely sensitive, 99.8% or more (206), but there is only one POC which has been 
approved by U.S. Food and Drug Administration (FDA), Determine HIV 1/2 Ag/Ab Combo (207).  
 
1.7.2. Viral load testing 
Viral load testing allows measuring VL (see section 1.4.1.1), in terms of number of copies of 
HIV-RNA per millilitre of blood. These assays were firstly used in the 1990s, as a research tool 
and they were crucial to help understanding the natural history of HIV and to evaluate more 
timely (compared to the use of CD4 count) the response to treatment in patients. In 1995 the 
minimum amount they could measure was 10,000 copies/mL, but this threshold has been 
decreasing over years, with the introduction of new generation assays: 400 or 500 copies/mL 
by 1996-97, 40 or 50 copies by 1998 and nowadays tests used for research can detect five or 
even one copy/mL. 
In high income countries, VL tests, whether commercially available (employing molecular 
technique) or for research purpose, are conducted in laboratory and they are widely available. 
In resource limited settings (RLS), standard VL testing is very rarely available, because of the 
necessity of expensive equipment, laboratory space and highly trained personnel (208). The 
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use of dried blood spots, which consist of individual spotting whole blood onto filter paper 
after a finger or heel prick and leaving it to dry at room temperature, is an encouraging option 
and has allowed reaching more remote areas (209). However, it requires shipping the dried 
blood spots stored with desiccant to central laboratories, with potential logistic issues. For this 
reasons researchers are working on developing a reliable point-of-care VL testing, which could 
be more feasible to use and affordable (210). 
 
 
1.8. HIV treatment 
The first drug found to be effective in significantly reducing death rates in people with AIDS 
was zidovudine (AZT), in 1986. Since then many more antiretroviral drugs (ARVs) have been 
developed and licensed. At the moment 36 ARVs are currently approved for the treatment of 
HIV by the FDA (211), including fixed-dose combinations (FDCs) (single pill containing multiple 
ARVs). They belong to six different classes of drugs, each of which attack different stages of the 
HIV life cycle (see  section 1.3). The classes are nucleoside reverse transcriptase inhibitors, 
NNRTIs, protease inhibitors (PI), fusion inhibitors, entry inhibitors (CCR5 co-receptor 
antagonist) and HIV integrase strand transfer inhibitors.  
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1.8.1. Nucleoside Reverse Transcriptase Inhibitors  
AZT is a nucleoside reverse transcriptase inhibitor (NRTI). It was initially developed as an 
anticancer agent (212), but in 1986 it was found to be efficacious in reducing mortality in 
people with AIDS (1 death in the AZT arm versus 16 deaths in the placebo arms out of 282 
patients in total), after only 6 months since the RCT was started (213). AZT was approved for 
the market in the US in March 1987 (211). 
ARVs belonging to this class interfere with the HIV life cycle phase called reverse transcription, 
during which the HIV enzyme RT converts HIV RNA into DNA. Nucleoside analogues are faulty 
versions of the building blocks necessary for HIV reproduction. When HIV RT enzyme uses a 
nucleoside analogue instead of a normal nucleoside, the DNA chain cannot be completed and 
so HIV cannot replicate in a cell (214).  
The first RCT evaluating the efficacy of AZT found that AZT could significantly decrease 
mortality and the frequency of OIs (215) over 24 weeks, but a higher frequency of serious 
adverse reactions were found in patients receiving AZT (216). Unfortunately the benefits of 
monotherapy treatment with AZT were found to be transient (217;218): the life of patients 
was prolonged only by 6 to 18 months (219) and resistance mutations in patients taking AZT 
for more than 6 months were reported (220-222). In an attempt to overcome the issue related 
to the development of resistance, some studies were conducted evaluating combinations of 
the drugs available: AZT, didanosine (ddI) and zalcitabine (ddC). Dual therapy using ddI or ddC 
in combination with AZT was found to delay death, and the development of new AIDS defining 
illnesses compared to AZT monotherapy (223) and dual-therapy with ddI was found to be 
more effective than with ddC (223). Nevertheless, in studies using the combination of the 
three drugs it was found that ddI and ddC had similar toxicities and cross resistance profile 
(224) and therefore they did not overcome the resistance issue.  
In the following years many other NRTIs have been developed and currently nine are approved 
in the US, Zimbabwe and South Africa (see Appendix I). Among NRTIs, use of ddC and ddI is 
very rare both in South Africa and Zimbabwe because since ART has been rolled out, they have 
never been recommended as first-line regimens. Stavudine (D4T), part of the first-line regimen 
when ART was rolled out in these two countries, is not recommended anymore as a 1st line 
regimen, because of its side effects, while AZT, lamivudine (3TC), emtricitabine (FTC) and 
tenofovir disoproxil fumarate (TDF) are most commonly used (225-230). 
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1.8.2. Protease Inhibitors  
PIs were introduced in 1995. Their availability changed HIV treatment dramatically, because it 
allowed a combination of three ARVs to be used which belonged to two different classes,  
(from this point onward I will refer to combination antiretroviral therapy when using the 
acronym ART). 
PIs work by restricting the function of the protease enzyme, which the HIV virus uses to 
produce infectious viral particles, so although the HIV virus is created, it is unable to go on and 
infect other cells (214).  
 
One of the first RCTs comparing combination ART with dual therapy was the ACTG 229 trial 
(128). They compared saquinavir in combination with AZT and ddC, to the dual therapy of AZT 
and ddC alone and found that the triple combination was well tolerated, reduced VL, increased 
CD4 count to a greater extent than those on dual therapy (128) and reduced the risk of AIDS 
and death (128;231;232). Part of the reason why dual therapy was found to be better than 
monotherapy, and triple therapy better than dual, is that drug resistance mutants pre-exist 
within the viral quasi-species (i.e. strains of HIV which are resistant to certain ARVs – discussed 
in more detail in section 1.9). Mutants resistant to a single ARV are fairly common, while 
mutants resistant to two or three ARVs are far less common, if not rare, especially if the three 
ARVs belong to two different classes. By using three ARVs which target two different phases of 
the replication, a mutant which is resistant to one of the three drugs will still be suppressed by 
the other two active ARVs. In addition, the regimen composed by more than one drug was 
more potent at suppressing VL.  
In the following year two other PIs were approved in the US: Indinavir and Ritonavir (RTV) 
(211). The first used in combination with two NRTIs, was found to be superior to dual therapy 
composed of two NRTIs (233;234). It quickly became the most frequently prescribed PI in the 
developed world, but its intake regulation was quite strict, the pill burden high (three two-pills 
doses per day preferably on an empty stomach and with the necessity of a high intake of fluid) 
and renal toxicities were associated with it (235). RTV was found to be very potent against HIV 
(236;237), but it was poorly tolerated due to several toxicities, including severe 
gastrointestinal symptoms (238-241) and so its use as an ARV in its own right was abandoned 
(235). A few years later it was demonstrated in RCTs that, in low doses, RTV was effective and 
better tolerated in boosting the activity of other PIs, due to the fact that RTV inhibits the 
elimination of the PI by the liver. RCTs comparing regimens containing PIs boosted with RTV 
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found that they were superior to a non-boosted PI regimen and generally safe (242;243). In 
2000, the introduction of lopinavir boosted with RTV (LPV/r) was demonstrated to be superior 
to nelfinavir (244), another PI, and saquinavir (245). In addition, it was demonstrated that 
patients on LPV/r had sustained efficacy even after 7 years of follow-up (246).  
Regimens based on atazanavir (ATV), developed a few years later, have shown non-inferiority 
compared to regimens based on LPV or fosamprenavir in drug-naïve subjects, generally with 
improved tolerance (247). From current evidence, tipranavir (241) and darunavir (DRV) (248), 
two new generations PIs are regarded as very potent ARVs. Tipranavir has been shown to be 
effective in people with multi-PI resistant HIV-1 (249). DRV, a PI designed to be active against 
HIV resistant to then-current 'first-generation' PIs, was found to be effective in reducing VL 
(61% vs 15% on a control PI had a reduction in VL of 1 log) in patients with experience of all 
three classes of ARVs available at the time the study began in 2004 and with relatively high 
levels of PI resistance (250). In treatment naïve patients, the ARTEMIS study demonstrated 
that once daily DRV/r was non-inferior compared to LPV/r and also had a more favourable 
safety profile (251). 
Currently there are eleven PIs approved for the market by FDA, but they are not all approved 
in South Africa and Zimbabwe (see Appendix I). The only PIs recommended in the Zimbabwean 
and South African guidelines are LPV/r and ATV/r as part of the second-line regimens (226-
230) and DRV as part of the third line regimen in South Africa (226).  
 
1.8.3. Non-nucleosides reverse transcriptase inhibitors   
Shortly after the first PIs were approved, NNRTIs were introduced (219), leading to a choice of 
combination ART options. Similarly to NRTIs, NNRTIs affect reverse transcription, in particular, 
NNRTIs bind to the RT enzyme, obstructing its ability to convert the HIV RNA into HIV DNA 
(214).  
The first NNRTI licensed was nevirapine (NVP) in 1996 (211). As with PIs, several RCTs 
demonstrated the superiority in suppressing VL using a combination of three ARVs belonging 
to two different classes, in this case one NNRTI in combination with two NRTIs, over dual 
therapy (252-254). In addition, NVP-based ART regimens were demonstrated to be at least as 
effective as nelfinavir-based ART regimens (255). Several studies evaluated the effect of 
switching from a PI-based ART regimen to NVP-based ART regimen (256-258), and found that 
patients could maintain a suppressed VL and that some could benefit from the improved 
quality of life and reduced toxicity.  
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Efavirenz (EFV) was licensed a couple of years later (211) and was also found to be a viable 
treatment option (259-261). In observational studies, EFV showed better virological outcomes 
than NVP (262-264) but when compared in RCTs they showed similar efficacy, but with 
differences in the safety profile (264), although both shared side effects such as hepatotoxicity, 
and severe rash (219). NVP, EFV and delavirdine are all classed as first generation NNRTIs and 
were approved by the FDA in the late 1990s (211). NVP was initially recommended for first-line 
therapy in both South Africa (225) and Zimbabwe (227). Current guidelines, both  in western 
countries (265;266), South Africa (226) and Zimbabwe (229) now recommend EFV in first-line 
treatment regimen, even for pregnant and breastfeeding women, with the exception of the 
EACS guidelines who recommend replacing EFV with rilpivirine (267).  Appendix I shows the 
five drugs in this class that have been approved for treatment of HIV (211).  
Etravirine and Rilpivirine are considered 2nd generation NNRTIs.  Etravirine, which is 
recommended to be considered as part of third line regimen in South Africa (226), but not in 
Zimbabwe, was approved in 2007 after two RCTs, DUET-1 (268) and DUET-2 (269). They 
demonstrated that etravirine was effective in patients with resistance to NNRTI and PIs. 
Rilpivirine is currently not recommended in any of these two countries  (226;229). 
 
1.8.4. Entry inhibitors, fusion inhibitors and integrase inhibitors  
Enfuvirtide the only approved fusion inhibitor (211) and Maraviroc, the only approved entry 
inhibitor were approved respectively in 2003 and 2007 by FDA (211), but they are not currently 
recommended in South Africa (226) or Zimbabwe  (229).  
The class of Integrase inhibitors has been developed more recently and it includes: raltegravir , 
dolutegravir and elvitegravir (211). Integrase inhibitors block the enzyme integrase, which HIV 
uses to integrate genetic viral material into its target host cell DNA (214;270).  Raltegravir has 
been recommended to be used by treatment experienced patients (265;266) and it is 
recommended as a third line option in South Africa (226), while dolutegravir and elvitegravir 
are not recommended. In ART-naïve patients, raltegravir (given in combination with TDF and 
FTC) was shown to be non-inferior to EFV-based regimen in terms of sustained viral 
suppression (271;272) and was associated with fewer drug-related clinical adverse events and 
smaller elevations in lipid levels (272). In addition it has been recently found to be safe and 
effective for pregnant women and babies (273).  
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1.8.5. Toxicities of ARV 
Although the availability of combination ART has transformed HIV from a terminal to a chronic 
disease (274), ART remains a life-long treatment. Drug toxicities, together with poor adherence 
and development of drug resistance, are the main causes of treatment failure (amongst people 
who have managed to access and pick up their ARVs) and these three factors are very closely 
interlinked.  In South Africa, the main barriers to remaining on ART are transport costs and the 
necessity to take time off work to attend the clinic (275) (see section 7.2.5), although ARV 
toxicities do play a role and in Europe, for example, they are the most frequent reason for 
discontinuation of a first-line regimen (276)  
 
Toxicities may be specific to a particular ARV or to the class of ARVs, and adverse events can 
vary in severity from mild to fatal (see grades in Table 1.3). Regardless of the severity of the 
toxicity experienced, it may have an impact on adherence. Therefore, discussing potential side 
effects before patient and clinician decide on the ART is important. Patients also need to learn 
how to recognise the symptoms and signs of severe toxicities.  
 
Table 1.3. Severity of toxicity (277) 
Grade Condition 
1: Mild  Transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required  
2: Moderate  Limitation in activity- some assistance may be needed; no or minimal 
medical intervention/therapy required  
3: Severe  Marked limitation in activity, some assistance usually required; medical 
intervention/therapy required hospitalization possible.  
4: Severe life 
threatening  
Extreme limitation in activity, significant assistance required; significant 
medical intervention/therapy required; hospitalization or hospice care  
 
Table 1.4 summarizes the toxicities of the ARVs most widely used in South Africa and 
Zimbabwe, whether included in the Synthesis model (indicated by ), those for which the 
evidence is more clear, or not (indicated by ). Appendix II contains a thorough description of 
all the toxicities indicated in Table 1.4. 
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Table 1.4. Toxicities of most commonly used ARVs in South Africa and/or Zimbabwe 
 
NRTIs NNRTIs PIs 
D4T AZT ddI 3TC/FTC TDF EFV NVP LPV/r ATV/r 
Nausea          
Diarrhoea          
Rash          
Decreased appetite          
Headache          
Asthaenia (i.e. 
weakness) 
   
  
    
Nail pigmentation          
Lipoatrophy          
Peripheral neuropathy          
Pancreatitis          
Steatohepatitis          
Hepatotoxicity          
Lactic acidosis          
Anaemia          
Neutropaenia          
Nephrotoxicity          
Osteopaenia          
Exacerbation of 
hepatitis B at 
withdrawal 
   
  
    
CNS          
Steven’s Johnson 
syndrome 
   
  
    
Fetal CNS malformation          
Hypersensitivity 
reaction 
   
  
    
Hypertriglyceridaemia, 
hypercholesterolaemia 
and risk of myocardial 
infarction 
   
  
    
3TC: lamivudine; ARV: antiretroviral drug; ATV: atazanavir; AZT: zidovudine; CNS: central nervous system; d4T: 
stavudine; ddI: didanosine; EFV: efavirenz; FTC: emtricitabine; LPV/r: lopinavir boosted with ritonavir; NVP: 
nevirapine; TDF: tenofovir;  ARV toxicity included in the Synthesis model;  ARV toxicity reported in the 
literature but currently not included in the Synthesis model; 
 
Among the drugs approved by the FDA, ddC and D4T are amongst those which cause the most 
serious adverse events. ddC was withdrawn from the market for adverse event concern at the 
end of 2006 and d4T is not recommended by WHO from 2009 due to the long-term irreversible 
side effects (278), although it has not been yet completely phased out. 
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1.8.6. When to initiate ART  
Recommendations for the initiation of ART are based on CD4 T lymphocyte counts and plasma 
VL levels (279). 
The WHO released new guidelines in July 2013 recommending initiating people on ART when 
CD4 count falls below 500 cells/μL (280) rather than at 350 cells/μL as recommended in the 
guidelines published in 2010 (277). Current South African guidelines recommend ART initiation 
when CD4 count is around 350 cells/μL (226) as do the European guidelines (266), while 
Zimbabwe revised the guidelines (229) following the new WHO recommendations. In the US, 
both the International Antiviral Society-USA (IAS-USA) guidelines (265) and the Department of 
Health and Human Services guidelines (281) recommend ART initiation for all adults with HIV, 
regardless of CD4 cell count. 
As illustrated by different guidelines in different settings, there is currently debate over the 
optimum time to initiate ART. VL levels tend to change only moderately over time in untreated 
individuals, with most at approximately 0.1 log copies/mL increase per year (99). Early therapy 
has the advantage of reducing viral replication early on, decreasing the risk of early CD4 cell 
depletion and the risk of HIV transmission to other people. Delayed therapy on the other hand, 
means avoiding the risk of toxic drug effects and relying on more potent and tolerable drugs 
becoming available by the time treatment begins. In a few observational studies, they assessed 
the impact of initiating at a higher CD4 cell count, generally supporting earlier ART initiation 
(282;283), however confounding cannot be excluded. The Strategic Timing of Antiretroviral 
Therapy trial (“START”) (284) is currently on-going aiming to answer this exact question: in 
people with CD4 above 500 cells/μL is it better to start ART or defer until the CD4 count 
reaches 350 cells/μL. The entire study is expected to take about 6 years, with follow-up ending 
in December 2015. Similarly the TEMPRANO study is aiming to evaluate the impact on 
mortality and severe HIV related disease of ART initiation at diagnosis (with CD4 count 
between 350 and 800 cells/μL) compared to deferral until CD4 falls below 350 cells/μL in Cote 
d’Ivoire (285) (see section 4.2.7 for more details). 
 
1.8.7. Effectiveness and durability of ART regimens 
The benefit of ART regimens in reducing the development of AIDS-defining illnesses and the 
risk of death is indisputable. Since the introduction of these combination ART regimens a 
dramatic reduction in AIDS and death rates have been observed in Europe (286;287) and the 
US (288;288). In Europe, the estimated death rates among people living with HIV on 
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combination ART decreased from 23.3/100 PYs in the period between March to September 
1995, to 4.1/100 PYs of follow-up in the period between September 1997 and March 1998 
(287) and in 2013 the death rate among people diagnosed with HIV in the UK was estimated to 
be 0.34/100 PYs (289). Overall, the risk of death for an HIV-positive patient in the combination 
ART era has been estimated to be >85% lower than in the pre-combination ART era (287).  A 
study on HIV patients living in Europe and North America found that life expectancy in HIV-
positive patients treated with combination ART increased between 1996 and 2005, and the 
average number of years remaining to be lived at age 20 years was about two-thirds of that in 
the general population in these countries (290).  Similar improvements in patients living with 
HIV on combination ART have been observed in South Africa (291-295) and more generally in 
East, West and Southern Africa (296). 
 
The main aim of using ART regimens is to suppress viral replication, which leads to increases of 
CD4 cell count and reduced risk of developing AIDS and death. It has been demonstrated that 
patients who receive ART have a lower risk of clinical progression for a given CD4 cell count 
and VL level compared to patients off ART (297;298). This demonstrates that ART may be 
protective against clinical progression beyond the protection conferred by lowering VL and 
increasing CD4 cell count. This could be due to an improvement in the overall 
immunodysfunction, beyond that captured by the measurement of CD4 cell count (299;300). 
 
Patients experience different immunological and virological responses after initiating ART 
(301;302). In clinical practice, 70-90% of patients starting combination ART achieve 
undetectable VL by 1 year since ART initiation. In people initiating combination ART between 
2000 and 2004 in Europe, 69% achieved virological suppression (VL<500 copies/mL) at the first 
measurement between 6 and 12 months, 86%, if patients with missing VL measurements at 6 
to 12 months are excluded (303). Similar levels have been observed in sub-Saharan Africa. In a 
systematic review by Barth et al (304) virological suppression was 78% at 6 months since ART 
initiation, 76% at 12 months and 67% at 24 months. The same proportion (76%) of patients 
achieving virological suppression at 12 months (VL<1000 copies/mL) was observed in the WHO 
resistance survey (305). When restricting to living patients still receiving ART at 12 months, 
90% had VL suppression. Among studies specifically in South Africa between 70% (306) and 
85% (307) of those on treatment at 12 months achieved virological suppression. 
59 
 
The reason why some patients do not achieve virological suppression could relate to the 
presence of drug resistance mutations (DRMs) in their viral population or to low levels of 
adherence or both (308;309). 
 
If viral replication is not fully controlled, emergence of resistance is likely to occur and this has 
been shown to limit the duration of virological suppression (308). People who experience 
rebound on the first-line of treatment have a lower chance of achieving viral suppression on a 
second or subsequent line of treatment because mutations to some of the drugs may already 
be present in the viral sub-species and because those who fail first-line are likely to have issues 
with adherence and thus more likely to fail second-line as well. For this reason guidelines tend 
to recommend a combination of three drugs, not only belonging to two different classes, but 
without any overlapping resistance mutations, to minimize the risk of resistance emergence 
(280).  
 
1.9. Antiretroviral drug resistance 
1.9.1. Genetic sequencing 
The HIV genome is composed of 9,749 nucleotides (base-pairs) (310) and the order of the 
nucleotides within the DNA or RNA defines the genetic sequence. There are four different 
nucleotide bases in the RNA: two purine bases, adenine and guanine and two pyrimidine 
bases, cytosine and uracil.  The adenine, cytosine and guanine bases are the same as those 
found in the DNA, but instead of the uracil base there is a pyrimidine base similar to uracil 
called thymine. When more than one kind of nucleotide can occur at a certain position, it is 
convention to use a single letter to represent a variety of possible nucleotides, for example the 
letters R and Y designate respectively the purines (adenine or guanine) and the pyrimidine 
(cytosine or thymine). 
Genes that code for proteins are composed of triplets of nucleotides called codons, which 
specify one of the twenty existing amino acids (see Appendix III). 
 
1.9.2. The HIV genome 
The HIV genome varies a lot, even within each infected individual (311). As mentioned in 
section 1.3, several enzymes are involved in replication of the HIV-1 genome, each with their 
own error rate. Reverse transcriptase, in particular, is very error-prone (error rate 1.4 x 105 per 
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base pair per cycle of replication (311), which is nearly one nucleotide mutation per replication 
cycle). The virus does not have a system to check and repair any error that occurs and 
therefore genetic mutations (alteration or mistake in the genetic code) occur during viral 
replication.  
Although people are usually infected with only a single or few original clones of HIV, the 
replication cycle is very fast, each day between 1 and 10 billion viral particles are produced and 
destroyed (312). These two processes combined generate this high diversity (313;314). For this 
reason the HIV virus is considered a quasi-species of a virus, because there are different 
versions of the virus which have related but non-identical mutant and recombinant viral 
genomes (312). 
The mutations are conventionally described by a combination of letters and numbers. The 
number relates to the position of the codon, the initial letter refers to the amino acid that is 
expected and the final letter to the amino acid that was found at that position (see Appendix 
III).  For example the mutation M184V, which is one of the most common mutations 
associated with resistance to 3TC, occurs at codon 184, the expected amino acid is methionine 
(M) but the amino acid which is found is valine (V). 
 
1.9.3. Emergence of antiretroviral drug resistance 
The emergence of DRMs which inhibit the activity of ARVs represents a major barrier to the 
success of ART (312) and this has been observed in all settings where ARVs have been used 
(235). In absence of treatment, a particular viral species will dominate and this is generally 
referred to as “wild-type” virus. These viruses are susceptible to all ARVs and usually are 
present at infection, although, transmission of drug resistant strain can occur and so people 
can have a non “wild-type” virus even at infection (315) (see 1.9.7). Throughout this thesis this 
term will be used to indicate viruses that do not contain any DRMs. 
As mentioned in section 1.9.2, many nucleotide changes can occur along the genetic 
sequences, generating a wide heterogeneity within the viral population of a person infected 
with HIV. A genetic mutation may result in a change in the amino acid that is present at a 
particular position. Some of these mutations impact the susceptibility of the virus to ARVs and 
therefore the activity of ARVs (235). When this occurs we say that a DRM has been acquired. 
These are usually distinguished in: “major” or “primary” DRMs which directly decrease the 
susceptibility of a certain ARV and may contribute to reduce the fitness of the virus (316) and 
“minor” or “accessory”  DRMs which have a minor impact on reducing susceptibility or do so 
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only in presence of a major resistance mutation. The two main ways by which resistance 
mutations may arise in the dominant viral population of an individual are: as a result of a viral 
drift (i.e. a nucleotide change in the predominant virus) or more realistically, as a result of a 
viral shift (i.e. a change in the dominant virus to a virus from a different viral quasi-species).  
The time for resistance to emerge, under drug selection pressure, differs across individuals. 
Factors that influence the mechanism and the speed of emergence of resistance mutations 
include (312;317): 
 number and type of DRMs before treatment is initiated 
 level of viral replication 
 the fitness of the mutants, which is the ability of the virus to replicate itself and infect 
new cells (fitness refers to a given environment – in the absence of drug virus with 
resistance mutations is usually slightly less fit than virus without mutations but in 
presence of drug it is more fit) 
 viral fidelity, a decreased probability of new mutations emerging per replication round  
 magnitude of drug selection pressure which depends on  the drug potency (i.e. the 
magnitude of decrease in plasma VL) 
 adherence to treatment  
 ARV genetic barrier (i.e. the number of mutations required to confer resistance to this 
particular ARV)  
 
1.9.3.1. Viral replication and emergence of resistance 
In the presence of an ARV and ongoing viral replication, a pre-existent resistance mutation can 
be selected by the drug. If replication under drug pressure continues the mutant will acquire 
further mutations that increase resistance or alter fitness, the ability of virus to replicate and 
infect new cells (in a given set of conditions, including presence of ARVs) (318;319). Patients on 
a failing ART regimen with high levels of viral replication are those who experience the highest 
risk for DRMs to emerge in their dominant virus population. In fact, if the rates of replication 
are high, there is a greater chance of an error occurring and, if these patients are also receiving 
ART, it is likely that mutations will emerge that allow the virus to prosper in the presence of 
that specific ARV. In the presence of ART, viruses with DRMs tend to be fitter than viruses 
without those mutations so they tend to out-grow the less fit wild-type population and to 
become the dominant species.  
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Resistance to a particular ARV is more likely to emerge when both the potency of the ARV and 
the genetic barrier to resistance (i.e. the number of mutations required to confer resistance 
(312)) of the ARV are low. In fact if the potency is low, it fails to fully suppress the viral 
replication and if the genetic barrier is low the drug activity is reduced as soon as one or a few 
DRMs are acquired. The genetic barrier depends on a number of factors, including the level of 
pre-existent resistance, the replication rate of the pre-existent resistant viral strain and the 
number of DRMs that are required for loss of activity of an ARV. 
Patients who are receiving a sub-optimal antiretroviral regimen (not combination ART) 
experience a rapid increase in VL and high chance of acquiring DRMs. Studies in people 
receiving monotherapy have shown that resistance emerges easily and rapidly to the ARV 
received (220). This is due to the fact that monotherapy inhibits replication initially, however 
once resistance emerges to the single ARV the patient is taking, the drug will not be effective 
anymore at suppressing the VL. Therefore, replication rates will increase with a consequent 
elevation in viral strains containing mutations that are resistant to the drug. The genetic 
barrier of dual therapy is higher than that of monotherapy because for replication to occur, the 
virus needs to develop resistance mutations to both drugs in the regimen. Because more 
mutations are generally necessary to confer resistance to two drugs rather than one, it 
generally takes longer for the VL to rise (320). Triple combination of ARVs is used to maximise 
antiretroviral activity and to inhibit viral replication. In order to maintain high the potency of 
the regimen and to avoid the emergence of resistance, adherence has to be good. 
 
1.9.3.2. Adherence and emergence of resistance 
Adherence to ART (i.e. taking the regimen as prescribed) is one of the main determinants of 
resistance emergence and long-term therapy success (321-324;324;325). In patients who 
received ART and had directly observed therapy (DOT) virological suppression rates up to 100% 
have been observed (326;327). Nevertheless it is not feasible to provide ART with DOT to all 
patients on ART. Different methods to assess adherence exist, such as self-report, self-
administered questionnaire, physician perception, drug prescription, pharmacy refills, plasma 
pharmacokinetics drug levels, medication event monitoring system and DOT. Nevertheless 
none of them have been proved to be completely reliable (328).  
 
The relationship between adherence and rates of emergence of resistance is an inverse U-
shape. If the adherence is optimal the ART regimen prevents replication from occurring and 
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therefore it is very unlikely to accumulate DRMs. At the other extreme, if the adherence is very 
low, there is insufficient potency to prevent replication but there is minimal selection pressure 
and thus the rates of mutation accumulation are low (329). The higher rates of resistance 
mutation accumulation occurs when the adherence is intermediate, although the level of 
adherence with the higher risk of accumulating resistance mutations and the magnitude does 
vary by drug-class (see Figure 1.6 (330;331)) and to some extent by specific drug (332). 
 
Figure 1.6. Relationship between medication adherence and the risk of developing drug 
resistance by drug class (330) 
 
NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; 
 
The level of resistance conferred by different mutations varies. Virus with DRMs located at, or 
near, the active sites of the enzymes targeted by an ARV, tend to have a higher ability to 
replicate in the presence of that ARV.  These mutations are typically along the reverse 
transcriptase or protease section of the pol gene. 
Some mutations cause resistance to a particular ARV but re-sensitize others (333-336), such as 
for example AZT and TDF in presence of M184V and thymidine analogue mutations (TAMS) 
(337;338), others improve the fitness of the virus under selective pressure from ARVs 
(339;340) and some lie along the pathway for developing major resistance mutations (341). 
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1.9.3.3. Classes of ARVs and emergence of resistance 
Because the  genetic barrier, potency, half-life and the mutations which confer resistance to an 
ARV are specific to each drug, the rate of emergence of resistance mutations differs by drug 
class and to some extent by individual drugs (330). Figure 1.7 shows the genetic barrier and 
the potency of the most common ARVs: NRTIs in black, NNRTI in green and PIs in red, integrase 
inhibitors in blue and entry inhibitors in purple. 
 
Figure 1.7. Scheme summarizing the genetic barrier to resistance and the potency of the 
main ARVs (312) 
  
3TC: lamivudine; ABC: abacavir; ARV: antiretroviral drug; ATV/r: atazanavir boosted with ritonavir; AZT: zidovudine; 
d4T: stavudine; ddI: didanosine; DRV: darunavir; ENF: enfuvirtide; EFV: efavirenz; FTC: emtricitabine; LPV/r: 
lopinavir boosted with ritonavir; MVC: maraviroc; NVP: nevirapine; RAL: raltegravir; TDF: tenofovir; VL: viral load; 
 
When used in monotherapy, NNRTI resistant mutations are the quickest to occur, in a matter 
of weeks, followed by DRMs which develop while on an unboosted PI (within months), while 
NRTI DRMs are generally those which take longer to develop, often a matter of years (see 
Error! Reference source not found.). Nevertheless there is variability even within class. An 
example is the mutation M184I/V which emerges in patients failing 3TC monotherapy in a 
couple of weeks, while K65R, along the RT gene, emerging on a failing ddI, abacavir (ABC) or 
TDF containing regimen, takes much longer, as do most of the other NRTI mutations.  
Figure not available due to copyright restrictions 
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Table 1.5. Efficacy and time to resistance emergence in people receiving monotherapy with 
specific ARVs (342) 
 
 
As shown in Figure 1.6 (page 63) people on NNRTI-based ART rarely develop resistance at high 
levels of adherence due to the virological effectiveness of these regimens. While when 
adherence drops at intermediate or lower levels, NNRTI resistance develops rapidly. In 
general, resistance to NNRTIs emerges quickly if VL is not kept below 50 copies/mL. 
Nevertheless new generation NNRTIs, such as etravirine, have a better resistance profile (219).  
 
Resistance to PIs is usually uncommon at low levels of adherence because of the significant 
fitness costs associated with these mutations (virus with these mutations remains less fit than 
wild-type). At high levels of adherence, people receiving ART regimens based on single PIs may 
develop resistance because residual viral replication is often seen on these regimens (332). On 
the contrary, if the regimen is based on RTV-boosted PI, the chances of accumulating DRM are 
Figure not available due to copyright restrictions 
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very low (see dashed lines in grey in Error! Reference source not found.) because this is 
possible only in a narrow range of drug levels (as the half-life of PI is short, the drug level at 
which DRMs can emerge is brief) and of adherence where there is sufficient drug around to 
select for mutations that reduce ‘fitness’, while still allowing residual viral replication so that 
new mutations can arise (330). Both tipranavir and DRV, new generation PIs, have a high 
genetic barrier to resistance and have activity against other PI-resistant strains (248).  
 
Figure 1.8. Relationship between adherence and resistance in patients receiving a nelfinavir 
or lopinavir/r containing regimen (332) 
 
PI: protease inhibitor; 
 
1.9.4. Cross-resistance 
Mutations acquired on a certain drug reduce susceptibility to that particular ARV.  In addition, 
some mutations can confer resistance to other ARVs, including drugs the patient has never 
taken before. This phenomenon is called cross-resistance. This is a very problematic issue, 
because although many ARVs are available, the emergence of mutation to a particular ARV 
could reduce susceptibility to other ARVs. This is more likely for NNRTIs than for either NRTIs 
or PIs, especially for first generation NNRTI.  
Figure not available due to copyright restrictions 
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Y318F mutation, located next to the connection domain, is associated with resistance to 
delavirdine, EFV and NVP and is part of the NNRTI binding pocket (343). The connection 
domain in the reverse transcriptase joins the polymerase and RNase H domains and plays a 
structural role in the protein (344). Recent studies have reported that mutations in the 
connection domains can be acquired when receiving ART but their impact on NRTI 
susceptibility and therefore on response to ART does not seem to be large (345).  
 Mutations which confer resistance to more than one PI are likely to be associated with amino 
acid substitutions at one of six different positions along the protease section of the pol gene: 
10, 46, 54, 82, 84 and 90. Other PI mutations, such as D30N, L33F, and G48V are relatively 
specific to certain PIs and are less likely to produce cross-resistance (346). 
Between drug classes, there is almost no cross-resistance at all (312), although mutations in or 
near the connection subdomain of HIV-1 RT (codon 322 to 440) can confer resistance to NRTI 
and NNRTI (347;348) (evidence is available for the mutations N348I, A376S and Q509L (349)). 
Although there is some overlap among mutations for NRTI and PI drugs, PIs tend to require 
several mutations for their efficacy to be compromised.  Therefore, the emergence of 
resistance of a single mutation is likely to result in reduced activity for some other ARVs from 
the same class but it should not compromise the use of ARVs from other classes.  
 
1.9.5. Benefits associated with the emergence of resistance  
The emergence of mutations, at least over the short term, may have some beneficial effect. 
Some mutations, for example, have been associated with hypersensitivity to other ARVs within 
the same class (350). Other mutations may affect the fitness of the virus. In vitro experiments, 
for example suggest that virus containing the M184V mutation have a lower fitness and higher 
fidelity compared to wild-type virus (351-358). 
These findings have been confirmed by in vivo studies. The E-184V study conducted on 
patients with limited treatment options found that people who had failed a 3TC containing 
ART regimen with M184V had better outcomes if they switched to 3TC monotherapy, and 
therefore M184V mutation was continuously detected, rather than interrupting treatment 
completely (359). By lowering the viral replication capacity and increasing the fidelity of the 
dominant virus, other mutations may emerge at a slower rate and so the activity of other ARVs 
in the regimen may be preserved for longer (360). Nevertheless a RCT comparing patients 
failing a 3TC-containing regimen randomized to continue the same regimen (On-3TC) or 
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discontinue 3TC (Off-3TC) whilst receiving ART combination, found no additional virological or 
immunological benefit of continuing 3TC in patients harbouring M1841/V (360).  
A reduction in viral fitness has been found in a few studies on people with DRMs (361-366). 
This could impact the ability of the virus to infect the T lymphocyte as efficiently (363) and 
therefore it may reduce the capacity of the virus to induce CD4 cell count decline. 
Nevertheless it is quite possible that this is not the case (367). A study evaluating the impact 
on CD4 count slope for a given VL level, in patients with VL above 500 copies/mL, did not find 
any difference according to the presence of specific DRMs or class of mutations (368).  
 
1.9.6. ART interruptions 
In the absence of ART, wild-type virus has the highest ability to replicate. Hence, if resistance 
mutations are present in majority virus (see 1.9.10), once ART is stopped wild-type strains are 
likely to become dominant again (369), because they are the fittest viruses (318). For some 
ARVs, the reversion to predominantly wild-type virus can happen in the first 4 to 6 weeks after 
the drugs are discontinued. This does not mean that DRMs disappear completely. In fact they 
are likely to remain present in plasma as low frequency mutants (not detected by 
commercially available resistance test, see 1.9.10) and also hidden in archived reservoirs of HIV 
proviral DNA. 
Once ART is restarted (see Figure 1.9), VL declines, as the replication of wild-type strain is 
constrained, but if they harbour strains of HIV resistant to the ARV the patient is receiving (as it 
is the case in Figure 1.9), DRMs will become dominant again under selective pressure, 
compromising the effectiveness of the treatment. 
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Figure 1.9. Relationship between viral load and resistance (370) 
 
  
Figure not available due to copyright restrictions 
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1.9.7. Transmitted drug resistance  
There is clear evidence that transmission of drug-resistant HIV strains can occur and may be 
associated with suboptimal virological response to 1st line regimens (371-374). The probability 
that a patient is infected with drug-resistant virus is linked to the prevalence of drug resistance 
in the HIV-infected population sexually active. The prevalence of transmitted drug resistance 
(TDR) mutations in people recently infected with HIV from East and Southern Africa has been 
estimated to be respectively 5.0% (375) and 5.6% (376). Among patients initiating ART in 
Lusaka Zambia a prevalence of 6% was found (377), while in Uganda the prevalence of TDR 
mutations was up to 8.6% (378). Up to 8%, but usually less than 5%, of transmitted viruses will 
exhibit resistance to drugs from more than one class (379-382). 
In the absence of therapy, in people infected with ARV resistant virus, TDR mutations tend to 
revert to wild-type. Nevertheless, resistance-associated mutations can often be detected in 
viruses that were transmitted several years earlier (383-385) and seem to be more stable than 
those selected under drug pressure. The rate of persistence seems to vary by specific 
mutations: most TAMs, which affect all NRTIs, and T215 revertants (but not T215F/Y) seem to 
be highly stable, while NNRTI and PI mutations have been found to be relatively less persistent 
(386).  
Standard resistance testing detects only mutations that are present in 15-20% of the viral 
population (this is described in more detail in section 1.9.10.1), therefore, even if resistant 
mutations are not detected, it is possible that resistant viruses are still present at low levels. 
Therefore the presence of resistant viruses, even at a low level, may still increase the risk of 
treatment failure (387-389). No prospective trial has so far assessed whether drug-resistance 
testing before initiation of therapy confers benefit in this population. However, data from 
several, but not all, studies suggest that virological responses in persons with baseline 
resistance mutations are suboptimal (371-374;390-392). 
 
1.9.8. Super-infection 
There is evidence that people infected with HIV can be re-infected, even after established 
immune response to the first infection (393-395). The incidence of this phenomenon is 
unclear, because it is inevitably very difficult to measure. Some suggest it could be similar to 
the incidence of the first infection  (396) while others consider it to be a very rare 
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phenomenon (397). Its relevance is due to the fact that people originally infected with wild-
type virus could be super-infected with a resistant virus, which could reduce their future 
treatment options. 
 
1.9.9. Virological failure and switching to second-line regimens 
Accumulation of DRMs is the underlying cause of most virological failures (VFs) in patients who 
have moderate to high adherence and optimal drug pharmacokinetics levels. The great 
majority of patients who initiate a first-line ART regimen and who are infected with wild-type 
virus have no DRMs present in their viral quasis-species at a level above 0.1%. Therefore their 
virus population is susceptible to all initiated ARVs.  
 
Patients who experience VF (an increase in VL above a certain threshold, usually defined as 
two consecutive VLs above 1,000 copies/mL while on ART, although lower thresholds such as 
50, 200, 400 and 500 are often used in high income countries) are very likely to have DRMs in 
their predominant virus population, to some, or all of the drugs in their regimen.  Among 
people failing first-line ART (see section 5.1), the prevalence of resistance (at least one DRM 
detected in their viral quasi-species) ranges between 70 and 90% (305;398-401). WHO surveys 
to monitor emergence of resistance in countries where resistance testing is not routinely 
available found that 72% of patients failing first-line at 12 months since ART initiation had 
resistance in the dominant virus (305) and 70% in the PASER study, which  included 13 cohorts 
from six countries in Africa (398). Levels around 85% have been found in Europe (399) and 
similar levels have been found in the South African public sector (82% (401), 87% (400)).  
Among patients on ART with detectable VL, in whom resistance was detected, the incidence of 
acquiring new DRMs per PY of follow-up has been estimated to be 1.61 (95% CI: 1.36, 1.91) 
(399). In patients who are starting ART the rate of new DRM acquisition, in the regions 
routinely sequenced at least, is likely to be slow at the beginning, because the selection of 
initial mutations may be difficult. But once initial mutations have emerged, the virus becomes 
more susceptible to the emergence of additional mutations so the rate of emergence is 
probably faster. Nevertheless, once the virus has become highly mutated, resistance 
accumulation rates slow down again, because only a finite number of mutations can emerge. 
In a study of patients kept on the same virological failing regimen for a median of six months 
(92% on a failing PI-containing regimen) considerable accumulation of DRMs was found, 
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especially in patients who had low levels of resistance to the failing regimen initially: in 25% of 
patients TAMs emerged, in 12% NNRTI DRMs and in 46% PI DRMs (402).  
 
To maximise the chances that people who failed first-line, achieve virological suppression, the 
best option is to switch them to ARVs that are active against the ARV resistant viruses 
acquired. Therefore it helps, if possible, to identify which mutations are present in the viral 
population, by using a resistance test.  In sub-Saharan Africa, including South Africa, where 
resistance tests are not routinely available, people who fail first-line, typically including two 
NRTIs and one NNRTI, are switched to a PI-based regimen (226), because there is no cross 
resistance between mutations acquired while on NNRTI and on PIs. 
The degree of susceptibility that the virus has to an ART regimen can be assessed by using a 
resistance test. 
 
1.9.10. Resistance testing 
Resistance tests allow assessment of the presence of expected resistance to each ARV 
individually and to the regimen as a whole. There are two types of resistance test: genotypic 
and phenotypic (403). However, as genotypic test is the preferred one I will present only 
this type of resistance test (281).  
 
1.9.10.1. Genotypic resistance testing 
The genotypic resistance test produces a list of the type and position of each mutation, 
comparing the genetic code of the sampled virus to that of a consensus sequence (404-407). 
While it always involves sequencing the RT, protease sections of the pol gene, which are the 
areas target by NRTI, NNRTI and PI (408), the sequencing of integrase and the envelope genes 
(gp41 for enfuvirtide and V3 for maraviroc) is not part of the standard test even in resource 
rich settings (281). The genotypic resistance test looks specifically for mutations which are 
known to confer phenotypic drug resistance (mutations which require a high amount of drug 
to inhibit replication of a viral isolate in vitro) or to compromise treatment response (407;409). 
In fact, phenotypic changes are always caused by genotypic changes (317).  
Since the relationship between presence of certain mutations and ARV activity is complex, 
there is disagreement on the impact of certain mutations on ARV predicted activity.  Over 
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twenty different genotypic interpretation systems have been proposed. Most of them rely on 
data derived from in vivo (clinical outcome data) or in vitro (phenotypic testing of subtype B 
virus) (410). The most commonly used is probably the one provided by Stanford University, 
freely available, called “HIVdb” (411). The Stanford University also maintains the Stanford 
University HIV Drug Resistance Database (http://hivdb.stanford.edu). The IAS-USA publishes a 
list of all significant resistance-associated mutations in the RT, PR, integrase, and envelope 
genes that are considered to indicate some level of resistance to the licensed ARVs (412). 
Resistance mutations are generally classified as primary and secondary mutations. The former 
are those that occur during therapy with a non-suppressive regimen and lead to a decrease in 
the sensitivity of the virus to the single ARV. Secondary mutations are those that occur over 
time if people remain on a failing regimen with ongoing viral replication and in general have 
less impact on drug efficacy than primary mutations. 
 
The HIVdb genotypic interpretation system (411) consists of: 
a. a list of penalty scores for each ARV DRM in a sequence 
b. estimates of decreased susceptibility for NRTIs, NNRTIs, PIs and integrase inhibitors 
c. comments about each ARV resistance mutation 
First of all, a list of differences in mutations between the submitted sequence and a consensus 
B sequence is generated. RT mutations are then classified into three groups: NRTI mutations 
(which reduce susceptibility to one or more NRTIs), NNRTI mutations (which reduce 
susceptibility to one or more NNRTIs) and other, which include mutations not associated or 
weakly associated with drug resistance and rare mutations whom effect on drug susceptibility 
has not been studied yet. Protease and integrase mutations are categorized as well in three 
groups: major (non-polymorphic mutations that by themselves reduce susceptibility to one or 
more inhibitors that usually occur during VF), minor (non-polymorphic or minimally 
polymorphic mutations that contribute to reducing the susceptibility in combination with 
major DRMs) and other (as for the RT category other but including rare non-polymorphic 
mutations). 
The mutation penalty scores have been assigned, trying to reflect the effect of individual 
mutations on drug susceptibility and how mutation penalties are combined to return reliable 
estimates of ARV susceptibility for the most common combination of ARV DRMs. The sum of 
the mutation penalty scores for each of the mutations present within a subsequent sequence 
gives the estimate of decreased ARV susceptibility, which is categorized into five groups:  
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1) Susceptible: no evidence of reduced susceptibility to ARV compared to wild-type (total 
score of 0-9) 
2) Potential low-level resistance: the virus is likely to be fully susceptible but there are 
mutations that may indicate previous ART exposure (total score of 10-14) 
3) Low-level resistance: possible reduction in in vitro ARV susceptibility and/or patients 
with these mutations may have suboptimal virological response (total score of 15-30) 
4) Intermediate Resistance: if the virus has intermediate resistance to a certain ARV (total 
score of 30-59), this ARV should in general only be used if the ARV has a high genetic 
barrier to resistance, such as some RTV-boosted inhibitors or if few other drugs are 
available 
5) High level resistance (total score > 60) is the highest in vitro drug resistance. Patients 
with this level of resistance will have little or no virological response to treatment with 
that ARV. 
 
To interpret genotypic test results it is necessary to know which mutations are selected by 
different ARVs and the potential for cross resistance to other drugs conferred by certain 
mutations. Clinical trials have demonstrated that consultation with specialists in HIV drug 
resistance improves virological outcomes (413). 
 
 
1.10. Prevention methods 
Several interventions have proven to be effective in reducing the risk of HIV transmission. This 
section summarizes the evidence for the prevention interventions which have been 
implemented in RLS and which are part of the analysis conducted in this PhD: condom use, 
voluntary medical circumcision (VMC) and earlier initiation of ART in HIV-positive people. 
This section does not cover prevention of mother-to-child transmission (PMTCT) by use of ART 
during pregnancy, caesarean section at delivery and avoidance of breastfeeding, because the 
focus of this thesis is on adults.  
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1.10.1. Condom use 
Condom use is the prevention method which confers the highest level of protection against 
sexual transmission of HIV and confers protection not only against HIV but also against other 
STIs, which are known to enhance the risk of HIV acquisition. The efficacy of male condoms in 
reducing transmission has been estimated to be at least 80% in heterosexual transmission and 
to confer 64% protection in anal sex among MSM, if used consistently and correctly (414). 
Nevertheless these estimates do not come from RCTs and it is likely that the effectiveness 
when used consistently and correctly is much higher. A study by Varghese et al found that the 
use of male condoms was associated with a 20-fold reduced risk (26). Even fewer data are 
available for the efficacy of female condoms in protecting from HIV transmission, but evidence 
suggests they can have similar efficacy in preventing HIV (415). Nevertheless their availability is 
not nearly as widespread as male condom use. 
 
1.10.2. Circumcision 
The practice of circumcision is common in some countries for religious and cultural reasons. 
The hypothesis that circumcision could reduce the risk of HIV transmission came from the 
observation that the risk of HIV transmission was higher among uncircumcised men (18∙5% per 
act [95% CI: 2.3, 34.8]) than among circumcised men (2∙2% per act [95% CI: 0.0, 6.4]) (416). 
Among those with GUD, estimates of HIV transmission were six times higher among 
uncircumcised men (42.8% per act [95% CI: 1.26, 73.0]) than among circumcised men (6.7% 
per act [95% CI: 0.0, 19.2]), while in the absence of GUD, no HIV transmission occurred in 
circumcised or uncircumcised men (416). A more recent study estimated the F-to-M 
transmission among uncircumcised men to be approximately 2.6 times higher compared to 
circumcised men (1.3% per act [95% CI: 0.5, 2.0] compared to 0.5% per act [95% CI: 0.3, 0.7]) 
and 4.5 times larger in non-circumcised than circumcised men in the presence of GUD (1.8% 
per act [95% CI: 0.0, 3.7] compared to 0.4% per act [95% CI: 0.0, 0.9]) (417). These results are 
consistent, yet somewhat higher, with the results of two previous meta-analyses (418;419). 
To evaluate whether the reduction in the risk of HIV transmission observed in people 
circumcised was due to the circumcision itself or to other factors, three RCTs of VMC were 
conducted among heterosexual sero-different couples (420-422). 
They found an efficacy of VMC in reducing the risk of HIV acquisition for men who have sex 
with women between 50 and 60% for men. This led WHO to recommend VMC as an 
intervention to reduce HIV transmission (423). Although this intervention does not directly 
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reduce the risk of transmission from M-to-F (45), it can reduce the risk indirectly by reducing 
the risk of heterosexual men becoming infected with HIV (419). 
The potential role of VMC among MSM has not been fully investigated, and so far no RCT have 
been conducted to evaluate the efficacy of VMC in this population (424). A meta-analysis 
published in 2008 (425) found that the rate of HIV infection was non-significantly lower (14% 
decreased risk of HIV acquisition) among men who were circumcised compared with those 
who were not circumcised. Among those primarily engaging in insertive sex a bigger reduction 
in risk was found (30%), but still not statistically significant. A few studies (426;427), published 
more recently, found an association between circumcision and a reduction in HIV incidence, in 
participants who reported a preference for the insertive role in anal intercourse. The first 
followed a cohort of almost 1,500 HIV-negative homosexual men in Sydney (427), the second 
1,824 HIV sero-negative MSM from Peru and the US, who participated in a placebo RCT of 
HSV-2 suppression for HIV prevention (HPTN 039) (426). 
 
1.10.3. Antiretroviral therapy 
As mentioned in section 1.4.1.1, early studies identified the VL level of the infected partner as 
the strongest predictor of sexual transmission in heterosexual serodifferent people who were 
not receiving ART (31;35;36). The ability of ART to suppress VL, led some researchers (428) to 
suggest that earlier initiation of ART, regardless of CD4 cell count, in HIV-positive people not 
eligible yet for ART according to guidelines, could prevent sexual transmission of HIV by 
reducing the infectiousness of HIV-positive people. Several observational studies of HIV 
serodifferent heterosexual couples (429-431) reported that transmission was rare in patients 
on ART, particularly in those with low VL concentrations. The definitive answer came in 2011 
when the RCT trial HPTN 052 (432) reported the final results. This RCT was designed to 
compare the effect of early versus delayed ART on transmission of HIV. Overall, 1,763 
heterosexual serodifferent couples in which the HIV-positive person was ART naive and had a 
CD4 count between 350 and 550 cells/μL were recruited from nine countries. Couples were 
randomized to either the early therapy arm, in which ART was initiated at study entry, or the 
delayed therapy arm, in which ART was initiated after two consecutive CD4 counts of 250 
cells/μL or less. The primary endpoint was HIV infection in HIV-negative partners, with 
evidence based on genotyping that the infecting virus was likely to be from the partner. Three 
months after baseline, 89% of participants in the early therapy group had achieved viral 
suppression (<400 copies/mL) compared with 9% of the delayed therapy group. A total of 28 
virologically linked transmissions were observed; of these 28 transmissions, only one was in 
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the early therapy group. This represents a 96% relative reduction in linked HIV transmissions as 
a result of initiating ART compared with deferral. These findings provide support for the use of 
ART in the prevention of HIV among heterosexuals and are believed to be a result of sustained 
suppression of VL in genital secretions. Further details are discussed in section 4.2.5. 
 
The cost-effectiveness of changing the eligibility criteria to initiate ART in the context of South 
Africa is evaluated in Chapter 4, while its impact on the levels of resistance is evaluated in 
Chapter 5. 
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2. The HIV epidemic in South Africa and Zimbabwe 
 
2.1. South Africa 
2.1.1. Brief demographic introduction 
2.1.1.1. Population size and age distribution  
Since South Africa’s first democratic election in 1994 three official censuses have been 
conducted, respectively in 1996, 2001 and 2011. They documented an increase in the total 
population from 41 million in 1996 up to almost 52 million in 2011 (see Table 2.1). The rate of 
growth for the South African population has increased slightly from 2002 to 2013: from 1.30% 
between 2002 and 2003 up to 1.34% between 2012 and 2013 (433) and in 2012 United 
Nations (UN) revised its estimate for South Africa, estimating it would reach 59.5 million by 
2035. 
 
Table 2.1. South Africa population estimates and projections 
Source Year All population (in million) 15-65 years old 
(in million) 
South Africa censuses (434) 
1996 40.58 24.7 
2001 44.82 28.2 
2011 51.77 - 
Central intelligence agency (CIA) (435) 
2011 49.00 32.26 
2013 48.60  31.88  
Statistics South Africa (433) 
2011 50.59 32.24 
2013 52.98 34.79 
UN Secretariat (436) 
2010 51.45 - 
2015 53.49 (+4.0% from 2010) - 
2020 55.13 (+3.1% from 2015) - 
2025 56.67 (+2.8% from 2020) - 
2030 58.10 (+2.5% from 2025) - 
2035 59.53 (+2.5% from 2030) - 
UN: United Nations; 
 
Figure 2.1 shows the age and gender distribution in South Africa in 1996 (the first census with 
all information on all South Africa), before HIV impacted markedly on it. The graph shows that 
over 30% of the population is younger than 15 years old and the percentage of women with an 
age above 45 years old is higher than in men. 
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Figure 2.1. Population Structure Census 1996 (434) 
 
 
2.1.1.2. Mortality 
The South African civil registration system of vital events is maintained by the Department of 
Home Affairs and regulated by an Act stipulated in 1992. Nevertheless in 1994 this system was 
still not representative at all (437). In 1996 it was estimated that only 67% of all deaths were 
registered, while in 1997 this had increased up to 80% for men and 78% for women and in the 
period between 2001 and 2007 it went up to 93% (438). 
Statistics South Africa released data on numbers of deaths and causes of deaths, reported in 
the South African civil registration system starting from 1997. The cause of death comes from 
the death notification forms filled by medical practitioners and other certifying officials. This is 
the only national source of information regarding mortality in South Africa (438).  When a 
death is registered, the Department of Home Affairs issues a death certificate and updates the 
National Population Register, but only if the person who died was a South African citizen or 
permanent resident and his/her birth was already registered at the time of death. Therefore 
the number of deaths reported by the Statistics South Africa is always higher than that 
reported by National Population Register (see Figure 2.2). Figure 2.2 illustrates the number of 
registered deaths over calendar year from 1997 until 2010. The number of deaths increased 
from just over 300,000 in 1997, it peaked in 2006 at around 600,000 deaths, and then it 
started declining again. The number of deaths in the group considered in the Synthesis model 
Figure not available due to copyright restrictions 
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(15-64 years old) in 2010 was 337,846, 62% of the total number of deaths in the entire 
population, 543,856 (calculated from Table 2.2). 
 
Figure 2.2. Number of registered deaths in South Africa (438) 
 
Stats SA: Statistics South Africa; DHA: Department of Home Affairs; NPR: National Population Register; 
Figure not available due to copyright restrictions 
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Table 2.2. Number of deaths by gender and age in 1997 and 2010 in South Africa (438) 
Unsp: unspecified; 
 
Figure 2.3 shows the death rates in South Africa by gender for the calendar year 1997 and 
2004 and overall for the period 2006-2010, in different age groups. In 1997 and 2004, men 
aged 15 to 64 years have higher death rates than women, for example in 1997 in the age group 
15 to 19 years old the death rate for women was 165/100,000 compared to 235/100,000 in 
men.  However a different pattern of death rates can be observed in 1997 (indicated by filled 
squares) compared to 2004 (indicated by empty squares) or the years to follow. The former 
being characterized by an increase in death rates as age increases, steeper in men than in 
women: in the age group 60 to 64 years old the death rate in men is estimated to be 
3,614/100,000 compared to 2,201/100,000 in women. In 2004 the pattern is dramatically 
different with very high death rates in women aged 30 to 34 years (2,267/100,000), more than 
4 times higher than in 1997 in the same age group and similar to the level in the age group 60 
to 64 years old in 2004. In men aged 30 to 44 years the death rates more than doubled 
compared to 1997. The pattern of death rates observed from 2006 onwards is  similar to that 
in 2004, although it is possible to observe an increasing decline in death rates across all age 
groups as calendar year increases. For example the death rate for the age group 30 to 34 years 
old has been declining gradually from around 2,200 per 100,000 in 2004 down to 1,100 in 
Figure not available due to copyright restrictions 
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2010. The increase in death rate observed between 1997 and 2004, more in young women, 
more pronounced in young women, was attributed mainly to TB and AIDS and the slow decline 
afterwards to the introduction and scale up of ART since 2004 (see section 2.1.8) and to the 
more intensive interventions to provide TB treatment, after a national emergency was 
declared in 2005. 
Figure 2.3. Age and gender specific death rates (per 100,000) in 1997 and 2004 and from 
2006 to 2010 in South Africa (437;438) 
 
 
 
 
 
 
 
 
 
 
Overall, in 2013 the World Bank estimated a death rate for South Africa of 17.36 per 1,000 
(439). 
 
2.1.2. Sexual behaviour in South Africa 
Data on sexual behaviour for South Africa have been collected in population–based HIV sero-
prevalence surveys, conducted in 2002, 2005, 2008 and 2012 by Human Sciences Research 
Council (HSRC) (440). Nevertheless surveys on sexual behaviour are often affected by social 
desirability bias and recall bias (441).  
 
2.1.2.1. Sexual debut 
Given the high prevalence of HIV in younger age groups, especially for women (see section 
2.1.3.1), it is important to understand at which age people start being at risk of contracting 
HIV. Information on age of sexual debut was collected among young people aged 15-24 years 
Figure not available due to copyright restrictions 
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in all four HSRC surveys. Figure 2.4 shows the proportion of men and women who reported 
sexual debut before the age of 15 years. At the last survey 10.7% reported sex before the age 
of 15, but this was more than three times in men compared to women (see Figure 2.4). It is not 
clear whether this difference is due to underreporting of sexual behaviour by females or over 
reporting by males or whether it is a true phenomenon that males tend to have earlier sexual 
debut than females. 
 
Figure 2.4. Age of sexual debut by gender of respondents in the 15–24 years old in South 
Africa (440) 
 
 
2.1.2.2. Condom use 
The South Africa Demographic and Health Survey (DHS) conducted in 2003 (442) highlighted 
that although condoms were  available in South Africa, in people with multiple partners they 
were  mainly used with non-primary partners (46.5%), while the use with primary partners was 
quite low (15.4%).  
From 2002 the percentages of adults who reported condom use at last sex increased 
significantly from 2002 to 2008 and then decreased from 2008 to 2012 for all three age-sex 
groups considered: 15-24 years, 25-49 years and over 50 years (see Figure 2.5). 
In people aged 15-24 years in men it was 57.1% in 2002, it peaked at 85.2% in 2008 and it 
declined to 67.5% at the last survey. In women of the same age group the pattern is similar, 
Figure not available due to copyright restrictions 
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but the peak reached in 2008 was 66.5% and in 2012 only 49.8% report condom use at last sex. 
As age increases, the use of condoms decreases, with levels in 2012 of 36.1% and 32.7% in 
men and women respectively aged 25 to 49 years. In the oldest group considered, 50 years old 
and above: 14.5% of men reported condom use at last sex compared to 8.2% in 2002 and in 
women the peak was reached in 2012 with 9.4% of women reporting condom use.  
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Figure 2.5. Condom use at last sex by age group and gender in 2002, 2005, 2008 and 2012 in 
South Africa (440) 
 
 
2.1.2.3. Intergenerational sex: partners age differences 
The practice of having sex with partners with a substantially different age (usually defined as 5 
or more years of difference), especially young women having sex with older men, has been 
identified as a risk factor for contracting HIV (443).  
In all HSRC surveys, data on the age difference between sexual partners in people aged 15 to 
19 years were collected. In all surveys almost 95% of men had a partner within 5 years of their 
own age, while among women 70% of them (with the exception in 2005 were it was 81%) had 
Figure not available due to copyright restrictions 
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a sexual partner within 5 years of their age. Overall a substantial increase was observed in the 
percentage of people reporting sex with a person with more than 5 year difference from 9.6% 
in 2005 to 19.8% in 2012 (440). 
 
2.1.2.4. Multiple sexual partners 
Concurrency, or in other words having multiple sexual partnerships overlapping in time, 
represents a major risk factor for contracting HIV. This information is quite difficult to capture 
but what is usually collected is the number of partners in the last 12 months. Figure 2.6 shows 
clearly that the group with the highest proportion of people reporting multiple partners in the 
last year is the age group 15 to 24 years. In this age group the proportion reporting more than 
one partner increased from 23% in 2002 to 37% in 2012 in men, while in women it remained 
quite stable between 6% and 9% (440). The older risk groups are characterized as well by a 
much lower proportion of women reporting multiple partners compared to men at much 
lower levels compared to those aged 15-24 years. 
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Figure 2.6. Percentage of adults reporting more than one sexual partner in the last year in 
South Africa (440) 
 
 
2.1.3. The HIV epidemic 
The first reported AIDS cases in South Africa were in two white homosexual men, who were 
diagnosed with AIDS in 1982 with HIV subtype B (444); five years afterwards, in 1987 the first 
black South African was diagnosed with AIDS (445). 
  
Figure not available due to copyright restrictions 
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2.1.3.1. HIV prevalence 
South Africa is now the country with the largest HIV epidemic worldwide, with an estimated 
number of people living with HIV in 2012 of 6.4 million and an HIV prevalence of 12.2% (95% 
CI: 11.4, 13.1) (440). When restricting to the population aged 15-49 years, the HIV prevalence 
was estimated to be 18.8% (95% CI: 17.5, 20.3) (440), similar to the estimate of 18% from Joint 
United Nations Programme on HIV/AIDS (UNAIDS) corresponding to 6.1 million adults aged 15-
49 years living with HIV (446). UNAIDS  estimates that worldwide 35.3 million people (95% CI: 
32.2 million, 38.8 million) were living with HIV in 2012 and 2.3 million new HIV infections 
occurred in the same year, the lowest number since mid-1990s when it was around 3.5 million 
(447). At the same time, the number of deaths due to AIDS-related causes has been 
decreasing, from 2.3 million (2.1 million, 2.6 million) in 2005 to 1.6 million (1.4 million, 1.9 
million) in 2012. Of the 2.3 million new infections, 1.6 million, almost 70% occurred in sub-
Saharan Africa and 75% of AIDS-related deaths (1.2 million). 
 
Since 1990, annual anonymous surveys have been conducted in sentinel antenatal clinics 
(ANCs) to estimate HIV prevalence among women attending public ANCs (448) (See Figure 
2.7). These sentinel surveys document a very rapid increase in HIV prevalence from less than 
1% in 1990 up to 25% 10 years after and since 2004 the level has been relatively stable at 
round 30%. 
These data have been extremely important to inform policy makers regarding the magnitude 
of the HIV epidemic among the sexually active population, but they could be biased 
estimations of the HIV prevalence in the general population. On one side they could be over 
estimations because only pregnant women, that by definition had condom-less sex, are 
included in these surveys; on the other side, they could be biased upwards because of the 
lower fertility observed in women with HIV (449).  
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Figure 2.7. HIV Prevalence among women attending sentinel ANC in South Africa (448) 
 
 
The HSRC surveys, which are nationally representative, documented a slow increase in HIV 
prevalence between 2002 and 2008, from 15.6% to 16.9%, followed by a more rapid increase 
up to 18.8% in 2012 (see Table 2.3). Given the South African population is increasing (see 
section 2.1.1.1) with a stable HIV prevalence the total number of people living with HIV would 
still  increase by approximately 100,000 people every year, according to the Spectrum model 
(450) [This was based on estimates before the 2012 HSRC were published in April 2014].  
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Table 2.3. HIV prevalence and number of people living with HIV in South Africa 
Source Age group Year HIV prevalence 
(95% CI) 
Number of people 
living with HIV (in 
million) 
HSRC surveys (440) 2+ years old 2002 11.4 (10.0, 12.7) - 
2005 10.8 ( 9.9, 11.8) - 
2008 10.9 (10.0, 11.9) - 
2012 12.6 (11.7, 13.5)  
15-49 years old 2002 15.6 (13.9, 17.6) - 
2005 16.2 (14.9, 17.7) - 
2008 16.9 (15.5, 18.4) - 
2012 18.8 (17.5-20.3)  
15-24 years old 2002 9.3 (7.5, 11.4) - 
2005 10.3 (8.7, 12.0) - 
2008 8.7 (7.2, 10.4) - 
2012 7.1 (6.2, 8.1)  
ASSA2008 (page 51 in 
(450)) 
0+ years old 2010 10.9 5.5 
Spectrum (page 51 in 
(450)) 
2009 - 5.63 
UNAIDS (446) 0+ years old 2012 - 6.1 (5.8, 6.4) 
15+ years old - 5.7 (5.5, 6.0) 
Females 15+ years 
old 
- 3.4 (3.2, 3.6) 
15-49  years old 17.9 (17.3, 18.4)  - 
Johnson (451) 15+ years old 2011 - 5.6 
CI: confidence interval; HSRC: Human Sciences Research Council; UNAIDS: Joint United Nations Programme on 
HIV/AIDS 
 
In South Africa, as in most countries with generalized HIV epidemics, the HIV prevalence 
remains higher for female than for males (see Figure 2.8). In females, the peak in HIV 
prevalence was in the 30-34 year age group, when over a third of them (36.0% in 2012) were 
HIV-positive (440). In the previous three surveys the 25-29 year age group was the most 
affected with a prevalence around 30% (452). In men, the higher HIV prevalence was observed 
in those aged 35 to 39 years, where over one in four men (28.8% in 2012) was estimated to be 
HIV-positive. Potential explanations for the higher prevalence of HIV in women than in men 
are the higher susceptibility to the HIV virus and social factors making women more vulnerable 
to HIV. The higher susceptibility (more pronounced during adolescence, pregnancy and early 
post-partum period) seems to be related to vaginal microbial ecology and physiology, 
hormonal changes, higher prevalence of sexually transmitted diseases (453) and possibly the 
use of hormonal contraceptive (although the evidence is mixed) (454). The social determinants 
include gender disparities, poverty, cultural and sexual norms, lack of education, violence and 
some intravaginal practices (i.e. using cloth or paper to clean the vagina, insertion of products 
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to dry or tighten the vagina and intravaginal cleaning with soap). This last behaviour has been 
associated with the development of bacterial vaginosis, which in turn, together with disrupted 
vaginal flora is associated with an increased risk of HIV acquisition. However a direct causal link 
between intravaginal cleaning with soap, disruption of vaginal flora, and HIV acquisition has 
not been demonstrated (455). 
 
Figure 2.8. Age and gender specific HIV prevalence in 2012 in South Africa (440) 
 
 
2.1.3.2. HIV incidence 
Knowing the HIV prevalence is fundamental. This is the result of the HIV incidence (i.e. the rate 
of new HIV infections) and of mortality among the HIV-positive population and it is important 
to know how these two components are varying over time and result in the HIV prevalence 
observed.  
Figure 2.9 shows the estimated number of people living with HIV, the number of new HIV 
infections and AIDS related deaths in South Africa estimated by the Spectrum model, used by 
UNAIDS to estimate HIV prevalence in countries with generalized epidemics. According to this 
model, the reason why HIV prevalence is not declining despite the decrease in HIV incidence is 
due to the fact that the number of new HIV infections (in green) is higher than the number of 
AIDS related deaths, due to the beneficial effect of ART in increasing survival. 
 
Figure not available due to copyright restrictions 
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Figure 2.9. Total number of people living in South Africa, number of people living with HIV, 
number of new HIV infections and number of AIDS related deaths estimated by the 
Spectrum model (456) 
 
AIDS: Acquired Immune Deficiency Syndrome; PCP: Pneumocystis cariniii Pneumonia; 
 
In the HSRC conducted in 2012, HIV incidence was measured using two methods: directly, 
using newly available assays able to identify recent infections (Limiting-Antigen Avidity EIA) 
and using a mathematical model (440). Using the first method the HIV incidence in the 
population 15 to 49 years old was estimated to be 1.72 (95% CI: 1.38, 2.06), almost double in 
females compared to men: 2.28 (95% CI: 1.84, 2.74) vs 1.21 (95% CI: 0.97, 1.45) (440). This 
corresponds to almost 400 thousand new HIV infections in the population 15 to 49 years old in 
2012 (396000; 95% CI: 318000, 474000). Using the second method (457), they estimated an 
HIV incidence in the period 2008 to 2012 in the population 15 to 49 years old of 1.9 (95% CI: 
0.8, 3.1) and higher in women compared to men: 2.1 (95% CI: 1.0, 3.4) vs 1.6 (95% CI: 0.6, 2.7).  
In the previous HSRC survey (2008) (452), HIV incidence was estimated using two different 
methods: a direct method using the assays available at the time to detect recent infections 
(BED-CEIA) and an indirect method to estimated HIV incidence in people aged 15 to 20 years 
using data from HIV prevalence in this age group. Basically this second method calculates HIV 
incidence using single calendar year estimates of HIV prevalence for each age and assuming 
that the difference in HIV prevalence between age group represent incident HIV infections. 
This method is appropriate for young people where AIDS related mortality is likely to have a 
minor impact because it is unlikely they have been infected for HIV for long enough to develop 
AIDS  (458). 
Using this second method the HIV incidence in the population aged 15 to 20 years was 
calculated as well for the previous HSRC surveys, 2002 and 2005 (See Figure 2.10). They show 
Figure not available due to copyright restrictions 
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an increase in HIV incidence between 2002 and 2005 in people aged 15 to 20 years from level 
varying from 0.8% to 2.0% to levels between 1.0% and 2.2%, while a drop in HIV incidence has 
been observed in 2008 to levels around 0.5%-0.6% in people aged between 15 and 17 years up 
to a maximum of 1.7% in people aged 20 years in 2008. 
The best way to estimate HIV incidence in a population is to follow a cohort of people over 
time and test them routinely for HIV (as often as possible), in order to observe the proportion 
of people who acquire HIV in a certain time frame. This method is referred to as “direct 
measurement of HIV incidence” and has been used in some circumstances (for example see 
section 2.2.3.2), but it is very laborious, expensive and not feasible at national level. 
Laboratory-based algorithms using assays able to distinguish between recent (usually within 
four to twelve months) and non-recent infection are a promising alternative to measure HIV 
incidence. They have been used in the last two HSRC surveys conducted in South Africa; 
however their accuracy is still matter of debate (459).  
In addition, there are at least two indirect ways of estimating HIV incidence: (a) indirect 
estimation from HIV prevalence in young, recently exposed populations, and (b) by using a 
mathematical model either using HIV prevalence estimates from surveys repeated in series or 
using assumptions on risk behaviour and risk of HIV transmission. The former has been used in 
the HSRC surveys in 2002 and 2055 and has been described above. The second has been 
performed in the HSRC survey conducted in 2012. This latter method is used by UNAIDS to 
provide national estimates of HIV incidence around the globe, but its estimates clearly depend 
on the robustness of the assumptions underlying the model (risk behaviour, prevalence and 
transmission rates). 
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Figure 2.10. HIV incidence in South Africa (452) 
 
 
2.1.3.3. Mortality in HIV-positive people 
As mentioned in section 2.1.1.2, the difficulty in knowing the number of AIDS deaths is due to 
the fact that the vital registration is often not complete and the cause of death could be 
misclassified or missing. A study published in 2005 (460) reported that a large proportion of 
deaths caused by HIV in the period between 1996 and 2001 were classified as several different 
AIDS related conditions, without reference to HIV and these contributed to around 60% of the 
total HIV linked adult deaths. 
As shown in Figure 2.9 (page 92) and in Table 2.4, the number of AIDS related deaths has been 
estimated to gradually increase up to a peak in 2005 of 345,000 deaths, representing almost 
half of all deaths occurring in that year to then decline to levels of almost half in 2013 with 
178,000 deaths estimated. 
UNAIDS updated the estimates regarding the HIV epidemic in South Africa using the Spectrum 
model and estimated that in 2012 240,000 [220,000-270,000] AIDS related deaths occurred. 
 
The leading cause of death in South Africa and in people living with HIV in this country is TB. It 
was estimated that 65% of people living with active TB in 2012 were co-infected with HIV 
(461).  
 
Figure not available due to copyright restrictions 
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Table 2.4. Number of AIDS deaths and with HIV as specific cause in South Africa 
Source Year Age-group Number of 
AIDS related 
deaths (% of 
AIDS deaths) 
Number of 
registered 
deaths with 
cause HIV 
Groenewald (460) 2000-01 Males 15 to 59 years old - 53,185 
Females 15 to 59 years 
old 
- 59,445 
Statistics South Africa 
“SA Statistics” (462) 
2006 0+ years old - 14,948 
2007 - 13,571 
2008 - 15,172 
2009 - 17,570 
Statistics South Africa  
“Findings from death 
notification” (438)a 
2008 0+ years old - 15,179 
2009 - 17,785 
2010 - 18,325 
15 to 49 years old - 14,493 
15 to 24 years old - 1,126 
Republic of South 
Africa – ASSA 2011 
(450) 
2005 0+ years old 257,000 - 
2010 194,000 - 
UNAIDS HIV and AIDS 
estimates (463) 
2012 0+ years old 240,000 (95% 
CI: 220,000, 
270,000) 
- 
a: HIV underlying cause of death; CI: confidence interval; UNAIDS: Joint United Nations Programme on HIV/AIDS; 
 
2.1.4. Response to HIV: history 
Some steps to respond to the HIV epidemic when it was still below 1% were taken, such as for 
example the formation of the National AIDS Coordinating Committee of South Africa in 1992 to 
develop the first national strategic plan (NSP) on HIV and AIDS (464). However, it was only in 
1994 that the NSP was adopted and these steps did not prove to be sufficient to avoid the 
rapid spread of HIV in South Africa.  
In 1996 and 1997 it became clear that the government was not tackling HIV and the major 
crisis this disease was creating appropriately and was actually obstructing the conduct of 
clinical trials to test ARVs.  
In 1998 activists and researchers started campaigning asking the South African Government for 
the provision of AZT to pregnant women to prevent vertical transmission and later for the 
provision of ARVs for people living with HIV. 
In 1999 a new President of South Africa was elected, Thabo Mbeki. He openly declared that 
HIV did not cause AIDS and continued to deny this causal link for many years. In 2000 the 
National AIDS Council was created and it launched two major programmes: 
 The National Integrated Plan for children infected and affected by HIV and AIDS (465) 
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 HIV/AIDS/STD NSP for South Africa 2000-2005 (466) 
 
It was only in 2003 that the Government finally approved a plan for scaling up universal ART 
and this was started in 2004. 
In 2006 a new NSP was released, the “HIV & AIDS and STI Strategic Plan for South Africa 2007-
2011” (467), with the primary aims to: 
“ 
 reduce the rate of new HIV infections by 50% by 2011 
 reduce the impact of HIV and AIDS on individuals, families, communities and society by 
expanding access to appropriate treatment, care and support to 80% of all HIV-positive 
people and their families by 2011.” 
In 2009, when Jacob Zuma was elected as new president of South Africa, HIV and AIDS were 
finally recognized as major challenges and the government acknowledged the importance of 
knowing the HIV status. In 2010, his government launched a media campaign of HIV testing 
and counselling (HTC) (468), including several prevention initiatives such as the provision of 
100 condoms to each person receiving HTC, information on HIV prevention, education and 
mass mobilisation. 
 
In June 2011 in New York, South Africa signed the UN General Assembly 2011 Political 
Declaration on HIV and AIDS. This declaration states ten targets to be achieved by 2015: 
“ 
1. To reduce sexual transmission of HIV by 50%; 
2. To reduce transmission of HIV among people who inject drugs by 50%; 
3. To eliminate new HIV infections among children by 2015 and substantially reduce AIDS-
related maternal deaths; 
4. To reach 15 million people living with HIV with lifesaving antiretroviral treatment; 
5. To reduce tuberculosis deaths in people living with HIV by 50%; 
6. To close the resource gap; 
7. To eliminate gender inequalities, gender-based abuse and violence and increase the 
capacity of women and girls to protect themselves from HIV infection; 
8.  To eliminate stigma and discrimination against people living with HIV; 
9.  To eliminate HIV-related restrictions on entry, stay and residence; and 
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10.  To eliminate parallel systems for HIV-related services to strengthen integration of the 
AIDS response in health and development efforts. “ 
 
In 2010 and 2011 several achievements were finally reached (450): 
 95% of HIV-positive pregnant women received PMTCT in 2010 (see Appendix IV) 
 MTCT was reduced to 3.5% 
 55% of people in need (CD4<350 cells/μL or co-infected with TB) of treatment were 
receiving it (the target was 80%) 
 13 million were reached by the national HTC campaign by June 2011 (the target was 15 
million) 
 
At the end of 2011 a third NSP on HIV, sexually transmitted diseases and TB for the period 
2012-2016 was launched (469), with five main goals, reflecting the targets set in the UN 
General Assembly 2011 Political Declaration on HIV and AIDS: 
“ 
(1) Reduce new HIV infections by at least 50% 
(2) Initiate at least 80% of eligible patients on antiretroviral treatment (ART), with 70% 
alive and on treatment five years after initiation 
(3) Reduce the number of new TB infections as well as deaths from TB by 50% 
(4) Ensure an enabling and accessible legal framework that protects and promotes human 
rights in order to support implementation of the NSP 
(5) Reduce self-reported stigma related to HIV and TB by at least 50%“ 
 
2.1.5. Awareness of HIV status 
In South Africa, client-initiated voluntary counselling and testing (VCT) was introduced in the 
early 1990s (470). However, by 2002 only around 20% of the population aged 15 years or more 
had ever tested for HIV and by 2005 still only 27.6% of men and 32.9% of women had tested 
(443). To address the issue of low uptake of HTC, since 2007 WHO has recommended provider-
initiated testing and counselling (i.e. offer of HTC to anyone presenting at healthcare 
institutions, PITC) for countries with generalized epidemics (471) and South African guidelines 
for HTC released in 2010 emphasize this approach (472). 
98 
 
The last two HSRC surveys reported that 43.0% of men and 56.7% of women had ever tested 
for HIV in 2008 and in 2012 59% of men and 71.5% of women in 2012 (440). 
Ever having had a test for HIV does not mean being aware of their current HIV status, 
especially given the high HIV incidence observed in South Africa. For this reason the proportion 
of people tested in the last 12 months has been collected in HSRC surveys conducted in 2005 
and 2008 (see Figure 2.11). This increased overall from 11.9% to 24.7% and more markedly in 
women than men.  Of those who ever tested for HIV at the HSRC survey conducted in 2008, 
49.1% tested in the last 12 months compared to 66.2% in 2012, underlying how the uptake 
and frequency of testing is increasing over time. 
 
Figure 2.11. Proportion tested in the last 12 months in South Africa (452) 
 
 
In February 2010 the “National HIV Counselling and Testing Policy Guidelines” were published 
(472) recommending all health facilities to offer PITC. As mentioned, in April 2010, the largest 
HTC campaign in the world was initiated in South Africa aiming to test 15 million South 
Africans by 2011 (in 15 months). They estimated that in 20 months more than 20 million were 
tested for HIV within the campaign (473) and in addition the private sector provide HTC for 
some businesses employees (290,000 tested in 2011) (450). In occasion of the World AIDS day 
on 1st December 2013, the National AIDS Council re-launched the campaign (440). 
 
 
Figure not available due to copyright restrictions 
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2.1.6. Pre-ART care 
Since 2004 national guidelines on how to deliver ART to eligible patients have been released 
(225). The first contained no information regarding how often to monitor people who were not 
yet eligible for ART. The 2nd national ART guidelines, released in 2010 (230), indicated clearly 
the actions to take on the day of diagnosis: 
 Check HIV result  
 Clinical staging and CD4 count measurement if HIV-positive  
 Ask if pregnant or planning to conceive  
 Screen for TB symptoms  
 Haemoglobin (Hb) or full blood count (FBC) if available, to detect anaemia or 
neutropenia 
In addition they indicated that patients not yet eligible for ART according to the current 
guidelines should be advised to visit the programme regularly for follow-up and their CD4 
count should be tested every 6 months. During these follow-up visits they should receive 
information on how to avoid HIV transmission to sexual partner and children, if asymptomatic 
for TB isoniazid prophylaxis and counselling on nutrition and contraceptive and an annual 
cervical smear (230). 
The national guidelines released in 2013 (226) are very similar to the previous one: they point 
out the need to confirm the HTC result with a rapid antibody test, ensuring that national 
testing algorithm has been followed, to actively screen for pregnancy and TB symptoms (using 
the WHO questionnaire) and to make sure the CD4 count measurement is conducted on the 
same day. 
They all contain limited recommendation regarding the care of patients who are not eligible 
for ART and how programmes should organize themselves to care for these patients. To my 
knowledge there are no national data regarding how many people have been diagnosed for 
HIV, how many have been linked to care (received ART eligibility assessment) and how many 
are currently in pre-ART care. Programmes providing care for HIV-positive people have 
published data on their specific programme. The linkage to care and the retention in pre-ART 
care is generally poor; these are discussed in detail in sections 7.3.2 and 7.3.3. 
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2.1.7. ART initiation and procedures to monitor people on ART 
The eligibility criteria for ART initiation in the public sector are indicated in the national 
guidelines. Those published in 2004 (225) follow the 2003 WHO guidelines for RLS (CD4 count 
<200 cells/μL or WHO stage 4 disease) (474). These were updated in 2010 (230), when people 
were considered eligible if they fulfilled one of the following criteria: 
 CD4 count <200 cells/μL irrespective of clinical stage  
 CD4 count <350 cells/μL for patients with TB/HIV or pregnant women  
 WHO stage 4 irrespective of CD4 count  
In 2013 they were revised (226) to consider eligible for ART, people with: 
 CD4 count <350 cells/μL irrespective of WHO clinical stage  
 All types of TB (In patients with TB/HIV drug resistant or sensitive TB, including extra 
pulmonary TB), HIV-positive women who are pregnant or breast feeding and patients 
with Cryptococcus meningitis or TB meningitis (defer ART for 4-6 weeks). All these 
patients are eligible irrespective of CD4 count. 
 WHO stage 3 or 4 irrespective of CD4 count  
 
In the first guidelines released in South Africa (225), lots of attention was paid to make sure 
only patients who expressed willingness and readiness to take ART adherently were initiated 
on ART. In particular, once patients were identified as clinically eligible, they needed to 
demonstrate the ability to attend the clinic regularly (usually they are asked to attend the clinic 
for 3 or more visits before being initiated). During these preparatory visits they receive ART 
and adherence education and counselling and they discuss issues related to disclosure of their 
own HIV status to friends and family. 
The ART regimens recommended in the South African guidelines are summarized in the Table 
2.5. 
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Table 2.5. ART regimen lines recommended in South Africa 
Source Line Drugs Notes 
2004 (225) 1 d4T+3TC+EFV/NVP For women of child bearing age, not on reliable 
contraception, NVP is preferred.  
2 AZT+ddI+LPV/r - 
2010 (230) 1a TDF+3TC/FTC+EFV/
NVP 
For TB co-infection EFV is preferred.  
For women of child bearing age, not on reliable 
contraception, NVP is preferred.  
1b d4T+3TC+EFV Only if currently on d4T based regimen with no 
side-effects. Substitute d4T with TDF if at high 
risk of toxicity (high BMI, low Hb, older female)  
1c AZT+3TC+EFV/NVP  If TDF is contraindicated (renal disease) 
2a TDF+3TC/FTC+LPV/r  Failing on a d4T or AZT-based 1st line regimen 
2b AZT+3TC+LPV/r Failing on a TDF-based 1st line regimen 
3 Specialist referral - 
2013 (475) 1a TDF+FTC/3TC+EFV  
FDC preferred 
First choice.  This regimen is mandatory for 
people currently on d4T-based regimen 
experiencing toxicity or at high risk of toxicity 
(high BMI or pregnant). Switch to TDF if virally 
suppressed and the patient has normal 
creatinine clearance, even if well tolerated. 
1b TDF+FTC/3TC+NVP If EFV is contraindicated (patients with significant 
psychiatric co-morbidity or intolerance to EFV or 
where the neuropsychiatric toxicity of EFV may 
impair daily functioning, e.g. shift workers.) 
1c AZT+3TC+EFV/NVP If TDF is contraindicated (renal disease or the use 
of other nephrotoxic drugs e.g. aminoglycosides) 
1d d4T+3TC+EFV/NVP If TDF and AZT are contraindicated (Renal disease 
and anaemia or the use of other nephrotoxic 
drugs, aminoglycosides) 
1e ABC+3TC+EFV/NVP If TDF, AZT and d4T are contraindicated (Renal 
disease, anaemia, peripheral neuropathy, or the 
use of other nephrotoxic drugs, aminoglycosides) 
2a AZT+3TC+LPV/r Failing on a TDF-based 1st line regimen. Patients 
with anaemia and renal failure switch to ABC. 
2b TDF+3TC/FTC+LPV/r Failing on a d4T-based 1st line regimen 
2c Switch LPV/r to 
ATV/r 
Dyslipidaemia or diarrhoea associated with LPV/r 
3 Specialist referral 
(Most likely 
regimen: 
Raltegravir/ DRV/ 
Etravirine adjusted 
according to 
genotype 
Interpretation) 
Should be expert and genotype resistance testing 
based decision and supervised care. 
The drugs for third line will be managed 
centrally.  
 
3TC: lamivudine; ABC: abacavir; ATV/r: atazanavir boosted with ritonavir; AZT: zidovudine; BMI: body mass index; 
d4T: stavudine; ddI: didanosine; DRV: darunavir; EFV: efavirenz; FDC: fixed-dose combination; FTC: emtricitabine; 
Hb: Haemoglobin; LPV/r: lopinavir boosted with ritonavir; NVP: nevirapine; TB: tuberculosis; TDF: tenofovir; /: or, 
except for when is “LPV/r” or “ATV/r”, where it indicates that those antiretrovirals are boosted with ritonavir;  
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Once initiated on ART, it is indicated in the guidelines released in 2004 (225) that patients need 
to visit the clinic as follows: 
- monthly to collect ART medication.  
- at 4, 8 and 12 weeks and 3-monthly afterwards to be monitor for drug tolerability, 
adverse events and adherence (pill count should be conducted at each visit) 
- patients on NVP should be seen by the nurse at 2 weeks in addition  to check: 
o for adverse events 
o do more blood tests (alanine aminotransferase [ALT]) 
o ensure the correct dosing 
- to measure CD4 count and VL 6-monthly while patients on the 1st line. 
 
In 2010 (230) the frequency for CD4 and VL measurement has been reduced to month 6, 12 
and then annually. In addition specific tests have been indicated to identify toxicities to specific 
drugs: ALT if on NVP and develops rash or symptoms of hepatitis , FBC at month 1, 2, 3 and 6 if 
on AZT, creatinine at month 3 and 6 and then annually if on TDF and fasting cholesterol and 
triglycerides at month 3 if on LPV/r. 
 
The guidelines published in 2013 (226) recommend the same frequency of monitoring as the 
2010 guidelines, except for a few details specified below: CD4 is recommended to be 
measured only at 1 year since ART initiation, for patients on AZT, FBC is recommended only at 
month 3 and 6 and finally for patients on TDF creatinine monitoring is recommended at month 
3, 6, 12 months and  then annually. 
 
2.1.8. Roll out of antiretroviral therapy 
The roll out of ART in public clinics started in April 2004 (476). However demonstration 
projects have been conducted since 2001 providing ART to patients with advanced disease in 
Khayelitsha in the Western Cape (477) and in Gugulethu (initiated in September 2002) 
(293;307;478). The scale up was relatively slow in these first years, but from 2010 the uptake 
(up to 30,000 initiations per month) increased dramatically (see Table 2.6). This was due to 
several contributions: the revision of the ART guidelines which increased the number of people 
who are considered eligible, the fact that regimens available have become safer and more 
effective, the shifting of tasks from doctors to nurses and counsellors in the management of 
HIV patients (this has been referred to as nurse-initiated management of patients on ART) and 
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the increase in the number of facilities providing ART, most of them primary healthcare clinics 
(described in section 7.2.8) and to the reduction in the price of ARVs (450). 
Currently, the South Africa HIV treatment programme is the largest in the world, with over 2 
million people on ART in 2013 (479). In November 2012 the South African Department of 
Health managed to get a tender awarded for a FDC for the first-line of ART (TDF+FTC+EFV), so 
these were available for patients from 1st April 2013. This allowed not only to reduce the pill 
burden for patients but also to reduce the cost of the first-line by 38%. 
 
Table 2.6. Number of people on ART in South Africa 
Source Year Age 
Group 
 Number on ART ART coverage  
2010 
eligibilit
y  
2004 
eligibilit
y All Males Females 
Johnson (451) 2004 15+ 
years 
old 
43,300 17,700 25,600 - - 
2005 101,100 37,500 63,600 - - 
2006 213,000 75,000 138,000 - - 
2007 347,000 120,000 228,000 - - 
2008 537,000 183,000 354,000 - - 
2009 836,000 283,000 553,000 - - 
2010 1,174,000 396,000 777,000 - - 
2011 1,641,000 551,000 1,090,000 52%- 79% 
DoH (480) (not 
available online, 
referenced by 
Statistic South 
Africa (481)) 
2005 15+ 
years 
old 
101,416 - - - - 
2006 215,875 - - - - 
2007 386,315 - - - - 
2008 609,762 - -  44% 
2009 839,519 - - 37% 56% 
2010 1,058,399 - - - - 
Republic of South 
Africa (450) 
2010 0+ 
years 
old 
- - - - 58.3% 
2011 1,600,000 - - - 75.2% 
SANAC (473) 2013 0+ 
years 
old 
2,150,880 - - - - 
UNAIDS (479) 2013 0+ 
years 
old 
2,200,000 - - - - 
DoH: Department of Health; SANAC: South African National AIDS Council; UNAIDS: Joint United Nations Programme 
on HIV/AIDS;  
 
2.1.9. Retention on antiretroviral treatment and adherence 
Once initiated on ART, in order to gain the maximum health benefit, people should not 
interrupt treatment. Especially in the first years of ART roll-out, lots of people died in the first 
year of ART mainly due to the very late diagnosis and therefore initiation of ART at low CD4 cell 
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count (477;482). Among those who remain alive by the 1st years of ART, a consistent 
proportion interrupt ART for various reasons and some of them are LTFU. 
Data at a national level regarding how many people are in care and how many have 
interrupted or are LTFU are not available. Several studies have assessed how many people are 
LTFU in different ART programmes in South Africa (see section 7.3.5), nevertheless only a 
couple of studies (483;484) have distinguished between people who interrupted ART (i.e. 
come back to care after interruption) and those who are LTFU. 
One of these studies (483), estimated that in the first year since ART initiation, among over 
11,000 patients initiating ART between 2004 and 2008, 30% missed laboratory visits, and of 
these 40% of them returned back to care by 12 months since initiation. These people, who 
interrupted ART during the first year were estimated to have a 30% increase in detectable 
viraemia compared to those who remained continuously in care. The other study (484) 
estimated the rate of defaulting treatment (having stopped all ARVs for more than 30 days) 
and the rate of resuming ART in those who had interrupted in a cohort of over 1,000 people 
who initiated ART between 2004 and 2009. They estimated the rate of defaulting treatment to 
be 12.8/100 PYs (95% CI: 11.4, 14.4) and the rate of restarting ART 21.4/100 PYs (the 
probability within 3 years of defaulting therapy was 42%). Both these studies highlighted the 
fact that not all those who are reported in the literature as LTFU are actually permanently lost 
and there is a good chance of them coming back to care at a later point. 
 
Not only do patients need to be on ART, but they need to take the ARVs daily and as 
prescribed. Adherence to ART is difficult to measure: self-reported measures are affected by 
desirability bias and more objective measures are often very expensive and can represent an 
actual intervention in themselves, making the results non generalizable to settings where 
these are not available. Self-reported adherence is generally the only way adherence is 
routinely monitored in South Africa. A systematic review in 2006 (485) estimated a pooled 
average adherence of 77% in Africa (95% CI: 68%, 85%) compared to 55% (95% CI: 49%, 62%) 
in North America. In South Africa the studies which reported the proportion of people with 
>95% adherence found levels from 57.2% (referring to doses in the previous 7 days)  (486) to 
88% (referring to doses in the previous 30 days) (487) and similar levels were reported by 
Darder and colleagues (488). Based on pharmacy-refill and pill count, Orrell estimated that 
over 48 weeks 63% of the population took 90% of their pills or more (489).  Others, such as 
Dahab (490) looked at a more objective indication of low adherence, such as having a drop in 
VL of less than 1 log by 6 weeks. They estimated, based on this virological measure, that 85% 
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of the patients were adherent. More recently a study conducted in KwaZulu-Natal reported 
very good adherence in the first 6 months since ART initiation with 83% reporting being 
adherent using a visual analogue scale and 71% using a scale specific to the study (Adult AIDS 
Clinical Trials Group) (491). Nevertheless, it is not clear whether people in Africa, and more 
specifically in South Africa, have optimal adherence or whether the tools used to measure 
adherence are inappropriate to detect suboptimal adherence. A small study (n=165) in 
KwaZulu-Natal evaluated the sensitivity and specificity of five different adherence questions 
(492). None of them performed well, the best measure was the Likert scale. Using this scale 
when defining non-adherence as self-reported adherence less than ‘‘excellent’’, the sensitivity 
for detecting virological or immunologic failure was 100% and the specificity 5%, when 
defining non-adherence as self-reported adherence less than “very good’’ the sensitivity was 
42% and the specificity 55% and finally when defining it as less than ‘‘good’’ the sensitivity was 
25% and the specificity 95%.   
 
2.1.10. Virological outcome and development of resistance on first-line regimen 
The outcome of people initiating ART regarding whether they are still in the same clinic, 
transferred to another one, lost or died is summarized in section 7.3.5 and Appendix XX, since 
Chapter 7 is focused on evaluating the impact of improvements at different steps of the 
cascade of care. In summary, it has been found that retention on ART varies between 63% at 
13 months (483) up to 92% at 12 months since ART initiation (493). There was initially lots of 
concern regarding the high proportion of people not retained in care. Afterwards, it was found 
that actually lots of people not coming back to care were dead and misclassified as LTFU and 
as many were transferred to other clinics and were therefore still on ART (494).  
In this section I summarize the evidence concerning the virological outcome of people 
initiating ART in South Africa. The risk of developing drug resistance among those who fail ART 
in South Africa is described in detail in section 5.1. 
 
Virological response among people on ART has been found to be relatively good (see Appendix 
V). Studies estimated that among people retained in care at 12 months between 66% (304) 
and 96% (307) had VL<400 copies/mL. Fewer studies reported these outcomes at 24 or 36 
months, but a similar proportion of people suppressed were reported: at 24 months ranging 
from 60% (495) to 96% (307) and at 36 months between 61% (495) and 88% (292). This same 
study (292) reported that at 5 years 84% were still virologically suppressed. When looking at a 
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lower limit of detection (the assays available when the studies were conducted were not 
always capable of detecting lower level of viraemia), around 65% (304) and 85% (307) 
achieved a VL <50 copies/mL at 12 and 24 months. 
When looking at the virological outcome using as a denominator those initiated on ART a 
certain length of time ago, so taking into account the fact that some people are not in care 
anymore in the same clinic, these outcomes are obviously lower: at 12 months it varies from 
55% (46% if VL<50 copies/mL) (496) to 77% (VL<25 copies/mL) (497) and at 24 months: from 
18% (VL<50 copies/mL) (496) to 75% (304). While at 36 months 63% had VL below 50 
copies/mL in the only study reporting this outcome, 80% if only those with more than 3-month 
follow-up were included (498). 
Several studies also investigated the occurrence of VF after having achieved initial virological 
suppression (see Appendix VI). The definition of VF within the ART national guidelines has 
changed over time. In 2004 the requirement for VF was a VL above 5000 copies/mL preceded 
by a VL above 400 copies/mL, despite an adherence intervention conducted after the first VL 
above 400 copies/mL after at least 6 months on ART (225). They recommended a confirmatory 
VL in 3 months if a VL above 5000 copies/mL was measured and in 6 months if the initial raised 
VL was between 200 and 5,000 copies/mL. In addition it was indicated to switch people to 
second-line only if their adherence was above 80%. In 2010 the threshold for the confirmatory 
VL has been reduced from 5,000 to 1,000 copies/mL, with the indication of repeat VL within 6 
months if the initial VL is between 400 and 1,000 copies/mL and within 3 months if above 
1,000 copies/mL and finally in 2013 this has been newly revised to two consecutive VL>1,000 
copies/mL, with the 2nd VL conducted two months after the first raised VL (226). 
 
When asking for two consecutive raised VL the proportion of people on ART at 12 months who 
virologically fail is around 3% regardless of the exact definition of VF: 2 consecutive VL>1,000 
copies/mL (VL measured every 4 months and adherence intervention in patients with a 
VL>1,000 copies/mL) (307) or 2 consecutive VL the first above 400 or 1000 copies/mL and the 
2nd above 5,000 copies/mL (VL measured 6 monthly) (499). At 24 months the proportion 
experiencing VF varies between 5% (2 consecutive VL>1,000 copies/mL) (307) and 8% (2 
consecutive VL the first above 400 or 1000 copies/mL and the 2nd above 5,000 copies/mL) 
(499). Only one study reported this outcome at 3 years with a level of 15% if the first VL is 
above 1,000 copies/mL followed by a consecutive VL above 5,000 or 16.9% if the first raised VL 
is above 400 copies/mL (499). Similar levels were observed in a study of patients enrolled in a 
workplace programme (17.9% experienced VF over a median follow-up of 2.6 years) (500). 
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Finally, Boulle and colleagues found that at 5 years (292) 14% (95% CI: 12%, 16%) had 
experienced VF (2 consecutive VL>5,000 copies/mL, despite enhanced adherence promotion 
after the first VL>5,000 copies/mL). 
 
2.1.11. Switch to second-line and outcome on second-line regimen 
Despite people failing the 1st line regimen, there is evidence that not many people are 
switched to a second-line regimen, from as low as 17% at 12 months since VF (500) up to 74% 
for those with at least 6 months of follow-up (499) and if they do usually not in a timely 
manner (292;499;501). This issue is further discussed in section 7.3.6 and Appendix XXI.   
 
Once switched to a second-line regimen, people tend to have a slightly less optimal virological 
outcome than on 1st line (see Appendix VII). The proportion who achieved virological 
suppression by 12 months varies from around 60% using as cut off either 500 copies/mL (502) 
or 50 copies/mL (503) up to 86% (VL<400 copies/mL) (292). Very similar levels were found at 
24 months, where it varies from around 65% (VL<50 copies/mL (503), VL<400 copies/mL (504)) 
up to 75% (VL<400 copies/mL (503); VL<1000 copies/mL (505)).  Nevertheless it is not obvious 
whether this is due to having spent a long time on a failing regimen or to the fact that people 
who are switched to second-line are less likely to be adherent than those who did not fail the 
first-line regimen. 
 
2.1.12. Circumcision 
In 2007 WHO and UNAIDS recommended scaling up VMC in thirteen priority countries with 
generalized epidemics and low prevalence of circumcision (506). At the end of 2011, UNAIDS in 
collaboration with WHO published the “Joint Strategic Action Framework to Accelerate the 
Scale-Up of Voluntary Medical Male Circumcision for HIV Prevention in Eastern and Southern 
Africa: 2012–2016” (507) with the following goals: 
“ 
 Voluntary medical male circumcision prevalence of at least 80 percent among 15–49 
year old males,  
 Established a sustainable national programme that provides VMMC services to all 
infants up to two months old and at least 80 percent of male adolescents.” 
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 In 2009, the prevalence of circumcision in South Africa was 42% (508) and they estimated that 
in order to achieve 80% circumcision coverage, 4.3 million men had to be circumcised (509). By 
the end of 2011 over 442,000 VMCs, 10.2% of the target, were performed (5190 in 2008, 9168 
in 2009, 131117 in 2010 and 296726 in 2011).  In the NSP for the period 2012–2016 the scaling 
up of VMC was outlined (469). In 2012 alone, 422,000 VMCs were performed, allowing the 
circumcision coverage to increase up to 55%.  The plan now is for 900,000 men per year to be 
circumcised in order to achieve the target (473).  
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2.2. Zimbabwe 
2.2.1. Brief demographic introduction 
2.2.1.1. Population size and age distribution  
Population censuses have been conducted in Zimbabwe since 1931. I am going to focus on the 
three censuses which have been performed since the first cases of HIV were observed, 
respectively in 1992, 2002 and 2012 (510;511). An increase in the total number of people living 
in Zimbabwe has been observed: from 10 million people in 1992 up to 13 million at the last 
census in 2012 (see Table 2.7). In the future it is projected that the Zimbabwe population is 
going to reach 20.3 million by 2030, with a decreasing rate of population change over time. 
 
Table 2.7. Zimbabwe population estimates and projections 
Source  Year Age group Population size (in million) 
All Males Females 
1992 Population Census cited in 
(511) 
1992 0+ years old 10.41 - - 
2002 Population Census (511)  2002 11.63 5.6 6.0 
2012 Population Census (510) 2012 13.06 6.28 6.78 
UN Population Fund (512) 2011 0+ years old 12.8 - - 
CIA (513)  2013 0+ years old 
15-64 years old 
15-24 years old 
25-54 years old 
55-64 years old 
13.77 
8.00    
3.05 
4.45 
0.50   
6.87 
4.00 
1.53 
2.30 
0.18 
6.90 
4.00 
1.52 
2.15 
0.32 
UN Secretariat (436) 2010 
2015 
2020 
2030 
0+ 13.08 
15.05 (+2.8a) 
17.12 (+2.6a) 
20.29 (+1.6a) 
- 
- 
- 
- 
- 
- 
- 
- 
CIA: Central Intelligence Agency; UN: United Nations; a – annual rate of population change in the previous five 
years; 
 
Figure 2.12 shows the age and gender distribution estimated by the Census in 2002. The 
Zimbabwean population is very young with 41% of the population being below 15 years old 
and only 4% above 65 years old. 
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Figure 2.12. Population pyramid (%) in Zimbabwe in 2002 (511) 
 
 
2.2.1.2. Mortality 
The best way of estimating mortality is through vital registry, however the vital registry in 
Zimbabwe is not complete and this was still the case when the results from the census 
conducted in 2012 were published (510). Therefore the two main sources on mortality at a 
national level are the DHSs, which collected data on sibling survival and the censuses. Gregson 
and colleagues (514) conducted a thorough review of the epidemiological data for Zimbabwe 
on HIV prevalence, HIV incidence, mortality and sexual risk behaviour in an attempt to 
determine whether HIV prevalence was declining and to identify the determinants. Historical 
data on the mortality rate in Zimbabwe from the 1990s are summarized in Table 2.8. 
Gregson et al. reported that in Zimbabwe the mortality rate started increasing in the late 
1980s in urban areas and a few years later, at the beginning of 1990s in the rural areas (515). 
Both main sources of mortality data, although with different absolute estimates, documented 
an increased death rate; in particular, for example, in Harare the death rate was estimated to 
be around 6 per 1,000 in 1992 and it was estimated to be 10.6 ten years later. The DHS in 1994 
estimated a death rate for women 15-49 years around 3/1,000 and around 4/1,000 for men 
and these death rates were more than double at the subsequent survey in 1999 (see Table 
2.8).  The peak in death rate was reached in the survey conducted in 2005-06 and at the last 
survey a slight reduction was observed: in men 11.5/1,000 compared to 13.3/1,000 in 2005-06 
and in women 11.4/1,000 from 12.7/1,000 in 2005-06. 
  
Figure not available due to copyright restrictions 
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Table 2.8. Death rate estimates for Zimbabwe at national level 
Source Year Age-group and 
area (if not 
national) 
Crude death rate 
(Death/1000 people) 
Average Life 
expectancy at 
birth All Males Female
s 
Population 
Census 
cited by 
Gregson 
(514) 
1992 Harare 
Bulawayo 
6.2 
6 
- 
- 
- 
- 
- 
- 
(511) 2002 National 
Harare 
Bulawayo 
17.22 
10.60 
13.89 
- 
- 
- 
- 
- 
- 
- 
- 
- 
(510) 2012 National 
Harare 
Bulawayo 
10.2 
7.7 
9.3 
- 
- 
- 
- 
- 
- 
38 
- 
- 
DHS (516) 1994 15-49 years old - 4.17 3.34 - 
(517) 1999 15-49 years old - 11.35 9.14 - 
(518) 2005-06 15-49 years old - 13.30a 12.66a - 
(519) 2011 15-49 years old 
15-19 years old 
20-24 years old 
25-29 years old 
30-34 years old 
35-39 years old 
40-44 years old 
45-49 years old 
- 
- 
- 
- 
- 
- 
- 
- 
11.5a 
2.3 
3.4 
6.4 
14.0 
23.1 
30.0 
32.0 
11.4a 
2.5 
5.2 
9.6 
16.4 
20.7 
23.3 
22.6 
- 
- 
- 
- 
- 
- 
- 
- 
DHS: Demographic and Health Survey; a: age standardized; 
 
Figure 2.13 and Figure 2.14 illustrate the age specific death rates in Zimbabwe estimated in the 
DHS conducted in 1994, 1999 and 2005-06, respectively for women and men. To note is the 
dramatic increase especially in the age group 30 to 39 years old which increased by 2 fold from 
1994 to 1999, while from 1999 to 2005-06 the increase in mortality was in the older age group. 
The last DHS survey conducted in 2010-11 (519) found a similar pattern of age and gender 
specific mortality to that observed in 2005-06. 
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Figure 2.13. Age specific mortality among women aged 15-49 years (Rates per 1,000 person-
years), Zimbabwe, 1994-2006 (518) 
 
ZDHS: Zimbabwe Demographic and Health Survey; 
 
Figure 2.14. Age specific mortality among men aged 15-49 years (Rates per 1,000 person-
years), Zimbabwe, 1994-2006 (518) 
 
ZDHS: Zimbabwe Demographic and Health Survey; 
 
2.2.2.  Sexual behaviour 
Data on sexual behaviour for Zimbabwe have been collected in several national population–
surveys: 
 The DHSs conducted in 1988, 1994, 1999, 2005-06 and 2011 (516-520) 
Figure not available due to copyright restrictions 
Figure not available due to copyright restrictions 
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 Knowledge, attitudes, practices and beliefs surveys commissioned by Population 
Services International (PSI) surveys conducted in 1997, 1999, 2001, 2003, 2005, 2006, 
2007 referenced by Gregson et al. (514) 
 National Youth Reproductive Health Survey conducted in 1997 (521) 
 Zimbabwe Young Adult survey (YAS) in 2001 (522) 
 National youth survey conducted by United Nations Children's Fund in 2004 
referenced by Gregson et al.(514) 
 Survey to evaluate the of Zimbabwe's National Behaviour Change Programme (523) 
 
2.2.2.1. Sexual debut 
Gregson et al. summarised all the estimates available regarding age at sexual debut from 
national surveys conducted in Zimbabwe (see Figure 2.15). The median age at sexual debut has 
been relatively stable, between 17 and 20 years in both males and females. The most recent 
DHS conducted in 2010-11 (519) found that among people aged 15-24 years, less than 50% 
had had sexual intercourse before entering in this age group. For this reason the median age at 
first sex for age group 15-24 years was not reported, nevertheless in the older age groups the 
age at sexual debut was between 18 and 19 years in women and 20-21 years in men.  
 
Figure 2.15. Median age at sexual debut for respondents aged 15-24 years in Zimbabwe (514) 
 
DHS: Demographic and Health Survey; IQR: interquartile range; PSI: Population Services International; UNICEF: 
United Nations Children's Fund; YAS: Zimbabwe Young Adult survey;  
 
In the DHS the percentage of men 15 to 19 years reporting having ever had sex fell from 33% 
in 1994 to 24.7% in 2011, while in women it increased from 29.7% to 34.0%.  The percentage 
Figure not available due to copyright restrictions 
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of men aged 15-19 years who reported having had sex before the age of 15 was 7.9% in 1994 
and it decreased to 3.6% in 2011; similarly in women it was 5.2% in 1994 and 3.9% in 2011 
(519). 
 
2.2.2.2. Multiple sexual partners 
Most of the surveys attempted to capture the information regarding faithfulness by asking 
whether they had one or more non-regular partner (usually defined as non-marital non–
cohabiting) in the last 12 months. 
 
Figure 2.16 shows the proportion reporting a non–regular sexual partner in the last 12 months 
(in grey data from DHS and in white PSI surveys). Similarly to what has been described for 
South Africa, in Zimbabwe a much lower proportion of women (maximum 20%) reported a 
non-regular sexual partner in the last year compared to men, where it ranges from around 20 
to 35% in the PSI surveys and between 45% and 60% in the DHS surveys. The data suggest a 
reduction in the proportion reporting a non–regular sexual partner for men, but this is less 
clear for women. 
 
Figure 2.16. Percentage of people aged 15–29 years reporting a non-regular sexual partner in 
past 12 months in Zimbabwe (514) 
a. Males      b. Females 
 
 
The concept of concurrency, defined as more than one partner during the same period of time, 
was newly introduced in the last DHS survey (519). They reported that among women 15-24 
years old only 0.6% had concurrent relationship in the last 12 months and 4.8% of men. 
Figure not available due to copyright restrictions 
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A representative household surveys of people aged 18 to 44 years in 16 districts found that the 
proportion of men with 2 partners or more in the last 12 months declined from 29.1% to 
24.4% from 2007 to 2011 and in women from 7.4% to 5.1% (523).  
 
2.2.2.3. Paid sex 
In sexual intercourse where one of the two partners pays for sex it may often be difficult to 
negotiate condom use. For this reason and due to the high number of partners a person who is 
paid to have sex usually has, it is more likely this person is HIV-positive (524). Therefore it is 
very important to monitor which proportion of men report paying for sex and whether they 
use condoms during such sex. Table 2.9 shows that the percentage of men who paid for sexual 
intercourse in the past 12 months decreased over time from 7% in 1994 to 3% in 2011, in 
addition the proportion of men who reported using a condom at the last paid sexual 
intercourse increased from 82% up to 90%. 
 
Table 2.9. Percentage of men reporting paying for sex and using condom at last paid sexual 
intercourse in Zimbabwe 
Source Year Age % of men who paid for 
sexual intercourse in the 
past 12 months 
% reporting condom use at 
last paid sexual intercourse 
DHS  (516) 1994 15-54 6.9 - 
15-19 7.6 - 
(517) 1999 15-54 7.0 81.5 
15-19 3.0 74.5 
(518) 2005-06 15-54 3.9 73.6 
15-19 1.1 76.6 
(519) 2010-11 15-54 3.0 87.8 
15-19 
15-24 
1.2 
2.5 
NA 
90.4 
DHS: Demographic and Health Survey; NA: Not available, because sample size considered too small; 
 
2.2.2.4. Condom use 
Since the late 1990s when the first surveys were conducted the proportion of males aged 15-
29 years reporting condom use at last sex with a non-regular partner varied between just 
above 60% up to around 90% (See Figure 2.17: in grey data from DHS, in black YAS and in 
white PSI survey). In women there is even more variability: from 40% up to just above 80%. At 
the last DHS survey this information was collected among people aged 15-24 years and it was 
73.7% in men and 48% in women. Nevertheless, condom use at last sex among all those who 
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have at least 2 partners in the last 12 months was only 33% in men and 48% in women. The 
relationship between age and condom use is different in men and women, while younger men 
are more likely to report condom use at last sex (15-24 years, 50.5%), young women are less 
likely to use condom (15-24 years, 38.5%). 
 
The evaluation of Zimbabwe's National Behaviour Change Programme reported that condom 
use at last sex with all non-regular partners in the last 12 months, increased from 23.5% in 
2007 to 39.9% in 2011 (523). 
 
Figure 2.17. Condom use at last sex with a non-regular sexual partner in people aged 15-29 
years in Zimbabwe (514) 
b. Males      b. Females 
 
 
2.2.2.5. Intergenerational sex: partners age differences 
The DHS surveys started collecting data on intergenerational sex among people aged 15 to 19 
years who had sex in the last 12 months from 2005. They found that 5% of women in 2005-06 
had sexual intercourse with a man 10 years or older and this increased to 15.3% in 2010-2011, 
while it was 0.3% in men in the same year. 
 
2.2.3. The HIV epidemic 
2.2.3.1. HIV prevalence 
The first documented case of AIDS in Zimbabwe was reported in 1985 (525). By 1990, when 
they started conducting HIV sero-prevalence surveys in the ANCs, the HIV prevalence was 
Figure not available due to copyright restrictions 
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already more than 10%. Zimbabwe is currently 5th highest globally in terms of HIV prevalence, 
with an HIV prevalence in the adult population aged 15 to 49 years of 14.7% (95% CI: 13.8, 
15.6) (526), preceded by South Africa on 4th place (446).  
The number of adults (above the age of 15 years old) living with HIV was estimated to be 1.2 
million in 2012 (95% CI: 1.1, 1.3) and in the same year 39,000 (95% CI: 34000, 45000] people 
were estimated to have died because of AIDS. 
 
The sentinel ANCs where HIV prevalence surveys were conducted initially varied from year to 
year and large differences were observed within the same clinics (see Figure 2.18), questioning 
the validity of these surveys. They suggested that HIV prevalence increased between 1990 and 
around 1995 and then reached a plateau. In 2000 the HIV surveillance in sentinel ANCs was 
improved by selecting a higher number of clinics, especially in the rural areas and by 
documenting more thoroughly the procedures (527). In 2000, the Genscreen test was used for 
HIV testing. This test was subsequently found to be not very specific, for this reason from 2002 
a combined test algorithm was used (527).  Afterwards (not shown in the graph) the HIV 
prevalence in the sentinel clinics declined from 26% in 2002 to 16% in 2009. 
 
Figure 2.18. HIV Prevalence estimates for individual ANC sites and from The Zimbabwe 
Young Survey and trends in HIV prevalence in adults 15-49 years as estimated by Estimation 
and Projection Package (EPP) (528) 
 
Figure not available due to copyright restrictions 
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The last two DHS surveys, conducted in 2005-6 and in 2010-11 have collected data on HIV 
prevalence documenting a decline in the population aged 15-49 years (see Table 2.10) from 
18.1 (95% CI: 16.9, 19.3) to 15.2 (95% CI: 14.3, 16.1), more dramatic in women, where it 
declined from 21.1 to 17.7 than in men, where it declined from 14.5 to 12.3 (519). 
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Table 2.10. HIV prevalence and number of people living with HIV in Zimbabwe 
Source Age 
group 
Year HIV prevalence (95% CI) Number of 
people living 
with HIV 
(million) 
All Males Females 
Mahomwa (527) 
and Zimbabwe 
Ministry of Health 
and Child Welfare 
(529) (not found 
online, cited by 
(514;530)) 
15-49 
years 
old 
2000 - - 32a - 
2001 - - 30a - 
2002 - - 30a, 25.8b - 
2004 - - 21.3b - 
2006 - - 17.7b - 
2009 - - 16.1b - 
15-24 
years 
old 
2002 - - 20.8 - 
2004 - - 17.4 - 
2006 - - 12.5 - 
2009 - - 11.6 - 
Zimbabwe 
Ministry of Health 
and Child Welfare  
(531), (not found 
online, cited by 
(530;532)) 
15-49 
years 
old 
1990 10.0 - - - 
1992 18.0 - - - 
1994 23.0 - - - 
1996 28.0 - - - 
1998 28.0 - - - 
2000 25.0 - - - 
2002 22.0 - - - 
2004 20.0 - - - 
2006 18.0 - - - 
2008 15.0 - - - 
2009 14.3 - - - 
2010 13.6 - - - 
2011 13.1 - - - 
15+ 
years 
old 
1997 26.5 - - - 
2001 23.7 - - - 
2005 18.4 - - - 
2009 14.3 (13.4-15.3) - - 1.04 (0.9-1.2) 
2010 13.6 (12.7-14.7) - - 1.02 (0.9-1.1) 
2011 13.1 (12.1-14.3) - - 1.02 (0.9-1.1) 
YAS (522) 15-29 2001-
02 
- 10 22 - 
15-24 - 5 17 - 
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Source Age 
group 
Year HIV prevalence (95% CI) Number of 
people living 
with HIV 
(million) 
All Males Females 
DHS (518) 15-49 2005-
06 
18.1 14.5 21.1 - 
15-54 - 14.8 - - 
15-19 4.6 3.1 6.2 - 
20-24 11.6 5.8 16.3 - 
25-29 21.8 13.1 28.8 - 
30-34 32.9 29.5 35.5 - 
35-39 33.4 32.1 34.5 - 
40-44 28.9 32.9 25.7 - 
45-49 21.4 26.0 18.0 - 
50-54 - 20.0 - - 
DHS (519) 15-49 2010-
11 
15.2 12.3 17.7 - 
15-54 - 12.7 - - 
15-19 3.8 3.4 4.2 - 
20-24 7.5 3.8 10.6 - 
25-29 15.8 10.3 20.1 - 
30-34 23.7 17.3 29.0 - 
35-39 27.3 25.2 29.1 - 
40-44 25.9 26.2 25.7 - 
45-49 25.5 29.9 22.5 - 
50-54 - 19.5 - - 
a: Genscreen HIV result; b: combined HIV test result; CI: confidence interval; DHS: Demographic and Health Survey; 
YAS: Zimbabwe Young Adult survey;  
 
2.2.3.2. HIV incidence 
At least two studies estimated HIV incidence in Zimbabwe, respectively in a cohort of pregnant 
women and in a cohort of male workers in Harare. The first reported an HIV incidence of 
4.8/100 PYs (95% CI: 3.1, 6.5) in 1992 (533) declining to 3.4/100 PYs in 1999 (534), while in the 
cohort of male workers it declined from 3.0/100 PYs (95% CI: 2.5, 3.5) in 1994-95 (535) to 
1.3/100 (95% CI: 1.0, 1.8%) in 2002-03 (536). 
At the last DHS survey (see Table 2.10) the HIV prevalence in women aged 15 to 19 years was 
4% compared to 6% in 2005-06, while in men aged 15-19 years it remained stable at 3% and 
this is an indication that the HIV incidence in this group is declining. 
UNAIDS, using the Spectrum model, estimated that the HIV incidence in the adult population 
(15-49 years) peaked in the early 1990s at around 6/100 PYs and it has been declining since 
then to levels below 1 in 2009 (532). In terms of new HIV infections, in the entire population 
this corresponds to around 260,000 new HIV infections per year at its peak down to around 
74,000 in 2009 (532) and 46,000 in 2011 (530).  
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2.2.3.3. Mortality in HIV-positive people 
The sources of data available to estimate the mortality since the start of the HIV epidemic in 
this country are: 
 Census, which collected information regarding death in the household of siblings 
 Vital registration 
 Population cohort data, which are not at national level 
All these sources of data are characterized by incomplete recording and misreporting.  
 
The vital registration data capture the cause of death but as mentioned is characterized by 
very low reporting rate; in 1995 for example the number of registered deaths was less than 
half the number of deaths estimated from the census conducted in 1997 (537). In an attempt 
to estimate the burden of disease in Zimbabwe, Chapman and colleagues explored the pattern 
of causes of deaths reported in the vital registration in 1995 and compared it to previous age 
specific death rates in Zimbabwe. They observed a significantly higher death rate in the 
population aged between 20 and 60 years and they noticed that initially only 14% of deaths 
were attributed to HIV, but that an increased death rate in the same age group was observed 
for common diseases including lower respiratory infections, TB, diarrhoeal diseases and 
meningitis, which are all associated with HIV infection.  
Zimbabwe experts suggested that this could be due to wrong assignment of the underlying 
cause and that more deaths would have been expected to have HIV as underlying cause. For 
this reason they reassigned the underlying cause of death assuming that 95% of the difference 
between the age specific death rate between 1995 and 1984 was due to HIV, this meant 
reallocating 29% of all deaths. They concluded that of the 167,808 deaths in 1997, 54% were 
considered to be attributable to HIV.  
Such a burden of deaths translates into a life expectancy at birth of 51.1 years in males and 
47.0 in females. 
 
UNAIDS estimate the number of AIDS deaths using the Spectrum model (see Figure 2.19). They 
estimated the number of AIDS deaths peaked in early 2000s and it has been declining since, 
with 39,000 (34,000-45,000) AIDS deaths estimated in 2012 (526). 
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Figure 2.19. Annual number of AIDS deaths in Zimbabwe (526) 
 
 
 
2.2.4. Response to HIV: history 
As happened in other countries, the first cases of HIV were met with some denial  by the 
government  and it was  only in 1990 that HIV/AIDS issues were discussed publicly (538).  
Several policies and strategic plan were developed since then: 
• 1987: Emergency Short Term Plan  
• 1993: Mid Term Plan 1  
• 1994-99: Mid Term Plan2 
• 1999: National Policy on HIV and AIDS  
• 2000-04: National HIV and AIDS Strategic Framework 
• 2006-10: Zimbabwe National HIV and AIDS Strategic Plan 
• 2011-15: Zimbabwe National HIV and AIDS Strategic Plan 
 
In 1985, as the first case of HIV was identified, universal screening of blood for HIV before 
transfusion was introduced and in 1987 a one year Emergency Short Term Plan was developed 
to train health personnel on the prevention and containment of HIV and AIDS and to make the 
population more aware of this issue. 
Nevertheless it took six years, until 1993 to release the Mid Term Plan 1 aimed at promoting 
behavioural change especially in target groups, prevention, treatment of STIs and support for 
people living with HIV. The 2nd part of this plan, 5 years long was published in 1994, it 
concentrated on mobilizing non-health sectors to integrate HIV and AIDS issues. 
 
Figure not available due to copyright restrictions 
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Finally in December 1999 a national policy on HIV and AIDS was announced by the 
Government (539), this represented a major change. It sets five precise strategies: 
“ 
1. Establish a multi-sectorial National AIDS Council (NAC) with a clear mandate to ensure 
overall management and co-ordination of the National response to HIV/AIDS 
2. Ensure that HIV/AIDS is recognised and treated as a major priority for political support 
and social and resource mobilization 
3. Ensure that all sectors and organisations integrate HIV/AIDS into their planning and 
programming 
4. Mobilise resources to support the national response to HIV/AIDS/STI 
5. Promote effective monitoring and evaluation of all programmes/projects on 
HIV/AIDS/STI” 
 
Shortly after, the National AIDS Council was created through an Act of Parliament. In 2000 it 
was functioning and developed the National HIV and AIDS Strategic Framework 2000-2004, in 
line with the National Policy, with three main components: 
- Prevention of new HIV infections, through PMTCT (see Appendix VIII), VCT, condom 
distribution, HIV awareness, STIs treatment and maintenance of blood safety. 
- Treatment and care provided for OIs mainly through home-based care 
- Mitigation and support in particular for orphans and vulnerable children in terms of 
food and nutrition, livelihoods, educational and stigma and discrimination control 
As part of the mitigation strategy, in order to partly face the cost of responding to the HIV 
epidemic, the National AIDS Trust Fund (AIDS Levy) was set up: it consisted of a 3% tax on 
employed people and corporate earnings (538). 
In May 2002 the Government declared HIV/AIDS a national emergency, with the long term aim 
of being able to use generic ARVs and in 2004 the national ART programme was launched. 
 
By 2005, it was evident that the HIV prevalence was declining, although still high, and a new 
Zimbabwe National HIV and AIDS Strategic Plan was developed for the period 2006-2010 (540) 
after a thorough review of the achievements and challenges experienced. At that time only 7% 
of those in need of ART were receiving it, only about 20-30% from orphans and vulnerable 
children were benefiting from some form of assistance and 3,000 people were dying every 
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week because of HIV (540). The Zimbabwe National HIV and AIDS Strategic Plan  2006-10 was 
inspired by the principles of considering HIV as an emergency, the importance of tackling 
gender inequality and stigma, the necessity for all stakeholders to collaborate in a multi-
sectorial response, the need for adequate resources, the fundamental of respecting 
commitment to international goals and the requisite to adopt evidence based strategies to 
address the epidemic. In 2006 the Behaviour Change Communication programme (541) was 
launched with the goal of reducing HIV incidence by: 
1. “enabling environment for behavioural change created including through increased 
leadership and gender-equality as well as reduced stigma associated with PLWHA 
[people living with HIV and AIDS] 
2. Increased adoption of safer sexual behaviour and reduction in risk behaviour 
3. Increased utilization of HIV prevention services (T&C [testing and counselling] including 
post-test support, PMTCT, PEP [post-exposure prophylaxis]) 
4. Improved national and sub-national institutional frameworks to address behavioural 
change “ 
The programme covered 26 districts (out of 62) until 2009, but since then it has been 
expanded to cover the entire country. 
 
Zimbabwe, as South Africa, participated at the UN General Assembly in June 2011 to assess 
progress made in the HIV and AIDS response since 2001 and signed the  “Political Declaration 
on HIV and AIDS: Intensifying our Efforts to Eliminate HIV and AIDS”, with concrete goals to 
reach by 2015 (see section 2.1.4).  
These were included in the Zimbabwe National HIV and AIDS Strategic Plan 2011-2015: 
- Reduction of HIV incidence by 50% in adults: from 0.85% (48, 168) in 2009 to 0.435% 
(24,084)  
- Reduction in HIV incidence among children from 30% in 2010 to less than 5% by 2015 
- Reduction in HIV and AIDS related mortality by 38%: from 71,299 (2010) for adults and 
13,393 for children (2009) to 44,205 for adults and 8,304 for children 
- Improvement in efficiency and effectiveness of the national multi-sectorial response: 
improvement in the National Commitments and Policy Instruments rating (not 
described here) from 6.2 in 2010 to 9.0. 
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2.2.5. Awareness of HIV status 
HIV testing in Zimbabwe was initially introduced in 1985 to screen blood for transfusion and 
from 1986 it was used to diagnose hospitalized clinical cases, but in 1999 VCT was still 
available only in Harare (542). Since 1999 the DHSs collected information on whether people 
ever tested for HIV and more recently whether they tested in the last 12 months (see Table 
2.11). In 1999, only 9% of men and 11% of women had ever tested for HIV and this increased 
to respectively 16% of men and 22% of women by 2005-06, still only 7% were tested in the last 
12 months. 
 
The Zimbabwe National HIV and AIDS Strategic Plan 2006-2010 (540) recognized HTC as a 
crucial part of the HIV national response and in 2008 the Zimbabwe National HTC Strategic 
Plan 2008-2010 was adopted, with a clear target: increase the percentage of the Zimbabwean 
population who know their HIV status, from 20% to 85% by 2010. To this purpose the number 
of services offering HTC increased and diversified: HTC were offered in VCT centres, 
outpatients wards and as well in PMTC, STI, TB, family planning community and home-based 
care, etc. (530). In addition, PITC was implemented in 2007 (543)(This reference is not 
available on line, but referenced by (544)) and recommended on top of  the previously 
available VCT, campaigns and outreach activities were conducted at provincial level (530) and, 
starting from April 2011, primary counsellors were allowed to perform HIV testing (545). This 
allowed offering HTC to over 1.7 million people in 2010 and 1.8 in 2011 (530). This substantial 
uptake of HTC was captured as well by the DHS, which reported that 36% of adult men and 
57% of women had ever tested for HIV of which respectively 20% and 34% in the last 12 
months. Similarly the mid-term evaluation of the National Behaviour Change Programme (546) 
reported that 50% of the participants (aged 15 to 44 years) tested for HIV. In 2013 96% of the 
primary healthcare clinics were offering PITC (547). 
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Table 2.11. Levels of HIV testing in Zimbabwe 
Source Year Age % ever tested 
(and received 
results from 
2005-06) 
% tested in the 
last 12 months 
Number 
of people 
tested for 
HIV (in 
million) Males Females Males Females 
DHS (517) 1999 15- 49(f),  54(m) 
years old 
9.2 11.8 - - - 
15-19 years old 2.8 6.1 - - - 
(518) 2005
-06 
15- 49(f), 54(m) 
years old 
16.4 21.7 6.6 6.6 - 
15-19 years old 6.9 12.0 2.9 4.8 - 
(519) 2010
-11 
15- 49(f), 54(m) 
years old 
36.2 57.4 20.4 33.6 - 
15-19 years old 10.3 24.7 7.0 18.4 - 
MIM survey (548) 2009 15-49 years old - 44.9 - - - 
Republic of 
Zimbabwe (530) 
2010 0+ years old - - - - 1.7 
2011 0+ years old - - - - 1.8 
Langhaug (546) 2010 18-44 years old 50 (district with 
NBCP 
programme), 
36% 
(comparison) 
- - - 
Cowan (549)  2011 - 50 75 - - - 
Mabugu (545) 2010 0+ years old 
- 
- 
- - - - 1.4 
2011 - - - - 1.9 
2012 - - - - 1.1 
2013 
(Jan-
Mar) 
- - - - 1.6 
DHS: Demographic and Health Survey; f: female; m: male; MIM: Multiple indicator monitoring; NBCP: National 
behavioural change programme; 
 
2.2.6. Pre-ART care 
Despite the fact that the national guidelines on HTC published in 2005 (550) stressed the need 
to discuss linkage to care following the HIV diagnosis and pointed out that all sites providing 
HTC should have worked out all the possible linkages in the community to help in the referral, 
in 2013 linkage to HIV care was still considered poor and a major challenge to tackle (547). The 
ART programme manager in Zimbabwe pointed out that the major challenges were the fact 
that the clinics are congested, the distance to the clinic and consequently the high transport 
cost, competing priorities, insufficient referral information and limited capacity in term of CD4 
machines (547). 
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To the best of my knowledge there are no data at a national level or from single programmes 
regarding linkage to care in Zimbabwe; three recent systematic reviews did not find any such 
studies (551-553). 
 
2.2.7. ART initiation and procedures to monitor people on ART 
Zimbabwe has released national guidelines on ART since 2005 (227). Those, in line with the 
2003 WHO guidelines for RLS (474), were recommending ART for people with CD4 count <200 
cells/μL or WHO stage 4 disease or CD4 count <350 cells/μL and WHO stage 3 disease and 
provision of CTX for all symptomatic people (WHO stage 2, 3 and 4) and/or CD4 count<200 
cells/μL. 
These were revised in 2010 (228), when the eligibility criteria were modified as follows: 
 CD4 count <350 cells/μL, if CD4 count available, otherwise if WHO stage 3 or 4 are 
present 
 all HIV-positive pregnant women with WHO stage 3 or 4 or CD4 count <350 cells/μL 
 all TB patients irrespective of CD4 count 
 
In November 2013 the Ministry of Health and Child Care launched new guidelines (229) 
following the WHO guidelines published in 2013 (280) recommending ART for people with: 
 CD4 count <500 cells/μL irrespective of WHO clinical stage, with priority to people with 
CD4<350 cells/μL 
 TB patients co-infected with HIV, HIV-positive pregnant and breastfeeding women 
(Option B+), patients co-infected with HBV and in serodifferent relationship; all 
irrespective of CD4 count. 
 
The ART regimens recommended in the Zimbabwe guidelines are summarized in Table 2.12. As 
in many other developing countries, when ART was rolled-out D4T was part of the first-line, 
due to its very low cost. Since April 2011, following WHO recommendation in 2010 (277), 
clinicians in Zimbabwe have been allowed to replace D4T with less toxic drugs, such as TDF in 
adults. By December 2011, 9.5% of adults and adolescents were switched away from D4T (the 
target by 2011 was 20%) (530). The preferred first-line regimen is now composed of TDF, 3TC 
and EFV. 
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Table 2.12. ART regimen lines recommended in Zimbabwe 
Source Line Drugs Notes 
2005 (227) 1a D4T+3TC+NVP - 
1b AZT+3TC+NVP - 
1c D4T+3TC+EFV - 
2a TDF+3TC+LPV-r - 
2010 (228) 1a TDF+3TC+NVP Patients on D4T should be 
moved to this regimen 
1b AZT+3TC+NVP  Monitor patients for anaemia 
2a TDF+3TC*+LPV/r Failing on a AZT-based 1st line 
regimen 
*Can be replaced with FTC 
2b AZT+3TC+LPV/r Failing on a TDF-based 1st line regimen 
2c ABC+ddI+LPV/r or ATZ/r - 
2d TDF+3TC+AZT+LPV/r or 
ATZ/r 
- 
2013 (229) 1a TDF+3TC+EFV  
FDC preferred 
First choice. 
If FDC not available dual 
TDF/3TC and EFV separately 
1b TDF+3TC+NVP Pregnant or breastfeeding 
women already on ART and 
stable should be continued on 
current ART regimen. 
Patients stable on this regimen 
should continue until national 
stock up runs out 
3TC: lamivudine; ABC: abacavir; ATV/r: atazanavir boosted with ritonavir; AZT: zidovudine; d4T: stavudine; ddI: 
didanosine; EFV: efavirenz; FDC: fixed-dose combination; FTC: emtricitabine; LPV/r: lopinavir boosted with ritonavir; 
NVP: nevirapine; TDF: tenofovir;  
 
Once initiated on ART, the patient is seen in the clinic to monitor for ART efficacy and toxicities 
at 2 and 4 weeks since ART initiation and monthly thereafter for another 3 months and 
afterwards, if stable, every 3 months. It is recommended that at these follow-up visits the 
following parameters are monitored: patient weight, WHO clinical stage, development of OIs, 
FBC (every 6 months), ALT (every 12 months), serum creatinine (every 12 months), and if 
available CD4 counts (every 6 months). In practice access to CD4 testing, at least between 2007 
and 2009, was available mainly in district hospitals or higher level facilities and at other sites 
which were initiating people on ART (554).  
Although the national guidelines mention that the ideal would be to monitor the efficacy of 
ART by measuring both CD4 count and VL 6 monthly, in practice the access to VL testing is very 
limited and a study of patients initiating ART between 2007 and 2009 found that more than 
half of the patients did not have a documented CD4 count at ART initiation (554). The 
guidelines reference the DART trial, which took place in Uganda and Zimbabwe (555), where it 
was found that it is safe to clinically monitor people on first-line regimen for toxicities without 
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routine laboratory monitoring (although it is useful when clinically indicated). Regarding the 
efficacy monitoring (CD4 count monitoring in this study), they found that it did provide a 
significant, although small, benefit in terms of disease progression and survival, likely due to 
the earlier identification of treatment failure and thus more timely switch to second-line. They 
reported that these benefits on progression, provided by CD4 monitoring, were seen only from 
the third year on ART, underlining that at least in the first years this is not indispensable. 
However, they found that in the arm receiving CD4 monitoring only 12% switched with a 
VL<400 copies/ml compared to 27% in the arm clinically monitored. They determined that a 
confirmatory CD4 measurement when clinical failure is identified, with confirmed treatment 
failure only if the CD4 is below 250 cells/μL, could identify 80% of those with VL<400 
copies/mL, that therefore are less likely to benefit from switching to second line (556). 
While ART is provided for free to patients, the consultation fee and lab-associated cost, like 
CD4 count, FBC are expected to be paid by the patients (554). 
The guidelines defined treatment failure as either: 
 clinical failure: new or recurrent WHO stage 3 or 4 after at least 6 months on ART 
 immunological: either reduction in CD4 count to pre-ART levels or 80% reduction from 
the on-ART peak or persistent CD4 count <100 cells/μL (in 2005) or <200 cells/μL (in 
2010) 
 virological: VL>5,000 copies/mL 
It is stressed that efforts to understand whether the patient is adherent should be made and 
the decision to switch a person to second-line should not be taken lightly. 
 
2.2.8. Roll out of antiretroviral therapy 
The ART programme was launched in Zimbabwe in 2004 (530), during a socio-economic crisis 
which lasted at least until 2009, with very high levels of recession and hyperinflation. At the 
start, in April 2004, only five sites in the entire country were providing ART and there were 
shortages of health workers and medical supplies due to the crisis (557). Since 2008 both ART 
initiation and follow-up of people on ART have been decentralized to lower level facilities (554) 
and by 2011, 590 sites were providing ART, of which 141 initiating people on ART (530). This 
corresponded with a massive increase in the number of people who could receive ART, (see 
Table 2.13), in particular by 2011 Zimbabwe achieved 80% of ART coverage with 476,000 
people receiving ART (530).  
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Table 2.13. Number of people on ART in Zimbabwe 
Source Year Number of people on 
ART (thousands) 
ART coverage; 
Eligibility if CD4: 
All (0+) Adults <350 cells/μL <200cells/μL 
Global AIDS Response (530) 2004 8 - - - 
2005 24.5 - - - 
2006 66.9 - - 11% 
2007 97.7 - - 26.5% 
2008 148.1 - - - 
2009 219.4 - - 56.1% 
2010 326.2 298.0 - - 
2011 476.3 436.2 79.7% - 
Global fund reports (545) 2010 326.2 - - - 
2011 401.4 440.0 77% - 
2012 558.5 514.7 - - 
2013 593.2 544.2 84% - 
 
2.2.9. Retention on antiretroviral treatment and adherence 
Very limited data are available regarding retention and outcome of patients receiving ART in 
Zimbabwe. Systematic reviews conducted a few years ago evaluating retention on ART (1;2) 
did not find any studies conducted in Zimbabwe; more recently a few studies have been 
conducted, to my knowledge three within ART programmes run by non-governmental 
organizations (NGOs) (558-560) and one is a nationally representative multi-stage 
retrospective cohort study of the national ART programme (554) (see Appendix IX). They all 
reported around 90% retention on ART at 6 months, between 78% (554) and 97% (560) 
retention at 12 months and between 64% (554) and 75% (559) at 3 years. These results are in 
line with the estimates on retention in sub-Saharan Africa (1). 
The Global AIDS progress report for Zimbabwe published in 2012 reported that in 1997 93.1% 
were retained on ART at 1 year since ART initiation, 75% in 2009 and 85.7% in 2010 (530). 
Interestingly the MSF programme in Buhera (560) found that the retention was significantly 
better in the patients initiated on ART in the health centres and among those referred to the 
health centres for follow-up on ART compared to the patients in the hospital, highlighting the 
fact that decentralization could improve retention on ART. Nevertheless it must be borne in 
mind that those who were referred to the health centres were more likely to be stable than 
those still in care at the hospital. 
Dzangare and colleagues assessed whether clinics in Zimbabwe (17 clinics in 2007, 40 in 2008 
and 24 in 2009) were meeting the minimum target of maximum of 20% being LTFU at 1 year 
since ART initiation, as part of monitoring WHO early warning indicators (561). They found that 
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in the 8 clinics with information for all three years the proportion of clinics not meeting this 
target decreased from 70% in 2007 to 33.3% in 2009. The report on drug resistance early 
warning indicators for 2013, including 74 clinics located across all 10 provinces reported that 
23% of the clinics still had  levels of retention below 75% and one of them (1.4%) did not 
collect this information (562). 
 
Adherence to ART in adults living with HIV in Zimbabwe, to my knowledge, has been 
investigated only by the DART trial (563-565). Systematic reviews on adherence conducted a 
few years ago (485;566;567) have not found any studies from Zimbabwe. Within the DART trial 
they initially described the pattern of adherence, using drug possession rate (% of drugs taken 
between visit based on pill count) categorized as complete (if 100%) or good (≥95%) for 
monthly intervals (length of time between pharmacy refills) in almost 3,000 participants either 
in Zimbabwe or Uganda (565). They reported that 90% of the patients had pill counts 
performed at every visit and that the proportion with good adherence increased over time 
from 87% at 4 weeks to 94% at 48 weeks, nevertheless only 49% had good adherence at all 
visits in the first year of ART highlighting the variability of this phenomenon over time. 
 
2.2.10. Virological outcome and development of resistance on first-line regimen 
The only source of data which reported on virological outcome in patients receiving ART in 
Zimbabwe comes from routine cohort monitoring at sentinel sites. This is not surprising given 
that VL is generally not available. Between 2009 and 2011 these sentinel clinics reported that 
10.4% of around 1,000 patients had a VL above 1000 copies/mL at 12 months after ART 
initiation. They found that after excluding those who had resistance at baseline the proportion 
that had acquired HIV drug resistance was 8.9% (reported in the “Report on the National HIV 
Drug Resistance Monitoring at Sentinel sites (2009–2011)” cited by (554)). The nationally 
representative retrospective study conducted by Mutasa-Apollo and colleagues reported that 
only 0.2% of patients (over a median follow-up of 1.4 years) had documented treatment 
failure, based on clinical or immunological monitoring, and were switched to second-line ART 
regimens (554). This is lower than the treatment failure rate of 2.64/100 PYs (95% CI: 1.73, 
3.56) reported by a systematic review for Africa (568) using clinical/immunologic criteria to 
identify people with treatment failure. A few studies evaluating VF and risk of resistance have 
included patients from Zimbabwe, but without presenting the analysis by country (398;569). 
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I could not find any studies which evaluated the outcomes of people on second-line regimens; 
this is probably due to the fact that not many people have been switched to second-line so far. 
 
2.2.11. Circumcision 
As for South Africa, Zimbabwe is one of the priority countries indicated by UNAIDS for scaling 
up VMC (506), with only 10% of the male population circumcised in 2007 (518). It was 
estimated that in order to achieve 80% coverage of VMC, Zimbabwe had to conduct around 
1.9 million VMCs.   
In 2009, a policy on VMC was launched (“Zimbabwe Policy Guidelines on Safe and Voluntary 
Male Circumcision” cited by (530)) and a pilot programme was rolled out in five sites which 
were able to circumcise 2801 males (530). Since then VMC has been available for adolescent 
and adult men through a collaboration between the government and other agencies (“Strategy 
for safe medical male circumcision scale up to support comprehensive HIV prevention in 
Zimbabwe.” cited by (538)) and in 2010 a five-year strategy for VMC was adopted, involving 
traditional circumcisers and by conductive  community mobilization. This allowed a dramatic 
increase in the number of men circumcised in 2010 and 2011, but the target is still out of sight. 
By the end of 2011 only 50,580 VMC (2.6% of the target) were performed (None in 2008, 2801 
in 2009, 11176 in 2010 and 36603 in 2011) (509). 
A further communication strategy for VMC was developed in 2011 and hopefully it will be able 
to mobilize the target population for circumcision (530). 
 
2.3. Brief comparison of the HIV epidemic in South Africa and Zimbabwe 
South Africa, with an estimated population at the last census (2011) of almost 52 million (434) 
is four times the size of Zimbabwe (510). Both these countries experienced a dramatic increase 
in mortality, especially in people aged between 25 and 39 years, mainly caused by the spread 
of HIV. In Zimbabwe it started in the late 1980 in the rural areas and a decade later in the 
urban areas (515), while in South Africa it is documented since the end of 1990s (438) and in 
both countries the peak in mortality was reached in 2005-2006 (438;519). 
National household surveys have been conducted in South Africa and Zimbabwe collecting 
data on self-reported sexual behaviour. The two countries present quite a different profile, 
however it is not clear whether they do reflect real differences in sexual habits or whether 
different attitudes in reporting sexual behaviour. In terms of percentage of people who 
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reported sex before the age of 15: in South Africa among females it remained stable at 5% 
from 2002 to 2012, while among males it was between 11 and 13% between 2002 and 2008 
and it peaked at 17% in 2012 (440); in Zimbabwe, this information was asked to people age 15 
to 19 years old and among males it halved from 7.9% in 1994 to 3.6% in 2011, while among 
females it declined from 5.2% in 1994 to 3.9% in 2011 (519). The condom use at last sex 
increased markedly in South Africa from 2002 to 2008 especially in young people, where it 
reached levels of 85% in men, but it then declined in 2012 (440). In Zimbabwe this information 
was collected only among people 15 to 29 years old and for contacts with non-regular partner, 
so these two pieces of information are not directly comparable. Here, levels between 60 and 
90% were observed among males and between 40 and 90% among females (514). Data on 
intergeneration sex have been collected in people aged 15-19 years old. This has been found 
to double in South Africa from 9.6% in 2005 to 19.8% in 2012, due to an increase in 
intergenerational sex among females (440). Similar pattern was observed in Zimbabwe where 
it increased by 2-fold from 5% in 2005-06 to 15% five years later (519). In an attempt to assess 
the level of concurrency, the number of partners in the last year was collected in South Africa 
and the number of non-regular partners in Zimbabwe. In South Africa, the age group 
characterized by the higher percentage of people reporting more than one partner is the 
group aged 15 to 24 years: an increase from 23% in 2002 to 37% a decade later was observed 
among males while among females it increase from 6% to 9% in the same time frame (440). On 
the contrary, in Zimbabwe in people age 15 to 29 years old a decline seems to have occurred 
between the end of ‘90s and mid-2000 but similarly to South Africa the level reported by males 
was much higher than that reported by females (20%-60% vs 0-20%) (523).  
The HIV epidemics in both Zimbabwe and South Africa are amongst the worst worldwide with 
an estimated prevalence in people aged 15-49 of 18.8% in South Africa in 2012 (440) and of 
14.7% in Zimbabwe in 2011 (526) and 240,000 and 39,000 AIDS deaths in 2012 respectively in 
South Africa (463) and Zimbabwe (526). This epidemic hit Zimbabwe much earlier than in 
South Africa: by 1990 the HIV prevalence in ANC was above 10% in Zimbabwe (528) while in 
South Africa it was still less than 1% (448). In Zimbabwe a decline in HIV prevalence has been 
observed since mid-1990s both in ANCs and household surveys (519), on the other hand in 
South Africa HIV prevalence is still increasing (440). This difference in profile is likely to be due 
to the fact that HIV spread later in South Africa, to the fact that ART, which increases markedly 
life expectancy of people living with HIV, became largely available when the HIV prevalence 
has already peaked in Zimbabwe and to the fact that a reduction in sexual behaviour seems to 
have occurred.  
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The response to this terrible epidemic came quite late in South Africa, only in 2009 the 
government finally recognized this as a major plague and finally in 2010-11 the first major 
achievements were obtained: 95% of women receiving PMTCT, 55% of people in need of ART 
were receiving it(450). In Zimbabwe there was some initial response, such as the introduction 
of universal screening for blood and training for health personnel and the introduction of a tax 
to face the cost of addressing this issue. Unfortunately, a terrible economic crisis hit this 
country and it was only at the UN General Assembly in 2011 that concrete goals were 
established. 
In order to be able to reach HIV care, first of all people need to be aware of their HIV status. 
Over the last few years, HIV testing has increased massively: at the last household survey 
conducted in South Africa in 2012, 65% of the population reported ever testing for HIV and 
43% testing in the last year (440), in Zimbabwe at the last DHS conducted in 2011, 36% and 
57% respectively of male and female reported ever testing, of which 20% and 34% in the last 
year (519). However linkage to care remains poor in South Africa and in Zimbabwe no data are 
available. The eligibility criteria to be eligible for ART differ between the two countries: a 
threshold of CD4<350 cells/μL is currently used in South Africa (226) while in  Zimbabwe this 
has been moved to 500 cells/μL (229). The coverage of ART was estimated to be 79% in 2011 
in South Africa, when considering people with CD4<200 cells/μL as eligible, but only 52% when 
considering a threshold of 350 cells/μL, while in Zimbabwe using this latter threshold the 
coverage has been estimated to 80% in 2011 (530). In both countries, programmes reported 
level of retention around 90% at one year, but the data are not available at national level and 
very few studies are available for Zimbabwe.  Self-reported adherence to the therapy has been 
observed to be very high in the few programmes which collected this information; however 
there is evidence that this measure of adherence is biased. Virological response has been 
reported to be relatively good in South Africa with proportion of the population suppressed at 
one year since ART initiation up to 96% (307), although levels as low as 66% have been 
observed (304). At five years levels of suppression as high as 84% were reported (292). As VL 
monitoring is not available in Zimbabwe data on this piece of information are very rare.  
Finally, both countries committed to reach 80% circumcision coverage (507), but by the end of 
2011 only 10.2% and 2.6% of the target was reached respectively in South Africa and 
Zimbabwe (509). Since then VMC campaigns have been launched and in South Africa there is 
evidence that a large number of men have been circumcised (423).   
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3. HIV Synthesis heterosexual transmission model 
 
3.1. Introduction 
This chapter aims to present in detail the HIV Synthesis transmission model and the method 
use to calibrate the model to the South African and Zimbabwean HIV epidemics, but first of all 
it is worth considering which other approaches could have been used to address this PhD 
research question and what are the main types of mathematical models for infectious 
diseases. The goal of this thesis is to assess the long term effect on HIV incidence, mortality 
and spread of resistance of different public health actions to curb the HIV epidemic in South 
Africa and Zimbabwe. The gold standard type of study to address this question is a randomized 
controlled trial, but it is not feasible or ethical to conduct trials involving such a large number 
of people (we evaluated the impact at national level), for such a long length of time and at a 
very high cost. For this reason, mathematical models are used. They combine epidemiological 
data with infectious disease theory and assumptions about future circumstances to make 
projections on the HIV epidemic. 
Mathematical models for infectious diseases can be divided in two main categories: 
deterministic and stochastic models. The former determine what happens on average in a 
population; therefore, given a set of input parameters, the results are going to be exactly the 
same, each time the model is run. On the contrary, in the stochastic model chance is 
incorporated and for each agent (in this case person) in the model there is a certain probability 
that a person becomes infected and/or move through different stages of the disease, thus 
given a certain set of parameters the model will provide the range in which an outcome can 
occur. 
Deterministic models are usually compartmental models, which means that the population is 
divided in subgroups based on whether they are infected with the disease or not, their disease 
stage, sometimes whether they belong to different risk groups, etc. To determine the dynamic 
of such models difference or differential equations can be used, the former illustrate the 
transitions between different compartments, by determining the number of people in a 
certain compartment at time t, based on the number in that compartment at time t-1. 
Stochastic models are usually individual-based models, as it is the case for the Synthesis 
model, which means that the model tracks the infection process for each individual. 
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Mathematical models can be divided as well in dynamic transmission models, if they include 
the process of people having contact between each other’s (and thus risk of transmitting the 
disease) and static models, if they do not model contacts and the force of infection is 
predetermined. In addition, there are network models which explicitly model the network of 
contacts. 
The HIV Synthesis heterosexual transmission model is an individual-based stochastic model of 
heterosexual transmission, progression and treatment of HIV infection.  The progression part 
of the model was originally created by Phillips and colleagues to reconstruct the HIV-infected 
population in the UK (570) and it was then developed further to include the dynamic process 
of HIV transmission and to be able to simulate a generalised heterosexual HIV epidemic (571).  
The aim of this model is to capture all the elements (e.g. sexual risk behaviour, HIV testing, 
PHI, VL, CD4 cell count, use of ART, adherence, resistance, drug failure, drug interruption, 
LTFU, occurrence of AIDS, non-AIDS death, etc.) for which we have a reasonable understanding 
of the underlying processes, based on data from clinical trials and observational studies, 
although not always from a sub-Saharan African setting. 
When I started working on the Synthesis model, it was already a dynamic model simulating a 
generalized heterosexual HIV epidemic. However, both the progression and the transmission 
components have been developed further since the first publication, with my input, due to a 
complete re-evaluation of every parameter value and also some small additions to the model 
structure. In particular, I calibrated the model to specific settings such as South Africa and 
Zimbabwe and I developed sections of the model needed to address the questions of my 
research interest. I introduced the process of HIV testing in women attending ANC and for the 
general population; for the version of the model calibrated to Zimbabwe an age and gender-
specific HIV testing process has been included, with the possibility of testing using ST. 
Regarding the pathway of care, I amended the model to capture all the steps HIV patients 
needs to go through and to be able to prepare outputs in the metrics agreed by the HIV 
Modelling Consortium. In addition, I added circumcision in the model, as VMC was 
demonstrated to be an effective prevention tool and both South African and Zimbabwe are 
now rolling it out.  Finally I included in the Synthesis model the possibility of using PrEP, its 
efficacy in reducing the risk of HIV acquisition and also the risk of acquiring resistance in 
people who are infected with HIV while on PrEP.  Because I contributed in developing the full 
model and I contributed to manuscripts published in peer-reviewed journals, sections of this 
chapter are part of the supplementary material of papers published in the literature on the 
Synthesis heterosexual transmission model (571-573). 
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In brief, the HIV Synthesis transmission model generates the life course of a random sample of 
all adult individuals in a population, for whom data are updated in 3 month periods. Most of 
the mathematical models are updated daily, in order to better capture concurrency and thus 
the instantaneous risk of transmission. Unfortunately, I could not reduce the time step, 
because of the time length the model takes to produce simulations. This certainly represents a 
limitation, however especially once the epidemic is established the model has been 
demonstrated to provide reasonable estimates. Each person in the model is simulated from 
the age of 15 years (before this age the only variable updated is age), when they are assumed 
to be potentially sexually active and they are followed until either death, or to any given 
calendar year of interest. For each simulated person, the model generates variables such as 
age, gender, calendar date, circumcision, whether they had an HIV test and variables 
characterizing the sexual behaviour: number of condom-less sex short-term (e.g. casual) 
partners and presence of a condom-less long-term (e.g. primary) partner. For HIV-infected 
people the main variables modelled are: PHI (a period of raised infectivity of 3 months 
duration), VL, CD4 cell count, presence of specific DRMs, HIV diagnosis, whether the person 
has been linked to care and retained in pre-ART care and after initiating ART, the antiretroviral 
regimen the person is currently on, adherence to ART and risk of AIDS and death. The 
progression model has been shown to provide a generally close fit to observed data relating to 
the natural progression and therapy outcomes (570;574;575). Given the richness of data in the 
literature on the progression of the disease in absence of ART and the impact of treatment on 
the progression and the use of objective measures to measure these phenomenons, I am quite 
confident about the parameters related to it. On the contrary, data on sexual behaviour are 
less often collected and although national survey are now asking information on this regard, 
there is evidence that they are heavily affected by desirability bias. Therefore I feel more 
uncertain about the parameters on sexual behaviour included in the Synthesis model.  
 
 
3.2. Demographic model 
Heterosexual transmission is the predominant mode of HIV transmission in both South Africa 
(452) and Zimbabwe (530). The epidemic is assumed to have started in 1989, close to when 
the first heterosexual AIDS cases were reported in South Africa (1987)(445) and Zimbabwe 
(1985)(525). The model runs for 45 years, with variables updated every 3 months. Each run of 
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the model simulates a cohort of 100,000 individuals, of which approximately 34,000 alive and 
aged between 15 and 65 years in 1989.  
 
3.2.1. Determination of age in 1989 and general population death rates 
The initial age and gender distribution for South Africa (see Table 3.1) is determined on the 
basis of the South African Census conducted in 1996 (576), because this is the first South Africa 
census where information was collected for all of South Africa. 48.2% of the South African 
population is assumed to be male. For Zimbabwe the distribution has been chosen so that it 
reflects the age distribution in 2015, when I want to evaluate the introduction of ST (see 
Chapter 8). The age distribution when the HIV epidemic is assumed started does not perfectly 
match with the age distribution reported for 1995 (577)(The closest in time age distribution I 
could find).  I will modify this for future work on the Zimbabwe model.  
The table below shows the age distribution of people within gender. The actual age of a person 
in a given a 10 year age group in 1989 is determined by sampling from a Uniform distribution. 
This means that, although it is taken into account the fact that the younger 10-year age groups 
represent a greater proportion of the population than the older age groups, due to increasing 
death rate as age increases (when not considering infant mortality), the model does not take 
into account the fact that the cohort of people aged 15 years old is going to be slightly bigger 
than the cohort of 16 years old, etc.. This is clearly an approximation; however it allows 
capturing the gender-specific age group distribution.   
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Table 3.1. Model assumptions on population age distribution 
 
Age group South Africa Zimbabwe 
Probability of 
being in age 
group in 1989 
Distribution of 
people aged 15-
65 years 
Probability of 
being in age 
group in 1989 
Distribution of 
people aged 15-
65 years 
Males 
(-35 - -24) - - 0.16075 - 
(-25 - -14) - - 0.14725 - 
(-15 - -4) - - 0.13375 - 
(-5 – 4) - - 0.12025 - 
(5 - 14) - - 0.10675 - 
(-30 - 14) 0.733 - - - 
(15 - 24) 0.091 0.34 0.09325 0.28 
(25 - 34) 0.072 0.27 0.07975 0.24 
(35 - 44) 0.067 0.20 0.0625 0.19 
(45 - 54) 0.053 0.12 0.05275 0.16 
(55 - 64) 0.019 0.07 0.03925 0.12 
Females   
(-35 - -24) - - 0.16075 - 
(-25 - -14) - - 0.14725 - 
(-15 - -4) - - 0.13375 - 
(-5 - 4) - - 0.12025 - 
(5 - 14) - - 0.10675 - 
(-30 - 14) 0.716  - - 
(15 - 24) 0.094 0.33 0.09325 0.28 
(25 - 34) 0.077 0.27 0.07975 0.24 
(35 - 44) 0.054 0.19 0.0625 0.19 
(45 - 54) 0.034 0.12 0.05275 0.16 
(55 – 64) 0.025 0.09 0.03925 0.12 
 
Those distributions are chosen to reflect the growth in population seen in both countries, 
more dramatic in Zimbabwe than in South Africa (433;510;576;578). In the table above it is 
indicated that for Zimbabwe the cohort of people entering the age group 15-24 is increasing 
over time (for example the probability of being in the group of age indicated as minus 35 to 
minus 24, which are going to be age 15-24 in 2039, is higher than those age minus 25 to minus 
14) (see Appendix VIII). This is not the case for South Africa, where it is assumed the number of 
people entering the age group 15 to 24 is constant, likely due mainly to an improvement in 
survival to 15 years of age, rather than increase in fertility (See Appendix IV ).   
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However the ART availability and other health intervention are prolonging life expectancy in 
South Africa increasing the population size. 
 
The only variable that is modelled and updated up to reaching the age of 15 is age itself.  The 
“youngest” person in 1989 is age -30 for South Africa (i.e. will be born in 2019 and reach age 
15 in 2034, when the modelled period ends) and -35 for Zimbabwe. This is due to the fact that 
the introduction of ST in Zimbabwe is assumed to occur in 2015, while the interventions began 
in South Africa in 2013.  
 
In each point in time, each individual (whether HIV-positive or not) has an underlying age and 
gender specific probability of dying (see Table 3.2).  
 
Table 3.2. Assumptions regarding  age and gender specific death rates (per 1,000 person-
years) in people without HIV based on (437;516) 
Age group Death rates (per 1,000 person-years) 
Males Females 
15-19 2 1.5 
20-24 3.2 2.8 
25-29 5.8 4.0 
30-34 7.5 4.0 
35-39 8.0 4.2 
40-44 10.0 5.5 
45-49 12.0 7.5 
50-54 19.0 11.0 
55-59 25.0 15.0 
60-64 35.0 21.0 
65-69 45.0 30.0 
70-74 55.0 38.0 
74-79 65.0 50.0 
80-84 100.0 70.0 
85 or more 400.0 150.0 
 
These underlying age and gender specific death rates  reflect broadly those estimated in South 
Africa in 1997 (437) (see 2.1.1.3) and in Zimbabwe in 1994 (516) (see 2.2.1.3), before the 
significant impact of HIV-related deaths. HIV-infected people will have an additional 
probability of dying from HIV related causes, as described in section 3.12.3. 
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3.3. Model of sexual behaviour and risk of HIV acquisition 
In this model, the sexual behaviour is characterized by two variables representing, 
respectively, the number of “short-term” or “casual” partners a person has sex with in the 3 
month period without using condom, from this point onwards called condom-less short-term 
(CLST) partners and whether the person has a current “long-term” or “main” partner the 
person has sex with without condom in each 3 month period, referred to as condom-less long-
term (CLLT) partner.  The status of CLLT partners is tracked over time (i.e. if they are infected, 
diagnosed, on ART, etc.).  CLST partners are not tracked over time, in that if a person has a 
CLST partner in time period t who is infected with HIV, this is independent of the probability 
that any short-term partner in time t+1 is infected with HIV.   
This model does not distinguish between whether a person had sex with a person using 
condom effectively or did not have sex, because it assumes that if correctly used condoms are 
100% effective in preventing HIV transmission. Condom break can be treated as no condom 
use. It is assumed that HIV transmission only takes place via condom-less sex, therefore only 
partners with whom subjects have sex  without using a condom are taken into account.  
 
The risk behaviour is mainly determined by the level of condom-less sexual contacts required 
to produce an epidemic as described.  Although some data on sexual behaviour for both 
countries are available (452;516-520;579), these data are often affected by social desirability 
bias and recall bias. Sexual risk behaviour tends to be under-reported particularly in women 
and higher levels of behaviour have to be assumed to generate epidemic of the proportions 
observed (443;452;518;519).  In addition, even if these data were not biased, it would be 
impossible to directly calibrate the Synthesis model (i.e. simply use values from the data as 
parameter values in the model) to these data because the number of sexual partners people 
have condom-less sex with is not usually collected.  
Both, the HSRC surveys for South Africa and the DHSs for Zimbabwe collect information on age 
of sexual debut among people aged 15-24 years and they reported that maximum around 10% 
had sex before the age of 15 years (see sections 2.1.2.1 and 2.2.2.1.) and no data are available 
on the age of first condom-less sex act. For simplicity the model assumes the minimum age of 
sexual debut is 15 years old. Since 2005 both HSRC surveys in South Africa and DHSs in 
Zimbabwe have collected data on age difference between sexual partners in people aged 15 to 
19 years (see sections 2.1.2.3 and 2.2.2.5). In this model the CLLT partner is assumed to be in 
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the same 10 year age-category, while CLST partners can belong to different age groups, as 
illustrated in the age-mixing matrix (see Table 3.6 at page 154). 
 
The parameter values relating to sexual behaviour are therefore derived by running the model 
several times sampling the parameters for the sexual behaviour and transmission rate from 
distributions (see Appendix XI), compare the model outputs to observed data, including HIV 
prevalence (see section 3.13), and select the set of parameters which minimize the distance 
between the simulations produced by the Synthesis model and the data from the literature.  
 
In this model five parameters determine the sexual behaviour:  
 the relative average sexual behaviour (newp_factor) 
 the skewness in the distribution of number of condom-less partners (determined by 
swn and highsa)  
 the rate with which new CLLT partnerships are formed (eprate), 
 the proportions of people who have a lifetime reduced likelihood of CLST partners (the 
proportion who experience very low sexual behaviour, p_rred_p) 
Several structures for the risk behavioural model (RBM) (combination of distribution of 
parameters) have been identified and the distributions indicated in Appendix X. 
 
3.3.1. Determination of number of condom-less short-term partners at period t 
The numbers of CLST partners is assumed to depend on gender, age, propensity to be sexually 
active, experiencing an AIDS defining condition, being diagnosed with HIV and change in risk 
behaviour in the general population. 
In a given 3-month period, the number of CLST partners is generated at random, according to 
which of four risk behaviour groups the person was in for the previous period. The four groups 
are:  
 zero CLST partners,  
 one CLST partner,  
 Medium: 2-10 CLST partners,  
 High: 10 or more CLST partners 
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The initial distribution is sampled among the distributions indicated in Appendix X Table A4 
(page 390). Each individual can transit from one of these categories, i.e. partner group 𝑖 at 
time 𝑡 − 1, to partner group 𝑗 based on transition probabilities 𝑝𝑔𝑖𝑗𝑎, given by: 
𝑝𝑔𝑖𝑗𝑎 =
𝑓𝑔,𝑖,𝑗 × 𝑟𝑔,𝑎
(𝑓𝑔,𝑖,1 + ∑ (𝑓𝑔,𝑖,𝑗 ∙ 𝑟𝑔,𝑎)
4
𝑗=2 )
  
Where: 
 g = 0, 1 for males, females, respectively,  
 a = 1-10 for age groups 15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 55-, 60-, respectively.  
 i=1-4 for the risk behaviour group 0, 1, 2-10, ≥10 CLST partner at time  𝑡 − 1, 
 j= 1-4 for the risk behaviour group 0, 1, 2-10, ≥10 CLST partner at time 𝑡 
Values of 𝑟𝑔𝑎 , determining relative level of sexual risk activity with CLST partners and 𝑓𝑔𝑖𝑗, the 
values determining probability of transitioning between CLST partner risk behaviour groups are 
given respectively in Table 3.4 at page 153 (table A4 at page 390 in Appendix X for alternative 
RBMs) and Table 3.5 at page 153 (table A5 at page 391 in Appendix X for alternative RBMs), 
respectively, and if j=1 then 𝑟𝑔𝑎=1. 
 
Values of 𝑟𝑔𝑎 are modified at time t by the following factors: 
 0.01 if the subject belongs to that subset of people who experience only very low 
sexual risk activity (i.e. with CLST partners) in their life (Random 35% of men and 50% 
of women, p_rred_p; See table A6 at page 393 in Appendix X for values of alternative 
RBMs)  
 0.2 if the subject has a current AIDS defining disease  
 0.83 (the actual value is ch_risk_diag_newp, sampled from the distribution indicated 
in the Appendix X) if the subject has been diagnosed with HIV in the last 6 months and 
by its square root afterwards.   
 The change in risk behaviour in the general population, which has been observed in 
both South Africa and Zimbabwe (and needs to be invoked in order to explain 
stabilisation and decline in incidence), is parameterized slightly differently for the two 
countries (this does not reflect a perceived difference in the two epidemics but rather 
choice between two alternative parameterization approaches):  
- In South Africa it is assumed it occurred in two phases: the first started between 
1992 and end of 1998 (date_ch_risk_beh, the value is sampled from a Uniform 
distribution) and finishes between 1999 and end of 2005 (date_ch_risk_beh_2, 
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the value is sampled from a Uniform distribution), the second phase finished 
between 2006 and end of 2009 (date_ch_risk_beh_3, the value is sampled from a 
Uniform distribution). The rate of annual decrease in risk behaviour for the first 
(rate_ch_risk_beh) and the second phase (rate_ch_risk_beh_2) are sampled from 
the distribution indicated in the Appendix XI, up to a maximum reduction of 0.95.  
Afterwards no change in risk behaviour is assumed (apart from changes as 
indicated above due to HIV diagnosis, etc.).  
- In Zimbabwe a certain threshold high HIV prevalence triggers the change in sexual 
behaviour (See section 3.3.2). 
 factor which is sampled in each simulation and changes the overall average level of 
condom-less sex with CLST partners (newp_factor) 
 
Actual transition probabilities between risk behaviour groups for each individual were 
determined by random sampling.  For the first two groups the number of partners in the 
period is given (i.e. no CLST partners, 1 CLST partner, respectively).  When a person was in the 
medium CLST partners group (2-9 CLST partners in a 3 month period), the number of partners 
is determined by sampling from a Poisson distribution with mean 1.5 for South Africa and 4.5 
for Zimbabwe (parameter called highsa). When the transition is to > 10 CLST partners the 
number of partners is determined by sampling from a Poisson distribution with mean 2 and 
multiplied by the parameter swn (the value is sampled from the distribution indicated in the 
Appendix XI) that determine the skewness of this distribution. 
 
3.3.2. Determination of having a condom-less long-term partner at period t 
As for short-term partners, only condom-less sex long-term partnerships are modelled. Thus if 
a person has a long-term partner but condoms are used on all occasions of sexual intercourse 
in a specific 3-month period then this is not counted as having a CLLT partner  for that period. 
In 1989, before any population level reductions in risk behaviour and without widespread 
availability of condoms, around 60% of the population is assumed to have a CLLT partner (See 
Appendix X Table A8 at page 394 for details). Data from the South African census in 2001(580) 
report that around 40% of the adult population was married and 5% cohabiting but not 
married, while in Zimbabwe in 1989, 63% of the population was considered married (520). 
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At each period, people with no current CLLT partner have age-dependent probabilities of 
starting having sex without using condom with a long-term partner as indicated in Table 3.8 at 
page 154 (Appendix X table A8 at page 394 for alternative RBMs). This can be due to (re-
)starting having condom-less with an existing long-term partner or starting a new partnership 
which involves condom-less sex. 
At the time a CLLT partnership is started, it is classified into 3 duration groups, each with a 
different tendency to endure.  The percent of people in each group is dependent on age and is 
shown in  
 
Table 3.7 (page 154); all the age groups have a 30% chance of having a CLST partnership of the 
shortest duration considered, but the older they are the less likely they are to have the highest 
probability of continuing the relationship (category 3). 
 
The status of the partner is not directly simulated. If the subject in the cohort simulated dis the 
relationship end and if the partner dies, this will be taken care by the length of relationship 
and by the fact that that the proportion of partnership formed by partners is balanced to the 
proportion of partnerships formed and ending by the subjects in the cohort simulated. 
 
At time period t, for people with a CLLT partner, the probability of the partnership continuing 
is: 
- 1 − (0.25 𝑐ℎ_𝑟𝑖𝑠𝑘_𝑏𝑒ℎ_𝑒𝑝⁄ ) if duration category is 1,  
- 1 − (0.05 𝑐ℎ_𝑟𝑖𝑠𝑘_𝑏𝑒ℎ_𝑒𝑝⁄ ) if duration category is 2,  
- 1 − (0.02 𝑐ℎ_𝑟𝑖𝑠𝑘_𝑏𝑒ℎ_𝑒𝑝⁄ ) if duration category is 3 
Where ch_risk_beh_ep is a parameter conveying the population level change in sexual 
behaviour with long-term partners that can occur (distribution indicated in the Appendix XI). 
In the South African epidemic, the date at which it is assumed a change in sexual behaviour in 
the population initiated (condom became more widely available) is indicated by the parameter 
date_ch_risk_beh. Before this date the parameter ch_risk_beh_ep assumes value of 1. After 
date_ch_risk_beh, the duration of these condom-less sex relationships is reduced, if 
ch_risk_beh_ep assumes value <1 (see distribution in Appendix XI). 
146 
 
In the Zimbabwean model, the change in sexual behaviour occurs at a certain date, triggered 
by an HIV prevalence above a certain threshold (sample from a Uniform distribution between 
0.1 and 0.4, the parameter is called prev_threshold_rb_change).  
 
Further, the probability of having a CLLT partner is reduced by a factor ch_risk_diag in the 3 
month period after a CLLT partner’s diagnosis, if a CLLT partner has HIV and is diagnosed (see 
distribution in Appendix XI). 
 
3.3.3. Determination of number of condom-less short-term partners who are HIV-
infected at time t 
For each CLST partner that a subject has at time t, the probability that the partner is infected is 
calculated.  This is dependent on the prevalence of HIV in those of the opposite gender, taking 
consideration of age mixing.  If the subject is of gender g and age group a, then for each CLST 
partner the first step is to determining by random sampling the age group of each given  CLST 
partner, ?̃? (in fact, for simplicity, all CLST partners at time t are assumed to be in this same age 
group).  The gender and age mixing probabilities (i.e. the proportion of CLST partnerships 
formed by men in age group am which are with females of age group af (𝑧𝑎𝑚,𝑎𝑓) and the 
proportion of CLST partnerships formed by females in age group af which are with men of age 
group am (𝑧𝑎𝑓,𝑎𝑚)) used to determine this are given by values in Table 3.6 (page 154). 
 
Then, for the given partner (of gender 1-g and age group ,?̃?), the probability that the partner is 
infected is then given by: 
𝑏 = 𝑃(ℎ𝑔,𝑎,𝑡 = 1|𝑥 = 1 − 𝑔, 𝑎𝑔𝑒𝑝 =  ?̃?) =
∑ 𝑆𝑖𝐿?̃?,1−𝑔,𝑡−1,𝑖𝑖
∑ 𝐿?̃?,1−𝑔,𝑡−1,𝑖𝑖
 
Where {
𝑆𝑖 = 1 𝑖𝑓 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑖𝑠 𝐻𝐼𝑉 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑆𝑖 = 0 𝑖𝑓 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑖𝑠 𝐻𝐼𝑉 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒
 
and: 
 ℎ𝑔,𝑎,𝑡 is the HIV status (1=yes, 0=no) of the CLST partner of a subject of gender g and 
age a at time t 
 x is the gender of the CLST partner, which is always the opposite, given the Synthesis 
model include only heterosexual relationships  
 ?̃? is the age group of the CLST partner 
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 𝐿?̃?,1−𝑔,𝑡−1,𝑖is the number of CLST partnerships had by person i, of age group ?̃? and 
gender 1-g in time period t-1 
 i is summed over all people of gender 1-g and age strata ?̃? 
The numerator is the total number of CLST partnerships had by people HIV-positive of the 
opposite gender in age group ?̃? at time t-1, while the denominator is the total number of CLST 
partnerships had by people of the opposite gender in age group ?̃? at time t-1 (regardless of HIV 
status). 
 
Since I assume that all CLST partners at time t are from this same age group, the total number 
of infected CLST partners that the subject i has at time t, 𝐿𝑖,𝑡,ℎ=1, is then given by: 
𝐿𝑖,𝑡,ℎ=1 = 𝑀𝑖𝑛(𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝑏𝑡 ∗ 𝐿𝑖,𝑡), 𝐿𝑖,𝑡) 
The distribution of numbers of partners by age and gender, before introduction of HIV, is 
illustrated for one example epidemic in Table 3.10 (page 156) and Table 3.11 (page 156). 
 
Apart from the age mixing, the sexual contacts are assumed to be practicly random mixing 
because there is not a higher likelihood of people with a higher number of short-term partners 
to have relationships with people with a higher level of partnerships and therefore more likely 
to have HIV.  
 
3.3.4. Determination of probability that a condom-less long-term partner is HIV-
infected at time t 
𝐸𝑡   indicates whether the subject has a CLLT partner at time t (𝐸𝑡 = 1 means that the subject 
has 1 CLLT partnership at time t, 𝐸𝑡 = 0 that the subject does not have CLLT partnership at 
time t). 
𝐻𝑡 indicates whether the subject has a CLLT partner at time t who is infected with HIV (𝐻𝑡 =
1 if infected with HIV, else  𝐻𝑡 = 0). A long-term partner at time t can be infected either 
because:  
i. a new CLLT partnership has been formed and the partner was already infected with 
HIV, 
ii. because a CLLT partner at t-1, which has remained a CLLT partner at time t, has 
become infected with HIV, or  
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iii. because a CLLT infected partner has remained as a CLLT partner. 
 
For (i): 𝐻𝑡 = 1 if 𝐿𝑖,𝑡−1,ℎ=1 ≥ 1 (i.e. if the subject had at least one CLST partner at time t-1 who 
was infected with HIV, then it is assumed that the new CLLT partner at time t is infected)  
 
For (ii): The probability that a CLLT partner of a subject of age group a and gender g becomes 
infected is dependent first of all on whether the long-term partner is “monogamous” (i.e. this 
is the only condomless relationship, long-term or short-term, the long-term partner has) or 
not. Based on the age and gender of the partner, it is determined whether the long-term 
partner is monogamous by sampling from a Binomial distributions with probability the 
proportion of people with monogamous relationships (only one long-term partner and no 
short term partners at time t). 
If the long-term partner is not monogamous, the probability of becoming infected with HIV is 
derived from the HIV incidence at t-1 for age group a (it is assumed the CLLT partner belong to 
the same 10 year age group) and gender 1-g among the sexually active population, either with 
a CLLT partner or at least one CLST partner, indicated as 𝑖𝑎,(1−𝑔),(𝑡−1) (which is given by the 
number of subjects newly infected in age group at time t-1 divided by the number of HIV-
uninfected subjects in age group at t-1,  who had condom-less relationships, either CLLT or 
CLST)  
{
𝐻𝑡 = 1, 𝑈 < 𝑖𝑎,(1−𝑔),(𝑡−1)  where 𝑈 randomly sampled from 𝑈𝑛𝑖𝑓𝑜𝑟𝑚(0,1)
𝐻𝑡 = 0, otherwise
 
If the long-term partner is monogamous, (s)he can be infected only from the subject the 
relationship is with and this is determined by taking into account the VL of the subject and 
applying the probability of transmission listed in section 3.3.5. 
In order to maintain the balance, for each gender, between the number of uninfected people 
with a CLLT partner who is infected, and the number of infected people with a CLLT partner 
who is uninfected, this incidence 𝑖𝑎(1−𝑔)(𝑡−1) is modified at time t depending on the degree of 
balance at time t-1.   
 
For (iii): If 𝐻𝑡−1 = 1  and 𝐸𝑡 ≥ 1  then assign  𝐻𝑡 = 1   
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3.3.5. Determination of the risk of infection from a condom-less short-term 
partner 
For each HIV-infected CLST partner of a subject of gender g and age group a, the VL group v of 
the partner is obtained by sampling from the VL distribution of those of the opposite gender.  
Thus I sample from Uniform(0,1), where the probability of the partner having VL in group v is 
given by:   
∑ 𝑆𝑖𝐿1−𝑔,𝑡−1,𝑖,𝑣𝑖
∑ 𝑆𝑖𝐿1−𝑔,𝑡−1,𝑖,𝑣𝑣,𝑖
 
where the numerator is the total number of CLST partnerships had by  HIV-infected subjects in 
VL group v and the denominator is the total number of CLST partnerships had by HIV-infected 
subjects (in any VL group).   
 
Table 3.3 shows the rate of transmission per 3 months, tv, by VL group of the infected partner, 
v. 
 
Table 3.3. Probability of transmission per 3 month period assumed in the model (43) 
Viral load group of the partner (v) tv 
< 2.7 log copies/mL Normal (tr_rate_undetec_vl,0.000025) 
2.7-3.7 log copies/mL Normal (0.01,0.0025) 
3.7-4.7 log copies/mL Normal (0.03,0.0075) 
4.7-5.7 log copies/mL Normal (0.06,0.015) 
≥5.7 log copies/mL Normal (0.1,0.025) 
Primary infection Normal (tr_rate_primary,0.075) 
 
The probabilities of transmission indicated in Table 3.3 are based on the estimates by 
Hollingsworth et al. (43) and are the rate of transmission per 3 months from a CLLT partner. 
Realization of whether the subject is infected by each CLST partner is determined by sampling 
from Uniform(0,1). These probabilities are increased by: 
- fold_tr_newp fold, if it is a CLST partnership due to the assumed lower number of sex 
acts 
- fold_change_w fold for female subjects aged ≥ 20 years  
- fold_change_yw fold for women aged < 20 years 
- fold_circ fold, if the subject is a man who is circumcised (420-422). 
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- fold_change_sti fold, if the person has an existing STI. The risk of a new STI in any one 
three month period is given by the number of CLST partners divided by 20 (or 1 if > 20 
CLST partners)) (581-583).  
See distribution of the parameters mentioned in Appendix XI. 
 
Prevalence of circumcision in men (parameter prev_circ) is assumed to be 42% in South African 
(508) and 10% in Zimbabwe (518), and it is assumed VMC is rolled out between 2008 (this 
parameter is indicated as mc_int) and the end of 2012, with an annual increase in the 
probability of having VMC of incr_anprob_circ, in men not diagnosed with HIV, to give a 
number of men with VMC which reflects its roll-out (509). 
 
Uncertainty in the transmission rate for different VL groups (except for the rate of transmission 
in PHI, and the rate of transmission when plasma VL is < 500 copies/mL) is incorporated by 
sampling for each epidemic (run of the model program) the parameter fold_tr (See distribution 
in Appendix XI), by which the transmission rate is multiplied. Uncertainty in the rate of 
transmission during PHI and when plasma VL < 500 copies/mL is incorporated by sampling 
respectively a value of the parameter tr_rate_primary and tr_rate_undetec_vl for each 
epidemic (See distribution in Appendix XI).  
 
I assume that super-infection can occur (i.e. a person can be re-infected with HIV with 
consequent risk of acquiring new mutations) (396), in the same way as HIV infection occurs in 
the first place.  
 
3.3.6. Determination of the risk of infection from a condom-less long-term partner 
Infected CLLT partners at time t are classified by whether they are in PHI (if infection occurred 
at time t-1), whether they are diagnosed with HIV, whether they are on ART, and whether their 
current VL is < 2.7 log copies/mL.   
The proportion of CLLT partners with HIV who have HIV diagnosed at time t, 𝛿𝑡  is determined 
with reference to the difference,𝑑𝑡−1, in the proportion of subjects with HIV who are 
diagnosed with HIV, 
∑ 𝐷𝑖,𝑡−1𝑇𝑖,𝑡−1𝑖
∑ 𝑇𝑖,𝑡−1𝑖
 and 𝛿𝑡−1;  
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𝑑𝑡−1 =
∑ 𝐷𝑖,𝑡−1𝑇𝑖,𝑡−1𝑖
∑ 𝑇𝑖,𝑡−1𝑖
− 𝛿𝑡−1 
Where, ∑ 𝐷𝑖,𝑡−1𝑇𝑖,𝑡−1𝑖  is the total number of subjects diagnosed with HIV at time t-1 and 
∑ 𝑇𝑖,𝑡−1𝑖  is the total number of subjects with HIV (diagnosed and undiagnosed) at time t-1.   
For the model calibrated to Zimbabwe        {
if 0 < 𝑑𝑡−1 ≤ 0.05  then 𝛿𝑡 = 0.4
if 0.05 < 𝑑𝑡−1 ≤ 0.10 then 𝛿𝑡 = 0.5
if 0.10 < 𝑑𝑡−1 ≤ 0.15  then 𝛿𝑡 = 0.9
if 0.15 < 𝑑𝑡−1  then 𝛿𝑡 = 0.95
 
For the model calibrated to South Africa      {if 𝑑𝑡−1 > 0  then 𝛿𝑡 = 𝑑𝑡−1 
 
The proportion of those diagnosed who are on ART and the proportion of those on ART who 
have VL<2.7 log copies/mL are determined in a similar manner. In this way the proportions 
diagnosed with HIV, on ART, and with current VL<2.7 log copies/mL are kept similar for the 
CLLT partners as in the simulated subjects themselves. 
 
Risk of infection from a CLLT infected partner is determined by sampling from a 
Normal(tr_rate_primary, 0.0752) if the CLLT partner is in PHI (i.e. infected at t-1), 
Normal(tr_rate_undetec_vl, 0.0000252) if the CLLT partner has VL <2.7 log copies/mL, and 
Normal (0.05, 0.01252) otherwise (See values and distributions of the parameters in Appendix 
XI). 
 
3.3.7. Transmitted resistance 
Distinction is made for each mutation as to whether it is only present in minority virus, and 
thus assumed non-transmissible, even if VL is high, or if it is present in majority virus (584;585).  
The presence or absence of resistant mutations does not influence the infectivity of a person, 
for a given VL.  For a newly infected person, the probability that the source partner has 
resistant virus in the majority circulating virus is determined by the prevalence of resistance 
among those (stratified by type of partnership) at that VL level, taking into account number of 
partnerships formed.   
 
In other words, for a subject infected by a person in VL group v the probability of a resistance 
mutation being present in the infected person is given by: 
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∑ 𝑉𝑖,𝑡−1𝑅𝑖,𝑡−1𝑖
∑ 𝑉𝑖,𝑡−1𝑖
 
𝑅𝑖 = 1 if the person has at least one DRM present in majority virus, 0 otherwise, and 𝑉𝑖 
assumes value of 1 if the person belongs to VL group v. 
The numerator is the total number of HIV-infected people with VL group v and with at least 
one DRM present in majority virus and the denominator is the sum over all HIV-infected 
subjects in VL group v.  Again, realization of whether the subject is infected by a person with at 
least one DRM in majority virus is determined by sampling from Uniform(0,1). 
 
For subjects infected from a source partner with a DRM, the probability that a specific 
mutation, m, is present in the source is given by:   
∑ 𝑀𝑖,𝑡−1𝑖
∑ 𝑅𝑖,𝑡−1𝑖
 
Where 𝑀𝑖 assume value 1 if the patient has a specific DRM m (if 𝑀𝑖 =1, by definition 𝑅𝑖=1). 
The numerator is the total number of HIV-infected subjects with DRM m present in majority 
virus and the denominator is the total number of HIV-infected subjects with at least one DRM 
in majority virus. 
 
It is not assumed that all DRMs present in majority virus in the source partner are established 
in the circulating virus of the newly infected person.  If a given DRM, m, is present in the 
source partner, the probability that the mutation is both transmitted and survives in the 
subject (i.e. that its presence will affect future response to drugs for which the mutation 
confers reduced sensitivity) is mutation specific, as shown in Table 3.9 (page 155). 
 
We consider uncertainty in the extent to which TDR mutations are effectively immediately lost 
(even from minority virus) by sampling from a distribution for parameter res_trans_factor (See 
distribution in Appendix XI).    
 
3.3.7.1. Loss from majority virus of transmitted mutations 
Once the mutation is transmitted and established in the new host, there is a probability per 3 
months of loss of persistence of TDR mutations from majority virus to minority virus (same for 
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each mutation) rate_loss_persistence (See distribution in Appendix XI). This assumption is 
based on the estimate by Castro and colleagues (386).   
 
 
Table 3.4. Values of rga (age and gender-specific factor determining relative level of sexual 
risk activity) 
Age group Males (g=0) Females (g=1) 
15- 0.65 (0.6 in Zimbabwe) 1.50 (1.60 in Zimbabwe) 
20- 0.65 (0.6 in Zimbabwe) 1.50 (1.60 in Zimbabwe) 
25- 1.00 1.00 
30- 0.80 0.80 
35- 0.65 0.50 
40- 0.50 0.35 
45- 0.40 0.10 
50- 0.35 0.05 
55- 0.25 0.04 
60- 0.15 0.02 
 
 
Table 3.5. Values of fgij  (values determining probability of transitioning between condom-less 
short-term partner risk behaviour groups) 
CLST partners 
group in period 
t-1 (i) 
CLST partners group in period t (j) 
0 (j=1) 1 (j=2) Medium (2-9) 
(j=3) 
High (≥10)  
(j=4) 
Poisson*  Poisson (mean 
of 2*swn) 
Males (g=0) 
0 0.89 0.08 0.03 0.00 
1 0.80 0.15 0.05 0.00 
Medium (2-9) 0.35 0.27 0.38 0.00 
High (≥10) - - - - 
Females (g=1) 
0 0.93 0.05 0.02 0.00025 
1 0.86 0.11 0.03 0.0005 
Medium (2-9) 0.54 0.08 0.38 0.001 
High (≥10) 0.05 0.05 0.10 0.80 
CLST: condom-less short-term; *mean of 1.5 for South Africa, 4.5 for Zimbabwe; 
The values reported in the table above refer to the risk behavioural model more often used. Different risk 
behavioural model have been considered (see Appendix X, table A5 391) 
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Table 3.6. Sexual mixing by age and gender.  
The proportion of condom-less short-term partnerships formed by men in age group am which 
are with females of age group af (𝐳𝐚𝐦,𝐚𝐟) and the proportion of condom-less short-term 
partnerships formed by females in age group af which are with men of age group am (𝐳𝐚𝐟,𝐚𝐦)).
  
 Females 
Age group (af) 
Males Age group (am) 15-24 25-34 35-44 45-54 55-64 
15-24 0.865 0.11 0.025 0.00 0.00 
25-34 0.47 0.43 0.10 0.00 0.00 
35-44 0.30 0.50 0.20 0.00 0.00 
45-54 0.43 0.30 0.23 0.03 0.01 
55-64 0.18 0.18 0.27 0.27 0.10 
 
 Males 
Age group (am) 
Females Age group (af) 15-24 25-34 35-44 45-54 55-64 
15-24 0.43 0.34 0.12 0.10 0.01 
25-34 0.09 0.49 0.30 0.10 0.02 
35-44 0.03 0.25 0.34 0.25 0.13 
45-54 0.00 0.00 0.05 0.25 0.70 
55-64 0.00 0.00 0.00 0.10 0.90 
 
 
Table 3.7. Percent of newly formed condom-less long-term partnerships. 
These are classified into each of three duration groups, each of which has a different tendency 
to endure (higher class, more durable).   
 Duration group 
Age 1 2 3 
15-44 30% 30% 40% 
45-54 30% 50% 20% 
55-64 30% 70% 0% 
 
 
Table 3.8. Probability of starting a condom-less long-term partnership per 3 months 
 South Africa Zimbabwe 
Age group 
partners 
15- 0.07 0.1 
25- 0.09 0.1 
35- 0.035 0.1/2 
45- 0.035 0.1/3 
55- 0.02 0.1/5 
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Alternative sexual behaviour model. 
In addition, alternative sexual behaviour structures have been developed (see Appendix X), 
including one where no woman or man has more than 10 CLST partners in a 3 month period; 
(so this means that I am then considering an epidemic in which there are essentially no sex 
workers). In the main sexual behaviour model a small number of women have very high 
number of CLST (≥10), while this is assumed to be very rare for men (See Table 3.10 at page 
156). 
 
 
Table 3.9. Table of probabilities that for a given mutation present in the source partner the 
mutation is both transmitted and survives in the subject. 
They are based on evidence from studies comparing distribution of resistance mutations 
between treated and antiretroviral naïve populations; e.g. (346;586). 
 Probability that for a given mutation the 
source partner the mutation is both 
transmitted and survives in the subject 
Mutation present South Africa Zimbabwe 
M184V 0.2 0.2 
K65R 0.2 0.2 
L74V 0.5 0.5 
Q151M 0.5 0.5 
TAMS 0.5 0.5 
NNRTI mutation 0.6 0.8 
PI (LPV) mutations (30,32,33, 
46,47,48,50L,50V,54,76,82,84,90) 
0.5 0.5 
LPV: lopinavir; NNRTI: non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitor; TAMS: Thymidine 
analogue mutations; 
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3.3.8. Example results from epidemics simulated using modal values of parameter 
distributions 
To illustrate some features of the epidemics generated, Table 3.10 shows the proportion of 
people with at least one, two, five, ten condom-less partners (as a total of CLST partner in 
addition to whether they have or not one CLLT partner) and shows the proportion of people 
with at least one (at least two) condom-less partners in the past year by HIV status and year 
using modal values for parameters. Table 3.13 shows the proportion of new infections that 
have been acquired from a person in PHI by year, and the proportion of new infections that 
have been acquired from a CLLT partner by year. Table 3.14 (page 158) shows HIV prevalence 
by age and gender and calendar year. 
 
Table 3.10. Proportion of people with at least one, two, five, ten condom-less short-term 
partners before introduction of HIV for one example epidemic using modal values for 
parameters (mean over 30 runs).     
 % with condom-less sex partners (short- or long-term) in past year 
Age 
group 
≥1 ≥2 ≥5 ≥10 ≥1 ≥2 ≥5 ≥10 
Male Females 
15- 71% 29% 1.2% 0.02% 75% 41% 2.6% 2.5% 
25- 85% 46% 2.0% 0.02% 82% 36% 1.8% 1.8% 
35- 74% 31% 1.2% 0.01% 67% 17% 0.8% 0.8% 
45- 65% 21% 0.8% 0.01% 54% 4% 0.1% 0.1% 
55- 53% 10% 0.4% 0.00% 45% 2% 0.1% 0.1% 
 
 
Table 3.11. Proportion of people with a condom-less long-term partner before introduction 
of HIV for one example epidemic using modal values for parameters (mean over 30 runs).     
 % with condom-less long-term partner  
Age group Males Females 
15- 48% 48% 
25- 57% 57% 
35- 48% 47% 
45- 41% 41% 
55- 35% 34% 
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Table 3.12. Proportion of people with at least one condom-less short-term partner in the 
past 3 months by HIV status (mean over 30 runs) for South Africa 
 Calendar year 
1990 1995 2000 2005 2010 
Whole population 24% 24% 18% 15% 13% 
HIV+ 59% 41% 28% 20% 16% 
HIV+ diagnosed - 40% 23% 17% 14% 
 
 
Table 3.13. Origin of new infections for the median over the simulations which provide a 
good fit. 
See section 3.13 for details on calibration of the model. 
This shows the proportion of new infections that have been acquired from a person in primary 
HIV infection by year, and the proportion of new infections that have been acquired from a 
condom-less long-term partner by year.  For infections from people with primary infection, 
there are little data from sub-Saharan Africa to my knowledge. Using data on sexual behaviour 
from Lilongwe in Malawi, Powers and colleagues estimated that 38.4% of HIV infections were 
from people who were themselves in PHI (587). For proportions of people infected by a 
condom-less long-term partner, the probabilities are comparable with (588). 
 Source of infection 
Partner in primary infection  Condom-less long-term partner 
1990 2000 2010 1990 2000 2010 
Overall 88% 43% 33% Male 0% 21% 41% 
 Female 45% 60% 68% 
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Table 3.14. Median HIV prevalence (%) by gender and age using the simulations which 
provide a good fit.   
See section 3.13 for details on calibration of the model. 
 Calendar year 
1990 1995 2000 2005 2010 
Males 
15- 0.2 4.8 7.3 7.1 5.8 
25- 0.4 7.5 14.5 18.7 18.7 
35- 0.3 5.5 11.8 15.9 18.3 
45- 0.2 3.9 7.7 9.4 11.2 
55- 0.0 2.4 4.7 5.1 5.7 
Females 
15- 0.2 5.5 12.8 12.7 10.7 
25- 0.2 7.0 17.8 25.2 27.8 
35- 0.1 4.5 13.3 21.2 28.0 
45- 0.05 2.5 6.8 10.7 14.7 
55- 0.0 0.7 2.0 3.6 5.5 
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3.4. Natural history of HIV infection 
The model of the natural history of HIV and the effect of ART has been derived previously and 
shown to provide generally a close fit to observed data relating to natural progression of HIV 
infection, comparing the output of the model with data coming mainly from observational 
studies conducted in Europe for the natural history (incubation period) (see (103;570;589), and 
associated supplementary material).  Below I set out the structure of the model and explain 
what parameters represent.  There is uncertainty associated with many of the values (see 
parameter distributions in Appendix XI).   
 
3.4.1. Determination of changes in viral load and CD4 count 
3.4.1.1. Initial viral load  
The initial log10 VL (Vset) is sampled from a 𝑁𝑜𝑟𝑚𝑎𝑙(4.0, 0.52) distribution, but truncated so 
that the maximum is 6.5.  
This viral load (Vset) is assumed to be that reached after  PHI.  It is not used to determine the 
risk of transmission in PHI itself.   Virus at the time of infection is assumed to be R5 tropic. 
 
3.4.1.2. Change in viral load  
VL change from period (𝑡 − 1) to period 𝑡 (i.e. in 3 months), 𝑣𝑐(𝑡 − 1), is given by sampling 
from a 𝑁𝑜𝑟𝑚𝑎𝑙(𝑔𝑥 ∗ 0.02275, 0.052), where gx is sampled from a 𝐿𝑜𝑔𝑁𝑜𝑟𝑚𝑎𝑙(𝑙𝑛(1), 0.202). 
 
3.4.1.3. X4 virus 
In each 3 month period, the virus can shift to be x4 virus with a probability given by 
10𝑣 ∗ 0.0000004, where v is the current log10 VL (see Figure 3.1). 
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Figure 3.1. Assumption on relationship between most recent viral load and probability of 
shift to x4 virus 
 
Comment: This translates into a rate of 5% per year in a person with VL 30,000 copies/mL and 
16% per year in a person with 100,000 copies/mL, which are broadly consistent with observed 
data (590). 
 
3.4.1.4. Initial CD4 count 
Initial CD4 count, modelled on the square root scale, 𝑐(𝑖𝑛𝑓) is partially dependent on initial VL, 
𝑣𝑠𝑒𝑡 and given by: 
𝑐(𝑖𝑛𝑓) = 𝑚𝑒𝑎𝑛_𝑠𝑞𝑟𝑡𝑐𝑑4_𝑖𝑛𝑓 − (2 × 𝑉𝑠𝑒𝑡) + 𝑁𝑜𝑟𝑚𝑎𝑙(0, 2
2) 
where 𝑚𝑒𝑎𝑛_𝑠𝑞𝑟𝑡𝑐𝑑4_𝑖𝑛𝑓~𝑁𝑜𝑟𝑚𝑎𝑙(30, 22)  for South Africa, while the mean is 27 for 
Zimbabwe. The reason for this discrepancy is due to finding evidence that people of black race 
are likely to have lower CD4 count at infection after setting parameter values for South Africa 
and before doing so for Zimbabwe (575). 
The initial CD4 count (not on square root scale) is truncated at the minimum and maximum 
value of respectively 324 (182) and 1500. 
 
3.4.1.5. Change in CD4 count 
As for VL, no attempt is made to model the dynamic CD4 count changes in PHI – the VL and the 
CD4 count are both assumed to have reached its settled state right from the first period. 
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The change in CD4 count from period (𝑡 − 1) to 𝑡, 𝑐𝑐𝑠𝑞𝑟(𝑡 − 1), are dependent on the current 
VL (i.e. VL at time t-1, v(t-1)) and are given by sampling from a Normal distribution with mean 
fx and variance (sd_cd4)2 multiplied by the values indicated in Table 3.15. 
 
Table 3.15. Mean square root CD4 change according to viral load 
Viral load at t-1, v(t-1) 
Mean square root CD4 change (per 3 months), ccsqr(t-1) 
South Africa Zimbabwe 
< 3.0 -0.03 0 
3.0- -0.08 -0.022 
3.5- -0.15 -0.085 
4.0- -0.20 -0.40 
4.5- -0.50 -0.40 
5.0- -1.00 -0.85 
5.5- -2.00 -1.30 
6.0- -2.50 -1.75 
 
The change in CD4 count additionally is affected by adding the values indicated in Table 3.16, 
based on the current age. 
 
Table 3.16. Additional change in square root CD4 count according to age 
Age Additional change in square root CD4 count 
< 20 +0.15 
20- +0.09 
25- +0.06 
30- +0.00 
35- +0.00 
40- -0.06 
45- -0.09 
50- -0.15 
60- -0.20 
 
People with X4 virus present experience an additional change in square root CD4 count of -
0.25. 
 
These estimates are derived based on synthesis of evidence from natural history studies 
(92;98;99;117;590-594) and were selected in conjunction with other relevant parameter 
values to provide a good fit to the incubation period distribution.  Differences that have been 
found in initial VL by gender and age are not currently incorporated in the model.   
162 
 
Table 3.17. Incubation period by age.   
Kaplan-Meier estimates with outcome WHO 4 event.  These are calculated as median over the 
simulations with a good fit.  Compare with (103;172). 
 Years from infection 
1 3 5 10 15 20 
15- 0.3% 3% 10% 43% 75% 91% 
25- 0.8% 5% 15% 55% 84% 95% 
35- 0.9% 9% 22% 64% 91% 98% 
45- 1.4% 11% 26% 74% 93% 99% 
55- 1.8% 11% 30% 75% 96% 100% 
 
 
3.5. HIV testing and diagnosis of HIV infection 
HIV testing is assumed to have become available in ANCs in 1990 in South Africa and in 1994 in 
Zimbabwe, while for the rest of the population at date_start_testing (1996 for both countries). 
 
For the South African model the basic probability of someone testing for HIV in any 3 month 
period, if he/she has not been tested for HIV in the last year, is assumed to increase linearly by 
test_increase_rate (see distribution in Appendix XI).   
 
For the Zimbabwean model, gender and age specific rates of testing, separately for first test 
and repeat test apply. They are calculated as: 
𝑝𝑟𝑜𝑏1𝑠𝑡 = [(𝑐𝑎𝑙𝑑𝑎𝑡𝑒(𝑡) − 1996)
2] ∗ 𝑖𝑛𝑐𝑟_1𝑠𝑡𝑡𝑒𝑠𝑡 
𝑝𝑟𝑜𝑏𝑟𝑒𝑝 = [(𝑐𝑎𝑙𝑑𝑎𝑡𝑒(𝑡) − 1996)
2] ∗ 𝑖𝑛𝑐𝑟_𝑟𝑒𝑝𝑡𝑒𝑠𝑡 
until calendar year 2011. 
The proportion ever tested and tested in the last year in 2006 and 2011, where DHS were 
conducted collected those data, is illustrated in section 8.2.2. 
 
The probability of testing is independent of presence of WHO stage 3 or 4 conditions and it 
applies only if the person did not test for HIV in the last year; in other words HIV testing is 
assumed to occur with a frequency no more than annual. 
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A proportion of the population (rate_noreached) is assumed to be “resistant to HTC” and can 
never be tested for HIV unless symptoms occur (WHO stage 4 disease). This proportion is fixed 
and sampled from 𝐿𝑜𝑔𝑁𝑜𝑟𝑚𝑎𝑙(𝑙𝑛(0.25), 0.122) for South Africa, while for the Zimbabwean 
epidemic, this proportion is assumed to be 20% in 1996, when HIV testing is introduced, and it 
declines linearly so that 5% are resistant by end of 2010 and it remains at that level afterwards. 
Justification for this assumption is given in section 8.2.3. 
 
In addition those who did not have condom-less sex since last HIV test are assumed to have a 
10-fold reduction in the probability of being tested for HIV for the South African model. While 
for the Zimbabwean model a 3-fold reduction in HIV testing is assumed for people who never 
had condom-less sex. Justification for this assumption is given in section 8.2.3. 
 
In addition some individuals experience an additional probability of being tested for HIV based 
on their condition in the previous 3 months and on the calendar year (See Table 3.18). 
 
Table 3.18. Probability of HIV testing for symptomatic people in 1989 and rate of increase 
over time 
Situation Probability of HIV 
testing in 1996 
Rate of increase per 3 
months (Up to a 
probability of 0.95) 
Current AIDS defining condition 0.2 0.008 
Current TB, but not an AIDS defining 
condition 
0.1 0.005 
Current WHO stage 3 disease, but not TB 
nor an AIDS defining condition 
0.003 0.0012 
AIDS: Acquired Immune Deficiency Syndrome; TB: tuberculosis; WHO: World Health Organization; 
 
The result of the HIV test is assumed to be available immediately and to be 100% sensitive and 
specific, except during PHI (assumed to last 3 months) therefore people who are infected with 
HIV for at least 3 months and who get tested are diagnosed with HIV. From 2013 onwards the 
probability of being tested for HIV is assumed constant. These parameters have been chosen 
to reflect the situation respectively in South Africa (452) and Zimbabwe (519). In section 7.3.1 
for South Africa and 8.2.2 for Zimbabwe the fit of HIV testing to data from national surveys is 
shown. 
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Among those who are not “resistant to HTC” (determined by rate_noreached), the proportion 
of HIV-positive people who are linked to care and therefore received a CD4 measurement and 
result to evaluate whether they are eligible to initiate ART is determined as the sum of 
rate_noreached and prop_linkedtocare_diag (See the value and distribution of these two 
parameters in Appendix XI). 
  
3.5.1. HIV testing in antenatal clinics 
The reason why pregnancies are included in this model is mainly to be able to simulate HIV 
testing in ANCs, and therefore a higher rate of testing in women overall, and to capture the 
impact of receiving ARVs to prevent MTCT on the development of resistance. Vertical 
transmissions are not modelled. 
 
Given a woman had a CLLT partner in a 3 month period, and did not give birth in the last 9 
months, in the model the probability that she becomes pregnant is age dependent. The 
probability for a woman aged 25 to 35 years is determined by the parameter 
prob_pregnancy_base (See distribution in Appendix XI). For the other age groups (15 to 25 
years old up to 55 to 66 years), the following multiplicative factors, respectively 
fold_preg1525, fold_preg2535, 1, fold_preg4555, fold_preg5565 (See distribution in Appendix 
XI) are multiplied by prob_pregnancy_base, to determine the probability of pregnancy in 
women who had condom-less sex in the previous 3 months. If they had condom-less sex with 
short-term partners the probability of pregnancy from each of the CLST partner is multiplied by 
the factor fold_tr_newp, to take into account of the lower number of sex acts per CLST partner 
than per CLLT partner. 
 
These parameters have been chosen to reflect the cumulative average number of children 
ever born per woman, for the age group 15-24 up to 45 to 49 years old, estimated in a 
community survey in South Africa conducted in 2007 (595). 
 
In pregnant women, who are not “resistant to HTC” the probability per pregnancy of attending 
an ANC and receiving an HIV test (for women not diagnosed yet with HIV) is assumed to 
increase over time. This probability from 1990 to 2013 for South Africa and to 2015 for 
Zimbabwe, is given by: 
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[(𝑐𝑎𝑙𝑑𝑎𝑡𝑒(𝑡) − 1990)2] ∗ 𝑟𝑎𝑡𝑒_𝑡𝑒𝑠𝑡𝑎𝑛𝑐_𝑖𝑛𝑐 
See distribution of rate_testanc_inc in Appendix XI. 
The maximum probability of attending an ANC is assumed to be 0.975.  
 
Pregnant women who are diagnosed with HIV, since 2004 (date_pmtct), the year when PMTCT 
with use of single dose NVP is assumed was introduced. The chances of receiving PMTCT are 
assumed to increase over time as given by: 
(𝑐𝑎𝑙𝑑𝑎𝑡𝑒(𝑡) − 𝑑𝑎𝑡𝑒_𝑝𝑚𝑡𝑐𝑡) ∗ 𝑟𝑎𝑡𝑒_𝑠𝑑_𝑛𝑣𝑝 
The maximum I assumed again to be 0.975. 
 
With this parameter choice, 90% of pregnant women receive PMTCT by 2011, as has been 
estimated for South Africa (596). 
 
 
3.6. Use of ART  
3.6.1. Initiation of ART 
ART is assumed was introduced in 2002 in South Africa and 2003 in Zimbabwe (ART_intro_date 
in Appendix XI). Eligibility criteria to be initiated on ART follow the national guidelines and in 
the time period where not available WHO guidelines (see sections 2.1.7 and 2.2.7). 
 
3.6.2. Adherence to antiretroviral treatment 
Each patient has a fixed “tendency to adhere”, which is assumed constant for their entire 
lifespan. Nevertheless, their actual adherence varies from period to period, both at random 
and according to the presence of symptoms, depending on their underlying “tendency to 
adhere”.  Adherence is measured on a scale of 0 to 1 (sometimes reported as between 0 and 
100%). 
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3.6.2.1. Adherence component which is fixed over time for a given patient 
The “tendency to adhere” is indicated by the parameter adhav, while the period-to-period 
variability is indicated by the parameter adhvar.  Adherence at any one period is determined 
as follows (although with modifications explained below):  
𝑎𝑑ℎ(𝑡) = 𝑎𝑑ℎ𝑎𝑣 + 𝑁𝑜𝑟𝑚𝑎𝑙(0, 𝑎𝑑ℎ𝑣𝑎𝑟) 
where  𝑚𝑖𝑛[𝑎𝑑ℎ(𝑡)] = 0  and  max[𝑎𝑑ℎ(𝑡)] = 1 
 
Table 3.19. Adherence pattern used 
Proportion of the population Adhav Adhvar 
South Africa Zimbabwe 
0.15 0.05 0.49 0.2 
0.15 0.10 0.79 0.2 
0.5 0.65 0.90 0.06 
0.2 0.2 0.95 0.05 
 
These estimates are based partially on observed adherence data (330;485;565) (see section 
2.1.9 and 2.2.9 for more information), but also on adherence levels required to produce 
observed estimates of rates of resistance development and VF and also data on the proportion 
of patients at first VF who have no resistance mutations present (398;597-599). The choice of a 
slightly worse adherence pattern for South Africa compared to Zimbabwe was driven by the 
fact that I did not want to underestimate the potential development and transmission of 
resistance for South Africa.  It is clear from data, mainly from South Africa, that the great 
majority of patients who started ART with 3 or more drugs are sufficiently adherent that VF 
rates (and so resistance accumulation is likely to have been slow also) are low (499;504;568). 
See section 2.1.10 for more detail on VF in patients on ART in South Africa and section 2.2.10 
regarding Zimbabwe. 
 
3.6.2.2. Effective adherence 
We also considered the concept of effective adherence, 𝑒_𝑎𝑑ℎ(𝑡), which reflects predicted 
adequacy of drug levels, whereby for those on regimens that do not include an NNRTI the 
effective adherence is as the adherence, but for those on NNRTI-containing regimens the 
effective adherence is considered to be 0.1 higher (on a scale from 0 to 1, this parameter is 
referred to as add_eff_adh_nnrti in Appendix XI), reflecting the long half-life of these drugs 
(600). Additionally, it is assumed that patients on ART are susceptible to occasional (rate 0.02 
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per year) severe temporary drops in drug level (i.e. effective adherence level), leaving them 
susceptible to viral rebound (but with low risk of resistance as the effective adherence drop is 
so profound).  This phenomenon is assumed to be 3 times more frequent among those on PI 
regimens.  This latter assumption is the only plausible means (at least within this model 
framework), together with the fact that the patient interrupt treatment without the clinician 
knowing it (see section 3.6.4) to explain why VF occurring on boosted PI regimens often occurs 
in the absence of resistance.   
 
3.6.2.3. Effect of viral load measurement above 1000 copies/mL on adherence 
Studies have indicated that VL frequently returns to undetectable levels after a measured 
VL>1000 copies/mL, largely attributable to targeting of adherence support (307;597).  
Adherence is assumed to be incremented by an average adh_effect_of_vm_pop (by an amount 
that varies by individual) when the VL has been measured to be above 1000 copies/mL in the 
past 6 month period (it can apply only once for each individual). In addition in 50% of the 
patients with a measured VL>1000 copies/mL there is a 0.2 probability of a one-off increase in 
adherence.  For those with an increase in adherence the increase is sampled from a Uniform 
distribution with extremes 0 and 0.8, up to a maximum of 1 for the adherence. 
 
Having a measured VL above 1,000 copies/mL in the last six months is assumed to have an 
effect on the probability of restarting ART in people who have interrupted. In particular this is 
multiplied respectively by 1.5, 2, 3 and 5 if the individual increase in adherence due to this 
effect is respectively 0.05, between 0.05 and 0.10, 0.10 and 0.25 and above 0.25. 
 
The impact of a VL measurement on adherence is not modelled in Zimbabwe because it is 
assumed VL monitoring is not available. 
 
3.6.3. Interruption of ART  
The basic rate of interruption due to patient choice (rate_int_choice) is assumed to be 0.02 per 
3 months. This rate depends on the person’s underlying tendency to adhere and whether they 
have current toxicity. Table 3.20 shows by how much rate_int_choice is multiplied by for 
different levels of adherence and presence of toxicity. 
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Table 3.20. Multiplicative factor for rate of ART interruption based on underlying tendency 
to adhere and presence of toxicity on the rate of interruption 
 Current presence of toxicity 
Underlying tendency  to 
adhere 
No Yes 
≥0.8 1 2 
0.5-0.79 1.5 3 
<0.5 2 4 
 
These rates are reduced by half for people who have been continuously on ART for two years. 
 
If ART is interrupted because of patient choice the probability per 3 month period that the 
interruption coincides with the interrupting/stopping visits to the clinic (i.e. LTFU) is 
determined by the parameter prob_lost_art (0.3) for patients with adherence average of 0.8 or 
more.  
Patients with “tendency to adhere” between 0.5 and 0.8 experience a 50% higher probability 
of being lost per 3 month during ART interruption, while those with “tendency to adhere” less 
than 0.5 a double probability of being lost compare to those with high “tendency to adhere” 
(>0.8). 
The rate of interruption due to choice and therefore the retention of people on ART are likely 
to vary by setting.  The above rates were derived to be consistent with data from South Africa 
and Zimbabwe (291;554;601).  
 
The basic rate of interruption per 3 months due to interruption of the drug supply 
(prob_supply_interrupted) is assumed to be 0.01 (See distribution in Appendix XI). 
 
3.6.4. Interruption of ART without clinic/clinician being aware 
It is known that in some instances, people on ART have such poor adherence that they have in 
fact interrupted or stopped ART entirely but, in the same way that the clinician is not always 
aware of the true adherence level, they are also not always aware when the person has 
completely interrupted ART.  This means that the clinician may think a patient is virologically 
failing, because VL is high, when in fact this is due to interruption rather than resistance having 
developed.  This can be seen from studies on people with VF in which a proportion have no 
identified DRMs (398;597;598) .  Thus, when a person interrupts ART (but remains under care) 
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a variable is introduced, that indicates whether the clinician is aware, clinic_aware_int_frac 
(See distribution in Appendix XI). If a patient has interrupted ART with the clinician unaware 
then not only is the patient (wrongly) classified (by the clinician) as virologically failing, but a 
switch to second-line can potentially occur. 
 
3.6.5. Re-initiation of ART after interrupting in patients still under follow-up 
For patients who have interrupted ART due to choice but are still under clinic follow-up, the 
probability of restarting ART per 3 months in the base model is rate_restart (See distribution in 
Appendix XI).  This probability is increased 3-fold and 5-fold if respectively a new WHO 3 and a 
new WHO 4 condition have occurred at t-1. 
In addition, as mentioned in section 3.6.2, if VL monitoring is available a measured VL above 
1,000 copies/mL in the last 6 months triggers an adherence intervention which can increase 
the rate of restart. 
 
For patients who have interrupted ART due to interruption of supply the probability of 
restarting ART per 3 months (prob_supply_resumed) is 0.8. 
 
3.6.6. Switch to second-line after failure of first-line ART 
Whatever the definition of first-line ART failure (i.e. the criterion for the need to switch to 
second-line ART), the probability of switching per 3 month period after the criterion is met 
(pr_switch_line) is assumed to be 0.25 for South Africa and 0.15 for Zimbabwe. This 
corresponds to a median time to switch of 5 months for South Africa, as found in the clinic 
described by Fox and colleagues (499). It is possible that the switching rates at national level 
are even lower and that, if anything, I have overestimated the current number of people on 
second-line of treatment. Less data are available on number of people switched to second-line 
in Zimbabwe but data on the number of people on second-line suggest even lower switching 
rates than in South Africa (602). 
 
3.6.7. Loss to follow-up while off ART 
The probability per 3 months of interrupting/stopping clinic visits (i.e. being LTFU) while off 
ART (rate_lost) applies to patients both ART-naïve and ART-experienced. 
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In South Africa, in the first year since diagnosis it is assumed to be 0.3 for people with 
“tendency to adhere” (See section 3.6.2) of 0.8 or above; this is due to the necessity to match 
to data which found very low retention in pre-ART care (2;551-553).  After one year since 
diagnosis, in the model for South Africa the probability of being LTFU is assumed to be a 
quarter of what it is in the first year: 0.075. This reduction was assumed to reflect the fact that 
retention of patients who have started ART is much better (291;530;601). 
For Zimbabwe the data on retention in pre-ART care are substantially not existent and few 
data are available for retention on ART (554). I decided, in collaboration with Andrew Phillips 
who led the choice for the parameters in Zimbabwe, to have a simpler parameterization for 
Zimbabwe and assume it is 0.05, regardless of the length of time since diagnosis. 
These parameters are increased by 1.5 fold if “tendency to adhere” (described in section 3.6.2) 
is between 0.5 and 0.8 and by 2-fold if the “tendency to adhere” is below 0.5.   
See sections 7.3.3 and 7.3.5 for more details on retention in pre-ART care and once initiated on 
ART for South Africa and section 2.2.6 and 2.2.9 for Zimbabwe. 
 
For people LTFU who are asymptomatic, the probability of returning to clinic per 3 months 
(rate_return) is 0.05 for South Africa, 0.04 for Zimbabwe, if the “tendency to adhere” is 0.8 or 
above.  This is decreased by 2-fold if the “tendency to adhere” is between 0.5 and 0.8 and by 
3-fold if the “tendency to adhere” is below 0.5. If a person develops a new WHO 3 or 4 event 
then they are assumed to return to the clinic with probability 0.8. These will vary by setting 
(1;483;484;603-605).  
 
 
3.7. Effect of ART on viral load, CD4 count, resistance development and 
drug toxicity 
3.7.1. Determination of viral load, CD4 count and acquisition of new resistance 
mutations while on ART 
Potent ART regimens are known to reduce VL, which in turn leads to recovery of CD4 cell 
counts (606-608). Changes in the VL and CD4 counts whilst an individual is on ART are 
modelled differently to when an individual is ART-naïve. 
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Determination of VL, CD4 count and acquisition of new DRMs (variable newmut(t)) between 
(𝑡 − 1) to 𝑡 depends on:  
 effective adherence between (𝑡 − 1) to 𝑡,  
 number of active drugs (nactive(t-1)),  
 time on the current regimen,  
 current VL  
 
The way the values are generated is detailed in Table 3.21-Table 3.26 (page 172-page 177). For 
those on NNRTI regimens the new mutations risk is assumed to be that for the effective 
adherence category of 0.5 – 0.8 (i.e. maximal) even if e_adh(t)< 0.5, reflecting the fact that 
NNRTI resistance develops easily, even when drug exposure is very low.   
 
In the following sections, ‘starting current regimen’ means starting ART for the first time or 
following a treatment interruption.  
 
The changes in VL and CD4 count are based on observed data and observational studies (and 
to some extent RCTs, although responses tend to be better in trial participants), and provide 
long term estimates of VF rates and CD4 count increases in ART which are broadly consistent 
with observed data.  Values of the “new mutation risk” parameter, newmut(t), have been 
chosen in conjunction with the translation of presence of DRMs into reduce drug activity to 
provide estimates of resistance accumulation consistent with those observed in clinical 
practice (264;607-614). 
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Table 3.21. Viral load (mean change from viral load max), CD4 count change (mean change between t-1 and t), and new mutation risk in first 3 months since 
ART initiation 
The initial 3-month change in VL is described as the mean change from the patient’s maximum VL to that point (vmax) on the log scale. This is the mean of a 
normal distribution with variance 0.22, from which the patient’s value/change is sampled.  
The change in CD4 count is described as the mean change between periods (𝑡 − 1) and 𝑡. This change is then multiplied by a factor which represents each 
individual’s underlying propensity for CD4 count rise whilst on ART (given by the parameter pt_cd4_rise_art).  
For the new mutation risk, this is a number that is multiplied by the VL (mean of values at (𝑡 − 1) to 𝑡). The resulting number, newmut(t), is used when assessing 
whether a new DRM(s) have arisen.   
  
‘Effective 
adherence’ 
between t-1 & t 
Number of active drugs 
3 2.75 2.5 2.25 2 1.75 1.5 1.25 1 0.75 0.5 0.25 
Viral load (log 
change from 
vmax) 
> 0.8 -3 -2.6 -2.2 -1.8 -1.5 -1.25 -0.9 -0.8 -0.7 -0.55 -0.4 -0.3 
> 0.5, < 0.8 -2 -1.6 -1.2 -1.1 -0.9 -0.8 -0.6 -0.5 -0.4 -0.25 -0.1 -0.05 
< 0.5  -0.5 -0.4 -0.3 -0.25 -0.2 -0.15 0 0.05 0.1 0.1 0.1 0.1 
CD4 count 
change (t-1 to t) 
> 0.8 50 45 40 35 30 25 20 17 13 10 5 -2 
> 0.5, < 0.8 30 30 23 20 15 13 10 8 5 3 0 -7 
< 0.5  5 4 3 2 1 -1 -3 -6 -10 -11 -12 -13 
New mutation 
risk (x log viral 
load) 
> 0.8 0.002 0.01 0.03 0.05 0.1 0.15 0.2 0.3 0.4 0.45 0.5 0.5 
> 0.5, < 0.8 0.15 0.15 0.2 0.25 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 
< 0.5  0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
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Table 3.22. Summary of viral load values between 3-6 months since starting current regimen and after 6 months if viral load at t-1 > 4 log copies/mL 
This table applies to patients for whom it has been between 3 and 6 months since starting their current regimen, as well as patients who have been on their 
current regimen for more than 6 months but who have a VL > 4 log copies/mL (e.g. due to previous poor adherence). The change in VL is described as the mean 
change from the patient’s maximum VL to that point (vmax) on the log scale. Otherwise, if the number in the table is underlined, it is the mean absolute value. 
This is the mean of a normal distribution with variance 0.22, from which the patient’s value/change is sampled. 
‘Effective adherence’ 
between t-2 & t-1  
‘Effective adherence’ 
between t-1 & t 
Number of active drugs 
3 2.75 2.5 2.25 2 1.75 1.5 1.25 1 0.75 0.5 0.25 
> 0.8 
> 0.8 
 
0.5 0.8 1.2 1.4 2.0 2.7 -1.7 -1.15 -0.9 -0.75 -0.6 -0.4 
> 0.5, < 0.8 1.2 1.2 1.2 1.4 -2.0 -1.6 -1.2 -1.05 -0.9 -0.7 -0.5 -0.35 
< 0.5  1.2 1.2 1.2 1.4 -2.0 -1.6 -1.2 -1.0 -0.9 -0.7 -0.5 -0.2 
> 0.8 
> 0.5, < 0.8 
1.2 1.6 1.8 2.2 2.4 -2.4 -1.5 -0.9 -0.7 -0.55 -0.4 -0.3 
> 0.5, < 0.8 2.5 2.5 2.5 2.5 -1.2 -1.1 -0.8 -0.65 -0.5 -0.35 -0.2 -0.05 
< 0.5  -2.0 -1.8 -1.5 -1.35 -1.2 -1.1 -0.8 -0.65 -0.5 -0.2 -0.2 -0.05 
> 0.8 
< 0.5  
-0.5 -0.4 -0.3 -0.25 -0.2 -0.15 -0.10 -0.05 +0 +0 +0 +0 
> 0.5, < 0.8 -0.5 -0.4 -0.3 -0.25 -0.2 -0.15 -0.10 -0.05 +0 +0 +0 +0 
< 0.5  -0.5 -0.4 -0.3 -0.25 -0.2 -0.15 -0.10 -0.05 +0 +0 +0 +0 
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Table 3.23. Summary of CD4 count change (mean change between t-1 and t) between 3-6 months since starting current regimen and after 6 months if viral load 
at t-1 > 4 log copies/mL 
This table applies to patients for whom it has been between 3 and 6 months since starting their current regimen, as well as patients who have been on their 
current regimen for more than 6 months but who have a VL > 4 log copies/mL (e.g. due to previous poor adherence). 
The change in CD4 count is described as the mean change between periods (𝑡 − 1) and 𝑡. This change is then multiplied by a factor which represents each 
individual’s underlying propensity for CD4 count rise whilst on ART (given by pt_cd4_rise_art). Once the mean of the underlying CD4 count is obtained, to obtain 
the (underlying) CD4 count, variability (SD = 1.2) is added on the square root scale. 
‘Effective adherence’ 
between t-2 & t-1  
‘Effective adherence’ 
between t-1 & t 
Number of active drugs 
3 2.75 2.5 2.25 2 1.75 1.5 1.25 1 0.75 0.5 0.25 
> 0.8 
> 0.8 
+30 +28 +25 +23 +21 +19 +3 -5 -9 -10.5 -12 -14 
> 0.5, < 0.8 +30 +28 +25 +23 +7.5 +1.5 -4.5 -7 -9 -11 -13 -14.5 
< 0.5  +30 +28 +25 +23 +7.5 +1.5 -4.5 -7.5 -9 -11 -13 -16 
> 0.8 
> 0.5, < 0.8 
+15 +13 +10 +8 +7 +4 +0 -9 -11 -12.5 -14 -15 
> 0.5, < 0.8 +15 +13 +10 +8 -4.5 -6 -10 -11.5 -13 -14.5 -16 -17.5 
< 0.5  +7.5 +4.5 +0 -2 -4.5 -6 -10 -11.5 -13 -16 -16 -17.5 
> 0.8 
< 0.5  
-13 -14 -15 -15.5 -16 -16.5 -17 -17.5 -18 -18 -18 -18 
> 0.5, < 0.8 -13 -14 -15 -15.5 -16 -16.5 -17 -17.5 -18 -18 -18 -18 
< 0.5  -13 -14 -15 -15.5 -16 -16.5 -17 -17.5 -18 -18 -18 -18 
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Table 3.24. Summary of new mutation risk between 3-6 months, and after 6 months if viral load at t-1 > 4 log copies/mL 
This table applies to patients for whom it has been between 3 and 6 months since starting their current period of continuous therapy, as well as for patients whom 
it has been more than 6 months since their current period of continuous therapy but who have a high VL (e.g. due to previous poor adherence). The numbers 
given in the table below correspond to the ‘new mutation factor’, which is a number that is multiplied by the VL (mean of values at (𝑡 − 1) to 𝑡). The resulting 
probability, newmut(t), is used when assessing whether a new mutation or mutations have arisen. 
‘Effective adherence’ 
between t-2 & t-1  
‘Effective adherence’ 
between t-1 & t 
Number of active drugs 
3 2.75 2.5 2.25 2 1.75 1.5 1.25 1 0.75 0.5 0.25 
> 0.8 
> 0.8 
0.002 0.01 0.03 0.05 0.05 0.1 0.2 0.3 0.4 0.45 0.5 0.5 
> 0.5, < 0.8 0.002 0.01 0.03 0.05 0.05 0.1 0.2 0.3 0.4 0.45 0.5 0.5 
< 0.5  0.05 0.05 0.03 0.05 0.05 0.1 0.2 0.3 0.4 0.45 0.5 0.25 
> 0.8 
> 0.5, < 0.8 
0.10 0.15 0.2 0.2 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 
> 0.5, < 0.8 0.10 0.15 0.2 0.2 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 
< 0.5  0.10 0.15 0.2 0.2 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.25 
> 0.8 
< 0.5  
0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
> 0.5, < 0.8 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
< 0.5  0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
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Table 3.25. Summary of viral load (mean change from viral load max), CD4 count change (mean change between t-1 and t), and new mutation risk after 6 
months, where viral load at t-1 < 4 log copies/mL. 
Summary of VL (mean change from VL max), CD4 count change (mean change between t-1 and t), and new mutation risk after 6 months, where VL at t-1 < 4 logs.  
For VL this is the mean of a Normal distribution with standard deviation 0.2, from which the patient's value/change is sampled.  For the CD4 count patients vary in 
their underlying propensity for CD4 rise on ART (given by given by pt_cd4_rise_art) and the CD4 count change given here is multiplied by this factor.  For the new 
mutation number, this is a number that is multiplied by the VL (mean of values at (𝑡 − 1) to 𝑡). The resulting probability, newmut(t), is used when assessing 
whether a new mutation or mutations have arisen. 
  
‘Effective adherence’ 
between t-1 & t 
Number of active drugs 
3 2.75 2.5 2.25 2 1.75 1.5 1.25 1 0.75 0.5 0.25 
Viral load (log 
change from vmax) 
> 0.8 0.5 0.9 1.2 1.6 -2.5 -2.0 -1.4 -1.15 -0.9 -0.75 -0.6 -0.3 
> 0.5, < 0.8 1.2 1.2 1.2 1.2 -1.2 -1.0 -0.6 -0.5 -0.4 -0.3 -0.1 -0.1 
< 0.5  -0.5 -0.4 -0.3 -0.25 -0.2 -0.2 -0.1 -0.1 -0.1 -0.1 -0.1 0 
CD4 count change 
(t-1 to t) 
> 0.8 +30 +28 +25 +23 +21 +19 +3 -5 -9 -10.5 -12 -12 
> 0.5, < 0.8 +15 +13 +10 +8 -4.5 -7.5 -10 -12 -13 -14 -15 -15 
< 0.5  -13 -14 -15 -15.5 -16 -16.5 -17 -17 -18 -17 -17 -17 
New mutation risk 
(x log viral load) 
> 0.8 0.002 0.01 0.03 0.08 0.1 0.15 0.2 0.3 0.4 0.45 0.5 0.5 
> 0.5, < 0.8 0.15 0.18 0.2 0.25 0.3 0.3 0.3 0.35 0.4 0.45 0.5 0.5 
< 0.5  0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
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3.7.2. Changes in viral load, CD4 count and new mutation risk if the number of 
active drugs in current regimen = 0 
For 0 active drugs, these are the changes regardless of time from start of regimen.  
 
Table 3.26. Changes in viral load, CD4 count and new mutation risk if the number of active 
drugs in current regimen is zero 
  
‘Effective 
adherence’ 
between t-1 & t 
Number of active drugs 
0 
Viral load (log 
change from vmax) 
> 0.8 -0.3 
> 0.5, < 0.8 -0.1 
< 0.5  0 
CD4 count change 
(t-1 to t) 
> 0.8 -15 
> 0.5, < 0.8 -17 
< 0.5  -18 
New mutation risk 
(x log viral load) 
> 0.8 0.5 
> 0.5, < 0.8 0.5 
< 0.5  0.05 
 
3.7.3. Factors which affect the CD4 count rise   
There are a number of effects and factors which are taken into account before the final CD4 
count rise per 3 months is determined, as detailed below. There is a maximum CD4 count 
achievable when on ART, which is fixed for each patient, cmax. This estimate is based on 
observed CD4 counts in HIV-seronegative people (95;136). 
 
3.7.3.1. Variable patient-specific tendency for CD4 count rise on ART 
Patients are assumed to vary in their underlying propensity for CD4 count rise whilst on ART. 
Each person is given a value for their propensity, ‘pt_CD4_rise_art’. This value is fixed and 
remains constant for the individual over time and is the factor by which the CD4 count change 
is multiplied by in Table 3.21 (page 172), Table 3.23 (page 174), Table 3.25 and Table 3.26. 
 
To reflect the fact that the rate of CD4 count increase on ART tends to diminish with time 
(609;615), for those with pt_CD4_rise_art > 1, this factor is modified by a factor 0.67 after 1 
year of continuous treatment and by a factor of 0.5 after 3 years of continuous ART. 
 
178 
 
3.7.3.2. Accelerated rate of CD4 count loss if PI not present in regimen 
The rate of change in CD4 count in people on failing regimens is largely based on data from the 
PLATO collaboration, for which patients were mainly on regimens containing a PI (129). If the 
regimen does not contain a PI, the change in CD4 count per 3 months is modified (additive 
effect) by poorer_cd4_rise_on_failing_nnrti, (See values in Appendix XI).  This applies 
regardless of VL level, so PIs are assumed to lead to a more beneficial CD4 count change than 
NVP or EFV (the only two NNRTIs currently included in the Synthesis model for sub-Saharan 
Africa).  
 
3.7.3.3. Variability in individual (underlying) CD4 counts for people on ART 
Once the mean of the underlying CD4 count is obtained as described above for people on ART, 
to obtain the CD4 count, variability (sd_cd4) is added on the square root scale: 1.2 is the 
standard deviation. The estimate was based on unpublished analyses. 
 
3.7.3.4. Viral load and CD4 count changes during ART interruption 
During ART interruption, VL returns to previous maximum VL (vmax) in 3 months and adopts 
natural history changes thereafter.   
 
The rate of CD4 count decline returns to natural history changes (i.e. those in ART-naïve 
patients) after 9 months, unless the count remains > 200 cells/μL above the CD4 count nadir, 
cmin(t). 
 
Before returning to the natural history, for the first 9 months, the rate of CD4 count decline 
depends on current VL (See Table 3.27).  
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Table 3.27. Summary of changes in CD4 count during ART interruption according to time off 
ART and current viral load 
Time off ART Current viral load 
(log copies/mL) 
Distribution of change in 
CD4 count (cells/μL) 
3 months, or >3 months and CD4 count in 
previous period is >300 above the 
minimum CD4 count to date 
VL > 5 Normal (-200,10) 
4.5 ≤ VL < 5 Normal (-160,10) 
VL < 4.5 Normal (-120,10) 
6 months VL > 5 Normal (-100,10) 
4.5 ≤ VL < 5 Normal (-90,10) 
VL < 4.5 Normal (-80,10) 
9 months VL > 5 Normal (-80,10) 
4.5 ≤ VL < 5 Normal (-70,10) 
VL < 4.5 Normal (-60,10) 
 
If these changes lead to 𝑐(𝑡) < 𝑐𝑚𝑖𝑛(𝑡) then 𝑐(𝑡) = 𝑐𝑚𝑖𝑛(𝑡), i.e. current CD4 count is set as 
the CD4 count nadir. 
 
These values are broadly based on evidence from a number of analyses of the effects of ART 
interruption (276;319;616-625).  
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3.8. Emergence of specific resistance mutations and their effect on drug 
activity 
3.8.1. Modelling resistance 
Resistance is modelled in terms of the presence or absence of mutations specific to the drugs 
in use.  The choice of mutations to include reflects a balance between the desire to capture 
important specific effects and the need to limit the complexity of the model and the number of 
variables simulated. The IAS-USA resistance guidelines provided the basis for choice of 
mutations (626).   
 
We do not specify the mutated amino acid for each position; it is assumed that for a given 
codon position, the mutations considered are those that confer resistance (e.g. for M184 this 
is I or V).  
 
Unlike all other resistance mutations, M184 is assumed not to persist in majority virus after 
HIV infection; although like all other mutations, it does persist as minority virus. 
 
3.8.2. Accumulation of resistance mutations 
Newmut(t) (see Table 3.21 at page 172, Table 3.24 at page 175, Table 3.25 at page 176 and 
section 3.7.2) is a probability used to indicate the level of risk of new mutations arising in a 
given 3 month period. As mentioned this parameter and therefore the probability of acquiring 
resistance depend on: the number of active drugs, the time spent on ART (since initiated for 
the first time or since restarting it) and the effective adherence between t-1 & t and t-2 & t-1. 
If this chance comes up in a given 3 month period (determined by sampling from the binomial 
distribution) then the following criteria operate (presented per drug class): 
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Table 3.28. Probability of specific mutation arising 
Resistance mutation 
Probability 
of arising Conditions 
M184 0.8 if (on 3TC)  
# TAMS increases by 1 0.2 if (on AZT or D4T) and (not on 3TC nor FTC) 
0.12 if (on AZT or D4T) and (on 3TC or FTC) 
# TAMS increases by 2 0.01 if (on AZT or D4T) and (not on 3TC nor FTC) 
0.01 if (on AZT or D4T) and (on 3TC or FTC) 
K65 0.01 (0.02*) if (on TDF or DDI) and (on AZT or D4T)  
0.04 (0.10*) If (on TDF or DDI) and (not on AZT or D4T)  
L74 0.01 if on DDI   
Q151 0.02 if (on DDI or D4T or AZT)  
NNRTI mutations* 0.80 If on NVP or EFV 
K103** 0.2 If on NVP 
0.7 If on EFV 
Y181** 0.4 If on NVP 
0.1 If on EFV 
G190** 0.2 If on NVP 
0.1 If on EFV 
V32 0.04 if on LPV/r 
I47 0.04 If on LPV/r 
V82 0.04 If on LPV/r 
*NNRTI mutations are considered all together in the model for South Africa; **the model for Zimbabwe was 
developed further to distinguish among the primary NNRTI DRMs. 
3TC: lamivudine; AZT: zidovudine; d4T: stavudine; ddI: didanosine; EFV: efavirenz; FTC: emtricitabine; LPV: lopinavir 
boosted with ritonavir; NNRTI: non-nucleoside reverse transcriptase inhibitor; NVP: nevirapine; TAMS: Thymidine 
analogue mutations; TDF: tenofovir; 
 
These values are chosen, in conjunction with values of newmut(t), to provide estimates of 
accumulation of specific classes of mutation consistent with those observed in clinical practice 
(611;613;614;627-629). They reflect a greater propensity for some mutations to arise than 
others. This probably relates to the ability of the virus to replicate without the mutations (e.g. 
probably very low in the presence of 3TC for virus without M184V) as well as the replicative 
capacity of virus with the mutations.  Over time as more data accumulate it may be possible 
improve these estimates of rates of accumulation of specific mutations. 
 
3.8.3. Accumulation and persistence of resistance mutations in pregnant women 
receiving prevention of mother-to-child transmission 
As described in section 3.5.1, the model simulates pregnancies in women who engage in 
condom-less sex, whether they are tested in ANC and whether they receive ARVs for PMTCT. 
The scale up of PMTCT services and the regimen recommended are described in Appendix IV 
for South Africa and Appendix VIII for Zimbabwe. 
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Single dose NVP and the most recent regimen have been associated with different risk of 
NNRTI resistance emergence (630): the first (prob_nnresmaj_sd_nvp) is assumed to be 0.35 
per pregnancy and the second (prob_nnresmaj_dual_nvp) 0.045 (630). 
 
There is evidence that even if NNRTI mutations are acquired in women receiving PMTCT, they 
tend to be lost and this does not seem to affect their virological response when in the future 
they start ART for their own health (631). It is assumed women who have acquired NNRTI 
resistance due to PMTCT, experience a rate of losing these mutations from majority virus per 3 
months (rate_loss_nnres_pmtct_maj) and once they are present only in minority virus a rate of 
losing them completely (rate_loss_nnres_pmtct_min) of 0.25.  Once they are lost completely 
then even if they start an NNRTI regimen, the mutations are not going to re-emerge. 
 
3.8.4. New resistance to NNRTI arising as a result of ART interruption 
It is assumed that, due to the long half-life of NNRTIs, stopping a regimen containing either EFV 
or NVP is associated with a probability of an NNRTI resistance mutation arising 
(risk_res_stopping_nn). This is assumed to be of 0.05 per 3 months for South Africa. In the 
model for Zimbabwe, NRRTI DRMs where modelled separately (K103, Y181 and G190) and the 
chance of each of them arising are respectively: 0.018, 0.006, 0.006. 
In Chapter 6, I estimated the risk of NNRTI resistance emerging after interruption of NNRTI-
based regimen. 
 
3.8.5. Loss of acquired mutations from majority virus 
It is assumed that DRMs acquired while on ART tend to be lost from majority virus with a 
certain probability from 3 months after stopping to take a drug that selects for that DRM, 
although these mutations will remain in minority virus. 
The probability of losing mutations per 3 months (from 3 months after stopping) is 
summarised in the Table 3.29. These values were chosen based on the analysis conducted in 
Chapter 6 and evidence from studies in people interrupting ART (352;369;386;632-636). 
Note that these probabilities all relate to people who have started ART and are not about 
persistence of TDR mutations (which is currently assumed to be indefinite, except for M184V).  
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Table 3.29. Mutation-specific probability of loss of resistant mutation from majority virus 
 
 
 
 
 
 
 
 
 
 
 
NNRTI: non-nucleoside reverse transcriptase inhibitors; TAMS: Thymidine analogue mutations; 
 
3.8.6.  “Regaining” mutations in majority virus after restarting ART 
Mutations previously present in majority virus, remain in minority virus, are regained in 
majority virus when one of the drugs selecting for that mutation is restarted (see Table 3.30). 
 
3.8.7. Determination of level of resistance to each drug and calculation of activity 
level of each drug 
The level of resistance conferred by each DRM to ARVs is displayed in Table 3.30, where a 
value of 1 means full resistance, while a value of 0 means that the drug is fully active. 
  
Resistance mutation Probability of loss (per 3 months) 
M184V 0.8 
L74V 0.6 
K65R 0.6 
Q151M 0.6 
TAMS (lose all) 0.4 
NNRTI mutations 0.2 
Protease mutations 0.2 
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Table 3.30. Summary of level of resistance conferred by specific mutations 
Mutation Drug Level of 
resistance 
Condition 
M184V 3TC 0.75  
1-2 TAMS AZT or D4t 0.5 (no 3TC or FTC in regimen) 
0.5 (3TC or FTC in regimen- no M184V ever) 
0.25 (3TC in regimen- M184V ever) 
3-4 TAMS AZT or D4t 0.75 (no 3TC or FTC in regimen) 
0.75 (3TC or FTC in regimen- no M184V ever) 
0.5 (3TC in regimen- M184V ever) 
5-6 TAMS AZT or D4t 1.00 (no 3TC or FTC in regimen) 
0.75 (3TC or FTC in regimen- no M184V ever) 
0.75 (3TC in regimen- M184V ever) 
2-3 TAMS TDF  0.5 (no K65R ever, no 3TC in regimen) 
0.5 (no K65R ever, 3TC in regimen, no M184V ever) 
0.5 (no K65R ever, 3TC in regimen,       M184V ever) 
>=4 TAMS TDF 0.75 (no K65R ever, no 3TC in regimen) 
0.75 (no K65R ever, 3TC in regimen, no M184V ever) 
0.5 (no K65R ever, 3TC in regimen,      M184V ever) 
> 3 TAMS DDI 0.5  
Q151M AZT or D4T 0.75  
DDI 0.75  
K65R D4T or TDF 0.5  
DDI 0.75  
L74V DDI 0.75  
NNRTI mutation NVP or EFV 1.00  
1 from Pr 32, 47, 
76, 82 
LPV/r 0.25  
2 from Pr 32, 47, 
76, 82 
0.5  
3 from Pr 32, 47, 
76, 82 
0.75  
2-3 from Pr 46, 
76, 82, 84, 90  
max(r_lpr, 
0.25) 
 
4     from Pr 46, 
76, 82, 84, 90 
max(r_lpr, 
0.5) 
 
*NNRTI mutations are considered all together in the model for South Africa; **the model for Zimbabwe was 
developed further to distinguish among the primary NNRTI DRMs. 
3TC: lamivudine; AZT: zidovudine; d4T: stavudine; ddI: didanosine; EFV: efavirenz; FTC: emtricitabine; LPV/r: 
lopinavir boosted with ritonavir; NNRTI: non-nucleoside reverse transcriptase inhibitor; NVP: nevirapine; TAMS: 
Thymidine analogue mutations; TDF: tenofovir; 
 
These rules approximately follow the interpretation systems for conversion of mutations 
present on genotypic resistance test into a predicted level of drug activity (or, equivalently, of 
resistance; e.g. (637-640)). Currently interpretation systems differ in their prediction of activity 
for some drugs.  
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3.8.8. Calculation of activity level of drug 
Every ARV is treated as being equally potent because virological efficacy depends only on 
number of active drugs, not which specific drugs they are on that are active. In reality, ARVs 
differ in potency but to my knowledge no reliable estimates are available to use. The exception 
is for boosted-PI drugs which are assumed to have double potency of all other drugs, based on 
their efficacy as monotherapy (641;642).  
 
The number of active drugs in the regimen at time t, nactive(t), is given by 1 – level of 
resistance, as described in section 3.8.7. Activity levels of each drug in the regimen are 
summed to give the total number of active drugs. 
 
 
3.9. Toxicities 
Toxicities including gastrointestinal symptoms, rash, hepatoxicity, CNS toxicity, lipodystrophy, 
hypersensitvity reaction, peripheral neuropathy and nephrolithiasis can occur with certain 
probability on certain specific drugs.  In section 1.8.5 and Appendix II, it is indicated which 
toxicities are included in the Synthesis heterosexual model and the evidence available from 
RCTs and cohort studies is summarized in Appendix II. For some of the conditions there are no 
common definitions and it is therefore more complicated to understand the actual incidence 
of these conditions across different studies. All toxicity variables are binary, i.e. if the individual 
develops a certain toxicity in a given 3-month period, it takes the value 1, otherwise 0.  
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3.9.1. Incidence of new current toxicity 
All individuals do not have any toxicity before initiating ART. Table 3.31 presents the 
probability of respectively developing and continuing having a toxicity in any given 3-month 
period. 
 
Table 3.31. Risk of development of toxicities to ART in the model (643-648) 
Toxicity Drug Risk of development 
per 3 months 
Probability of 
continuation if pre-
existing 
Nausea LPV, ddI, AZT 0.03 (5-fold higher in 1st year) 0.5 
Diarrhoea LPV 0.03/0.02* 0.2/0.5* 
ddI 0.05 0.2/0.5* 
Rash EFV 0.03 (one-off risk in 1st 3 months)  
NVP 0.1 (one-off risk in 1st 3 months)  
CNS EFV 0.1 (in 1st year, 0 after) 0.8 (in 1st year) 
0.9 (after 1st year) 
Lipodystrophy d4T 0.05 1.0 
AZT 0.015 1.0 
Peripheral 
Neuropathy 
d4T 0.02 (1.5 fold higher in 1st year) 1.0 if remain on d4T, 0 
otherwise 
DdI 0.01 (1.5 fold higher in 1st year) 1.0 if remain on ddI,0 
otherwise 
Acute hepatitis NVP 0.02 (one off risk in first and 2nd 3 
month periods) 
 
Anaemia AZT 0.03 (1.5 fold higher in 1st year) 0.2 
Headache AZT 0.1 (1.5 fold higher in 1st year) 0.4 
Pancreatitis ddI, d4T 0.001/0.0002*  
Lactic acidosis AZT, ddI, d4T 0.0002  
AZT: zidovudine; d4T: stavudine; ddI: didanosine; EFV: efavirenz; LPV: lopinavir; NVP: nevirapine; TDF: tenofovir; *: 
Zimbabwe; 
 
3.9.2. Switching of drugs due to toxicity 
If toxicity is present then individual drugs may be switched due to toxicity.  In most cases, the 
switch is to another in the same class, if such a drug (that has not been previously failed nor 
stopped due to toxicity) is available.  This will vary by setting and availability of alternative 
drugs.  
      
187 
 
3.10. First-line ART failure definition 
The definition for first-line failure depends on the availability of CD4 count and VL measures 
for monitoring. 
I assumed that monitoring of people on ART follows the recommendation on national 
guidelines in South Africa: VL monitoring (See section 2.1.7).  
In Zimbabwe it is assumed CD4 is measured 6 monthly from 2003 and treatment failure is 
defined as CD4<200 cells/μL (confirmed by a subsequent CD4 at the same visit <200 cells/μL), 
after at least one year on ART. This is a simplification of what is indicated in the guidelines (see 
section 2.2.7). 
 
 
3.11. Outcomes from the model of patients on ART 
Table 3.32-Table 3.36 (page 189-page 191) present outcomes of patients initiated on ART. In 
particular, Table 3.32 gives an overview of the status of patients over time since ART initiation. 
It shows that at one year since ART initiation 88% are still attending the clinic (most of them 
are still on ART, 86%), while the remaining are either dead (5%) or lost from care (7%). This 
closely reflects what reported in the literature (see Appendix XX, page 471). However because 
the Synthesis model is at national level, it does not model the transfer of people from one 
clinic to another and thus people who transfer from one clinic to another would be considered 
retained in care in the Synthesis model. As time moves on from ART initiation, the proportion 
of people retained on ART diminishes, with 63% still retained on ART at 10 years since ART 
initiation. Of those not retained, 68% of them are going to be dead (26% of those who initiated 
ART 10 years before), 24% to be lost from care (9% of % of those who initiated ART 10 years 
before) and the remaining are going to be in care but off ART, because they chose to interrupt 
ART but they are still engaged in care. 
Table 3.33 summarizes the immunologic, virological and resistance outcome up to 20 years 
since ART initiation.  It shows that by one year 13% (when considering definition a) will 
experience virologic failure and this will increase up to 40% by 20 years. This is going to be 
accompanied by development of resistance in most cases. However, by one year almost half of 
those who initiated ART will experience an increase of CD4 of at least 100 cells/μL (12% of 200 
cells/μL) and by 5 years over 90% (80% if considering an increase of 200 cells/μL). These 
assumptions are comparable to data from the literature (499;649).   
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To fully describe the immunological reconstitution in people receiving ART, Table 3.34 (page 
190) presents the increase in CD4 count in people exposed to ART and restricting to those 
currently on ART. It shows that by one year since ART initiation the median increase in CD4 cell 
count is 71 cells/μL, when considering all those initiated on ART and 81 cells/μL in those still on 
ART after one year. By five and ten years the median increase in CD4 cell count reaches levels 
respectively over 200 and 300 cells/μL.  
Table 3.35 (page 190) illustrates the risk of interruption of ART, of being LTFU and of death by 
length of time since ART initiation. By one year since ART initiation 14% are assumed to have 
interrupted ART, however only 5% are assumed not to be engaged anymore and 4% to be 
dead. ART interruptions are assumed to be a quite common phenomenon and by ten years 
more than half of the patients are assumed will have had some ART interruption, however only 
a subset are going to be lost (18% by five years and 46% by twenty years). 
Finally, Table 3.36 (page 191) presents, for those who have been LTFU, the risk of death and of 
returning back into care. Although people who have been lost can return into care, there is 
evidence that ART interruptions are very detrimental on the chance of surviving. This table 
shows that by 1 year since the first time a person is lost after ART initiation 9% will be dead, 
while 16% will be back in care. This increases over time, with 30% and 69% people dying by 
respectively three and ten years since the first time they were lost from care. Most of those 
who disengage from care return into care by five years, however afterwards the rate of 
returning into care slows down and only 63% return by ten years. 
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Table 3.32. Cross sectional analysis at 1, 5, 10 and 20 years since ART initiation of status of 
patients initiated on ART 
These were estimated using parameter values which provided the best fit, in the context of 
CD4 at ART initiation of 310 cells/μL*.  
 Years from start of ART   
1 3 5 10 
On ART 86%         78%    74%     63%     
Off ART,  
attending the clinic 
2%      2%      2%   3%  
Off ART, lost from care      7% 8% 9% 9% 
Dead 5% 12% 15% 26% 
ART: antiretroviral therapy; *In both South African and Zimbabwe the CD4 at ART initiation is much lower, such a 
higher CD4 was determined to minimize the time to produce these tables. 
 
 
 
Table 3.33. Kaplan-Meier estimates of virological failure, resistance and immunological 
recovery 
Kaplan-Meier estimates of percent with virological failure (> 500 copies/mL after at least 6 
months on ART (a) or two consecutive VL, the 1st >400 copies/mL, followed by a value above 
1000 copies/mL (b)), resistance (predicted susceptibility < 50%) to at least one drug, CD4 count 
rise of > 200/μL, using parameter values which provided the best fit, assuming no ART 
interruption and restricting to people with no transmitted drug resistance and assuming no 
super-infection with resistant virus, in the context of CD4 at ART initiation of 270 cells/μL. 
Compare, for example, with (499;649).   
 Years from start of ART 
1 3 5 10 20 
Virological failure (a) 13% 21% 27% 32% 40% 
Virological failure (b) 9% 19% 25% 31% 39% 
Resistance 12% 19% 24% 29% 45% 
CD4 count rise of >200/μL  12% 61% 80% 93% 96% 
CD4 count rise of >100/μL 46% 82% 91% 97% 98% 
ART: antiretroviral therapy; 
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Table 3.34. Median and interquartile range in change in CD4 cell count from ART initiation in 
people exposed to ART (i.e. ever started on ART) and in those on ART. 
These were estimated using parameter values which provided the best fit, in the context of 
CD4 at ART initiation of 310 cells/μL.  
 Years from start of ART 
Change in CD4 count 1 3 5 10 
 In ART exposed people 71 (1,143)     121 (-27,238) 220 (-42,367) 304 (97,478) 
 In people on ART 81 (17,143) 151 (88,308) 261 (89,375)   356 (182,498)  
ART: antiretroviral therapy; 
 
 
Table 3.35. Kaplan-Meier estimates of percent interrupting ART, lost to follow-up after 
starting ART, and dead. 
This is using parameter values which provided the best fit, in the context of CD4 at ART 
initiation of 310 cell/μL.  Both restricting to those in care and including those lost to care. 
 Years from start of ART 
1 3 5 10 20 
Interruption of ART* 14% 33% 45% 67% 88% 
Loss to care 5% 12% 18% 30% 46% 
Death (in those under care) 3% 7% 10% 18% 40% 
Death (including those lost) 4% 8% 14% 28% 56% 
ART: antiretroviral therapy; *The interruption of ART does not mean that the patient is not 
attending the clinic, but simply that it is not taking ART. As mentioned above, the people not in 
care can go back to HIV care and restart ART. 
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Table 3.36. Cumulative risk of death and returning to care after first being lost to follow-up 
after starting ART. 
These were estimated using parameter values which provided the best fit, in the context of 
CD4 at ART initiation of 310 cells/μL. 
 Years from first lost (after starting ART) 
1 3 5 10 
Death while lost 9% 30% 50% 69% 
Return after loss to care 16% 43% 55% 63% 
ART: antiretroviral therapy; 
 
 
3.12. Risk of clinical disease and death in HIV-infected people 
The choices of parameter estimates in this section are broadly based on references 
(123;126;129;148;650). Factors were chosen to provide results consistent with observed data, 
including the incubation period for death and the time from AIDS to death in untreated people 
(103;117;651-653). 
 
3.12.1. Occurrence of WHO stage 4 event 
Occurrence of WHO stage 4 diseases (see (126;129;148)) is assumed to depend on CD4 cell 
count (see Table 3.37), VL (see Table 3.38 at page 193), age (See Table 3.39 at page 193), PCP 
prophylaxis and ART regimen. 
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3.12.1.1. Independent effect of CD4 cell count 
Table 3.37. Rate of WHO 4 disease according to CD4 count in the model 
CD4 cell count Rate of WHO 4 diseases per 3 months 
(per 100 person-years) 
≥650 0.2 
[500-650) 1.0 
[450-500) 1.3 
[400-450) 1.6 
[375-400) 2.0 
[350-375) 2.2 
[325-350) 2.5 
[300-325) 3 
[275-300) 3.7 
[250-275) 4.5 
[225-250) 5.5 
[200-225) 6.5 
[175-200) 8 
[150-175) 10 
[125-150) 13 
[100-125) 17 
[90-100) 20 
[80-90) 23 
[70-80) 28 
[60-70) 32 
[50-60) 40 
[40-50) 50 
[30-40) 80 
[20-30) 110 
[10-20) 180 
[0-10) 250 
 
3.12.1.2. Independent effect of viral load 
The impact of VL on the rate of experiencing WHO stage 4 diseases is obtained by multiplying 
the CD4-specific rate by the factors indicated in Table 3.38. 
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Table 3.38. Multiplicative factor based on viral load on the rate of experiencing WHO stage 4 
disease 
Viral load level Multiplicative factor 
       < 3.0 log copies/mL 0.2 
3.0 - 4.0 log copies/mL 0.3 
4.0 - 4.5 log copies/mL 0.6 
4.5 - 5.0 log copies/mL 0.9 
5.0 - 5.5 log copies/mL 1.2 
      > 5.5 log copies/mL 1.6 
 
3.12.1.3. Independent effect of age 
To take into account the fact that the risk of experiencing WHO stage 4 increases as age 
increases the rate is determined as: 
𝑟𝑎𝑡𝑒𝑊𝐻𝑂4 = 𝑟𝑎𝑡𝑒𝑊𝐻𝑂4 ∗ (
𝑎𝑔𝑒
38
)
1.2
 
See examples in Table 3.39. 
 
Table 3.39. Example of multiplicative factor based on age on the rate of experiencing WHO 
stage 4 disease 
Age Multiply rate by 
20 0.46 
30 0.75 
40 1.06 
50 1.39 
 
3.12.1.4. Independent effect of PCP prophylaxis 
If the patient is on PCP prophylaxis, the rate of WHO stage 4 occurring is multiplied by 0.8. 
From 1996, patients with a measured CD4 count below 350 cells/μL are assumed to have an 
80% chance of starting PCP prophylaxis and those with a current WHO stage 3 or 4 condition 
90% chance of starting it. They interrupt the use of PCP once they have a measured CD4 cell 
count above 350 cells/μL, if CD4 cell count is measured, or if the patients has been 
continuously on ART and did not experience WHO stage 4 or 3 in the last 6 months. 
 
3.12.2. Occurrence of WHO stage 3 event 
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To obtain the rate of WHO stage 3 diseases occurring, the rate of WHO stage 4 occurring is 
multiplied by 5 (fold_incr_who3). 
 
3.12.3. Occurrence of HIV-related death 
To obtain the base rate of occurrence of an HIV related death, the rate of WHO stage 4 
occurring is multiplied by 0.25 (fold_decr_hivdeath). 
 
The base rate of HIV related death is then affected by presence of current TB and whether the 
patient has an AIDS defining condition. In the first case the rate is multiplied by 5 in South 
Africa and 10 in Zimbabwe (incr_death_rate_tb), in the second case by 2 and 10 
(incr_death_rate_adc). 
This different assumption regarding the impact of TB and AIDS on mortality in Zimbabwe 
compared to South Africa was necessary to be able to reproduce an epidemic such as that 
observed in Zimbabwe (in terms of the observed decline in HIV prevalence and death rates). 
It is assumed 15% of HIV-related deaths (i.e. not including deaths that arise due to background 
mortality rates) are classified as non-HIV-related.  
 
 
3.13. Calibration of the model 
To calibrate the model to the South African epidemic, I used Approximate Bayesian 
Computation methods (654). In essence, this involves running multiple simulations which 
sample unknown parameter values from suitable distributions, which are meant to reflect the 
uncertainty around them, and then selecting those parameter sets where simulated model 
outputs are most consistent with observed data, by assessing the fit using a summary statistic. 
In the Synthesis model, there are multiple parameter values describing various elements of the 
underlying progression of HIV and the effect of ART.  The model has been shown to give a 
good fit to data on these processes and, for the purposes of fitting the model to the HIV 
epidemic in a given country, I hold these parameter values fixed (58 for the South African 
model and 69 for the Zimbabwean model).  They, thus, become part of the model structure 
rather than parameters to be sampled from. Nevertheless, some of the parameters are fixed 
and different in the model calibrated to South Africa and Zimbabwe, either because I decided 
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in collaboration with the other people working on the model to further develop the model, 
this is for example the case for including separately NNRTI mutations in the Zimbabwean 
model or because it was necessary to be able to calibrate the model to observed data (see 
section 3.12.3). Other differences are due not generally to new data becoming available but, 
especially for areas with more uncertainty such as resistance, give conservative results and so 
for example not underestimating the potential impact of resistance. 
The parameters for which values are sampled from distributions of plausible values are mainly 
those which determine levels of condom-less sex and the rate of HIV transmission (28 for the 
South African model and only one for the Zimbabwean model). When sampling parameters 
which determine the HIV incidence and prevalence it is important to ensure that the 
parameter space sampled is chosen to be large enough to allow for extremities and that the 
parameterization is sufficiently flexible but also restricted enough to limit computation time. 
So for each run of the simulation model, I sampled at random a set of parameter values for 
those listed in Appendix XI with the distribution, and generate the HIV epidemic until the end 
of 2012. In order to improve the efficiency of the sampling I assumed correlation between the 
three following parameters: (a) Fold difference in transmission rate for a given VL (fold_tr), (b) 
rate of transmission in PHI (tr_rate_primary) and (c) factor to change overall average level of 
condom-less sex with short-term partners (newp_factor). 
This is repeated 10,000 times in order to search for the best fitting parameter sets. For each 
run, the fit of the model to the observed data was assessed using a fit score; the sum of the 
deviances from the observed data (summed over the number of years data was available for, 
and for each type of data available), is quantified by 
|𝐷−𝑀|
𝐷
 , where D is the observed data and 
M is the estimate produced by the Synthesis Model.  
The data used to fit the model to the South African HIV epidemic are (41 points): 
 HIV prevalence among adults aged 15 to 49 years (available for 2002, 2005, 2008, 
2011) (452) 
 HIV prevalence among young people, aged 15 to 25 years (available for 2002, 2005, 
2008)  (452) 
 the proportion, gender-specific, of people who ever had an HIV test (available for 
2002, 2005, 2008) (452) 
 the number, gender-specific, who started ART (available from 2001 to 2011)  (655) 
 the proportion of new diagnoses with resistance (available from 2005 to 2010) (305).  
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Half weight was assigned to the deviance to the proportion of new diagnoses with resistance, 
because this estimate refers to southern Africa, rather than specifically South Africa and it may 
be not representative of all South Africa. The 30 simulations with the best fit (out of 10,000), in 
terms of average deviance, were selected (average deviance of less than 0.94). 
 
The data used to fit the model to the Zimbabwean HIV epidemic (128 points) are: 
 HIV prevalence among adults aged 15 to 49 years, separately from men and women 
(available for 2006, and 2011) (518;519) 
 HIV prevalence for women aged 15 to 49 years in 1995 cited by Gregson (514) 
 HIV prevalence in all 5-years age group between the age of 15 and 49 for women and 
54 for men (available for 2006 and  2011)  (518;519) 
 the proportion, gender-specific, of people who ever had an HIV test (available for 2006 
and  2011)  (518;519) 
 the proportion, gender-specific, of people who ever had an HIV test in all 5-years age 
group between the age of 15 and 49 for women and 54 for men (available for 2006 
and  2011)  (518;519) 
 the proportion, gender-specific, of people who had an HIV test in the last 12 months 
(available for 2006 and  2011)  (518;519) 
 the proportion, gender-specific, of people who had an HIV test in the last 12 months 
separately for all 5-years age group between the age of 15 and 49 for women and 54 
for men (available for 2006 and  2011)  (518;519) 
 the proportion of pregnant women who receive an HIV test in the ANC (available for 
2006 and  2011)   
 the proportion of pregnant women who receive an HIV test in the ANC separately for 
all 5-years age group between the age of 15 and 49 for women (available for 2006 and  
2011)   
 
A weight of 1 was assigned to all the deviance between the gender-specific estimate for the 
entire population 15 to 49 years old, while to the deviance for each 5-years age group was 
assigned a weight so that, all the age group together would sum up to a wait of 1. 
Only the simulation with the best fit was selected and in Chapter 8 this simulation is illustrated 
together with the observed data used to calibrate the model. The fact that only one simulation 
is selected means that I could not present the 90% uncertainty range and so how the 
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parameters uncertainty propagated (only one parameter was sampled, while the other 
parameters were hand tuned). This choice was driven by feasibility; I do plan to use 
approximate Bayesian computational methods to calibrate the Zimbabwe HIV epidemic and to 
present 90% uncertainty range. 
 
The purpose of fitting is to select those combinations of parameters which more closely reflect 
the HIV epidemic observed and, by selecting appropriate distribution from which to sample 
the parameters and appropriate threshold to select simulations that fit, produce some 
indication of the parameter uncertainty. In order to reflect in the output, the uncertainty in 
the input parameters, for South Africa I selected a subset of simulations who provided a good 
fit, rather than only one single simulation, and I presented the 90% uncertainty range (the 5th 
and 95th estimate across the simulations for that particular outcome). This measure of 
uncertainty clearly depends on the cut-off used to determine whether a simulation is consider 
to fit to the data or not and it is in some way an arbitrary choice. However the choice of the 
distributions from which parameters are sampled from are arbitrary as well, because it is 
difficult to quantify the uncertainty.  
 
In order to fit the Synthesis model to observed data and to produce output measures up to 
2013, expressed in absolute terms, which are relevant respectively for South Africa and 
Zimbabwe, I multiply the modelled population size by the ratio between the estimated adult 
population size (for South Africa in mid-2011 (481), for Zimbabwe in mid-2013 (434)) and the 
size of the modelled population (673 for South Africa, 222 for Zimbabwe). 
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3.14. My view on the Synthesis model 
As mentioned, when I started working on the Synthesis model, the core of the model was 
already developed. Thus, I could not have the privilege of choosing how to model some 
processes within it. However, if there were processes or assumptions I was uncomfortable 
with, these were discussed with the other colleagues working on it and an agreement was 
found. 
I think this model can provide (and has already provided) important contributions to inform 
policy decisions making processes, given its peculiarities. Differently from most of the other 
HIV mathematical models, which are deterministic compartmental models, it is an individual 
based stochastic model. This allows including a higher level of details, such as for example all 
the single steps in the continuum of care, while at the same time taking into account the 
emergence and transmission of resistance. In addition, it is very suitable to run cost-
effectiveness analysis which are more and more often used, or at least considered, when 
making decisions. 
On the other hand, its complexity and richness of details sometimes make it difficult to 
understand which parameters are driving the results observed and, although it improved over 
time, it still takes long time to run and therefore not always it is possible to run extensive 
sensitivity analyses.   
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4. Cost-effectiveness of expanding the population in care 
and/or the population eligible for antiretroviral 
therapy 
 
4.1. Outline of the chapter 
In the previous chapters the South African epidemic has been introduced and the Synthesis 
model has been thoroughly described. In this chapter the Synthesis model is used to evaluate 
the impact of expanding diagnosis, improving retention and modifying the eligibility criteria for 
ART initiation in South Africa.  
There is in fact lots of debate regarding when to initiate  ART on the basis of the clinical and the 
preventive benefit. The evidence on the clinical benefit is presented and a formal literature 
review on the preventive benefit of ART has been performed. Several mathematical models 
have addressed this question comparing slightly different strategies and different outcomes. 
To enable a straightforward comparison, the HIV Modelling Consortium, which is funded by Bill 
and Melinda Gates Foundation with the aim to enhance the scientific support in the decision 
making processes related to HIV public health and led by Imperial College (656), asked 
modellers using different mathematical models to evaluate exactly the same intervention in 
the South African setting. They collected in a systematic way the standardized outcomes from 
different models. The findings of the cost-effectiveness analysis using the Synthesis model are 
presented in this chapter and the results are compared to the findings from other 
mathematical models, which took part in this collaborative project led by the HIV Modelling 
Consortium. 
 
 
4.2. Literature review of the preventive benefit of antiretroviral 
treatment 
4.2.1. Background 
The idea that ART could be used not only to reduce morbidity and mortality amongst HIV-
positive people, but also to prevent onwards sexual HIV transmissions, by reducing the 
infectiousness of HIV-positive people, is not new. The ability of ART to suppress VL is well 
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documented (609;657;658) (see section 1.8.7) and many observational studies have found a 
strong association between plasma VL and the risk of onwards transmission (31;38;42;659).  
In January 2008 some researchers formulated what has been called the ‘Swiss Statement’ 
(660), stating that: 
“the risk of sexual transmission of HIV is negligibly low if three conditions are met: (i) 
the HIV-positive person is receiving antiretroviral therapy with excellent adherence; (ii) 
blood VL has consistently been undetectable (<40 copies per mL) for more than 6 
months; and (iii) no [sexually transmitted diseases] STDs are present in either of the 
partners.”  
This ignited a vigorous debate on whether there was strong enough evidence to support this 
statement.  
 
The principle that ART can reduce HIV infectiousness to varying degrees at an individual level is 
largely agreed. However, at a population level, several factors could potentially limit the 
reduction in secondary transmission. These include the longer potential duration of 
infectiousness due to the longer survival of people receiving ART, the potential difficulty in 
maintaining viral suppression over long periods of time (mainly driven in sub-Saharan Africa by 
drug supply issues, adherence and being able to attend the clinic regularly), the fact that 
transmission often occurs when people are still in PHI or undiagnosed, and potential increases 
in sexual behaviour as a result of feeling better due to ART or being aware that ART reduces 
infectiousness. In addition, some have doubts as to whether ART initiation for all HIV-positive 
people should be implemented due to ethical difficulties, in particular the fact that there is no 
agreement regarding the individual clinical benefit of starting ART earlier, and whether it is the 
most cost-effective strategy.  
The aim of this section is to present the results of a formal literature review on the population-
effect of earlier initiation of ART to prevent new infections. This work was performed as part of 
the preparation of a technical report commissioned by the European Centre for Disease 
Prevention and Control (661) aimed at evaluating HIV treatment as prevention (including ART 
as prevention in HIV-positive people, PMTCT and post-exposure prophylaxis) and at discussing 
the implications for Europe. The review has been updated on the 19th November 2013 and it 
has now been published (662).  
 
4.2.2. Conduct of the formal literature review  
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A formal literature search was conducted to identify all relevant original papers published in 
the most recent years, regarding the impact of using ART as prevention, rather than as 
treatment to prevent morbidity and mortality in HIV-positive individuals, focusing on the 
population-level effect. The search was conducted on all databases available on Web of 
Knowledge: Web of Science, MEDLINE, BIOSIS Citation Index, BIOSIS Previews and Journal 
Citation Report. I searched for all papers (excluding case report, biography, editorial, book, 
correction, report, review, patent, meeting, news, bibliography, letter) written in English, in 
several relevant subject areas (infectious diseases, virology, social issues, behavioural sciences, 
social sciences other topic, mathematics, life sciences biomedicine other topics, biomedical 
social sciences, mathematical computational biology) in the last 8 years (2006-2013) with topic 
‘HIV*’ and ‘antiretroviral*’  and (‘prevent*’ or ‘transmi*’)) NOT Topic=(‘child*’ or ‘mother*’ or 
‘vertical’ or ‘prophylaxis’ or ‘pregnan*’ or ‘herpes’ or ‘breast*’ or ‘tuberculosis’). The search 
was restricted to studies published after 1 January 2006 because this is the period in which 
most studies concerned with the impact of ART for prevention have been published. Relevant 
papers published before this period (e.g. Quinn NEJM 2000 (31)) were selected by hand 
searching papers already known to the authors and by checking the references of all selected 
papers and were also included in the review. In addition, for all papers selected it was checked 
whether there were any corrections. A possible limitation is the fact that the search was 
restricted to papers written in English. Nevertheless, journals with the highest impact factor 
are generally published in English and therefore I believe the likelihood that important studies 
on this topic were omitted from our review is minimal.  
 
The search on Web of Knowledge for the European Centre for Disease Prevention and Control 
review was performed on the 5th September 2011 and updated on 19th November 2013. 
Papers found through the computerised database searching on Web of Knowledge were 
combined with those identified by hand-searching. Jemma O’Connor and I independently 
screened the records identified in September 2011 and I screened those identified thereafter, 
by reviewing the title and abstract to identify those eligible for full-text appraisal. If 
disagreement was found in the papers selected, these were discussed and an agreement was 
found. For the papers identified in September 2011 we both assessed the papers included 
based on the full text and information on the type of study, setting, follow-up period, sample 
size, population and outcome measures collected. All studies that evaluated the impact of ART 
on preventing new HIV infections compared to absence or delayed treatment in HIV-positive 
populations were included in the review, regardless of study design. There were no specific 
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requirements regarding the outcome measure used; any measure of HIV incidence or 
prevalence was considered acceptable. I interpreted the results and together with the other 
authors the manuscript was prepared. 
 
5,805 (n=2,105 on 5th September 2011) papers were identified with the computerised 
database search and 34 through hand searching. After removing duplicates and excluding 
references considered not relevant by two independent persons (only the records published 
before 5th September 2011 were screened by two persons), 205 (n=166 on 5th September 
2011) publications were fully reviewed and 62 (n=32 on 5th September 2011) were included in 
the formal literature review. 
For the purpose of this chapter I excluded the papers where mathematical models were used 
to evaluate the impact of earlier ART initiation in specific settings different from sub-Saharan 
Africa, because these were beyond the scope of this PhD thesis. The results of the search are 
shown in Figure 4.1 and the papers identified by these literature searches are summarised in 
Appendix XII. 
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Figure 4.1. Flow chart of literature search 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Records identified through 
computerised database searching 
(n=5,805) 
Additional records identified 
through other sources 
(n=37) 
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duplicates removed 
(n=5,833) 
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reviewing titles and 
abstract (n=5,623) 
 
 Full-text articles assessed 
for eligibility 
(n=210) 
 
 Records excluded after 
reviewing full text  
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 Studies included in the 
qualitative synthesis 
(n=67) 
 
 Papers excluded because 
modelling papers not 
relevant to SSA (n=18) 
 Studies included in this 
section (n=49) 
[1 RCT, 
17 observational studies 
6 ecological studies 
25 mathematical models] 
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4.2.3. Observational studies 
The association between VL and heterosexual transmission of HIV-1 has been reported by 
many observational studies of HIV serodifferent heterosexual couples (31;35;36;38;663).  
The first evidence of an association between use of ART and HIV prevalence came from cross-
sectional studies. Castilla and colleagues (430) observed in 393 steady heterosexual couples in 
Madrid, Spain, that the prevalence of HIV was 8.6% among partners of index cases who had 
not received ART, whereas no partner was infected in couples in which the index case had 
been on ART (p = 0.0123). Similar findings were reported by a small study (n=93 of 
serodifferent couples), where none of the new HIV infections was from couples where the 
partner was on ART (664).  
Concordant results were found in longitudinal studies. In 2010, a very large observational 
study of people recruited to the ‘Partners in HSV/HIV transmission’ study (3381 couples) (431) 
confirmed the evidence of a reduction in HIV transmission for people on ART (the HIV-positive 
person was co-infected with HSV-2 and had a CD4≥250 cells/μL). They observed 103 
genetically linked HIV-1 transmissions where only one occurred from an infected participant 
who had started ART, corresponding to a transmission rate of 0.37 (95% CI: 0.09, 2.04) /100 
PYs, compared with 2.24 (95% CI: 1.84, 2.72) /100 PYs in those who had not initiated ART. In a 
study conducted in Spain (659) no HIV SCs occurred in 144 couples where the HIV-positive 
partner was taking ART in over 7,000 condom-less sex acts (corresponding to a risk of 
transmission of 0 and a 95% CI of 0 to 0.0005 per condom-less sex act), while 5 HIV SCs 
occurred in 341 serodifferent couples and over 10,000 condom-less acts of intercourse in 
which the HIV-positive partner was not taking ART (a risk of 0.0004 per condom-less 
intercourse; 95% CI: 0.0001, 0.0010). Similarly, the Rakai study (665), although on a small 
number of couples, reported that no HIV-1 transmissions occurred during 53.6 PYs on ART. A 
study following 2,993 couples from Rwanda and Zambia (5,609 PYs of follow-up) reported an 
HIV incidence of 0.7/100 PYs in couples where the HIV-infected partner was on ART, and 
3.4/100 PYs in couples where the HIV-infected partner was not on ART (666). They were 
interested in investigating whether the impact of ART in reducing transmissions was different 
in the two genders and reported that if the woman was infected with HIV and on ART the 
incidence was 1.4/100 PYs (95% CI: 0.4, 3.7), 3.2/100 PYs (95% CI: 2.5, 3.9) if she was off ART, 
0/100 PYs (95% CI: 0.0, 1.4) if the man was infected with HIV and on ART and 3.6/100 PYs (95% 
CI: 2.9, 4.5) if he was off ART. A very large study from China (n=38,862 serodifferent couples, 
101,295 PYs of follow-up) was published in 2013 (667). They estimated a rate of HIV-infection 
of 2.6/100 PYs (95% CI: 2.4, 2.8) among the couples where the HIV-positive partner was ART-
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naïve and 1.3/100 PYs (95% CI: 1.2, 1.3) among the couples where the HIV-positive partner was 
on ART. Interestingly, in this study they found that among people who inject drugs, the 
association between the risk of HIV transmission and the HIV-positive partner being on ART 
could not be confirmed (667). A word of caution came from a couple of studies from China and 
Uganda (668;669), that did not observe a statistical differences in SC rate between couples 
where the HIV-positive partner was receiving ART or not. The former (669) is a retrospective 
study conducted in the province of Henan, China, where 1,927 serodifferent couples were 
followed. One possible explanation to why they did not find any impact of ART in reducing the 
risk of HIV transmission could be low rates of viral suppression in those on ART (669).  The 
second study (668) followed 586 couples in rural Uganda, of which in 60% the HIV-positive 
partner was on ART. In this setting, VL monitoring is not available and therefore it is not clear if 
those on ART had a suppressed VL. 
 
Evidence that ART is reducing HIV incidence outside of controlled and well monitored settings, 
as is the case for RCTs, came from a very large cohort of HIV-uninfected individuals living in 
KwaZulu-Natal, South Africa (670). They observed that people living in areas with high 
coverage of ART had a lower risk of becoming infected with HIV than people living in areas 
with low coverage (e.g. the risk of HIV acquisition for a person living in a community with an 
ART coverage of 30–40% of all HIV-infected individuals was 38% less than for someone living in 
a community where ART coverage was less than 10% of all HIV-infected individuals). 
 
Several meta-analyses have been conducted to estimate the risk of HIV transmission, 
according to ART status (429;671-673).  One meta-analysis (429) on observational cohort 
studies of heterosexual HIV-serodifferent couples observed no transmissions among couples 
where the HIV-positive partner was treated with ART and had VL levels below 400 copies/mL 
(rate of 0/100 PYs; 95% CI: 0, 1.27). Loutfy et al. (674) considered the level of detectability 
specific to each study (which varied from 50 to 500 copies/mL) and estimated the risk of HIV 
transmission in people fully suppressed on ART to be 0 (95% CI: 0, 0.05) /100 PYs when VL was 
confirmed at the time of transmission and 0.14 (95% CI: 0.04, 0.31) /100 PYs when the VL was 
not confirmed.  In a meta-analysis (672) of observational studies of serodifferent couples, 
when they restricted to data with adequate follow-up and in which triple ART was used, they 
estimated that ART reduces the risk of HIV transmission by 64% (RR = 0.36; 95% CI: 0.17, 0.75).  
Baggaley et al. (673) systematically reviewed the data on observational cohort study of 
serodifferent couples. Using the studies where it was possible to quantify the impact of ART on 
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the risk of HIV transmission, they estimated that ART reduces per-partner HIV-1 incidence rate 
by 91% (95% CI: 79, 96%).  
 
In contrast to the many observational studies which have evaluated the relationship between 
VL and the risk of transmission among heterosexual couples, the direct empirical evidence 
regarding the relationship between ART use and the risk of HIV transmission in MSM is limited 
and only from high income countries (63). This topic is not discussed further given the main 
source of transmission in South Africa and Zimbabwe is through heterosexual sex and this 
version of the Synthesis model does not include transmission through people of the same sex. 
 
4.2.4. Ecological Studies 
Several ecological studies have provided evidence of a population-level association between 
the implementation of wide-scale ART and a decline in the number of new diagnoses (675-
677), although a number of other studies, particularly amongst MSM have not concurred 
(678;679). An ecological study conducted in British Columbia, Canada (677) reported a strong 
and significant association between increased ART coverage and a decline in the number of 
new HIV diagnoses per year. Between 1996 and 2009 ART coverage in British Columbia 
increased by 547% and the number of new diagnoses decreased by 52%. Similar findings were 
reported from another study based on a cohort of all HIV-positive individuals in San Francisco 
(675). Community VL (i.e. the average VL among all individuals diagnosed with HIV) was 
calculated and analysed as a population-level marker of HIV transmission risk. A significant 
association was found between decreases in annual community VL and temporal decreases in 
the number of new HIV diagnoses. The authors observed that HIV incidence fell by over one-
third in the years 2006 to 2008. Interestingly, during the same period there was an increase in 
the number of reported cases of rectal gonorrhoea. Although data on sexual risk behaviour 
were not collected, data on rates of rectal gonorrhoea were used as a surrogate marker for 
sexual risk behaviour. The authors argued that the reduction in the number of new infections 
in a period where risky sexual behaviour probably increased substantiates the hypothesis that 
achieving high level ART coverage is an effective and important approach towards the 
prevention of HIV transmission. 
In Taiwan, a study was conducted using nationwide surveillance data (676) to assess the 
impact of a policy to provide free ART to all HIV-positive individuals on the rate of 
transmission. The introduction of the policy was associated with a 53% decrease in the rate of 
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transmission and was accredited with the effective control of the HIV epidemic in Taiwan. The 
incidence of syphilis was analysed in order to distinguish between the effect of ART and that of 
behavioural modifications. During the study period there was no statistically significant change 
in the incidence of syphilis in both the general population and the HIV-positive population. 
With thousands of new cases of syphilis reported each year, it is evident that risky sexual 
behaviour is prevalent and therefore, the authors argued that it is unlikely that the reduction 
in the HIV transmission rate was due to decreases in sexual risk behaviour. However, three 
studies (678-680) whose primary aim was to observe trends in recent HIV infections in MSM 
found that HIV incidence is increasing. These studies were conducted in Amsterdam, the UK 
and more generally in Europe and North America. This suggests that on-going HIV transmission 
is occurring despite access to effective ART.  
 
The findings from ecological studies should be examined with extreme caution. Firstly, there is 
the possibility of ecological fallacy, whereby inferences about specific individuals are based 
solely upon aggregate statistics collected for the group to which those individuals belong, in 
which case the generalizability of the results is limited. Secondly, as with all observational 
studies it is difficult to rule out confounding which means that establishing causality can be 
problematic. Thirdly, the studies were restricted to measuring numbers of new diagnoses 
rather than the main aspect of interest: incidence of new HIV infections. 
 
4.2.5. Randomized Controlled Trials 
The strongest evidence to date on the ability of ART to reduce heterosexual HIV transmission 
comes from the HPTN 052 RCT (432). This study was designed to compare the effect of early 
versus delayed ART on transmission of HIV. 1,763 heterosexual serodifferent couples in which 
the HIV-positive person was ART-naive and had a CD4 count between 350-550 cells/μL were 
recruited from nine countries and couples were randomized to either immediate ART, or 
delayed initiation (ART was initiated after two consecutive CD4 counts ≤250 cells/μL). The 
primary endpoint was genetically linked HIV infection in HIV-negative partners. Three months 
after baseline, 89% of participants in the early therapy group had achieved viral suppression 
(<400 copies/mL) compared with 9% of the delayed therapy group. A total of 28 virologically 
linked transmissions were observed; only one occurred in the early therapy arm. This 
represents a 96% relative reduction in linked HIV transmissions as a result of initiating ART 
compared with deferral (hazard ratio [HR] = 0.04; 95% CI: 0.01, 0.27; p<0.001). These findings 
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are believed to be a result of sustained suppression of VL in genital secretions (432) and 
provide support for the use of ART in the prevention of HIV among heterosexuals. Analysis of 
the genetic sequences of HIV of two people who got infected with HIV in the HPTN 052 study, 
one in the early arm and one in the delayed arm, who were diagnosed after the index partner 
had initiated ART revealed that these infections occurred either before their HIV-positive 
partner initiated ART or at least before the viral replication was suppressed (681). This 
strengthens the evidence that people with suppressed VL induced by ART use have very low 
chances of transmitting HIV. 
 
Although this study provides the most definitive evidence currently available to support use of 
ART to prevent sexual transmission of HIV, it is not without its limitations. Trial participants 
were in stable HIV- serodifferent relationships and may not be a representative sample of all 
heterosexual serodifferent couples in the general population. These couples were also 
receiving free condoms, couples counselling on risk-reduction, and treatment for sexually 
transmitted infections (STIs) which may have impacted upon the low incidence of HIV 
transmissions in the early therapy group; although it is not obvious that this could result in a 
bias between the arms. Reported condom use in the HPTN 052 study was extremely high: 96% 
of those in the early-therapy group and 95% of those in the deferred-therapy group reported 
100% condom use during the study. This very high reported condom use rates are unlikely to 
reflect real life conditions and may be due to a social desirability bias.  
Also, the findings are mainly applicable to vaginal heterosexual sex and uncertainty remains 
over the ability of ART to reduce infectivity through anal sex and through exchange of blood 
products (e.g. through needle sharing in people who inject drugs). The strong evidence in the 
context of heterosexual (mainly vaginal) transmission suggests that there are likely to be 
similar reductions in infectivity through other routes. However, given important biologic 
differences in transmission mechanisms for these transmission routes, it is not possible to 
confidently extrapolate existing evidence based mostly on vaginal transmission. In particular 
due to the higher per-contact probability of HIV transmission through anal intercourse 
compared to vaginal intercourse, it may be that the transmission threshold through anal 
intercourse may be lower and therefore that the risk of HIV transmission in people virologically 
suppressed may not be negligible (682;683). It is important that research in these areas is 
prioritized to support policy decisions regarding the use of ART as prevention. 
 
      
209 
 
For ethical reasons, HPTN 052 compared the effect of condoms alone among those not 
receiving ART and the effect of condoms and ART for the HIV-positive person on the 
probability of HIV transmission. Therefore the absolute risk of transmission on the early ART 
arm (1 in 893) does not represent the risk through condom-less sex when the HIV-positive 
person is on ART; rather the risk in the context of 96% consistent self-reported condom use 
plus ART. The risk of transmission through condom-less vaginal and anal sex for a person who 
has suppressed plasma VL remains uncertain and represents another knowledge gap. The 
PARTNER study, which is taking place in Europe amongst serodifferent couples, is addressing 
this question (684). So far we reported 0 genetically linked HIV transmission over 894 couple-
years of follow-up in serodifferent couples (a third being MSM couples) where the index 
partner was on suppressive ART (VL<200 copies/mL) and we reported having condom-less sex, 
corresponding to a rate per 100 couple-years of follow-up of 0 (95% CI: 0, 0.4) (63). When 
restricting to follow-up where the HIV-negative partner reported anal sex within the couple, 
the rate was estimated to be 0 but with more uncertainty (95% CI: 0, 0.96). My role within the 
PARTNER study is to clean the data collected and to conduct the statistical analyses. 
 
4.2.6. Mathematical Models 
The effect of increasing the number of people receiving ART on HIV transmission and its cost-
effectiveness has been analysed using several mathematical models (685-692). 
 
Baggaley et al. (688), who were amongst the earliest to investigate the impact of increased 
ART coverage in a sub-Saharan epidemic, concluded that expanded ART coverage would not be 
an effective transmission prevention measure. They implied that this approach would not work 
regardless of the degree of ART coverage, as the total number of infections prevented would 
be marginal.  
More recently, several modelling studies have suggested that expanded ART and increased 
testing would be effective in reducing HIV incidence (686;687;689) and could therefore offer 
public health benefits. Abbas et al. assessed the potential impact of ART on the heterosexual 
spread of HIV in a generalized epidemic in sub-Saharan Africa (687). The results of this study 
indicate that increasing ART coverage in 2006 at a national HIV prevalence of 5% would be 
more effective than later implementation when the prevalence of HIV was at 40%; the 
predicted reduction in the number of new HIV infections was 33% at 5% prevalence and 27% 
at 40% prevalence.  
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Wilson et al. (693) investigated the implications of the Swiss statement (660) at a population 
level, by means of a simple mathematical model. On the basis of Rakai study (31), they derived 
a mathematical relation between VL and the risk of HIV transmission per condom-less 
penetrative sexual contact. By assuming that each couple had 100 sex acts per year they 
calculated the cumulative probability of transmission to the serodifferent partner each year. 
The authors concluded that the risk of HIV transmission in heterosexual partnerships in the 
presence of effective ART is low but non-zero, and that the transmission risk in male 
homosexual partnerships is high over repeated exposures. Therefore they underlined the 
potential danger that the claim of non-infectiousness in effectively treated patients could 
cause if widely accepted, and condom use subsequently reduced. 
 
The estimated effect of universal voluntary testing (annual testing of 90% of the entire 
population) and initiation of ART upon diagnosis, often referred to as “Test and Treat”, varies 
between models with implications as optimistic as HIV elimination (686) ranging to net harm 
under specific circumstances (694).  
In 2009 Granich et al. (686) predicted, using a model calibrated to the epidemic in South Africa, 
that the test and treat strategy would reduce HIV incidence to less than 1 case per 1,000 
people per year by 2016 and the prevalence to less than 1% within 50 years of its full 
implementation and that elimination could be feasible by 2020. Following the paper in 2009, 
they (691) evaluated the cost-effectiveness of different CD4 count threshold for ART initiation 
(CD4 count<200 cells/μL, CD4<350 cells/μL, CD4<500 cells/μL; any CD4 count) in the context of 
South Africa over the time frame 2011-2050, assuming high level of HIV testing (90% of the 
population tested annually). They concluded that all scenarios were cost-saving compared with 
the scenario where people were eligible to initiate ART when CD4 falls below 200 cells/μL, with 
a higher number of HIV infections and deaths saved as the CD4 count threshold increases: 
respectively 1.4, 2.9 and 4.3 million new HIV infections saved with CD4 count threshold of CD4 
below 350 cells/μL, below 500 cells/μL and regardless of CD4 count respectively, while the 
number of deaths averted was respectively 1.5, 3.0 and 3.9 million. In sensitivity analysis they 
found that poor retention in care and predominant acute phase transmission played an 
important role and could reduce savings by 7%. 
Kretzschmar et al. (695) generalized the model used by Granich et al. (686) to generate a 
number of hypothetical HIV epidemics and explore in which circumstances of ART uptake and 
drop out, HIV elimination would be achievable and whether it was cost-effective. They 
concluded that this goal was feasible only in populations with very low R0 (basic reproduction 
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number; approximately 2 or lower) and high annual treatment uptake (approximately 85% 
coverage). 
Hontelez et al. (696) assessed the impact of nine different model structures, capturing 
different levels of realism, on the long term outcome of universal voluntary  test and treat (as 
defined by (686)). The most complex structure considered was the STDSIM model, while the 
simplest was very similar to Granich et al. model (686). They concluded that HIV elimination 
would be achieved by 2050 by universal test and treat and that this would be cost-effective. 
Nevertheless they predicted that the time to achieve this target is much longer than the 7 
years estimated by Granich if more realism is included in the model. 
Palombi et al. (697) used data from the Drug Resource Enhancement Against AIDS and 
Malnutrition Program (in Malawi and Mozambique), collected between January 2002 and July 
2009 to evaluate the impact of initiating ART at different CD4 count thresholds. They 
compared a scenario of universal treatment (annual universal voluntary testing of adults, 
immediate ART of HIV-infected individuals with CD4 count <350 cells/μL and/or WHO stage 3 
or 4 and treatment of patients with CD4 count >350 cells/μL when reaching this CD4 count 
threshold over time, and treatment of all HIV-infected pregnant women, regardless of CD4 or 
VL) to a scenario where 45% of individuals eligible for ART in Malawi receive it in each year. 
They estimated that annual incidence of HIV infection would decline from 7% to 2% in 2 years, 
the prevalence would halve, from 12% to 6%, in 11 years and mortality in HIV-infected 
individuals would decline by 50% in 5 years.  
 
Some mathematical models focused their attention on specific aspects either of the cascade of 
care (689;690;698), or of characteristics related to treatment, such as toxicities, adherence 
(694) or survival of people on treatment (699). 
A model by Bendavid (689) assessed the health benefits of four different strategies which 
involved combinations of test and treat, improved linkage to care and reduced LTFU. Model 
parameters were based on the epidemic in South Africa, where HIV transmission is 
predominantly heterosexual. Findings from the study showed that a comprehensive strategy 
which involves 90% of the population being tested and all HIV-positive individuals receiving 
ART within 6 months of diagnosis, perfect linkage to care and no LTFU, would result in a 73% 
reduction in the number of potential new infections in the South African population, over a 10 
year period.  
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Andrews et al. (690) focused on understanding the impact of two important structural 
assumptions of mathematical models: linkage to care and population migration. In particular, 
they modified a previously published model, by including the process of linkage to care and 
population mobility, using data from a township near Cape Town in South Africa. They 
conclude that universal HIV testing and ART initiation upon diagnosis would not result in HIV 
elimination (defined as an incidence of <0.1%) within 30 years, even with optimistic 
assumptions about the linkage to care.  
Anglaret et al. (694) explored, using a mathematical model mimicking the population living in 
sub-Saharan Africa with a CD4 count >500 cells/μL, under which circumstances initiating ART 
upon entry to care rather than when CD4 falls below 350 would result in more harm than 
benefit, focusing on mortality. They reported that initiating ART upon entry into care would 
result in lower mortality in 15 years in time (51.8% vs 56.7%). The circumstances where this 
was not the case are: if the rate of fatal ART toxicity was >1.0/100 PYs, if the rate of 
withdrawal from care was >1.2-fold higher or if the rate of ART failure due to poor adherence 
was >4.3-fold higher or if moderate rates of fatal ART toxicity (0.25/100 PYs) were combined 
with increased rates of withdrawal from care (>1.1-fold higher) and increased rates of 
treatment failure (>2.1-fold higher). 
Klein et al. (698) evaluated the assumptions on retention on ART, when evaluating the cost-
effectiveness of expanding treatment by either modifying the eligibility criteria from CD4<350 
cells/μL to all people diagnosed with HIV or by improving HIV testing and linkage to care so 
that 80% of the population are in care when becoming eligible. They found that improving 
retention on ART should be prioritized because it is the strategy associated with the lowest 
incremental cost-effectiveness ratio (ICER) (see section 4.3.2.2), and only afterwards the focus 
should be on initiating more people on ART, and this should be pursued by improving HIV 
testing and linkage rather than more modifying the eligibility criteria.  
Wagner et al. (699) investigated the importance on the assumption regarding survival time 
once initiated on ART. In particular, they considered that the assumption used by Granich et al. 
(686) of six additional years in people on ART whom CD4 count has fallen to 350 cells/μL 
compared to untreated people who reached that CD4 was too low. They assumed that people 
who initiated ART after their CD4 count reached 350 had 60% chance of surviving an additional 
20 years or more. They found that modifying this assumption reduces the probability of 
eliminating HIV (defined as HIV incidence < 0.1/100 PYs), in particular using the long survival 
time, after 40 years the HIV incidence is around 0.3/100 PYs. Regarding the cost, they 
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estimated that over a 40 years period the annual cost would be doubled, by using the longer 
survival, and the cumulative cost 22% higher than reported by Granich et al. (691). 
 
Eaton et al. (685) summarized and compared the findings from twelve independent 
mathematical models calibrated to South Africa. To eliminate the discrepancies assumed by 
different models in ART roll out they asked contributing modellers to assume ART was not 
available before 2012. From 2012, 84 scenarios where considered as a combination of 
different CD4 count thresholds for ART eligibility, level of ART access and level of retention. 
Three different CD4 count thresholds for ART eligibility were considered (CD4 count <200 
cells/μL, CD4 count <350 cells/μL, and all HIV-infected individuals), seven different level of ART 
access, defined as the proportion of eligible individuals who eventually initiate ART, assumed 
to happen within one year since being eligible (50%, 60%, 70%, 80%, 90%, 95%, and 100%) and 
three different levels of retention, defined as the percentage of individuals remaining on ART 
after 3 years since initiating ART, excluding from both the numerator and the denominator 
those who had died while on ART (75%, 85%, 95% and 100% (no dropout)). In the short term (8 
year time span) the models generally agreed and for example in a scenario with 80% access, 
85% retention and ART initiation at CD4<350 cells/μL they found an HIV incidence between 
35% and 54% lower than in a counterfactual scenario where ART was not introduced at all. 
More variability was found in the long-term (38 year time-frame). A subset of the models (n=7) 
investigated as well the impact ART had in South Africa, given the actual roll-out of ART. They 
estimated that current HIV incidence in South Africa was 17% to 32% lower than it would have 
been if ART were not available. 
Johnson et al. (700) used two models calibrated to South Africa, the STI-HIV model and the 
ASSA 2003 model to understand the role condom use and ART roll-out had on reducing HIV 
incidence. They estimated, by reproducing the epidemic from 2000 to 2008, using household 
surveys and antenatal HIV prevalence data and mortality data, that the HIV incidence was 
2.11/100 PYs (95% CI: 1.97, 2.26) in 2000–2005 and 1.86 (95% CI: 1.73, 2.00) in 2005–2008, 
using the STI-HIV model and be 1.90 (95%CI: 1.77, 2.03) in 2000–2005 and 1.62 (95% CI: 1.45, 
1.79) in 2005–2008 using the ASSA 2003 model. They estimated that without use of condom 
the incidence would have been between 37% (95% CI: 34, 41%) (STI-HIV model) and 23% (95% 
CI: 14, 34%) (ASSA2003) higher, while without the use of ART between 8.1% (95% CI: 6.0, 9.4%)  
(STI-HIV model) and 1.4% (95% CI: 0.7, 2.6%) higher. This exercise underlined the importance 
condom use had in the decline in HIV incidence observed in South Africa. 
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Several authors of mathematical modelling studies have argued that the benefits of wide scale 
ART could be offset by increases in unsafe sexual practices (688;701).  
Yusuf et al. (701) investigated which is the optimal combination of change in sexual habits and 
ART coverage that minimize the cost and the HIV incidence in the context of South Africa. They 
compared a scenario where only people with AIDS symptoms are eligible to receive ART to a 
scenario where individuals are eligible as soon as they have pre-AIDS stage and concluded that 
the optimum is reached by initiating people when they progress to pre-AIDS stage and by 
individuals remain faithful to their sexual partners, reduce the number of sexual partners to 
the minimum possible and avoid extra-marital affairs for the rest of their lives. With this 
scenario, in 10 years it could be possible to be close to eradication. 
 
More recently, several mathematical models have investigated the impact of combination of 
prevention strategies (702-706), including HTC (and its impact on risk behaviour), VMC, Pre-
Exposure Prophylaxis (PrEP) and high coverage of ART and/or ART at higher CD4 count. 
Alsallaq et al. (702) evaluated the effect on HIV incidence of a combined intervention including 
high coverage of HTC, risk reduction following HIV diagnosis, VMC for HIV-uninfected men, and 
ART for HIV-infected people with CD4 count≤350 cells/μL, using a model calibrated to data 
from KwaZulu-Natal, the province in South Africa with the highest prevalence. They found that 
a dramatic effect could be achieved: 47% reduction in HIV incidence within 4 years and almost 
60% within 25 years. Nevertheless they predicted an even higher reduction if ART was initiated 
upon diagnosis: 63% within 4 and 76% within 15 years.  
Baernighausen et al. (704) investigated whether by increasing coverage of VMC and ART 
(maintaining the current CD4 count threshold to be eligible for treatment in South Africa) it 
was possible to achieve the same effect on HIV incidence, as universal testing and ART 
(frequent testing of the entire population and initiation of ART upon entry to care). They 
reported that the impact over the time span 2009-2020 would be approximately the same, but 
that $5 billion would be saved.  
Hallett et al. focused on the impact of different PrEP implementation strategies in 
serodifferent couples in South Africa: (i) always, once the couple is identified as serodifferent, 
(ii) only until one year after the HIV-positive partner has been initiated on ART (promptly when 
CD4<200 cells/μL), (iii) only until ART initiation of the HIV-positive partner, (iv) only when 
trying to conceive a pregnancy or during pregnancy. In addition they evaluated the impact of 
PrEP strategy iii in combination with ART initiation at CD4<200 cells/μL or CD4<350 cells/μL, to 
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early ART initiation, CD4<500 cells/μL. They found that in low risk serodifferent couples (HIV 
incidence 1.8/100 PYs at risk) the most cost-effective strategy appeared to be ART initiation at 
CD4<500 cells/μL for the HIV-positive partner, while in high risk couples (HIV incidence around 
8/100 PYs at risk) it was the combination of PrEP with ART initiation at CD4<350 cells/μL. 
Cremin et al. (703) focused on the potential role of PrEP in combination with earlier ART 
initiation (on average at one year since HIV infection) and VMC and assessed the potential 
cost-effectiveness. They concluded that in a setting with a hyper endemic level of HIV, 
expanding early ART use (80% initiated one year since diagnosis), rather than providing PrEP to 
HIV-negative individuals, leads to a higher number of infections being averted and more 
quality-adjusted life-years (QALYs), but that on its own ART is not going to reduce HIV 
incidence to very low levels. 
Finally, Alistar et al. (706) evaluated the impact of combination of ART use considering people 
eligible at CD4<350 cells/μL or for all those diagnosed with HIV and PrEP either in the general 
population or in high risk group. They considered 4 different coverage levels for this 
intervention: 25%, 50%, 75% and 100%. They concluded that ART initiation at diagnosis is the 
most cost-effective strategy at all coverage levels investigated (ICER ranging from $160 to $220 
per QALY gained) and that the use of PrEP provides only a limited additional benefit. 
 
Other mathematical models have evaluated the impact of early ART initiation in target 
populations, on the basis of VL (707), HIV stage (587) or of partner status, for example 
serodifferent couples (708;709). 
Given VL is the main predictor of risk transmission, Murnane et al. (707) evaluated the impact 
of using VL measurements to determine whether to initiate people on ART. They used cross-
sectional data on sexual behaviour collected during a RCT of HIV serodifferent couples from 
HIV-infected people with CD4 count >350 cells/μL to calculate the number of infections, using 
estimates of per sex-act infectivity. They compared the following scenarios: (i) ART initiation in 
all those with a CD4 count <500 cells/μL, (ii) ART initiation in all those with a VL ≥50,000 
copies/mL, (iii) ART initiation in all those with a VL ≥10,000 copies/mL and (iv) ART initiation in 
all those infected with HIV. They reported that these interventions would avert respectively 
1,569 (47.6%) (scenario i), 1,336 (40.5%) (ii), 2,401 (72.8%) (iii) and 3,165 (96.0%) (iv) of new 
HIV infections. 
They underlined that in order to avert 40.5% of HIV infections (obtainable by initiating ART in 
all those with a VL ≥50,000 copies/mL) it would be necessary to treat 19.8% of infected 
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persons with CD4 counts above 350, while initiating ART when their CD4 count falls below 500 
cells/μL would require treating 41.8% and would only avert around an additional 8% of HIV 
infections. 
Powers and colleagues (587) investigated the impact of theoretical prevention interventions 
which would reduce the per contact transmission probability to 0.000033 targeted at PHI only, 
chronic infection only or both stages. The model was informed by comprehensive data on 
sexual behaviour and virological data collected in an STIs clinic in Lilongwe, Malawi. They 
estimated that 38.4% (95% credible interval:  18.6-52.3) of HIV infections were attributable to 
the PHI. Nevertheless, they found that an intervention that targeted this stage (assumed to 
start 3 weeks after infection and to last until the end of this phase, duration of 4.8 months) 
would not allow eliminating HIV even with 100% coverage. They considered a scenario 
comparable to test and treat, where people received an intervention on average 6 months 
since infection which reduces their infectiousness, as indicated above, and increases their life 
expectancy by 10-15 years. They found that only if the coverage was >99% would this lead to 
elimination in 30 years (annual HIV incidence <1/1,000). 
El-Sadr (709) formulated a mathematical model in order to forecast the epidemic impact of 
treating HIV serodifferent couples with ART, to prevent transmission. The model was 
parameterised using data from Ghana, Lesotho, Malawi and Rwanda. It was concluded from 
this study that although treatment of serodifferent couples would not be sufficient to single-
handedly control the HIV epidemic, achieving high ART coverage levels for serodifferent 
couples could significantly reduce incidence and prevent a substantial number of new 
infections in certain countries.  
Walensky et al. (708) used data from serodifferent couples recruited in the RCT HPTN 052 to 
evaluate the cost-effectiveness of initiating ART when the CD4 count is between 350 and 550 
cells/μL compared with when the CD4 count falls below 250 cells/μL, as in the HPTN 052 RCT, 
in the setting of South African and India. They found that in South Africa it was cost-saving in 
the short term (5 year horizon) and very cost-effective over a life time (ICER of $590 per life-
year gained compared with a per capita gross domestic product [GDP] of $8,100), while in 
India it was cost-effective in the short term ($1,800 per life-year gained compared with a per 
capita GDP of $1,500) and very cost-effective over a life time ($530 per life-year gained). 
Therefore they concluded that early ART in this subgroup at such as high risk of HIV acquisition 
should be rolled out in resource limited settings (RLS). 
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As with all research methods, mathematical modelling studies are subject to limitations. The 
validity of conclusions drawn from models depends upon the reliability and completeness of 
the assumptions, on which the model parameters are based on. Therefore, the findings from 
mathematical modelling studies should be interpreted with this caveat in mind. It is difficult to 
identify the drivers of the difference between mathematical models. This is due to the fact that 
often they have different structures, make different assumptions, due to the uncertainty 
regarding some of the processes included in these models, evaluate slightly different scenarios 
and present results with different metrics. These last points are true as well when conducting 
analyses using data collected from observational studies, the only field where the analyses 
tend to be reported using a standardized approach are RCTs. An attempt towards 
understanding whether models are reaching different conclusions and why has been 
undertaking by the Modelling Consortium (685;692). 
 
4.2.7. Recommendations on when to start antiretroviral treatment and rationale 
The decision on when to start ART in an ART-naive person remains controversial. After a phase 
in the late 1990s, when in some settings ART was started in almost all people diagnosed with 
HIV in the hope of being able to eradicate HIV (and improve clinical outcomes), the decision on 
when to start ART has been driven by the clinical prognosis of the HIV-positive individual.  The 
striking results of HPTN 052 (see section 4.2.5), showing that initiating ART reduces the risk of 
sexual transmission by 96%, had a big impact on guidelines recommendations. There is 
generally agreement on the fact that ART should be started once the CD4 count falls below 
350 cells/μL, while there is no definitive agreement among the scientific community on 
whether, and to what extent, the CD4 count threshold should be higher. This is due to the fact 
that experts differ in the amount of evidence that they consider necessary and on the level of 
current evidence (710). It has not been established yet in a RCT whether initiating ART when 
the CD4 count is above 350 cells/μL is associated with a clinical benefit for the HIV-positive 
person compared to deferral to when the CD4 count reaches this level.  
 
The HPTN 052 RCT compared clinical outcomes as a co-primary outcome. They found a 
significantly reduced risk of clinical disease in the intervention group (ART initiated at CD4>350 
cells/μL; control group: ART initiated at CD4<250 cells/μL), mainly driven by a reduction in 
extrapulmonary TB, although the study power was low for serious clinically manifest disease 
endpoints.  
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In particular they found that the hazard of new onset of AIDS event was 36% lower (HR: 0.64; 
95% CI: 0.43, 0.96) in those assigned to the early ART arm (CD4 between 350 and 500 cells/μL) 
compared to delayed ART. Similarly it decreased the incidence of the primary outcome 
(including AIDS clinical event and serious cardiovascular or vascular disease, serious liver 
disease, end-stage renal disease, new-onset diabetes mellitus and non-AIDS malignant disease) 
with an HR of 0.73 (95% CI: 0.52, 1.03) and halved the hazard of developing TB (HR = 0.49, 95% 
CI: 0.28-0.89) (711). Further evidence comes from the Strategies for Management of 
Antiretroviral Therapy (SMART) trial. In this RCT, participants were randomized either to 
continuous ART or to the “drug conservation arm”, which meant ART was deferred until the 
CD4 count was below 250 cells/μL and continued until the CD4 count increased above 350 
cells/μL, with subsequent stops and restarts using these CD4 counts as cutoffs. In a subset of 
the participants with CD4 count >350 cells/μL who were ART-naive at baseline, there was a 
reduced risk of clinical disease in those initiating ART upon entry into the study compared with 
those who deferred it (CD4 count <250 cells/μL), but the size of this subsample was small 
(n=477) (712). Both these trials were based on a comparison involving deferral until the CD4 
count fell below 250 cells/μL, which is now no longer the standard of care. Therefore the 
potential long-term risks, such as adverse events and acquisition of drug resistance, of 
initiating ART at CD4 levels above 350 cells/μL remain uncertain. The START trial aims to 
answer this research question, in particular to determine whether very early ART (initiation 
when CD4 count >500 cells/μL) is superior to deferred ART (CD4 count <350 cells/μL, or when 
diagnosed with AIDS or other symptoms of HIV infection) in delaying the occurrence of a 
composite outcome consisting of AIDS, serious non-AIDS conditions, or death from any cause. 
This trial will help to establish whether any risks of very early ART initiation will be outweighed 
by the benefits to the individual, in terms of reduction in risk of serious clinical disease (284). 
The TEMPRANO trial is evaluating the impact on mortality and severe HIV related disease of 
four different options regarding the eligibility criteria to initiate ART and the treatment for TB: 
initiating treatment at diagnosis (upon recruitment in the study; with a CD4 count between 
350 cells/μL and 800 cells/μL) with and without 6-month isoniazid prophylaxis for TB (285) 
compared to initiating ART according to 2010 WHO guidelines, CD4 below 350 cells/μL, again 
with or without 6-month isoniazid prophylaxis for TB. If the benefits of initiating ART at a 
higher CD4 count outweigh the disadvantages, then it makes sense clinically as well as from a 
public health perspective to recommend early ART initiation in all people diagnosed with HIV 
infection. If, on the other hand, there is found to be net harm as a result of this strategy, then 
a policy of earlier ART initiation in order to reduce transmission risk may be inappropriate in 
most circumstances. But if the risks and benefits appear to balance, the decision to initiate ART 
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would take into consideration an individual’s preference, and in particular whether the 
individual wishes to use ART in order to reduce transmission risk. Thus, to a large extent, policy 
in this area will be driven by the results of the START and the TEMPRANO trial (and any similar 
trials that might take place), together with clinical considerations and individual choice (713). 
Unfortunately the TEMPRANO trial is not scheduled to be completed before the end of 2014 
(285) and the START trial not before 2015 (284;713).  
Although it might be considered difficult to imagine that starting ART earlier would result in a 
higher risk of mortality or morbidity, based on current knowledge, there is no evidence to 
guarantee that this is not the case.   In addition to this main consideration when deciding 
whether to start treatment earlier, an HIV-positive person should take into consideration other 
factors. Firstly, the person should know that once treatment is started it should be continued 
for life, because interrupting ART increases AIDS-related and non-AIDS-related morbidity and 
risk of death (714). Secondly, high levels of adherence to ART should be maintained over time. 
This factor is crucial to achieve and maintain virological suppression, particularly on NNRTI 
based therapies, and therefore to delay disease progression, minimise the risk of resistance 
development and of onward HIV transmission. Thirdly, the person should bear in mind that 
although ARVs available now are much better tolerated, they can still have side effects. 
Tolerability may be an issue if a person is aware that these drugs could potentially not yet have 
any benefit for their own health, and that the long-term effects of some drugs are still 
unknown.  It is important that this is made clear to people in whom ART is being initiated with 
a view to reducing infectiousness. Some wonder whether it is ethically acceptable to offer the 
possibility of starting ART earlier in absence of this evidence. Most would probably agree that 
it is ethical if the patient has received all the information necessary to make an informed 
decision. 
 
Guidelines differ in the recommendation regarding when to initiate ART (see section 1.8.6). In 
the light of the evidence from the HPTN 052, WHO released “Guidelines on couples HIV testing 
and counselling and treatment and prevention for serodifferent couples” (715). They 
recommend that voluntary HTC with support for mutual disclosure should be offered to 
couples in antenatal care settings and to individuals with known HIV status and their negative 
partners and that the HIV-positive partner in serodifferent couples, even with CD4 count above 
350 cells/μL should initiate ART to reduce the risk of HIV transmission. 
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The current debate, especially in countries with generalized epidemics, is whether ART should 
be initiated for all persons diagnosed (irrespective of CD4 count) as a preventive public health 
policy. Most of the discussion revolves around the implementation of such a program, the 
affordability and sustainability of this strategy in the long term and on whether high ART 
coverage in people in need of ART for clinical reason (CD4<350 cell/μL) should first be 
achieved. This is an area in which there are no trials, although community RCTs where some 
communities are allocated to higher testing and immediate ART initiation and others to 
standard of care, with HIV incidence as outcome, are currently ongoing in sub-Saharan Africa 
(PopART Study (716), Treatment As Prevention (Tasp) trial in KwaZulu-Natal (717), the 
Mochudi Prevention Project in Botswana (718)).  
 
 
4.3. Cost-effectiveness of different adult ART eligibility criteria and 
coverage scenarios in South Africa 
4.3.1. Rationale and description of the project 
The finding that ART reduced the probability of transmitting HIV by 96% in stable serodifferent 
couples (432) suggested the potential, by increasing the number of people on ART, of curbing 
the HIV epidemic in countries with generalised epidemics. Nevertheless it is clear that 
implementing interventions such as - in the extreme - test and treat requires a large amount of 
resources and currently not all those with CD4≤350 cells/μL, which was the threshold 
recommended by WHO in 2010, are receiving ART. In South Africa in 2011 69% were estimated 
to be receiving ART of those eligible at that time and 80% in 2012 and overall in LMIC only 63% 
of those with CD4<350 cells/μL were receiving ART in 2012 (719). Even in countries who have 
achieved high coverage, many people still initiate ART late, due to lack of early HIV diagnosis or 
low linkage and retention in care (551;553). A large cohort study which included two sites in 
South Africa, Khayelitscha and Gugulethu, both in Cape Town, reported a median CD4 count at 
diagnosis respectively of 100 and 101 cells/μL for these two sites for the period 2004-2007 
(720). A more recent study, conducted in Durban, reported that of people diagnosed between 
August 2010 and November 2011, 34% were diagnosed with a CD4 count <100 cells/μL (721).  
Stakeholders, including donors and governments must make a decision on how to invest their 
limited resources in order to maximize the health gain, in this particular context whether to 
modify the eligibility criteria to initiate people on ART and increasing linkage and retention 
care or whether to implement other health programmes (704;722). Mathematical models can 
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give insights on the long term consequences in terms of epidemiological impact and costs of 
these different strategies (723). Many of them have evaluated the impact of modifying the ART 
eligibility criteria (i.e. different CD4 count thresholds) on the HIV epidemic in different 
countries (686;688;691;724-728). Nevertheless it is often difficult to compare the results 
because of the different metrics used in reporting the results and the different implementation 
of these results. 
As part of the revision process of the guidelines for the use of ARVs, released in July 2013 
(280), the WHO asked the HIV modelling Consortium to assess the cost-effectiveness of 
different ART eligibility criteria in different countries, by comparing the results from different 
mathematical models. Four countries were selected, South Africa, Zambia, India and Vietnam 
and twelve independent mathematical models took part in this comparison. I contributed by 
using the Synthesis model to evaluate the cost-effectiveness for South Africa, as did six other 
models. I programmed the strategies agreed and the outcome in the Synthesis model using the 
metrics indicated, I run the simulations and provided the outcomes to Jeff Eaton (both the 
health outcomes and the components of the programs: number of people receiving treatment, 
number of HIV tests used, etc.). Jeff Eaton summarized the results provided by the different 
mathematical modellers and together with economists (Nick Menzies and John Stover) they 
decided on the appropriate costs and applied them to the units provided. The results are 
presented and compared only for this country. The aim was to evaluate the impact and cost-
effectiveness of changes to adult ART eligibility guidelines and improvements in HIV testing 
and linkage to care. 
 
4.3.2. Methods 
4.3.2.1. Scenarios considered and outcomes metrics 
Three different thresholds for initiating adults in care on ART were considered: (1) CD4≤350 
cells/μL, (2) CD4≤500 cells/μL and (3) all HIV-positive adults and two different scenarios: (a) 
maintenance  of current levels of HIV testing, linkage to and retention in pre ART care, and ART 
uptake, referred to as the ‘status quo’ healthcare access scenario and (b) extensive increase in 
HIV testing and linkage to care so that 80% of those  living with HIV are in care when they 
become eligible for ART. For all the simulations when evaluating this last scenario 80% of them 
were in care, however the fact that the CD4 threshold for example was modified to CD4≤500 
cells/μL does not mean that all people with a CD4 below that threshold were initiated on ART. 
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They are assumed to be initiated the first time they have a visit and a measured CD4 is 500 
cells/μL or less. 
These 6 combinations were simulated over a twenty year period from 2014 to the end of 2033. 
Modifications in ART eligibility criteria were assumed to happen at the beginning of 2014 while 
changes in access, by increasing HIV testing and linkage to care, were assumed to be 
implemented over two years starting from the beginning of 2014. To evaluate the health 
benefit of the different strategies, modellers taking part in the project were asked to provide 
the HIV incidence and disability-adjusted life-years (DALYs) averted and information on the 
number of people on ART, the number of people initiating ART and the number of ART-naïve 
people in care and not in care, by CD4 count. 
 
4.3.2.2. Cost and cost-effectiveness analysis 
The cost-effectiveness analysis was conducted from a health system perspective, using the 
same costing across all models. The costs included are the service delivery cost of identifying 
people as HIV-positive and linking them to care, the service delivery cost of providing pre-ART 
care and ART-care, including the cost of programmatic support and supply chain (Table 4.1). All 
the costs indicated in Table 4.1 are in addition to the expenditure required to running the 
program and the cost of setting up the infrastructure which is spread over their useful life, 
rather than upfront. The sources of the costs indicated in Table 4.1, are indicated in the 
Supplementary Information of the manuscript (692). This work on cost sources has been 
conducted by Jeff Eaton, John Stover and Nicholas Menzies, and for this reason is not reported 
in detail here. 
For the summary measure for the cost-effectiveness analysis, ICERs were calculated as the 
incremental cost per DALY averted over 20 years of an intervention compared to a less 
effective, less costly alternative. It indicates whether an intervention is likely to represent good 
value from available health sector resources. The number of DALYs averted takes into account 
increments in survival and quality of life, due to the clinical benefit for the HIV-positive person 
of receiving ART and due to the ability of ART to reduce infectiousness and therefore the 
number of new infections. Cost and health benefits were discounted by 3% per annum (729). 
To determine cost-effectiveness an ICER needs to be compared to a cost-effectiveness 
threshold (CET). The CET represents opportunity costs of health sector resources - in terms of 
the health gains foregone as a result of resources being unavailable to deliver other scenarios 
(730). According to WHO recommended benchmarks (729), an intervention is considered ‘very 
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cost-effective’ if its ICER is less than the country’s per capita GDP (South Africa in 2012 $8,040) 
(731) and ‘cost-effective’ if it is less than three times per capita GDP. Nevertheless it is likely 
that the real CET is much lower: for example, in the UK, where in 2013 the per capita GDP was 
$37,300, the current CET used by NICE (National Institute for health and care excellence) is 
$22,000 (£ 13,000), much lower than the current GDP (732). This difference in determing the 
CET is due to the fact that in the UK, since years, cost-effectiveness analyses have been used to 
determine which health interventions will be provided by the national health system and 
which are not. Therefore, based on the budget available for health, the National Institute for 
health and care excellence determines the cost-effectiveness threshold for UK. The same 
cannot be said for most of the countries and, least of all, for sub-Saharan African countries, 
where healthcare, especially for people with HIV, is funded mainly by international donors 
rather than by the national government. For this reason, WHO indicated some benchmarks. In 
this analysis the CET recommendation by WHO are used. 
The disability weights used come from the Global Burden of Disease Study 2012, which 
evaluated the value of life-years lived with defined health conditions, compared to full health, 
by sample surveys conducted in different parts of the world (733). 
Table 4.1. Unit costs and disability weights (all costs in 2012 US dollars) (692) 
 Costs in      
South Africa 
Health state Disability 
weighta 
On ART, ARV cost (per PY) $143 
HIV+, CD4 >350 
(untreated)b 
0.053 
On ART, non-ARV cost (per PY) $422 
HIV+, CD4 200–
350 (untreated) 
0.221 
ART initiation, from pre-ART care (per initiation) $95 
HIV+, CD4 ≤200 
(untreated) 
0.547 
ART initiation, not in pre-ART care (per initiation) $126 HIV+, on ART 0.053 
Pre-ART care, CD4 > 350 (per PY) $205 TB disease 0.331 
Pre-ART care, CD4 200–350 (per PY) $238 
 
 
Pre-ART care, CD4 ≤200 (per PY) $359 
 
 
HIV testing & linkage: general pop. (per client) $20 
 
 
Healthcare utilization, CD4 >350, not in care (per 
PY) 
$13 
  
Healthcare utilization, CD4 200–350, not in care 
(per PY) 
$46 
  
Healthcare utilization, CD4 ≤200, not in care (per 
PY) 
$167 
  
End of life cost (per death) $160 
  
TB treatment (per case treated) $364 
  
Supply chain management (percentage mark-
up)c 
20% 
  
Programmatic support (percentage mark-up)d 50% 
  a 
Disability weights based on Salomon et al. (733). For individuals with co-morbidity (e.g. concurrent HIV and TB 
disease), disability weights were compounded multiplicatively. 
b 
It was assumed that HIV-infection with CD4 ≥350 
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incurs the same disability, 0.053, as individuals receiving ART. 
c
 Mark-up assessed on ARVs cost. 
d 
Mark-up assessed 
on all costs except for ARVs. ART: antiretroviral therapy; ARV: antiretroviral drug; PY: person-year; TB: tuberculosis; 
 
4.3.3. Results 
Using the Synthesis model (bar in yellow in Figure 4.2), I found, as did the other six models 
which simulated the different strategies in the context of South Africa, that changing the 
eligibility criteria to initiate ART to CD4 ≤500 cells/μL or all HIV-positive people was estimated 
to be very cost-effective over 20 years. In particular, the cost per DALYs averted over 20 years 
of changing ART eligibility criteria from CD4 ≤350 cells/μL to CD4 ≤500 cells/μL was $1,691 
using the Synthesis model, and varied from $273 (Goals Model) to $1,560 (EMOD model) in 
the other 5 models (Menzies did not simulate this comparison), while the cost for changing the 
eligibility criteria from CD4 ≤350 cells/μL to all HIV-positive adults was $2,133 in the Synthesis 
model and it ranged from $438 (Goals Model) to $3,790 (STDSIM model) in the other 6 
models. 
 
Figure 4.2. The incremental cost per DALY averted for expanding ART eligibility criteria by 
model in South Africa (692) 
 
DALY: disability-adjusted life-year; 
Note to Figure 4.2 (692): Results calculated over 20 years, with all costs and health benefits discounted at 3% per 
year. All costs are in 2012 US dollars. Values below the upper dashed line (three times per capita GDP) are defined 
as cost-effective; those below the lower dashed line (per capita GDP) are defined as very cost-effective. The 
Menzies model simulated only expanding eligibility to all HIV-positive adults. *Indicates that eligibility for patients 
with CD4 counts of 500 cells per μL or less is dominated by the other strategy (i.e. produces fewer health benefits at 
higher cost).  
Figure not available due to copyright restrictions. 
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The cost per DALYs averted over 20 years of expanding HIV testing and linkage to care so that 
80% of those who become eligible for ART are in care, while maintaining the CD4 threshold of 
350 cells/μL to be eligible for treatment is $1,398 using the Synthesis model and it ranges from 
$686 (Menzies model) to $2701 (STDSIM model). Therefore using the Synthesis model the 
most cost-effective strategy among those considered is to expand HIV testing and linkage with 
a CD4 threshold for ART eligibility of CD4 ≤350 cells/μL (see Figure 4.3). This result suggests 
that the most cost-effective health intervention among those considered in the context of 
South Africa in the long term (20 years) is to first of all invest in expanding HIV testing and 
linkage to care to improve ART coverage among those in greatest need (CD4 ≤350 cells/μL); 
only once this intervention is fully implemented, to simultaneously adopt a threshold for ART 
eligibility of CD4 count of CD4 ≤500 cells/μL  ($1,497) and afterwards to all HIV-positive people 
($1515, see Figure 4.3). However if resources were very limited, in particular if the cost-
effectiveness threshold for South Africa was less than $1,398, which is the lowest ICER across 
the interventions considered, using the Synthesis model (i.e. universal expansion with CD4 
threshold to initiate ART of 350 cells/μL), my model suggests that South Africa should not try 
to implement any of the interventions considered, but if there are other interventions not 
considered here characterized by ICER lower  than South Africa cost-effectiveness threshold 
these other interventions should be implemented. 
 
Over a shorter time period ICERs were much higher. Over a 5 year period the most cost-
effective strategy according to the Synthesis model is to modify the eligibility criteria to those 
with CD4<500 cells/μL, with an ICER of $4,892 per DALY averted, which is still very cost-
effective, compared to an ICER of $1,691 per DALY averted over 20 years period. Across the 
models, the ICER over 5 years of modifying the eligibility criteria to those with CD4<500 
cells/μL varied from $2,140 (Goals model) to $11,646 (EMOD) per DALY averted. This higher 
cost per DALYs averted over short period is due to the fact that the benefit of preventing new 
transmissions increases over time. 
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Figure 4.3. Cost-effectiveness analysis over 20 years using the Synthesis model 
DALY: disability-adjusted life-year; SQ: status-quo (i.e. current patterns of healthcare access, see 4.3.2); UE: 
uniformly expanded healthcare access (i.e. 80% of those living with HIV are in care when they become eligible for 
ART); 
 
The impact on HIV incidence of these different strategies of modifying the eligibility criteria to 
those with CD4<500 cells/μL, is relatively modest, 5% over 20 years using the Synthesis model, 
and it varied from 4% (Goals model) to 12% (EMOD model). Expanding ART coverage by 
improving HIV testing and linkage to care with a CD4 threshold of 350 cells/μL would reduce 
HIV incidence by 6% in the Synthesis model, but by a higher amount in the other models: from 
15% (BHH model) to 28% (Goals model). If all HIV-positive adults are eligible for ART and 
access to care is not expanded 9% of infections would be averted and 19% if it is expanded. 
The other models found similar magnitude of increase: between 12% (Goals) and 32% 
(Menzies) without access to care expansion and between 36% (BBH) and 60% (Goals) if HIV 
testing and linkage to care is improved. 
 
The cost of strategies involving expansion of access to care is much higher than the costs of 
strategies which only involve only a change in the eligibility criteria (see Figure 4.4 at page 
228). Figure 4.4 (page 228) shows the incremental undiscounted costs (in 2012 US dollars) for 
different ART eligibility and access strategies compared to continuation of the current 
situation. The portion of the bar underneath the horizontal line represents the cost saving and 
the total incremental cost is indicated by the solid dots. Each bar, within each strategy 
represents a model, in the same order as in Figure 4.2 (page 224), so the Synthesis model is 
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the sixth bar in each group and it is indicated by an orange arrow. The incremental cost of 
starting on ART earlier people who are already in care (i.e. attending the clinic regularly) is 
relatively low, due to the fact that the cost of additional years on ART is partially compensated 
by saving in the cost of pre-ART care and other healthcare cost. On the contrary, by expanding 
treatment access through increase HIV testing and linkage to care, there is an incremental cost 
due to additional HIV testing, pre-ART care monitoring and ART care for the additional people 
diagnosed. 
228 
 
Figure 4.4. The incremental cost over 20 years for different ART eligibility and access strategies compared to reference scenario (continuation of 2010 eligibility 
guidelines and status quo access to care)(692) 
 
Instead of a bar there is an ‘x’ for the Menzies model for the strategy with CD4<500 cells/μL strategy, because Menzies did not simulate this strategy. 
ART: antiretroviral therapy; 
 
Figure not available due to copyright restrictions. 
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Findings from the Synthesis model, together with two other models (Menzies and EMOD), 
suggest that if the aim is to maximise the health gain per dollar spent, expanding access would 
have the lower cost per DALY averted (i.e. lowest ICER) and should be therefore the most 
appropriate choice. Nevertheless the four other models found that the strategy with the 
lowest cost per DALY averted is either changing the eligibility criteria to CD4<500 cells/μL 
(Goals, STDSIM and POPART) or to all HIV-positive people (BBH), without expanding access. 
Ultimately, both ways of expanding the number of people on ART: by changing the eligibility 
criteria or by improving HIV testing and linkage would be considered very cost-effective, 
according to WHO benchmarks, the differences among the models are mainly about which 
way to proceed first. 
The results were quite sensitive for most of the models to the assumptions on the cost of 
testing and linkage to care and of pre-ART care (see Figure 4.5). Figure 4.5 shows the strategy 
with the lowest ICER for a given change in the cost of HIV testing and linkage to pre-ART care 
and pre-ART care. All the strategies are compared to the reference strategy assuming 
continuation of the current level of access to care and eligibility criteria to be initiation on ART 
of CD4 ≤350 cells/μL. The ‘x’ indicates the base scenario (i.e. 0% change in cost of HIV testing 
and linkage to pre-ART care and 0% change in the cost of pre-ART care). As the cost of testing 
people and linking them to care and the cost of pre-ART care decrease (bottom left corner) it 
becomes cost-effective to expand access to care (areas identified in green), while at the other 
extreme (top right corner) it becomes cost-effective only to change the eligibility criteria (area 
in purple). The Synthesis and the EMOD model show a similar pattern, with the combination of 
improvement in HIV testing and linkage to care and all the positive people being eligible for 
treatment being the most cost-effective strategy in a situation where the cost in diagnostic 
and linkage is reduced while the cost of pre-ART care increases (top left corner). 
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Figure 4.5. Threshold analysis showing the strategy with the lowest cost per DALY averted 
for different combination of percentage change in the cost of pre-ART care (vertical axis) and 
in the cost of HIV testing and linkage to care (horizontal axis) (692) 
 
ART: antiretroviral therapy; 
 
4.3.4. Discussion  
In the context of South Africa, all the strategies considered were very cost-effective over a 20 
year period, with a maximum ICER of $3,790 per DALY averted found for the strategy involving 
changing the eligibility criteria to all positive people in the STDSIM model. This cost per DALY 
averted is still less than half the 2012 South Africa per capita GDP ($8,040). These results can 
be partly explained by the relatively low cost of providing additional years of ART to people in 
care and by the clinical benefit and reduction in infectiousness in people receiving ART which 
results in a reduction in the number of new transmissions. 
The models differ in identifying the most cost-effective strategy and therefore it is difficult to 
say the one that should be prioritized because it produces the greatest health benefit per 
dollar spent. Four models found that the most cost-effective strategy is to change the eligibility 
criteria, three to those with CD4 count <500 cells/μL and one to all those positive, while three 
models found that expansion of access to care should be prioritized.  Despite differences in the 
most cost-effective strategy, all the models found almost a double reduction in HIV incidence 
could be achieved if access for those most in need (CD4<350 cells/μL) is improved so that 80% 
are in care when becoming eligible for treatment compared to only changing the eligibility 
criteria. 
 
Figure not available due to copyright restrictions. 
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In this project, situations where resources were severely constrained, with waiting lists for 
patients eligible for treatment were not considered. In South Africa there are no longer waiting 
lists for ART initiation. In April 2013 the new South African guidelines recommended initiation 
to ART in patients with CD4 less than 350 cells/μL (226) and in the WHO guidelines released in 
July 2013 (280) it is recommended that if it is not possible to treat all those in need, treatment 
should be prioritised for patients most in need (CD4 ≤350cells/μL). 
 
Increasing the number of people receiving ART, whether by changing the eligibility criteria or 
expanding access to care, requires high upfront costs but it generates health benefits and it is 
very cost-effective in the long term. Therefore it should be considered as a long term 
population health investment. Earlier mathematical models (691;734) which evaluated the 
cost-effectiveness of changing the eligibility criteria in the context of South Africa found that it 
could be even cost-saving over a 20 year period. This was not confirmed by any of the models 
included in this analysis. 
 
In this exercise, only an increase up to 80% of people eligible being in care was considered. 
However, it is worth mentioning that an increase of further 10% up to 90% of the population 
eligible being in care is likely to cost more than the increase from 70 to 80%, for example. This 
is due to the fact that people easy to reach at this point would have been reached already and 
it becomes increasingly difficult to reach new people. This would require putting in place more 
efforts, at a higher cost. 
 
As mentioned, all the seven independent models which evaluated the impact of expanding 
treatment in the context of South Africa agreed that all the strategies considered were very 
cost-effective over a twenty year period. Nevertheless there were differences in the order in 
which these strategies should be implemented and so which one should be prioritized. In 
particular, both the Synthesis model and the EMOD model, which are both individual-based 
stochastic models and include in more detail the steps HIV-positive people need to go through 
in order to be on successful ART, concluded that rather than modifying the eligibility criteria, 
the priority should be to increase the number of people in care. This suggests that the level of 
detail included is possibly having an impact on the results. In addition, the differences across 
models are believed to partially reflect the different structure of the models and the 
uncertainty in some of the parameters representing the epidemiology of HIV transmission and 
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different assumptions regarding the future treatment uptake in the reference scenario and 
long term effectiveness of treatment. 
A parameter of particular importance for this analysis is the presence and magnitude of clinical 
benefit of starting treatment at a higher CD4 count for the person receiving treatment. As 
mentioned in section 4.2.7, two RCTs are currently on-going to address this question 
(284;285). Another source of uncertainty is whether it is feasible to scale up the prevention 
benefits observed in RCTs (735) and whether starting people at a higher CD4 count would 
affect their risk behaviour. As mentioned in section 4.2.3, there is evidence from KwaZulu-
Natal in South Africa that people living in areas with higher coverage of ART experience a lower 
risk of HIV infection (670) and so far studies have not observed an increase in sexual behaviour 
among people initiating ART at higher CD4 count (736). As more data become available 
regarding these parameters and more generally on other assumptions underlying these 
models, this analysis should be updated. 
 
The data on the cost of scaling up and running HIV care programmes and HIV testing services 
at a higher level than currently and the magnitude of the flow of patients are scarce and this 
contributes to the uncertainty on the estimates. As programmes providing HIV testing and care 
develop and become more established there is evidence that the unit costs tends to decrease 
(737;738). Nevertheless, it is not clear whether this would be true if expansion of access to 
care so that 80% of those who become eligible are in care at a national level, because it is likely 
that to achieve this it would not be enough to expand the existing sites but new infrastructure 
would also be required. Therefore the countries who first will adopt these strategies will 
provide important information on the epidemiological and economic impact of rolling out 
these strategies. 
 
The fact that all these strategies are very cost-effective does not exclude the existence of other 
health interventions, which could provide a greater health benefit for the same amount of 
dollars spent. Barnighausen et al., as mentioned before, found for example that an 
intervention providing VMC to a larger number of people could have a lower cost per DALY 
averted than increasing ART coverage (739) and Njeuhmeli found that it could even be cost 
saving in the long term (740). 
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In response to the release of new guidelines from WHO, which it is likely took into account the 
impact on the population of expanding the eligibility criteria (i.e. this project), countries need 
to take decisions on whether to take those recommendations on board and to which extent. 
The Synthesis model suggests that increasing HIV testing and linkage to care should be the 
priority, but that modifying the eligibility criteria to all those with CD4<500 cells/μL, as 
recommended by WHO is very cost-effective and should be considered against other very cost-
effective health interventions. 
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5. Predicted levels of HIV drug resistance in South Africa: 
potential impact of expanding diagnosis, retention 
and eligibility criteria for antiretroviral therapy 
initiation 
 
5.1. Rationale 
In the previous chapter the evaluation of the impact of expanding ART by increasing the 
number of people in care or/and modifying the threshold to consider people eligible for 
treatment in the context of South Africa and its comparison to the other mathematical models 
was presented. 
The Synthesis model is the only one, among those included in the comparison for South Africa, 
to include the emergence and transmission of resistance. For this reason, I decided to focus my 
attention on the impact on the level of HIV drug resistance of modifying the eligibility criteria 
to initiate ART or alternatively expanding the number of people in care, by increasing HIV 
testing, linkage to care and retention in pre-ART and on-ART care. In fact the models included 
in the HIV Modelling consortium comparison (692) (see section 4.3) differ substantially in the 
level of detail incorporated and very few have thus far captured all the various processes that 
we have a reasonable understanding of due to extensive data sets (e.g. sexual risk behaviour, 
testing, PHI, VL, CD4 count, use of ART, adherence, resistance, drug failure, drug interruption, 
LTFU, occurrence of AIDS, non-AIDS death, etc.). This is not surprising as this requires a 
complex and highly parameterized model which has the disadvantage over simpler models 
that it is difficult to analyse and interpret. However, such models may have a useful role in 
providing more quantitative predictions of the effect on HIV incidence, of greater testing and 
earlier ART initiation in a given setting and have the advantage of carrying a level of detail 
which makes them suitable to be used as a basis for detailed economic analyses. The Synthesis 
model is one of them.   
 
There is concern that the expansion of ART roll-out may impact future drug resistance levels 
and hence compromise the benefits of ART at an individual and population level.  In one study 
in South Africa it has been estimated that 2.5% experience VF (two consecutive VL>5,000 
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copies/mL, despite an adherence promotion following the first raised VL) by one year since 
ART initiation, 12% at 5 years (292), and that 87.6% are virogically suppressed (VL<400 
copies/mL) by one year. However, virological suppression estimates as low as 66% have been 
reported (304). Among people with VF in South Africa between 66% and 86% 
(597;597;598;627;741;742) had resistance detected in majority virus.  Similar estimates have 
been observed in a study conducted in six African countries where at one year since ART 
initiation, among people with VL>1000 copies/mL, 70% had at least one DRM detected and 
49% at least two, of which the most common were M184V (53.5%), K103N (28.9%), Y181C 
(15.5%) and G190A (14.1%) (398). A systematic review of RCTs estimated that around 5% of 
the participants experienced VF at 48 weeks. Of the samples successfully genotyped M184V 
mutation was present in 35% of those who started NNRTI-based regimen compared to 21% of 
those who started a boosted PI-based regimen, while the incidence of K65R was much lower: 
5.3% in those who initiated an NNRTI-based regimen compared to 0% in people started on a 
boosted PI-based regimen (743). A more recent meta-analysis of RCTs comparing boosted PI-
based regimens to NNRTI-based regimens found that at 48 weeks 3.3% of those receiving 
NNRTI-based regimen had resistance detected compared to 1.6% in those receiving boosted-PI 
regimens, with lower incidence of K65R (1.3% vs 0.7%) and M184V/I (3.2% vs 1.4%) (744). A 
meta-analysis aimed at assessing the impact of different frequencies of monitoring in patients 
on ART with CD4 count <200 cells/μL, reported that 88% of those monitored infrequently (not 
monitored or every 3 to 6 months) had resistance at VF, compared to 61% in those monitored 
frequently (3 months or more often) (745). 
Selection of DRM is a concern not just for individual patients, who may have reduced 
treatment options, but also for society because of potential transmission of drug-resistant HIV, 
which could compromise the effectiveness of available first-line regimens for a substantial 
portion of the population and increase the need for costly second-line regimens.  In the 2012 
WHO HIV drug resistance report (305), among 44 population-based surveys conducted in 
recently infected populations in Africa between 2004 and 2010, the percentage of surveys 
reporting moderate (5-15%) levels of TDR increased from 18% in 2004-2006 to 41% in 2007-
2010. A meta-analysis estimating trends in prevalence of HIV-1 drug resistance in recently and 
chronically infected ART-naïve individuals found a relative increase of 14% per year in the 
prevalence of NNRTI resistance in southern Africa (746). This is consistent with the finding that 
the proportion of people with NNRTI resistance at ART initiation increased from 3.4% in 2007 
to 5.4% in 2010 in Africa (305).  
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One of the first surveys on TDR conducted in South Africa took place between 2002 and 2004 
in the province of Gauteng, where the National ART programme began providing treatment in 
April 2002 and reported a low level of TDR (747). Surveys were conducted between 2005 and 
2009 on women pregnant for the first time aged less than 25 years in the provinces of Gauteng 
and KwaZulu-Natal in South Africa. They showed that the prevalence of TDR was less than 5% 
for all drug classes in all the surveys conducted in the Gauteng province; while in the KwaZulu-
Natal province NNRTI TDR seemed to be increasing over time reaching a level of between 5 
and 15% in 2009 (748). In Cape Town the prevalence of TDR has been estimated at 2.5% (95% 
CI: 0-5.3%) in a study conducted in the public sector between 2002 and 2007 (742). 
Contrasting results came from a literature review and data mining (n=1618 sequences) 
conducted to estimate the trend over time in TDR in South Africa (749). They reported that the 
highest TDR rate was in 2002 (6.67%; 95%CI: 3.09-13.79%) and that it has been below 5% since 
then. Nevertheless, a recent study conducted among women of reproductive age who 
presented to screen for an HIV prevention trial in Durban reported that 7.4% of those with a 
VL>200 copies/mL (96% of those HIV-positive) had DRMs present in majority virus (750) and in 
people who experienced VF 21% of them were found to harbour NNRTI-resistance mutations 
at ART initiation (306). The PASER-M study, collecting data from patients living in Kenya, 
Nigeria, South Africa, Uganda, Zambia and Zimbabwe estimated a prevalence of drug 
resistance at ART initiation of 5.6%, with prevalence of TDR in the three sites in South Africa 
Pretoria, White River and Johannesburg of respectively 1.1%, 4.8% and 4.5% (376). These data 
stress the importance of having regular estimates of the incidence and prevalence of HIV drug 
resistance at country level, and projections of potential future levels.   
 
Wider ART coverage is highly likely to lead to an increase in the proportion of new infections 
with TDR; however it is difficult to predict whether the benefits of reduced incidence will out-
weigh this risk of higher levels of resistance.   As countries consider embarking on ART-based 
approaches to HIV prevention, an increased understanding of the potential effects of this 
policy shift on resistance is needed.   I used the HIV Synthesis model calibrated to South 
Africa’s epidemic to estimate and project current and future incidence and prevalence of drug 
resistance (acquired on ART and transmitted) under the current conditions. These outcomes 
are compared to the projected level of resistance in the context of expanded eligibility criteria 
to initiate ART (CD4 <500 cells/μL and in all people diagnosed with HIV compared with CD4 
<350 cells/μL) and enhancements in diagnosis and retention in care.   
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5.2. Scenarios investigated 
As mentioned before, there are two main approaches to increase the number of people 
receiving ART, either changing the CD4 threshold for ART initiation, or (not mutually exclusive) 
concentrating on maximising rates of diagnosis and linkage and retention in both pre-ART and 
ART care. This second approach would require substantial augmentation of health system 
infrastructure and reduction in social stigma associated with HIV and as such it represents a 
more ambitious undertaking than modifying the ART initiation threshold. 
We consider two potential scenarios regarding diagnosis and retention.  In one (“enhanced 
diagnosis and retention”) significant improvements in HIV testing, linkage to care and 
retention in pre-ART care are made so that 80% of people who become eligible for ART are in 
care, and in addition retention on ART is improved so that 92% of patients are retained on ART 
one year after ART initiation (representing a 50% reduction in LTFU while on ART).   These 
interventions are scaled up over 2014 and 2015. This is compared with a scenario assuming no 
change after 2012 in these factors, so the likelihood of moving along the continuum of care is 
assumed to remain as described in 2012 and so are the adherence levels, the availability of 
drugs and the likelihood of being initiated on ART if eligible. Within each of these two 
scenarios, three different ART initiation policies are considered: at CD4 count below 500 
cells/μL (currently recommended by WHO (280)), at time of diagnosis regardless of CD4 count, 
or continuation of the existing policy in South Africa of initiation at CD4 counts below 350 
cells/μL (226).   
The simulations from 2013 to the end of 2032 started from the epidemics which provided a 
good fit to the observed data (n=30, see section 3.13). Multiple runs for each scenario and ART 
initiation policy have been generated and the median or the mean is presented, as indicated.  
The median is presented with the uncertainty range: the 5th and 95th percentile across all 
simulations, so it captures part of the uncertainty in the parameters. It is important to note 
that for the reduction in HIV incidence from 2012 to 2032, both the 95% CI and the 90% 
uncertainty range (UR) are presented. The first reflects the stochastic variability, while the 
second the uncertainty on the parameters.  
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5.3. South African HIV epidemic at the end of 2012 predicted by the 
Synthesis model 
The characteristics of the epidemic, as predicted by the model, at the end of 2012, are 
summarised in Table 5.1 (page 239). The median and 90% uncertainty range (90% range across 
the 30 simulations with the best fit to the South African epidemic) are reported (on average 
they differ by less than 18% to the data used to calibrate the model, see section 3.13). The 90% 
uncertainty range reflects my choice of the a priori distribution for the parameters sampled 
and the choice of the threshold to consider a simulation as fitting to the observed data. 
We estimated that of the 33.6 million people aged 15 to 65 years living in South Africa 5.3 
million are infected with HIV, which corresponds to an HIV prevalence of 15.9%. Of these 73% 
are predicted to be diagnosed with HIV. The median CD4 count at diagnosis, across all those 
who have been diagnosed up to the end of 2012, is assumed to be relatively high at 367 
cells/μL. However, the median CD4 count at ART initiation, across all those who have initiated 
ART up to 2012, is much lower at 116 cells/μL. Based on fitting to data on the proportion with 
TDR amongst those just diagnosed with HIV from the WHO surveillance data from sub-Saharan 
Africa up to 2010, the modelled percentage of newly diagnosed people with DRMs present in 
majority virus in 2012 is 5.9% and the proportion initiating ART with NNRTI-resistant virus in 
majority virus (NRMV) is 3.7%. On the other hand, the median percentage of people infected 
with HIV in 2012 who have TDR is much higher at 13.8%, with a slightly lower proportion 
infected with key NNRTI-associated mutations (10.4%).  
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Table 5.1. Descriptive characteristics at baseline (end of 2012) simulated by the Synthesis model  (adult population, 15-65 years old) compared to data from the 
literature 
 Median (90% range)a Value reported in the literature Notes and source 
Number alive in population (in millions) 33.6 (32.7 - 34.1) 31.9 2013 (435) 
34.8 
 
2013 (433) 
Number of people living with HIV (in millions) 5.3 (4.6 - 6.2) 5.7 (5.5-6.0)   
 
2012, age 15+ (450)  
 HIV prevalence (%) 15.9 (13.6 - 18.4) 18.8 (17.5-20.3) 
 
2012, age 15-49 (440) 
 HIV Incidence (per 100 PYs) 1.1 (0.6-1.6) 1.72 (1.4, 2.1) 
 
2012, age 15-49 Lag-Avidity EIA 
(440)   
 
1.9 (0.8, 3.1) 
 
2008-12, Mathematical Model 
(440) 
 
Death rate  
(per 100 PYs)d 
among HIV- people  0.7 (0.6 - 0.8) 1.4 M, 0.8 F   
 
Whole pop 15-65, 1997 (437) 
among people on ART with CD4>350 cells/μL 0.8 (0.2 - 1.7) Month 1: 14.7 (10.5–20.7); 
Month 2: 10.6 (7.1–16.0); 
Months 3-4: 5.1 (3.3–7.7); 
Months 5-6: 5.1 (3.3–7.9); 
Months 7-12: 27 (19–40); 
 
Low income settings (751) 
 among people on ART with CD4≤350 cells/μL 5.1 (2.8 – 9.1) 
among HIV+ ART-naïve (diagnosed or not) 3.7 (2.7-4.9) - - 
among HIV+ people, exposed to ART, off ART   14.4 (8.2 - 21.5) - - 
Testing 
% of men ever tested for HIV 57.3 (52.9 - 62.1) 59.0 (57.2 - 60.8) 
 
2012, age 15+ (440) 
% of women ever tested for HIV 66.2 (61.6 - 69.9) 71.5 (70.1 - 72.9) 
 
2012, age 15+ (440) 
% of people who tested for HIV in the last year   36.1 (30.8 – 39.4) 
 
43.4 
 
2012, age 15+(440) 
% of HIV-positive people diagnosed 73.5 (70.7 - 77.3) 37.8 M, 55.0 F 
 
“Aware HIV positive” 2012, age 
15+ (440) 
 
Median CD4 count at diagnosisb 367  (340 - 388) 100 (45-161) 
 
2004-08, Khayelitsha (720) 
 357 (238–500) 
 
2010-11, Johannesburg (752) 
 Antiretroviral treatment 
Number of men on ART (in 1000s) 639 (482 - 795) 551 
 
2011 (451) 
Number of women on ART (in 1000s) 1,111 (909 - 1,281) 1,090 
 % of HIV-positive people on ART 32.0 (29.7 - 36.2) - - 
% of HIV diagnosed people on ART 43.3 (41.1 - 47.2) - - 
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% on ART of those not ART-naive or with current CD4<200 
cells/μL 
64.0 (62.3 – 66.6) 79 (70-85) 
 
2011 (451) 
Median CD4 at ART initiationb  116  (105 - 128) 123 (55-184) 
 
2005-09 (753) 
 103 (45-164) 
 
2002-08 (601) 
 % with VL suppressed among those on ART 89.5 (88.4-91.2) 12 months: 87.6;  
36 months: 88.1;  
60 months: 83.8; 
 
2001-07 (292) 
 
% of people on ART on second-line 9.9 (8.7 - 11.4) - - 
Resistance 
% of new infections with TDR (any class)d 13.8 (5.1 - 26.7) - - 
% of new infections with NNRTI resistanced 10.4 (4.1 - 20.3) - - 
% of new diagnoses with TDR (any class)d 5.9  (2.0 - 9.6) <5 2005-2009 on women pregnant for 
the 1st time aged<25 years in 
Gauteng (748) 
between 5 and 15 2009 on women pregnant for the 
1st time aged<25 years in Kwazulu-
Natal (748) 2.5 (95% CI: 0-5.3) Public sector between 2002 and 
2007 in Cape Town (742) 
6.67 (95%CI: 3.1-13.9) 2002, literature review and data 
mining (749) 
<5 Since 2002, literature review and 
data mining (749) 
% of people on ARTc with VL>500 copies/mLd with resistance 84.9 (81.0 - 88.1) 66 and 86 Programmes in South Africa 
(597;597;598;627;741;742) 
% with less than 3 active drugs at ART initiationd,e 9.3 (4.8 - 13.8) - - 
% with NRMV at ART initiationd 3.3 (1.4 - 7.0) 3.4 2007 Africa (305)  
5.4 2010 Africa (305) 
5.6 Any resistance, three sites in South 
Africa (376) 1.1 ny resistance, Pretoria 
4.8 Any resistance, White River 
4.5 Any resistance, Johannesburg 
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% of HIV+ with resistant mutation in majority virusd 9.6 (8.1 - 11.7) - - 
% of HIV+ with NNRTI resistant mutation in majority virusd 7.4 (5.9 - 9.7) - - 
a – 90% range over the 30 simulations who provided the best fit, b – across all adults who have been respectively staged or initiated on ART by end of 2012, c – at least 6 months on ART are required, 
d - average over 1 year (2012), e – In the model having less than 3 active drugs correspond to have drug-resistant mutations present in majority or minority virus; ART: antiretroviral therapy; F: 
female; Lag-Avidity EIA: enzyme-linked immuno assay Limiting Antigen Avidity; M: male; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRMV: non-nucleoside reverse transcriptase inhibitor 
resistant virus in majority virus;  TDR: transmitted drug resistance; VL: viral load; 
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5.4. Impact of different diagnosis and retention scenarios 
5.4.1. Impact on the number of people on treatment 
Figure 5.1 presents the number of people HIV-positive and receiving first and second-line 
treatment under the two different diagnosis and retention scenarios and the three ART 
initiation policies. In 2012, 5.3 million are estimated to be HIV-positive and 1.8 million adults to 
be receiving ART, of which 9.9% are second-line regimens. 
By 2032, assuming current levels of diagnosis, retention and ART initiation eligibility criteria are 
maintained, 3.3 million are projected to be receiving ART, with 35% (1.1 million) on second-line 
regimens.  Changing the threshold at which a person is eligible for treatment is predicted to 
have minimal impact on the number of people on ART and on the number requiring second-
line regimens.  However, under a scenario of enhanced diagnosis and retention between 4.9 
and 5.2 million will be on ART, of which 40%-42% (2.0-2.1 millions) on a second-line regimen. 
 
Figure 5.1. Estimated number of people HIV+, stratified by first-line or second-line of 
treatment regimen (median value and 90% uncertainty range [UR]) 
 
Median % (90% 
UR) proportion 
on second-line 
9.9 
(9-11) 
34.6 
(30-39) 
35.7 
(31-41) 
37.6 
(32-42) 
39.6 
(35-44) 
40.5 
(36-44) 
42.0 
(38-45) 
 
ART: antiretroviral therapy; UR: uncertainty range; 
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5.4.2. Impact on HIV incidence 
In Figure 5.2 the average HIV incidence, stratified by whether the virus is drug-sensitive or 
drug-resistant in 2012 and in 20 years time is displayed. Overall HIV incidence is predicted to 
be  22% lower (95% CI: -23%, -21%) in 20 years time under the current scenario. With no 
enhancement in diagnosis and retention, changing ART eligibility criteria, from 350 cells/μL to 
500 cells/μL or at diagnosis, has only a moderate effect: an additional 3% and 6% reduction in 
incidence respectively (up to 28%). The same reduction in HIV incidence (28%) can be achieved 
if, instead, there is an enhancement in diagnosis and retention and the ART initiation threshold 
is maintained at CD4<350 cells/μL. A change in initiation threshold to CD4<500 cells/μL, in 
addition to the enhancement in diagnosis and retention, confers 36% reduction in HIV 
incidence in 20 years time and ART initiation at diagnosis leads to a 48% reduction (95%CI:-
49%,-47%). Average HIV incidence with TDR is estimated to be 0.16 occurrences per 100 PYs in 
2012. Modifying the CD4 count at which a person is eligible to initiate ART (from 350 cells/μL 
to 500 cells/μL or at diagnosis regardless of CD4) has a negligible impact on future incidence of 
new infections with TDR, whatever the scenario on diagnosis and retention. Because the 
number of new infections is increasing, the proportion of new infections with TDR does 
increase as the eligibility criteria expand and if improvement in diagnosis and retention occurs. 
The reason why the number of new infections with TDR remains stable despite HIV incidence 
decreasing, as more people receive ART (more from the left to the right in Figure 5.2), is due to 
the fact that more people are on suppressive treatment but more people are exposed to ART 
and develop resistance and these represent a greater percentage of those who are 
transmitting HIV. 
  
244 
 
Figure 5.2. HIV incidence with drug sensitive and drug-resistant virus in 2012 and in 2032 
(average and 95% confidence interval for HIV incidence change), according to access to care 
and retention on ART and ART initiation policy 
 
Med (90% 
UR) % of new 
infections 
with TDR 
13.8 
(5-27) 
22.5 
(9-41) 
24.1 
(10-43) 
26.2 
(11-45) 
27.7 
(12-48) 
30.0 
(12-51) 
33.6 
(14-56) 
 
Med (90% 
UR) % of new 
diagnosis 
with TDR 
5.9 
(2.0-9.6) 
14.0 
(5.5-25.6) 
12.2 
(4.3-22.2) 
9.6 
(3.4-18.2) 
15.2 
(6.1-27.4) 
9.1 
(2.9-17.8) 
1.5 
(0.0-5.1) 
 
Med HIV 
incidence 
(90% UR) 
1.1 
(0.7-1.7) 
0.9 
(0.4-1.6) 
0.8 
(0.4-1.4) 
0.8 
(0.4-1.3) 
0.8 
(0.4-1.4) 
0.7 
(0.3-1.3) 
0.6 
(0.3-1.0) 
 
Med % 
reduction in 
HIV incidence 
(90% UR) 
- -24 
(-46,+8) 
-26 
(-50, +3) 
-30 
(-51,-0) 
-29 
(-52,-0) 
-37 
(-64,-7) 
-49 
(-72,-19) 
 
Med: median; TDR: transmitted drug resistance; UR: uncertainty range; UR: unceratinty range; 
 
5.4.3. Impact on the number of people living with resistant virus 
Figure 5.3 shows the estimated number of people living with any resistance in majority virus 
(i.e. detectable and assumed transmissible) in 2012 and projected numbers in 20 years’ time in 
South Africa.  In 2012, 9.6% of those living with HIV are estimated to be living with resistant 
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virus in majority virus (represented by the entire bar), corresponding to 508,800 people, of 
which 77% (the section of the bar in grey) NNRTI resistant virus, which is of more interest, 
given NNRTI are used on first-line. 
 
Figure 5.3. Estimated number of people living with resistance in majority virus in South 
Africa in 2012 and 2032 (median and 90% UR) 
 
% with 
resistance in 
majority virus 
of those 
living with 
HIV (15-65) 
9.6 28.4 31.2 34.3 38.2 41.4 44.2 
(8.1-11.7) (22.7-35.1) (25.1-37.8) (27.9-40.4) (32.4-43.9) (35.5-46.9) (38.6-49.2) 
% with 
resistance In 
majority virus 
in adults 15-
65 
1.5 4.5 4.9 5.2 6.6 7.0 6.7 
(1.3-1.9) (3.4-5.8) (3.7-6.4) (3.9-6.7) (5.2-8.4) (5.4-8.9) (5.0-8.6) 
NNRTI: non-nucleoside reverse transcriptase inhibitor; 
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Figure 5.4 focuses on the number of people living with NNRTI-resistant virus (majority or 
minority) in 2012 and in 20 years’ time and illustrates whether it is present in majority virus 
and with a VL above or below 500 copies/mL or whether it is present only in minority virus and 
therefore assumed not transmissible.  In 2012, 652,000 people are estimated to have NNRTI 
resistance, of which 42% (approximately 275,000) are people with NRMV with VL above 500 
copies/mL (see footnote of Figure 5.4), and therefore have an increased risk of transmitting 
NNRTI drug-resistant virus (43). If existing policies continue, the number of people living with 
NNRTI resistance is predicted to be 2.8-fold higher in 2032 (from 652,000 in 2012 to 
1,862,000). Of these, 68% are predicted to be on ART with suppressed VL or to have resistance 
in minority virus. Therefore the subset of the population with an increased risk of transmitting 
NNRTI-resistant virus (VL>500 copies/mL and NRMV) is approximately 594,000.  Modifying the 
CD4 threshold at which a person is eligible to start ART from 350 cells/μL to 500 cells/μL or to 
all people diagnosed with HIV, regardless of CD4 count, without the enhancement in diagnosis 
and retention, results in a 3.0- and a 3.2-fold increase, respectively, in the number of people 
living with NNRTI resistance, compared to the level in 2012.   
 Alternatively, with enhanced diagnosis and retention and people with CD4 between 350 and 
500 cells/μL additionally becoming eligible to initiate ART, the number of people carrying 
NNRTI resistance in 2032 is expected to be 4.1 fold higher than in 2012. However, 73% are 
predicted to be on ART with suppressed VL or have the resistant virus in minority virus, 
yielding approximately 719,000 individuals with a VL above 500 copies/mL and NRMV.  
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Figure 5.4. Estimated number of people living with NNRTI drug resistance in South Africa in 
2012 and in 2032 (median value and 90% UR) 
 
Med (90% UR) 
number (in 
thousands) of 
people with 
NRMV and 
VL>500 
copies/mL 
275 
(204-350) 
594 
(423-850) 
620 
(447-841) 
625 
(428-837) 
706 
(498-1010) 
719 
(508-942) 
655 
(482-881) 
 
% (90% UR) 
with NRMV of 
those living 
with HIV (15-
65) 
7.4 
(6-10) 
26.4 
(25-27) 
29.1 
(27-30) 
32.1 
(30-32) 
36.0 
(34-36) 
38.7 
(37-39) 
41.3 
(39-41) 
 
% (90% UR) 
with NRMV 
amongst all 
adults 15-65 
1.2 
(1.0-1.4) 
4.1 
(3.1-5.2) 
4.5 
(3.4-5.8) 
4.8 
(3.6-6.1) 
6.1 
(4.9-7.7) 
6.5 
(5.1-8.2) 
6.3 
(4.7-8.0) 
 
Status of people living with NRMV:  
 NRMV with 
VL≥500 
copies/mL 
42% 32% 32% 30% 27% 27% 26%  
 NRMV with 
VL<500 
copies/mL 
21% 50% 53% 56% 63% 65% 67%  
 In minority 
virus 
37% 18% 15% 14% 10% 8% 7%  
Med: median; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRMV: non-nucleoside reverse transcriptase 
inhibitor resistant virus in majority virus; UR: uncertainty range; VL: viral load;  
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Figure 5.5 goes into even more detail and shows the characteristics of people living with 
NNRTI-resistant virus in majority virus and VL≥500 copies/mL (indicated in Figure 5.4 in dark 
grey). Starting from the bottom of the bar, this population has been divided in (i) 
“Undiagnosed – TDR”, people infected with NNRTI-resistant virus living with undiagnosed HIV, 
(ii) “Diagnosed ART-naïve – TDR”, people infected with NNRTI-resistant virus, diagnosed with 
HIV but not initiated on ART, (iii) “ART exposed  - TDR”: people infected with NNRTI-resistant 
virus, who have been exposed to ART, but currently off treatment, (iv) “ART exposed  – 
acquired”, people infected with NNRTI-sensitive virus, who have been exposed to ART, but 
currently off treatment, (v) “on ART VL≥500 – TDR”, people infected with NNRTI-resistant 
virus, who are currently on ART with VL≥500 copies/mL, (vi) “on ART VL ≥500 – acquired”,  
people infected with NNRTI-sensitive virus, who are currently on ART with VL ≥500 copies/mL.  
In 2012, 20% of people living with NRMV and VL≥500 copies/mL are undiagnosed, around 20% 
are diagnosed but ART naïve, 15% have been exposed to ART but are currently not on 
treatment and 45% of them are on ART. In 20 years’ time this last group is expected to 
represent between 45 and 50% if the current access to care is maintained and between 65 and 
75% if an improvement in access to care and retention on ART occurs. 
Regarding the source of these resistant cases, whether acquired or transmitted, I found that 
the percentage of people with resistant virus which can be originally ascribed to TDR is 
predicted to increase from 33% in 2012 to 38% in 2032 without enhancement of diagnosis and 
retention, but to remain stable at approximately 33% should an enhancement in diagnosis and 
retention and a change in the CD4 threshold at which people are eligible to initiate ART to 
CD4<500 cells/μL, occur. 
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Figure 5.5. Estimated number of people living with NRMV and VL above 500 copies/mL in 
South Africa in 2012 and 2032 (median and 90% UR) 
 
Status of people living with NRMV and VL>500 copies/mL  
 Undiagnosed 20% 12% 13% 14% 11% 12% 13%  
 Diagnosed ART-
naïve 
19% 21% 13% 8% 11% 3% 0%  
 ART exposed 15% 20% 26% 27% 13% 15% 13%  
 On ART VL≥500 
copies/mL 
45% 46% 49% 51% 65% 69% 75%  
ART: antiretroviral therapy; NRMV: non-nucleoside reverse transcriptase inhibitor resistant virus in majority virus; 
TDR: transmitted drug resistance; VL: viral load;  
 
Figure 5.6 shows the estimated number of people with resistant mutations in majority virus 
which reduce susceptibility to LPV, a PI used as second-line, at least by half. I estimated that at 
the end of 2012 there are no people for whom susceptibility to LPV is reduced at least by half. 
In 20 years’ time, as second-line use become more prevalent, around 30,000 are expected to 
have resistance mutations which reduce LPV activity at least by half and around 100,000 if 
improvement in retention and diagnosis occur. The impact is going to be very similar if ATV is 
used in second-line. Nevertheless this is only a minority compared to the total number of 
people living with resistant mutations in majority virus, given the low probability of acquiring 
PI mutations in the first place. 
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Figure 5.6. Estimated number of people with resistant mutations in majority virus which 
reduces lopinavir activity at least by half 
 
LPR: lopinavir; 
 
 
5.5. Discussion  
There is great interest in expanding ART by increasing the number of HIV-positive people in 
care and by changing the initiation threshold.  My results suggest that prevalence of drug 
resistance and need for more expensive second-line regimens are likely to increase 
substantially in future years as ART roll-out continues, even if policies are not changed.  This is 
an inevitable consequence of having an increasing number of people on ART. Nevertheless, if 
current levels of diagnosis, retention, eligibility criteria to initiate ART (CD4<350 cells/μL) and 
VL monitoring  are maintained, in 20 years’ time over 60% of people with drug resistance to 
first-line agents are projected to be on a suppressive, second-line regimen. Likely due largely to 
the increase in the number of people on ART with viral replication suppressed, overall HIV 
incidence is predicted to drop by 22% in 20 years, if current levels of diagnosis and retention 
are maintained. It is noteworthy that by substantially improving diagnosis and retention, while 
maintaining as ART initiation policy CD4<350 cells/μL, it is possible to achieve the same 
reduction in HIV incidence as a change in the ART initiation threshold to all people diagnosed, 
with the important difference that the first will avoid ART initiation in persons for whom the 
individual health benefits remain unproven and will allow more deaths to be averted. 
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However, the feasibility of implementing the scenario of enhanced diagnosis and retention is 
difficult to assess.  
The decrease is predicted to be 36%, if diagnosis and retention are increased substantially and 
a policy of ART initiation at CD4 below 500 cells/μL is adopted. Incidence of HIV infections with 
TDR is predicted to remain stable. However, due to an overall decrease in HIV incidence the 
proportion of new infections with TDR is projected to increase substantially (from 14% in 2012 
to 30% in 20 years’ time).    
 
It must be recognised that the high levels of increase in diagnosis and retention assumed in 
these simulations would require major investment, not only to provide treatment to higher 
numbers of people, but to significantly strengthen health systems  to dramatically improve 
pre-ART and on ART retention and care.  Public health interventions to promote social 
acceptance and reduce stigma will be necessary to achieve these high levels of diagnosis, 
linkage to care and retention. Interventions such as home-based HTC (754), self-testing (755) 
and mobile voluntary counselling and testing (VCT) supported by community mobilisation 
(756) have been demonstrated to be feasible and effective in increasing the number of people 
tested for HIV. Provision of POC CD4 measurement at the same time and place of HIV testing 
(757) and formal pre-ART care services providing counselling, regular review, clinical staging, 
social and psychological support and prevention and management of OIs, such as TB, have 
been shown to increase, both, the proportion evaluated for ART eligibility and, the number of 
people, initiated on ART (758). Once on ART, models of care which require less frequent 
contact with the health service and adherence monitoring by community groups have been 
found to be effective in minimising the number of people LTFU (753).  
 
Data on new infections with TDR come mainly from WHO surveillance studies. In these, a 
resistance test is conducted among samples from newly diagnosed individuals less than 25 
years of age and/or with a CD4>500 cells/μL (if available) and no previous pregnancy, if female 
(759). These criteria increase the likelihood that people surveyed are likely to have been 
recently infected with HIV and ART-naive.  In this work, the modelled proportion of new 
diagnoses with resistance in 2012 is 5.9%, similar to that obtained when restricted to people 
with the criteria used in WHO surveys (data not shown). This figure is much lower than the 
percentage of new infections with TDR estimated to be 14% by the Synthesis model.  The 
difference between the proportion with TDR at infection and at diagnosis may be explained by 
the time-lag between infection and diagnosis, in that those currently diagnosed with HIV may 
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have been infected earlier, when resistance levels were lower.  In addition, some DRMs may 
not persist in majority virus after infection (386).   
 
Other mathematical models find that in RLS the prevalence of acquired and transmitted 
resistance will increase with greater ART availability (688;760). Blower et al. predicted that 
providing ART to 10%-50% of an HIV-infected population, was likely to result in 5.9% of new 
infections having resistance in 10 years after treatment roll-out (760). Given the initial plan to 
roll out ART in Africa to 3 million individuals ((761) reference by (726)) corresponding to 5–10% 
of the HIV-infected population, Blower et al. (726) estimated that after 10 years, the  
proportion of new infections with TDR to be below 5%.  Recently, Wagner et al. (699) 
investigated the impact of universal access to treatment compared to a universal “test and 
treat” strategy in South Africa on HIV incidence and TDR. They predicted that the incidence of 
TDR would remain below 0.1% and that widespread access to treatment could, in some cases, 
even reduce transmission due to the increased selection of drug-resistant strains in people on 
ART, which were assumed to be 50% less transmissible than wild-type strains. 
Nichols and colleagues (762) evaluated the impact of three different ART eligibility thresholds 
(CD4<200 cells/μL, CD4<350 cells/μL and CD4<500 cells/μL) on the number of infections 
averted and TDR prevalence, in two different settings: Kampala (Uganda) and Mombasa 
(Kenya). Similarly to my analysis, they observed a reduction in HIV incidence in both settings by 
raising the CD4 threshold at which people living with HIV are eligible for ART from 350 cells/μL 
to 500 cells/μL, driven by a reduction in HIV incidence. They found an increase in prevalence of 
TDR from levels of 8.3% in Kampala and 12.3% in Mombasa, up to around 19% in 10 years’ 
time in both locations if ART is initiated at CD4<500 cells/μL, while if the ART eligibility 
threshold is CD4 below 350 cells/μL the increase is much more contained. Although I reported 
a slightly different outcome (i.e. the proportion of new infections and of new diagnosis with 
TDR), I also found an increase in TDR when raising the CD4 threshold to be eligible for ART. 
 
These general trends in drug resistance I have predicted for South Africa may well be relevant 
for other countries in sub-Saharan Africa, but there are differences worth noting. One main 
factor is that VL monitoring is routinely available in South Africa, therefore people failing first-
line regimens may be expected to switch to second-line more quickly after VF than in other 
settings and we have previously shown, using the Synthesis model, that TDR levels are 
diminished with introduction of VL monitoring (571).  Furthermore, levels of adherence, 
virological suppression and rates of ART interruption (TI) between settings are likely to result in 
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differences in resistance (763), but I suggest that any relatively small difference between 
countries in these factors would have a modest impact on my main overall predicted trends.   
 
In 20 years’ time, which is the time frame used in this analysis, it is possible that in South Africa 
current NNRTIs will not be part of the first-line regimen anymore.  Integrase inhibitors, such as 
dolutegravir, could potentially be available soon in FDC with a similarly low cost and lower 
level of toxicity. The new South African guidelines recommend a third-line regimen (226) but 
currently the public health service offers two lines of treatment. Given the uncertainty 
regarding when these drugs will actually become available, it was considered appropriate to 
assume as ART regimen those currently in use in South Africa, and therefore those who fail the 
second-line regimen will remain on a boosted PI-regimen. 
It is plausible as well that, in the future, POC VL will become available with possibility for more 
frequent VL measurements which could slightly reduce TDR.  Therefore, my estimates are 
potentially conservative for predicted NNRTI resistance. In addition, if high levels of TDR 
emerge, it is possible that WHO would recommend, for example, changing the first-line to a 
boosted PI-regimen. This possible policy change has not been included in these simulations 
and would sharply curb the transmission of resistant-virus. These model projections could be 
updated in the future if it becomes clearer that important changes in ART programmes have 
occurred.     
In conclusion, my results suggest that while increases in prevalence of drug resistance are 
likely as ART coverage is increased, incidence of resistance is unlikely to significantly rise and 
concern over resistance development should not, in itself, inhibit increases in ART coverage.      
Health system strengthening to improve treatment diagnosis and retention in care, to increase 
community acceptance and to reduce stigma may limit incident infection and mitigate 
transmitted and acquired drug resistance. 
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6. Determinants of presence of NNRTI-resistance 
mutations after interrupting or stopping ART which 
contained an NNRTI 
 
6.1. Introduction 
In Chapters 4 and 5 I used the Synthesis model to evaluate the impact, and cost-effectiveness, 
of increasing the number of people on ART in South Africa and in particular the impact on 
resistance dynamics. In order to address those questions I had to make assumptions regarding 
the presence of NNRTI-resistance mutations in people who had been exposed to NNRTIs. 
NNRTIs constitute the foundation of ART regimens in LMIC, including Zimbabwe (228) and 
South Africa (226), with more than 9.7 million people on ART in LMIC at the end of 2012 (764). 
It is therefore crucial to understand the potential scope for resistance to develop to such 
regimens and if present in majority virus, potentially be transmitted (584). This has important 
implications for the number of people who are going to be in need of second-line therapy once 
they restarted ART and on the number of new infections with TDR.  One critical under-
researched aspect of this is the extent to which NNRTI mutations are present in majority virus 
amongst people who have interrupted or stopped ART.  There are two main circumstances 
under which this can happen. People can have drug resistance mutations (DRMs) present in 
majority virus while being off treatment because they interrupted ART after having 
experienced VF while on ART and developed resistance and these DRMs persisted in majority 
virus (369). The second circumstance under which this can occur is in people who interrupted 
an NNRTI-regimen without having experienced VF, who then acquire DRMs, due to the long 
half-life of NNRTIs compared to the nucleoside backbone rendering people effectively on 
NNRTI monotherapy for several weeks after stopping all ART (763;765;766). 
 
Although treatment programmes have generally been successful, it is relatively common for 
people to interrupt ART and potentially to be LTFU. The most frequent reported reasons for 
interrupting treatment are toxicities, adverse events and side effects, but other reasons 
include patients’ decision, pill burden, treatment fatigue, perceived lack of benefit, costs, 
pharmacy stock out and poor access to drugs (767). In some cases people who are not 
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attending the clinic any more are not LTFU but they have simply transferred to another clinic 
without informing the clinic.   
In the first years since roll-out of ART in Sub Saharan Africa, the loss to follow-up at 12 months 
since ART initiation was estimated to be 15%, with variability ranging from 0% to 44% across 
thirteen different African cohorts (751).  A systematic review including more recent studies in 
the same area (1) reported an attrition rate at 12 months of 22.6% (range 7-45), of which 59% 
were LTFU and the remainder had died. Nevertheless the high attrition rate tends to decline 
over time with an attrition of 25% and 29% respectively at 24 and 36 months. A large cohort 
study from South Africa reported a rate of ART interruption of 12.8/100 PYs (95% CI: 11.4, 
14.4) with up to three TIs per patient and a rate of resuming therapy of 21.4/100 PYs (484). 
Another large (n=11,397) retrospective cohort study in South Africa including patients starting 
ART between 2004 and end of 2008, reported that in the first year on ART, 60% of patients 
remained in care and 12% missed laboratory visits and came back to care by 12 months (483). 
Even in developed countries it is common for people to be LTFU or to interrupt treatment. In 
the UK, for example, the rate of potential LTFU (no CD4 measured for ≥1 year) is 12/100 PYs 
(768), while the rate of interruption has been estimated to be 2/100 PYs in the UK (769) and up 
to 6/100 PYs in Eurosida, a large cohort study including mainly countries in Europe (770). 
 
This chapter has two main aims. The first aim is to evaluate in patients who have documented 
NNRTI-resistance while on ART who then stopped all ARVs composing the regimen, the 
persistence of NNRTI mutations over time, I will refer to this as the “analysis on persistence of 
NNRTI mutations”. The second is to quantify the extent to which NNRTI mutations can be 
detected in the rebound viraemia following TI of suppressive NNRTI-based ART, I will refer to 
this as the “analysis on emergence of NNRTI mutations”.  
 
 
6.2. Literature review 
6.2.1. Treatment interruptions 
As mentioned previously, patients on ART may ask the clinician if they can have a break off 
treatment, because of either side-effects of the drugs they are taking or because they 
experience treatment fatigue, regardless of tolerability or for other personal reasons.  One 
option that was considered by clinicians until a few years ago was to undertake what was 
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referred to as a “structured treatment interruption”, as a strategy to postpone their next 
regimen until the majority virus has reverted back to wild-type. Because, in the absence of 
ART, wild-type virus is the fittest virus and therefore becomes the predominant virus, it was 
hypothesized that interrupting ART could expand treatment options for patients in need of 
salvage therapy (i.e. the last treatment option available).  
Two main types of structured TIs were considered: CD4-guided, where ART was stopped at a 
high CD4 count and re-initiated at a certain low CD4 both defined a priori (714;771;772) and 
timed-cycle strategy, where ART is stopped for a fixed period of time (319;773;774). Pant Pai 
conducted two systematic reviews evaluating the impact of structured TIs, one in in chronically 
suppressed (775) and one in unsuppressed (776) people. They concluded that there was a lack 
of benefit in terms of morbidity and mortality for people with unsuppressed VL and potential 
harm in people suppressed. The largest RCT which evaluated the impact of CD4 guided 
structured TI, the SMART study (“Strategies for Management on Antiretroviral Therapy”), 
showed that these structured TIs increase the hazard of progression to AIDS or death by 2.6 
(95% CI: 1.9, 3.7) and of serious non-AIDS events by 6.6 (95% CI: 1.5, 29.1) compared to 
patients who remained continuously on treatment throughout the period (714). For these 
reasons TIs are not recommended and if patients wish to discontinue the regimen they are 
receiving they are encouraged to switch to another regimen (777). 
 
6.2.2. Persistence of NNRTI-resistance mutation in people who virologically fail 
with resistance detected who then stopped treatment 
As mentioned before, despite the increasing effectiveness of ART, the proportion of people 
experiencing VF in South Africa is not negligible (292;304) and most of them harbour 
resistance  in majority virus (597;598;627;742) (See section 5.1).  
Even in developed countries, including the United Kingdom, where the data used in this 
chapter come from, it is not rare to experience VF. A paper published in 2005 using the UK 
CHIC data, the cohort used in this chapter, reported that by 6 years since ART initiation the 
cumulative risk of VF was 36% and of developing resistance to at least one major IAS-USA 
mutation, 27% (614).  These estimates were recognised by the authors as lower limit 
estimates, because sequencing results were not available for many VFs. On the other hand 
there is evidence that in settings with more recently approved ARVs, characterized by higher 
effectiveness, the proportion of people failing treatment with multi-drug resistance is 
decreasing (778). 
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The first studies to quantify the persistence over time of DRMs after interrupting (779;780) or 
switching treatment regimen (781;782) focused on mutations which confer resistance to AZT.  
Subsequently, several small studies, looking at a wider range of mutations, showed that TIs 
could lead to a more drug sensitive circulating virus (318;369;634;783-786).  
Devereux et al. (369) looked at the prevalence of DRMs (primary DRMs considered were 30N, 
461I/L, 82A, 90M, 70R, 184I/V and 215Y/F, none of them is an NNRTI mutation) in people who 
had been exposed to several regimens (mean=5, range 3 to 9)  and had developed resistance 
while on treatment with a subsequent resistance test available after stopping treatment 
respectively within 2 weeks, between 2 weeks and 2 months since stopping treatment and 
between 2 and 6 months. They estimated that in all people with a resistance test within 2 
weeks DRMs were detected, and respectively in 68% and in 15% if the resistance test was 
conducted within 2 months or afterwards. This study, although small (n=25) clearly indicated 
that the majority of DRMs would not be detectable anymore after a relative short time since 
stopping ART. This finding was confirmed by few small studies which evaluated the persistence 
of mutations conferring resistance to NRTI and PI (318;783;787;788). Verhofstede et al. 
reported that in 86% of patients, whether they switch to a regimen containing only PI (n=5) or 
whether they interrupted treatment (n=9) DRMs were not present anymore within 14 days to 
2 months since stopping a reverse transcriptase inhibitor based regimen (only one patient was 
exposed to NNRTI and NNRTI-resistance mutations were therefore not investigated) (783). 
Deeks et al. (318) observed that in patients (n=16) with multi drug resistance on PIs, the virus 
appeared susceptible on sequencing to PIs after 12 weeks of TI. In order to determine the 
length of persistence of DRMs, Bi et al. designed a small study where plasma and peripheral 
blood mononuclear cells were sampled and analysed monthly in 16 people (n=7 exposed to 
NNRTI but without NNRTI-resistance) with resistant virus who had interrupted treatment 
(788). They estimated that the median time to complete reversion to wild-type was 6.3 
months (interquartile range [IQR]: 3.2-20.7 months) if looking at plasma samples and 9.2 (IQR: 
5.7-13.8 months) using peripheral blood mononuclear cells samples and using plasma samples 
by 3.2 months 50% of the DRMs had switched to wild-type. A larger study (n=132) was 
published in 2009 (787) looking at persistence of NRTI DRMs. They found that NRTI-resistance 
mutations vary in persistence over time and become undetectable independently of each 
other in the majority of patients.  
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The studies which included the persistence of NNRTI mutations reported a less rapid shift to 
wild-type virus (634;784-786;789-792). In a study of 38 patients with multiple failing regimens 
who had interrupted ART for 3 months, 32% of which with at least one NNRTI mutations (11 
with K103N, 6 with Y181C and with G190A/S), in around 60% of patients wild-type virus was 
found after 3 months of TI but among those with NNRTI mutations only 17% (n=2) reverted 
back to wild-type (784). Among those who interrupted treatment while having a detectable VL 
(n=48), Miller et al. reported that in 62% the virus shifted completely to wild-type and in 
particular the prevalence of NNRTI-resistance at ART interruption in those who interrupted an 
NNRTI was 58% for EFV, 73% for NVP and 87% for DLV and by the end of the TI (at least 2 
months) these were reduced respectively to 12%, 37% and 37% (785). In Birk et al. only four 
primary (three K103N and one G190A) and two secondary (one L100I and one  K101E) NNRTI 
mutations were detected and half of them disappeared during a median observation time of 
respectively 25 and 14 days (634). Similarly Delaugerre et al. observed that in 55% of patients 
who interrupted treatment for a median of 8 weeks (range: 4 – 24 weeks), DRMs for at least 
one of the classes of drugs they were resistant to were no longer detected in majority virus; in 
particular in nine out of eleven patients with NNRTI-resistance mutations, these were no 
longer detected in majority virus (786). Halfon et al. (792) assessed in 11 patients who failed 
multiple drug regimens, the persistence of DRM during a 3 month structured TI, using two 
different assays: DNA sequencing and line probe assay. Only 18% (n=2) of patients completely 
reverted to wild-type virus, according to both genotyping assays and two additional people 
reverted to wild-type but only according to one of the two assays. In particular they observed 
that the LiPA assay detected the resistance mutant population for up to 52 days longer than 
sequencing in over 60% of the codons. Ruiz et al. (789) looked at the prevalence of DRMs after 
12 weeks of structured TI in people who had been exposed to at least two different triple 
combinations of ART for at least 6 months each, had failed all previous regimen and who had 
two consecutive VL above 1,000 copies/mL at TI (n=22). At the time of the TI, 95% of 
participants had NRTI-resistance mutations, 80% NNRTI-resistance mutations and 90% PI-
resistance mutations. After 12 weeks of TI 35% of them reversed completely to wild-type virus 
and the median number of DRMs detected decreased from 6 to 1.5 in the RT gene (4 to 1 for 
mutations conferring resistance to  NRTIs and 1 to 0 for mutations conferring resistance to 
NNRTI) and from 5 to 1 in the PR gene. Similarly to Ruiz et al., Benson et al. (790) used the data 
from patients randomized to the structured interruption arm in the AIDS Clinical Trial Group 
Protocol A5086, to evaluate the persistence of DRM after 16 weeks of TI in 41 patients with 
DRMs conferring resistance to multiple classes of drugs. After 16 weeks of TI 28% had 
complete reversion of primary DRMs and 39% partial reversion (reversion of at least one but 
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not all primary DRMs conferring resistance). Outside of the context of RCTs, Balduin et al. (791) 
observed that in people who interrupted treatment, for various reasons including toxicities, 
patient choice and resistance, 21% (3 out of 14) lost all the DRMs present before interrupting 
treatment (at the resistance test in median 67 day after TI, IQR: 21-159), 50% (n=7) had a 
reduction in the number of DRMs and in the remaining 29% (n=4) no change in the number of 
DRM was observed. Most of them were exposed to the first three classes of drugs, and at 
interruption 10 had resistance to NNRTI and around 40% of them lost from majority virus 
NNRTI-resistance mutations during the TI. 
 
The largest study (n=90) to my knowledge to investigate the pattern of loss of DRMs from 
majority virus, including NNRTI-resistance mutations, used data collected in the CPCRA 064 
study at baseline (at TI) and at 2 and 4 months since structured TI beginning (765). The CPCRA 
064 was a RCT which assessed the effect of 4 months of structured TI followed by salvage 
treatment in patients virologically failing with multi-drug resistance. They observed that after 4 
months of structured TI only 33% of the participants had completely reverted to wild-type and 
confirmed that the mutations reversion rate was higher in patients with higher baseline CD4 
(318). Among the DRMs conferring resistance to NNRTI considered (those present in more 
than 10% of the sample: V108I, Y181C, K103N, L100I, G190A), the most prevalent at baseline 
(at the beginning of TI) was K103N (53.6%) followed by Y181C (39.3%), V108I and G190A 
(21.4%) and L100I (14.3%). Between 39% (Y181C) and 62% (K103N) of these DRMs revert by 
the end of the 4 months and generally the rate of reversion increased over the 4 months of 
structured TI. 
 
6.2.3. Emergence of NNRTI mutations, in people who stop NNRTI-based regimen 
without having experienced virological failure  
Among people who have not experienced VF and who interrupt an NNRTI-based regimen, 
there is a risk that they then develop NNRTI-resistance. This is due to the prolonged half-life of 
NNRTIs (plasma half-lives between 35 and 45 hours, with persistence in some cases for two 
weeks or more (793-795)) compared to ARVs from other classes (for example most NRTIs have 
half-lives between 2 and 6 hours (796)) and to their very low genetic barrier, with only one 
mutation sufficient to confer a high level of resistance to these drugs. If the drugs forming a 
regimen have dissimilar half-lives, as is the case for  patients  receiving an NNRTI in 
combination with two NRTIs, and all drugs are interrupted simultaneously, this may result in a 
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functional NNRTI monotherapy in the days and weeks after discontinuation of the regime, 
unable to maintain virological suppression and leading to a risk of emergence of resistance 
(777). In patients receiving NNRTI monotherapy, NNRTI-resistance mutations emerge relatively 
quickly (797). Therefore to avoid the potential for NNRTI monotherapy, if the patient wants to 
stop treatment it is recommended to stop the NNRTI five to seven days before the other ARVs 
or switch the NNRTI to a PI and then stop the whole regimen in a few weeks (793;798;799).  
 
There is variability across people of different ethnicity in plasma half-lives of NNRTIs; in 
particular, there is evidence that people carrying a G→T substitution at position 516 of the 
cytochrome P450 2B6 gene, which is more common in people of black-African descent, have 
slower clearance of EFV. In patients with GG genotype at position 516 plasma EFV 
concentrations are estimated to exceed the 95% inhibitory concentrations for wild-type virus 
(i.e. 46.7 ng/ml) for a median of 5.8 days (IQR: 4-8 days) compared to 7 days (IQR: 5-8 days) for 
people with 516 GT and 14 days (IQR: 11-21 days) for people with genotype TT at position 516 
(800). Other studies highlighted that non-caucasian people have a slower clearance of EFV, as 
well as women (801). Within the DART trial, set in Uganda and Zimbabwe, they conducted a 
small sub-study (n=21) aimed to evaluate NVP elimination in people undertaking a structured 
TI with NVP stopped 7 days before AZT and D4T (“staggered interruption”). They measured 
NVP concentrations at 0, 1, 2, 3 and 4 weeks after TI: 83% had NVP detected at 1 week, 26% at 
2 weeks, while in the samples collected afterwards NVP was not detected, suggesting that 
probably the interruption of NVP in  African people should be staggered by additional 7-10 
days (802).  
 
Several studies have investigated the emergence of NNRTI-resistance in people interrupting an 
NNRTI-containing regimen, mainly in the context of studies investigating the efficacy of 
structured TIs (763;766;799;803-805). Among people with suppressed VL structured TIs do not 
provide any benefit (775) and there is evidence that NNRTI-resistance can emerge in up to 23% 
of those who interrupt it (805).  
The first studies to investigate the emergence of resistance after TIs either focused on NRTI 
and PI-resistance mutations (806;807) or were very small in sample size (805;808), but they 
highlighted the fact that DRMs could emerge after people had stopped treatment. In particular 
in the study by Arnedo et al. (805) genotypic resistance test was conducted at ART initiation, 
immediately before interrupting the treatment and two weeks after the structured TI. They 
reported that at two weeks after TI, DRMs were detected in 26% of patients, in 54% of them 
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these mutations were not found either at baseline or at the time of interruption. Regarding 
NNRTI-resistance mutations, they found that 23% of those receiving NNRTI-based regimen (3 
out of 13) had NNRTI-resistance mutations detected two weeks after interrupting it and they 
were all de-novo. Hare et al. conducted an analysis similar to that subsequently undertaken by 
Geretti et al. (766); they used standard population sequencing and allele-specific polymerase 
chain reaction to assess the presence of NNRTI-resistance mutations at the first virological 
rebound (VL>5000 copies/mL) after TI. They reported that 41% experience virological rebound 
within 4 weeks since TI, 85% within 8 weeks and 100% within 60 weeks and that 20% of 
patients had NNRTI-resistance mutations detected, with higher prevalence (45%) in people 
with VL between 51 and 400 copies/mL at TI compared with people with VL below 50 
copies/mL (14%) (803). Izopet et al. used a subsample (n=86) of patients recruited in the ANRS 
Window trial and randomized to the intermittent arm (8 weeks off ART and 8 weeks on). They 
observed an increase in NNRTI-resistance mutations by the end of the study in people 
receiving NNRTI-based regimen (96 weeks) with 9% having NNRTI-resistance  detected at time 
0, 3% at 8 weeks (after 8 weeks of ART interruption)  and 12% at 96 weeks, with a peak of 27% 
at 88 weeks (804). Similarly, the Trivacan trial (773) evaluated the efficacy of fixed structured 
TIs with a different length of time (2 months off treatment followed by 4 months on ART (“2/4 
ART arm”)) compared with continuous treatment in terms of the proportion of people with 
CD4<350 cells/μL at 24 months (primary outcomes), mortality, morbidity, cost of care, 
genotypic resistance, adherence and toxicity. Although they found that the “2/4 ART arm” was 
non inferior, one of the reasons why they concluded that the “2/4 ART” strategy should not be 
recommended was the considerably higher risk of developing resistance. At 24 months since 
the introduction of the strategy they found that 9% of the participants in the continuous arm 
had at least one DRM compared with 24% in the “2/4 ART arm”. When focusing on the NNRTI-
resistance mutations, 3% had at least one NNRTI-resistance mutation in the continuous arm at 
24 months compared with 21% in the 2/4 ART arm and concluded that the additional risk of 
NNRTI-resistance mutations acquiring was around 5% per NNRTI interruption. Dybul et al. 
(809) investigated the impact of cycles of 4 weeks of structured TIs followed by 8 weeks on 
ART compared to continuous ART. This RCT was prematurely interrupted (after 52 patients had 
been enrolled), due to the frequent emergence of resistance in people assigned to the 
intermittent arm, receiving an EFV-based regimen (3 out of 8). The same happened to the 
fixed-cycle structured TI arm (one week on ART and one week off ART) in the Staccato study, 
where 53% (n=19) of those assigned to this arm developed VF and 20% of those on a NNRTI 
regimen had resistance mutations detectable in majority virus (774).  
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The TIBET RCT (771), where people with CD4 count>500 cells/μL and VL below 50 copies/mL 
were randomized either to continuous therapy or CD4 guided structured TIs, confirmed the 
finding from the SMART trial of the risks of ART interruptions (714). In addition they observed 
that 32% of those assigned to the CD4-guided TI arm on an NNRTI-based regime with 
resistance test available (n=19) acquired NNRTI-resistance mutations de-novo during the TI. 
 
The largest analysis to the best of my knowledge is the one conducted by Geretti et al. 
published in 2013 (766) on a subsample (n=131) of patients enrolled in the SMART trial (See 
section 4.2.7). Using data from this RCT in 2008 Fox et al. (763) showed that in people assigned 
to the conservation arm with virological suppression (VL<400 copies/mL) at the time of TI, 
emergence of NNRTI-resistance (at least one NNRTI mutation) within 2 months since TI 
occurred in respectively 16.4% of those who interrupted simultaneously, 12.4% of those who 
had a staggered interruption (i.e. they interrupted NNRTI on average 7 days before the other 
ARVs in the regimen) and 4.2% with switched interruption (i.e. the NNRTI was switched with a  
boosted-PI for a short period before interrupting the regimen all together). Following this 
project, Geretti et al. (766) aimed to estimate the risk of resistance emerging in people 
interrupting suppressive NNRTI-regimen using a more sensitive testing (Sanger sequencing, 
allele-specific polymerase chain reaction, and ultra-deep sequencing) and to evaluate the 
association between resistance detection and NNRTI concentration after TI and virological 
response after treatment re-initiation. They reported that at four weeks since NNRTI 
interruption 61% (out of 31) and 87% (out of 39) patients had measurable concentrations of 
NVP (>0.25 ng/ml) or EFV (>5 ng/ml) respectively. After NNRTI interruption, 17% had at least 1 
NNRTI-resistance mutation on resistance test, conducted a median of 8 weeks after TI. In 36% 
(n=8) of the patients with NNRTI-resistance detected, it was detected only by sensitive testing. 
They found that the odds of finding NNRTI-resistance was almost 8-fold higher if NVP or EFV 
concentrations were above the median measured in the study population. In contrast to what 
was found by Fox et al., they found on the same population, but using more sensitive assays, 
that people who had staggered TI did not have a lower risk of NNRTI mutations arising and had 
a risk four times higher of NRTI mutations being detected compared to simultaneous TIs.  
Contrary to the findings of most RCTs on structured TI, Palmisano et al. reported that people 
assigned to five structured TIs of respectively 1, 1, 2, 2 and 3 months off-ART each followed by 
3 months on ART were more likely to develop resistance to PIs (47% of 30) than to NNRTIs 
(20% of 99) (810). No difference was found in the cumulative risk of having VF (24% in the 
continuous ART arm, 95% CI: 15.3, 32 and 26% in the structured TI arm, 95% CI: 15.4, 36.2). In 
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those randomized to have structured TI 28% had resistance detected on at least one occasion, 
with 50% of them having one single mutation and 29% having two. The most frequent 
resistant mutations were M184V/I (33%), K103N (11.4%) and M41L (7%).  
 
Unstructured TIs have an even worse impact in terms of morbidity and mortality (767) and 
should therefore be avoided. Very few studies investigated the development of resistance 
mutations following an unstructured TI (811-814) and unfortunately there are no large cohort 
studies from developing countries reporting on this issue (767). A study conducted in France 
(811) evaluated the predictors of NNRTI-resistance acquisition in 71 patients with early 
virological response. They observed over a median of 29 months that 28% (n=20) experience 
VF and 60% of those with a resistance test had major NNRTI-resistance mutations in majority 
virus. Interestingly they found that VF occurrence was associated with repeated drug holidays 
(defined as ≥48 h of unplanned drug cessation), and this was the only predictor of NNRTI-
resistance emergence. Sanchez et al. (812) focused their attention on 20 patients who had 
interrupted treatment while virologically suppressed, because of adverse events, 
comorbidities or patients’ choice. At one month since TI 90% of them were virologically 
unsuppressed. Of 15 patients who were receiving EFV or NVP, 27% (n=4) patients developed 
major NNRTI-resistance in majority virus (three K103N and one V106A/V). Among patients 
initiating fixed-dose NNRTI-based regimen (3TC, D4T and NVP) in Uganda, 65% interrupted 
treatment for more than 48 hours, according to electronic medication monitors. In this group 
13% had developed resistance by the end of the study, while among those who never 
interrupted treatment none of them developed resistance (813). Another study in Uganda 
looked at the level of virological suppression among participant on ART, mainly (91%) on 
NNRTI-based regimen. Among those on NNRTI regimen 22% (n=27) experience VF over a 
median follow-up of 38 weeks, and in 72% of those with a resistance test NNRTI mutations 
were detected in majority virus, with the most common mutation being K103N (814). 
 
 
6.3. Methods 
6.3.1. Study population 
I conducted analyses to address, firstly the persistence of NNRTI-resistance mutations in 
patients who have documented NNRTI-resistance while on ART who then stopped all ARVs, 
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and secondly to assess the extent to which NNRTI mutations are detected in the rebound 
viraemia in patients interrupting suppressive NNRTI-based ART.  
Both the analyses used data from patients in the UK resistance database (see section 6.3.1.1) 
linked to the UK CHIC cohort study (see section 6.3.1.2), who have interrupted/stopped an 
NNRTI-base regimen (not necessarily simultaneously, but with NNRTI stopped maximum 14 
days before the other drugs). 
For the first analysis (“analysis on persistence of NNRTI mutations”), participant were eligible 
to be included if they had a resistance test while on ART which detected NNRTI-resistance 
mutations, who then stopped all the ARVs composing their ART regimen, while, for the second 
analysis (“on emergence of NNRTI mutations”), eligibility criteria were having stopped an 
NNRTI regimen (not necessarily simultaneously) despite being virologically suppressed (VL 
below 200 copies/mL after at least 6 months on ART) at TI, without having experienced VF nor 
having evidence of NNRTI-mutations on previous resistance tests. 
 
6.3.1.1. The UK HIV drug resistance database 
The UK HIV drug resistance database includes over 90% of the HIV resistance tests performed 
as part of routine clinical practice throughout the UK. It was established in 2001 by the UK 
Collaborative Group on HIV Drug Resistance formed by laboratories performing HIV resistance 
test in the UK, clinical sites using resistance tests for clinical practice, experts on HIV drug 
resistance, the MRC Clinical Trials Unit, UCL Centre for Virology, the UK CHIC study, Public 
Health England (at the time called Health Protection Agency) and the UK Department of 
Health. The reasons for setting up the UK HIV drug resistance database were to assess the 
prevalence of drug resistance in recent and untreated infections over time, to characterize the 
pattern of drug resistance in patients failing therapy, to evaluate the effect of specific 
mutations on virological response and to help identify the determinants of HIV antiretroviral 
drug resistance (815). This collaboration was initially funded by the UK Department of Health 
as surveillance data on the level of HIV drug resistance in treated and untreated patients. It 
contains data on resistance tests conducted in the UK between 1996 and the end of 2007 
(tests performed in 2008 for which information are available are also included) and it includes 
50,224 resistance tests (version provided in January 2009). By the end of 2012 over 101,000 
tests were available, nevertheless I decided not to update this analysis using this more 
updated dataset, because it is unlikely to result in a much higher number of people eligible in 
this analysis (patients who interrupted NNRTI), given it is recommended not to interrupt ART. 
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Nineteen centres currently contribute data to the UK HIV drug resistance database: ten in 
London (the Chelsea and Westminster Hospital, the Guy’s and St. Thomas’ NHS Foundation 
Trust, PHE London, Imperial College Health NHS Trust, King's College Hospital, Royal Free 
Hospital, St George's Hospital, St Bartholomew’s and The London NHS Trust, St Mary's 
Hospital, University College London Hospitals) and nine in the rest of the UK: the 
Addenbrooke’s Hospital (Cambridge), PHE Birmingham Public Health Laboratory (Birmingham), 
Leeds Teaching Hospitals NHS Trust (Leeds), Liverpool Specialist Virology Centre - Royal 
Liverpool University Hospital (Liverpool), Manchester Specialist Virology Centre - Central 
Manchester Foundation Trust (Manchester), Royal Infirmary of Edinburgh (Edinburgh), Royal 
Victoria Infirmary (Newcastle), South Tees Hospitals NHS Trust (Middlesbrough), West of 
Scotland Specialist Virology Centre - Gartnavel General Hospital (Glasgow).  
Each centre provides all the full nucleotide sequences analysed in the previous calendar year. 
These are then aligned to an amino acid reference sequence and the mutations found are then 
fed into Stanford’s HIVDB algorithm (411) (see section 1.9.10.1). In addition, information on 
patient demographics, clinical details, ART history and laboratory markers at the time of the 
resistance test are collected. All these data are collected by the MRC Clinical Trials Unit which 
coordinates the study. 
These data are then linked to the UK CHIC study, because there is substantial overlap in the 
centres taking part in these two studies. 
 
6.3.1.2. The UK CHIC study 
The UK Collaborative HIV Cohort Study (UK CHIC study) is a prospective cohort study pooling 
data collected for routine clinical care of people with HIV who attended one of the 19 clinics in 
the UK taking part in this study since 1st January 1996. This study was initiated in 2001 and is 
funded by the MRC. The aim is to assess the uptake of and response to ART, to identify the 
predictors of virological and immunological failure in patients receiving ART and to 
characterize changes over time in AIDS-defining illnesses and mortality.  
People living with HIV may have attended more than one clinic and therefore there could be 
duplicate records between centres contributing to the study. All patients attending one of 
these centres were matched on the basis of their soundex code, date of birth and other clinical 
information if considered potential duplicates were flagged and electronically and manually 
checked. If they were identified as duplicates, a composite record for this patient was 
included. The data collected include demographics, laboratory data such as absolute and 
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percent CD4 count, VL levels, Hb, platelets, etc. and ART history (start and stop dates as well as 
reasons for stopping) and AIDS diagnosis and deaths. 
To date, 19 centres take part in the UK CHIC database: 10 in London (Chelsea & Westminster 
Healthcare NHS Trust, Kings College Hospital NHS Foundation Trust, Mortimer Market Centre - 
Royal Free and University College Medical School, Royal Free NHS Trust and Royal Free 
University College Medical School, St. Mary's Hospital - Imperial College Healthcare NHS Trust, 
Barts and The London NHS Trust, North Middlesex University Hospital NHS Trust, Homerton 
University Hospital NHS Trust, South London Healthcare NHS Trust,  St. George's Healthcare 
NHS Trust) and nine in the rest of the UK, Brighton and Sussex University Hospitals NHS Trust 
(Brighton), The Lothian University Hospitals NHS Trust (Edinburgh), North Bristol NHS Trust 
(Bristol), University Hospitals of Leicester NHS Trust (Leicester), South Tees Hospitals NHS 
Foundation Trust (Middlesbrough), York Teaching Hospitals NHS Foundation Trust (York), 
Coventry & Warwickshire NHS Trust (Coventry), The Royal Wolverhampton NHS Trust 
(Wolverhampton) and Ashford & St.Peter's Hospitals NHS Foundation Trust (Chertsey and 
Ashford in Surrey). These centres contributed to over 47,200 patients. 
 
6.3.2. Statistical analysis 
To assess the persistence of NNRTI mutations in people who experienced VF with presence of 
NNRTI-resistance mutations, the proportion with NNRTI-resistance in majority virus at the first 
resistance test after TI was calculated as well as the median time between the TI and the 
resistance test, if performed. Baseline covariates were examined and compared between 
patients who had and did not have a resistance test after discontinuing ART to investigate 
whether people who received a resistance test were different compared to those who did not 
receive it. Baseline covariates assessed were gender, age, ethnicity, mode of infection, 
calendar year of TI, presence of a resistance test pre-ART and, if applicable, presence of NNRTI-
resistance mutations pre-ART, VL level and CD4 count at TI, CD4 count nadir, time between the 
resistance test conducted while on ART and the TI, type of TI (staggered or simultaneous), 
specific NRTI and NNRTI exposure, specific NNRTI-resistance mutations detected before TI, HIV 
subtype and reason for TI. The categorical variables were compared between people with and 
without a resistance test following TI using Chi-squared test and Fisher’s exact test (when the 
expected frequency of one cell was <5), while the continuous variables using the Kruskal-Wallis 
non parametric test. A modified Poisson regression approach (see Appendix XIII) was used to 
assess adjusted RRs (aRRs) of having a resistance test performed.   
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Those who had a resistance test following TI were included in the main analysis aimed at 
estimating the persistence time of NNRTI-resistance mutations and identifying the predictors 
of presence of NNRTI-resistance mutations. The mutations associated with resistance to EFV or 
NVP considered were those indicated in the IAS-USA December 2011 list (816), except for 
K103S, which was include in the IAS-USA list in 2011 but not in 2008. To identify the risk factors 
for having NNRTI-resistance mutations present in majority virus after TI and quantify the 
strength of the association the same approach mentioned in the previous paragraph was used 
(modified Poisson regression approach). The key covariate of interest for this analysis was 
clearly the length of time between TI and the resistance test performed off-ART. Other 
covariates investigated, established a priori, include calendar year of TI, VL at TI, specific NNRTI 
mutations detected at the resistance test performed while on treatment, subtype, VL and CD4 
count at resistance test off-ART, exposure to specific NNRTI and NRTI’s and type of TI 
(staggered or simultaneous). 
 
Similarly, for the analysis on emergence of NNRTI-resistance mutations in patients who 
interrupted a suppressive NNRTI regimen (VL consistently below 200 copies/mL after at least 6 
months on ART), who had no evidence of NNRTI-mutations on previous resistance tests, I, 
firstly, evaluated whether there were significant differences between those who had a 
resistance test performed during the TI and those who did not and then investigated the 
predictors of NNRTI-resistance emerging. The same statistical approach used for the previous 
analysis was used and similar baseline covariates were considered: demographic variables, 
ARVs experienced, length of virological suppression, time from TI to resistance test, CD4 count 
nadir, CD4 count at TI and at resistance test, VL at TI, maximum VL ever measured and 
subtype. 
Several sensitivity analyses were considered for this second analysis. The first restricting to 
patients who interrupted an NNRTI-based regimen, without having experiencing VF, with a VL 
of 50 copies/mL or less at TI. The rationale for this analysis is that people with such a low VL 
are unlikely to store mutations in majority virus and therefore if mutations are observed at the 
following resistance test while off treatment it is very likely that they have been selected de-
novo. The second sensitivity analysis focused on people who had a resistance test performed 
within 2 and 6 months since stopping the ART regimen. In fact, mutations that arise during an 
ART interruption could rapidly be lost if the patient remains off ART, but this is unlikely to 
occur in a shorter period of time. In addition I investigate whether there was a difference in 
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the detection of NNRTI-resistance mutations in people who interrupted ART simultaneously or 
who had a staggered TI. 
All statistical analyses were performed using SAS 9.3. 
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6.4. Results on persistence of NNRTI mutations over time 
6.4.1. Patient characteristics 
Out of the 4,892 patients in the UK CHIC study who had at least one resistance test performed 
after starting ART, 32% (n=1,567) had NNRTI-resistance mutations detected in majority virus 
and among these, 353 interrupted an NNRTI-regimen following the resistance test. The 
patients eligible for this analysis (n=353) were primarily men (78%), mostly having acquired 
HIV through sex with men (62%) with a median age of 40 years old (IQR: 35-44) and subtype B 
(75%). The ART discontinuations occurred between 1998 and 2008, median June 2004 (IQR: 
August 2002 – February 2006). Only a minority of those who interrupted treatment after 
having experienced VF with NNRTI-resistance mutations detected were virologically 
suppressed (<50 copies/mL) and they had a median CD4 count at TI of 309 cells/μL (IQR: 163-
475). The NNRTI-based regimen was interrupted simultaneously only in 35% of cases with a 
median of 10 months (IQR: 2 months – 2.4 years) after the resistance test detected NNRTI-
resistance in majority virus. Unfortunately the reason for TI was poorly reported in the 
database (80% unknown) and for this reason its association with the risk of NNRTI-resistance 
persisting over time was not evaluated. For 86% of the sample there was no resistance test 
available before initiating treatment and so it is not possible to exclude they were infected 
with a resistant virus. The NRTI most people had been exposed to was 3TC (92%) followed by 
AZT (83%), and ddI and d4T with around 70% exposed to each of them. Among the NNRTI, 
people were exposed either to NVP (64%) or EFV (45%), and the most common NNRTI 
mutations harboured were K103N (51%), Y181C (18%) and G190A (11%) (See Table 6.1 and 
Table 6.2 at page 271). 
 
Out of 353 patients included 68 (19.3%; 95% CI: 15.5, 23.8) had a resistance test after 
interrupting treatment, a median 4 months after TI (IQR: 1 month - 1.3 years). These people 
were not significantly different, based on the factors considered, to those who did not have a 
resistance test performed after TI, except for age, calendar year of TI and having being 
exposed to TDF. In particular those with a resistance test were a median 2 years younger 
(medians: 38 vs 40), were more likely to have interrupted treatment in an earlier calendar year 
(medians: June 2003 vs August 2004) and were less likely to be exposed to TDF (25% vs 40%).
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Table 6.1. Baseline characteristics, according to the presence of a resistance test off-ART 
  All sample (n=353) Patients with a resistance test during this off-ART period: 
Yes (n=68) No (n=285) p-value 
Gender, n male (%) 274 (78%) 56 (82%) 218 (76%) 0.30 
Age, med (IQR)  40 (35-44) 38 (42-23) 40 (35-44) 0.02 
Ethnicity, n (%)* White 245 (71%) 48 (72%) 197 (71%) 0.95 
Black 87 (25%) 16 (24%) 71 (25%) 
Other 14 (4%) 3 (4%) 11 (4%) 
Mode of infection, n (%)** 
  
MSM 214 (62%) 47 (72%) 167 (60%) 0.06 
Heterosexual 103 (30%) 17 (26%) 86 (31%) 
Other 27 (8%) 1 (2%) 26 (9%) 
Calendar year of TI, med (IQR) Jun2004 Aug2002-
Feb2006 
Jun2003 Nov2001-
May2005 
Aug2004 Nov2002-
Apr2006 
0.0023 
VL suppression at TI, n (%) 86 (24%) 12 (18%) 74 (26%) 0.15 
VL suppression at resistance test off-ART, n (%) - - 5 (7%) - -  
Simultaneous TI, n (%) 124 (35%) 26 (38%) 98 (33%) 0.55 
NNRTI-resistance, pre-ART, n (%)  No resistance test 303 (86%) 59 (87%) 244 (87%) 0.58 
No NNRTI mutations  47 (13%) 8 (12%) 39 (12%) 
NNRTI mutations 3 (1%) 1 (1%) 2 (1%) 
Years between resistance test on ART and TI, med (IQR) 0.8 (0.2-2.4) 0.8 (0.3-1.9) 0.8 (0.2-2.4) 0.75 
Years between TI and resistance test off ART, med (IQR) - - 0.31 (0.1-1.3) - - - 
CD4+ cells count (cells/μL) at TI, med (IQR) 309 (163-475) 356 (178-516) 300 (160-473) 0.48 
CD4+ nadir count (cells/μL), med (IQR) 102 (33-190) 94 (19-171) 102 (38-200) 0.37 
CD4+ cells count (cells/μL) at resistance test off-ART, med 
(IQR) 
- - 218 (86-370) - -  
*n=346;**n=344; ART: antiretroviral therapy; IQR: interquartile range; med: median; MSM: men who have sex with men; NNRTI: non-nucleoside reverse transcriptase inhibitor; TI: treatment 
discontinuation; 
VL: viral load; 
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Table 6.2. Additional baseline characteristics, according to the presence of a resistance test 
off-ART  
 All sample 
(n=353) 
Patients with a resistance test during 
this off-ART period: 
Yes (n=68) No (n=285) p 
NNRTI exposure, n 
(%) 
NVP 226 (64%) 42 (62%) 184 (65%) 0.67 
EFV 160 (45%) 26 (38%) 134 (47%) 0.19 
NRTI exposure, n 
(%) 
AZT 293 (83%) 57 (84%) 236 (83%) 0.84 
DdC 56 (16%) 13 (19%) 43 (15%) 0.41 
DdI 247 (70%) 50 (74%) 197 (69%) 0.48 
D4t 238 (67%) 47 (69%) 191 (67%) 0.74 
3TC 323 (92%) 64 (94%) 259 (91%) 0.48 
ABC 145 (41%) 33 (49%) 112 (39%) 0.16 
TDF 131 (37%) 17 (25%) 114 (40%) 0.02 
FTC 18 (5%) 3 (4%) 15 (5%) 1.00 
Follow-up NNRTI-
resistance 
mutations before 
TI, n (%) 
L100I 1 (0%) 0 (0%) 1 (0%) 1.00 
K101E 8 (2%) 1 (1%) 7 (2%) 1.00 
K101H 0 (0%) 0 (0%) 0 (0%) nc 
K101P 1 (0%) 0 (0%) 1 (0%) 1.00 
K103N 179 (51%) 40 (32%) 139 (49%) 0.14 
V106A 9 (3%) 2 (1%) 7 (2%) 0.69 
V106M 9 (3%) 2 (1%) 7 (2%) 0.69 
V108I 9 (3%) 1 (3%) 8 (3%) 1.00 
Y181I 1 (0%) 0 (0%) 1 (0%) 1.00 
Y181C 62 (18%) 12 (4%) 50 (18%) 0.98 
Y181V 0 (0%) 0 (0%) 0 (0%) nc 
Y188C 3 (1%) 2 (1%) 1 (0%) 0.10 
Y188L 22 (6%) 3 (1%) 19 (7%) 0.78 
Y188H 1 (0%) 1 (0%) 0 (0%) 0.19 
G190S 8 (2%) 1 (0%) 7 (2%) 1.00 
G190A 38 (11%) 3 (4%) 35 (12%) 0.08 
P225H 2 (1%) 0 (0%) 2 (1%) 1.00 
Subtype at 
resistance test 
after TI, n (%)^ 
  
A 18 (5%) 2 (3%) 16 (6%) 0.48 
B 265 (75%) 51 (75%) 214 (75%) 
C 37 (10%) 8 (12%) 29 (10%) 
CRF11_CPX 1 (0%) 1 (1%) 0 (0%) 
D 8 (2%) 0 (0%) 8 (3%) 
F (F1) 1 (0%) 0 (0%) 1 (0%) 
G 6 (2%) 2 (3%) 4 (1%) 
H 1 (0%) 0 (0%) 1 (0%) 
U 16 (5%) 4 (6%) 12 (4%) 
^Subtype A1 and A2 have been merged, as only one person had A2;  
3TC: lamivudine; ABC: abacavir; AZT: zidovudine; d4T: stavudine; ddC: zalcitabine; ddI: didanosine; EFV: efavirenz; 
FTC: emtricitabine; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase 
inhibitor; NVP: nevirapine; TDF: tenofovir; TI: treatment interruption; 
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6.4.2. Estimation of the persistence of NNRTI-resistance mutations in people 
interrupting NNRTI-based regimen 
Out of the 68 people with a resistance test available after stopping ART, a considerable 
proportion, 41% (95% CI: 31, 55; n=28), had NNRTI-resistance mutations detected in majority 
virus. The resistance test was conducted a  median 4 months after stopping ART, more rapidly 
in those in which resistance was detected (median time 1 month, IQR: 11 days-10 months) 
than in those were NNRTI-resistance was not detected any more (median time 6 months IQR: 1 
month-1.3 years; p-value=0.0435). 
 
The factors which a priori were established could impact on the presence of NNRTI-resistance 
mutations at the test performed after TI are those included in Table 6.1 (page 270) and Table 
6.2 (page271). The variables significantly associated with the outcome were calendar year of 
TI, time between TI and the day the resistance test was performed, being exposed to NVP, 
presence of K103N at the resistance test conducted before TI, being exposed to FCT, and 
previous use of FTC. These, except for previous use of FTC, because only 3 persons were in this 
category, were all included as covariates in univariate (continuous line in Figure 6.1) modified 
Poisson regression models. In addition I considered all the NNRTI mutations with a frequency 
of at least two.  
In the multivariable model (dashed line) only the variables associated with NNRTI-resistance in 
univariate analysis were included. Figure 6.1 shows that although the two factors which were 
found to predict presence of NNRTI mutations in univariate analysis (being exposed to NVP 
and presence of K103N) are not independent predictors in the multivariate analysis, the 
interpretation of the result does not really change. 
The risk of detecting resistance mutations seems to decline as time since stopping treatment 
(lines in light blue) and calendar year (lines in purple) increase, although neither  were  
statistically significant in univariate or multivariate analysis (aRR per additional year since 
stopping ART=0.82; 95% CI: 0.61, 1.10; aRR per additional calendar year=0.94; 95% CI: 0.83, 
1.07). People exposed to NVP, rather than EFV, seem to be less likely to have resistance 
detected (aRR=0.63; 95% CI: 0.37, 1.08) and people harbouring K103N, the most common 
NNRTI-resistance mutation (n=40), seem to have a higher chance of having resistance detected 
after stopping ART (aRR=1.90; 95% CI: 0.95, 3.82). As indicated by the very wide CI, due to the 
very small sample size, unfortunately it was not possible to properly assess the role of the 
other NNRTI mutations.   
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Figure 6.1 Relative risk of NNRTI-resistance being detected at resistance test (univariate and 
multivariate results) 
 
 
 
6.5. Results on presence of NNRTI mutations in patients who stopped an 
NNRTI regimen without having experienced virological failure 
6.5.1. Patients’ characteristics 
Among 16,472 people living with HIV enrolled in the UK CHIC database who had been exposed 
to NNRTIs, 2,439 patients interrupted NNRTI-based ART, according to medical records and had 
VL data available, so it was possible to ascertain whether they were suppressed (See Figure 
6.2). Among these, 1,636 patients, who had interrupted NNRTI-based treatment, had no 
evidence of NNRTI mutations on a resistance test (although people without a resistance test 
before TI were included), had VL suppressed (<200 copies/mL) at TI and had not experienced 
VF, defined has a VL>200 copies/mL after at least 6 months on a certain regimen, were 
included in this analysis. 
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Figure 6.2. Overview of patients eligible for the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
16,472 patients in UK CHIC had 
been exposed to NNRTI 
287 excluded because of absence of 
virological data before TI 
1,636 patients: 
(1) had no evidence of 
NNRTI resistance pre-TI 
(2) had VL<200 copies/mL 
at TI 
(3) did not experience 
virologic failure 
13,746 excluded because they did 
not interrupt ART 
2,439 patients: 
– interrupted NNRTI-based 
ART  
– had VL data available 
28 excluded because they had 
NNRTI resistance mutations pre-TI 
338 excluded because they failed 
NNRTI pre-TI 
437 patients excluded because 
they had a VL>200 copies/ml at TI 
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The patients, included in this analysis, come from the same cohort of patients used for the 
analysis previously described in this chapter and therefore present very similar characteristics 
(see Table 6.3): mainly composed by men (69%), of white ethnicity (54%), slightly younger 
median age (38 years old vs 40 years old in the previous analysis), less dominated by MSM 
(45% compared with 62% in the previous analysis). The median calendar year of TI, among 
these patients who did not experience VF, was April 2004 (IQR: February 2002-December 
2006), after a median of 20 months (IQR: 8 months-3 years and 8 months). At TI 87% had a VL 
<50 copies/mL and CD4 count of 415 cells/μL (median; IQR: 271-586) and they had been 
suppressed (VL<200 copies/mL) for 12 months (median, IQR: 4-30 months). The reason for TI is 
not reported in the table because 80% is unknown and it could not be considered as a 
potential covariate. Of those included, most (77%) did not have a resistance test pre-ART 
nevertheless given their consistently suppressed VL it is assumed unlikely that they harboured 
resistance mutations to the regimen they were receiving. As was the case for the previous 
analysis, the NRTI most people had been exposed to was 3TC (83%) followed by AZT (66%), 
while the other NRTI drugs had been used in 25% of the patients or less. Regarding the NNRTIs, 
60% had been exposed to EFV and 51% to NVP while the other drugs were used by less than 
1% (data not shown). At TI 53% were on EFV, 48% on NVP, 72% were on 3TC, followed by 48% 
on AZT and 23% on TDF. 
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Table 6.3. Baseline characteristics according to the presence of a resistance test after TI 
 All sample 
(n=1636) 
Patients with a resistance test after TI 
 (while off-ART) 
Yes (n=208) No (n=1428) p-value 
Sex, n male (%) 1137 (69%) 136 (65%) 1001 (70%) 0.1678 
Ethnicity*, 
n (%) 
White 885 (54%) 113 (56%) 772 (55%) 0.4005 
Black 595 (36%) 71 (35%) 524 (38%) 
Other 115 (7%) 19 (9%) 96 (7%) 
Mode of 
infection**, 
n (%) 
MSM 732 (45%) 115 (57%) 617 (47%) 0.0089 
HT 683 (42%) 80 (40%) 603 (46%) 
Other 97 (6%) 6 (3%) 91 (7%) 
Age, median (IQR) 38 (33-45) 35 (30-40) 38 (33-45) <.0001 
Calendar year of TI, 
med (IQR) 
Apr 
2004 
(Feb200; 
Dec2006) 
Jan 
2003 
(Sep2001; 
Sep2004) 
Sep 
2004 
(Mar2002; 
Apr2007) 
<.0001 
VL at TI <50 copies/mL, 
n(%) 
<50 
1421 (87%) 172 (83%) 1249 (87%) 0.0600 
Maximum VL achieved 
on ART***, med (IQR) 
251 (50-2,780) 400 (60-18,500) 230 (50-2010) 0.0040 
Length of time with 
VL<200 (months), med 
(IQR) 
12 (4-31) 8 (2-23) 12 (4-32) <.0001 
Resistance test pre-
ART, n (%) (if done, no 
NNRTI mutations 
detected) 
384 (23%) 51 (25%) 333 (23%) 0.7029 
Years ART initiation - 
TI,  
med (IQR) 
1.70 (0.63-3.62) 1.05 (0.40-2.71) 1.77 (0.68-3.69) <.0001 
Most recent CD4 count 
(cells/μL) at TI, med 
(IQR) 
415 (271-586) 456 (305-640) 408 (270-576) 0.0102 
CD4+ nadir count 
(cells/μL), med (IQR) 
295 (140-466) 379 (230-513) 280 (135-453) <.0001 
NNRTI at TI, 
n (%) 
NVP 779 (48%) 127 (61%) 652 (46%) <.0001 
EFV 864 (53%) 81 (39%) 783 (55%) <.0001 
DEL 2 (0%) 1 (0%) 1 (0%) 0.2382 
TMC-125 3 (0%) 0 (0%) 3 (0%) 1.0000 
NRTI at TI, n 
(%)  
 
AZT 778 (48%) 132 (48%) 646 (45%) <.0001 
DdC 2 (0%) 1 (0%) 1 (0%) 0.2382 
DdI 176 (11%) 20 (7%) 156 (11%) 0.5692 
D4t 229 (14%) 33 (12%) 196 (14%) 0.4060 
3TC 1179 (72%) 177 (64%) 1002 (70%) <.0001 
ABC 253 (15%) 34 (12%) 219 (15%) 0.7066 
TDF 369 (23%) 21 (8%) 348 (24%) <.0001 
FTC 240 (15%) 8 (3%) 232 (16%) <.0001 
# of drugs 
exposed to, 
n (%) 
<3 2 (0%) 0 (0%) 2 (0%) 0.5254 
3 886 (54%) 108 (52%) 778 (55%) 
4 or 5 544 (33%) 68 (33%) 476 (33%) 
6-12 204 (12%) 32 (15%) 171 (12%) 
*n=2,440; **n=2351; ***n=2,181; 
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3TC: lamivudine; ABC: abacavir; ART: antiretroviral therapy; AZT: zidovudine; d4T: stavudine; ddC: zalcitabine; ddI: 
didanosine; DEL: delavirdine; EFV: efavirenz; FTC: emtricitabine; HT: heterosexual; IQR: interquartile range; med: 
median; MSM: men who have sex with men; nc: not possible to calculate; NNRTI: non-nucleoside reverse 
transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NVP: nevirapine; TDF: tenofovir; TI: ART 
interruption; VL: viral load; 
 
6.5.2. Estimation of the risk of having NNRTI-resistance detected after interrupting 
a suppressive NNRTI-based regimen 
Of 1,636 eligible patients, 13% (n=208; 95% CI: 11%, 14%) had a resistance test performed 
after stopping suppressive NNRTI-based ART and were therefore eligible to estimate the risk of 
having NNRTI-resistance detected in the rebound viraemia.  
The covariates significantly associated with the presence of a resistance test after TI in 
univariate analysis (see Table 6.3)  were included in the multivariate model, except for the 
drugs people were exposed to, because it was preferred to include the drugs they were 
actually on when they interrupted treatment . Independent predictors of having a resistance 
test were older  calendar year of ART interruption (range 1997-2008, aRR per 1 more recent 
calendar year=0.89; 95% CI: 0.85, 0.93; p<0.0001), higher maximum VL achieved on ART pre-TI 
(aRR per 1 log increase=1.14; 95% CI: 1.04, 1.26; p-value=0.0042), younger age (aRR per 1 year 
older=0.96; 95% CI: 0.94, 0.97; p<0.0001), higher CD4 count nadir (aRR per 100 cells/μL 
increase=1.08; 95% CI: 1.04, 1.12; p<0.0001) and being on 3TC at TI (aRR=1.99; 95% CI: 1.39, 
2.87; p<0.0001).  
Among the 208 individuals with a resistance test performed after stopping suppressive NNRTI-
based ART, 12% (n=25, 95% CI: 8, 17) had ≥1 NNRTI-resistance mutation detected at the first 
resistance test following TI. In those with at least one NNRTI resistance mutation detected the 
median time between TI and the resistance test was 12 months (IQR: 3-20 months). The most 
frequently detected NNRTI mutation is by far K103N (55% out of 29 mutations, present in 64% 
of patients, n=16), followed by G190A (10%, n=3), three mutations (K101E, V108I, Y181C) with 
7% (n=2) (see Figure 6.3) and four mutations L100I, V106A, Y188L, P225H with only 1 
occurrence (3.4%). There was no occurrence of K101H/P, V106M, Y181/V, Y188C/H or G190S. 
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Figure 6.3. Distribution of NNRTI-resistance when detected after ART interruption 
  
When including in a multivariate model the factors found significant in univariate analysis with 
detection of NNRTI-resistance mutations (data not shown; CD4 count at TI, CD4 nadir and NVP 
at TI, NVP exposure), except for NVP exposure because collinear with NVP at TI, the only 
independent predictor was CD4 nadir, with a higher chance of NNRTI-resistance being 
detected the lower the CD4 nadir (aRR for 100 cells/μL increase in CD4 nadir=0.67; 95% CI: 
0.53, 0.85; p=0.001). 
 
In sensitivity analysis, it was evaluated whether restricting to patients who stopped their ART 
regimen while having a VL of 50 copies/mL or below would affect the results. As shown in 
Table 6.3 (page 276), 1421 patients (87%) had a VL of 50 copies/mL or less and were included. 
A similar proportion, compared with 13% (95% CI: 11%, 14%) in the main analysis, had a 
resistance test performed after ART interruption: 12% (n=172, 95% CI: 10, 13). Of those with a 
resistance test, 12% (20/172; 95% CI: 7, 17%) had NNRTI-resistance detected, the same as in 
the main analysis (12%; 95% CI: 8, 17). 
The second sensitivity analysis focused on people who had a resistance test performed within 
2 months since stopping ART (n=55/208, 26%). Their chance of NNRTI-resistance being 
detected at the resistance test performed after interrupting treatment was 7% (4/55; 95% CI: 
2, 17%). When considering a window of 6 months rather than 2, the results were still similar: 
9% (95% CI: 4, 17%). 
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In addition, similar levels of NNRTI-resistance were observed in people with simultaneous 
(n=188) and staggered interruptions (n=20): 12% (23/188; 95% CI: 7, 17%) and 10% (2/20; 95% 
CI: 1, 32%), although only less than 10% had simultaneous interruption and therefore it is 
difficult to draw conclusions given the very small sample size. 
 
 
6.6. Discussion and conclusions 
6.6.1. Summary and interpretation of main results 
To the best of my knowledge this is the largest study to evaluate the detection of NNRTI-
resistance in the rebound viraemia that follows interruption of a suppressive NNRTI-based 
regimen and amongst the largest, with the exception of the study conducted by Paquet et al. 
(765), to estimate the persistence of NNRTI-resistance mutations in people interrupting 
treatment after having experienced VF. These data allow me to address these two questions in 
the context of clinical routine, outside of the context of well controlled RCTs, as is the case for 
most studies evaluating the emergence of NNRTI-resistance mutations. 
 
The studies which have evaluated the length of time NNRTI-resistance mutations persist in 
majority virus, with the risk of being transmitted, often did not focus specifically on NNRTIs 
and are characterized by substantial variability with estimates of prevalence of NNRTI-
resistance mutations in patients with resistance test after interrupting between 20 and 83%. 
This variability can partly be explained by the very small sample size of these studies that when 
selecting patients who were on NNRTI-based regimen range from 4 (634) to a maximum of 90 
patients (765), this can produce very biased estimates. Another reason for this discrepancy is 
due to the fact that the prevalence of NNRTI-resistance mutations has been estimated at 
different times after interrupting treatment: from 25 days to 4 months and this can off course 
contribute to the variability in estimates, due to the decay of resistance mutations in absence 
of drug pressure.  
In this study I found that in patients who have documented NNRTI-resistance while on ART 
who then stopped all ART, 41% had NNRTI-resistance persisting at the first resistance test after 
interrupting treatment (in median performed 4 months after stopping ART). As expected the 
patients who had NNRTI-resistance mutations detected had the resistance test conducted 
more rapidly compared to those in which NNRTI mutations were not detected (median = 1 
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month, IQR: 11 days-10 months, vs a median time of 6 months, IQR: 1 month-1.3 years; p-
value=0.0435), suggesting that the loss of DRMs may occur as a consequence of emerging 
wild-type virus and the reversion to a more fit state (318;765;817). The estimate of a 
prevalence of 41% in people who had a resistance test in median 4 months after the TI is lower 
than previously reported by most studies (765;784;790), but in line with others (785). 
Nevertheless it is difficult to compare my estimates to previous published studies because in 
the UK resistance database study, given its observational nature, it was not predefined when 
the resistance test was performed, while in some of these studies the resistance test was 
performed at a precise time after TI. 
The main factor of interest for this analysis was the time between the TI and the resistance 
test performed off-ART. The data seem to suggest that the risk of detecting resistance 
mutations declines over time by 18%, although this was not statistically significant potentially 
due to the relatively small sample size. This risk seem to decline slightly (6%) as well as 
calendar year increases and this is likely to be to the fact that people who had the first ART 
interruption more recently in time are more likely to have been exposed to a lower number of 
regimens. This data seem to suggest that K103N, the NNRTI-resistance mutations most 
commonly found in this study, is more likely to persist. This has been previously reported by 
some studies (797), but not in others (765). 
 
Regarding the emergence of NNRTI-resistance mutations in patients interrupting suppressive 
NNRTI-base regimen, this study confirms that the detection of NNRTI-resistance is a relatively 
common phenomenon, occurring in 12% of patients who have a resistance test (in median 
conducted 12 months after the TI; IQR: 3-20 months).  Previous studies (763;766;799;803-805) 
estimated emergence of NNRTI-resistance mutations between 11% (766) and 37% (809), but 
this was measured either between 2 weeks (805) and 2 months (763) since TI or at the end of 
few cycle of structured TI (773). Studies have shown that when interrupting suppressive NNRTI 
regimen, NNRTI-resistance mutations can emerge and then in absence of drug pressure they 
can disappear again (804), therefore given the long time between the TI and when the 
resistance test was performed it is possible that in this study more than 12% selected NNRTI-
resistance de novo, but they were not detectable anymore by standard assays by the time the 
resistance test was conducted.  
To explore this hypothesis I restricted to people who had a resistance test performed within 2 
months since stopping ART (26% of the sample), but I found that the chance of NNRTI-
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resistance being detected at the resistance test was even lower, 7%,  but with an upper limit of 
the 95% CI of 17%.  
By far the most common NNRTI mutation detected off-ART was K103N, which emerged in 55% 
of patients with a resistance test available. This is not surprising and it has been previously 
reported (803;805). The only factor that was found to independently predict the selection of 
NNRTI-resistance mutations was the CD4 nadir with a higher chance of NNRTI-resistance being 
detected the lower the CD4 nadir, as previously found by other studies (766).  
When restricting to patients who stopped their ART regimen while having a VL of 50 copies/mL 
or less, the results did not change, contrarily to what has been found in other studies, where 
people interrupting treatment with a VL below 50 copies/mL were less likely than those with a 
VL between 50 and 400 copies/mL (766) to acquire NNRTI-resistance mutations. In this study 
only 13% had a VL between 50 and 200 copies/mL, therefore there was not enough power to 
detect that difference. 
Finally I investigated whether the results changed if staggered interruptions are used, rather 
than simultaneously, as has been previously shown (763). This study was not able to establish 
the extent to which these results change, because only 20 people had a staggered TI (95% CI 
for detection of NNRTI-resistance mutations: 1, 32%) and the remaining 188 simultaneously 
interrupt treatment. 
 
6.6.2. Limitations of the analysis 
There are several limitations that characterize this study. For both analyses, although a subject 
could have more than one TI after being exposed to NNRTI, I looked only at the first NNRTI 
interruption. For the analysis on emergence of resistance the interest was on the de novo 
selection of NNRTI-resistance mutations so I considered only the first treatment NNRTI 
interruption to minimize the chances that NNRTI-resistance mutations were present before 
stopping ART. In fact, there is evidence that repeat interruptions of the same regimen increase 
the risk of acquiring DRMs (804;818). Some individuals did not acquire DRMs at the first 
interruption, but they did after more interruptions of the same regimen (818). On the 
contrary, Arnedo Valero et al. found that the number of mutations did not increase as the 
number of interruptions did (805). 
In the analysis on the emergence of NNRTI-resistance mutations in people interrupting 
suppressive NNRTI regimen, it is not possible to exclude these NNRTI-resistance mutations 
being present, in minority or majority virus, before the TI. The great majority did not have a 
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resistance test pre-ART or before the TI while on ART, therefore it was not possible to 
distinguish between the re-appearance of previous existing mutations that emerged as a result 
of previous regimens or was transmitted and selection of de novo mutations. Since all of the 
patients eligible for this analysis had a VL suppressed at TI (<200 copies/mL in the main 
analysis and <50 copies/mL in sensitivity analysis) it was not possible to conduct (nor would it 
have been clinically indicated) a genotypic resistance testing and so there is no information on 
which mutations were present at interruption. Highly sensitive assays have demonstrated that 
drug resistant viruses can be selected and replicate despite ART induced VL suppression (819). 
In addition, I investigated whether there were any differences at baseline among those who 
received a resistance test or not after interrupting a suppressive NNRTI-based regimen and I 
identified the independent predictors of having a resistance test performed in multivariate 
analysis. I considered all the variables agreed a priori, among those available within the UK 
CHIC and UK resistance database, which were hypothesized could have an impact on the 
decision on whether the patient would receive a resistance test. However, it is not possible to 
exclude the presence of other unmeasured factors, or not available to me, which could have 
had an influence on whether a patient would receive a resistance test or not. 
For both analyses, the presence of NNRTI-resistance mutations was determined by population 
sequencing rather than more sensitive assays. Studies using both standard genotyping assays 
and ultra-sensitive genotyping (e.g. Sanger sequencing, allele-specific polymerase chain 
reaction or ultra-deep sequencing) have shown that more NNRTI mutations (i.e. low frequency 
drug resistant variants) are detected when ultra-sensitive assays are used (766;803;808). 
Therefore patients may be believed to have wild-type virus at the time of the resistance test if 
mutations are present in low frequency (808). Thus this estimate is likely to be an under-
estimate of the selection of de novo resistant mutations when treatment is interrupted. The 
same is true for the persistence of NNRTI mutations, it is possible that they still persist but in 
such small frequencies that standard genotyping test is not able to detect them. 
 
In addition these data contain information routinely collected in clinics and whether the 
patient received a resistance test after interrupting treatment was not part of a protocol study 
but depended on the clinician choice. Therefore, although I did not find major differences 
between those who received and those who did not receive a resistance test, it is not possible 
to exclude confounding and likely that those with a resistance test performed had a higher 
chance of NNRTI-resistance mutations being present.  
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6.6.3. Conclusions 
To conclude, this study confirmed that emergence of NNRTI-resistance mutations is common 
in people interrupting treatment and this is relevant because it has consequences on the 
efficacy of treatment once it is restarted. In those who interrupt after having experienced VF 
due to resistance emergence around 40% had NNRTI-resistance mutations detected after a 
median of 4 months since interrupting and this has serious implications for the transmission 
and spread of resistant virus. These estimates are useful for informing models that incorporate 
HIV drug resistance emergence and transmission and provide additional evidence for the 
potential risk on resistance of ART interruptions. 
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7. How should the South African ART programme be 
enhanced to cost-effectively deliver health gains?  
 
7.1. Introduction 
In chapters 4 and 5 I presented the findings from the assessment of the impact on HIV 
incidence and on the levels of drug-resistance of expanding access to care and eligibility 
criteria for ART initiation in South Africa. I found that expanding access to care to 80% of the 
HIV-infected population, while maintaining the eligibility criteria to initiate ART at CD4<350 
cells/µl is the most cost-effective strategy according to the Synthesis Model, while some other 
models found that the most cost-effective strategy is to modify the eligibility criteria to 
CD4<500 cells/µl or to all people diagnosed with HIV, without expanding the number of people 
in care (692). The reason why different models reach different conclusions is not completely 
clear, but could be due to different assumptions in the models, different structures, including 
due to different levels of detail being included. As well as explicitly modelling the development 
and transmission of drug resistance, the Synthesis model allows for people to be lost from care 
after being initiated on ART and to come back to care, which is not the case for all models 
included in the comparison. 
The WHO 2013 ART guidelines set ambitious goals, including initiating all patients on ART at 
CD4<500 cells/μL (280).  However, several programmes in South Africa have highlighted that 
losses from the cascade of care represent a major barrier to maximizing population health 
benefits from ART. It is increasingly recognized that engagement in HIV medical care plays a 
crucial role in maximizing health outcomes at a population level: maintenance of viral 
suppression in people HIV-positive, reduction in their risk of progressing to AIDS, and reduction 
in the risk of HIV transmission. The possibility that reinforcing the “cascade of care” (defined in 
section 7.1.1) could be one of the best options to produce further health benefits, at least in 
the short term, has been previously suggested (820). Programme managers face a difficult 
decision over levels of resources and effort to commit to initiating patients earlier on ART 
compared to improving implementation of ART delivery. For these reasons I decided to try to 
understand which step in the cascade of HIV care, from being diagnosed with HIV to being 
virologically suppressed on ART, is most influential on HIV incidence and death, and which step 
is the most cost-effective to improve. This question requires the use of mathematical models, 
because it is not straightforward to understand whether more deaths can be averted for 
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example by avoiding late ART initiation (achievable by improving linkage to care and retention 
in pre-ART care) or by improving retention once on ART; in particular, as it is unclear for 
example whether people who are not engaged into care would look for healthcare when 
developing symptoms. Similar reasoning is true for averting HIV infections. 
 
7.1.1. Definition of cascade of HIV care 
As discussed before, an incredible expansion in ART availability has been observed in LMIC, 
nevertheless lots of people do not receive ART for very long, because of the early mortality and 
loss to follow-up. Patients who initiate ART with a low CD4 count experience a very high 
mortality: 3-fold higher for those with CD4 count at ART initiation below 25 cells/μL compared 
to above 50 cells/μL (493), largely due to ADCs and OIs such as TB and cryptococcus meningitis 
(821;822). There is also strong evidence that interrupting ART is detrimental for the patient 
(714;770). 
 
In an effort to understand what are the obstacles and challenges to successful treatment, a 
number of stages the patient has to go through to be successfully treated have been identified 
and they are referred to as the “cascade of care” (823-825). Fox et al. provided first of all a 
series of definition for concepts related to pre-ART care (See Table 7.1) and proposed a 
nomenclature for the stages of pre-ART care (See Figure 7.1):  
i. from being diagnosed with HIV (i.e. first positive HIV test) to ART eligibility assessment 
(i.e. receipt of the CD4 result or clinical assessment and refer to either pre-ART or ART 
care), also referred to as “linkage to care”. 
ii. from completion of the first ART eligibility assessment (which should correspond to the 
referral to pre-ART care) until ART eligibility (this applies only to people who are not 
eligible for ART at the ART eligibility assessment), also referred to as “retention in pre-
ART care”. 
iii. from determination of ART eligibility to ART initiation (this period includes “treatment 
readiness” visits, adherence training and treatment education). 
Once they are initiated on ART a fourth step is required to achieve and maintain VL 
suppression (823;825): 
iv. adherence to ART medication, which includes being retained in care. 
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Table 7.1. Definitions of key concepts in pre-ART care (824) 
 
 
Figure 7.1. Stages of pre-ART care (551) 
 
 
More recently Hallett and Eaton (820) proposed to modify the cascade of care to allow for 
alternative path through the steps, already identified and proposed by others (823;824), in 
particular to allow people who dropped out from the cascade of care at early stages to come 
back into care. They noticed that the number reported to be initiated on ART with very low 
CD4 counts was not compatible with the numbers reported regarding the different steps in the 
cascade of care. They hypothesize that the reason for this discrepancy is that many people 
who initiate ART had not been retained in pre-ART care since their first HIV test, so they drop 
out during the pre-ART care and then come back later, when their CD4 is already very low or 
reinitiate ART after being lost, rather than initiating it for the 1st time. 
Figure not available due to copyright restrictions 
Figure not available due to copyright restrictions 
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Unfortunately, many patients are lost at each step of the cascade (551). Lots of patients 
initiate ART late, a long time after eligibility criteria had been met, even in settings with high 
ART coverage (826;827) and many fail to achieve VL suppression once initiated on ART (304). 
Strengthening the cascade would allow increased survival, as more people would initiate ART 
at a CD4 count closer to the eligibility threshold and higher levels of viral suppression. 
It is therefore important to have accurate measures of loss to follow-up. Measuring 
engagement and retention in HIV care is difficult, because this process includes multiple clinic 
visits over time and because the fact that a person may not be attending a specific clinic does 
not necessarily mean that the patient is not receiving HIV care. 
 
7.1.2. Definition of loss to follow-up when enrolled in an ART programme 
Being able to follow people who are on ART over time is critical to ensure adherence to 
treatment, to assess treatment response, to evaluate the potential emergence of drug 
resistance and toxicities and to access other healthcare services (828).  
There is not a consensus definition for being LTFU (829;830), although some have been 
proposed (829;831;832), making it very difficult to compare performance across different 
programmes and countries. Different reference time points have been used: since the last 
scheduled appointment (833-837) and since the last clinic visit (493;751;838;839) and with 
different time lengths.  
The definition of LTFU proposed by WHO is more than 90 days from the missed clinical visit or 
drug pick-up (832). Chi et al. used data from a cohort in Lusaka to determine after which 
length of time it is most appropriate to consider a person LTFU. In particular they looked at 
how many people were coming back to care in the following year of those considered LTFU 
and found that considering a person LTFU 56 days after a missed visit was the definition 
characterized by higher accuracy (Sensitivity of 84%; 95% CI: 83, 85; specificity of 97%; 95% CI: 
97, 98), and lowest misclassification: 5% (95% CI: 5, 5).  For this reason 60 days which 
performed similarly well, was proposed (831). In 2011 Chi and colleagues repeated this 
analysis but using observational data from 111 health facilities representing over 180 
thousands patients from 19 different countries (829). They found that the definition of LTFU 
which minimised misclassification was an interval of 180 days since last patient visit (7.7% of 
misclassification, 95% CI: 7.6%, 7.8%) and therefore they recommended this definition.  
 
288 
 
A couple of studies evaluated characteristics associated with LTFU (830) and the estimated 
rates of LTFU, AIDS-defining events, and death (840) according to the LTFU definition used. 
Shepherd and colleagues found that in Mozambique at two years since initiating ART, 
depending on the LTFU definition used, the estimates of LTFU varied from 22% to 84%, 
estimated mortality from 11% to 16%, and occurrence of AIDS-defining events from 6% to 8% 
(840). Li and colleagues found that the proportion considered LTFU in a study in Lusaka, 
Zambia, varied from 26% if the definition of LTFU was >=365 days late since last appointment 
to 36% if the definition was >=90 days since last encounter and respectively the LTFU rate per 
100 PYs ranged from 8.7 to 13.6. Li and colleagues reported that in their population the patient 
characteristics associated with LTFU were consistent across definitions: younger age, male 
gender, lower body mass index (BMI), higher CD4 count, and lower Hb (830), therefore 
although it is important to have a standardised definition for comparability this should not 
affect the ability to identify those in whom interventions should be tailored to. 
In 2010 Fox and colleagues published a systematic review, including 39 cohorts in sub-Saharan 
Africa, estimating programme attrition (sum of deaths and LTFU) to be 22.6% at 12 months, 
25.0% at 24 months, and 29.5% at 36 months (1). The studies conducted in South Africa 
assessing retention on ART are summarised in section 7.3.5. 
 
Regardless of the length of time to consider a person LTFU, the rates of loss reported in the 
literature have been very high and concern has grown in the scientific and public health 
community. On the other hand, most of the studies assessing loss to follow-up in resource 
limited settings (RLS) have been conducted from the clinic point of view and considered people 
LTFU if the person did not come back to that specific clinic, while it is possible that they 
transferred to another clinic and were therefore still being seen elsewhere in the country’s 
healthcare system. For this reason, tracking studies, in which people considered LTFU and 
either eligible to initiate ART (841) or initiated on ART (837;838) are traced to ascertain their 
vital status, have become quite popular. In these studies clinical trackers, either trained 
healthcare workers or volunteers search in the community for patients who are considered 
lost from the clinic through telephone calls, home visits and social networks. 
A meta-analysis of these tracing studies (842), reported that 63% of patients could be 
contacted and their status ascertained (range across studies: 45%-86%), 40% of these had died 
(95% CI: 33%, 48%), with significant heterogeneity across studies. Within the African programs, 
the mortality among patients considered LTFU ranged from 12% to 87% and this was inversely 
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associated with the rate of LTFU up in the programme. Tracing studies conducted in South 
Africa are described in more detail in section 7.3.5.  
Understanding the real magnitude of the problem and the reasons for disengaging from care 
are fundamental to improve retention in HIV care and on ART and, thus, long-term benefit of 
ART. It is not surprising that many people who are considered LTFU have in fact transferred to 
another clinic, given the population movements, rapid ART scale-up and decentralization of 
care. In most countries in sub-Saharan Africa with generalized epidemics, ART delivery was 
initially provided in urban hospital centres and later expanded to lower-level health clinics and 
rural sites (843;844). Another common reason for disengaging from care, transferring to a 
different clinic or not adhering to treatment is the fear of stigma and discrimination, which has 
been reported in a few studies (845-847). 
 
 
7.2. Brief literature review on barriers to HIV care and effective 
interventions to reduce the loss from the cascade of care 
It is important to be able to identify which patients are at highest risk of being lost from the 
cascade of care and what are the reasons behind it, so that interventions can be targeted to 
this group. Nevertheless, it is not clear what is the most effective intervention to improve long-
term retention among people living HIV and it is likely that the effectiveness of interventions 
differs across programmes and within programmes between different groups of patients. I am 
briefly going to list for each step of the cascade of care the main barriers to access and 
engagement with HIV care in sub-Saharan Africa, and then which interventions have proven to 
be effective in overcoming these issues in these settings. More detail (which was excluded 
from the main text due to the word limit) is provided in Appendix XIV. Interventions for 
specific subgroups of the population, such as MSM, female sex workers, people who inject 
drugs and adolescents are not discussed because they are outside the scope of this thesis.  
 
7.2.1. Awareness of HIV status: barriers and effective interventions 
Barriers to HIV testing are numerous, including fear of learning HIV status, of stigma and 
discrimination, lack of perceived HIV risk, perceived lack of confidentiality of the HIV test 
result, the inconvenience and opportunity costs of testing, the lack of capacity of the health 
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system due to staff shortages and high workload and poor infrastructure, to encourage and 
test for HIV more widely (471;848;849). 
 
The low uptake of HIV testing until around ten years ago led to the development of alternative 
approaches to the standard client-initiated voluntary counselling and testing (VCT). These 
include: 
 PITC, which consists of the health workers routinely offering HIV testing to all people 
attending the clinic with the option for them to “opt-out”. This strategy is 
recommended by WHO since 2007 for all adults and adolescents in countries with 
generalised epidemics (471). This strategy has been shown to be highly acceptable and 
feasible (849;850), contributing to increasing the uptake of HIV, especially in ANCs 
(851). Efforts to increase HIV testing, through PITC, in specific groups of patients such 
as TB patients and inpatients, have been extremely successful (850;852).  
 Couple VCT, was conceptualized as a means to increase HIV testing among men, given 
the success observed of PITC in ANCs. A few RCTs investigated the efficacy of 
encouraging couple counselling and testing of sexual partners within ANCs with mixed 
findings (853-855). 
 Home-Based Voluntary HIV Testing (HBT), where mobile teams go door-to-door and 
offer an HIV test to generally all adults, or adults living with HIV-positive household 
members and children aged 0-14 years with an HIV-infected mother living in the 
household, has given very successful results. This strategy has allowed the reaching of 
groups of the population previously underserved, such as poorer people (856) and 
people living in rural areas, reducing late diagnoses (857) and more generally 
increasing the probability of being tested for HIV (754;858-862) and of receiving the 
result of the test (863). More recently, some studies have assessed interventions 
addressing simultaneously multiple steps of the cascade of care including HBT, with 
successful results [see (864) in section 7.2.8]. 
 Workplace HIV counselling and testing, where people are offered the possibility to be 
tested for HIV at the workplace, has been demonstrated to be very efficacious in a RCT 
(865). Nevertheless there is huge variability in uptake using this strategy across studies 
(862). A factor that seems to be important to guarantee the success of this strategy is 
that the services are led by people openly living with HIV (866). 
 Mobile HIV testing, which consists of offering HIV testing and counselling (HTC) in 
public locations, generally accompanied by mass-media campaigns, has been widely 
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assessed with very successful results. A meta-analysis estimated the uptake of HTC 
through mobile testing to be 87% (95% CI: 85%, 88%) with a wide range from 27% in a 
study conducted in Zimbabwe (867) up to 100% in Kenya (868).  
 School-based HIV educational programs (excluding very young children, <5 years old), 
have been evaluated only in one study in sub-Saharan Africa. This took place in 
KwaZulu-Natal in South Africa and targeted high school girls (aged 12-25) (869), as 
they are at higher risk of becoming HIV-positive than boys of that age. Here they found 
that the uptake was similar to other community based approaches: 85% (95% CI: 83%, 
86%). 
 HIV self-testing (ST) consists of an individual collecting their own sample (typically 
saliva or a finger prick blood sample), and performing the test in private on their own 
(870). This approach has been found to lead to very high uptake both in the general 
population, in Blantyre, Malawi (755;871;872) and among healthcare workers in Kenya 
(873) and in Cape Town (874). 
 
7.2.2. Linkage to care: barriers and effective interventions 
While HIV testing has increased dramatically in the last few years due to the massive effort to 
scale up HIV testing, a problem that is now emerging is the fact that people who test positive 
fail to be subsequently linked to care (i.e. to receive ART eligibility assessment, including the 
result of the CD4 count test if conducted), leading to late presentation for ART. It has been 
estimated that in sub-Saharan Africa only 57% (95% CI: 48, 66%) of those who are aware of 
their HIV-positive status completed assessment of ART eligibility (553). The estimates on 
linkage to care in South Africa are presented in section 7.3.2. 
Several studies have been conducted to identify the reasons for people not linking to care (16 
reported in a systematic review from South Africa). The most common major barriers were 
transport costs and distance, stigma and fear of disclosure to their partner and/or family, 
human resource shortages at the clinics, long waiting times, fear of drug side effects, the need 
to take time off work and, for women, fear of violence or relationship break-up (875-877). A 
consistent finding across studies was that males and people of younger age were less likely to 
link to care. 
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Despite the dramatic losses at this point, most of the research has focused on interventions to 
boost HIV testing and retention in care, once initiated on ART, while much less research is 
available regarding this step and the retention in pre-ART care. 
Implementation studies demonstrated that it is possible to substantially reduce the loss at 
linkage to care. Successful interventions are:  
 referral programs (878), which facilitate referral from HIV testing to health centres 
where people can receive ART eligibility assessment (often the HIV testing and ART 
eligibility assessment are not conducted in the same site); 
 patient/peer navigators (876), which are people living with HIV trained as counsellors 
that visit the people newly diagnosed with HIV to support them to be enrolled into HIV 
care; 
 use of POC CD4 count testing at time of receipt of positive HIV test result (757;879); 
these are portable devices which generally allow for the result of the CD4 count to be 
available on the same day that it is measured.  
 home-based ART initiation for those who self-test positive (880), which consists in 
offering the possibility of being initiating on ART at home rather than having to attend 
the local clinic facility for confirmatory test and ART eligibility assessment. 
 
7.2.3. Retention in pre-ART care: barriers and effective interventions 
Loss to follow-up in people who have been diagnosed with HIV and found not eligible at ART 
assessment can be very high. At least three systematic reviews have assessed the attrition 
between diagnosis and ART initiation (551-553). Rosen et al. estimated that in sub-Saharan 
Africa more than 50% of the people could be lost during this stage (551), although it is likely 
that some would return back into care if symptoms present.  Estimates specific for South Africa 
are summarised in section 7.3.3. The barriers reported for this stage of the cascade of care are 
similar to those reported for linkage to care and for retention once initiated on ART: distance 
to the clinic, transport costs, other competing necessities and for some the fact that, if their 
CD4 count is very high, they are aware they are not going to be eligible for a while (875). 
 
Interventions shown to be effective, although not always in RCTs, include: 
 structural services, such as cash transfers for transportation (881) and food assistance 
programs  (882) (although this study was conducted outside of sub-Saharan Africa in 
Haiti); 
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 free CTX prophylaxis (883); 
 intensified post-test counselling, provided by trained counsellors, and enhanced peer-
support, involving monthly home visits by community support agents (884);  
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7.2.4. Prompt initiation on ART: barriers and effective interventions 
Barriers to timely initiation on ART once identified as eligible also include issues related to the 
health system such as not offering ART and drug stock outs, but also resistance from the 
patients, who fear drug toxicities and drug interactions (885). In a study in Soweto of newly 
diagnosed people, they found that of those found eligible 20% refused to be referred to 
initiate ART and most of them (92%) did not change their mind even after 2 months of 
counselling. The major reason reported was 'feeling healthy' (37%), despite their CD4 being 
below 200 cells/μL (886). 
Interventions found to enhance prompt initiation on ART include: 
 POC CD4 measurements (757;887); 
 postponement of adherence counselling from the period between being identified as 
eligible and ART initiation to the period after ART initiation (888); 
 
7.2.5. Retention on ART and adherence: barriers  
In order to be adherent to ART, it is necessary to be able not only to follow dosing regimens 
but also to refill prescriptions. Thus barriers to retention and adherence overlap. For this 
reason they are presented in the same section.  
 
There are disparate reasons for being lost from care, after ART initiation. They have been 
divided into “unintentional” and “intentional (889). 
Among the “unintentional” the following have been reported: 
 competing needs, such as education or food for their children (890;891); 
 financial constraints, in particular transport costs (275;892-894) and the necessity to 
pay for ART (847); 
 time needed for clinic attendance (i.e. the necessity to take time off work to visit the 
clinic)(275); 
 alcohol abuse (567); 
 mental disorders, such as symptoms of depression (491;567;895) and anxiety (895); 
 fear of disclosing HIV status (485;846;890;896) and more generally fear of stigma and 
discrimination (275;847;890;892;897); 
Among the “intentional” reasons: 
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 dissatisfaction with care due to low-quality services  (e.g. lack of confidentiality and 
privacy, drug stock shortages, problems with missing paperwork such as transfer 
papers or clinic cards, constrained number of health personnel and therefore not 
sufficient time spent with the provider) (275;847;890); 
 dissatisfaction with care due to poor access (e.g. long waiting time and unavailability of 
extended and weekend clinic hours ) (275); 
 healthcare providers’ attitudes and poor communication skills (890;891); 
 medication side effects (847;893); 
 complexity of drug regimens (846;889); 
 religious beliefs or the use of traditional medicine (847;890;892;897;898;898;899) and 
in particular not believing in the higher efficacy of ART compared to traditional 
medicine; 
 
The evidence regarding factors which can boost adherence is scarcer. Having a social role (e.g. 
having a family) and the social responsibilities connected to it (e.g. having to provide for 
children) often represents a strong incentive to adhere (847), together with desires for the 
future, such as getting married or having children and believing in the value of treatment 
(891;898-901). This positive attitude depends clearly on the ability to cope with an HIV 
diagnosis  (847) and of being able to get social support through family, treatment support 
groups, or faith-based organizations (890;891;899).  
 
Finally, some studies focused on identifying risk factors associated with a higher risk of being 
LTFU. Factors commonly reported are:  
 having initiated ART while pregnant (753;902;903); 
 having initiated ART as inpatients (753); 
 a high nadir CD4 count (above 200 cells/μL) or CD4 count at baseline (484;753), 
although the opposite has been reported as well: people initiated on ART with a CD4 
between 200-350 cells/μL being less likely to be LTFU than those with a CD4 at 
baseline <200 cells/μL (904); 
 male gender (484;892); 
 younger age (753;903); 
A factor which, on the contrary, has been found to be associated with a higher probability of 
being maintained in care is having received 6 months of pre-ART care (753;905;906). 
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Predictors of sub-optimal adherence include issues related to the delivery and characteristics 
of ART regimens, such as: 
 not speaking the same language as site staff (898); 
 having a complex dosing regimen (489) and therefore difficulty with the schedule of 
doses (487); 
 running out of pills (487); 
 medication adverse events (907;908) and perceived side effects (898); 
 long waiting times (898); 
Similar factors to those which characterize people more likely to be LTFU, characterize people 
more likely to have suboptimal adherence: 
 younger age (489);  
 male gender (488);  
 lower education (488); 
 being single (never married) (909); 
 being away from home (487;898;910); 
 feeling better on treatment (898); 
 fear of being stigmatised (487); 
 being malnourished or at least not able to have at least three meals per day (911); 
 low monthly income (909) or being unemployed (487); 
 contact with psychiatric care service (908) and alcohol use (898); 
 being too busy or forgetting it (910); 
 use of traditional medicine (898); 
 
7.2.6. Retention on ART: effective interventions 
Several interventions have been found effective in improving retention on ART. These include:  
 tracing systems, which means that community health workers either call or visit the 
patients after missed appointments to ascertain their status (whether they had 
stopped treatment, whether they had transferred to another clinic or whether they 
had died) and invite those who had interrupted treatment to come back to care 
(494;842;912); 
 community-based ART programs (CBART), which include a quite wide range of 
different interventions, but all aimed at reducing the number of visits to the clinic and 
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at providing support to the patients through peers or community health workers (913-
920); 
 nurse rapid assessment model, which consists of nurses briefly contacting weekly or 
bi-weekly individuals initiating ART with CD4 counts of 100 cells/μL or less  (921); 
 structural services, consisting of payment of school fees or rent, provision of shelter, 
employment at the program, interest-free loans, adult literacy instruction, income-
generating activities, transport, skills-building activities, food assistance for patient in 
need monetary supplements (912;922); 
 
7.2.7. Adherence: effective interventions 
Interventions which have been demonstrated to be effective in improving adherence in RLS 
include: 
 mobile phone short messages, in particular weekly messages, in some cases where 
the patients were asked to reply within 48 hours (923;924); 
 individual adherence counselling at the time of ART initiation (925); 
 use of community based treatment partners (including DOT) (926); 
 patient adherence treatment supporter (usually a family member, a friend, a 
community health worker or a peer health worker), which either provides 
psychosocial support, educates them on ART use, measures the patient’s adherence, 
reminds them to pick up the medications or assesses their adverse events and triages 
to other healthcare providers if necessary. The evidence for this intervention is mixed 
(927-929); 
 DOT (930) in combination with: 
o patient adherence treatment supporter (926;931;932), although some 
negative results have been found (933); 
o educational counselling (932); 
 modified DOT, which consists of 24 weeks of twice weekly health centre visits for 
nurse-observed pill ingestion, adherence support, and medication collection (926); 
 structural services, such as monetary supplements and food rations, in patients with 
food insecurity or underweight at ART initiation (934-936), although the impact in 
some cases was found on BMI but not reflected on VL or adherence outcomes (937). 
This intervention has been found to be quite costly compared to the others (938). 
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7.2.8. Approaches which improve the cascade of care at multiple steps 
To date no single intervention has been found to be effective in improving substantially the 
whole continuum of care. Nevertheless different interventions have tackled losses at more 
than one step in the cascade, especially because the barriers across the continuum are often 
similar. 
Interventions which have been demonstrated effective at improving more than one step in the 
cascade of care include: 
 Decentralization of HIV care provision and task-shifting, in other words delegating 
tasks usually performed by physicians (at least in high income countries) to staff with 
lower-level qualifications, such as nurses or other non-physician figures. This practice 
has been found to be efficacious at improving several outcomes: 
o level of HIV testing (939); 
o access to ART (number of people initiated) (939); 
o clinic efficiency (940); 
o retention in care (843;941-944) (without compromising the level of healthcare 
in patients on ART (945)); 
o Adherence to ART (946); 
This strategy is recommended by WHO (947) for countries with severe health worker 
shortages. 
 Integration of HIV/AIDS services into other healthcare services, such as:   
o TB services (948) (949). This has increased dramatically the level of HIV testing 
in people with TB (948) (949) and enrolment into HIV care (949); 
o ANCs (950-953). This integration has been found to improve dramatically 
enrolment of pregnant women on ART (953;954) and it is now widely 
implemented; 
 Health information system (i.e. electronic medical records) have been effective in 
reducing: 
o the number of missed appointments, and therefore the clinic efficiency (955); 
o the waiting time to see the provider (955); 
o the proportion of people LTFU (955); 
 
In addition, combinations of approaches, aimed at improvements across the entire continuum 
of care, are now being considered. Those found effective are the following: 
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 HBT in combination with POC CD4 count testing and lay counsellor follow-up visit at 
months one, three and six (864) demonstrated efficacious at improving: 
o uptake of HIV testing; 
o linkage to care; 
o retention in pre-ART care; 
o viral suppression in people on ART; 
 pre-ART care package characterized by three main features: task shifting to nurses and 
lay HIV counsellors, focus on a patient care pathway and active patient tracing for 
patients not presenting at the clinic for an appointment (758). This package improved: 
o linkage to care; 
o prompt initiation of ART for eligible patients; 
 
 
7.3. Cascade of HIV care in South Africa 
Figure 7.2 summarizes how people diagnosed with HIV transition between the different steps 
in the cascade of care within the Synthesis model. Most of the parameters are not directly 
informed by studies, but outcomes of the cascade of care are (the proportion linked to care, 
retained in pre-ART care, etc.; see Figure 7.3-Figure 7.7  at page 301-305)). By one year since 
diagnosis the Synthesis model assumes at least 60% are linked to care, where they are staged 
to evaluate whether they are eligible for ART. If eligible, it is assumed there is a probability of 
initiating ART that increasing over calendar years up to 0.95 in 2013. It was necessary to 
assume such a high probability of ART initiation in order to fit to the number of people on ART 
reported in the literature (see section 2.1.8). If staged and not eligible they are monitored in 
pre-ART care, where they have a probability of 0.075 of being lost per 3 month and a 
probability 0.04 per 3 month of returning into care, but much higher (0.8 per 3 months) if they 
have a WHO stage 4 condition. If on ART, it is assumed they have a probability of 0.02 per 3 
months of interrupting ART in the first two years and 0.01 per 3 months afterwards. Those 
who have interrupted ART experience a rate of 0.4 per 3 months of restarting ART and if they 
have interrupted ART they can be lost from care at the same rate they are lost from pre-ART 
care. 
Figure 7.3-Figure 7.7 (page 301-page 305) show the values for various steps in the cascade of 
care assumed in the Synthesis model (median across simulations in black dotted line [brown 
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for women in Figure 7.3] and UR black line [brown for women in Figure 7.3]) and observed 
(data) on the ground (dots in different colours). 
Figure 7.2. Transitions within the cascade of care in the Synthesis transmission model 
 
Notes to Figure 7.2: The rates are per 3 months; *This applies only to people without  WHO4, WHO3 events or TB in 
the last 6 months, those have a rate of 1; ** for a person with high  person-specific tendency to adhere (PSTA);  rate 
of loss 2-fold for people with low PSTA; rate of return half and a 1/3 if the person has  respectively medium or low 
PSTA; ^for a person with high PSTA and no current toxicities; up to 4 times higher for person with low PSTA and 
current toxicities; After 2 years  is halved^^ 3 and 5 times higher for respectively people with  WHO3 and 4; 
 
7.3.1. HIV testing in South Africa 
The first step in the cascade of care is being tested for HIV. The uptake of HIV testing in South 
Africa has been described in section 2.1.5 (Appendix IV contains information on PITC uptake in 
ANCs). In the Synthesis model the rates of HIV testing have been chosen by fitting to observed 
data on the gender-specific proportion of adults ever tested, collected in the HSRC surveys in 
2002, 2005 and 2008 (see Figure 7.3). 
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Figure 7.3. Proportion of adults (15-65 years old) ever tested for HIV 
 
UR: uncertainty range; LL: lower limit; UL: upper limit; SA HIV HSRC: South Africa National HIV HSRC surveys 
conducted in 2002, 2005 and 2008 
 
An indirect indication of the level of HIV testing is the median CD4 at diagnosis and the 
proportion of people who present with a low CD4 at diagnosis. The median CD4 count at 
diagnosis in South Africa has been found to vary from 100 cells/μL (720) to 489 cells/μL (956) 
and the proportion diagnosed late (with CD4 count < 200 cells/μL) from 9.6% (956) to 54.3% 
(957). The studies conducted in South Africa which reported this information are summarized 
in Appendix XV (This is not meant to be a systematic review but it includes the largest studies 
reporting these information). 
 
7.3.2. Linkage to care in South Africa 
Once diagnosed with HIV, people can be lost at different stages before or after starting ART. In 
South Africa, the proportion of people who received an ART eligibility assessment (i.e. received 
the CD4 count result or were clinically evaluated to determine whether eligible to be initiated 
on ART) after being diagnosed at national level is unknown. HIV care programmes have found 
levels from 29% in a study conducted in 2001 (958) up to level of 78% (956), defined as a 
person returning for CD4 count result (although only 42% of these were reported to enrol into 
care) in a study conducted in 2008-09. 
Figure 7.4 shows the proportion of people who received ART eligibility assessment within 3 
months of diagnosis, as proposed by Fox et al. (824), from 1998, when a significant number of 
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people were tested for HIV and ART was available. The coloured dots represent estimates from 
different studies and they are positioned in terms of calendar year, approximately half way 
through when the study was conducted. The studies indicated in Figure 7.4 are summarised in 
Appendix XVI.  
 
Figure 7.4. Stage 1: Proportion linked to care (who received ART assessment, “staged”) 
within 3 months since diagnosis 
 
UR: uncertainty range; LL: lower limit; UL: upper limit; 
 
7.3.3. Retention in pre-ART care in South Africa 
Figure 7.5 shows the proportion of those who were not eligible at staging, who visit the clinic 
within the next year, in accordance with one of the definitions proposed by Fox et al. (824), 
except for the fact that I did not distinguish according to whether they were ART eligible at last 
assessment or not. 
In South Africa, this has been found to vary from 31% (604) to 57% (959) (see Appendix XVII). 
This is well captured by the model; in fact most of the estimates are included within the 90% 
UR. The estimates which are not in this range are lower than the levels reconstructed by the 
model. Nevertheless the observed data could potentially underestimate retention due to the 
fact that people go to different clinics. There is evidence from studies which investigated what 
happens to people who are considered LTFU, that many of them have actually attended a 
different clinic in the last three months (960-962). 
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Figure 7.5. Stage 2: proportion of people not eligible at staging who visit the clinic within the 
next year 
 
UR: uncertainty range; LL: lower limit; UL: upper limit; 
 
7.3.4. Initiation of ART, once eligible, in South Africa 
Figure 7.6 shows the proportion initiated on ART of those who have been eligible to start ART 
for 12 months, starting from 2003 when ART became available. This has been estimated in 
studies, conducted mainly between 2003 and 2009 to be between 39% (963) and 68% (958) 
(see Appendix XVIII). The proportion of patients eligible for one year who initiated ART as 
reconstructed by the model is lower than the estimates from the single studies, but this reflect 
the fact that those estimates come from areas/clinics where ART was available, while the 
model reflects the situation in South Africa overall. In order for the model to reflect the 
number of people who have initiated ART (451), it was necessary to assume that by 2013 95% 
of those eligible for ART (measured CD4 count <350 cells/µl and in care) were initiated on ART. 
In addition, Appendix XIX summarizes the median CD4 count at ART initiation reported in 
South Africa. This ranges from 43 cells/µl in one of the first sites who provided ART (477) up to 
279 cells/µl, reported by Kranzer et al. for the calendar year 2006 (484) (In most of the setting 
at that calendar year ART eligibility criteria was CD4<200 cells/µl, therefore this represent an 
exception). 
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Figure 7.6. Stage 3: Proportion initiated on ART among those identified as eligible for at least 
one year 
 
UR: uncertainty range; LL: lower limit; UL: upper limit; 
 
ART is assumed to have been introduced in 2003 and the eligibility criteria for ART initiation 
reflects national ART guidelines for South Africa: <200 cells/μL or WHO stage 4 before mid-
2010 (225), CD4 counts ≤350 cells/μL irrespective of the WHO clinical stage after mid-2010 
(230) (See section 2.1.7). In 2005, approximately 100,000 HIV-infected adults were receiving 
ART in South Africa and this number increased to 1.6 million by mid-2011 (451).   
 
7.3.5. Retention on ART in South Africa 
One of the first studies to evaluate the retention on ART in sub-Saharan Africa was conducted 
by Braitstein et al. (751). They found, across 13 African cohorts that on average 15% were LTFU 
at 12 months following ART initiation, with variability ranging from 0% to 44% across 
programs.  Subsequently Rosen and colleagues conducted a systematic review of studies which 
evaluated retention and reported a weighted mean attrition rate, over 33 African cohorts, of 
1.8%–3.3% per month (2). This was updated in 2010 (1). 
Patients can be lost from care at any point in time, before and after having initiated ART. It is 
estimated that the proportion retained on ART at 1 year since initiation varies between 55% 
(964) and 93% (965) (See Appendix XX for a summary of the studies).  
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Figure 7.7. Proportion of people retained on ART at 1 year since ART initiation 
 
 
7.3.6. Switch to second-line in South Africa 
The number of people who are switched to second-line in South Africa is relatively low. Among 
those who experienced VF (see section 2.1.10 and Appendix VI) only between 16.9% at 12 
months since VF (500) and 62% (74% switch to second-line of those who experience VF with at 
least 6 months of follow-up after failure) over a median follow-up of 15.6 months (499) were 
switched to second-line regimen.  The time to switch people to second-line from identification 
of VF among those who did switch has been estimated to be between 5 (4.6 months; IQR: 2.1- 
8.7) (499); 5.3 months (IQR: 2.2-11.2) (292)) and 12 months (501). However, the fact that for 
example Johnston and colleagues found that at 12 months only 17% were switched to second-
line clearly indicates that not all patients in need of switch are switched to second-line and the 
fact that the time taken to switch people can be much longer than 5 months. 
Among all people initiating on ART it is estimated that 1% are switched to second-line at 1 year 
(499;966), around 4% at 3 years (495) and 10% at 5 years (499).  
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7.4. Methods 
The ‘HIV Synthesis’ model calibrated to South Africa and described in detail in Chapter 3 was 
used to evaluate the value of potential improvements in each step of the cascade of care and 
of changing in the eligibility criteria to initiate ART, over 20 years in South Africa. 
 
7.4.1. Analysis details 
The impact of seven single different improvements characterized by an increase in the number 
of people receiving (appropriate) ART, implemented over 2014 and 2015, was considered (the 
letter code to be used as a label for the scenario is given in parentheses): 
1. modifying the eligibility criteria to be initiated on ART to CD4<500 cells/µl (F), 
2. modifying the eligibility criteria to be initiated on ART to all HIV-positive people (D),  
3. increasing HIV testing so that 85% ever tested for HIV (T),  
4. reducing the proportion of people lost at diagnosis so that 85% are linked to care by 1 
year since diagnosis (L),  
5. improving pre-ART retention, so that 72% are retained in pre-ART care at 1 year since 
staging, of those not eligible  (P), 
6. improving retention on ART, so that 92% are on ART at 1 year since initiating (A), 
7. reducing the time to switching to second-line to 5 months after VF (S).  
These improvements were compared to a reference scenario, referred to as option R, 
characterized by the maintenance of the current level of testing, linkage to care retention in 
pre-ART care and on ART and rate to switch to second-line, in people experiencing VF.  In 
addition I considered twelve combinations of the scenarios indicated above, including a 
combination of all the scenarios considered.  
Although I did not indicate specific ways of achieving these improvements, their magnitude is 
in line with the efficacy of scenarios found to be effective (see section 7.2). The only 
exceptions are the change in the CD4 threshold to initiate people on ART and the reduction in 
the delay to switch people to second-line, for which there is no evidence yet on how easy and 
feasible it is to implement them. I assumed the scenarios were fully implemented and people 
eligible for treatment and in care are assumed to have a probability of 0.95 of initiating ART 
within 3 months.   
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One key assumption relating to people who are LTFU is that if a WHO stage 4 condition is 
experienced then it is assumed there is an 80% chance of coming back into care. While the 
literature on loss to follow-up and its predictors is very rich, although variable, very few studies 
have investigated how many people resume therapy after interrupting ART and not attending 
the clinic (and therefore be considered LTFU) (967). They estimated that 42% of those who 
interrupted treatment for more than 30 days returned to care within 3 years and identified as 
predictors of resuming therapy being a woman, being older than 30 years old and being within 
the first year since stopping therapy. They did not mention whether patients resuming ART 
were more or less likely to have had a WHO stage 4 in the meantime, but reported that their 
CD4 at resumption (median=150) was similar to their CD4 at ART initiation (median=138), 
suggesting that being sick could potentially play a role. Other mathematical models considered 
even more dramatic assumptions such as assuming that people who are lost before ART 
initiation come back to care only when sick (690). 
 
VF, in line with South African Guidelines (225;226;230), was defined until mid-2010 as a VL 
above 400 copies/mL followed by a consecutive VL above 5,000 copies/mL (VL measured 6 
monthly), afterwards as a VL above 400 copies/mL followed by a consecutive VL above 1,000 
copies/mL, measured within 3 months (VL measure at 6 and 12 months and then annually). 
 
7.4.2. Economic analysis 
The 20 scenarios (7 single improvements and 13 combinations of single improvements) are 
compared on the basis of their costs and health outcomes, which are both discounted to 
present value at 3% per annum (729), over 20 years.  Health outcomes are summarised in the 
form of QALYs: a continuous measure capturing both mortality and morbidity effects including 
those related to onward HIV transmission. One year of healthy life corresponds to one QALY, 
while if a person is dead a value of zero QALYs is given. For this analysis some conditions are 
assumed to reduce the QALYs to less than 1: toxicities (0.95), WHO stage 3 (0.78), TB (0.60) 
and WHO stage 4 (0.46) (968).   
Costs are estimated based upon resource use (e.g. number of tests, number of clinic visits) and 
associated unit costs are listed together with the sources in Table 7.2. 
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Table 7.2. Unit cost and disability adjusted weights and their sources 
Item Cost (US $) Source where available 
ART cost (1st line: 
TDF+3TC+NVP)  
$97 per year (969) 
WHO stage 4* $200 - 
WHO stage 3* $20 - 
TB* $50 - 
CTX $5 per year - 
Clinic Visit $40 - 
CD4 measurement   $15 (970) 
VL measurement $45 (970) 
HTC (all costs fully loaded)  $10 (692) 
*This cost is incurred every 3 months where the person has this condition. 
3TC: lamivudine; ART: antiretroviral therapy; CTX: co-trimoxazole; HTC: HIV testing and counselling; NVP: 
nevirapine; TB: tuberculosis; TDF: tenofovir; VL: viral load; WHO: World Health Organization; 
 
The benefits of improving implementation are investigated, firstly without any additional costs 
for implementation initiatives and then with the following indicative fixed implementation 
delivery costs: 
 $0.50 per person without diagnosed  HIV (so either HIV-negative or positive and not 
diagnosed; i.e. the target population for testing) if the  scenario includes  increased 
testing , 
 $50 per person linked to care, per PY retained in pre-ART care, per PY retained on ART 
and per person switch to second-line was applied if, respectively, the scenario included 
increased linkage to care, retention in pre-ART care, on ART and reducing the time to 
switch to second-line. 
 
Results are presented across a range of CET (see section 4.3.2.2): from $1,000 up to $12,000, 
similar to current South African per capita GDP (In 2013 $11,500 (971)). Despite WHO 
recommended benchmarks being one per capita GDP for an intervention to be considered 
“very cost-effective” (729), I decided to present results based on much lower CETs, because 
these are more likely be used on the ground.  
 
Costs and health outcomes are rescaled to provide figures relevant to the entire adult 
population (15-65 years old) of South Africa.   
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7.4.3. South Africa - current situation modelled 
Table 7.3 illustrates the situation regarding the cascade of care at the end of 2013 as 
reconstructed by the model.  
By 2013 I estimated 62% would have been ever previously tested for HIV, comparable to the 
estimate from the HSRC national survey conducted in 2012 reporting 65.5% ever tested for HIV  
(440). Regarding the linkage to care, there is lots of variability in the literature in the way this 
estimate is expressed, making the comparison more difficult. I assumed 71% were linked to 
care by one year (i.e. received the result of the CD4 measurement to evaluate whether eligible 
for treatment and clinical staging) and 42% were retained in pre-ART care at 1 year since 
diagnosis among people found not eligible for ART. In order to match with the total number of 
people newly initiated on ART I had to assume the probability of initiating treatment when 
accessing care and eligible for treatment increased over time and reached levels of 95% by 
2013 (not shown in Table 7.3, see Figure 7.6 at page 304). 84% were assumed to be retained 
on ART at 1 year since having initiated ART and the time to switch to second-line once having 
virologically failed is 12 months (501). 
 
Table 7.3. Characteristics of the epidemic at the end of 2013 
 Model, median (UR) -  
End of 2013 
Observed data 
CD4 eligibility criteria to be initiated on 
ART (in cells/µl) 
CD4<350 CD4 <350 (226) 
% ever tested for HIV  62% (29% in the last 
year) 
51% in 2008 (24.7% in the 
last year) (452), 65.5% ever 
tested in 2012 (440) 
% linked to care by 1 year since 
diagnosis 
71% (63%-76%) 35% by 3 months since 
diagnosis (957) to 78% (956) 
% retained in pre-ART care at 1 year 
since diagnosis in those not eligible for 
ART at staging 
42% (38%-47%) 31% (604) to 57% (959) 
% retained on ART care at 1 year since 
ART initiation 
84% (80%-88%) 55% (964) to 93% (965) 
Median time to switch to second-line  
since VF 
12 months (12 
months-12 months) 
5 months (499) to 12 months 
(501) 
90% UR: 90% uncertainty range; 
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7.5. Results 
In the reference scenario over the next 20 years the model estimates 797 million of life-years 
are accumulated in the entire adult population of South Africa (aged 15-65). Figure 7.8 shows 
the life-years gained over 20 years in South Africa by implementing each of the scenarios 
described in the section 7.4.1 compared to the reference scenario. Figure 7.9 (page 312) and 
Figure 7.10 (page 313) show respectively the number of deaths averted among HIV+ people 
and the number of HIV infections prevented. 
The single improvement which leads to the highest increment in total life-years over 20 years 
is the improvement in retention on ART (7.5 million life-years gained in the country over 20 
years) (see Figure 7.8), which leads to the greatest reduction in deaths among HIV+ people 
(923,000 adult deaths averted in South Africa over 20 years) (see Figure 7.9 at page 312), 
despite only an assumed relatively modest increase in retention (8%). Modifying the eligibility 
criteria so that all people diagnosed with HIV are eligible to initiate ART saves the highest 
number of new HIV infections (760,000) (see Figure 7.10 at page 313), but results in an 
increment in life-years of 3.4 million, compared to 7.5 million obtained by improving retention 
on ART. By improving all steps of the cascade of care and modifying the eligibility criteria so 
that all people diagnosed with HIV are eligible for ART, 15 million life-years over 20 years can 
be gained (see Figure 7.8). 
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Figure 7.8. Impact of single and combination of improvements in the cascade of care, in terms of life-years gained over 20 years 
 
EC: eligibility criteria; 
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Figure 7.9. Impact of single and combination of improvements in the cascade of care, in terms of deaths averted among HIV+ over 20 years 
 
EC: eligibility criteria; 
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Figure 7.10. Impact of single and combination of improvements in the cascade of care, in terms of HIV infections averted over 20 years 
 
EC: eligibility criteria; 
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Figure 7.11a and Figure 7.11b illustrate the value of strengthened implementation in South 
Africa, without including the cost of the implementation initiatives (Figure 7.11a), representing 
therefore the maximum value achievable, and the value including some illustrative costs 
(Figure 7.11b). By not including the cost of implementation, I mean that the cost of attracting 
people to test for HIV, in care or to restart ART is not included, but the cost of higher number 
of tests being conducted or more people receiving ART, because of the intervention, would be 
included (All the costs included are listed in Table 7.2). In each of them two cost-effectiveness 
frontiers are presented: one across the scenarios aimed at improving how care is delivered 
(scenarios T, L, P, A, S and their combinations) and one across the scenario where the eligibility 
criteria to be initiated on ART are modified to either CD4<500 cells/μL, as recommended by 
WHO (280) or to all people diagnosed with HIV. The area between the two frontiers represents 
the area of potential gain from improving implementation. 
Figure 7.11a shows that improving retention on ART (indicated by the letter A, dot in blue) 
while maintaining the eligibility criteria to CD4<350 cells/μL would deliver 2.7 million more 
discounted QALYs compared to modifying the eligibility criteria to all people diagnosed with 
HIV with the current leaky cascade. When including a cost of $50 per PY on ART, improving 
retention on ART is still preferred compared to increasing the eligibility criteria to CD4<500 
cells/μL or at diagnosis. 
The results illustrated in Figure 7.11 indicate that strengthening the cascade should be 
prioritized before increasing the eligibility criteria. In particular it suggests that the initiative 
that should be prioritized is reducing the delay in switching to second-line from 12 to 5 
months, given that this initiative is characterized by the lowest ICER (US$ 734 when including a 
cost of $50 per person switched). This is followed by improving retention on ART at 1 year to 
92% and reducing the delay in switch (ICER = US $1,314 per QALY gained), assuming a cost of 
$50 per person-year on ART is considered, as well as a cost of $50 for each person switched to 
second-line. The next steps, if the country can afford it, would be to improve all steps 
considered while still maintain the current eligibility criteria in South Africa and only once this 
is fully implemented to also move to change  the eligibility criteria to initiate ART to all people 
diagnosed with HIV (ICER: US $1,563 per QALY gained). 
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Figure 7.11. Value of strengthened implementation in South Africa 
a. Maximum value (no costs of implementation initiatives included) 
 
See legend in Figure 7.11b. QALY: quality-adjusted life-years; 
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b. Indicative value (illustrative costs of implementation initiatives included) 
 
QALY: quality-adjusted life-years; EC: eligibility criteria; 
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The aim of this analysis is to provide a framework to design ART programme improvements (as 
conveyed by the scenarios I compared) that could strengthen the cascade of HIV care, without 
focusing on the specific improvements which would be characterized by a certain efficacy and 
cost.  Therefore, I calculated the maximum cost these initiatives can have in order to still be 
cost-effective, at different CETs (see Table 7.4). 
These results show that at a CET of US $1,000 improving HIV testing, linkage to care or 
retention in pre-ART care should not be implemented. This is likely to be due to possible 
inefficiency of pre-ART care at higher CD4 levels (i.e. patients attending the clinic visits at cost, 
but without any benefit, because not yet eligible for treatment), given that in the reference 
scenario it is assumed people who are lost from care experience an 80% chance of coming 
back into care when symptomatic. 
Conversely, at a CET of US $1,000, an intervention  that improves retention on ART from 84% 
to 92% could cost up to $16 per PY on ART, and an intervention to reduce the delay from 12 to 
5 months could cost up to $171 per person-switched. This is simply another way of expressing 
the same results. As the CET increases, all five scenarios become worth considering and it 
becomes increasingly possible to spend more for each of them because they all provide 
additional health benefit. 
 
Table 7.4. Maximum cost of the scenario to be cost-effective at the CET indicated (South 
Africa GDP in 2012 $11,600) (considering only the single scenarios) 
Potential scenario $ cost is per.... Cost –effectiveness threshold (CET) 
$1,000 $2,000 $5,000 $12,000 
T: Improve HIV testing person not diagnosed 
with HIV 
- $0.80 $3 $10 
L: Improve Linkage to care person linked to care  - $54 $261 $743 
P: Improve retention in Pre-ART PY in pre-ART care - $278 $1,279 $3,616 
A: Improve retention on ART PY on ART $16 $108 $382 $1,023 
S: Improve Switch to second-line person switched to 
second-line 
$171 $624 $1,985 $5,159 
ART: antiretroviral therapy; PY: person-year; 
 
 
7.6. Discussion 
Policymakers need to determine how best to spend available resources on ART to generate 
health gains in the population. I found that, in the context of South Africa at least, the single 
improvement which leads to the highest increment in total life-years over 20 years is to 
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improve retention on ART, mainly due to the fact that it allows aversion of the greatest 
number of deaths over 20 years. When assessing whether to try to better implement  the 
current recommended policies or to modify the eligibility criteria to initiate people earlier, I 
found that, even though modifying the eligibility criteria to initiate ART at diagnosis averts the 
highest number of new HIV infections, it results in a lower health gain  (in terms of QALYs) and 
at a higher cost.  
The initiative characterized by the lowest ICER, and which should be prioritized, is the 
reduction in the delay in switch in those failing treatment virologically from 12 to 5 months. An 
improvement of this magnitude is feasible and a median delay of 5 months has been reported 
in a programme in South Africa (499). For this initiative an additional cost of $50 was applied 
for each switch that occurred (on top of the cost of VL monitoring of $45 for the VL 
measurement conducted at 6 and 12 months and then annually, the cost of the visit, $40 every 
3 months, and of the other costs listed in Table 7.2), it is possible that to achieve this 
improvement the cost is higher (although note that this $50 does not include the costs of the 
VL tests needed to diagnose VF or the cost of the second-line drugs, only cost of instigating the 
switch). The maximum cost per person switched that this scenario can be varies from $171 if 
the CET is $1,000 up to $5,159 if the CET is $12,000. Given the illustrative cost assumed, if the 
actual CET of South Africa is $1,314 or more, the initiatives of improving retention on ART 
combined with reducing the delay to switch to second-line should be implemented. This allows 
accrual of almost 5 million extra discounted QALYs compared to the reference scenario, and 
4.5 million more compared to the scenario where only the delay in switch is reduced, but it is 
associated with a higher cost per QALY gained ($1,314). Improving retention on ART so that at 
1 year up to 92% are retained on ART (although this would have an impact on longer term 
retention as well) seems feasible: at 6 months retention of 93% has been reported (965) and 
levels of 90% have been reported at 12 months in the earlier year of ART scale up (if I ignore 
whether they received ART in the same clinic or transferred to another clinic) (478;601). 
Only once this initiative is implemented, it is appropriate to move to more expensive initiatives 
and if the CET is $1,563 or more and the improvements can be delivered at the cost indicated 
it is cost-effective to pay to improve HIV testing, linkage to care, retention in pre-ART care, 
retention on ART, switch to second-line and offering ART to all people diagnosed with HIV. 
 
When looking at the maximum these initiatives can cost to be cost-effective, I found that at 
the CET of $1,000 it is not appropriate to invest in HIV testing or in increasing linkage to care or 
retention in pre-ART care. This is likely to be due to the fact that the model assumes, as 
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mentioned in 7.4.1, that people experiencing a WHO stage 4 condition have an 80% chance of 
coming back into care in care . 
 
7.6.1. Findings from other mathematical models 
A few mathematical models have evaluated the impact of improvement at different single 
steps of the cascade of care, such as HIV testing in several countries in sub-Saharan Africa 
(860;972-976), prevention of loss to follow-up in Cote d’Ivoire (977) and return into care of 
patients initiated on ART through tracing in Malawi (978) or more generally the impact of 
improving the return to  HIV care of people lost from care, after having initiated ART in South 
Africa (698). 
 
Here I focus only on models which evaluated the impact of improvement in at least one step in 
the cascade of care in South Africa. In 2011, Walensky et al. (979) assessed the cost-
effectiveness of an HIV screening conducted once, every 5 years or every year. They reported 
that a one-off HIV screening was dominated by the other strategies and that five-year 
screening was the most cost-effective with an ICER per QALY gained of $1,570. This analysis is 
not directly comparable to my results but in line with the Synthesis model, which in the 
reference scenario assumes around 30% of the population are tested every year, finds that a 
more frequent HIV testing, such as every year, is not cost-effective. 
Andrews et al. (690) aimed to evaluate the impact of including in a simple mathematical model 
(previously used to assess the impact of test and treat, i.e. annual HIV testing and ART 
initiation at diagnosis (686)) two additional elements: the fact that only a modest proportion 
accept to be tested for HIV and, if positive, to be initiated on ART and the fact that those who 
either refuse to test or are lost before ART initiation are less likely to come back into care.  
Related to improvements in the cascade of care, they evaluated the impact of modifying two 
assumptions. They compared the impact of modifying the probability of initiating ART in 
patients eligible at HIV diagnosis from 92% (assumed by Granich et al. (686)) to 53% as found 
in a study evaluating the linkage to care from mobile testing unit (956). In addition they 
assessed the impact of modifying the conditions that allow people who decline HIV testing or 
who are LTFU before starting ART to come back into care: either people who are lost before 
ART initiation or who refuse testing have the same probability of coming back to care (so that 
with a linkage to care of 92%, 99.9% would be in care within 3 years), as assumed by Granich 
et al. (686), or only at the final stage of HIV infection with symptomatic disease. They found 
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that HIV incidence would drop from 2.5% to 0.07% by 2030 and 0.03% by 2040 with 92% 
linkage and to respectively 0.11% and 0.05% if the linkage to care is more realistically 53%. 
Once assuming that people who are lost from care come back to care only when symptomatic 
(a more strict assumption than mine) the HIV incidence was reduced to 0.26% by 2030 and 
0.15 by 2040 if the linkage is 92% and respectively 0.49% and 0.33% if the linkage is 53%. 
That model is a much simpler model and does not distinguish between the linkage to care step 
(i.e. receiving the CD4 result to assess for ART eligibility) and, for those found eligible, the 
probability of initiating ART.  I did not investigate the combination of improving linkage to care 
(from 71% to 85%) and modifying the eligibility criteria to all people diagnosed with HIV, but I 
compared simultaneously modifying improvement in linkage to care (from 71% to 85%) and 
retention in pre-ART care (from 42% to 72%), referred to as “L+P” and initiating people on ART 
at diagnosis (although with my  assumption regarding these improvements not being as 
optimistic as Granich et al. (686)). I found that 957,000 HIV infections can be averted over 20 
years, compared to if linkage and retention in pre-ART care are increased, and  831,000 
infections averted if people are initiated at diagnosis without improving the linkage and the 
retention in pre-ART care. 
Another model evaluated the impact on mortality of reducing the time to initiate ART in 
patients found eligible for ART (980). This was certainly an issue in the past and studies 
conducted in South Africa reported this issue in the early years of ART roll-out: up to 2005 
(293;981), nevertheless this is likely to be much less of an issue nowadays given the eligibility 
criteria to be initiated on ART has been raised from below 200 cells/μL to 350 cells/μL, by the 
fact that to my knowledge there are no longer  waiting list to be treated and the median CD4 
at diagnosis and ART initiation increased over time.  For this reason, and in order to fit with the 
number of people newly initiated on ART, I had to assume the probability of initiating ART 
within 3 months in patients in care increased over time up to levels of 0.95 by 2013.  
A mathematical model recently published (698) (see section 4.2.6), evaluated the impact of 
increasing the proportion who would come back to care in patients lost from care after ART 
initiation and compared this to modifying instead the eligibility criteria so that all people 
diagnosed with HIV are eligible for ART. Similarly to me, they found that improving retention 
on ART should be prioritized compared to modifying the eligibility criteria. 
 
A possible limitation of my analysis is the fact that instead of evaluating the long-term effect of 
precise scenarios such as, for example, tracing of patients LTFU or offer of transport voucher or 
food rations to retain people on ART, I assessed the cost-effectiveness of different 
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improvements at single steps of the cascade of care, assuming each of them roughly halves the 
proportion of people lost at each step. The reason for this choice is that I wanted to provide 
some indication regarding which steps attention should be focused on in the cascade of care, 
in terms of recommending areas where interventions could be useful.   
 
 
7.7. Conclusions 
In conclusion, this modelling exercise helps us to understand which scenarios will have the 
most impact on maximising life-years, and shows that improving retention on ART would have 
the greatest impact.  This analysis indicates that policymakers should seek to strengthen the 
cascade of HIV testing and treatment (in particular by improving retention on ART and switch 
to second-line treatment as appropriate) before raising the CD4 count eligibility criteria.  
Further research on what initiatives could improve implementation of ART, and how much 
these are likely to cost, would be very valuable. In the longer term, greatest health gains can 
be achieved by both improving implementation and increasing eligibility for ART, but this 
requires substantial commitment of resources. 
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8. Assessment of the potential impact and cost-
effectiveness of HIV self-testing in resource limited 
settings 
 
8.1. Introduction 
8.1.1. Background 
In RLS, many people living with HIV in need of ART still do not have access to treatment, or HIV 
care more broadly, due to being unaware of their HIV status. HIV testing in RLS has been 
increasing dramatically in the last five years, from a level of 20% of people living with HIV 
knowing their HIV status (10% overall) in 2005 and 2007 in countries with high HIV burden 
(982) to 50% in 2012 (983), and South Africa and Zimbabwe are not exceptions (see sections 
2.1.5 and 2.2.5). Nevertheless, at least 50% of people living with HIV are unaware of their 
status (984) and cannot therefore access HIV care and treatment and thus take measures  to 
reduce their risk of  infecting other people. In Zimbabwe, according to the last Demographic 
and Health survey (DHS) conducted in 2011, only 20% of men and 34% women had tested for 
HIV in the last year (519). The reasons for not actively seeking an HIV test through current HIV 
testing strategies provided by healthcare workers (standard voluntary counselling and testing 
[VCT], PITC, etc.) are numerous, including fear of stigma and discrimination, perceived lack of 
confidentiality, and the inconvenience and opportunity costs of testing.  
 
Given the need for expanding HIV testing uptake and frequency, it is important to consider 
new delivery strategies.  One such option is HIV self-testing (ST), which has been described in 
section 7.2.1.  Many of the barriers people encounter when having an HIV test may be 
addressed through the use of ST. For these reasons, stakeholders, including donors and 
government are considering whether investments should be made in developing and 
promoting the marketing and delivery of ST in RLS, in order to increase uptake of HIV testing.   
 
In both RLS and high-income countries regulated ST kits are generally not available, with the 
US and Kenya being among the few exceptions. In July 2012, the FDA approved the first kit 
which can be used for ST, the OraQuick In-Home HIV Test (985), which is now sold over the 
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counter in the US for US $40. The Kenyan government has promoted their use by, for example, 
making available 10,000 Calypte Aware HIV 1/2 Oral Mucosal Transudate rapid tests to the 
public in 2007, through the National AIDS and STD Control Programme. In addition, in sub-
Saharan Africa preliminary research on the use of ST has been conducted in Kenya (873), 
Malawi (755;871;872), Zambia (986) and South Africa (874;987) and studies are currently 
ongoing.  
 
8.1.2. Potential advantages and disadvantages of HIV self-testing 
The main advantages of ST over the standard HTC, provided by a healthcare worker, are its 
convenience, confidentiality and empowerment for users. These characteristics could 
potentially allow people who have never tested before to test but also increasing the 
frequency of repeat testing in those who have previously tested.  Empirical research on 
acceptability and uptake of ST in the general population (872) and among health workers 
(873;874) is very high, although the evidence is quite limited, while no data are available for 
other subgroups at high risk of HIV infection in sub-Saharan Africa (See section 8.2.2.1).  In 
addition, ST could reduce the overall cost of testing due to limited or no involvement of 
healthcare workers at the time of screening and the lack of requirement for infrastructure 
(988) (see section 8.2.2.7) and reduce transmissions, by making more people aware of their 
HIV status.  In fact, awareness of HIV status can have important consequences for risk 
behaviour. There is evidence from a systematic review on developing countries that people 
who receive VCT and test HIV-positive report lower condom-less sexual behaviour than people 
who did not receive VCT (48) and among those testing HIV-negative using VCT there is no 
evidence of higher condom-less sexual behaviour compared to those who did not receive VCT 
(48). The evidence is more mixed regarding the impact on sexual behaviour of PITC (47) and to 
my knowledge there are no data available from RLS on the potential change in risk behaviour 
following ST (see section 8.2.2.6). 
 
There are some concerns related to ST: firstly, the risk that people who self-test positive do not 
look for a confirmatory HTC and subsequently may not be linked to care (i.e. not receive ART 
eligibility assessment); secondly, the psychological impact of receiving an HIV-positive result 
without the immediate support of a person trained in post-test counselling, with potentially 
serious consequences. A cluster RCT conducted in Malawi (755) evaluated the impact of a 
proactive intervention to enable confirmatory HTC and linkage to care, home ART initiation, 
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highlighting the need for a proactive intervention following ST to ensure people engage into 
care upon a positive ST (See sections 8.2.2.3 and 8.2.2.4). In the same study, they collected 
information on coercive ST (872) (See section 8.2.2.5).  
 
Finally, accuracy of ST is a concern (989). The FDA approved OraQuick in-Home HIV test kit has 
shown very high sensitivity and specificity (over 99%) when conducted and interpreted by 
trained providers (985;990), and when conducted by lay people but read by a provider (991). 
However, when conducted by and interpreted by lay people, the specificity is still very high 
(over 99%) (871;874;985;992), while data on sensitivity are more variable (871;874;985;992) 
(See section 8.2.2.2).  
 
Formative research is currently ongoing regarding the accuracy of oral ST in the field, the 
acceptability across different subgroups of the population, how to deliver ST and how to 
ensure that people receive confirmatory test, if self-tested positive, and, once diagnosed with 
HIV, be linked to care and the potential harms of ST (993).  
 
8.1.3. Rationale and aim 
Mathematical models can provide insight into the potential impact of introducing ST at a 
population level over a longer term, and can help determine whether introducing free or 
subsidized ST kits would be cost-effective.  
Several mathematical models have evaluated the impact and/or cost-effectiveness of 
expanding HIV testing in high income countries (994-1000) and in RLS (972-974;979).  To my 
knowledge, the impact of introducing ST in RLS has not yet been evaluated.   
 
 
8.2. Methods 
To address this aim, the HIV Synthesis model, described in detail in Chapter 3 is used.  This 
section presents the main assumptions related to the introduction of ST, together with the 
evidence to support them and the details on how the analysis has been conducted. 
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8.2.1. Setting 
For this study, I calibrated the HIV Synthesis Transmission Model to reflect the HIV epidemic in 
Zimbabwe. This decision was driven by the need to model realistic gender and age specific 
levels of HIV testing and prevalence to accurately predict the impact of introducing ST. 
The choice of Zimbabwe as the setting was guided by several factors: first, the Zimbabwe 
government is interested in exploring ST; second, because I am involved in other projects in 
Zimbabwe and I have links with the Zimbabwe Ministry of Health and health economists 
working there and third, because I wanted to choose a country with a relatively high HIV 
prevalence to maximise the efficiency of the simulation for another project I am working on 
aimed at evaluating the potential impact and cost-effectiveness of using resistance testing in 
RLS to monitor people on ART. 
The HIV epidemic in Zimbabwe has been extensively described in section 2.2. Table 8.1 
summarizes the main demographic information for Zimbabwe and its response to the HIV 
epidemic. The population the HIV Synthesis model focuses on is the adult population aged 15 
to 65 years, which was estimated to be 7.5 million in mid-2013 (513). The HIV prevalence in 
people aged 15 to 49 years was at levels of 15% in 2011 (519), but as shown in Figure 8.1, it 
peaked in the mid-90s and has declined since then.  
As is the case in much of sub-Saharan Africa, HIV testing has been increasing dramatically in 
Zimbabwe in the last few years (see section 2.2.5). In the DHS conducted in 2006 and 2011, the 
estimated percentage who reported ever testing for HIV was in 2006, 26% for women and 19% 
for men and in 2011, 60% for women and 39% for men (519). The estimated percentage tested 
in the last 12 months, which better informs the current levels of testing compared to the 
percentage ever tested, increased from 7% in 2006 to around one quarter of the population in 
2011, with higher levels in women (34%) than in men (20%) and significantly lower levels in the 
youngest age group (15-19 years old: 18% in women, 7% in men) and in the oldest group 
considered (40-49 years old: 26% in women, 23% in men (519). In ANCs, in 2011, 59% of 
pregnant women were tested, received the result of the test and received HIV counselling 
(45% in women aged between 15 and 19 years) (519). 
ART is now widely available in Zimbabwe with  over 500,000 people receiving ART by the 1st 
quarter of 2013, representing 80% of those in need [based on the Zimbabwe 
recommendations at the beginning of 2013 (CD4<350 cells/µl) (228)]. Retention on ART is 
relatively high: 86% at 12 months from start of ART. 
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Table 8.1. Information on the HIV epidemic in Zimbabwe 
 Value Year Source 
Population 0+ years old (in million) 13.2 2013.5 CIA (513) 
Population 15-65 years old, n (in 
million) 
7.5 2013.5 CIA (513) 
HIV prevalence, 15-49 15.2% 2011 DHS (519) 
% ever tested 39% M, 60% F 2011 DHS (519) 
% of pregnant women attending 
ANCs tested for HIV 
59%* 2011 DHS (519) 
% tested in the last year 20% M, 34% F 2011 DHS (519) 
Number of adults on ART 544,158 1st quarter 
2013 
Global fund 
report(545) 
ART coverage 80% 2011 Zimbabwe Global AIDS 
response progress 
report (530)2012 
Of those who started ART 12 months 
ago, % known to be still on 
86% 2011 
*It refers to the last two years; ANC: Antenatal clinic; ART: antiretroviral therapy CIA: Central Intelligence Agency; 
DHS: Demographic and Health Survey; M: males; F: females;  
 
Figure 8.1 shows the HIV prevalence, gender-specific, in red for women and in black for men, 
reconstructed by the Synthesis model together with prevalence data estimated from nationally 
representative surveys (519) and other sources (514).  
 
Figure 8.1. Gender-specific HIV prevalence – reconstruction by the HIV Synthesis model 
 
DHS: Demographic and Health Survey; 
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8.2.2. Main assumptions relevant for the implementation of the introduction of 
self-testing 
8.2.2.1. Assumptions on scale up of HIV testing 
In the Synthesis model, HIV testing was assumed introduced in 1996 (see section 1.14.5). At 
that time I assumed 20% of the population were “resistant to HTC” (in the Synthesis model this 
means they have no possibility to getting tested for HIV unless symptomatic) and that this 
decreased linearly to 5% by the end of 2010. Limited data are available to inform this 
parameter (proxy variables are the proportion who reported never being tested for HIV and, 
more precisely, the proportion who refuse HTC); nevertheless I considered it important to take 
this into account, given the evidence that not everyone accepts HIV testing for various reasons 
(1001).  The level of acceptability of PITC in RLS is extremely variable from levels of 99%, 
observed in inpatients in Uganda (852) to 31% among outpatients in South Africa (1001). 
Among pregnant women the level of acceptability of PITC seems to be higher, varying from 76 
to 99.9% (851), while the estimated acceptability of HBT has been estimated in a meta-analysis 
to be 83% (754). This huge variability seems to be related mainly to the quality of the 
intervention delivered and to calendar time.   Acceptability seems to have increased over time 
due to the reduction in stigma and higher availability of ART.  
 
For the remainder  of the population (“non-resistant to HTC”), increasing gender and age-
specific rates of HIV testing (for the 1st time and of repeat testing) since 1996 were assumed, 
to reflect the level of testing observed in the DHS (519). Pregnant women experience an 
additional probability of being tested in the ANC, which increased over time (519). 
For people who never had condom-less sex (recall that the model does not distinguish 
between not having sexual intercourse and having a sexual intercourse using condom) a 3-fold 
reduction in the rate of testing was assumed.  This has been observed in the Zimbabwe DHS 
where people who reported never having had sex are less likely to test for HIV: the proportion 
ever tested for HIV in this subgroup was 15% in men and 17% in women and the proportion 
tested in the last year 8% and 9% compared to 20% and 34% in the population 15-49 years old 
overall (519).  
People with acute symptoms (WHO stage 4, 3 or active TB) are assumed to have a higher 
chance of testing for HIV in that 3 month period and a higher chance of being linked to care 
once diagnosed. In 2015 the probability of testing as a result of the symptoms was 0.8, 0.48 
and 0.12 for people with WHO stage 4 event, TB and WHO stage 3 event respectively. 
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Figure 8.2 and Figure 8.3 show, respectively, the proportion ever tested for HIV and the 
proportion tested for HIV in the last year in 2006 and 2011,  as assumed by the model and as 
observed in the DHS surveys in the different age groups (15-19,20-24, 25-29,30-39,40-49 and 
overall) among men and women (519). 
The model does not distinguish how the standard HTC is delivered, whether it is PITC, VCT or 
home-based HTC, but only on whether it is conducted by a healthcare worker (referred to as 
HTC) or by the individual him or herself (i.e. ST).  
 
Figure 8.2. Gender and age-specific proportion ever tested for HIV reconstructed by the 
model and observed in DHS surveys 
The percentages indicated in the graphs are the overall estimates from the DHS. DHS: Demographic and Health 
Survey;  
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Figure 8.3. Gender and age-specific proportion tested in the last year, reconstructed by the 
model and observed in the DHS surveys 
 
The percentages indicated in the graphs are the overall estimates from the DHS. DHS: Demographic and Health 
Survey;  
 
8.2.2.2. Assumptions on HIV self-testing and HIV testing and counselling accuracy 
Aspects to consider for any HIV test, whether conducted by a healthcare worker or as a ST, are 
the accuracy (sensitivity and specificity) and the time between HIV infection and when the test 
can reliably detect infection (the “window period”). As mentioned, poor accuracy of ST has 
long been a concern (989), but more recent studies have consistently found moderate 
accuracy, with variability across different ST kits.  The FDA approved OraQuick kit, when used 
and interpreted by lay people, has shown specificity over 99% (871;874;985;992), while 
sensitivity has been found to vary from 66.7 (95% CI: 30.9-91.0), reported in a small pilot study 
of unsupervised ST conducted among healthcare workers in South Africa (874), up to over 99% 
(871;992). In addition, minor procedural errors and request for extra help have been reported 
in a small proportion (10%) of populations evaluated (871). Accuracy has been evaluated for a 
few other HIV kits used for ST, including Calypte AWARE HIV-1/2 Oral Mucosal Transudate 
(1002;1003), Abbott Determine HIV1/2 (1004;1005), Capyllus HIV-1/2 (1005)  and Determine 
HIV Combo (1006). The latter test, in contrast to the other kits, can detect both antibodies and 
antigens, decreasing the HIV ‘window period’. There are several studies on-going evaluating 
the accuracy of kits for ST by lay people.  
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For the purpose of this analysis, I assumed the sensitivity of the ST to be 92% and the 
specificity 99%, as found in the studies conducted pre-FDA approval (985). The standard HTC, 
using rapid test, conducted by a healthcare worker, is assumed to be more accurate than ST; 
with a sensitivity of 98%, as it has been estimated (990) and a specificity of 100%. The 
specificity of the HTC is believed to be relatively high, I assumed it to be 100% because 
confirmatory tests are conducted when a person has an initial HIV-positive test and therefore 
it is unlikely that a person will be diagnosed with HIV if not infected. The other reason for 
assuming the specificity to be 100% is that it was an issue to simulate in the model elements, 
such as VL, in people who are diagnosed HIV-positive when not infected with HIV. In addition, 
both HIV tests, whether conducted by a trained person or as ST, are assumed to be an 
antibody tests and therefore not able to detect HIV infection during the first 3 months since 
HIV infection. This is the window period usually reported and it is the minimum it can be 
assumed in the Synthesis model given variables are updated 3-monthly. 
 
8.2.2.3. Assumptions on probability of having a confirmatory HIV testing and counselling 
following a positive HIV self-test 
A crucial modelling parameter is how many of those who test HIV-positive using ST have a 
subsequent confirmatory test conducted by a healthcare worker, which can allow them to be 
truly diagnosed from the perspective of the healthcare system and provides the first stage in 
linkage to care. This parameter will be difficult to measure given the confidentiality inherent in 
ST. Some indication comes from a study conducted in Malawi (872), where 89% of used ST kits 
were anonymously returned. Analysis of results of these used ST kits suggests that 75% of 
positive results were disclosed to a counsellor. If this disclosure means they had a confirmatory 
HTC this would suggest around 75% of positive people were formally ‘diagnosed’ (i.e. received 
a confirmatory HIV test performed by a trained person). 
In the Synthesis model, I assumed that once a person has a positive result using ST, an HTC, 
performed by a trained person, is necessary in order for the person to be considered 
“diagnosed with HIV” and therefore potentially being linked to care and eventually being 
initiated on ART. I assumed people who had a positive ST result had an 80% chance by 1 year 
of having a confirmatory HTC as a direct consequence of the ST. After more than 1 year since 
the positive ST result, if an HTC has not been done, the probability of having a HTC as a direct 
consequence of the positive self-test is 0 (see Figure 8.4).  
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Figure 8.4. Proportion of people who received a confirmatory HIV testing and counselling 
performed by a healthcare worker as a direct consequence of a positive self-test by different 
time points 
  
HTC: HIV testing and counselling; 
 
8.2.2.4. Assumptions on linkage to care and eligibility criteria to initiate ART 
A further concern is the possibility for low linkage to care, as well as differential retention in 
care, once a confirmatory HTC has been done (i.e. the person is truly diagnosed, from the 
health system perspective). This is an issue providers already struggle with under the current 
HIV testing strategies. If the population choosing to self-test is fundamentally different from 
those who choose to have standard HTC (for example, more marginalized), it is possible that 
retention in care after diagnosis may be more challenging. In the study conducted in Malawi, 
one year after ST and with home-assessment being available 78% of those who disclosed their 
reactive ST result to counsellors linked to care (872).  There are no other data on this topic, to 
the best of my knowledge though research is currently underway.  
I assumed linkage to care following diagnosis, (where diagnosis is defined as a positive result to 
an HTC) to be 60% at one year since diagnosis. When this analysis was conducted the data by 
Choko et al. (872) were not yet available , therefore if anything I may have underestimated the 
impact of ST. A systematic review on linkage to care in sub-Saharan Africa found that the 
proportion of people who received CD4 count results or clinical staging by one year since 
diagnosis was 59% (median; range: 35%-88%) (551). I assumed that those who were 
diagnosed, as a consequence of having a positive ST, once diagnosed with HIV had the same 
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chance of being linked to care as those who were diagnosed with HIV without having a 
previous positive ST. 
Once in care the eligibility criteria to initiate ART was assumed to be CD4 <500 cells/μL, in line 
with the Zimbabwe (229) and WHO ART guidelines (280). On the other hand, I did not model 
potential future implementation of prevention of mother-to-child transmission (PMTCT) 
option B+ (provision of life-long ART for pregnant and breast-feeding women).  
 
8.2.2.5. Assumptions on psychological impact of HIV self-testing 
An additional concern is regarding the psychological impact of receiving an HIV-positive result 
without the immediate support of a trained counselor.  In terms of modeling, this could have 
implications for cost-effectiveness, since a lower quality of life among a proportion of those 
who test positive using a ST would be factored into measures of effectiveness (QALYs or 
DALYs).  A study conducted in Malawi in the general population reported that 2.9% of the 
participants who self-tested were coerced into HIV testing and men were more likely to be 
coerced than women (872). However, 94% of those who were coerced into ST would still 
recommend ST and so it remains unclear whether this finding should be a serious concern. 
No other data are available to my knowledge from RLS in this regard and no serious harms 
have been reported in other settings (988). In addition, there are no data available regarding 
the psychological impact via other testing methods (988). Research studies assessing the 
impact of introducing ST are currently collecting information on potential social harms or 
abuse associated with ST. For this reason I did not assume any reduction in the quality of life 
after conducting an ST or a standard HTC. 
 
8.2.2.6. Assumptions on change in risk behaviour following an HIV test 
Learning one’s HIV status may lead to behaviour modification to reduce the risk of becoming 
infected, or of infecting others. A meta-analysis reported that people who test HIV-positive 
through VCT in LMIC have significantly lower odds of reporting an increased number of 
partners, compared to those who did not have an HIV test (OR = 0.61; 95% CI: 0.37, 0.997; p = 
0.048) and higher odds of reporting condom use (OR = 3.24; 95% CI: 2.29, 4.58; p < 0.001) (48). 
Among those who tested HIV-negative, there was no evidence of behaviour change, (although 
only a couple of studies evaluated this (1007;1008)). With PITC (47), most studies, but not all, 
reported an increase in condom use among different subgroups of the population and in 
different countries, in both people who tested HIV-negative and positive. Regarding ST, to my 
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knowledge, the only data available come from a study among MSM in New York, which  
reported that the 10 people identified as HIV-positive through ST did not have sexual 
intercourse after learning their result (1009). 
The model assumes that there is no change in condom-less sex in people who test HIV-
negative, while those who test HIV-positive reduce condom-less sex with casual partners by 
17% in the first 8 months (9% afterwards) and by 13% with CLLT partners. The same behaviour 
is assumed following ST. 
 
8.2.2.7. Assumptions on HIV self-testing and HIV testing and counselling cost 
A few studies have highlighted that the cost could potentially be a significant barrier to 
accessing ST, even in high income countries (991;1010;1011), given that where currently 
available ST kits must be purchased while HTC is generally free.  In a study in Singapore only 
28% of respondents reported they would pay at least US $15 for a self-test kit (991).  In a study 
among MSM in Seattle similar findings were reported: 13% would only use ST if it was free, 
and 42% would pay US $20 or more for a ST kit (1011). Cost is likely to be an even greater 
barrier to ST in RLS.  
Research studies on ST so far have distributed ST kits for free in order to evaluate the 
acceptability and accuracy of ST and if provided, pre-test counselling and demonstration on 
how to use ST kits has been provided by community counsellors (755), likely at a lower cost 
than if delivered by a healthcare worker. Studies in which people were repeating ST in RLS 
have not been conducted, but it is possible that the pre-test counselling could be reduced and 
maybe even omitted when repeating ST. 
The cost of the rapid HIV test kit used in the clinic is relatively low. In RLS it ranges between US 
$0.50 and US $2 (1012). Although the cost WHO and other agencies pay for the oral fluid–
based test, OraQuick (the version to be used by trained people), in RLS is among the highest 
among the leading rapid tests, costing around US $4 (1013). The price is variable depending on 
the country and volume purchased. Moreover, the method of distribution is likely to have a 
major impact on the cost of ST.   The overall cost of delivering the HTC, including distribution of 
the kit, infrastructure, personnel cost is substantially higher than the cost of delivering ST. On 
average, it has been estimated to be US $10 in a study in Zambia (692), with a much higher 
cost for conducting an HIV-positive test, mainly driven by the post-test counselling, compared 
to an HIV-negative test. I assumed the fully loaded costs of a HTC being US $9 for a negative 
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test and US $25 for a positive test or a confirmatory test following a positive ST, so that the 
average is around US $10. 
The cost of ST is assumed to be US $3 per unit. There are no data on the fully loaded costs of 
delivering ST in RLS mainly because it has not been scaled yet at national levels and the cost is 
likely to depend on how the self-tests are distributed. 
 
8.2.3. Analysis details  
I used a single simulation of the Zimbabwean HIV epidemic until 2015 based on a single set of 
parameter values, with levels of HIV prevalence, proportion ever tested and tested in the last 
12 months comparable to those observed in the DHS (519) (see Figure 8.1 at page 326, Figure 
8.2 at page 328, Figure 8.3 at page 329).  
From 2015, I compared two possible base case scenarios: a reference scenario (RS), where ST 
is not introduced and there is continued reliance on HTC alone and the ST scenario, where ST is 
made available to the general population aged 15-65 years from 2015.  In the reference 
scenario, the rates of first time and repeat testing increase linearly by 0.005 per year (the 
proportion tested for HIV in the last year is 37% in 2015 increasing up to 50% in 2035) and the 
rate of being linked to care, retained in pre-ART care and initiated on ART, if eligible, continues 
as before 2015. Multiple runs were simulated from 2015 for 20 years to reduce stochastic 
variation. Figure 8.5 shows the modelled proportion non-resistant to HTC test (willing to 
receive an HIV test), the proportion ever tested for HIV and the proportion tested for HIV in 
the last year from the epidemic start to 2035. 
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Figure 8.5. Summary of the assumption on HIV testing in the reference scenario 
 
The introduction of ST is assumed to have three main effects: 
 halving of the population unwilling to receive a HTC (from 5% to 2.5%) 
 substitution of 10% first time and 30% repeat HTC with ST 
 increase in the rate of first time and repeat testing by 20%, due to the availability of ST 
Availability of ST is not assumed to affect HTC conducted in ANC. These assumptions are based 
on limited current evidence available (described in sections 8.2.3.1-8.2.3.3) but overall are 
believed to be conservative in estimating the potential benefits of ST.   
 
8.2.3.1. Data on uptake of HIV self-testing among those resistant to HIV testing and 
counselling 
In sub-Saharan Africa, a few studies have evaluated hypothetical acceptability of ST (871;987), 
and some the actual uptake of ST when made available, and in particular among people who 
are resistant to testing by existing available means (871-874). A study conducted in Malawi, 
where ST was made available through community counsellors, found that 76% of over 16,000 
residents had used ST at 12 months since its introduction, with 43% being first time testers 
(872). A study conducted among healthcare workers in 7 hospitals in Kenya found that the 
uptake was 89%. Among healthcare workers who self-tested, most (92%) had tested before, 
and from these data I cannot estimate how many of those who accepted the self-test were 
resistant to HTC (873). Similarly a pilot study conducted among healthcare workers in Cape 
Town, reported a 93% uptake of unsupervised ST (874), with 13% being first time testers. 
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Other studies have evaluated the uptake of ST, without distinguishing whether these people 
were resistant to HTC or not, or on whether they were first-time or repeat tests, but not in 
sub-Saharan Africa (1009).  A recent meta-analysis, including all the studies published at the 
time of its preparation (3 studies), estimated uptake of ST to be 87% (862).  While studies are 
few and may not be generalizable, they represent the available data regarding the uptake of ST 
and more specifically the potential uptake among those who may currently be resistant to 
HTC. Formative research is currently being conducted in Kenya and Zimbabwe to evaluate 
acceptability and/or uptake in subgroups of the population at high risk for HIV infection, such 
as MSM, sex workers and serodifferent couples. 
 
8.2.3.2. Data on impact of HIV self-testing availability on the rate of HIV testing among 
those not resistant to HIV testing and counselling 
I am also interested in the extent to which availability of ST would, by providing a convenient 
and confidential option, increase the probability of testing in people who are not resistant to 
HTC but who have never been tested before; similarly, I am interested in the frequency of 
repeat ST. To my knowledge the only relevant information comes from a study among MSM in 
Australia (1014), unlikely to be applicable in the context of sub-Saharan Africa. No data on the 
long term impact of ST availability on the frequency of HIV testing are available. Reasonably, 
the research thus far has focused on evaluating accuracy, acceptability and uptake of ST. 
 
8.2.3.3. Data on the substitution of HIV testing and counselling, conducted by a 
healthcare worker, with HIV self-testing 
A further important consideration when modelling the potential effectiveness and cost-
effectiveness of ST is what proportion of future tests (that would have occurred under 
provider-delivered strategies), would be conducted via ST if available.  Again, this might be 
different for first time versus repeat testing and will depend on the cost of different strategies. 
It may be cost-saving to introduce ST if its provision is less expensive than HTC, despite its 
lower sensitivity and the necessity for a confirmatory HTC for those self-testing positive.  
 
It is therefore important to quantify the extent of uptake of this substitution and the 
characteristics of those who would substitute HTC with ST, particularly regarding sexual 
behaviour. The only research which provides some indication of this parameter is reported 
preferences for ST versus HTC methods, and these data are largely from high income countries 
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(871;1004;1015-1018). I may not be able to accurately estimate this parameter until ST is more 
widely available. For example, 38.9% of MSM in Madrid reported that ST would be the most 
favorable way of receiving an HIV test (1015), 61% of known HIV-positive people recruited in a 
clinic in Seattle reported that they would have preferred to self-test if they did not know their 
status (1016), and among people attending an HIV testing facility in the US 89% would have 
preferred to self-test (1004). Of those who took part in an evaluation of ST in tablet computer-
based-kiosks within the emergency department, 96.9% reported they would "probably" or 
"definitely" test themselves at home if ST kits were available to buy, but 26% preferred ST 
compared to 34% who preferred HTC (1018). From RLS, among potential HIV testers in India, 
86% preferred ST over clinic-based testing (1017), and in a study conducted in Malawi 92% of a 
general population of community members opted for supervised ST (ST followed by 
confirmatory HTC) over standard VCT (871).  
 
8.2.3.4. Sensitivity analysis 
The parameters characterized by more uncertainty were varied in sensitivity analysis to 
understand how they affect the results (see section 8.3.2) and therefore what the impact 
might be if the main assumptions are not correct. Nine parameters were varied in univariate 
sensitivity analyses:  cost of ST, sensitivity of ST, probability of confirmatory HTC as a direct 
consequence of a positive ST, probability of being linked to care by one year after a positive 
HTC (whether prompted by a ST or not), reduction in condom-less sex for those diagnosed 
with a positive ST, eligibility criteria to initiate ART, magnitude of increase in the rate of first 
and of repeat testing due to the introduction of ST, and the level of substitution of ST for HTC.  
The three most determinant parameters of cost-effectiveness were also varied in bivariate 
analyses to explore whether there were particular combinations of these parameters where ST 
was cost-effective.  
 
8.2.4.  Assumptions on health benefits and costs  
The two scenarios (RS and ST scenario) were compared on the basis of their costs and health 
outcomes (729). Health outcomes are expressed in terms of DALYs averted, which take into 
account both improvements in survival, quality of life associated with averted HIV infections 
and reduced HIV symptom burden in people receiving ART (733). Both the DALYs and the costs 
(See Table 8.2), from a healthcare prospective, are summed over a 20 year time horizon 
starting in 2015, rescaled to provide figures relevant to the entire adult population of 
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Zimbabwe and discounted by 3% per annum in accordance with WHO-CHOICE 
recommendations (729).   
 
In order to calculate the DALYs the disability weights used are (733):  
 0.55: for WHO 4 event 
 0.40: for TB 
 0.22: for WHO 3 event 
 
Table 8.2. Unit costs and their sources 
Item Cost (US $) Sources where available 
ART cost (1st line: TDF+3TC+NVP)  $97 PY (969) 
ART cost (second-line AZT+3TC+ATZ/r) $279 PY (969) 
Supply chain of ARVs 20% of the cost of ARVs - 
WHO stage 4* $200 - 
WHO stage 3* $20 - 
TB* $50 - 
CTX $5 PY - 
Clinic Visit $20 - 
CD4 measurement   $10 - 
HTC (all costs fully loaded)  $9 for negative, $25 for 
positive, on average $10 
(692) 
ST $3 Assumption 
*This cost is incurred every 3 months where the person has this condition; 3TC: lamivudine; ART: antiretroviral 
therapy; ARVs: antiretroviral drugs; ATZ/r: atazanavir boosted with ritonavir; AZT: zidovudine; CTX: co-trimoxazole; 
HTC: HIV testing and counselling; NVP: nevirapine; PY: per-year; ST: HIV self-testing; TB: tuberculosis; TDF: 
tenofovir; 
 
Results from cost-effectiveness analyses inform us on the cost to gain a life-year or to avert a 
DALY compared to the cheapest option. This information is important for the decision maker 
and it is usually compared to the CET  (See section 4.3.2.2) (i.e. the “willingness to pay” to gain 
a life-year or to avert a DALYs), which, as mentioned in section 4.3.2.2,  is usually below three-
times the country’s per capita GDP (Zimbabwe US $ 500 in 2012 (1019)) (729).  
Results are presented across a range of CET: from $0 (an extreme case, implying a health 
system would only be concerned with reducing costs) to $10,000 (a relatively high threshold 
only likely to be relevant in well financed health systems with full coverage of interventions 
offering health gains at less than this amount).   
Due the stochastic variation inherent in the model a high number of simulations are required 
so figures are presented on a discrete rather than a continuous scale. 
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8.3. Results 
8.3.1. Main results 
Introduction of ST, as assumed in the base case scenario, led to a 6% higher proportion tested 
for HIV in the past year compared to the reference scenario in 2035 (56% vs 50%, see Table 
8.3) and to 83% of the population ever being tested for HIV, compared to 79% if ST is not 
introduced. Although it is assumed ST would result in a slightly higher proportion of the 
population ever tested and tested in each year, it results in a very similar proportion of people 
diagnosed with HIV (<1% higher for ST scenario), because not all those who receive a positive 
ST would access a confirmatory test performed by a health care worker and would therefore 
be considered diagnosed. Thus, as only people diagnosed can be linked to care and eventually 
be initiated on ART, the proportion on ART is very similar as well. 
The total discounted costs over 20 years for HIV testing and resulting HIV care and ART under 
the reference scenario base case assumptions is estimated to be almost US $3.2 billion (see 
Figure 8.6).  Of this, 43% is attributable to the cost of ARVs, around a quarter to the cost of 
clinic visits and almost 20% to HTC.  The ST scenario, would lead to savings over 20 years of US 
$53 million (95% CI: 49, 58 million), a reduction of 1.7% in costs, due primarily to a partial 
replacement of more expensive HTC conducted on HIV-negative people with cheaper ST, 
although the cost of diagnosing a positive person would be slightly higher, because this person 
would receive a ST ($3), before being identified as positive with an HTC ($25).  The 
introduction of ST would result in a relatively small health gains, with approximately 102,000 
DALYs averted (95% CI: 62,000-142,000) (see Table 8.4 at page 342), because it allows to 
identify slightly more people as positive and slightly higher number of people receiving ART. As 
the introduction of ST (as specified) produces health benefits and allows saving money, it can 
be considered cost-saving. 
 
Table 8.3. Predictions over time in the two main scenarios (median over simulations) 
 Data Model 
DHS (519) Baseline Reference Self-testing 
2011 2015 2025 2035 2025 2035 
HIV prevalence (%) 15 14 11 7 11 7 
% ever tested for HIV 50 65 77 79 80 83 
% tested for HIV in the last year 28 37 46 50 53 56 
% diagnosed - 83 94 96 95 96 
% on ART (of those HIV+)  - 53 71 76 71 76 
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ART: antiretroviral therapy; DHS: Demographic and Health Survey;  
 
Figure 8.6. Total discounted cost over 20 years in US $ billions 
ART: antiretroviral therapy; CTX: co-trimoxazole; HTC: HIV testing and counselling; RS: reference scenario; ST: HIV 
self-testing; STS: HIV self-testing scenario; TB: tuberculosis; 
 
8.3.2. Sensitivity analyses 
I conducted several sensitivity analyses to evaluate whether the results were robust to 
changes in the main parameters. Table 8.4 (page 342) summarizes the cost-effectiveness of 
the base case and alternative assumptions in sensitivity analyses at different CETs, as well as 
the increments in total discounted costs and total discounted DALYs averted (with 95% CI) with 
ST scenario compared to the reference scenario.   
 
In general, for any scenario in which DALYs are averted, the probability that ST is cost-effective 
will increase with increasing CET, because at some point the cost of the DALYs averted become 
affordable.  In contrast, for scenarios which lead to a loss in DALYs, ST is less likely to be cost-
effective with increasing CET because at some point the money saved from ST scenario is not 
worth the loss in DALYs.   
 
The results are particularly driven by costs.  If the cost of ST is the same as a negative HTC test 
(US$ 9) it is only cost-effective at a CET of US $5,000 per DALY averted or more because it 
results in higher costs (US $118 million greater than under reference scenario), but relatively 
small health gains.  If, however, ST was to cost US $5 or less, then the ST scenario would be 
cost-effective even at a CET of US $500, keeping other base case assumptions fixed (Table 8.4 
at page 342, Figure 8.8 at page 343 and Figure 8.9 at page 344). 
The level of substitution of HTC with ST affects the results, at first sight, in a slightly counter-
intuitive way (See Figure 8.7 at page 343). The reason why at a low CET, once  a certain level of 
substitution occurs (horizontal axis), the introduction of ST is cost-effective, regardless of the 
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probability of HTC as direct consequence of a positive self-test (and therefore the chance of 
being diagnosed), is that at low CET whether an intervention is cost-effective is determined 
mainly by the costs. The substitution of more expensive HTC with ST in negative people allows 
saving money and even if it does not result in a health gain, it results as cost-effective. 
However, at higher CETs more concern is given to health gains meaning that ST is only cost-
effective at higher levels of substitution if it is likely to lead to a confirmatory HTC resulting in 
future health gains for patients, because patients once self-tested positive have a high chance 
of being diagnosed and therefore access HIV care and treatment.  The programmatic 
implication is that high levels of support to ensure linkage to care are likely to offer even 
greater value in better resourced health systems, but ST support programmes are likely to be 
important in all settings for ST to be effective in improving health.   
Both Figure 8.8 (page 343) and Figure 8.9 (page 344) illustrate that ST is clearly more likely to 
be cost-effective the lower the cost of ST, and in particular even if the CET is of $1,000 
(assuming the other parameters do reflect reality) ST cannot cost more than $8, but for this to 
be so high, only a very modest increase in ST must occur (Figure 8.8). Figure 8.8 shows that if 
the substitution of standard HTC with ST is modest (for example 20% for the substitution of 
repeat test and 7% for first time test), the cost of ST has to be low: $3 or less if the CET is $1 
and up to $4 at higher CET.  However if the level of substitution of HTC with ST is higher, more 
money can be spent for each ST and it would still result as a cost-effective intervention.  
Regarding the levels of increase in the rate of first test and of repeat testing due to the 
availability of ST (Figure 8.9 at page 344), I found that the greater the levels of increase, the 
greater the health gains associated with ST but also the greater the cost.  Therefore, as the 
CETs increase the health gains from ST become relatively more important and more expansive 
use of ST would be preferred.  This also has important programmatic implications for delivery 
of ST and shows that appropriate targeting of ST is likely to be particularly important in less 
well-resourced health systems.  
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Table 8.4. Cost-effective scenarios (HIV self-testing- or reference scenario) under base case and alternative assumptions, according to cost-effectiveness 
threshold 
 
Cost-effectiveness threshold in US $ Total incremental 
discounted costs* in US 
$ millions, compared to 
RS (95% CI) 
Discounted incremental 
DALYs averted* in 
thousands, compared to 
RS (95% CI) 
0 500 1,000 5,000 10,000 
Base case (See section 8.2.3) STS STS STS STS STS -53 (-58;-49) 102 (62;142) 
Cost of ST = US $9   (B: US $3) RS RS RS STS STS 123 (119;127) 102 (62;142) 
Sensitivity of ST = 0.55 (B: 0.92) STS RS RS RS RS -77 (-81;-74) -157 (-193;120) 
Probability of HTC as a direct consequence of a pos ST = 0.37  
(B: 0.8) 
STS RS RS RS RS -79 (-83;-75) -166 (-203;-130) 
Probability of linkage to care following diagnosis for those who had 
a ST by 1 year = 0.4 (B: 0.6) 
STS STS RS RS RS -93 (-98;-88) -166 (-211;-122) 
ART initiation at CD4 < 350 cells/μL (B: CD4 < 500 cells/μL) STS STS RS RS RS -159 (-163;-155) -252 (-293;-211) 
No reduction in condom-less sex following a pos ST (B: as HTC) STS STS RS RS RS -75 (-79;-70) -129 (-173;-86) 
Increase in rate of 1st test due to ST (B: 20%) 2.5% STS STS RS RS RS -86 (-92;-79) -141 (-206;-76) 
7.5% STS STS RS RS RS -85 (-91;-77) -138 (-202;-75) 
Increase in rate of repeat test due to ST (B: 20%) 2.5% STS STS RS RS RS -100 (-106;-94) -117 (-176;-57) 
7.5% STS STS RS RS RS -93 (-98;-88) -96 (-144;-47) 
Substitution (B: 30% repeat, 
10% 1st test) 
5% of repeat, 2% 1st test RS STS STS STS STS 47 (42;53) 209 (163;255) 
15% of repeat, 5% 1st test STS STS STS STS STS -2 (-11;8) 139 (55;223) 
25% of repeat, 8% 1st test STS STS STS STS STS -35 (-43;-26) 118 (36;198) 
B: base case assumptions; CI: confidence interval; DALY: disability-adjusted life-year; HTC: HIV testing and counselling; pos: positive; RS: Reference scenario; ST: HIV self-testing; STS: HIV self-testing 
scenario; the discounted total cost of the RS over 20 years from 2015 is US $3,168 million. 
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Figure 8.7. Cost-effective scenario under different assumptions of substitution and 
probability of HIV testing and counselling as a direct consequence of a positive self-test 
 
CET: cost-effectiveness threshold; HTC: HIV testing and counselling; ST: HIV self-testing 
 
Figure 8.8. Cost-effective scenario under different assumptions of substitution and cost of 
self-test 
 
CET: cost-effectiveness threshold; ST: HIV self-testing; 
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Figure 8.9. Cost-effective scenario under different assumptions of increase in the rate of 1st 
test and of repeat test and cost of self-test 
CET: cost-effectiveness threshold; ST: HIV self-testing 
 
 
8.4. Discussion  
ST holds the promise of expanding the reach of HIV testing.  It may enable some people to test 
who would otherwise not choose provider-based HTC due to issues of stigma, confidentiality, 
cost, or other barriers to access. It may also support more frequent testing for all in the 
population due to greater convenience.  As the basis for affirming HIV status, leading to linkage 
to care, receipt of ART for those eligible, as well as prompting individuals who learn they are 
HIV-positive to reduce the risks of onward HIV transmission to others, the potential health 
gains from ST are clear.  What is more, my results show that ST may also reduce costs, enabling 
savings in HIV testing programmes that can be reinvested in further expansion of testing or in 
delivery of other HIV and healthcare interventions. 
 
Overall, given the characteristics of ST specified in the base case assumptions, I estimate that 
the introduction of ST will allow savings of around US $50 million over 20 years in Zimbabwe, 
with a modest (102,000, in the context of an adult population of 7.5 million in mid-2013) 
number of DALYs averted.   If these assumptions hold in other settings, ST should always be 
introduced regardless of how poorly or well-resourced a health system is – it leads to a win-
win situation of better health outcomes at reduced cost.  If I assume a CET of $500 (similar to 
Zimbabwe per capita GDP in 2012), the US $50 million saving could be used to avert at least 
100,000 DALYs by introduction of interventions with ICERs ≤ $500 per DALY averted.  The 
monetary value of introducing ST to Zimbabwe (calculated as net monetary benefit: health 
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gains times CET plus cost savings (730)) would be US $104 million over 20 years; indicating 
huge benefits associated with supporting the availability of ST in the country.   
 
However, the population costs and health effects of ST depend upon a range of complex and 
interacting factors, and not all plausible scenarios will unambiguously result in health gains 
and/or lower costs.  The sensitivity analyses provide insight into what determines the 
magnitude of population health gains and suggest what programmatic recommendations may 
support optimal implementation of ST.   
Firstly, the cost of ST relative to HTC appears to be the most important factor determining 
cost-effectiveness, particularly at lower CETs.  The OraQuick HIV test kit designed for clinical 
use was sold for US $4 in low income countries in 2005 (1013).  Lower cost alternatives to ST 
would lead to additional gains. The cost of distributing ST cannot be ignored, but it is expected 
to be significantly lower than the cost of providing HTC. To the best of my knowledge, data on 
the cost of rolling out ST are not currently available, and the only study conducted in sub-
Saharan Africa evaluating the uptake of ST distributed the kit through community counsellors 
(755).    
Secondly, I evaluated the impact of introducing ST in addition to HTC in a setting such as 
Zimbabwe, with a high level of HIV diagnosis and ART coverage; in 2015, before the 
introduction of ST, an estimated 82% of people with HIV are diagnosed. It is likely that the 
impact of introducing ST would be even greater the higher the proportion of people with HIV 
who are undiagnosed.  
Thirdly, in some circumstances, ST may lead to improved health outcomes but also higher 
costs as compared to the reference scenario, if the overall level of testing (i.e. the increase in 
the rate of first time and repeat testing) increases dramatically due to the availability of ST.  
The few studies conducted so far on uptake of ST have found it to be extremely acceptable 
(872-874). Studies in Malawi, for example, have shown that 76% of adult avail themselves of 
ST by 12 months following its introduction (872).  In settings with higher CETs the potential for 
health improvement will usually outweigh higher costs, but when the CET is lower the cost 
burden from an increased number of tests will be felt more acutely.  Appropriate targeting of 
ST is likely to be necessary in such situations.   
There is also a risk in some circumstances that ST may lead to worse health outcomes if ST is 
substituted for HTC but the likelihood an individual will receive confirmatory HTC is low. This 
suggests that, to be translated into health gains, there is perhaps a limit to the degree to which 
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ST should be substituted for HTC, and importantly, that ST needs to be accompanied by 
proactive interventions to support confirmatory HTC. A study in Malawi (755) investigated one 
scheme that could provide complementary benefits - offering ART initiation at home among 
people who self-test - and found this significantly increased the probability of initiating ART 
within 6 months.   
Finally, there is always potential for unintended adverse consequences associated with any 
public health intervention, so countries should closely monitor their experiences with 
introducing ST. Linkage to care, promoting counselling services, reporting of testing outcomes 
needs to be strengthened in support of such public health interventions.  
 
There are a few limitations which affect these analyses. First I assumed that people who are 
“resistant to HTC” are a random sample of the population. The people who are classified as 
“resistant to HTC” are in fact not likely to be a random sample, but possibly more marginalized, 
or people with many sexual partners who fear stigma in attending the clinic. The Synthesis 
model could incorporate the effect of age, gender and condom-less sex, for example, as data 
accrue to inform the magnitude of any effects. The issue is finding good evidence to inform 
this parameter.  
Another limitation, linked to the previous one, regards the characteristics of people who opt 
for ST. Again I evaluated the introduction of ST in the entire population aged 15-65 years, 
assuming the uptake of ST is random among those non-resistant to HTC. Since the earliest 
debates on ST, one of the advantages cited has been the potential for increased 
confidentiality, which could appeal to marginalised groups more affected by stigma, such as 
sex workers and MSM. To my knowledge there are no data available yet on the characteristics 
of those who opt for ST rather than HTC, except for some data regarding uptake of ST by age 
(872),  and on the uptake of ST in marginalized groups.   
Mathematical models are a simplification of reality, so they would not include all variables 
which characterize these groups. The Synthesis model for example could incorporate 
dependence on age, gender and sexual behaviour while other models may include specific 
subgroups, characterised by different routes of HIV transmission. This parameter is particularly 
important because if ST availability encourages testing in those resistant to HTC, and who are 
at increased risk of HIV, this could impact their risk behaviour and/or their infectiousness (if 
they receive ART), and therefore the number of new infections they contribute to. 
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8.5. Conclusions  
In conclusion, these results suggest that the introduction of ST may well be not only cost-
effective, but cost-saving under the assumptions described in the base case scenario.  Under 
these assumptions, ST should be made available even in the most resource constrained 
settings.  It has great potential to increase knowledge of HIV status in RLS, where over half of 
HIV-infected individuals are currently unaware of their status.   
Notably, in some circumstances it may be necessary to target ST to those with certain risk 
factors and it is likely ST will need to be accompanied by other measures to encourage 
confirmatory HTC. 
This analysis and mathematical modelling more generally can help to answer this question, 
though field data is required in order to accurately estimate important model parameters.  
While some data exist on the acceptability, uptake and accuracy of ST, there are several 
parameters for which evidence is limited. To increase the accuracy of this model and better 
inform policy making it is necessary to collect more data from well-powered studies on the 
cost of ST, the magnitude of replacement, the probability of having a HTC test following a 
positive self-test and the magnitude of increase in the rate of first and repeat testing if ST is 
introduced.   
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9. Summary and Conclusions 
 
9.1. Summary of main findings 
The discovery of highly effective ARVs and the increased availability of these treatments in 
sub-Saharan Africa, by far the area of the world most affected by this epidemic, means that 
many people now have a life expectancy than seemed impossible only a few years ago.  
However, despite extraordinary advances in the scale up of HTC and ART availability, many 
people still cannot benefit from them. By the end of December 2012, 9.7 million in LMIC were 
estimated to be receiving ART, of which 1.7 million initiated on treatment over 2011 (764). 
Further efforts are needed to reach the target of 15 million people receiving ART by 2015.  
Donors and stakeholders are faced with important decisions on how to maximise the health 
benefit, given the limited resources available, taking into account potentially negative 
consequences of these interventions, and which interventions provide the greatest value.  
 
In Chapter 1, after a brief introduction on the biology of the virus, I reviewed how the HIV virus 
is transmitted, how the disease progresses in people infected with HIV, which treatments are 
available and recommended for HIV-positive people, how ART resistance can develop and be 
transmitted and the HIV prevention methods available included in the Synthesis model; while, 
in Chapter 2, I provided a short background on the HIV epidemic in South Africa and in 
Zimbabwe. This extensive introduction was necessary, given that all these components are 
related or included in the Synthesis model of HIV transmission, progression and the effect of 
treatment, which is used to address four of my research questions. Increasing focus has been 
placed on resistance to ART, because this is a growing concern in countries where ART is scaled 
up and not many mathematical models capture this factor, particularly not in a way that is 
specific to ARVs.  In developed countries, patients usually receive a resistance test before 
initiating ART to determine whether they have any detectable DRMs (due to TDR or previous 
use of ART) so that they can be initiated on fully active regimens. In LMIC this is not the case. In 
addition, while VL monitoring is usually routinely conducted in developed countries to identify 
treatment failure in a timely way, this is not the case in most countries in sub-Saharan Africa. 
South Africa is an exception, VL monitoring has been available there and recommended to 
monitor people on ART; nevertheless many people are not switched to second-line even after 
prolonged VF. Factors which facilitate the development of resistance are suboptimal 
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adherence and TIs. The latter has been found to be relatively common in sub-Saharan Africa 
for various reasons including drug stock outs, difficulties for patients in attending the clinic due 
to competing priorities or because of the distance from the clinic. All these factors contribute 
to the onward transmission of HIV drug resistant virus. 
 
Chapter 3 describes the HIV Synthesis transmission model, which is used to address the 
research questions addressed in Chapter 4, 5, 7 and 8. The original core of the model was 
developed by Andrew Phillips but together with a colleague working on the progression model, 
Fumiyo Nakagawa, and I, we have jointly modified the model in several ways over time.     One 
of my major contributions has been to focus on calibrating the model to specific settings such 
as South Africa and Zimbabwe and in developing parts of the model necessary to answer the 
questions I was interested in. Regarding HIV testing, I introduced the process of HIV testing in 
the general population and in women attending ANC in the South African model and a more 
detailed age and gender-specific HIV testing process with the availability of ST in the Zimbabwe 
model. Regarding the linkage to care, retention in pre-ART care and on ART, I modified the 
model to better reflect the cascade observed on the ground and to be able to provide results 
in the format agreed with the HIV Modelling Consortium. I developed as well the part of the 
model on circumcision, given VMC has been found to be an effective prevention intervention 
and both the countries considered in this thesis are scaling up VMC programmes.  In addition I 
developed the possibility of using PrEP within the Synthesis model and its impact in reducing 
the risk of acquiring HIV, but as well the possibility that people who are infected with HIV while 
on PrEP could develop resistance. This has not been included in the PhD. 
 
Chapter 4 has two main parts: the first presents a formal literature review on the preventive 
benefit of ART, while the second part aims to evaluate the impact and cost-effectiveness of 
changes in adult ART eligibility guidelines and improvements in HIV testing and linkage to care 
in the South African setting. The literature review has been conducted in collaboration with 
the European Centre for Disease Prevention and Control, but includes evidence on the efficacy 
of ART in reducing the risk of transmitting HIV from high, middle and low income countries. 
The strongest evidence available on the preventive benefit of ART is the HPTN052 RCT (432). 
Using the Synthesis model I evaluated the cost-effectiveness of alternative strategies for 
expanding access to ART. I found that modifying the eligibility criteria to initiate ART from 
CD4≤350 cells/μL to CD4 ≤500 cells/μL or to all HIV-positive people was very cost-effective 
over 20 years. Nevertheless I estimated that the cost per DALY averted of changing ART 
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eligibility criteria to CD4 ≤500 cells/μL or to all HIV-positive people was quite substantial, 
respectively $1,691 and $2,133, among the highest costs across the mathematical models 
which addressed this question within the HIV modelling Consortium. I found that the most 
cost-effective option amongst those considered was instead expanding HIV testing and linkage 
to care so that 80% of those who become eligible for treatment are in care, while maintaining 
the CD4 threshold of 350 cells/μL; this option would cost $1,398 per DALY averted.  
 
Since the Synthesis model was the only model within the HIV Modelling Consortium addressing 
the question in Chapter 4 for South Africa which included resistance, in Chapter 5 I attempted 
to estimate the impact of different ways of expanding access to ART in South Africa on the 
levels of HIV drug resistance. I found that, even if new policies are not put in place and the roll-
out of ART continues at the current pace, the number of people carrying HIV drug resistant 
virus and the consequent need for second-line regimens is going to increase by at least 2 fold. 
This is a consequence of having an increasing number of people on ART and it is due to the fact 
that people interrupt treatment and fail to perfectly adhere to treatment for various reasons 
and the fact that this resistant virus can then be transmitted. However, the Synthesis model 
suggests that 60% of those who in 20 years’ time will have developed resistance to drugs in the 
first-line regimen could be virologically suppressed on a second-line regimen. In addition I 
found that by substantially improving diagnosis and retention while maintaining the eligibility 
criteria at CD4<350 cells/μL, it is possible to reduce the number of new HIV infections to the 
same extent that could be achieved by expanding the eligibility criteria to all people diagnosed 
with HIV, while saving more deaths and avoiding initiating ART in people for whom the clinical 
benefit is still under discussion.  
 
When modelling the development and transmission of DRMs, two pieces of information for 
which the evidence is limited, even from developed countries, are the extent to which 
resistance mutations persists in people who stopped treatment after experiencing VF due to 
development of resistance and the extent to which NNRTI mutations can be acquired following 
interruption of treatment due to the long half-life of NNRTI compared to the other 
components of the regimen. To address this question, in Chapter 6, I used data from an 
observational study performed in the UK and used these estimates to inform the Synthesis 
model. I found that among patients in the UK HIV drug resistance database who have 
documented NNRTI resistance while on ART who then interrupted it, 41% had NNRTI 
resistance which persisted at the first resistance test after interrupting treatment (in median 
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performed 4 months after stopping ART). While, in those who interrupted suppressive NNRTI-
based regimen, 12% of patients who had a subsequent resistance test had NNRTI resistance 
detected (in median conducted 12 months after the interruption; IQR: 3-20 months).   
 
As HTC and ART is scaled up in South Africa and other settings in sub-Saharan Africa, it is 
becoming apparent that one of the most crucial issues once people are diagnosed with HIV is 
to make sure they are maintained along the continuum of care, so that they can initiate ART in 
a timely way once eligible and then achieve the maximum benefit while on ART. In Chapter 7, I 
explored at which steps within the cascade of care from diagnosis to maintenance of 
virological suppression while on ART, it is worth intervening to reduce the losses, in particular 
in terms of HIV infections, deaths averted and cost-effectiveness. I found that among 
improvements which would reduce the losses by 50% at the following steps: linkage to care, 
retention in pre-ART, retention on ART, switch to second-line, the improvement which 
provides the greatest health benefit is the one aimed at increasing retention on ART. This is 
due to the fact that it allows a substantial reduction in the number of deaths. In addition, 
when comparing these strategies where the cascade of care is strengthened with modification 
in the eligibility criteria by raising the CD4 count threshold, I found that policy-makers should 
first strengthen the cascade of care and only as a second step expand the eligibility criteria. To 
inform this decision, I estimated what is the maximum cost the intervention could cost in order 
to be cost-effective. The interventions for which more money can be spent are those who 
provide more value in terms of health benefit, those leading to improved retention on ART and 
timely switch to second-line.  
 
In Chapter 8, a different public health intervention was explored: the introduction of ST. I used 
the Synthesis model to evaluate the cost-effectiveness of introducing ST in the general 
population in Zimbabwe taking into account the potential advantages and disadvantages of ST. 
The advantages include the fact that ST represents a good opportunity to save money given 
the lower cost of providing this type of test and the fact that it could reach people who are not 
willing to have an HTC, provided by a counsellor. The disadvantages include the lower accuracy 
of ST compared to HTC, conducted by trained counsellors and the need to have a confirmatory 
test to be diagnosed with HIV and potentially linked to care and initiated on ART if necessary. I 
found that ST may well be cost-saving, given its lower cost and the fact that, by reaching more 
people, provides a moderate health benefit.   
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9.2. Relevance and limitations of main findings 
In this thesis, I have focused on the impact of different public health actions (different ways of 
expanding access to care and whether to introduce HIV ST) mainly on HIV incidence, resistance 
dynamics and cost-effectiveness in two settings in sub-Saharan Africa, South Africa and 
Zimbabwe. 
 
The evidence of the preventive benefit of ART has triggered lots of discussion and some of the 
most widely used guidelines now recommend either ART initiation in all HIV-positive people 
(265;281)  or below CD4 count ≤500 cells/μL (280). As part of the revision process of the 
guidelines that WHO then published in July 2013, WHO asked the HIV Modelling Consortium to 
evaluate the value of expanding the eligibility criteria by increasing the CD4 count threshold, 
compared to the expansion of access to care in people eligible for ART according to the 2010 
WHO guidelines (277). I took part in this collaboration, using the Synthesis model and these 
results are presented in Chapter 4 and compared to the findings from the other mathematical 
models which were involved. This process is very useful to facilitate comparisons across 
mathematical models and collaborations between modellers. When the results are consistent 
across each other, it is very reassuring, while on the other hand, when discrepancies arise, it is 
often quite difficult to be able to disentangle exactly what drove those differences, due to 
different structures of the models.  In this comparison for example all models agreed that 
modifying the eligibility criteria was very cost-effective, nevertheless three out of seven 
models, including the Synthesis model, found that the priority should be the expand access to 
care rather than modifying the eligibility criteria. 
 
Subsequently I used the same model to evaluate the impact on resistance of expanding access 
to care including an improvement in retention on ART. These findings are presented in Chapter 
5; on one hand, they can reassure decision makers regarding the fact that expanding the 
eligibility criteria should not increase the number of people carrying the NNRTI resistance 
mutations (and they should lead to a reduction in the total number of new HIV infections), on 
the other hand they should make them aware of the fact that a considerable proportion of 
people will be in need of more expensive second-line treatment. The price of the first-line 
regimen has been reduced dramatically over time in LMIC, and FDC for the first-line regimen 
have been available in South Africa since April 2013.  Efforts should now be put in place to 
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reduce further the cost of second-line treatment, given many people will be in need of it in the 
future. 
 
When addressing the question in Chapter 5, I realized that there are relatively few data 
available on resistance from RLS; VL monitoring is only performed in a few countries and 
resistance test data are very rarely available. It is well established that people who initiate ART 
should avoid interrupting treatment, given the detrimental effect on health (714); nevertheless 
ART interruptions do occur for various reasons. Data on people who interrupt ART are difficult 
to collect, given clinicians do not recommend this practice and it is unlikely that a resistance 
test is performed if a person interrupts treatment while on a suppressive regimen. The 
analyses presented in Chapter 6 on presence of resistance in people after TI, although 
performed on a relatively small sample size, are among the largest studies conducted to 
answer these questions. They have important implications for the transmission of drug 
resistant virus and confirm the fact that both the persistence of DRMs in people who have 
stopped treatment and the emergence of NNRTI resistance in people who interrupted 
suppressive ART are common phenomenon.  
This analysis was conducted on the UK HIV drug resistance database, which contains resistance 
tests routinely performed in the clinics, linked with the UK CHIC study which contains clinical 
information on HIV patients from most of the large HIV clinics in the UK. Given TIs are not 
recommended any more, most of the data that contributed to these analyses are relatively 
dated and come from patients who potentially have been exposed to a large number of 
regimens and to less effective ones than those currently available. In addition, these data were 
collected in patients living in the UK, who are mainly infected with viral subtype B, therefore it 
is not possible to exclude that these estimates would be different in a setting such as sub-
Saharan Africa, where the main subtype is C. It would be interesting to be able to collect 
information on ART interruptions and resistance mutations in patients on ART in South Africa 
to be able to refine my estimates on predictions of resistance in this country. 
 
Different interventions have been evaluated in different settings to strengthen the cascade of 
care and some of them, such as POC CD4 counts, CBART programmes, and structural 
interventions including monetary supplements and food rations, have been found to be 
effective. In Chapter 7, I highlighted the fact that the step in the cascade at which an 
improvement (that reduces the loss by 50%) is more effective is retention on ART, this 
corresponds to an increase of 8% retained on ART at one year from initiation. The most cost-
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effective intervention is to reduce the delay to switch people to second-line; this is the step at 
which more money can be spent given it provides the greatest health benefit. I provided the 
maximum cost the single intervention could cost in order to be cost-effective; this piece of 
information provides a useful framework to design interventions that could improve the 
cascade of HIV care. The time required to switch to second-line, once having experienced 
virological failure, are not available at a national level in South Africa. Nevertheless the delay in 
switching to second-line has been flagged up as an issue (500;501) and there is evidence from 
South Africa that in some clinics it is possible to reduce the time before switching to 5 months 
(499). However it is not clear how much it would cost to implement such an intervention and a 
similar situation is true for improving retention on ART. It would be interesting, now that I 
suggested that these steps in the cascade of care are those research should focus on, to assess 
how to achieve those improvements.  
In addition, models which  incorporate the process of being lost from care and of coming back 
into care, need to make assumptions regarding whether symptomatic people are more likely 
to come back to care. The evidence available is mainly anecdotal because it is very difficult to 
collect information on people who are disengaged from care. 
 
I believe the findings in Chapter 8 are of key importance. ST has been approved by the FDA in 
2012 (985), and several countries, stakeholders and donors, including the Bill and Melinda 
Gates Foundation who prompted this work, are now evaluating whether ST should be 
introduced and therefore whether investment should be made in marketing and distribution of 
this technology. To my knowledge, this is the first study which evaluated the cost-effectiveness 
of introducing ST in RLS. The finding that ST is not only cost-effective in a setting such as 
Zimbabwe but that it could even be cost-saving could contribute in convincing stake holders 
and decision makers in investing in the marketing and distribution of this diagnostic 
technology. The assumptions for this analysis are based mainly on the strong evidence coming 
from a study conducted in Blantyre, Malawi, for what concerns accuracy (871;872), probability 
of having a confirmatory test (872) and acceptability and uptake of HIV testing  (872). It is clear 
that, if assumptions do not hold in other settings, the impact of ST could be very different, but 
there is no reason to believe this should be the case in a setting such as Zimbabwe or in other 
countries in sub-Saharan Africa.  
In addition I highlighted the factors which mostly contribute to determine whether the 
introduction of ST is cost-effective; this should help informing what future research should 
focus on in this regard. 
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Generally, mathematical models can provide useful insights in the decision making process, 
nevertheless they depend on which evidence is available and on whether this is captured 
appropriately by the model. The fact that the Synthesis model was usually in line with the 
other models involved in the HIV Modelling Consortium is reassuring, although all models 
could be wrong because of each relying on the same incorrect assumptions or the same 
unrepresentative data. 
When evaluating the impact and the cost-effectiveness of a policy it is standard to look at the 
impact over a  relatively long time frame such as 20 years or even longer (e.g. life-time) to 
make sure the policy introduced has time to produce the full benefit. It is important to bear in 
mind that the longer the time-frame the more the estimates are characterized by uncertainty. 
I made quite conservative assumptions regarding the scale up of ART and of interventions such 
as VMC and I assumed, for example, that the ART regimens available would not change in the 
next 20 years, although this is unlikely to be true. It is standard practice to assume the current 
situation will remain for the length of the time frame, given it is unknown what and when the 
changes will be implemented in the future. 
 
 
9.3. Concluding remarks 
Decisions regarding how to expand access to ART in South Africa and whether Zimbabwe and 
other countries in sub-Saharan Africa should introduce ST are very complex. In this thesis I 
evaluated the cost-effectiveness of different strategies and highlighted the benefits and the 
disadvantages of the different options and in particular addressed the concerns regarding the 
spread of drug resistant virus. I hope this thesis will inform the decision making process 
regarding how to maximise health benefits in these countries and indicate where further 
research is needed to help refine my findings and make better informed decisions. 
 
  
356 
 
Appendix I. Licensed antiretroviral drugs 
Class of 
drug 
Generic name Acronym FDA approval 
(211) 
Medicines 
Control 
Council 
South Africa 
approval 
(1020;1021) 
Medicines 
Control Authority 
of Zimbabwe 
approval (1022) 
NRTIs abacavir ABC 1998 2001 2002 
didanosine  ddI 1991  1992 Before 2004 
(1023) 
didanosine ddI EC 2000 2003 - 
emtricitabine  FTC 2003  2007 2013 
lamivudine  3TC 1995  1996 1997 
stavudine  D4T 1994  1998 2004 
tenofovir  TDF 2001  2007 2008 
zalcitabine  ddC 1992 (no longer 
marketed) 
1993 Before 2004 
(1023) 
zidovudine  AZT  1987  1992 1989 
PIs amprenavir  APV 1999 (no longer 
marketed) 
2001 Before 2004 
(1023) 
atazanavir  ATV 2003 2007 2010 
darunavir  DRV 2006 2010(1024) 2012 
fosamprenavir  FOS-APV 2003 2012 - 
indinavir  IDV 1996 1996 Before 2004 
(1023) 
lopinavir and 
ritonavir  
LPV/r 2000 2002 2003 
nelfinavir  NFV 1997 1999 Pending in 2003 
(1023) 
ritonavir  RTV 1996 1997 2000 
saquinavir 
(hard gel)  
 1997 (no longer 
marketed) 
1999 Not approved in 
2003 (1023) 
saquinavir (soft 
gel)  
SQV 1995 1997 Pending in 2003 
(1023) 
tipranavir  TPV 2005 NL by Oct 
2013 (1025)1 
Not approved 
NNRTIs delavirdine  DLV 1997 NL by Oct 
2013 (1025)1 
Not approved in 
2003 or by 2014 
efavirenz  EFV 1998 1999 2006 
etravirine  ETV 2008 2011 (1026) Not approved  
nevirapine  NVP 1996 1998 2000 
rilpivirine RPV 2011 NL by Oct 
2013 (1025)1 
Not approved  
Entry 
inhibitor  
maraviroc MVC 2007 2013 (1027) Not approved  
Fusion 
inhibitor 
enfuvirtide T-20 2003 Not L by Oct 
2013 (1025)1 
Not approved 
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Class of drug Generic name Acronym FDA 
approv
al (211) 
Medicines 
Control Council 
South Africa 
approval 
(1020;1021) 
Medicines 
Control 
Authority of 
Zimbabwe 
approval 
(1022) 
Integrase 
inhibitors 
raltegravir  RAL 2007 2011 (1028) Not approved  
dolutegravir DTG 2013 Not approved Not approved  
Elvitegravir - 20122 Not approved Not approved 
Combined 
NRTI 
abacavir + 
lamivudine 
ABC+3TC 2004 2012(1029) 2013 
abacavir + 
zidovudine + 
lamivudine 
ABC+AZT+3TC 2000 2003 2002 
emtricitabine + 
tenofovir 
FTC+TDF 2004 2007 2009 
lamivudine + 
zidovudine 
3TC+AZT 1997 2000 1999 
lamivudine + 
tenofovir 
3TC+TDF - 2012(1030) 2010 
lamivudine + 
stavudine 
3TC+D4T - 2010(1031) 2004 
Multiclass 
combination 
efavirenz + 
emtricitabine + 
tenofovir   
EFV+FTC+TDF 2006 2010 (1031) 2010 
efavirenz + 
lamivudine +  
tenofovir   
EFV+3TC+TDF - 2012(1032) 2012 
efavirenz + 
lamivudine +  
zidovudine 
EFV+3TC+AZT - 2010 (1024) 2007 
nevirapine + 
lamivudine + 
stavudine 
NVP+3TC+D4T - 2010 (1033) 2004 
nevirapine + 
lamivudine + 
zidovudine 
NVP+3TC+AZT - 2011 (1034) 2006 
nevirapine + 
lamivudine + 
tenofovir 
NVP+3TC+TDF - - 2013 
emtricitabine + 
rilpivirine + 
tenofovir 
FTC+RPV+TDF 2011 2013 (1035) - 
elvitegravir + 
cobicistat + 
emtricitabine + 
tenofovir 
ELV+COB+FTC+TDF 2012 - - 
1 - The Medicine Control Council [South Africa] lacks a publicly accessible database of antiretrovirals registered 
since 2004, these drugs where not listed in the drugs registered; 2 - Elvitegravir and cobicistat have been approved 
only in fixed-dose combination together with tenofovir and emtricitabine; 
EC: enteric-coated (this formulation has a delayed release); FDA: U. S. Food and Drug Administration; NNRTI: non-
nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor;  
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Appendix II. Toxicities to antiretrovirals most used in 
South Africa and Zimbabwe 
Toxicities to stavudine 
D4t is very well tolerated over the first 6 months but can lead to several serious side effects 
and it has been estimated in a study from South Africa that almost a third of patients 
discontinue d4T, due to toxicity within 3 years (645). The most frequently (>5%) reported 
adverse events of d4T are headache, nausea, lipodystrophy and peripheral neuropathy (644). 
The most serious adverse events are lipodystrophy, pancreatitis, lactic acidosis and 
steatohepatitis (rare) (644).  
Peripheral neuropathy consists of nerve damage in the feet, legs, and hands, and may cause 
numbness, tingling, or severe pain in the extremities. This occurs in between 15 and 30% of 
people receiving d4T (643;646), particularly in those on higher doses, with more advanced HIV 
disease, or who were also taking ddI (1036). A study in Cambodia found that 7% of people 
developed peripheral neuropathy within the first year, 17% by the third year and 19% by the 
sixth year (1037). If d4T is stopped, the neuropathy usually gets better after about two weeks 
and if symptoms disappear, d4T can be restarted at half the recommended dose.  
Another major concern with the use of d4t is the development of lipodystrophy, changes in 
body fat distribution and more specifically usually fat loss from the limbs, buttocks, and face. It 
can occur in between 30% (1038) up to 72% of those treated with d4T by 6 years (1037). A RCT 
comparing NRTI-containing and NRTI-sparing regimens in ART-naïve patients found higher 
frequency of lipoatrophy, defined as at least 20% loss in extremity fat, in people receiving d4t: 
42% by 96 weeks of treatment (1039). Its prevalence in RLS has been estimated 34% in 
Rwanda (1038) and 46% in western India (1040). This side effect can have important 
psychological effects, such as depression (1041) and has also been found to be associated with 
increased risk of metabolic disorders and cardiovascular disease (CVD) (1042-1044), although 
the D:A:D study, a very large study including more than 30,000 HIV-infected patients in high 
income countries, failed to find an association between D4T and CVD (1045). This fat loss 
seems to stop after the dose of d4T is reduced to 30mg twice daily, stopped altogether (1046) 
or people are switched from d4T to ABC or TDF for example (1047-1049). Generally people 
who switch away from d4t tend to gradually gain limb fat over time, compared to those who 
continue on d4t, who generally lose limb fat (1048;1050;1051). Nevertheless, it has been 
observed to persist after 5 years in some studies, even if the implicated drugs are discontinued 
(1052).  
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Severe steatohepatitis, a type of liver disease, characterized by inflammation of the liver with 
concurrent fat accumulation in liver, and/or pancreatitis, a very serious condition 
characterised by sudden onset of abdominal pain, fever, vomiting or general worsening of 
health due to inflammation of the pancreas, can lead to a metabolic abnormality called lactic 
acidosis (1053). This is a life-threatening condition characterised by the following symptoms: 
nausea, fatigue, weight loss, abdominal pain, dyspnoea and eventual circulatory collapse (644). 
Its incidence in people receiving NRTIs has been estimated between 0.85 and 2.7/1,000 PYs 
(1054-1056), although higher rate up to 1% have been observed in southern Africa (1057;1058) 
and among women. A study of people initiating ART in South Africa and Soweto found a rate of 
lactic acidosis of 16.1/1,000 PYs among women and a much lower rate in men (1.2/1,000 PYs) 
(1059). Of all NRTIs, D4T has been associated with a two to three fold higher risk of having 
hyperlactatemia compared to people receiving AZT-based regimens (1060;1061). It usually 
develops within the first few months of treatment with d4T, and if NRTIs are not stopped it can 
lead to death.  
Pancreatitis occurs in around 2-3% of people taking d4T monotherapy and <1% receiving d4T 
based-ART regimens although the risk of this occurring is greater in patients who have had 
pancreatitis in the past.  
Less serious side-effects of d4T, which are most likely to occur during the early weeks of 
treatment, are nausea, vomiting, listlessness, chills, fever, diarrhoea, constipation, headaches, 
abdominal pain and dehydration. 
Given the severe toxicities d4T can cause, especially peripheral neuropathy and lipodystrophy, 
a meta-analysis  was conducted to re-assess whether a lower dose of d4T compared to that 
which was originally recommended (40mg twice daily), could reduce the side-effects without 
affecting the efficacy. They found a trend towards a lower frequency of side-effects at a lower 
dose but no difference in efficacy between doses of 40 mg, 30 mg or 20 mg. On the basis of 
this meta-analysis the WHO in 2007 recommended countries to switch to a 30mg dose (1062).  
Despite these side effects, D4T played a critical role in the scaling up of ART, due to its low 
cost, availability in dual and triple FDC, easy intake (no administration with food or large 
amounts of liquids required) and no requirement of laboratory monitoring.  In 2009, WHO 
recommended to phase out completely d4T (278), but at the end of 2009, 57% of HIV regimen 
in LMIC still contained d4t (1063). The generic combination of TDF, FTC and EFV, currently 
recommended as 1st line costs US $158 (with 3TC and EFV US $139), around 3-times more than 
d4t in combination with 3TC and NVP (US$ 55) (969). This has led to delay in phasing out d4T. 
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An RCT is currently ongoing in South Africa, Uganda and India led by Francois Venter evaluating 
whether low dose (20 mg) D4T is non inferior to TDF-based regimens (1064).  
 
Toxicities to zidovudine 
The severe toxicities which can occur when using AZT are lactic acidosis, lipoatrophy, anaemia 
(1-4%) and neutropaenia (1-2%), and the most common (>5%) are headache, asthaenia, 
nausea and nail pigmentation (644). In a study from South Africa it has been estimated that 8% 
discontinue AZT, due to toxicity within 3 years (645). 
Hyperlactatemia can occur when receiving AZT, although the frequency is two to three folds 
lower than in people receiving d4T-based regimens, typically less than 1% (1060;1061).  There 
is some evidence that AZT triggers lipodystrophy, but in smaller proportions than D4T. For 
example, a study comparing the proportion of people with leg fat measures <10% threshold 
value among people receiving respectively AZT or D4T found a prevalence respectively of 48% 
and 67% (1065) and a RCT comparing different NRTI-containing and NRTI-sparing regimens in 
ART-naïve patients found a frequency of lipoatrophy, defined as at least 20% loss in extremity 
fat, of 42% in people receiving d4t and of 27% in people receiving AZT by 96 weeks of 
treatment (1039). Switching away from AZT has been found to lead to gain in limb fat over 
time, compared to those who continue on AZT (1048;1050;1051;1066). 
Anaemia consists of a decrease in number of red blood cells or in a reduction in Hb in the 
blood, and is usually accompanied by quite vague symptoms, but it has been found to be 
negatively associated with quality of life (1067), disease progression and survival (1068;1069). 
Presence of anaemia (Hb<10 g/dL) in HIV patients before starting ART is quite common and in 
Southern Africa is around 15 and 20% (647;1070;1071). Studies in patients receiving AZT 
generally found a substantial increase in Hb maintained at 48 weeks, both in high income 
(1072-1074) and low income countries (648), nevertheless the incidence of anaemia differs in 
the two settings.  
In RLS the incidence of anaemia (Hb<10g/dl) in patients receiving AZT is very variable: 18.2/100 
PYs in the Western Africa, 6.6 in Eastern Africa, 9.7 in Southern Africa, 22.9 in Central Africa, 
11.8 in Asian, 19.5 in Caribbean and Central and South America regions (647). A study in 
Cambodia found that 13% developed anaemia within the first 6 months receiving AZT, 2.5% 
severe anaemia (1075). These data come from observational studies and it is possible that 
patients with documented Hb measurements are more likely to be at risk of anaemia than 
patients without assessment. Nevertheless in an analysis conducted in the DART trial (carried 
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out in Zimbabwe and Uganda) where patients with anaemia at baseline were excluded, 11.8% 
developed grade 2-4 anaemia, 6.6% grade 4 (Hb<6.5 g/dL) by week 48 (648) and in a RCT in 
Botswana 3.7% developed anaemia (Hb<10 g/dL) within 2 years (1076). AZT has been found to 
double the risk of anaemia, but other factors have a similar impact including higher VL, lower 
Hb levels before starting therapy, female sex, older age, previous clinical AIDS disease, low CD4 
and BMI and African American ethnicity (645;647;648;1068;1070;1075-1077). 
Neutropaenia is a condition characterized by an abnormally low number of neutrophils, a type 
of white blood cell whom main function is to defend against infections by destroying bacteria 
in the blood. Thus, patients with these condition are more susceptible to bacterial infections 
(1078) and, without medical intervention, the condition may become life-threatening 
(neutropenic sepsis). These episodes tend to last around two weeks (1079). The prevalence of 
neutropenia (absolute neutrophil count ≤1.3×10⁹/l) at initiation of ART has been estimated to 
be 14% but there is significant variation across regions (1071). This study used data from the 
US, Haiti, Brazil, Peru, Malawi, South Africa, Zimbabwe, India and Thailand and found for 
example that the prevalence of neutropaenia in the US and South Africa were around 15%, but 
levels above 25% were found in Malawi (1071). In the phase II RCT for AZT absolute neutrophil 
counts fell after 12 weeks of treatment to < 1000/ul and < 500/ul respectively in 24% and 7% 
of patients with AIDS (216). A meta-analysis evaluating the impact of AZT-containing regimen 
compared with D4T-containing regimens reported a prevalence of neutropenia (at least on 
dose below 1500 mg) varying from 26% to 43% in patients receiving AZT compared to 15% to 
31% in patients on d4T (1080). In a study on patients with neutropenia they evaluated the 
incidence of bacterial infections, if AZT was temporarily discontinued only when the 
polymorphonuclear leukocytes (PMN) cell count fell to <500/µl (1081). They found that the 
incidence of bacterial infection during periods of severe neutropenia (PMN <500/µl) in patients 
receiving AZT was 230% higher than when the PMN count was between 500-1000/µl, and 
600% higher than when the count was > 1000/µl, but no significant difference in incidence of 
bacterial infections in patients with the PMN count between 500 and 1000/µl and non-
neutropenic periods, suggesting that AZT can be continued in patients with PMN of 500/µl. 
This was confirmed in subsequent studies. A RCT conducted in Botswana comparing different 
ART regimen options in ART-naïve people found that at 2 years since initiating AZT 2.3% 
developed neutropaenia which resulted in treatment modification, not significantly different 
from the level observed in people receiving d4t (1076). 
Less serious side effects such as headache, asthaenia (a condition characterized by lack of 
muscle strength, malaise, dizziness, or fatigue), nausea and nail pigmentation are quite 
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common (>5%) (644). Medicines to control nausea and headache are usually prescribed before 
starting AZT. 
 
Toxicities to didanosine 
ddI presents similar severe adverse events to D4T and AZT: lactic acidosis, steatohepatitis, 
pancreatitis (1-7%) and peripheral neuropathy. The most common adverse events (>5%) are 
nausea and diarrhoea (644). 
As mentioned before, both severe steatohepatitis and pancreatitis, which occur respectively 
between 1-2% and between 8% and 23% (1082-1084) when using ddI monotherapy, can cause 
lactic acidosis (1053). Pancreatitis usually develops after 10-18 weeks of treatment and 
represents one of the most important clinical toxicities of this agent (1083): 14% of the 
reported cases with ddI-induced pancreatitis were fatal cases (1085). Lactic acidosis is rare. ddI 
has been found to double the risk of hyperlactatemia (> 5 mmol/l, including those with 
acidosis), estimated to be 7.3/1,000 PYs, while the rate of lactic acidosis is 3.2/1,000 PYs 
(1086). 
Peripheral neuropathy also represents an important ddI-induced toxicity. It has been observed 
after 18 to 30 weeks of treatment in around 15% of patients exposed to it (1083). Nausea and 
diarrhoea are quite common and tend to occur in the first few weeks. 
 
Toxicities to lamivudine and emtricitabine 
3TC and FTC, in contrast with other NRTI, are largely safe drugs. Their commonest side-effects 
are headache, fatigue, and nausea, which tend to occur during the first weeks of treatment 
and to subside over time. Other less common side-effects include decreased appetite, 
diarrhoea, skin rash, and abdominal pain. In those infected with HBV, rebound of HBV viraemia 
which can lead to culminant hepatitis  can occur in patients discontinuing these drugs (644). In 
addition if they are used as the sole anti-HBV agent in HIV-positive people co-infected with 
HBV, resistance develops in 90% by 4 years with similar rebound phenomena seen.  
 
Toxicities to tenofovir disoproxil fumarate 
TDF does not have any common adverse events (>5%), but can have some serious events such 
as nephrotoxicity (a decline in kidney function acute or chronic secondary to a toxin, including 
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drugs), osteopaenia and exacerbation of HBV infection (in those co-infected) after withdrawal 
(644). 
Renal function is usually expressed in terms of creatinine clearance, which is a surrogate 
measure of glomerular filtration rate. It is generally considered normal if the estimated 
glomerular filtration rate (eGFR) ≥90 ml/min, mild renal dysfunction if the eGFR is between 60 
and 89 ml/min, moderate renal dysfunction if the eGFR is between 30 and 59 ml/min and 
severe renal dysfunction if eGFR<30 ml/min (1087). People infected with HIV, particularly 
those with pre-existing renal dysfunction are at higher risk of nephrotoxicity (1088-1094); a 
meta-analysis conducted in the US estimated a 3.87 higher risk of renal disease in people 
infected with HIV compared with uninfected people and a 3.32 higher risk for people with AIDS 
compared to others (1095). There is evidence that people in Africa have a 3 to 4 fold higher 
risk of chronic kidney disease (CKD) compared to people in high income countries (1096) and 
that generally people of African descent are at increased risk of renal failure (1097). Other risk 
factors of renal failure include CD4 cell count, late stage of HIV and age (1095). Glomerular 
proitenuria (large amounts of protein in the urine) has been found to be associated with older 
age, current use of TDF, HCV co-infection, AIDS and a CD4 count less than 200 cells/μL (1098). 
The DART trial reported that at baseline 45% of HIV-positive participants had mild renal 
insufficiency (eGFR between 60 and 89 ml/min/1.73m (2)), but in only 7% was moderate (eGFR 
between 30 and 59 ml/min/1.73m (2)), and 0.2% grade 3 or 4 (1099). In South Africa the 
prevalence of mild renal dysfunction was 30%: 5.2% had moderate renal dysfunction (1090) 
and 6% CKD (1100); in Zambia 25% had mild renal dysfunction, 7.8% moderate and 1.0% 
severe (1101). 
TDF is associated with a glomerular toxicity, a direct tubular disease and a 10% reduction in 
eGFR during the first year which then seems to reach a plateau (610;1102;1103). An analysis 
including ART-naïve patients involved in two RCTs in Europe, the US and South America 
comparing TDF found small differences in eGFR but failed to find clinically relevant renal 
disease or adverse events (1104). The incidence of renal serious adverse event of any type in 
patients receiving TDF was estimated to be 0.5/100 PYs and of graded increase in serum 
creatinine 2.2% (644). In prospective observational studies 2-3% of patients receiving TDF for 
an average of 1 year developed moderate or severe renal dysfunction (eGFR<60 ml/min) 
(1091). In Eurosida, for example, they found that HIV-positive people exposed to TDF for more 
than 3 years had an incidence of CKD approximately of 2.5/100 PYs compared with an 
incidence around 0.8 for people who were not exposed to TDF (1105). A large observational 
study conducted in the US came to a similar conclusion with a 34% increased risk of 
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proitenuria, 11% greater risk of rapid decline in kidney function (defined as ≥3 ml/min per 1.73 
m2 annual decline) and 33% higher risk of CKD per year of exposure to TDF (1106). A meta-
analysis of prospective studies including RCT and observational studies found a significantly 
higher loss of kidney function among people receiving TDF compared with control subjects 
(mean difference in calculated creatinine clearance approximately 4 mL/min), but a quite 
modest clinical manifestation: 0.7% higher risk (risk difference) of acute renal failure, no 
evidence of increased risk of severe proteinuria (1107). A more recent meta-analysis found 
that people on ART had a 46% reduction in risk compared to treatment-naïve people, while 
people who had been exposed to TDF had a 56% increased risk of renal failure compared to 
people treated with non-TDF therapy (1095). In the DART trial, by 4 years 2.8% experienced an 
eGFR<30 ml/min/1.73m2 and 5.0% CKD and the adjusted eGFR increased by respectively 1, 9 
and 6 ml/min/1.73m2 with respectively TDF, ABC and NVP (1099). In a cohort study in South 
Africa 2.4% experienced nephrotoxicity and the rate to develop it for those with respectively 
normal, mild and moderate dysfunction at baseline were 0.4, 2.5 and 10.7/100 PYs (1090). Of 
those who developed nephrotoxicity, it has been observed that 28.6% subsequently died with 
a median of 2.3 months since nephrotoxicity diagnosis (1090). Few studies evaluated the risk 
of mortality in HIV-positive patients according to their baseline renal functionality. A study 
conducted in Zambia found respectively a 70%, 130% and 330% increased risk of mortality at 
or before 90 days in those with mild, moderate and severe reduced creatinine clearance. After 
90 days they were still at higher risk of mortality compared to those with normal renal 
function: 1.4 folds for those with mild dysfunction, 1.9 for those with moderate and 3.6 for 
those with severe insufficiency (1101). 
Osteopaenia, osteoporosis and osteonecrosis have been observed in ART-naïve and ART-
treated patients. It is unclear the role ARVs play in reducing bone mineral density (BMD). 
Osteonecrosis is a condition caused by reduced blood flow to bones in the joints and can cause 
pain, arthritis and limited use of the joints interested. The prevalence of symptomatic 
osteonecrosis in HIV-infected patients has been estimated between 0.1 and 1.3% and 
asymptomatic osteonecrosis at 4% (1108). The odds of having a reduction in BMD in HIV-
positive adults has been estimated 6.4 fold and the odds of osteoporosis (a BMD of 2.5 
standard deviations or more below the mean peak bone mass which is the average of young, 
healthy adults) 3.7 fold compared with uninfected controls (1109). A RCT comparing d4T and 
TDF found a higher decrease in BMD from baseline in people receiving TDF compared to d4T 
(610). TDF has been found associated with a slightly increased risk of osteopaenia over 3 years 
(lumbar spine) but not with increased risk of fracture (610). 
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In addition if TDF is interrupted in people with HBV, against which TDF is active, this can lead 
to rebound of HBV DNA levels (“flares”) (1110-1112) which can cause fulminant hepatitis.  
Finally, rare  cases of lactic acidosis in people receiving TDF have been reported (1113). 
 
Toxicities to efavirenz 
Use of EFV is usually accompanied by few common (>5%) adverse events related to the CNS, 
such as headache, dizziness, insomnia, vivid dreams (>50%) and increased alanine 
transaminase levels and some severe adverse events such as rash, hepatotoxicity (HT), 
Stevens-Johnson syndrome and fetal CNS malformations (644). 
CNS side effects tend to occur in over half of the patients receiving EFV during the first one to 
four weeks of therapy (259;1114) and tend to be resolved by week 4 (259;1115). Nevertheless, 
symptoms like mild anxiety and bad dreams may last in up to 50% of patients for more than six 
months (1116;1117), even after two years since initiating (1118). They are generally only mild 
to moderate symptoms and only a small minority discontinue EVF because of CNS side-effects 
(in a RCT 6% (1115)). This toxicity seem to occur more frequently in African American than in 
European-Americans (1119;1120) and this is at least partially explained by different prevalence 
of polymorphism in the cytochrome which metabolizes EFV, associated with slower EFV 
clearance, increasing the exposure to EFV and the risk of developing CNS toxicity (1121;1122). 
Recent studies have reported that switching from the combination EFV, TDF and FTC to the 
combination containing RPV, FTC and TDF improves CNS side effects (1123). 
In people taking EFV, a mild-to moderate rash can develop within two weeks from initiating 
EFV-based ART in approximately 10 to 35% of the patients in RCTs (259); usually it can be 
controlled using antihistamines and it resolves within around two to four weeks since initiating 
EFV-based therapy and it does not tend to lead to discontinuation of EVF (2% or less in RCTs) 
(259;1124). The incidence of severe rash, such as erythema multiforme and in particular 
Stevens-Johnson syndrome, in patients receiving EFV has been estimated to be around 0.1% 
(644). Stevens–Johnson syndrome is a form of a life-threatening skin condition, in which cells 
die, because the epidermis separates from the dermis.  
HT has been found to be associated with most ARVs, including EFV (1125).  In high income 
countries, the monitoring of patients on ART are primarily based on serum alanine 
transaminase and aspartate transaminase (AST) levels, liver enzymes that serve as a ‘proxy’ for 
liver inflammation and damage. HT is classified into five categories (grades 0–4) (1126):  
 grade 0: <1.25 fold the upper limit of normal (ULN);  
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 grade 1: 1.25–2.5 fold the ULN;  
 grade 2: 2.6–5.0 fold the ULN,  
 grade 3: 5.1–10 fold the ULN;  
 grade 4: >10 fold the ULN  
The mechanism through which severe HT (grade 3 or 4) develops is direct antiretroviral 
toxicity, hypersensitivity, immune reconstitution in people with chronic viral hepatitis and 
steatohepatitis, which has been discussed earlier.   HT has been reported in around 2% of 
patients taking EFV, of which around 60% grade 3 and 20% grade 4 (1127). 50% of those with 
grade 3 HT had clinical signs or symptoms identified and most of those with grade 4 HT; 
nevertheless, in the first 6 months, HT has not been found to be associated with an increased 
risk of mortality (1127). HT tends to be more common in patients co-infected with HBV or HCV 
(1128), for example in an observational study in patients receiving EFV they found that the 
incidence of severe HT was 0/100 PYs in patients not co-infected with HCV and 10% in patient 
co-infected with HCV (1128). The prevalence of HCV in patients infected with HIV is not 
negligible: 34% in the Eurosida study (1129), 7.2% in Thailand (1130) and generally less in 
Africa with an estimated prevalence of 1.9% in the CAESAR study conducted in South Africa 
(1131) and 8.2% in a small study conducted in Nigeria (1132). 
There is limited evidence that, in pregnant women, EFV may harm the fetus during the first 
trimester, while in the second and third trimester EFV use is safe (644). In the early 2000s 
retrospective case reports were published of babies born with severe abnormalities attributed 
to neural tube defects (myelomeningocele), who had been exposed to EFV during the early 
phase of gestation (1133;1134). This led the manufacturer and the FDA to recommend 
avoiding the drug to pregnant women in March 2005 (1135). Nevertheless it is difficult to 
ascertain whether the incidence of abnormalities in babies is higher in women taking EFV 
compared to women not taking it and the causal relationship between EFV and birth defects. A 
systematic review and meta-analysis of prospective studies observed that treatment with EFV 
during the first three months of pregnancy did not increase the risk of birth abnormalities 
(1136). The overall incidence of birth abnormalities, in children born from women who 
received EFV in the first trimester of pregnancy, was 2.9%, and the prevalence of neural tube 
defects was 0.08%, comparable to ranges reported in the general population in many 
developed and developing countries. Nevertheless, many of the studies included in the meta-
analysis are characterized by small sample size and in some they did not control for 
confounding factors. Up against the ambiguity regarding the possible causal relationship 
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between EFV and birth defects, women receiving EFV are advised to use barrier contraception 
for vaginal sex and an additional form of contraception, such as oral contraceptives.   
 
Toxicities to nevirapine 
NVP is characterized by few severe adverse events similar to EFV, such as rash, HT and 
Stevens-Johnson syndrome and NVP hypersensitivity reaction; with the only common (>5%) 
adverse event being an increase in transaminase levels (644). In a study from South Africa it 
has been estimated that 8% of the patients discontinue NVP due to toxicity within 3 years 
(645). 
In the first RCTs, approximately 10% to 35% of people initiating NVP based ART regimen 
developed skin rash within one to four weeks of treatment (253;254;1137;1138). 
Subsequently, it was found that starting treatment with half the dose recommended and 
increasing it to reach the full dose within four weeks could reduce NVP-associated rash to 
approximately 5% and discontinuation due to NVP-associated rash down to 2% or less 
(1139;1140). Usually the rash resolves after two to four weeks (1140) and thereafter, most of 
the patients experience very few or no side-effects. In 2008 the FDA issued safety labelling 
revisions for NVP, recommending discontinuation of NVP in patients who experienced severe 
rash or any rash with constitutional symptoms and to wait increasing the dose in patients 
experiencing mild to moderate rash without constitutional symptoms during the 14-day lead-
in period of 200 mg/day until the rash has resolved, with a maximum total duration of the 
once daily lead-in dosing period of 28 days (1141). Stevens-Johnson syndrome is quite rare in 
patients receiving NVP with an incidence between 0.2% and 0.6% (644;1139;1140).   
 
HT represents one of the primary concerns regarding NVP use (264;294;1128;1142-1145).  
Both skin and hepatic reactions are hypersensitivity reactions which can occur in patients 
receiving NVP. The risk of HT has been estimated in a meta-analysis of RCTs conducted by the 
manufacturer to be 10.7% (1145), with extremes as high as 17% in an RCT conducted in South 
Africa (294). A recent trial in high income countries found a risk of 7% (1139). Similar estimates 
come from observational studies with a rate of severe HT varying from 18.6/100 PYs in 
patients receiving NVP in Thailand (1130) to as low as 1.1/100 PYs in a small study conducted 
in New York City with lower prevalence of HBV (9%) and HCV (12%) (1146). The presence of 
HCV (1142) or HBV (1128;1130) has been found to increase the risk of severe hepatoxicity by 2 
to 4 fold. 
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Around half of these hepatic reactions are accompanied with fever, rash or arthralgia and less 
by severe rash, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, 
conjunctivitis, facial edema, and only rarely, Stevens-Johnson syndrome or toxic epidermal 
necrolysis. These symptoms are signs of a hypersensitivity reaction which is likely to be linked 
to at least some of these hepatic failures. In the 2NN study, where NVP and EFV were 
compared, significantly more hepatobiliary abnormalities in people receiving NVP than EFV 
were observed and more frequently in those receiving once rather than twice daily NVP (264). 
Most of these transaminase elevations associated with NVP use occur within the first four, six 
weeks (1139;1145); thereafter the incidence is not greater than with other ARVs (1145). An 
RCT comparing the new NVP extended release (NVP XR) formulation dosed once daily to the 
NVP immediate release (NVP IR) found that 4.8% in the NVP XR had grade 3 or 4 alanine 
aminotransferase (ALT) abnormalities compared to 7.1% in the NVP IR group (1139). Hepatic 
events occurred in 9.1% of patients in the NVP IR group compared to 5.5% in the patients 
receiving NVP XR, but a much smaller proportion had symptoms of hepatitis: respectively 2.4% 
and 1.6% (1139).  
Analysis of reported events seems to suggest that women with high CD4 cell counts are at 
higher risk for symptomatic, even life-threatening, hepatic events (294;1147). Women have 
been found to have approximately a double risk of experiencing hepatic event, symptomatic 
hepatic event or grade 3 or 4 transaminase increase compared to men (1139). Contrasting 
results have been reported regarding the occurrence of HT in patients at different levels of 
CD4 cell count. Analysis of RCTs found a higher risk of HT in women than in men and in 
patients with higher CD4 cell counts (1147). Two women (0.5%) who received NVP in the non-
comparative trial FTC-302, died from fulminant hepatic failure and both had CD4 counts >400 
cells/µL (1147). Women who initiated NVP with a CD4 counts above 250 cells/µl had an 
incidence of symptomatic hepatic events 10-fold greater than in women with CD4 counts of 
250 cells/µl or less at NVP initiation and among men, those with CD4 counts greater than 400 
cells/µl at NVP initiation had a 6 fold risk compared with men with CD4 counts of 400 cells/µl 
or lower at NVP initiation (6.3% vs. 1.2%) and for some patients, hepatic injuries continued to 
progress even after interrupting  NVP (1147). Other studies have not found an association 
between CD4 cell counts at NVP initiation and severe NVP HT (1148;1149). A meta-analysis 
published in 2008 found no statistically significant difference in the occurrence of HT between 
those with high and low CD4 count (1150). 
 
      
369 
 
On the basis of the safety and efficacy data, mainly from RCTs, in 2005 the FDA and the 
European Medicine Agency added warnings in the NVP product information recommending 
against the use of NVP in adults men with a CD4 count >400 cell/µl and in women with a CD4 
count >250 cell/µl, with the exception of situations where the  benefits outweigh the risk 
beyond doubts (1151). The ART guidelines recommend not using NVP-based combinations as 
first regimen in women with CD4 count >250 cells/µl at ART initiation or in men with CD4 
count >400 cells/µl (281), while patients on ART with CD4 count above these thresholds as a 
consequence of NVP-containing therapy can safely continue the regimen they are on without 
an increased risk of adverse hepatic event (1152).  
Some studies have reported that pregnant women have an increased risk of severe HT (1153). 
Nevertheless, a meta-analysis evaluating the safety of NVP in pregnant women, estimated a 
39% lower risk of NVP-toxicity in women with CD4 <250 cells/µl compared to pregnant women 
with higher CD4 cell count, with consistent results when restricting to prospective studies or to 
severe HT (1154). 
 
Toxicities to lopinavir boosted with ritonavir 
The adverse event which can sometimes occur with LPV/r are hepatoxicity and nephrotoxicity, 
while common (>5%) adverse events include hypertriglyceridaemia, hypercholesterolemia, 
asthaenia, nausea and diarrhoea (644). 
In ART-naïve patients, LPV/r can cause moderate to severe elevation (grade 3 or 4, >5 ULN) in 
serum aminotransferase: in 1-12% elevation of ALT and between less than 1% up to 10% of 
AST (1155;1156). The incidence does not seem to differ if the dose is once or twice daily 
(1157;1158) and it does not seem to differ from other boosted PIs (251;1159-1162). 
These elevations are usually asymptomatic and can usually resolve even without modifying the 
ART regimen. In patients ART-experienced similar frequencies (<10%) of aminotransferase 
elevations have been observed, similarly to other boosted PIs (1155;1163-1166). 
LPV/r seems to lead to chronic renal impairment (1105), when administered in combination 
with TDF (1167-1169), even when selecting people without previous impairment (eGFR of≥90 
mL/min) independently of being co-administered with TDF (1170). In particular the rate of 
progression to a confirmed eGFR<70 mL/min seem to be increased by 11% per year of 
exposure to LPV/r while the rate of developing CKD seem to be increased even more (adjusted 
incidence rate ratio: 1.22 per year of exposure) (1170). 
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PIs, including LPV/r, have been associated with a higher increase in lipid levels, in particular in 
total cholesterol and low-density lipoprotein cholesterol levels, than NNRTIs, which are known 
to increase levels of high density lipoprotein cholesterol (1171), body fat changes and 
metabolic disorders. Body fat changes have been estimated to occur in 35% of patients after 
four years on LPV/r (1172). Among 10 and 25% of people receiving LPV/r experience elevated 
lipids, in particular those with high cholesterol or triglycerides before initiating treatment 
(1172-1175). These increases in lipids are mild in most of them and treatment discontinuation 
related to lipid elevation is rare (1176;1177). The increase in blood cholesterol and triglyceride 
levels is due to the low-dose RTV rather than the LPV component (1178).  
A few studies found an association between CVDs and use of PIs (1179-1181). The D:A:D study, 
a very large observational study, estimated the incidence of myocardial infarction (MI) in 
people not exposed to PI to be 1.53/1,000 PYs, while in people exposed to PI for more than 6 
years to be 6.01/1,000 PYs (1181). The RR of MI per year of exposure to PIs, adjusting for 
exposure to other drug classes and CVD risk factor (except for lipids), is 1.16 (95% CI: 1.10, 
1.23), compared to 1.05 per year of exposure to NNRTIs. This increased risk was only partially 
explained by increased in lipid levels, and in particular by total cholesterol and high density 
lipoprotein while the other half was unexplained (1181).  A more recent analysis conducted on 
the D:A:D study (1182), evaluated the risk of MI for specific ARVs and found an increased risk 
of MI in people exposed to LPV/r (relative rate per year of exposure of 1.13; 1.09 [95% CI: 1.01, 
1.17] after adjusting for lipids but not reduced further after adjusting for other metabolic 
parameters). A case-control study nested within a cohort study conducted in France (1183) 
also found a significant increase in risk of MI for LPV/r (1.33; 95% CI: 1.09, 1.61 per year) and 
the other PIs, with the only exception of SQV. A meta-analysis published in 2013 (1184) 
estimated a RR of MI in people recently exposed (usually defined as within last 6 months) to PI 
of 2.13 (95% CI: 1.06, 4.28) and a RR of MI of 1.22 (95% CI: 1.01, 1.47) per additional year of 
exposure to LPV. These results are in contrast with a previous meta-analysis based on 
secondary analyses of RCTs, which found no increased risk from CVD in people exposed to PIs 
for an average of 1 year, compared with people exposed to NRTI-only (1185). 
The most common side-effects when using LPV/r, as mentioned, are asthaenia, nausea and 
diarrhoea. Moderate or severe diarrhoea occurred in around 15% to 20% (1156;1157) in 
people receiving once-daily compared to between 5% and 15% in people receiving twice-daily 
LPV/r (1156;1157) in RCTs. The initial onset of this side effect tends to occur in the first week 
and after 4 months in less than half of those who experienced this side effects it still persists 
(1157). Nausea is quite common as well occurring in around 10% of study participants (644). 
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Toxicities to atazanavir boosted with ritonavir 
ATV is characterized by several of serious adverse events: first degree atrioventricular (AV) 
block and nephrotoxicity, including nephrolithiasis and by a common (>5%) adverse event, 
indirect hyperbilirubinaemia, an increase in bilirubin levels in the blood (644). 
The hyperbilirubinaemia induced by ATV is the commonest side effects, occurring in up to 45% 
of patients taking ATV. This side effect tends to appear during the first week of starting ATV.  It 
does not seem to be clinically relevant, no correlation has been found between increase in 
bilirubinaemia and hepatic transaminase levels (1186), but can cause jaundice, a yellowing of 
the skin and the whites of the eyes.  A large study of ART-naïve patients reported that 33% 
experienced severe hyperbilirubinaemia, but only 5% developed jaundice and less than 1% 
discontinued treatment because of hyperbilirubinaemia (1187). Studies in PI experienced 
patients, found higher incidence of grade 3-4 bilirubin elevations (≥2.6 ULN), up to 49% in 
those receiving ATV/r and 20% in those receiving ATV/SQV, of which respectively 9% and 2% 
very severe (grade 4), but none of the patients discontinued because of this side effect (1163). 
There seems to be a dose relationship between ATV, occurrence of jaundice and 
discontinuation because of this side effect: with 6% of patients experiencing jaundice with a 
dose of 200 mg and 400 mg and 12% if the dose is 500 mg and with discontinuation of 
respectively 5%, 6% and 9% with doses of 200 mg, 400 mg and 500 mg (1186). 
There is evidence that ATV prolongs the PR interval of the electrocardiogram in some patients, 
reflecting abnormalities in AV conduction (1188). These abnormalities, in healthy volunteers 
and in patients, have been found to be asymptomatic and generally limited to first-degree AV 
block. The prevalence of asymptomatic first-degree AV block in RCTs where 
electrocardiograms were conducted, was 5.9% in patients treated with ATV, 5.2% in patients 
treated with LPV/r and 10.4% in patients treated with nelfinavir and 3.0% in patients treated 
with EFV (1188). 
Subsequent studies reported a prolongation of the PR interval of the electrocardiogram at 1 
month since switching from other PIs to ATV (1189). Another studies of 75 patients receiving 
ATV found that at 1 year since start taking it, 56 individuals had a median increase in QRS 
interval of 5 milliseconds, new asymptomatic bundle blocks were observed in 4 patients and 
one further patient receiving the β-blocker atenolol developed first-degree AV block (1190). 
They also observed increases in PR interval after 1 year but these were not statistically 
significant. 
372 
 
The association between ATV and the risk of developing CKD seem to be even stronger than 
the association between LPV/r and renal outcomes in combination with TDF (1167;1168;1191)  
or not (1105), and even in patients without previous renal impairment (1170). In particular the 
D:A:D study found that ATV increase the rate of progression to a confirmed eGFR <70mL/min 
by 19% per year of exposure (1.19; 95% CI: 1.09, 1.32) in patients with an eGFR ≥90 mL/min 
before starting ATV/r (1170). ATV/r has been found associated as well with other renal 
impairments, such as acute interstitial nephritis (1088;1192), abnormal proximal renal tubular 
function (1193) or nephrolithiasis, calculi in the kidneys (1194-1196) which can result in renal 
failure (1197). These impairments are quite rare compared to for example the nephrotoxicity 
due to TDF. 
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Appendix III. List of standard abbreviations for amino-
acids 
Amino acid 3-letter 1-Letter Nucleotide triplets 
Alanine Ala A GCU,GCC,GCA,GCG 
Arginine Arg R GCU,CGC,CGA,CGG,AGA,AGG 
Asparagine Asn N AAU,AAC 
aspartic  acid Asp D GAU,GAC 
Cysteine Cys C UGU,UGC 
glutamic acid Glu E GAA,GAG 
Glutamine Gln Q CAA,CAG 
Glycine Gly G GGU,GGC,GGA,GGG 
Histidine His H CAU,CAC 
Isoleucine Ile I AUU,AUC,AUA 
Leucine Leu L UUA,UUG,CUU,CUC,CUA,CUG 
Lysine Lys K AAA,AAG 
Methionine Met M AUG 
Phenylalanine Phe F UUU,UUC 
Proline Pro P CCU,CCC,CCA,CCG 
Serine Ser S UCU,UCC,UCA,UCG,AGU,AGC 
Threonine Thr T ACU,ACC,ACA,ACG 
Tryptophan Trp W UGG 
Tyrosine Tyr Y UAU,UAC 
Valine Val V GUU,GUC,GUA,GUG 
A: adenine; G: guanine; C: cytosine; U: uracil; T: thymine; 
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Appendix IV. Fertility and prevention of mother-to-child 
transmission in South Africa 
 
Fertility  
Fertility estimates in South Africa are calculated through household surveys and census data, 
because it was only in the 1990s that South Africa started having regular collection of national 
data of vital events, and unfortunately births are still not universally reported. 
South Africa is characterized by the lowest fertility rates in sub-Saharan Africa and this has 
been so since 1960 (595).  Table A.1 shows the total fertility rate and the average number of 
children ever born per woman.  
 
Table A.1. Fertility in South Africa 
Source Year Women 
age group 
Total fertility rate 
(births per woman) 
Average number of 
children ever born 
per woman 
World Bank (1198) 1996 - 3.04 - 
2001 - 2.84 - 
2006 - 2.63 - 
2007 - 2.58 - 
2011 - 2.44 - 
Population census (595) 2006 - 2.84 - 
Community survey (595) 2006 - 2.80 - 
2007 15-24 - 0.361 
25-34 - 1.496 
35-44 - 2.726 
45-49 - 3.202 
 
Prevention of mother-to-child transmission 
A PMTCT national programme was introduced in South Africa only in 2002 after the court 
ordered the South African government to develop one within a year (1199). Nevertheless in 
2005 just under 50% of pregnant women were tested for HIV. 
In 2008 the Department of Health released guidelines for the implementation of the PMTCT 
programme (1200) recommending: 
 AZT and NVP from 28 weeks’ gestation 
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 NVP treatment for pregnant women during labour and for the babies within 72 hours 
since birth 
 ART for pregnant women with a CD4 count below 200 cells/μL 
In the same year, given the MTCT coverage was still around 12%, a national PMTCT accelerated 
plan (“The A-plan”) was rolled out, to ensure the NSP target of reducing MTCT to 5% by 2011 
was achieved (1199). 
 
By 2010, 98% of health facilities were offering PMTCT, 87% of HIV-positive pregnant women 
were receiving ART to reduce PMTCT and MTCT at six week was estimated to be 3.5% (450). 
 
In 2010, new guidelines for PMTCT were released in South Africa (1201), recommending: 
 AZT from 14 weeks,  
 ART for pregnant women with CD4 cell count of 350 cells/μL or less  
 NVP prophylaxis to the baby for six week (if the mother is on ART or not breastfeeding) 
or until one week after the cessation of breastfeeding  
In 2011 MTCT dropped even further from 3.5% in 2010 to 2.7% in 2011 (473).  
 
In 2013 PMTCT guidelines have been revised to offer: 
 ART for all HIV-positive pregnant women for the breastfeeding period with a CD4 
count above 350 cells/μL or forever if already eligible for ART according to national 
guidelines (CD4 of 350 cells/μL or less or with TB). 
 ART for all babies born from HIV-positive mother (regardless of the mother’s CD4 
count or stage) 
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Appendix V. Virological suppression in South Africa 
Source Population Year Follow-up 
months, 
median (IQR) 
Definition of  virological suppression % with virological 
suppression (95% CI) 
Orrell (489) 289 ART-naïve patients in a university 
clinic in Cape-Town  
1996-2001 - VL<400 copies/mL of those on triple ART 11 months: 70.9% 
Nachega (487) 66 patients in Chris Hani Baragwanath 
Hospital's Adult HIV Clinic in Soweto 
- 18 VL<400 copies/mL of those on  ART 73% (if adherence >95%); 
88% (if adherence ≤95%) 
Coetzee (477) 287 patients starting ART in a public 
community based programme in 
Khayelitsha 
2001-03 13.9 VL<400 copies/mL of those on triple ART 3   months: 88.1% 
6   months: 89.2% 
12 months: 84.2% 
18 months: 75.0% 
24 months: 69.7% 
Barth (306) 313 patients in Limpopo (rural) 
receiving 1 NNRTI and 2 NRTIs as 1st 
line regimen 
2003 - Achieved VL<50 of those on ART 12 months: 73% 
Wouters (1202) 268 in the Free State public sector ART 
program (eligible if CD4 count <200 
cells/ml and/or WHO stage 4) 
2004 - VL<400 copies/mL of those on ART 6 months: 83.5% 
12 months: 84.7% 
Orrell (307) 929 ART-naïve patients in Nyanga 
district, near Cape Town 
2002-05 6 (3-14). Total 
760 PYs 
VL<400 copies/mL of those on ART 12 months: 96% 
24 months: 96% 
VL<50 copies/mL of those on ART 12 months: 85% 
24 months: 85% 
Badri (1203) 360 patients enrolled in the Cape Town 
AIDS Cohort through participation in 
multicentre phase III RCT  
1996-2006 24.7 (4.7–51.6) 
Total 591 PYs 
Achieved VL<400 copies/mL 91.7 
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Source Population Year Follow-up months, 
median (IQR) 
Definition of  virological suppression % with virological 
suppression (95% CI) 
Boulle 2008 
(1204) 
3970 patients starting NVP or EFV based 
ART (some with concomitant rifampicin-
based antitubercular therapy) in a 
community–based ART program 
2001-06 - VL<400 copies/mL of those on ART At 6 months: 
NVP no TB: 91.7 (90.0-93.3) 
NVP       TB: 83.7 (76.5-89.4) 
EFV no  TB: 94.3 (91.6-95.3) 
EFV   TB: 93.6 (91.6-95.3) 
At 12 months: 
NVP no TB: 87.8 (85.3-90.0) 
NVP       TB: 80.0 (71.5-86.9) 
EFV no  TB: 91.9 (89.0-94.3) 
EFV   TB: 92.0 (89.0-94.4) 
At 18 months: 
NVP no TB: 86.0 (82.7-88.8) 
NVP       TB: 80.0 (69.6-88.1) 
EFV no  TB: 89.6 (84.9-93.2) 
EFV        TB: 88.5 (83.5-92.4) 
Barth (496) 609 ART-naïve adults in a PHC with GP 
administering ART in Elansdoorn (rural) 
2003-06 - VL<400 copies/mL of those on ART 12 months: 83% 
VL<400 copies/mL of those initiated on 
ART 
12 months: 55% 
Achieved VL<400 of those on ART 12 months: 94% 
VL<50 copies/mL of those on ART 12 months: 70% 
VL<50 copies/mL of those initiated on ART 12 months: 46% 
24 months:18% 
Achieved VL<50 of those initiated on ART 12 months: 83% 
Gandhi 2009 
(1205) 
119 TB/HIV co-infected patients enrolled 
in ART programme in a government 
hospital in Msinga in KwaZulu-Natal 
2003-06 - VL<400 copies/mL of those on ART 6 months: 83% 
12 months: 88% 
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Source Population Year Follow-up months, 
median (IQR) 
Definition of virological suppression % with virological 
suppression (95% CI) 
Bedelu (843) NGO programme in Lusikisiki (Eastern Cape) 2004-06 - VL<400 copies/mL of those on  ART 
with VL measurement (n=296) 
12 months: 89.5 (85.5–92.8) 
Boulle (292) 7,323 in 3 public PHCs in Khayelitscha in 
Western Cape 
2001-07 - VL<400 copies/mL of those on ART 12 months: 87.6% 
36 months: 88.1% 
60 months: 83.8% 
Innes (495) 1416 patients initiating ART (eligible if CD4 
<250 cells/μL, a WHO stage 4 condition or a 
WHO stage 3 condition and CD4 count <350 
cells/μL)in a multisite workplace programme 
2002-07 - VL<400 copies/mL of those on ART 24 months: 60%; 
36 months: 61% 
Fatti (1206) 29 203 from 47 PHCs, 9 district hospitals and 
3 regional hospitals in 4 different provinces 
2004-07 - VL<400 copies/mL of those with VL 
measure 
12 months: 86.6% (85.8%-
87.4%) 
24 months: 86.3% (84.8%-
87.6%) 
36 months: 85.7% (81.5%-
89.2%) 
Barth (304) Systematic review (Presented only summary 
of data from South Africa) 
Papers 
published 
before 
06/2009 
- VL<400 copies/mL of those on ART 6   months: 75%-92% 
12 months: 66%-90% 
24 months: 60%-72% 
36 months: 61% 
VL<400 copies/mL of those initiated 
on ART 
6   months: 83% 
12 months: 55%-77% 
24 months: 75% 
VL<50 copies/mL of those on ART 
  
6   months: 63%-83% 
12 months: 63%-70% 
24 months: 65% 
VL<50 copies/mL of those initiated 
on ART 
12 months: 46% 
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Source Population Year Follow-up 
months, 
median (IQR) 
Definition of  virological suppression % with virological 
suppression (95% CI) 
Sanne (1207) 7,583 patients in a public clinic in 
Johannesburg 
2004-08 20.3 (Total 
13,417 PYs) 
VL<400 copies/mL of those on ART with VL 
measurement 
1-6 months: 90.8% 
Mutevedzi 
(497) 
5,719 patients in PHCs in rural 
KwaZulu-Natal 
2004-08  VL<25 copies/mL of those initiated on ART 12 months:77% 
Barth (498) 735 patients initiated ART in Limpopo - 36 VL<50 copies/mL of those initiated on ART 63% 
80% if only those with > 3-
month follow-up included 
Achieved VL<50 copies/mL of those 
initiated on ART 
76% 
Hamers (966) 2588 ART naïve patients from 13 
clinics: 2 in Kenya, 1 in Nigeria, 3 in 
South Africa, 3 in Uganda, 3 in Zambia 
and 1 in Zimbabwe; 
2007-09 - VL<400 copies/mL of those on ART 12 months: 90% (95% CI: 89%, 
91%) 
VL<400 copies/mL of those initiated on 
ART 
12 months: 70% (95% CI: 68%, 
71%) 
Fatti (1208) 66,953 patients: 19,668 (29.4%)  
received community based adherence 
support and 47,285 (70.6%) patients 
who did not receive it 
2004-10 14.8 months 
(7.7–25.5; 
100,295 PYs) 
VL<50 copies/mL of those initiated on ART At 6 months: 
community based adherence 
support: 76.6% (75.8% to 
77.5%) 
No community based 
adherence support: 72% 
(71.3% to 72.5%) 
ART: antiretroviral treatment; CI: confidence interval; EFV: efavirenz; GP: general practitioner; IQR: interquartile range; NGO: non-governmental organization; NNRTI: non-nucleoside reverse 
transcriptase inhibitor; NRTI: nucleoside reverse transcriptase; NVP: nevirapine; PHC: primary healthcare clinic; PY: person-year; RCT: randomized controlled trial; TB: tuberculosis; VL: viral load; 
WHO: World Health Organization;  
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Appendix VI. Virological failure and development of drug resistance in South Africa 
Source Population Year Months of 
follow-up, 
median (IQR) 
Definition of virological rebound or failure % who experience 
Bisson 2008 (1209) Patients in private healthcare 
programmes from 9 
countries in southern Africa 
2000-03 21 (17-24) VL>1000 copies/mL among those who reached 
VL<400 copies/mL (n=1,101) 
14% 
VL>1000 copies/mL  6  months (n=958): 25% 
12 months(n=872): 26% 
Barth (306) 313 patients in Limpopo 
(rural) receiving 1 NNRTI and 
2 NRTI as 1st line regimen 
2003 - VL>1000 copies/mL after reaching VL<50 
copies/mL in the first year on ART 
13% 
Orrell (307) 929 ART-naïve patients in 
Nyanga district, near Cape 
Town 
2002-05 6 (3-14). Total 
760 PYs 
Single VL>1000 copies/mL (VL measured every 4 
months) 
12 months: 8% 
24 months: 17% 
2 consecutive VL>1000 copies/mL 12 months: 3% 
24 months: 5% 
% who re-suppress after VL>1000 copies/mL 53% 
Badri (1203) 330 patients enrolled in the 
Cape Town AIDS Cohort 
through participation in 
multicentre phase III RCT  
1996-2006 24.7 (4.7–
51.6) 
Total591 PYs 
VL>≥ 1,000 copies/mL following VL<400 
copies/mL 
54.2% 
Rate of viral failure of 24.7 
patient-months (IQR: 4.7–51.6) 
Barth (496) 609 adults; PHC with GP 
administering ART in 
Elansdoorn (rural) 
2003-06 - VL >1000 copies/mL among those who reached 
VL<400 
10% 
Boulle (292) 7,323 in 3 public PHCs in 
Khayelitscha in Western 
Cape 
2001-07 - 2 consecutive VL>5,000 copies/mL, despite 
enhanced adherence promotion after the first 
VL>5,000 copies/mL 
60 months: 14% (95% CI: 12%, 
16%)  
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Source Population Year Months of 
follow-up, 
median (IQR) 
Definition of virological rebound or failure % who experience 
Fox (499) 23,456 ART naïve patients I 5 
programs within the IEDEA-SA 
collaboration, including around 
10% of patients on ART in SA 
2000-08 15.6 (Range 
across sites: 13-
17), on ART 22; 
Total 29,935  
2 consecutive VL>400 copies/mL after 6 months 
on 1st line ART with the 2nd value >5000 
copies/mL despite stepped-up adherence 
12 months: 3.5% 
24 months: 8.5% 
36 months: 16.9% 
2 consecutive VL>1,000 copies/mL after 6 months 
on 1st line ART with the 2nd value >5000 
copies/mL despite stepped-up adherence 
12 months: 3.2% 
24 months: 8.0% 
36 months: 15.0% 
VL>5,000 copies/mL or 2 VL>400 copies/mL after 
having achieved VL<400 copies/mL 
16.5% (95% CI: 15.9, 
18.2) 
Barth (498) 735 patients initiated ART in 
Limpopo 
- 36  VL>1000 copies/mL during follow-up 16% 
20% if only those with 
>3-month follow-up 
included 
Hamers (398) 2588 ART naïve patients from 13 
clinics: 2 in Kenya, 1 in Nigeria, 3 
in South Africa, 3 in Uganda, 3 in 
Zambia and 1 in Zimbabwe; 
2007-09 - VL>1000 copies/mL of those on ART (VL measure 
at 0 and 12 months) 
12 months:8.2% 
Johnston 2012 (500) 13,537 patients starting 1st-line 
ART with at least 1 VL 
measurement after 6 months of 
ART in the Aurum Institute ART 
programme, including 56 clinics 
serving employees of large, 
predominantly mining companies 
and 81 urban and peri-urban 
private GP. ART free of charge 
2003-09 31.2 (20-42) 2 consecutive VL >1000 copies/mL ≤9 months 
apart, both ≥6 months after ART initiation 
17.9%:  
31.1% from workplace 
clinics  
10.7% from 51 
community clinics 
ART: antiretroviral treatment; CI: confidence interval; GP: general practitioner; IQR: interquartile range; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase; 
PHC: primary healthcare clinic; PY: person-year; RCT: randomized controlled trial; SA: South Africa; VL: viral load;  
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Appendix VII. Virological outcomes on second-line regimen in South Africa 
Source Population Year Follow-
up, 
median 
(IQR) 
Definition of  outcome Value of the outcome 
Barth (498) 735 patients initiated ART in Limpopo  36  % achieving virological suppression 
after switching to second-line 
81% 
Boulle (292) 7,323 in 3 public PHCs in Khayelitscha in Western 
Cape 
2001-07 - VL<400 copies/mL of those on 
second-line ART 
12 months since ART 
initiation: 80% 
24 months: 66% 
36 months: 79.4% 
48 months: 70.7% 
60 months: 75.9% 
Johnston 2012 (500) 1668 patients with VF enrolled in the Aurum 
Institute ART programme, including 56 clinics 
serving employees of large, predominantly mining 
companies and 81 urban and peri-urban private 
general practitioners. ART free of charge 
2003-09 Total PYs 
1921.8 
% who achieve virological 
suppression after VF 
12 months: 13.2% 
% dead at 12 months after VF 12 months: 4.6% 
Johnston 2012 
(1210) 
417 patients who switched regimen: 205 from a 
workplace programme and 212 from community 
programmes 
2003-10 - VL<400 copies/mL between 2 
weeks to 15 months of switching 
regimens 
15 months from switch: 
48.3% (workplace) and 
72.0% (community) 
VL rebound (>400 copies/mL after 
initial suppression after switch) 
35.6% (workplace)  and. 
13.2% (community) 
Johnston 2014 
(1211) 
122 patients who switched to second-line regimen 
with virological data 
2003-08  % who suppress (VL <400 
copies/mL 2 weeks to 15 months 
following switch) 
68% 
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Source Population Year Follow-
up, 
median 
(IQR) 
Definition of  outcome Value of the outcome 
Schoffelen (503) 210 patients switched to second-line at the Ndlovu 
Medical Centre in  Elandsdoorn (rural) 
2004-10 20 [IQR: 
11–35]. 
VL<400 copies/m of those on ART 12 months: 71.9% 
24 months: 75.0% 
VL<400 copies/m of those initiated 
on ART 
67.5% 
VL<50 copies/mL of those on ART 12 months: 60.9% 
24 months: 64.3% 
VL<50 copies/mL of those initiated 
on ART 
58.1% 
VL>1,000 copies/mL after initial 
virological response 
14.7% 
Murphy (505) 136 patients who switched to second-line regimen 
in the Sinikithemba Outpatient HIV/AIDS Clinic at 
McCord Hospital in Durban (PEPFAR and DoH 
funded) 
- 34 (20-
44) 
VL>1,000 copies/mL among those 
on ART 
12 months: 25% 
18 months:21% 
24 months: 25% 
Fox 2010 (1212) 328 on second-line therapy at an urban public 
sector clinic in Johannesburg 
2004-08 - Two consecutive VL >1000 
copies/mL on ART  
12 months (n=262): 22.6 
(17.8, 27.9) 
Van Zyl (502)  93 on second-line regimen in 2 public health clinic 
in Khayelitsha, Cape Town 
- 11.5** 
(9–21.5) 
VL >500 copies/mL 12 months: 39.89 (30.3, 
49.9) 
El -Khatib (504) 115 from 2 outpatient clinics at the largest hospital 
in Africa located outside Johannesburg 
2008 - VL>400 copies/mL of those on 
second-line ART 
24 months: 32.33 (24.1, 
41.1) 
Levison (1213) 202 starting second-line in the Gugulethu Clinic in 
Nyanga, a peri-urban township of Cape Town 
2002-10 6** % with viral failure (VL >400 
copies/mL) 
6 months (n=167): 25.30 
(19.0, 32.1) 
*: if not indicated it refers to switch to second-line, because of virological failure; **: mean time rather than median;  
ART: antiretroviral treatment; DoH: Department of Health [South Africa]; IQR: interquartile range; PEPFAR: President’s Emergency Plan for AIDS Relief; PHC: primary healthcare clinic; PY: person-year; 
PEPFAR: VF: virological failure; VL: viral load; 
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Appendix VIII. Fertility and prevention of mother-to-child 
transmission in Zimbabwe 
Fertility  
Fertility estimates for Zimbabwe have been estimated from the censuses. The civil registration of 
births and deaths was introduced in 1890 and was compulsory for white settlers until 1980. Since 
1986 notification and registration of the birth, still-birth or death of any person in Zimbabwe is 
compulsory (1214), nevertheless in the period 2000-2009 it was estimated only between 24 and 37% 
of deaths were reported (1215). 
 
The fertility in Zimbabwe has been declining in the last 30 years from 5.5 births per woman in the 
period 1984-88 (520) to a minimum of 3.8 documented in the DHS in 2005-06, while in 2011 it was 
slightly higher: 4.1 children per woman (519). In the future it is projected to decrease even further 
down to 2.74 in the period 2025-30. Table A.3 (page 387) summarizes the estimates on the total 
fertility rate in Zimbabwe.  
 
Prevention of mother-to-child transmission 
PMTCT has been an integrated part of the HIV response since 1999 (539).  Nevertheless at the end of 
2001 only 4% of those in need of PMTCT were receiving it (1216). In 2002, a national PMTCT 
programme was launched integrating PMTCT in the reproductive health services (528), providing 
single dose NVP (1217).  
 
The national guidelines for use of ART published in 2010 (228) contained recommendations on how 
to assess pregnant women and which regimens to prescribe. They recommend that all women 
should be tested for HIV at the first visit and then: 
 If HIV-negative they are recommended to retest after 3 months for HIV and to repeat the 
HIV test in the last trimester 
 If HIV-positive they should be assessed for ART eligibility and: 
o If eligible for ART (see section 2.2.7) they should be initiated on ART, but without 
using D4T or EFV, preferably TDF+FTC+NVP 
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o If not eligible they should initiate PMTCT prophylaxis and be reassessed for ART 
eligibility at every visit. The recommended PMTCT prophylaxis consists of twice daily 
AZT for the mother from 14 weeks of gestation, AZT+3TC+single dose NVP at labour 
and a 7 days course of AZT+3TC after the delivery and for the baby different dosages 
of NVP during the breastfeeding period. 
 
The coverage of HIV testing in ANC was still very low in 2005-06 at level of 23% (518); by 2011 it 
more than doubled (59%) (519), but it was still dramatically low compared to other countries such as 
South Africa for example where it is universal. Similarly, the PMTCT coverage among HIV-positive 
women was very low in 2007 with only 22% of women receiving PMTCT but by 2011 98% of women 
were receiving PMTCT (530).  
 
The new national antiretroviral guidelines, released in 2013 (229), recommend what has been 
referred to as option B+: initiation of life-long ART for all pregnant women. 
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Table A.2. Prevention of mother-to-child transmission in Zimbabwe 
Source  Calendar 
Year 
Population % pregnant 
women 
tested in ANC 
% of HIV+ 
pregnant 
women who 
received 
PMTCT 
Number of HIV+ 
pregnant women 
who received 
sNVP and/or other 
PMTCT regimen 
Zimbabwe 
DHS 
(518) 2006 15-49 
15-19 
20-24 
25-29 
30-39 
40-49 
22.6% 
20.2% 
25.7% 
20.8% 
22.5% 
11.9% 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
(519) 2011 15-49 
15-19 
20-24 
25-29 
30-39 
40-49 
59.1% 
44.9% 
59.6% 
66.5% 
58.8% 
49.1% 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Zimbabwe multiple 
indicators 
monitoring (548) 
 
2007-09 15-49 58.1% 
(53.4% 
received the 
result) 
-  
Global AIDS 
Response (530) 
2007 
2009 
2010 
2011 
 - 
- 
- 
- 
22% 
59% 
84% 
98% 
- 
- 
- 
- 
Global fund reports 
(545) 
2010 
2011 
2012 
Jan-
Mar2013 
- 
 
- 
- 
- 
- 
94.0% 
95.5% 
97.5% 
- 
44,444 
44,770 
59,224  
13,444 
ANC: antenatal clinic; DHS: Demographic and Health Survey; PMTCT: prevention of mother-to-child transmission; sNVP: 
single dose nevirapine;  
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Table A.3. Fertility in Zimbabwe 
Source Year Women age 
group 
Total fertility 
rate (births per 
woman) 
World Bank (1198) 2004 - 
 
4.0 
2005 4.0 
2006 3.9 
2007 3.9 
2008 3.9 
2009 3.8 
2010 3.7 
2011 3.6 
Zimbabwe YAS 2001-02 (522) 1999-2001 15-29 2.4 
Zimbabwe Population 
Census 
2002 (511)  2002 - 3.6 
2012 (510) 2012 - 3.8 
Zimbabwe DHSs 1988 (520) 1984-1988 - 5.5 
1994 (516) 1991-94 - 4.3 
1999 (517) 1996-99 - 4.0 
2005-06 (518) 2003-05 - 3.8 
2011 (519) 2010-11 - 4.1 
UNICEF (548) 2009 - 3.7 
CIA (513) 2014 - 3.56 
UN Secretariat (436) 1995-2000 - 4.20 
2000-05 4.01 
2005-10 3.90 
2010-15 3.51 
2015-20 3.20 
2025-30 2.74 
CIA: Central Intelligence Agency; DHS: Demographic and Health Survey; UN: United Nations; UNICEF: United Nations 
Children's Fund; YAS: Zimbabwe Young Adult survey; 
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Appendix IX. Retention on ART in Zimbabwe 
Author Setting Year of 
the 
study 
N (HIV+ 
who 
initiated  
ART) 
Lost to follow-up 
definition 
Median 
follow-
up 
(months) 
Months 
since ART 
initiation 
Total attrition Retained in care 
Died  Lost to 
follow-up 
Transferre
d to care 
Retained at 
original site 
Mutasa-
Apollo  
(554) 
Nationally 
representative multi-
stage retrospective 
cohort study of 
Zimbabwe National 
ART Programme 
2007-
10 
3,919 >90 days late for a 
scheduled visit with 
the healthcare 
provider or 
pharmacy 
16 6 4.1 4.9 Excluded 90.7 (86.1-93.8) 
12 4.8 16.1 78.1 (69.7-84.7) 
24 6.7 23.5 68.8 (58.5-77.5) 
36 8.5 25.2 64.4 (55.7-72.3) 
Bygrave 
(558) 
 
25 PHCs (MSF) in 
rural district of 
Buhera in Manicaland 
province among 
patients aged 10 to 
30 years 
2005-
08 
898 Not attended the 
clinic for >90 days 
since end of the last 
prescription 
15 (8-21) 6  Rate: 6.2 (95% 
CI: 4.9, 7.7) 
/100 PYs. 
Min in 10-15 
years old: 3.6 
(95% CI: 2.0, 
6.3) /100 
PYs, max in 24-
30 years old 7.7 
(95% CI: 5.8, 
10.4) /100 PYs 
Rates: min in 
10-15 years 
old: 4.2 (95% 
CI: 2.5, 
7.0)/100 PYs, 
max in 19-24 
years old: 
16.8 (95% CI: 
11.6, 24.3) 
/100 PYs 
- 87.5 in 19-24 
years old to 
98% in 10-15 
years old; 
 
12 83% in 19-24 
years old to 
93% in 10-15 
years old; 
24 75% in 19-24 
years old to 
92% in 10-15 
years old; 
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Author Setting Year of 
the 
study 
N (HIV+ 
who 
initiated  
ART) 
Lost to follow-
up definition 
Median 
follow-up 
(months) 
Months 
since 
ART 
initiation 
Total attrition Retained in care Transferr
ed to 
care 
Retained at 
original site Died  Lost to follow-
up 
Rasschaert 
(560) 
 
2 ART programmes 
(MSF), 1 in Thyolo 
district (Malawi) and 1 in 
Buhera, Manicaland, 
where patients could be 
in care always in hospital 
(HO), initiated in hospital 
and transferred to the 
health centre (HOT) or 
always in the health 
centre (HC) 
[People who interrupted 
ART are censored as 
well] 
2003-
08 
9,721 in 
Buhera 
≥90 days late 
for a scheduled 
visit  
- 6 Of those on 
ART: 
1% in HOT, 9% 
in HO 
Of those on ART: 
1% in HOT, 
13.5% in HO 
Censored 88% (78% in 
HOT to 98% in 
HO) 
12 2.5% in HOT, 
11% in HO 
2% in HOT, 18% 
in HO 
84% (75% in 
HOT to 97% in 
HO) 
24 4.0% in HOT, 
12% in HO 
3% in HOT, 23% 
in HO 
80% (71% in 
HOT to 94% in 
HO) 
30 4.5% in HOT, 
14% in HO 
4% in HOT, 24% 
in HO 
79% (66% in 
HOT to 92% in 
HO) 
Wandeler 
(559) 
 
6 ART programmes 
(SolidarMed, NGO): 2 in 
Zimbabwe (Bikita and 
Zaka, both in Masvingo 
Province), 2 in Lesotho 
and 2 in Mozambique, 
part of IEDEA 
collaboration 
2005-
2010 
1777 in 
Bikita, 1254 
in Zaka 
Not returning 
to the clinic for 
6 months or 
longer. 
- 12b 6.4 (5.5-7.4) 10.6 (9.4-11.8) Censored 83.1 (81.7-84.5) 
24b 7.4 (6.4-8.5) 13.4 (12.0-14.9) 79.2 (77.5-80.8) 
36b 9.0 (7.6-10.5) 15.7 (13.9-17.6) 75.1 (72.8-77.3) 
A: Kaplan-Meier estimates; b: Competing risk estimates; 
ART: antiretroviral treatment; CI: confidence interval; HOT: initiated in hospital and transferred to the health centre; HO: in care always in hospital; HC: in care always in the health centre; MSF: 
Medicins Sans Frontieres; NGO: non-governmental organization; PHC: primary healthcare clinic; PY: person-year; 
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Appendix X. Alternative sexual behavioural models 
As mentioned, an alternative sexual behaviour structure has also been developed, the table 
below shows how it differs compared to the main one (referred to as RBM =17).   
The main one is called the “asymmetric” model because it is asymmetric by gender, with the 
proportion of women having > 10 partners higher than for men, representing sex workers. 
 
The probability of sampling a symmetric model when simulating the South Africa epidemic was 
0.4: 0.05 for respectively RBM 2 and 5, 0.1 for respectively RBM 7, 10 and 12. In the remaining 
60% of cases an asymmetric RBM is sampled: 0.2 for RBM 17, 0.1 for respectively RBM 9, 11, 
13 and 4. 
 
Table A.4. Distribution of condom-less sex short-term partners at time 0, at the beginning of 
the epidemic 
 Males (g=1) Females (g=2) 
Symmetric 
RBM 
Asymmetric  
RBM 
(alternative) 
Symmetric 
RBM 
Asymmetric  
RBM 
(alternative) 
CLST 
partners in 
period t 
0 0.55 0.90 0.55 0.93 
1 0.30 0.07 0.30 0.05 
Medium (2-9)* 0.05 0.03 0.05 0.0185 
High (≥10)** 0 0 0 0.0015 
*Poisson(1.5); **Poisson(2*swn); CLST: condom-less short-term; RBM: risk behavioural model; 
 
There is a 5% chance that the symmetric RBM is sampled, 95% that the asymmetric is sampled 
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Table A.5. Values of fgij  (values determining probability of transitioning between CLST 
partner risk behaviour groups) for different risk behavioural model 
 
Table A.5a. Values of fgij   for RBM 4, 9, 11, 13, 17 (Probability of these RBM being sampled 
0.6) 
 CLST partners in period t 
0 1 Medium (2-9) High (≥10) 
Males 
CLST partners 
in period t-1 
0 0.89 0.08 0.03 0.00 
1 0.80 0.15 0.05 0.00 
Medium (2-9) 0.35 0.27 0.38 0.00 
High (≥10) 0.00 0.00 0.00 0.00 
Females 
CLST partners 
in period t-1 
0 0.93 0.05 0.02 0.00025 
1 0.86 0.11 0.03 0.0005 
Medium (2-9) 0.53 0.08 0.38 0.001 
High (≥10) 0.005 0.00 0.00 0.995 
CLST: condom-less short-term; RBM: risk behavioural model; 
 
 
Table A.5b. Values of fgij   for risk behavioural model 10, 12 (Probability of these risk 
behavioural model being sampled 0.2) 
 CLST partners in period t 
0 1 Medium (2-9) High (≥10) 
Males 
CLST partners 
in period t-1 
0 0.80 0.17 0.03 0.00001 
1 0.90 0.08 0.02 0.00001 
Medium (2-9) 0.15 0.35 0.50 0.00001 
High (≥10) 0.25 0.05 0.20 0.50 
Females 
CLST partners 
in period t-1 
0 0.80 0.17 0.03 0.00025 
1 0.90 0.08 0.02 0.00025 
Medium (2-9) 0.15 0.35 0.50 0.001 
High (≥10) 0.04 0.03 0.03 0.90 
CLST: condom-less short-term; 
 
  
392 
 
Table A.5c. Values of fgij for risk behavioural model 2, 7 (Probability of these risk behavioural 
model being sampled 0.15) 
 CLST partners in period t 
0 1 Medium (2-9) High (≥10) 
Males and Females 
CLST partners 
in period t-1 
0 0.77 0.13 0.10 0.00 
1 0.55 0.32 0.13 0.00 
Medium (2-9) 0.15 0.70 0.15 0.00 
High (≥10) 0.01 0.00 0.00 0.99 
CLST: condom-less short-term; 
 
 
Table A.5d. Values of fgij for risk behavioural model 5 (Probability of these risk behavioural 
model being sampled 0.05) 
 CLST partners in period t 
0 1 Medium (2-9) High (≥10) 
Males 
CLST partners 
in period t-1 
0 0.80 0.17 0.03 0.00 
1 0.90 0.08 0.02 0.00 
Medium (2-9) 0.15 0.35 0.50 0.00 
High (≥10) 0.00 0.00 0.00 0.00 
Females 
CLST partners 
in period t-1 
0 0.80 0.17 0.03 0.00025 
1 0.90 0.08 0.02 0.00025 
Medium (2-9) 0.15 0.35 0.50 0.001 
High (≥10) 0.005 0.005 0.00 0.99 
CLST: condom-less short-term; 
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Table A.6. Proportion of the population who experience only very low sexual risk behaviour 
(p_rred_p) and reduction in sexual behaviour in these subsamples 
 Proportion affected by the 
reduction 
Reduction in sexual 
behaviour 
Males (g=1) Females (g=2) 
Risk behavioural 
model 
2 0.2 0.2 0.01 
4 0.35 0.5 0.1 
5,7 0.2 0.35 0.01 
9-13, 17 0.35 0.5 0.01 
 
 
Table A.7.  Values of rga  (factor determining relative level of sexual risk activity) 
 Risk behaviour model 
2,7 4,9 17 5,10,12 2,7 4,9 17 5,10,12 
Males (g=1) Females (g=2) 
Age 
group 
15- 0.75 0.65 0.35 0.85 1.15 1.5 3.2 1.5 
20- 0.75 0.65 0.45 1.0 1.15 1.5 3.5 1.5 
25- 1.0 1.0 1.3 1.4 1.0 1.0 3.0 1.3 
30- 1.0 0.8 0.5 1.2 0.85 0.8 1.5 1.0 
35- 0.65 0.65 0.35 1.0 0.55 0.5 0.7 0.8 
40- 0.45 0.5 0.3 0.8 0.35 0.35 0.7 0.6 
45- 0.35 0.4 0.3 0.6 0.2 0.1 0.7 0.5 
50- 0.23 0.35 0.15 0.5 0.15 0.05 0.6 0.4 
55- 0.18 0.25 0.25 0.4 0.08 0.04 0.4 0.3 
60- 0.10 0.15 0.15 0.3 0.04 0.02 0.3 0.2 
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Table A.8. Proportion with a condom-less sex long-term partner at the beginning of the 
epidemic and probability of starting a CLLT partnership  
 Proportion with a CLLT 
partner at the beginning 
of the epidemic  
Probability of starting a CLLT  
Risk behavioural model 2,4,5,7,9-13 17 2,5,7,10,12 4,9,11,13 17 
Age group 
partners 
15- 0.4 0.42 0.15 0.10 0.07 
25- 0.5 0.65 0.10 0.07 0.09 
35- 0.5 0.65 0.05 0.05 0.035 
45- 0.5 0.58 0.01 0.01 0.035 
55- 0.5 0.45 0.005 0.005 0.02 
CLLT: condom-less long-term partner; 
  
      
395 
 
Appendix XI. Parameter values and distributions  
Parameters relating to sexual behaviour 
As mentioned in section 3.3, sexual risk behaviour is modelled as the number of short-term 
(e.g. casual) partners and presence of a long-term partner in each 3 month period and, as for 
all variables modelled, is updated in 3 month periods.  The status of the long-term partner, in 
terms of HIV infection, diagnosis and ART use, is tracked over time. The values of the 
parameter that determine the sexual behaviour are listed below. If they were sampled from a 
distribution the distribution is reported. 
 
For the parameters which are normally distributed the mean and the variance are indicated, 
while for the parameters lognormally distribution the mean and the variance of the variable’s 
natural logarithm are indicated. 
 
Table A.9. Parameters and distribution relating to sexual behaviour 
Parameter (variable name in the 
program) 
Value (or distribution) 
South Africa Zimbabwe 
Sexual behaviour 
Sexual behaviour model structure 60% base structure (RBM=4), 40% 
alternative structure (with no sex workers; 
see section 3.3, other RBMs) 
100% base 
structure 
Factor to change overall average 
level of condom-less sex with 
short-term partners (newp_factor) 
lognormal(ln10,0.32), if fold_tr*<=1 and 
tr_rate_primary*<=0.2; 
lognormal(ln4,0.32), if fold_tr>  1 and 
tr_rate_primary>  0.2; 
lognormal(ln6,0.32), otherwise; 
9 
Poisson mean for highest short-
term partner group (>10 CLST 
partner) (see section 3.3.1) (swn) 
Gamma(20,2) (mode=19/2=9.5) if 
fold_tr*<=1 and tr_rate_primary*<=0.2; 
Gamma(8,2) (mode=7/2=3.5) if fold_tr>  1 
and tr_rate_primary>  0.2; 
Gamma(14,2) (mode=13/2=6.5) otherwise; 
7 
Mean of the Poisson distribution 
from which is sampled the number 
of CLST partners (highsa) 
NA 4.5 
Probability of having a new CLLT 
partner for people in the age group 
15-35 (eprate) 
NA 0.1 
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Parameter (variable name in the 
program) 
Value (or distribution) 
South Africa Zimbabwe 
Change in propensity to have a long-
term condom-less sex partner (“risk”) 
after HIV diagnosis (i.e. mainly reflects 
the chance of starting to adopt 100% 
condom use or cease sexual 
intercourse) (ch_risk_diag) 
Beta (8,10) (mode=7/16=0.44)   
 
0.69 
Change in propensity to have short-
term (“new”) condom-less sex partners 
after HIV diagnosis 
(ch_risk_diag_newp) 
Beta(6,2)  (mode=5/6=0.83) 0.83 
Date at which population level 
reduction in condom-less sex with 
short-term and long-term partners 
started (date_ch_risk_beh) 
Uniform (1991,1998.75) 
 
NA 
Date at which the slope in the 
population level reduction in condom-
less sex behaviour with short-term 
partners changes (date_ch_risk_beh_2)  
Uniform (1999,2005.75) NA 
Date at which the population level 
reduction in condom-less sex 
behaviour with short-term partners 
stops (date_ch_risk_beh_3) 
Uniform (2006,2009.75) 
 
NA 
Annual reduction in propensity to have 
condom-less sex (“risk behaviour”) 
with short-term partners in the period 
between date_ch_risk_beh and 
date_ch_risk_beh_2  
(rate_ch_risk_beh) 
Lognormal(ln0.065,0.75) 
 
NA 
Annual reduction in propensity to have 
condom-less sex (“risk behaviour”) 
with short-term partners in the period 
between date_ch_risk_beh_2 and 
date_ch_risk_beh_3  
(rate_ch_risk_beh_2)  
lognormal(ln0.025,0.52) NA 
This parameter is the fold increase in 
the proportion who do not have 
condom-less sex, of those who had 
condom-less sex at the time before, 
relative to before date_ch_risk_beh 
(ch_risk_beh_ep) [This parameter 
applied after date_ch_risk_beh] 
(Beta(10,2)) [Mean=1.2] 0.5 
HIV prevalence threshold who triggers 
the reduction in  sexual behaviour 
(prev_threshold_rb_change) 
NA Uniform(0.1,0
.4)) 
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Parameter (variable name in the 
program) 
Value (or distribution) 
South Africa Zimbabwe 
Pregnancy  
Base probability of pregnancy per 3 
months of condom-less sex.  It applies 
to women 35-45. 
(prob_pregnancy_base) 
Uniform(0.035,0.075) 0.037 
Multiplicative factor to the base 
probability of pregnancy for women 
15 to 25 years old (fold_preg1525) 
Uniform(1.015,1.065) 1.04 
Multiplicative factor to the base 
probability of pregnancy for women 
25 to 35 years old (fold_preg2535) 
Uniform(1.005,1.055) 1.03 
Multiplicative factor to the base 
probability of pregnancy for women 
45 to 55 years old (fold_preg4555) 
Uniform(0.95,1.0) 0.975 
Multiplicative factor to the base 
probability of pregnancy for women 
55 to 65 years old (fold_preg5565) 
Uniform(0.9,0.95) 0.925 
*fold_tr is a multiplicative factor which change rate of transmission, tr_rate_primary is the rate of transmission in 
PHI. CLST: condom-less short-term; NA: not applicable; RBM: risk behavioural model; 
 
swn and newp_factor are sampled to be inversely correlated with a multiplicative factor which 
changes the rate of transmission (fold_tr) and rate of transmission in PHI (tr_rate_primary) to 
ensure that a high proportion of epidemics generate have a prevalence which fits to the South 
Africa epidemic (without this factor many more epidemics would be generated where 
prevalence is very low, if fold_tr, tr_rate_primary, swn and newp_factor are all low, or very 
high, if all four values are high – the aim is to achieve good sampling efficiency without 
imposing too much constraint on epidemics generated). 
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Parameters relating to HIV transmission  
Table A.10. Parameters and distribution of parameters related to HIV transmission, 
transmission of resistant virus and persistence of ARV-drugs resistance mutations 
transmitted 
Parameter (variable name in the program) Value (or distribution) 
South Africa Zimbabwe 
Fold difference in transmission rate for a given VL 
(see section 3.3.5) (fold_tr) 
Lognormal(ln1,0.52) 1 
Rate of transmission in PHI (lasting 3 months) 
(tr_rate_primary) 
beta(2,7) 
(mode=1/7=0.15) 
0.25 
Transmission rate when plasma VL is < 500 cps/mL 
(tr_rate_undetec_vl) 
lognormal(ln0.0001,12) 0.001 
Fold higher rate of acquisition for women 
compared to men (higher rate of transmission 
from men to women, compared with women to 
men) (fold_change_w) 
lognormal(ln1.5,0.52)  
 
1.5 
 
Fold higher rate of acquisition in young women 
compared with older women (fold_change_yw) 
lognormal(ln3,0.42)   
 
2 
Fold higher rate of acquisition in people with STIs 
(fold_change_sti) 
lognormal(ln3,0.32)   3   
Fold rate of acquisition in men circumcised 
(fold_circ) 
0.5 
Fold lower transmission rate per 3 months for 
short-term partners compared with long-term 
partners (reflecting average lower number of sex 
acts) (fold_tr_newp) 
beta(5,10) 
(mode=4/13=0.31) 
 
0.36 
Adjustment to factor determining extent to which 
some transmitted resistance is effectively 
immediately lost (even from minority virus) 
(res_trans_factor) 
lognormal(1,0.32) lognormal(1.0, 
0.32)     
Probability per 3 months of loss of persistence of 
transmitted mutations from majority virus to 
minority virus (same for each mutation) 
(rate_loss_persistence) 
lognormal(ln0.04,0.32)   0.04   
PHI: primary HIV infection; VL: viral load; 
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Parameters relating to natural progression  
For HIV-infected people the variables modelled include: PHI (a period of raised infectivity of 3 
months duration), VL, CD4 count, presence of specific resistance mutations, adherence to ART, 
risk of AIDS and death.   
 
Table A.11. Parameters relating to natural history of HIV 
Parameter (variable name in the program) Value (or distribution) 
South Africa Zimbabwe 
Initial CD4 count at infection (square root scale) 
(mean_sqrtcd4_inf) 
30 27 
Factor adjusting basic rate of natural cd4 decline  (see section 
3.4) (fx)   
0.9 1.4 
Factor adjusting basic rate of natural VL change  (see section 
3.4) (gx) 
1 1 
Fold increase in risk of WHO 3 condition, compared with risk of 
WHO 4 condition, for given level of CD4 count, VL and age 
(fold_incr_who3) 
5 5 
Fold decrease in risk of HIV-related death, compared with risk 
of WHO 4 condition, for given level of CD4 count, VL and age 
(fold_decr_hivdeath) 
0.25 0.25 
Increase in death rate in 3 months period in which a WHO 4 
condition is present (incr_death_rate_adc)  
5 10 
Increase in death rate in 3 months period in which TB is 
present (incr_death_rate_tb) 
2 10 
TB: tuberculosis; VL: viral load; WHO: World health Organization; 
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Parameters relating to circumcision, HIV testing, linkage to care and retention in pre-ART 
care and on ART 
Table A.12. Parameters and distributions on HIV care delivery (including circumcision) 
Parameter (variable name in the 
program) 
Value (or distribution) 
South Africa Zimbabwe 
Circumcision  
Baseline prevalence of circumcision 
(before VMC was rolled out for HIV 
prevention) (prev_circ) 
42% 10% 
Start date of VMC roll out (mc_int) 2008 2008 
Annual increase in probability of VMC 
(incr_anprob_circ) 
Between date of starting 
rolling out and mid-2009: 
0.001 
Between 2009.5-2010.5: 
0.015 
Between date of 
starting rolling 
out and beginning 
of 2015: 0.003 
HIV testing  
Date of start testing for HIV in ANCs 1990 1994 
Date of start of testing for HIV 
(date_start_testing) 
1996 1996 
Annual rate of increase in testing 
probability over time (test_increase_rate) 
Uniform(0.02,0.035) NA 
Annual quadratic increase in the 
probability of being tested in ANCs for 
pregnant women (rate_testanc_inc) 
0.00195 (rate_testanc_inc – 
only up to first trimester of 
2013) 
0.0025 
(rate_testanc_inc 
– only up to first 
trimester of 2015) 
Probability per 3 months of being tested 
for HIV for those with WHO stage 4 
condition (test_rate_who4) in 1996 
0.2 0.2 
Absolute rate of increase per 3 months of 
test_rate_who4; up to 2015) 
(inc_test_rate_who4) 
0.008 0.008 
Probability per 3 months of being tested 
for HIV for those with TB (test_rate_tb) in 
1996 
0.1 0.1 
Absolute rate of increase per 3 months on 
test_rate_tb; up to 2015. 
(inc_test_rate_tb) 
0.005 0.005 
Probability per 3 months of being tested 
for HIV for those with WHO stage 3 
condition (test_rate_who3) in 1996 
0.03 0.03 
Absolute rate of increase per 3 months on 
test_rate_who4; up to 2015. 
(inc_test_rate_who4) 
0.0012 0.0012 
Proportion of the population resistant to 
HIV testing (no probability of testing 
unless with WHO 4 condition, in which 
case they will be tested) (rate_noreached) 
lognormal(ln0.25,0.12) 
 
20% in 1996 it 
declines linearly 
to 5% by 2010 
and 5% thereafter 
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Parameter (variable name in the program) Value (or distribution) 
South Africa Zimbabwe 
Linkage to care 
Probability of being linked to care at 3 
months since diagnosis (for people without 
WHO4, WHO3 events in the last 3 months or 
TB in the last 6 months) 
(prop_linkedtocare_diag) 
0.4 0.4 
Probability of being linked to care at 3 
months since diagnosis for people with 
WHO4 events in the last 3 months or TB in 
the last 6 months 
1 0.95 
Probability of being linked to care at 3 
months since diagnosis for people with 
WHO3 events in the last 3 months  
1 0.85 
Retention in pre-ART care and on ART 
Rate of loss to follow-up per 3 months among 
those not on ART (rate_lost). 
0.3. 
This applies  in the first year 
since diagnosis, (actual 
probability also depends on 
average willingness to 
adhere – see section 3.6); 
after 1 year since diagnosis 
the parameter is a quarter 
of rate_lost: 0.075 
0.05 
Probability (per 3 months) of return to care 
for person LTFU within 1st year from 
diagnosis, if no WHO 4 condition present. 
0 0.05 
Probability (per 3 months) of return to care 
for person LTFU after at least 1 year since 
diagnosis, if no WHO 4 condition present 
(rate_return) (actual probability also depends 
on average tendency to adhere – see section 
3.6.7) 
0.04 0.05 
Probability (per 3 months) of return to care 
for person LTFU if WHO 4 condition occur 
0.8 0.8 
Probability (per 3 months) of simultaneously 
being LTFU amongst those stopping ART 
(prob_lost_art) (actual probability also 
depends on tendency to adhere – see section 
3.6.3) 
0.3 0.27 
Base probability (per 3 months) of restart of 
ART in those remaining under care who have 
stopped/interrupted ART (this is also 
influenced by presence of WHO 3 or 4 
conditions) (rate_restart) 
0.4 0.2 
ANC: antenatal clinic; NA: not applicable; TB: tuberculosis; VMC: voluntary medical circumcision; WHO: World 
Health Organization; 
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Parameters relating to antiretroviral treatment   
The model of progression of HIV and the effect of ART has been shown to provide a generally 
close fit to observed data relating to the effect of ART, comparing the output of the model with 
data coming mainly from Europe and South Africa (1218-1221).  
 
Table A.13. Parameters determining ART roll-out and effect of ART on progression 
Parameter (variable name in the program) Value (or distribution) 
South Africa Zimbabwe 
Delivery of ART care  
ART introduction date (ART_intro_date) 2002 2003 
PMTCT introduction date with sNVP 
(date_pmtct) 
2004 2004 
Annual rate of increase in use of PMTCT in 
pregnant women attending ANC (rate_sd_nvp - 
up to a maximum of 97.5) 
0.25 0.15 
Probability (per 3 months) of switching to 
second-line treatment, given first-line failure (by 
whatever definition is being used) 
(pr_switch_line) 
0.25 0.15 
Adherence to antiretroviral therapy   
Pattern of tendency to adhere across 
individuals, expressed as proportion of doses 
taken (adhav) 
15% adhav=0.49  
15% adhav=0.79 
50% adhav=0.90 
20% adhav=0.95 
5% adhav=0.49  
10% adhav=0.79 
65% adhav=0.90 
20% adhav=0.95 
Reduction in adherence resulting from presence 
of TB or a WHO 4 condition (red_adh_tb_adc) 
0 0.1 
Average reduction in adherence resulting from 
current toxicity (the actual reduction varies by 
individual person) (red_adh_tox) 
0 0.05 
Additional "effective" adherence for people on 
NNRTI regimens due to longer half-life 
(add_eff_adh_nnrti) 
0.1 0.1 
Average (amount differs by individual) increase 
in adherence in patients who have a measured 
VL in the last 6 months above 1,000 copies/mL  
(adh_effect_of_vm_pop) 
0.2 NA 
Extent to which the average CD4 change is more 
favourable on a virologically failing PI/r-regimen 
compared with an NNRTI-regimen 
(poorer_cd4_rise_on_failing_nnrti) 
-10 -6 
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Parameter (variable name in the program) Value (or distribution) 
South Africa Zimbabwe 
CD4  
Standard deviation for intra-subject variation in CD4 
count and (sd_cd4) 
1.2 1.2 
Standard deviation for the measurement error in CD4 
count (sd_measured_cd4) 
2.0 1.7 
Standard deviation representing inter-patient variation 
in rate of CD4 rise - when CD4 is rising 
(patient_cd4_rise_art) (after 2 years on ART is divided 
by 4) 
Lognormal(0,0.5) 
 
0.2 
ART interruption  
Underlying probability (per 3 months) of interrupting 
ART (actual probability also depends on presence of 
current toxicity and average adherence – see section 
3.6.3) (rate_int_choice) 
0.02 0.02 
Probability (per 3 months) of drug stock out, and 
hence ART interrupted (prob_supply_interrupted) 
0.01 0.01 
Probability (per 3 months) that drug supply resumed 
after stock-out (prob_supply_resumed) [i.e 80% chance  
that stock-out lasts 3 months only] 
0.8 0.8 
Acquisition of ART resistance mutations  
Fraction of people who stop ART (and are still visiting 
the clinic) for whom the clinic is aware of the 
interruption. If they are not aware they treat the 
patient as if they were on ART (and hence may switch 
to the next line having wrongly classified them as 
virologically failing) (clinic_aware_int_frac) 
0.5 0.7 
Probability of an NNRTI resistance mutation arising in 
the 3 months after having stopped NNRTI (due to 
effective monotherapy due the long half-life) 
(risk_res_stopping_nn) 
0.05 0.018 for 
K103, 0.006 
for Y181 and 
0.006 for G190 
Probability per pregnancy of NNRTI resistance 
emergence in pregnant women receiving sNVP for 
MTCT (prob_nnresmaj_sd_nvp) 
0.35 0.35 
Probability per pregnancy of NNRTI resistance 
emergence in pregnant women receiving AZT during 
pregnancy, sNVP + AZT during labour and TDF + FTC 
single dose after delivery (prob_nnresmaj_dual_nvp) 
0.045 0.045 
Probability per 3 months of loss of NNRTI mutations, 
acquired due to PMTCT, from majority virus to become 
only in minority virus (rate_loss_nnres_pmtct_maj) 
0.25 0.25 
Probability per 3 months of loss of virus with NNRTI 
mutations acquired due to PMTCT, from minority virus 
to effectively be extinct altogether 
(rate_loss_nnres_pmtct_min) 
0.25 0.25 
ANC: antenatal clinic; ART: antiretroviral therapy; AZT: zidovudine; FTC: emtricitabine; MTCT: mother-to-child 
transmission; NNRTI: non-nucleoside reverse transcriptase inhibitor; PMTCT: prevention of mother-to-child 
transmission; sNVP: single dose NVP; TB: tuberculosis; TDF: tenofovir; WHO: World Health Organization; 
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Appendix XII. Summary of selected papers on antiretroviral therapy for prevention of HIV 
transmission 
First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Randomized controlled trials 
Cohen, 
2011, 
New England 
Journal of 
Medicine  
(432) 
To compare the effect of early vs 
delayed ART on HIV transmission 
(early = ART at diagnosis; delayed = 
ART after  two consecutive CD4 
counts ≤250 cells/μL) 
RCT (HPTN 052)  1,763 HIV serodifferent couples from nine 
countries: Botswana, Kenya, Malawi, 
South Africa, Zimbabwe, Brazil, India, 
Thailand and United States 
2005–2010 
A total of 39 HIV transmission events were 
observed, of which 28 were virologically linked 
(incidence rate: 1.2 per 100 PYs; 95% CI: 0.9, 1.7). 
Of 28 linked transmissions, 1 was in the early-
therapy group. A HR in the early-therapy group of 
0.11 (95% CI: 0.04, 0.32; p<0.001). 
HIV- positive people starting ART at study entry 
had a clinical benefit compared with people 
starting ART when CD4 count falls below 250 
cells/μL. 
Results support the use of ART as a part of a public 
health strategy to reduce the spread of HIV 
infection. 
Ecological studies 
Das, 
2010, 
PLoS One  
(675) 
To assess relationships between 
mean and total community VL and 
annual numbers of newly diagnosed 
HIV cases 
Ecological/coho
rt study 
 
 
All reported HIV-positive individuals in San 
Francisco, United States (n=12,512) 
2004–2008 
Decreases in annual measures of mean and total 
community VL were observed and were 
significantly associated with temporal decreases in 
the number of new HIV diagnoses. 
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First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Dukers, 
2002, 
AIDS 
(679) 
To investigate whether dramatic 
increases in sexually transmitted 
diseases and sexual risk behaviour 
among homosexual men in 
Amsterdam, the Netherlands, 
indicate a resurgence of the HIV 
epidemic 
Ecological 
study/cohort 
study 
3,090 male participants from Amsterdam, 
who participated in 1991–2001 HIV 
prevalence surveys, who self-identified as 
homosexual (approximately 15% of all 
participants) and who consented to blood 
HIV testing (96.3% of all homosexual 
participants) were included 
The incidence of HIV increased during the study 
period, as did rates of syphilis and gonorrhoea. 
The authors also reported an increase in risk 
behaviour among homosexual men, highlighting 
the need for preventive action, especially for 
those who have recently been infected. 
Fang, 
2004, 
Journal of 
Infectious 
Diseases 
(676) 
To estimate the HIV transmission 
probability ratio in the Taiwanese 
population, before and after the 
implementation of the free-ART 
policy  
 
Ecological/coho
rt study 
 
 
4,390 HIV-positive individuals included in 
Taiwan’s HIV surveillance data 
1984–2002 
The authors noted that there was a 53% decrease 
in the HIV transmission rate during the period of 
free access to ART compared with the previous 
time period, and this contributed to the control of 
the HIV epidemic in Taiwan.  Therefore, they 
concluded that the widespread use of ART can be 
an effective measure to control HIV epidemics in 
countries with a low prevalence. 
 
To differentiate the effect of ART from that of 
behavioural changes, the incidence of syphilis in 
the general population and among HIV-positive 
patients was also analyzed, for comparison. There 
was no statistically significant change in the 
incidence of syphilis, in the general population or 
among HIV-positive patients, during the same 
period. 
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First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Grulich, 
2008, 
Sexual Health 
(680) 
To describe trends in HIV 
notifications and in other measures 
of HIV incidence in homosexual men 
in developed countries 
Literature 
review of 
ecological 
studies (search 
conducted in 
2007) 
Surveillance data from Europe, Canada, 
United States, Australia and New Zealand 
Data from 1996 
The study concluded that there was a near-
universal increase in notification of HIV diagnoses 
in homosexual men in the developed world. They 
reported that determining the degree and extent 
of the increases in incidence in homosexual men is 
very important for being able to develop 
appropriate public health responses in the 
evolving HIV epidemic. 
Montaner, 
 2010, 
Lancet 
(677) 
To estimate the association of new 
HIV-positive tests with VL, year and 
number of individuals on ART 
Ecological/coho
rt study 
 
British Columbia, Canada 
1996–2009 
 
The number of individuals actively receiving ART in 
British Columbia increased from 837 to 5,413 
(547%; p=0.002), and the number new HIV 
diagnoses fell from 702 to 338 cases per 100,000 
people per year (−52%; p=0.001). 
The overall correlation between number of 
individuals on ART and number of new HIV 
diagnoses per year was −0.89 (p<0.0001). 
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First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Mathematical models 
Abbas, 
2006, 
Journal of 
Acquired 
Immune 
Deficiency 
Syndromes 
(687) 
To estimate the potential impact of 
ART on the heterosexual spread of 
HIV infection and AIDS mortality in 
RLS 
Mathematical 
model 
The model parameter set was chosen to 
mimic an epidemic in a sub-Saharan 
African nation reaching an endemic 
prevalence of 40% in the sexually active 
population 15–49 years of age 
The authors suggested that implementing ART at 
5% HIV prevalence to 100% of AIDS cases would 
decrease the number of new HIV infections and 
cumulative deaths from AIDS after 10 years by 
11.2% (IQR: 1.8–21.4) and 33.4% (IQR: 26–42.8), 
respectively. 
A later implementation of ART at endemic 
equilibrium (40% prevalence) was predicted to be 
less effective, decreasing new HIV infections and 
cumulative deaths from AIDS by 10.5% (IQR: 2.6–
19.3) and 27.6% (IQR: 20.8–36.8), respectively. 
The authors concluded that ART is predicted to 
have individual and public health benefits that 
increase with time and with the proportion of 
infected persons treated. 
Alistar,  
2014, 
BMC 
Medicine 
(706) 
To evaluate the cost-effectiveness of 
different coverage for the 
combination of ART at CD4<350 
cells/μL and at diagnosis and PrEP in 
the general population and in high-
risk individuals 
Compartmental 
mathematical 
model 
The model reproduce the HIV epidemic in 
South Africa 
The authors found that modifying the eligibility 
criteria so that all people diagnosed with HIV are 
eligible is the most cost-effective strategy at all 
coverages considered (ICER ranging from 160-220 
per QALY gained). While PrEP provided only a 
limited additional benefit. 
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Alsallaq, 
2013 
PLoS One, 
(702) 
To assess the impact on HIV 
incidence of an intervention 
combining high coverage of HTC, 
risk reduction following HIV 
diagnosis, VMC for HIV-uninfected 
men, and ART for HIV-infected 
persons 
To identify the factors that influence 
this impact, and whether there is a 
synergy between the components 
Mathematical 
model 
The model was calibrated to data from 
KwaZulu-Natal, South Africa 
The authors found that, compared with current 
levels of HTC, VMC, and ART, the intervention with 
ART initiation at CD4 count <350 cells/μL could 
reduce HIV incidence by 47% (from 2.3 new 
infections per 100 PYs to 1.2 per 100 PYs) and by 
almost 60% (to 1 per 100 PYs) within 4 and 25 
years respectively.  
Drivers of the short-term impact were uptake of 
HTC and reductions in risk behaviour following 
testing, while drivers of the long-term effects were 
the periodic HTC and retention in ART 
programmes.  
If the intervention included ART initiation upon 
diagnosis, HIV incidence could be reduced by 63% 
and 76% respectively within 4 and 15 years. The 
authors found a synergy between the intervention 
components and highlighted that it takes 10–15 
years to see the full impact. 
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Andrews, 
2012 
Journal of 
Infectious 
Diseases, 
(690) 
To evaluate the importance of 
structural assumptions regarding 
linkage to care and population 
mobility 
Mathematical 
model 
The model was parameterized using 
demographic, clinical, migration, 
emigration and linkage data from a 
township in Cape Town, South Africa 
The authors used a previously published model 
and refined modelling linkage to care and 
population mobility. They found that elimination 
of HIV transmission (defined as an incidence of 
<0.1%) would not occur within 30 years, even with 
optimistic assumptions about the linkage rate.  
In addition they reported that models were more 
sensitive to structural assumptions about linkage 
to care than to parameter values, and that 
including population mobility further attenuated 
the reduction in HIV incidence due to ART as 
prevention.  
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Anglaret, 
2013 
Antiviral 
Therapy, 
(694) 
To understand the circumstances 
under which starting ART upon 
entry to care, rather than at CD4 
count <350 cells/μL could lead to 
more risks than benefits for patients 
with high CD4 counts 
Mathematical 
model 
Model parameters were chosen to mimic 
the HIV epidemic among sub-Saharan 
African adults with CD4 counts >500 
cells/μL 
15-year mortality was 56.7% if the eligibility 
criteria to initiate ART is CD4<350 cells/μL and 
51.8% if people initiate ART upon entry to care.  
15-year mortality was consistently lower with 
immediate ART unless the rate of fatal ART toxicity 
was >1.0/100 PYs or the rate of withdrawal from 
care was >1.2-fold higher or the rate of ART failure 
due to poor adherence was >4.3-fold higher if the 
eligibility criterion to initiate ART was CD4 count 
<350 cells/μL compared with upon entry to care.  
In multivariate sensitivity analysis, the authors 
reported higher mortality when ART was initiated 
upon entry to care compared with CD4 count <350 
cells/μL when moderate rates of fatal ART toxicity 
(0.25/100 PYs) were combined with increased 
rates of withdrawal from care (>1.1-fold higher) 
and increased rates of treatment failure (>2.1-fold 
higher). 
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Baernighause
n, 
2012, 
Proceedings 
of the 
National 
Academy of 
Sciences of 
the United 
States of 
America 
(704) 
To evaluate whether it is possible to 
achieve the same impact, 
obtainable by initiating ART upon 
entry into care, and possibly at a 
lower cost, by increasing coverage 
of VMC and ART at CD4 count 
<350/μL 
Mathematical 
model 
The model was calibrated to data from 
South Africa 
The impact of high ART coverage together with 
high VMC coverage on HIV incidence is 
approximately the same as obtained by initiating 
ART upon entry to care, for USD 5 billion less over 
2009–2020.  
The cost per infection averted is respectively $ 
1,096 for VMC, $6,790 for ART and $8,375 for 
treatment as prevention (defined here as frequent 
testing of the entire population and initiation of 
ART upon entry to care).  
The cost per death averted is $5,198 for VMC, 
$5,604 for ART and USD 7,739 for treatment as 
prevention.  
The authors concluded that the most cost-
effective HIV prevention strategy is to expand 
VMC coverage and then scale up ART, but the 
most cost-effective HIV-mortality reduction 
strategy is to scale up VMC and ART together.  
 
  
412 
 
First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Baggaley, 
2006, 
PLoS 
Medicine 
(688) 
To explore through the use of 
modelling, the epidemiological 
impacts of alternative strategies of 
initiating ART 
Mathematical 
model 
The model parameter set was chosen to 
mimic an epidemic in a resource-poor 
setting. 
The authors reported that ART cannot be seen as 
a direct prevention measure for HIV transmission, 
regardless of the degree of coverage and 
therefore that counselling of patients to promote 
safe sexual practices is crucial and must aim to be 
durable over time. 
Scaling up treatment of pre-AIDS patients resulted 
in higher number of infections being averted per 
PY of treatment, but the absolute number of 
infections averted remained small. 
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Bendavid, 
2010, 
Archives of 
Internal 
Medicine 
(689) 
To assess the epidemiological health 
effect of four different treatment 
strategies including test and treat, 
linkage to care and reducing loss to 
follow-up 
Mathematical 
model 
The model parameter set was chosen to 
mimic the South African HIV population 
where HIV transmission is predominantly 
heterosexual 
The authors estimated that the number of new 
infections in the adult South African population 
that would occur over the next 10 years is 4.5 
(95% CI: 3.8, 5.1) million in the status quo strategy, 
and 1.2 (95% CI: 0.9, 1.6) million in a 
comprehensive strategy; a 73.2% reduction. 
They found that even relatively modest 
improvements in linkage to care and prevention of 
loss to follow-up could lead to substantial 
reductions in mortality and number of new HIV 
infections. 
A 10% higher linkage and 6% reduction in loss to 
follow-up was associated with a 36% reduction in 
HIV infections compared with UTT alone. 
Cremin, 
2013, 
AIDS 
(703) 
To evaluate the potential impact 
and cost-effectiveness of ART-based 
HIV prevention strategies (PrEP for 
HIV-negative persons and ART 
initiation at higher CD4  count for 
HIV-positive persons) 
Mathematical 
model 
The model reflects a hyperendemic setting 
with relatively low levels of condom use 
Provision of ART to more HIV-positive individuals 
at a higher CD4 count, rather than providing PrEP 
to HIV-negative individuals, leads to a higher 
number of infections being averted and more 
quality-adjusted life-years. 
Nevertheless ART alone is unable to reduce HIV 
incidence to very low levels. 
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Eaton, 
2012, 
PloS Medicine 
(685) 
To compare the results from several 
mathematical models simulating the 
same ART intervention programmes 
to understand the extent to which 
models agree about the 
epidemiological impact of expanded 
ART 
12 independent 
mathematical 
models 
Models were calibrated to South Africa For a scenario in which 80% of HIV-infected people 
start ART on average 1 year after the CD4 count 
falls below 350 cells/ml and 85% remain on 
treatment after 3 years, the models found that HIV 
incidence would be 35–54% lower 8 years after 
the introduction of ART, compared with a 
counterfactual scenario where ART is not 
available.  
The models found heterogeneity in long-term 
projections (38 years) of HIV incidence, as well as 
on the impact of more optimistic interventions, 
such as immediate ART initiation. The number of 
PYs of ART per infection averted over 8 years 
varied from 5.8 to 18.7. Considering the actual 
roll-out of ART in South Africa, seven models 
estimated that current HIV incidence was 17% to 
32% lower than it would have been if ART were 
not available.  
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El-Sadr, 
2011, 
AIDS 
(709) 
To predict the epidemic impact of 
treating HIV serodifferent couples to 
prevent transmission 
Mathematical 
model 
The model was parameterized using data 
from Ghana, Lesotho, Malawi and Rwanda 
The model suggested that reduction in HIV 
incidence due to treatment of serodifferent 
couples will be greatest in populations with higher 
HIV prevalence and/or a greater percentage of 
couples in serodifferent partnerships. The authors 
conclude that, although treatment of serodifferent 
couples is unlikely to be the sole answer for 
controlling HIV epidemics, it could significantly 
reduce HIV incidence and prevent a substantial 
number of infections in certain countries if high 
coverage levels are reached. 
Granich, 
2009, 
Lancet 
(686) 
To explore the effect of various HIV 
testing and treatment strategies on 
the long-term dynamics of the 
epidemic  
Deterministic 
mathematical 
model 
 
 
The model parameter set was chosen to 
mimic the epidemic in South Africa as the 
test case for a generalized HIV epidemic, 
assuming an almost exclusively 
heterosexual epidemic 
The model suggests that UTT in the context of 
other prevention interventions could reduce 
transmission to the point at which elimination 
might be feasible by 2020 in a generalized 
epidemic, such as that in South Africa. 
 
  
416 
 
First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Granich, 
2012, 
PLoS One 
(691) 
To investigate the cost-effectiveness 
of expanded ART access in South 
Africa 
Mathematical 
model and 
economic 
analysis 
The model parameter set was chosen to 
mimic the adult South African HIV 
epidemic from 2011 to 2050, assuming 
90% annual HIV testing coverage. Four ART 
eligibility scenarios were considered, 
offering ART at: (i) CD4 count<200 cells/μL 
(current practice); (ii) CD4<350 cells/μL; 
(iii) CD4<500 cells/μL; (iv) any CD4 count 
Over 40 years, 7.6 million new HIV infections and 
10.4 million deaths were predicted under current 
standards (scenario (i)). For the other scenarios 
these figures were (ii) 6.2 and 8.9 (iii) 4.7 and 7.4 
(iv) 3.3 and 6.5, respectively. All scenarios were 
cost-saving compared with scenario (i), with 
breakeven by (ii) 2013 and (iv) 2023. 
Sensitivity analyses suggested that poor retention 
in care and predominant acute phase transmission 
could reduce savings by 7%. 
Expanding access to care could potentially reduce 
the number of new infections and result in cost 
savings. 
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Hallett, 2011,  
Plos 
Medicine, 
(705) 
To evaluate the cost-effectiveness of 
earlier ART and/or PrEP in 
serodifferent couples in South Africa 
Microsimulatio
n model  
The model simulates two types of stable 
serodifferent heterosexual couples in 
South  Africa: low risk (HIV incidence 
1.8/100 PYs at risk), similar to those 
recruited in the study Partners in 
Prevention HSV/HIV Transmission study 
cohort and what they considered more 
typical with an HIV incidence around 8 
/100 PYs at risk 
They compared 4 different PrEP implementations 
strategies: (i) always once the couple is identified 
as serodifferent, (ii) only until one year after the 
HIV-positive partner has been initiated on ART, (iii) 
only until ART initiation of the HIV-positive 
partner, (iv) only when trying to conceive a 
pregnancy or during pregnancy. This was 
evaluated in the context of the HIV-positive 
partner being initiated on ART at CD4<200 cells/μL 
or CD4<350 cells/μL. In addition they compared 
strategy (iii) with ART initiation in the HIV-positive 
partner at CD4<500 cells/μL. They found that 
strategy (iii) was the most cost-effective strategy 
because the initial higher cost of PrEP was 
counterbalance by saving in ART, because of the 
reduction in HIV incidence. When comparing to 
earlier ART initiation this was the most cost-
effective strategy for the low risk couples, while 
for the higher risk couples the combination of PrEP 
(iii) and ART initiation at CD4<350 cells/μL was 
associated with the best cost-effectiveness. 
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Hontelez, 
2013, 
Plos 
Medicine, 
(696) 
To explore the impact of different 
model structure and assumption on 
the long-term impact (38 years) of  
UTT (90% coverage of annual HIV 
testing and ART initiation at 
diagnosis) 
9 different 
mathematical 
models, from a 
deterministic 
model similar 
to Granich 
(686) to the 
most complex 
considered 
being STDSIM 
The model reproduces the South African 
HIV epidemic. 
They found that all model predicted that UTT 
would lead to HIV elimination (HIV incidence of 
<1/1,000) by 2050. However they found that 
models capturing a higher level of realism and 
complexity predict that it would take longer to 
achieve HIV elimination, but would still conclude 
that it is a cost-effective intervention. 
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Johnson, 
2012, 
Journal of the 
Royal Society 
Interface 
(700) 
To assess the extent to which 
prevention and treatment 
programmes have reduced HIV 
incidence 
Two dynamic 
mathematical 
models (STI-HIV 
Interaction 
Model and 
ASSA2003 AIDS 
and 
Demographic 
Model) 
The models mimic the adult South African 
HIV epidemic from 2000 to 2008, using 
household survey and antenatal HIV 
prevalence data and death data to 
estimate HIV incidence 
STI-HIV: 
Real-life incidence of HIV estimated to be 2.11 
(95% CI: 1.97, 2.26) in 2000–2005 and 1.86 (95% 
CI: 1.73, 2.00) in 2005–2008. Incidence was 
reduced by 37% (95% CI: 34, 41%) compared with 
if no condoms had been used, and by 8.1% (95% 
CI: 6.0, 9.4%) in the absence of ART,  
ASSA2003: 
Real-life incidence of HIV was estimated to be 1.90 
(95% CI: 1.77, 2.03) in 2000–2005 and 1.62 (95% 
CI: 1.45, 1.79) in 2005–2008. Incidence was 
reduced by 23% (95% CI: 14, 34%) compared with 
if no condoms had been used, and by 1.4% (95% 
CI: 0.7, 2.6%) in the absence of ART. 
Increased condom use therefore appears to be the 
most significant factor explaining the recent 
decline in HIV incidence in South Africa. 
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Klein,  
2014, 
AIDS, 
(698) 
To understand the impact of ART 
drop out and re-enrollment in HIV 
care once lost from care on the cost-
effectiveness of expanding access to 
care and modifying the eligibility 
criteria from CD4<350 cells/μL to all 
people diagnosed with HIV, see 
Eaton et al. (692) 
Individual 
based 
stochastic 
model, called 
EMOD-HIV, 
calibrated to 
South Africa 
The model was calibrated to the HIV 
epidemic in South Africa 
They considered three level of re-enrolment after 
being drop out: 0%, 50% and 100% and an 
additional strategy of 0% drop-out, under the 
circumstance of ART initiation at CD4<350 cells/μL 
and ART initiation at diagnosis. They found that 
the initial most cost-effective approach is to 
improve retention on ART and only once this 
target has been achieved it is cost-effective to 
initiate more people on ART. The most cost-
effective way to increase the number of people on 
ART they found was by increasing HIV testing and 
linkage to care, while maintaining the eligibility 
criteria at CD4<350 cells/μL rather than changing 
the eligibility criteria so that all people diagnosed 
are eligible for ART. 
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Kretzschmar,  
2013, 
Proceedings 
of the 
National 
Academy of 
Sciences of 
the United 
States of 
America 
(695) 
To determine whether a treatment 
as prevention strategy can lead to 
HIV elimination, and whether 
achieving this goal is likely to be 
cost-effective 
Deterministic 
mathematical 
model 
A number of hypothetical HIV epidemics 
were considered, defined according to 
their basic reproduction number (R0) 
When infectivity is set at its baseline values, 
annual treatment uptake of more 70% is needed 
for elimination, which corresponds, to 
approximately 85% coverage. 
The authors found that elimination is only feasible 
in populations with very low R0 (approximately 2 
or lower) and high annual treatment uptake. 
 
Murnane, 
2012, 
PLoS One 
(707) 
To investigate the utility of VL-
guided ART initiation to prevent HIV 
transmission 
Mathematical 
model 
The model uses data from an RCT of 3,381 
HIV serodifferent couples without ART 
from 7 countries in southern and east 
Africa 
Treating all with persons with a CD4 count <500 
cells/μL would avert 1,569 (47.6%) new infections.  
Treating all with persons with a VL ≥500,000 
copies/mL would avert 1,336 (40.5%) new 
infections. 
Treating all persons with a VL ≥100,000 copies/mL 
would avert 2,401 (72.8%) new infections. 
Universal treatment would avert 3,165 (96.0%) 
new infections. 
Inclusion of VL in ART initiation guidelines could 
permit targeting ART resources to HIV-1-infected 
persons who have a higher risk of transmission. 
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Palombi, 
2012, 
Clinical 
Infectious 
Diseases 
(697) 
To model the effect of initiating ART 
at CD4 count >350 cells/μL on HIV 
transmission, with the intent of 
extending ART to the entire HIV-
positive population within a short 
period of time 
 
Mathematical 
model 
The model mimics the HIV epidemic in 
sub-Saharan Africa using cohort data from 
the Drug Resource Enhancement Against 
AIDS and Malnutrition (DREAM) Program 
(in Malawi and Mozambique). 
January 2002–July 2009 
A 5-fold reduction in infectivity (from 1.6% to 
0.3%) occurred within 3 years when triple ART was 
used. The annual incidence of HIV infection 
decreased from 7% to 2% in 2 years, and the 
prevalence was halved, from 12% to 6%, in 11 
years. 
The authors concluded that treatment of all 
infected individuals could result in substantial 
reductions in incident HIV infections and argue 
that a targeted implementation strategy with wide 
population coverage would be feasible in sub-
Saharan Africa. 
Powers, 2011,  
Lancet, 
(587) 
To model the impact of an 
intervention reducing the per 
contact probability to 0.000033, 
targeted to early infection (first 6 
months), chronic infection or both 
Deterministic 
mathematical 
model 
The model included sexual behavioural 
data and virological data from a STIs clinic 
in Lilongwe, Malawi and calibrated to HIV 
prevalence data from sentinel ANC in 
Lilongwe. 
The authors found that the early stage is 
responsible for 38.4% (95% credible interval:  18.6-
52.3) of infections, but that targeting this stage 
(they assumed the intervention would reasonably 
be able to be introduced only 3 weeks from 
infection) would not lead to elimination in 30 
years. An intervention targeted at chronic 
infection would lead to <1/1,000 new infections 
per year, if the coverage is >95% and this does not 
lead to an increase in life-expectancy (as it is the 
case for ART) or if the coverage is >99% with an 
increase in life-expectancy of 10-15 years. 
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Wagner, 
2013, 
Mathematical 
Biosciences 
and 
Engineering, 
(699) 
To model the potential impact of a 
universal test-and-treat strategy, 
based on annual HIV testing for all 
South African adults and providing 
immediate ART for all HIV-positive 
adults regardless of CD4 count 
 
Mathematical 
model 
The model mimics the adult HIV epidemic 
in South Africa 
 
 
 
 
The authors found that modelling an increased 
length of survival time on ART in order to reflect a 
more realistic situation than previous studies had 
a significant impact on the probability of HIV 
elimination using a test-and-treat strategy. 
The authors concluded that an increased length of 
survival time on ART reduces the probability of 
eliminating HIV and decreases the cost-
effectiveness of using universal test-and-treat 
strategies.  
Walensky, 
2013, 
New England 
Journal of 
Medicine 
(708) 
To compare cost-effectiveness of 
early initiation of ART (CD4 count 
between 350 and 550 cells/μL) 
compared with delayed ART (<250 
cells/μL), for five-year and lifetime 
outcomes of cumulative HIV 
transmissions 
Mathematical 
model 
Model of HIV-positive partners in 
heterosexual serodifferent couples in 
South Africa and India (using data from 
HPTN 052 study) 
Early ART remained very cost-effective over a 
lifetime under most modelled assumptions in the 
two countries. 
The authors concluded that early ART for 
serodifferent couples in RLS could have individual, 
public health, and economic benefits. 
Wilson, 
2008, 
Lancet 
(693) 
To estimate the cumulative risk of 
HIV transmission from HIV 
serodifferent couples, where the 
index partner is effectively treated 
over a prolonged period 
Mathematical 
model  
Mathematical model of heterosexual and 
homosexual serodifferent couples applying 
HIV transmission risk calculated using data 
from the Rakai study to estimate HIV 
transmission risk and Australian data for 
sexual risk behaviour 
The risk of HIV transmission in heterosexual 
couples in the presence of effective treatment is 
low but not zero and the transmission risk in male 
homosexual partnerships is high over repeated 
exposures. There is potential for substantial 
increase in HIV incidence. 
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Yusuf, 
2012, 
Journal of 
Biological 
Dynamics 
(701) 
To model the effect of change in 
sexual habits and increased ART 
coverage to find the optimal 
combination of the two measures 
that will minimize cost while 
reducing HIV incidence 
Mathematical 
model 
Model parameters were chosen to mimic 
the HIV epidemic in South Africa 
2006 
 
 
The authors concluded that implementation of a 
proposed strategy whereby individuals remain 
faithful to their sexual partners, reduce the 
number of sexual partners to the minimum 
possible and avoid extra-marital affairs for the rest 
of their lives and initiation of ART in people in the 
pre-AIDS stage would reduce the number of new 
cases leading towards eradication by 10 years. 
Observational Studies 
Anglemyer, 
2013, 
Journal of the 
American 
Medical 
Association, 
(672) 
To evaluate the association of ART 
with risk of HIV transmission in 
serodifferent couples 
Meta-analysis  
 
9 observational studies (49,083 couples) 
and 1 RCT (1,763 couples) of HIV 
transmission risk in serodifferent couples 
according to whether the HIV-positive 
partner was on ART.  
Observational studies: Italy, Brazil, Spain, 
China, Zambia, Rwanda, Uganda, 
Botswana, Kenya, South Africa, and 
Tanzania. 
RCT: Botswana, Brazil, India, Malawi, 
Kenya, South Africa, Thailand, United 
States and Zimbabwe 
Published 1994–2012  
ART was associated with a lower risk of 
transmission partners in 8 observational studies 
(rate ratio ranged from 0.08 to 0.91), while in one 
study no association was found. 
The estimated summary rate ratio of 0.58 (95% CI: 
0.35, 0.96) was obtained for the 9 observational 
studies. In sensitivity analyses, excluding the 
studies without adequate person-time data or in 
which only one antiretroviral drug was used, the 
summary rate ratio was 0.36 (95% CI: 0.17, 0.75). 
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Apondi, 2011, 
AIDS 
(1222) 
To investigate HIV heterosexual 
transmission risk among HIV-
positive adults on ART 
Prospective 
cohort study 
928 HIV serodifferent couples in Uganda 
with the HIV-positive partner receiving 
ART; 81% had more than 3 years’ follow-
up 
Estimated HIV transmission risk decreased by 91% 
from 47.3 per 1,000 PYs at study entry to 4.2 per 
1,000 PYs after 36 months. 
Despite increased sexual activity among HIV-
positive individuals over 3 years on ART, risky sex 
and estimated risk of HIV transmission remained 
lower than baseline levels. 
Attia, 
2009, 
AIDS 
(429) 
 
To synthesize the evidence on the 
risk of HIV transmission through 
condom-less sexual intercourse 
according to VL levels in plasma and 
treatment with ART 
Systematic 
review and 
meta-analysis 
of 
observational 
cohort studies 
of HIV 
serodifferent 
couples 
11 cohorts reporting on 5,021 
serodifferent couples and 461 HIV-
transmission events 
The rate of transmission overall from ART-treated 
patients was 0.46 (95% CI: 0.19, 1.09) per 100 PYs, 
based on 5 events. The transmission rate from a 
seropositive partner with VL <400 copies/mL on 
ART, based on 2 studies, was 0 (95% CI: 0.0, 1.27) 
and 0.16 (95% CI: 0.02, 1.13) per 100 PYs if not on 
ART, based on 5 studies and 1 event. 
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First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Baggaley, 
2010, 
International 
Journal of 
Epidemiology 
(1223) 
To assess the per-act and per-
partner HIV transmission risk from 
anal intercourse exposure for 
heterosexuals and MSM and its 
implications for HIV prevention 
Systematic 
review and 
meta-analysis 
4 publications reporting per-act and 12 
publications reporting per-partner studies 
The predicted HIV transmission probabilities per-
act for condom-less vaginal intercourse or CLIAI 
and CLRAI with successful ART are 0.013 and 
0.061%, respectively, i.e. 96% lower than without 
therapy. Using another function of infectivity by 
plasma VL, the predicted per-act condom-less 
vaginal intercourse/CLIAI and CLRAI estimates with 
successful ART are 0.0002 and 0.0011%, 
respectively, i.e. 99.9% lower than without 
therapy. 
Baggaley, 
2013, 
Epidemiology 
(673) 
To systematically review the effect 
of ART on HIV transmission and to 
conduct a meta-analysis of HIV-1 
infectiousness per heterosexual 
partnership 
Systematic 
review and 
meta-analysis 
of 
observational 
prospective 
studies 
9 studies where it was possible to compare 
between ART and non-ART users within 
studies (ART-stratified studies) and 41 
studies  that did not stratify by ART use 
 
The authors estimate that incidence rates were 0.2 
per 100 PYs (95% CI: 0.07, 0.7) and 3.6 per 100 PYs 
(95% CI: 2.0, 6.5) for couples where the HIV-
positive partner was on ART and not on ART, 
respectively (p<0.001). This represents a 91% (95% 
CI: 79, 96%) reduction in per-partner HIV-1 
incidence rate with ART use. 
[The results are reported only for the 9 studies 
where the comparison was between ART and non-
ART users.] 
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First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Birungi, 
2012 
Journal of the 
International 
AIDS Society 
(668) 
To evaluate the association between 
the HIV-positive partner being on 
ART and the risk of the HIV-negative 
partner of becoming infected with 
HIV 
Observational 
cohort study 
586 serodifferent heterosexual couples 
aged ≥18 years, where the HIV-positive 
partner was a client of The AIDS Support 
Organization in Jinja, rural Uganda. 
The HIV-positive partner was on ART if 
eligible (CD4 count ≤250 cells/μL or WHO 
Stage III or IV disease) or not on ART, if not 
yet eligible 
There were 9 new HIV infections in serodifferent 
couple where the HIV-positive partner was on ART 
and 8 new infections in couples where the HIV-
positive partner was off ART, for an overall 
incidence rate ratio of 1.16 (p=0.564). 
Therefore the authors did not find an association 
between the HIV-positive partner being on ART 
and the risk of the partner becoming infected with 
HIV. 
Castilla, 
2005, 
J Acquir 
Immune Defic 
Syndr 
(430) 
To estimate the impact of ART use 
on HIV prevalence among steady 
HIV serodifferent couples 
 
Cross-sectional 
analysis 
 
393 steady HIV serodifferent couples seen 
in care between 1991 and 2003 in Madrid, 
Spain 
HIV prevalence among partners of index cases who 
had not received ART was 8.6%, whereas no 
partner was infected in couples in which the index 
case had been treated with ART (p=0.0123). HIV 
prevalence among non-index partners decreased 
from 10.3% during the pre-ART period (1991–
1995) to 1.9% during the late ART period (1999–
2003; p=0.0061). 
Del Romero, 
2010, 
British 
Medical 
Journal 
(659) 
To estimate the risk and probability 
of heterosexual transmission of HIV 
from people living with HIV on ART 
Cross-sectional 
and 
longitudinal 
analysis of a 
cohort study 
 
476 stable (reporting this sexual 
relationship as the only risk exposure) HIV 
serodifferent heterosexual couples 
followed in 1989 and in 2008 in Madrid, 
Spain 
 
9.2% HIV prevalence in non-index partners at 
enrolment, where the index partner was not on 
ART (n=44), 0% in couples where the index partner 
was on ART (n=149). The authors concluded that 
transmission of HIV from successfully treated 
people cannot be excluded. 
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First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Donnell, 
2010, 
Lancet 
(431) 
 
To assess the effect of ART use by 
HIV-positive people on risk of 
transmission to their uninfected 
partner 
Observational 
analysis of RCT 
data (Partners 
in HSV/HIV 
transmission 
study) 
Study of 3,381 HIV serodifferent couples 
from 14 sites in 7 countries in East and 
Southern Africa followed between 
November 2004 and October 2008; the 
index HIV-positive person was both HIV 
and HSV-2 positive with a CD4 count ≥250 
cells/μL 
1/103 genetically linked HIV transmissions were 
from an infected participant who had started ART, 
corresponding to transmission rates of 0.37 (95% 
CI: 0.09, 2.04) per 100 PYs in those who had 
initiated ART and 2.24 (95% CI: 1.84, 2.72) per 100 
PYs in those who had not – a 92% reduction 
(adjusted IRR: 0.08; 95% CI: 0.00, 0.57; p=0·004). 
Jia, 
2013, 
Lancet 
(667) 
To investigate the rate of HIV 
transmission between heterosexual 
HIV serodifferent couples, according 
to ART status of the HIV-positive 
partner 
Retrospective 
observational 
cohort study 
38,862 HIV serodifferent heterosexual 
couples (101,295 PYs of follow-up) 
participating in national HIV epidemiology 
and  treatment databases between 1 
January 2003 and 31 December 2011 in 
China 
Rate per 100 PYs of HIV infection were 2.6 (95% CI: 
2.4, 2.8) among couples where the HIV-positive 
partner was ART-naive, and 1.3 (95% CI: 1.2, 1.3) 
among couples where the HIV-positive partner 
was receiving ART. Adjusted HR was 0.74 (95% CI: 
0.65, 0.84) for ART-naive vs treated.  
This reduction was seen across almost all 
demographic subgroups except for people who 
people who inject drugs. Therefore treatment as a 
prevention strategy is a feasible public health 
strategy. 
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First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Jin, 
2010, 
AIDS 
(1224) 
To estimate per-contact probability 
of HIV transmission in homosexual 
men due to various forms of UAI in 
the era of ART 
Health In Men 
(HIM) study, 
observational 
longitudinal 
cohort study 
 
1,427 community-based HIV-negative 
homosexual men in Sydney, Australia 
followed from June 2001 to June 2007 
Estimated per-contact probability of HIV 
transmission: 
1.43% (95% CI: 0.48, 2.85) for receptive UAI if 
ejaculation occurred inside the rectum; 
0.65% (95% CI: 0.15, 1.53) for receptive UAI if 
withdrawal prior to ejaculation; 
0.11% (95% CI: 0.02, 0.24) for insertive UAI in 
circumcised men; 
0.62% (95% CI: 0.07, 1.68) for insertive in 
uncircumcised men. 
Loutfy, 
2013, 
PLoS One 
(674) 
To estimate the risk of heterosexual 
HIV transmission between 
serodifferent couples when the HIV-
positive partner has a fully 
suppressed VL on ART 
Systematic 
review and 
meta-analysis 
Systematic review of 1 RCT and 5 cohort 
studies estimating HIV transmission rate 
when an HIV-positive partner has a fully 
suppressed VL on ART, published up to 
November 2012 
The estimated HIV incidence was 0 (95% CI: 0, 
0.05) per 100 PYs when the suppressed VL was 
confirmed at the time of transmission and 0.14 
(0.04–0.31) per 100 PYs regardless of whether the 
VL was confirmed as suppressed or not. This 
corresponds to a pooled OR for on ART vs not on 
ART of 0.05 (95% CI: 0.01, 0.17). 
The authors suggest there is minimal risk of sexual 
HIV transmission for heterosexual serodifferent 
couples when the HIV-positive partner had full 
viral suppression on ART, with caveats regarding 
sexual intercourse type, STIs and condom use. 
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First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Melo, 
2008, 
Sexually 
Transmitted 
Diseases 
(664) 
To estimate sexual HIV transmission 
rates and assess the behavioural 
and clinical factors for HIV 
transmission 
Observational 
cohort study 
 
93 HIV-serodifferent couples from Porto 
Alegre, southern Brazil, followed between 
2000 and 2006 with no prior ART use 
 
Among couples where the index person started 
ART (n=41) no SCs occurred, while in the 
remaining couples (n=52), SCs were observed 
(incidence: 11.5%; 95% CI: 4.81, 22.45). 
Reynolds, 
2011, 
AIDS 
(665) 
To evaluate the impact of ART on 
HIV transmission rates among HIV 
serodifferent couples 
Observational 
cohort study 
(Rakai) 
 
250 HIV serodifferent heterosexual 
couples in Rakai, Uganda, followed 
between 2004 and 2009 
 
42 HIV transmissions were seen in 459.4 PYs 
before ART initiation (incidence: 9.2 per 100 PYs; 
95% CI: 6.59, 12.36). In 32 couples in which the 
HIV index partners started ART, no HIV 
transmissions occurred during 53.6 PYs.  
Sullivan, 
2009, 
IAS abstract 
(666) 
To estimate the incidence density of 
HIV transmission by ART status of 
the HIV-infected partner in the 
serodifferent couples 
Observational 
cohort study 
2,993 HIV-serodifferent couples in Rwanda 
and Zambia followed for 5,609 PYs in 
2002–2008 
There were 4 new HIV infections in the couples 
where the HIV-positive partner was on ART and 
171 in the couples where the partner was not on 
ART. The estimated HIV incidence density was 
0.7% in couples where the HIV-positive partner 
was on ART, and 3.4% when off ART (rate ratio: 
0.21; 95% CI: 0.08, 0.59).  
Tanser, 
2013, 
Science 
(670) 
To assess whether substantial 
reductions in HIV incidence can be 
obtained in practice, outside of RCTs 
and in the context of sub-Saharan 
Africa 
Observational 
prospective 
cohort study 
Cohort of individuals who were HIV-
negative at baseline (total follow-up 
16,667 PYs) in rural KwaZulu-Natal, South 
Africa followed between 2004 and 2011 
The authors found that the risk of HIV acquisition 
for a certain individual decreased significantly with 
increasing ART coverage in the surrounding local 
community.  
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First author, 
year of 
publication,  
journal, 
reference 
Study aim 
 
Study design  
 
Study population and study period 
 
Results/conclusions 
Wang, 
2010, 
J of Acquir 
Immune Defic 
Syndr 
(669) 
To estimate the HIV transmission 
risk and assess the behavioural, 
clinical, and quality-of-life risk 
factors for HIV transmission 
Observational 
cohort study 
 
1,927 HIV serodifferent heterosexual 
couples followed between January 2006 
and December 2008 in Henan, China. HIV-
positive individual was former plasma 
donor 
84 HIV transmissions occurred over 4918 PYs, an 
incidence of 1.71/100 PYs. Most respondents 
(80.4%) had spouses who were on ART. There was 
no statistical difference in the SC rates between 
those couples who had a spouse on ART (4.8%) 
and those couples whose HIV-positive spouse was 
not on ART (3.2%) (p=0.12). 
AIDS: acquired immunodeficiency syndrome; ART: antiretroviral therapy; CI: confidence interval; CLIAI: condom-less insertive anal intercourse; CLRAI: condom-less receptive anal intercourse; HIV: 
human immunodeficiency virus; HTC: HIV testing and counselling; ICER: incremental cost-effectiveness ratio; IQR: interquartile range; IRR: incidence rate ratio; MSM: men who have sex with men; OR: 
odds ratio; PrEP: pre-exposure prophylaxis; PY: person-year; QALY: quality-adjusted life-years; RCT: randomized controlled trial; RLS: resource limited settings; SC: seroconversion; STIs: sexually 
transmitted infections; UAI: condom-less anal intercourse; UTT: universal test and treat; VL: viral load; VMC: voluntary medical circumcision; 
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Appendix XIII. Modified Poisson Regression analysis 
 
This appendix presents the rationale and the theory behind the use of the modified Poisson 
regression analysis. It introduces briefly the logistic regression, generally used for bivariate 
data, and the Poisson regression, which has the advantage over the logistic regression of 
providing a more intuitive outcome and finally it describes the modified Poisson regression, 
which allows to correctly quantify the association between a certain outcome and a covariate, 
using the more intuitive RR and correctly estimating the error for the RR. 
 
Rationale  
Often, we wish to investigate whether or not the person experiences an event of interest, in 
this case whether they had a resistance test following ART interruption (Aim 1a) and in those 
who had a resistance test how many still had NNRTI resistance (Aim1b). In this case the 
outcome is binary (dichotomous), because there are only two possible outcomes, either they 
did have the resistance test or not. Most common binary outcomes in epidemiological 
research are success/failure, alive/dead. The outcome is often referred to as an event and we 
are interested in the probability of an event occurring. This can be expressed in terms of risk or 
odds. 
 
The risk on an event occurring by a certain time point (t) can be calculated as: 
𝑅𝑖𝑠𝑘 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡 = 𝑝
=
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑒𝑣𝑒𝑛𝑡 𝑑𝑢𝑟𝑖𝑛𝑔 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑝𝑒𝑟𝑖𝑜𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑡ℎ𝑒 𝑒𝑣𝑒𝑛𝑡 𝑎𝑡 𝑡ℎ𝑒 𝑆𝑇𝐴𝑅𝑇 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑝𝑒𝑟𝑖𝑜𝑑
 
while the odds of an event is defined as: 
𝑂𝑑𝑑𝑠 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑒𝑣𝑒𝑛𝑡 𝑜𝑣𝑒𝑟 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑝𝑒𝑟𝑖𝑜𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑡ℎ𝑒 𝑒𝑣𝑒𝑛𝑡 𝑜𝑣𝑒𝑟 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑝𝑒𝑟𝑖𝑜𝑑
=
𝑝
1 − 𝑝
 
Thus, p is used to calculate the odds of the event occurring.  
 
To measure the association between a certain event y and a certain factor x, for example 
exposed to a certain predictor (x=1) and unexposed (x=2), two common measures of 
association are the RR, also called risk ratio, defined as: 
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𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑟𝑖𝑠𝑘 =
𝑅𝑖𝑠𝑘1
𝑅𝑖𝑠𝑘2
=
𝑝1
𝑝2
 
and the odds ratio (OR): 
 
𝑂𝑑𝑑𝑠 𝑅𝑎𝑡𝑖𝑜 (𝑂𝑅) =
𝑜𝑑𝑑𝑠1
𝑜𝑑𝑑𝑠2
=
𝑝1 (1 − 𝑝1)⁄
𝑝2 (1 − 𝑝2)⁄
 
 
Both measures can vary from 0, when the risk/odds in the group exposed is 0, to ∞, when the 
risk/odds in the group unexposed is 0. A value of 1 means that the risk/odds of an event 
occurring in the two groups is the same, a value greater than 1 that the group exposed (x=1) 
has greater risk/odds of an event than the second, the opposite if the value is less than 1. 
 
When the outcome is rare, conventionally less than 10% (the probability of occurring is very 
small, p~0), the odds of an event is similar to the probability of an event and so the difference 
between a RR and an OR is negligible.  
 
When the outcome is dichotomous, the most commonly used techniques are logistic 
regression and Poisson regression; although Poisson regression can be used more generally for 
count data.  
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Logistic regression 
A probability (p) of an event is a number between 0 and 1. In order to perform a logistic 
regression analysis this has to be transformed so that it takes values between minus infinity (-
∞) and infinity (+∞). The transformation to use logistic regression is called logit, which is the 
logarithm of the odds of the event. The logistic regression is used to model the log of the odds, 
where the name logistic comes from the fact that we use the log transformation to do the 
analysis.  
 
Equation 8.1 Logistic regression model  
𝑙𝑜𝑔 (
𝑝
1 − 𝑝
) = 𝛼 + 𝛽1𝑥1 + 𝛽2𝑥2 + ⋯ + 𝛽𝑛𝑥𝑛 
The α is the intercept, the value of logit (log-odds) when all the covariates (x1,…xn) have a value 
of 0,  β1… βn are regression coefficients and x1...xn are explanatory variables, covariates.  
In equation 8.1, the coefficient (βi) from the model reflects the independent effect of the 
variable (xi) that is not explained by the other factors. The equation can be used to predict the 
probability that an event occurs for each individual by using the estimated for the intercept 
and the coefficient and the value of x1,…,xn for that particular individual. As you can see from 
equation 8.1, this type of model assumes a linear relationship between the explanatory 
variables and the log odds of an event. It can be used to estimate the OR that compares the 
outcomes from two groups of patients (exposed, x=1, and unexposed, x=2) by anti–logging the 
coefficients (βi).  
 
If not all people are followed for the same amount of time, the risk of an event, or the odds, 
are not the most appropriate measure, because they do not take into account for how long the 
patients have been followed for. When participants are followed for a variable length of time, 
the Poisson regression is regarded as an appropriate technique for analysing rare events. 
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Poisson regression analysis 
Poisson regression analysis, as well as survival analysis, allows dealing with follow-up time and 
censored data. An observation is censored if the value is only partially known. In case of time 
to event data, they can be right censored, left censored or interval censored. The figure below 
shows the three different kinds of censoring.  
 
Figure. Examples of different types of censoring 
 
  
The most common type of censoring, is right censoring, which occurs when the period of 
observation (follow-up) is stopped before the event of interest has occurred, therefore what is 
known is that by the end of the study the patient has not experienced the event of interest, 
but it is not known whether the event ever occurred after the date of censoring and when. Left 
censoring occurs when the patient has already experienced a period of time (without the 
event) before they are formally followed in the study, so usually the patient is not included 
into the study. Interval censoring happens when both occur. 
If censoring was ignored and only complete data considered, information would be 
disregarded and could bias the conclusion on the distribution of event times.  
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The Poisson regression analysis is similar to logistic regression, but the outcome variable is a 
rate, rather than the odds an event, although it can be applied to binomial data and in that 
case the outcome variable is the risk of an event. 
𝑅𝑎𝑡𝑒 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑜𝑝𝑙𝑒 𝑤𝑖𝑡ℎ 𝑡ℎ𝑒 𝑒𝑣𝑒𝑛𝑡 𝑑𝑢𝑟𝑖𝑛𝑔 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑝𝑒𝑟𝑖𝑜𝑑
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑒𝑟𝑠𝑜𝑛 − 𝑦𝑒𝑎𝑟𝑠 𝑜𝑓 𝑓𝑜𝑙𝑙𝑜𝑤 − 𝑢𝑝
 
 
One year of follow-up can be accumulated if a single person is followed for 1 year, or 12 
persons are followed for a month. If the rate is X per 100 PY of follow-up, this means that if we 
followed 100 people for 1 year we would expect X number of events to occur. A rate is a 
number between 0 and infinity. If more than 20 events are observed then 95% confidence 
intervals (CIs) are calculated using the normal approximation to the Poisson distribution. 
Where the number of events is ≤ 20 then the exact Poisson distribution is used to calculate the 
95% CI.  
Poisson regression analysis is used to model the rate ratios and again allows for adjustment of 
numerous different variables. As the assumptions of linear regression again are not met, the 
log of the rate or the risk is modelled and then it is transformed. The model is interpreted in a 
similar way to logistic regression, but instead of ORs the estimates are rates ratios or risk ratio, 
also called “relative rates”. Assuming that a certain subject i has an underlying risk indicated as 
𝜋(𝑥𝑖), which is a function of the factor xi, because  𝜋(𝑥𝑖) must be positive, as it is the case in 
the logistic regression, the logarithmic function is an obvious choice 
𝑙𝑜𝑔[𝜋(𝑥𝑖)] = 𝛼 + 𝛽1𝑥1 + ⋯ + 𝛽𝑛𝑥𝑛 
The RR is then giving by anti-logging the coefficient (𝑒𝑥𝑝(𝛽𝑖)). 
To calculate the 95% CI for the RR, the Delta method is used. The logarithm of the RR has a 
sampling distribution that is approximately Normal with a variance that can be estimated by a 
formula (Delta methods) based on the number of subject in each group and the event rate. 
Using this method, a CI which is symmetric around log(RR) can be defined as: 
𝐶𝐼 = 𝑙𝑜𝑔(𝑅𝑅) ± 𝑆𝐸 × 𝑧∝ 
Where zα is the standard score for the level of significance α (usually 0.05) and SE is the 
standard error. By anti-logging the lower and upper limit, an asymmetric CI around the RR can 
be obtained.  
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Modified Poisson regression analysis 
Despite the fact that only if the event is very rare the difference between an OR and a RR is 
negligible, the OR is often interpreted as a RR, leading to potential exaggeration of the effect 
communicated.  
For this analysis I wanted to express the results in terms of RR, so I wanted to use a Poisson 
regression model. The issue is that when Poisson regression model is applied to binomial data , 
the error for the estimated RR will be overestimated (1225).  
If the outcome is binomial the data can be summarized as: 
 
Table A.14. Notation for 2-by-2 table 
 y=1 (event) y=0 (no event) Total 
x=1 (exposed) A B n1=a+b 
x=0 (unexposed) c D n0=c+d 
   n=n1+n2 
 
By using the standard likelihood theory, it is obtained that the antilog of the intercept is the 
risk of event in the unexposed/reference group. 
𝑒𝑥𝑝(?̂?) =
𝑐
𝑛0
 
 
And the antilog of the coefficient βi , in case of binary outcome is: 
𝑅?̂? = 𝑒𝑥𝑝(𝛽?̂?) =
𝑎𝑛0
𝑐𝑛1
 
With the estimated variance of the RR given by 
𝑣𝑎?̂?(𝑅?̂?) =
1
𝑎
+
1
𝑐
 
When the distribution of the data is binomial, as mentioned the error is mispecified. This 
problem can be resolved by using a robust error variance procedure known as sandwich 
estimation. The corrected variance is calculated as: 
𝑣𝑎𝑟(𝑅?̂?) =
1
𝑎2
∑[𝑦𝑖 − 𝑒𝑥𝑝(𝛼 + 𝛽1 + ⋯ + 𝛽𝑛)]
2
𝑛1
𝑖=1
+
1
𝑐2
∑[𝑦𝑖 − 𝑒𝑥𝑝(𝛼 + 𝛽1 + ⋯ + 𝛽𝑛)]
2
𝑛0
𝑖=1
 
which is consistently estimated by 
438 
 
𝑣𝑎?̂?(𝑅?̂?) =
1
𝑎
−
1
𝑛1
+
1
𝑐
−
1
𝑛0
 
This estimator is identical to the Delta Method. 
If this technique is used I will refer to the Poisson regression as “modified Poisson regression”.  
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Appendix XIV. Literature review on barriers to HIV care 
and effective interventions to reduce the leakage in the 
cascade of care 
 
Additional details on effective interventions to improve awareness of HIV status 
Provider-initiated testing and counselling 
A cross-sectional study conducted in Botswana 11 months after the introduction of PITC in 
health centres reported a very favourable response from people who thought it could help to 
decrease barriers to test, HIV-related stigma and increase access to ART, but it raised concern 
due to the fact that over half of the people felt they could not refuse it (849). A systematic 
review focusing on the operational implementation of PITC programmes in sub-Saharan Africa 
(up to November 2010) reported that although the introduction of PITC had been effective in 
testing large number of people there was lots of variability across different programmes on the 
proportion of people who were offered PITC, varying from 24% in a study of outpatients in 
Ethiopia (1226) up to 94% in a study conducted in South Africa among TB patients (1227). 
Large variability was found as well on acceptability of PITC and linkage to care for those 
identified as positive, from 31% in a study among outpatients in South Africa (1001) up to 99% 
in a study of inpatients in Uganda (852).  
A case series study in two primary healthcare clinics in South Africa, where uptake of HIV 
testing was compared before and after PITC implementation, showed an increase in HIV 
testing from 31% to 55%. In addition after three months only 3.8% of those found HIV-positive 
had registered for onsite HIV treatment, highlighting the need for proactive interventions to 
link people to care once identified as HIV-positive (1228). 
A systematic review evaluating the impact of PITC in achieving universal testing of pregnant 
women estimated that before the implementation of PITC HIV testing uptake ranged from 
5.5% to 78.7% and afterwards it increased by a range of 9.9% to 65.6%, with testing uptake 
≥85% in eight out of ten studies identified (851). 
Nevertheless concerns about difficulty in refusing PITC have been reported (849) and in the 
literature there is high variability in the proportion of people who were offered PITC 
(1226;1227) and who accepted it (852;1001). The main barriers to optimal implementation of 
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PITC included issues related to the logistic, data systems, constraints in human resources in 
overstretched health systems (1229), but also l difficulty in ensuring linkage to care (1228). 
 
Among specific groups of patients such as TB patients and inpatients, successful results have 
been reported. In a pilot study conducted in an integrated TB and HIV services in Kenya, where 
PICT was offered to TB patients and suspects, after a community sensitization campaign and 
staff training, 89% agreed to test for HIV, showing very high acceptability in this group of 
patients (850). A RCT investigated the efficacy of offering inpatient PITC in an urban hospital in 
Uganda compared to offering referral cards and travelling reimbursement to test one week 
later, after discharge found that in the intervention group 99% tested for HIV compared to 
69% in the control group (852).  
 
Couple voluntary counselling and testing  
A study conducted in Dar El Salam, Tanzania (853) randomized women attending ANC to 
individual- or couple-VCT with their sexual partner to arrange at a subsequent visit: 71% of 
those assigned to individual-VCT tested for HIV compared to 39% of those randomized to 
couple-VCT. A study conducted in Khayelitsha, Cape Town, South Africa (855) randomized 
women attending ANC, to either invite (provided with a written invitation) their male sexual 
partner to VCT or to a pregnancy information session (control). The outcomes were women’s 
acceptance to invite their partners and uptake of VCT in their male sexual partner. In both 
arms all women accepted to invite their partners, 35% of women for whom their partner was 
invited for VCT brought their partner for an ANC visit compared to 26% of those who invited 
their partner for a pregnancy information session. Of more interest, those invited for VCT were 
almost twice as likely to test for HIV (32% vs 11%), highlighting that providing a written 
invitation is an efficacious strategy in increasing HIV testing in partner of pregnant women. A 
study conducted in Congo focused in understanding in which venue male partners were more 
likely to test for HIV between a neighbourhood health centre, bar or church (854). They found 
that the uptake of HIV testing in male partners was low: 26% in bars, 21% in church and 18% at 
the health centres. 
 
Home-based HIV voluntary counselling and testing 
Offering the possibility of VCT at a location of the patient choice, rather than at the clinic, was 
demonstrated in an early RCT conducted in Zambia to increase the probability of being tested 
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for HIV almost by 5 times (858). 84% of them chose home as favourite location.  One of the 
first studies  investigating the possibility of delivering HIV test results at home was conducted 
in rural Uganda: following a sero-survey conducted in 2001, delivery of HIV counselling and HIV 
results at home was offered in four study villages. This increased uptake of results from 10 to 
37%, and qualitative data within the same studies highlighted the main barriers to testing were 
inconvenience, fear of stigmatization, and emotional vulnerability of receiving results from 
public facilities (863). A meta-analysis of 21 studies conducted in five different countries in 
sub-Saharan Africa (Uganda, Malawi, Kenya, South Africa, and Zambia) reported that Home-
Based Voluntary HIV Testing (HBT) uptake ranged from 58% to 99.8%, with a pooled 
proportion of 83% (95% CI: 80%, 86%) (754), including studies were only household members 
of people living with HIV or on ART were offered HBT (859-861). Another recent meta-analysis 
estimating the uptake of different community based-approaches estimated 80% of those 
offered HBT accepted it and 88% if HBT was offered to household members of an HIV-positive 
person and people who may have been exposed to HIV (862). 
 
Workplace HIV counselling and testing 
The offer of testing for HIV at the workplace occupational clinic, rather than off-site was 
demonstrated in a RCT conducted in Zimbabwe to lead to an HIV testing uptake of 51% 
compared to 19% if people were given a voucher to test for HIV off-site at one chain of free-
standing VCT centres (865).  
A subsequent study conducted in Nigeria, evaluated whether the uptake of HTC at the 
workplace was different  if the peer education was coordinated by people openly living with 
HIV or by members of staff of unknown HIV status (866). They found that after six months of 
the intervention implementation the uptake of HTC was four times in the companies where 
people openly living with HIV were coordinating the intervention. 
Although this HIV testing strategy allows one to reach only people who are employed, and 
plausibly only in large businesses, this study clearly showed that convenience and accessibility 
to HIV testing are crucial factors. A meta-analysis (862), including in addition to this RCT few 
other observational studies mainly from sub-Saharan Africa, estimated an overall uptake of 
67%, with a wide range from 20% (1230) up to 92% (1231).  
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Mobile HIV testing for the general population 
In the Project Accept, one of the largest RCTs ever conducted, they implemented an 
intervention including community mobilization through HIV working groups and outreach 
coordinators, mobile VCT in community centres and other public places, and post-test support 
services (1232). The overall efficacy of this intervention (mean difference in the proportion of 
patients receiving HTC in the intervention community compared to control community) was 
40.2% (95% CI: 15.5, 64.7) (756). The proportion of people tested for HIV was in Tanzania 37% 
in the intervention communities compared to 9% in the control communities, in Thailand 69% 
vs 23% and in Zimbabwe 51% vs 5%. 
 
School-based HIV educational programs 
Only a handful of studies worldwide have evaluated the impact of school-based HTC and using 
observational studies. Across the community-based approaches, this is the one with the lowest 
uptake (62%; 95% CI: 40%, 85%). Nevertheless this estimate contains a small study conducted 
in US with an uptake of 20% and a study conducted in Zimbabwe in children aged 5 years or 
less, which are out of the focus of this thesis (862). The only study conducted in sub-Saharan 
Africa is presented in section 7.2.1 (869).  
 
Self-testing 
In sub-Saharan Africa most of the research on ST has been conducted in Blantyre, Malawi. 
Initially they conducted a feasibility study (871) where people sampled from the community 
were offered the possibility of ST plus confirmatory HTC (parallel testing with two rapid finger-
prick blood tests), standard HTC alone, or no testing. 92% opted for ST after a brief 
demonstration and illustrated instructions showing that ST was highly acceptable. In a 
subsequent study they offered ST through community counsellors to all communities involved 
in the study, and randomly assigned them to receive facility-based HIV care alone (control arm) 
or optional home-based assessment and initiation of HIV care (intervention arm) (755). After 
12 months 76% of over 16,000 residents had used ST at 12 months since its introduction and 
78% of those who disclosed their reactive ST result to counsellors linked to care (872). 
In addition, a couple of studies have been conducted among healthcare workers in sub-
Saharan Africa. The first reported that among healthcare workers from 7 hospitals in Kenya the 
uptake was 89% (873) and in a pilot study among healthcare workers in Cape Town 93% (874). 
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Additional details on effective interventions to improve linkage to care 
Referral programs and patient navigator 
Only very few studies have evaluated the impact of this intervention. In a study in a rural 
district in northern Tanzania a referral system to link people diagnosed at a VCT clinic with a 
government-run HIV treatment clinic in a nearby city was conducted. This system consisted of  
the use of two detachable-part referral forms, with unique matching numbers on each side to 
make it easier to access HIV clinics and to allow clinics to check whether people enrolled into 
HIV care, and to trace those who had given consent, were introduced (878). In addition they 
provided transportation allowances and a "community escort" from a local home-based care 
organization in patients attending the HIV clinic, who could offer counselling services. They 
observed that in the first 18 months the proportion of patients who enrolled at the HIV clinic 
within a week increased from 18% to 64%, although the proportion who did not register went 
never below 17%. This intervention was followed by a national HIV testing campaign, which 
produced a 70% increase in the number of clients referred to HIV compared to the previous 6 
months and unfortunately also an increase (7%) in the proportion who remained unregistered.  
In a cross-sectional study conducted in Nyanza Province, Kenya during August–September 
2009, they assessed the linkage to care following a community-based HTC campaign, of an 
intervention for people found HIV-positive including: provision of a referral to care, offer of a 
rapid CD4 count (most received the result within 3h, 30% of them were asked to come back 
the following day to collect the result) and offer of being visited by a “patient navigator”, who 
could guide them to enrol into HIV care (876). They found that 87% of patient newly identified 
as positive received a CD4 count measurement, 63% reported they were enrolled into HIV care 
within 3 months and 81% reported being enrolled by 10 months (although only 80% could be 
located and therefore reported whether they were linked to care or not). 
 
Point-of- care CD4 
Compared to the traditional laboratory methods, POC CD4 assays do not require transport of 
blood samples to a centralized laboratory, high technical expertise to conduct flow cytometry 
and often complex software or systems to ensure results are returned to the patients when 
they come back to the clinic (879). This technology increased substantially the likelihood of 
having a CD4 count measured (OR = 4.2; 95% CI: 3.5, 4.9) and of receiving the CD4 count result 
in those who had a CD4 count measurement (OR = 2.8; 95% CI: 1.5, 5.6).  
444 
 
An important example comes from a cohort study in Mozambique where the introduction of 
POC CD4 in the primary healthcare clinics allowed a decrease in loss to follow-up before 
completion of ART assessment (defined as having ART assessment within 90 days from 
enrolment) from 57% to 21% (757). 
 
Home-based ART initiation following positive self-test 
A cluster RCT evaluated this intervention in Blantyre, Malawi (755). In this study, given the 
confidentiality of ST, they could not measure how many of those who self-tested positive had 
ART eligibility assessment during a certain time period, for this reason they compared the 
percentage of adult initiating ART in the two arms and found that it was almost 3-fold in the 
communities where there was the possibility of home-ART initiation (RR = 2.9; 95% CI: 2.1, 
4.2).  In addition they found that there was no difference in the % of adults initiating ART if ST 
was available without home-based ART initiation or if ST was not available, underlining the fact 
that in order for ST to be effective a proactive intervention to link people to care must be in 
place. 
 
Additional details on effective interventions to improve retention in pre-ART care 
Structural services (free services, cash transfer for transportation, food rations) 
To overcome the fact that distance to the clinic is often reported as a barrier to retention in 
care, some studies have evaluated whether cash transfers for transportation could partly solve 
this problem. A RCT conducted in Mbarara, Uganda evaluated the impact of a cash transfer of 
10,000 to 15,000 Uganda Shillings ($5–$8) to be used for transportation. Only 18% (n=14) of 
those receiving the cash transfer were LTFU compared to 34% (n=23) in the control group 
(881) [This paper is not currently available on line because of issues in the CROI website, but 
this study represents the only RCT evaluating the impact of cash transfer and it has been 
mentioned in many reviews, for example (828)]. 
A cohort study in central Haiti evaluated the impact of targeted food assistance programs to 
people with HIV and either: TB, a BMI<18.5kg/m2, CD4 count <350/μL (in the prior 3 months) 
or severe socio-economic conditions within a comprehensive HIV program. At both 6 and 12 
months, timely attendance at monthly clinic visits was better in the food assistance group than 
in the non-food group. The mean number of scheduled visits attended at 6 months (out of 6 
visits) was 5.5 for the food assistance group compared to 2.8 (p < 0.0001) among those who 
did not received the support, and at 12 months (out of 12 visits) it was respectively 9.7 and 8.3 
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(p = 0.007). This study included both patients not yet eligible for ART (30%) and receiving ART, 
so it does not distinguish between retention in pre-ART care and on ART (882). 
It has been demonstrated that food incentives are effective in improving retention in pre-ART 
care, for example in a study conducted among children in India (1233), nevertheless this has 
not been assessed yet in sub-Saharan Africa (1234). 
 
Free co-trimoxazole prophylaxis 
The provision of free CTX prophylaxis to people not yet eligible for ART has been observed to 
be effective in improving retention in care in a cohort study in Kenya. They observed that 
retention in care at 12 months was 84% when free CTX prophylaxis was provided compared to 
63% before this happened. After adjusting for confounders, patients enrolled before the 
introduction of free CTX were more than twice (adjusted HR = 2.6, 95% CI: 1.9, 3.6) as likely to 
be LTFU compared to those who received free CTX (883). 
 
Intensified post-test counselling and enhanced peer-support 
Based on the hypothesis that a reason for the low retention in pre-ART care is the lack of 
understanding of the importance of engaging in pre-ART care, a RCT was conducted in Uganda 
evaluating the efficacy of intensified post-test counselling, provided by trained counsellors, 
together with monthly home visits by community support agents. They found that the 
proportion who enrolled in pre-ART care (by attending the nearest health centre for a clinical 
check-up in the subsequent five months) increased by 80% (RR = 1.8, 95% CI: 1.4, 2.1) (884). 
 
 
Additional details on interventions to improve prompt initiation on ART 
Point-of-care CD4 
POC CD4, which has been shown to increase linkage to care, is also effective in increasing 
initiation of ART in those eligible. In a three arm RCT conducted in South Africa patients were 
randomized to either receive a CD4 count result at time of HIV diagnosis (using POC CD4), to 
receive written information and standard of care (CD4 collection after 1 week) or standard of 
care alone. They observed 49% attrition in the standard of care arms and those who received 
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CD4 result at diagnosis were significantly more likely to present for ART initiation by 3 months 
(RR = 2.1; 95% CI: 1.4, 3.2) (887). 
Similarly in Mozambique they found that the introduction of POC CD4 in the primary 
healthcare clinics, which allowed completing ART eligibility assessment within three days 
(median) rather than thirty-two, increased the proportion of patients initiating ART within 60 
days from 12% to 22% (757). 
 
Postponement of adherence counselling during the early treatment period 
As mentioned, before initiating treatment patients need to undergo adherence counselling 
visits, nevertheless this is not always the case and it is not clear whether there is a benefit in 
receiving this adherence counselling session before initiating ART rather than at ART initiation.  
A study in Uganda reported that the first resulted in a 49 day delay in ART initiation (since the 
person was identified as eligible) compared to a 14 day delay if the adherence counselling is 
provided at ART initiation, without providing any benefit in the first three months in terms of 
the proportion with average adherence >90% (adjusted OR = 0.8; 95% CI: 0.4, 1.5), absence of 
treatment gaps longer than 72 hours (adjusted OR = 0.7; 95% CI: 0.2, 1.9), or proportion with 
VL>400 copies/mL at the visit after 3 months (adjusted OR = 1.1; 95% CI: 0.4, 3.1) (888). 
 
Additional details on barriers to retention on ART and adherence 
The first studies to investigate the obstacles in retaining people in care in South Africa were 
conducted in the Themba Lethu clinic in Johannesburg (892;893). They highlighted the fact 
that financial constraints was among the major barriers (34% in (892) and 14% in (893)) in 
particular the transport cost and the necessity to pay for ART. A study conducted in Uganda 
reported that patients could spend between 30% and 50% of their monthly income to cover 
transport cost to the access clinic care and ART (894). While side effects of ART were  initially 
reported by 19% of patients LTFU as a reason for it (893),  this proportion  soon decreased to 
very low levels in more recent studies(<5%) (892;892;960).  
A few psychological barriers have emerged as well as predictors of low retention, such as the 
fear of disclosing their HIV status (892;897), and religious beliefs or the use of traditional 
medicine (892;897). 
In more recent years factors which have been identified as predictors of adherence to ART 
include mental disorders, such as symptoms of depression (491;567;895), although there are 
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some mixed results (567), anxiety (895) and alcohol disorders, although there are very limited 
data (567).  
 
Several qualitative studies, designed to better understand the reasons why people are lost 
from care, have been conducted in South Africa (275;847;890;898;900;901). Major reasons 
reported for not adhering to ART were related to the health system: having to pay for ART 
(847), experiencing low-quality services  (e.g. lack of confidentiality and privacy, drug stock 
shortages, problems with missing paperwork such as transfer papers or clinic cards, 
constrained number of health personnel and therefore not sufficient time spent with the 
provider), issues related to access to care (e.g. long waiting time, difficulty in taking time off 
work and in booking appointments, risk of forced disclosure due to attending certain clinics or 
support groups) and feeling better on treatment (275;847;890;898). 
Healthcare providers’ attitudes and poor communication skills during counselling were also 
found to be associated with poor adherence to ART (890;891). In addition, it is not uncommon 
for people to deny the existence their own HIV status, to have more trust in traditional 
medicine providers than western medicine (847;890;898;899) and in particular not to believe 
that ART is superior to alternative treatments and in few cases were even poisonous. Finally 
HIV infection is often perceived as a consequence of a ‘bewitchment’, which requires therefore 
consultation with traditional medicine practitioners or faith healers in conjunction or instead 
of science-based medicine (890;898;899). 
 
Among the unintentional barriers to adherence, costs, as mentioned before, whether direct 
(treatment cost) (847) or indirect (e.g. transport cost) (275;847) represent one of the  key 
issues, especially because people need to balance amongst compelling competing needs, such 
as, for example, education or food for their children (890;891). Even more so in situations 
characterized by the absence of social security and health insurance, social networks play a key 
role in providing emotional and economic support (847;891;900). It is very difficult to achieve 
optimal adherence without disclosing HIV to anyone, because it is difficult to reorganize daily 
activities to include treatment without help from a supporter (847;891) or to get the resources 
to attend the clinic without help (847;891;900). On the other hand many people are worried 
about disclosing their HIV status because of fear of stigma and of being rejected by their 
partners (485;846;890;896). Nevertheless a more recent study found stigma was much less 
influential than, for example, structural barriers (275). If people managed to disclose their HIV 
status, they usually receive adherence support and help from group support and family. This 
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seems to make them feel responsible for treatment success as a form of reward to these 
people and at the same time it seems like they feel the need to succeed to guarantee help for 
the future (1235). 
 
Some studies investigated risk factors associated with a higher risk of being LTFU. These 
include being pregnant at ART initiation (753;902;903), plausibly due to the burden of 
attending both ANCs and HIV clinics, although there are some contrasting results (1236), and 
having initiated ART as inpatients (753). An additional factor is having a high nadir CD4 count 
(above 200 cells/μL) or CD4 count at baseline (484;753), although some conflicting evidence 
comes from a study conducted in Lesotho, where they found that people initiated on ART with 
a CD4 between 200-350 cells/μL were 39% less likely to be LTFU than those with a CD4 at 
baseline <200 cells/μL (904). These conflicting results can partially be explained by the fact 
that patients with high CD4 counts are more likely to move for work-related reasons while 
those with low CD4 levels are at higher risk for unascertained deaths (i.e. died but considered 
lost by the clinic). 
A factor, which emerged as protective against being LTFU is having received 6 months of pre-
ART care (753) and noticeably in the private sector where it has been found to lead to lower 
direct cost and decreased mortality (905;906).  
Demographic factors associated with a higher risk of being LTFU include male gender 
(484;892), younger age (753;903) which was found below the age of 30 years to double the 
risk of being lost from care (903).  
 
Additional details on effective interventions to improve retention on ART 
Tracing systems 
Following the alarming level of LTFU, several studies have attempted to ascertain the real 
status of people who were not attending the clinic anymore and to reliably determine whether 
they were dead, transferred to another clinic or had stopped treatment. In order to do so they 
implemented tracing systems where people who were considered lost by the clinic (i.e. they 
had not attended the clinic usually for 3 months) were contacted either by phone or visited at 
home. This requires a good recording system regarding visit attendance and patient contact 
information in order to be able to identify the patients who defaulted and to be able to 
contact them. 
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A meta-analysis of treatment outcomes of patient considered LTFU (842) reported that the 
treatment status of 63% of the patients could be ascertained (range across studies: 45% - 86%) 
and among these 40% were dead (95% CI: 33%, 48%; range across studies: 12%-87%). Not 
surprisingly they found an inverse association between the rate of LTFU and mortality, which 
declined from around 60% to 20% as the proportion patients lost to the programme increased 
from 5% to 50%. 
A systematic review of the effect of physical tracing on the estimates of retention on ART, 
updated to 2011 (494) found that ART programmes which included physical tracing activities 
classified less people as LTFU  (7.6% vs. 15.1%; p<.001), more as dead (10.5% vs. 6.6%; p = 
.006) and retained more people on ART (80.0 vs. 75.8%; p = .04), of which more retained at the 
original clinic (80.0% vs. 72.9%; p = .02). Therefore these interventions seem not only to 
improve the knowledge of patients’ vital status, but also the actual re-engagement into care. 
 
Confirmation of the efficacy of tracing systems in improving retention on ART comes also from 
a very large ecological study including clinics from ten countries in sub-Saharan Africa (912). 
They reported that attrition was significantly lower in the clinics offering some form of tracing, 
either by phone, letters, or home visits for patients missing scheduled visits, (53% of the 
clinics) at 6 months (aRR = 0.86; 95% CI: 0.73, 0.99) and at 12 months since ART initiation (aRR 
= 0.84, 95% CI: 0.74, 0.96). 
 
Community-based ART programs (including task-shifting and decentralization) 
Community-based ART programs (CBART) have been developed as a response to congested 
health services, to deliver ART to patients underserved because of long distances to HIV care 
services and to sustain ART adherence.  
These programmes can be divided at least into three main groups (913):  
(i) home-based ART care, where community health workers, peer community health 
workers or volunteers visit patients at home to deliver ART medications, monitor  
patients clinical status by using a checklist (including signs and symptoms of 
toxicities or disease progression), referring sick patients to the clinic and provide 
adherence support. 
(ii) patient-led community, where patients clinically stable on ART can join community 
ART groups and they take in turns to visit the clinic to collect ART medications for 
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all the members of the group and report on clinical status of the other members 
(913).  
(iii) “adherence club” care, where patients stable on ART meet 2 monthly to receive 
pre-package medications, health assessment and to discuss HIV related topics. 
 
The first type of CBART have been evaluated and implemented in Uganda and Kenya, the 
second in Mozambique and the third in South Africa.  
A cluster RCT conducted in Uganda demonstrated that home-based HIV care through trained 
lay workers (4-6 weeks training, responsible for 35-40 patients) visiting patients at home every 
month was equivalent to standard clinic-based care in terms of VF (at 12 months: 84% of those 
receiving CBART had VL<500 copies/mL compared to 83% in the facility based cohort), 
mortality (11% in both arms), LTFU (1% in the CBART and 2% in the facility-based cohort) and 
proportion of patients reporting 100% adherence (94% in CBART versus 91% in facility-based 
care group) (914). After 36 months, the two arms were still equivalent with 14% of patients 
having died in the CBART program and 13% in the facility-based care group (916). Several other 
prospective observational studies in Uganda where CBART was implemented found similar 
outcomes at 12 and 24 months. Again in Uganda, another type of CBART program was 
implemented. The difference compared to the previous model is that this was run by 
community volunteers, who received two days of training and visited weekly a maximum of 
five  people living with HIV to deliver the ART medications, offer them adherence support and 
refer them to the clinic if they were sick. This prospective cohort study showed that treatment 
outcomes were similar between patients receiving CBART and facility-based care, with 30% 
attrition (i.e. LTFU or death) at 24 months (917;918). 
In Kenya, community health workers were selected among people living with HIV and receiving 
ART, they were referred to as community care coordinators and given 7-day didactic training 
followed by two months of practical training (919). Each of them is responsible for up to 20 
clinically stable patients and their duty is to visit the patients monthly to deliver ART 
medication, monitor and support adherence, and refer them to the clinic if there is clinical 
need. Otherwise the patients visit the clinic only every three months compared to monthly for 
the patients not in the CBART programme.  They found no significant difference in terms of 
clinical outcomes (including VL, CD4 count and risk of OIs) between the two groups after 1 year 
since the implementation of the intervention in terms of LTFU (5% in both arms), mortality (1% 
in the CBART arm vs 0% in the facility-based arm) and VL suppression in those retained on ART 
(89% in the CBART arm vs 86% in the facility-based arm). 
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Observational cohort studies of similar forms of CBART have confirmed these findings. An 
example comes from Rwanda where they compared CBART programs (including offer of home 
visits from a community health worker, DOT, food rations, transportation stipends, and other 
support as needed) to the Rwanda national model programs (920). They found that being in a 
CBART was associated with a reduced chance of being dead or LTFU in the first year of ART (HR 
= 0.17; 95% CI: 0.09, 0.35; p < .0001).  
 
In Mozambique, the second type of CBART was implemented. Given the highly resource 
constrained circumstances the Mozambique Minister of Health in collaboration with MSF 
designed an ART programme, where patients who had been on ART for at least six months, 
who had a CD4 count above 200 cells/μL and clinically stable on ART could join a community 
ART group of maximum six people. This allowed a reduction in the number of times each 
person has to visit the clinic (producing a saving in cost and time for the patients) and allowed 
patients to receive support and health monitoring from people in the same situation. This 
programme has so far produced excellent results with 97.5% of patients retained on ART 
(median follow-up 13 months) (1237) and 95.7% still in care at a median follow-up of 21 
months (913). 
 
The third type of group-based model of care was assessed in Khayelitsha, South Africa (915). In 
this case adult patients who had been on ART for at least 18 months, with current CD4 count 
>200 cells/μL and virologically suppressed were invited to take part in "adherence clubs", 
occurring outside of the clinical consultation area. These were composed of 15–30 patients 
and occurred every two months facilitated by trained counsellors. During these “adherence 
clubs”, the counsellor distributes pre-packaged medicines to all participants, weighs the 
patients, administers a symptom-based general health assessment and leads group discussion 
on HIV related topics requested by the participants. Patients who report symptoms of HIV 
progression, adverse drug events or who have lost weight are referred to the clinic to be 
assessed by a nurse. Once a year, a nurse takes part in the adherence clubs to measure CD4 
and VL in all participants. Outcomes were compared to patients attending clinic-based nurse-
led care. The rate of LTFU (i.e. absence of contact with the service in the 6 months following 
the analysis closure) or death was 30/1,000 PYs in those taking part in the adherence club 
compared to 117/1,000 PYs for those receiving routine facility-based nurse-led care, while the 
rate of virological rebound was respectively 32 and 90/1,000 PYs. After adjusting for 
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confounders, “adherence club” participation reduced LTFU by 57% (HR = 0.43, 95% CI: 0.21, 
0.91) and virological rebound by 67% (HR = 0.33, 95% CI: 0.16, 0.67). 
 
Nurse-based rapid assessment  
In LMIC the mortality in people receiving ART peaks in the first 3 months of ART, driven by 
people initiating ART at very low CD4 count. In an attempt to contain this phenomenon, an 
intervention called “High Risk Express Care”, providing weekly or bi-weekly rapid contacts with 
nurses for individuals initiating ART with CD4 count of 100 cells/μL or less was implemented in 
Kenya. This was found to be effective in reducing mortality (adjusted HR = 0.6; 95% CI: 0.4, 
0.8), and LTFU (adjusted HR = 0.6; 95% CI: 0.5, 0.7) in people receiving this intervention 
compared with standard care (943). 
 
Structural services (monetary supplements, food supplements) 
Given the cost of transport and the conflicting needs have often been reported as a barrier to 
retention of people on ART, studies have assessed the impact of providing socioeconomic 
support on retention and mortality. 
A study in an outreach community program in Uganda offering socio-economic support, such 
as school fees, rent payment or provision of shelter, employment at the program, interest-free 
loans, adult literacy instruction, income-generating activities, transport, skills-building 
activities, and food assistance for patient in need reported that after 10 years 41% were 
retained in the clinic and those not retained in care were either LTFU (74%, of which 50% 
transferred to another clinic) or dead (26%) (922). They found that patients who did not 
receive socio-economic support were significantly more likely to be LTFU compared to people 
who received one (HR = 1.5; 95% CI: 1.4, 1.6) or two or more (HR = 6.7; 95% CI: 5.6, 7.7) socio-
economic supports. Similarly for mortality, people who did not receive support were more 
likely to die compared to those who received one (HR = 1.5; 95% CI: 1.2, 1.9) and two or more 
(HR = 4.3; 95% CI: 2.9, 6.2). 
A large ecological study  conducted in ten countries in sub-Saharan Africa found a marginal 
effect of the availability of food rations to support adherence (available in 17% of the clinics) 
on retention on ART at 6 months (aRR = 0.82, 95% CI: 0.64, 1.05) but not at 12 months (aRR = 
0.98, 95% CI: 0.78, 1.21) (912). 
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Additional details on effective interventions to improve adherence 
Mobile phone short messages 
A systematic review on adherence interventions in sub-Saharan Africa published in 2011 (927) 
and a meta-analysis on the same subject (1238) both identified only two studies, both RCTs 
which investigated the impact of mobile short messages (923;924). They were both conducted 
in Kenya and they both found this intervention to be efficacious. Lester et al. conducted a 
multisite RCT (“WelTel Kenya1”) (924) where patients initiating ART were randomized to either 
receive weekly short message service (SMS) from a clinic nurse and asked to reply within 48 
hours or to standard care. They found that people receiving the intervention were more likely 
not only to report to be adherent (self-reporting having taken >95% of prescribed doses in the 
past 30 days), 61% compared to 50%, but also more likely to be virally suppressed (57% vs 
48%), although these were still very low. Pop-Eleches et al. (923) evaluated four different SMS 
reminder interventions: daily short message, daily long message, weekly short message and 
weekly long message. They found that 53% of those receiving weekly messages had an 
adherence of at least 90% (measured using the medication event monitoring system over 48 
weeks) compared to 40% in the control arm and they were slightly less likely to have ART 
interruptions of 48 hours or more (81 vs. 90%, P = 0.03). Conversely, daily messages and long 
weekly text messages were not found to be efficacious in improving adherence. 
 
Education and counselling 
A factorial RCT conducted in Kenya comparing four different options, counselling alone (three 
counselling sessions around the time of ART initiation), alarm (pocket electronic pill reminder 
carried for 6 months), counselling and alarm, and none of both, demonstrated that individual 
adherence counselling at the time of ART initiation could reduce the risk of VF (VL ≥5,000 
copies/mL) by 18 months by 59% (HR = 0.41; 95% CI: 0.21, 0.81; p = 0.01) and the chance of 
having adherence below 80% at the monthly visit by 29% (HR = 0.71; 95% CI: 0.49, 1.01; p = 
0.055)  (925). On the contrary the alarm was not found to be effective in improving any of the 
outcomes. 
 
454 
 
Patient adherence treatment supporter 
Several studies have evaluated specifically the role of community based treatment-supporters 
on retention on ART and specifically on adherence (928). In these studies the treatment 
supporter is generally a member of the family, a friend, a community health worker or a peer 
health worker (another person infected with HIV), but their  role varies across studies from 
providing psychosocial support to the patient to educating them on ART use, to measuring  the 
patient’s adherence, to reminding them to pick up the medications (including DOT) to assess 
their adverse events and triage to other healthcare providers (927). The results on the 
effectiveness of this intervention are mixed, whether from RCTs or observational studies (927). 
To my knowledge only two RCTs (928;929), evaluated the effect of “treatment supporters” on 
their own and another three in combination with other adherence interventions 
(931;933;1239). 
A cluster RCT was conducted in Rakai Uganda, where the treatment supporter was a peer 
living with HIV who provided clinic and home-based counselling on clinical aspects and 
adherence to ART, and social support. They found no difference in lack of adherence (pill count 
<95%), cumulative risk of VF or at 24 week VF, but at VF rates at 96 weeks were significantly 
lower in those receiving treatment support (RR = 0.5; 95% CI: 0.3, 0.8) and the same at 192 
weeks (RR = 0.59, 95% CI: 0.22, 1.60) (929). Similarly, a small RCT conducted in a district 
hospital Uganda (928), in which a treatment supporter intervention was offered in addition to 
the standard adherence package (use of adherence diaries to self-monitor adherence; regular 
individual and group education by peer-workers and late attendee tracing) provided to all 
people receiving ART failed to find a significant difference in mean adherence (monthly clinic-
based pill counts; at 28 week 99.1% vs 96.3%). 
 
Two of the three RCTs which evaluated combinations of adherence interventions including 
treatment supporter found them to be effective: one including DOT and education (931) and 
one only DOT (1239). 
The first of the three RCTs which evaluated combinations of adherence interventions including 
DOT was conducted in Beira in Mozambique (931). In this study, education about treatment 
and adherence was provided by peers, who were responsible for identifying and helping to 
overcome adherence barriers,  observing medication intake 6 days a week and of generally 
supporting the patient . Significantly higher adherence (self-reported adherence over the last 7 
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days) was observed at 6 months (92.7% vs. 84.9%; difference 7.8; 95% CI: 0.02, 13.0) and at 12 
months (94.4% vs. 87.7%, difference 6.8; 95% CI: 0.9, 12.9) in the intervention group.  
The second study was conducted in Nigeria (1239) and found that patients in the intervention 
arm were  2 times more likely to have optimal adherence (drug pickup adherence ≥ 95%) at 
week 24 (OR = 3.1, 95% CI: 1.9, 4.9) and almost 100% more likely at week 48 (OR = 1.9; 95% CI: 
1.3, 2.9). Nevertheless the intervention did not provide a long-term (at 48 weeks) clinical 
benefit in term of immunological response (CD4 count increase) or mortality, while in terms of 
virological response it increased by 60% the probability of achieving undetectable VL at week 
24 (61.7% vs 50.2%; OR = 1.6, 95% CI: 1.1, 2.3), but this effect was no longer significant by 
week 48 (65.3% vs 59.4%; OR = 1.3, 95% CI: 0.9, 1.8).  
Finally in Tanzania, a RCT with three different adherence interventions was conducted (933): (i) 
regular adherence counselling (control), (ii) regular counselling plus a calendar and (iii) regular 
counselling with a treatment supporter failed to find differences in self-reported adherence 
over a mean of 14.5 months and only 0.7% reported adherence of 95% or below, potentially 
due to desirability bias. 
 
Structural services (monetary supplements, food supplements) 
Since one of the main barriers to collect medication is the cost of transport and the necessity 
to take time off work to attend the clinic, quite recently a few studies have started 
investigating the impact of structural services, such as monetary supplements and food rations 
on adherence to antiretroviral medications. 
Cantrell et al. conducted a pilot RCT in patients with food insecurity in Zambia, which 
demonstrated that food supplementation was associated with improved adherence to ART, 
measured as medication possession ratio (70% having >95% adherence in the intervention 
group vs 48% in the control arm), but the study failed to find a direct benefit on immunological 
response or weight gain, potentially because of lack of power to detect a difference (934). 
A RCT conducted in Malawi in patients initiating ART underweight (BMI<18.5) reported that 
receiving ready-to-use fortified spread for 14 weeks was more efficacious than corn-soy blend 
in increasing BMI (2.2 vs 1.7) and fat free body mass (2.9 vs 2.2 kg), while no significant 
difference in terms of CD4 count, VL, quality of life, or adherence was found between the two 
groups (937). Nevertheless this benefit in BMI was not maintained 9 months after having 
stopped the supplementary food (1240). A cohort study in Zambia confirmed the findings from 
RCTs: higher adherence after 6 months (measured using pharmacy dispensation records) in 
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people receiving food assistance compared to non-recipients (98% vs 89%), but again no 
significant effects in terms of weight gain or immunological response (CD4 count change) 
(935). More promising results came from a small observational study conducted in Nigeria 
(n=180) where they compared the treatment outcomes of two groups initiating ART, one 
receiving standard of care and the other receiving material support if they had CD4<200 
cells/μL and/or  WHO stage 3 or 4 or with BMI<18.5 kg/m2. They found that people who 
received support were less likely to die (death rate ratio = 0.19; p<0.05), had a greater increase 
in CD4 count (+ 114 vs. + 68 CD-4 cells/μL; p<0.05) and were more likely to be adherent (98.4% 
vs 77.5%; p<0.005) (936). 
Compared to the other interventions to improve adherence, this intervention has significant 
costs, a retrospective study in Mozambique estimated the cost of providing food assistance to 
patients living with HIV in 2009 to be $288 over 3 months per patient, of which 1% is capital 
and 99% is recurrent cost and it is mainly due to the cost of food (49%), followed by the cost of 
transport (24%) (938). 
 
Additional details on approaches which improve the cascade of care at multiple steps 
Decentralization of HIV care provision and task-shifting  
In the last few years the provision of HIV care has expanded from few hospitals located in the 
main cities to a greater number of smaller clinics, often requiring shifting of activities to nurses 
and lay counsellors. Task shifting (see section 7.2.8) is considered an inevitably required means 
to expand rollout of ART in RLS, given the shortage of human resources. This different 
approach of delivering care has been introduced in several countries in sub-Saharan Africa 
(Kenya, Uganda, Rwanda, Zambia, South Africa, Lesotho, Mozambique, Malawi, Democratic 
Republic of Congo, and Nigeria). The efficiency has been demonstrated to increase in 
programmes taking on board this approach, because it gives senior clinical staff more time to 
spend with complicated patients and non-HIV related tasks, and it reduces waiting time and, 
plausibly as a consequence, LTFU (940).   
The fact that structural barriers, such as the distance from the clinic and transportation 
represent major obstacles to retention in care was clearly demonstrated by the fact that 
decentralized programmes offering ART through primary healthcare clinics and community 
support, such as the Medicine Sans Frontiers programme in Lusikisiki, a rural district in South 
Africa (843) were able to minimize LTFU (2% compared to 19% at the central hospital site). A 
study from Lesotho, one of the first countries to decentralize HIV care services, reported that 
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women initiating ART in hospitals rather than in nurse-led decentralized health centres were 
not more likely to be retained in care at three years (defined as alive and receiving ART; 69.7% 
compared to 68.7%) while men were more likely to be retained in the decentralized health 
centres (68.8%) compared with  the hospital (54.7%), and even after adjusting for 
confounders, such as CD4 count and WHO stages, this effect persisted (in men OR of being 
retained in decentralized services: 1.53, 95% CI: 1.20, 1.96) (1241).  
 
A few other studies have shown that decentralizing of health centres can reduce LTFU 
substantially (941-944). An additional benefit is that it can reduce dramatically clinic costs, 
given doctor salaries can be the largest cost in an antiretroviral clinic budget.  
 
Although it has been found that decentralizing care reduces waiting time, loss to follow-up and 
costs, it is crucial to ensure that task-shifting does not result in a lower level of healthcare. To 
my knowledge there is only one RCT which evaluated the effectiveness of task-shifting for ART 
delivery in sub-Saharan Africa. They found that nurse-managed ART care was non-inferior to 
doctor-managed care in urban clinics in Johannesburg and Cape Town, South Africa, with HRs 
for composite failure (including mortality, viral failure, treatment-limiting toxic effects, and 
adherence to visit schedule) of 1.09 (95% CI: 0.89, 1.33) over a median follow-up of 120 weeks 
(945). 
 
An example of decentralization comes from the Thyolo District in Malawi (939), where since 
mid-2003, the Ministry of Health in collaboration with Medecins Sans Frontiers implemented a 
model of care decentralizing HIV care to health centres and task-shifting some activities to lay 
counsellors. One of the activities which were delegated to lay counsellors was HTC and this led 
to an increase in uptake of HIV testing from 1300 tests per month to 6500 test per months in 
2009. 
As mentioned in section 7.2.1 regarding improving access to HIV testing, decentralization of 
HIV services to peripheral health centres, combined with task shifting has been effective also 
in improving ART initiations. These studies have not evaluated whether people were initiated 
promptly when found to be eligible but more broadly whether it increased access to ART. In a 
study in Malawi for example, delegating ART initiations to non-physician clinicians almost 
doubled ART enrolment, with good programme outcomes (939). Another successful example 
of decentralization comes from Cameroon (946). In a cross-sectional survey of HIV-positive 
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patients (response rate 90%) from different level of the healthcare delivery (central, provincial 
and district), they found that although not surprisingly district treatment centres had more 
limited technical and human resources, after adjustment for other explanatory factors, 
immunological outcomes were similar in patients to those followed up at the central district 
level, and adherence to ART was actually better than at the central level. 
Similarly, a study from a rural district in Malawi evaluated the outcome of people who were 
monitored, once initiated on ART in decentralized health centres or not. They found that 
people who were decentralized were less likely to die (adjusted OR = 0.19; 95% CI: 0.15, 0.25) 
and to be LTFU (adjusted OR = 0.48; 95% CI: 0.40, 0.58). Nevertheless this could be due to the 
fact that stable patients are more likely to be decentralized (844). 
 
Integration of HIV/AIDS services into other healthcare services 
Another barrier that became clear was the fact that people had to attend different clinics for 
different health issues. To overcome this issue integration of HIV care services into other 
healthcare services such as TB services and antenatal services was implemented in some 
programmes in South Africa, and integration of ANC is widely adopted in RLS. The idea was as 
well that this approach could strengthen the whole health system.  
 
A systematic review published in 2013 (953) found only four studies (all cohort studies), which 
compared services where ART provision was integrated into ANC vs services which did not 
integrate ART, in terms of ART coverage (proportion on ART of those eligible based on national 
guidelines), enrolment on ART, retention on ART, mortality or HIV transmission (950-952). 
They did not find any studies which assessed this comparison in maternal and child health 
clinics. They estimated that enrolment of pregnant women on ART was double in clinics where 
ART was provided within (RR = 2.09; 95% CI: 1.78, 2.46) and that ART coverage was also slightly 
higher (RR = 1.37; 95% CI: 1.05, 1.79). Retention on ART was reported only in one of these 
studies (950), which found no difference in the retention on ART after 90 days (87.8% in the 
ANC clinics where ART was integrated and 91.3% in the referral HIV clinics for pregnant women 
on ART). A more recent retrospective cohort study conducted in Cape Town (South Africa) 
compared three different settings where to initiate ART for pregnant women: ART integrated 
into ANC clinic, ART services located close to the ANC clinic and at some distance from the ANC 
clinic (954).  Among almost 15,000 women seeking antenatal care of which 17% HIV-positive 
and eligible for ART (based on CD4 count <200 cells/μL), 55% initiated ART if ART provision was 
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integrated into ART compared to 38% and 45% if ART was provided respectively next or at a 
certain distance from the ANC clinic. 
To my knowledge the only RCT which evaluated the effects of integrating HIV treatment into 
ANC was conducted in rural Kenya (1242). They compared six clinics which provided fully 
integrated services (HIV treatment services provided in the ANC clinic) to six clinics which did 
not provide integrated services (ANC clients referred to a separate HIV clinic for ART). The final 
results have not been presented yet but they reported facing major challenges including 
frequent staff turnover, stock-outs of essential supplies, transportation challenges, and 
changes in national guidelines. 
 
Given the wide overlap between the HIV epidemic and TB (almost a quarter of HIV related 
deaths attributable to TB) WHO recommends integrating HIV and TB services. A systematic 
review (1243) estimated that on average 87% of patients with TB tested for HIV (standard 
deviation = 12%) and that on average 38.4% received ART during TB treatment (95% CI: 17.5, 
59.3; range across studies: 14%-100%). The low uptake of ART could partly be due to 
differences in ART eligibility, nevertheless for example a study in Zambia found that 88% of 
patients co-infected with TB and HIV were eligible for ART but only 59% enrolled (1244). One 
of the first examples of integration of HIV and TB services came from Khayelitscha in South 
Africa, an area where around three quarters of people with TB are co-infected with HIV. Here 
since 2002 the integration of these services was evaluated and subsequently implemented 
(948). They reported that the proportion of TB patients who were tested for HIV increased 
from 30% to 56% in a clinic which integrated TB and HIV services; in particular 87% of patients 
who were offered HIV testing accepted it.  
A study from Lusaka in Zambia evaluated the feasibility of integrating HIV care into primary 
healthcare clinics (together with the introduction of PITC). They reported high acceptability of 
this approach, between 50 and 60% of patients accepted HIV testing and between 42% and 
58% enrolled in care (949). 
 
Health information systems (i.e. electronic medical records) 
It seems obvious that electronic medical records (EMR) can be very helpful in delivering better 
medical care and in being able to identify people who drop out of care and attempt to re-
engage them in care. In addition, patients who miss a clinical appointment and then attend the 
clinic for unscheduled visits affect the ability to plan the work load in the clinic. A 
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demonstration of the contribution EMR can make came from a study conducted in a 
community-based HIV clinic in Kampala, Uganda, (955) serving patients on ART (62%) or not 
yet eligible for treatment. They introduced EMR and same day patient tracing and observed 
that the mean number of missed appointments per day reduced from 21 (out of an average of 
78 scheduled visits per day) to 8 (out of 70 scheduled visits per day), 6 months after the 
implementation of the EMR and tracing, that LTFU reduced from 11% to 5% and the median 
waiting time to see the provider from almost 5 hours to an hour and a half. 
 
Short message service communication 
The increasing availability of mobile phones among people living with HIV in LMIC represent a 
good opportunity to easily contact patients and potentially to improve retention in care. 
A RCT, WelTel Kenya1, is currently being conducted in Nairobi (Kenya) evaluating whether 
weekly text messages over 1 year following diagnosis, requiring a reply within 48 hours are 
effective in improving linkage to care (i.e. completion of ART eligibility assessment), retention 
in pre-ART care leading to timely ART initiation (in those not eligible for ART) and adherence 
and VL suppression among those initiating ART (1245). 
 
Combinations of approaches 
A pilot study has been conducted in rural KwaZulu-Natal in South Africa combining HBT with 
POC CD4 count testing and follow-up visits to smooth the linkage of HIV-infected people to 
local HIV clinics. The uptake of HIV testing was 91%, confirming the high acceptability of HBT 
strategy and 90% of those not receiving ART at baseline (whether new diagnoses or people 
aware of their HIV-positive status who were not engaged in care) had visited an HIV clinic by 3 
months, and of those eligible for treatment (CD4 ≤200 cells/μL in South Africa guidelines when 
the study was conducted) 80% had initiated ART. Among HIV-infected participants who were 
eligible for ART at baseline, mean VL decreased by 3.23 log copies/mL (p<0.001) and the 
proportion with VL suppression increased from 20% to 80% between baseline and the sixth 
month (864). 
Another package of interventions which has been successfully implemented in Swaziland, is a 
pre-ART care package characterized by three main features: task shifting to nurses and lay HIV 
counsellors, focus on a patient care pathway and active patient tracing for patients not 
presenting at the clinic for an appointment. This intervention led to improvement at different 
steps of the cascade of care: linkage to care (proportion who received eligibility assessment) 
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increased from 59% before the intervention to 76% at the end of follow-up, prompt initiation 
of ART for eligible patients which increased from 53% to 81% and the median time from being 
identified as eligible for treatment to initiation decreased from 61 to 14 days (758).
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Appendix XV. Median CD4 count at diagnosis in South Africa 
Author Setting Year of the 
study 
N (newly diagnosed 
with HIV) 
Definition of late 
stage disease 
Late stage HIV 
disease at 
diagnosis 
Median (IQR) 
CD4 cells/μL at 
diagnosis  
April (958) Hospital, PHC in Cape Town 2001-06 1,340 CD4<200 cells/μL Overall: 36%* 
 
Overall: 276* 
Bassett (841) Semi private hospital in Durban (patients 
are charged) 
2006 501** - - 159 (65–299) 
Ingle (1246) 36 public sector clinics in Free state Province 2004-07 44,844 - - 170 (76-318) 
May (720) Gugulethu and Khayelitsha, both in Western 
Cape Province*** 
2004-08 Gugulethu: 1,611; 
Khayelitsha: 4,397; 
- - 101 (48-159); 
100 (45-161); 
Larson (957) Public academic hospital in Johannesburg 2008-09 352 CD4<200 cells/μL 54.3% 185 (67-353) 
Govindasamy (956) Mobile testing unit in Cape Metropolitan 
Region, Western Cape 
2008-09 192 CD4<200 cells/μL 9.6% 489 (457-
520)**** 
 
Drain (721) 4 outpatient clinics VCT in Durban 2010-11 830  CD4<100 cells/μL 33.6% 186 (70-345) 
Clouse (752) PHC in Johannesburg (pregnant women) 2010-11 300 - - 357 (238–500). 
*Not significant trend over time; ** The study was restricted to people eligible for ART (CD4≤200 cells/μL or WHO stage 3 or 4); ***Results for cohort outside South Africa are not presented; 
****Mean (95% CI); IQR: interquartile range; PHC: primary healthcare clinic; VCT: voluntary counselling and testing; 
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Appendix XVI. Proportion linked to care (completed ART assessment) in South Africa [modified 
from (551;553)] 
Author Setting Year of the 
study 
N (newly 
diagnosed 
with HIV) 
CD4 measurement (95% CI) 
[time] 
Returned for CD4 results (95% CI) 
[time] 
Enrolled in 
HIV care 
[time] 
April (958) Hospital, PHC in Cape Town 2001-06 1,123 -  2001: 29% [6 months] 
2006: 67% [6months] 
- 
Ingle (1246) 36 public sector clinics in Free 
state Province 
2004-07 44,844 74% [by study censor date] - - 
Losina (1247) Semi-private hospital in 
Durban 
2006-07 454 55% (50%-59%) [8 weeks] 85% (81%-89%) [of those who 
measured CD4 within 8 weeks] 
Overall 47% (42%-51%) [by study 
censor date] 
 
Bassett (963) Semi private hospital in 
Durban 
2006-08 1,474 69% (66%-71%) [3 months] - - 
Luseno (1248) Community based trial in 
Gauteng Province 
Not 
reported 
199 - - 46% [by 
study 
censor 
date] 
Naidoo (1249) Clinic in Johannesburg Not 
reported 
224 - 47% (41%-54%) [1 week] - 
Faal (887) Urban healthcare clinic in 
Johannesburg (RCT) 
2008  344  49% [1  week]  
Kranzer (967) Hospital, PHC in Cape Town 2004-09 988 63% (60%-66%) [6 months] - - 
Larson (957) Public academic hospital in 
Johannesburg 
2008-09 416 85% [12 weeks] 35% (30%-40%) [12 weeks] - 
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ART: antiretroviral treatment; PHC: primary healthcare clinic; RCT: randomized controlled trial; 
 
  
Author Setting Year of the 
study 
N (newly 
diagnosed 
with HIV) 
CD4 measurement (95% CI) 
[time] 
Returned for CD4 results (95% CI) 
[time] 
Enrolled in 
HIV care 
[time] 
Govindasamy (956)  Mobile HIV testing service in 
Cape Town 
2008-09 192 Self-reported access to HIV 
care 
78% (72%-84%) [by study censor 
date] 
 
42% [by 
study 
censor 
date] of 
those who 
received  
CD4 count 
Clouse (959) PHC in Johannesburg 
(pregnant women excluded) 
2010 842 - 70% (67-73%) [3 months since 
diagnosis] 
- 
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Appendix XVII. Proportion retained in pre-ART care in South Africa [modified from (551;553)] 
ART: antiretroviral therapy; PHC: primary healthcare clinic;   
Author Setting Year of 
the study 
N (HIV+ not 
eligible for ART) 
Definition of 
retention in pre-ART 
care 
Retention in pre-ART care (95% CI) [time] 
Lessells (1250) Public sector clinics in rural 
KwaZulu-Natal 
2007 4,233 Repeat CD4 count 45% (43-46%)  
[13 months since 1st CD4 count] 
CD4 201-350: 51.6% (49.1-54.0) 
CD4 351-500: 43.2% (40.5-45.9) 
CD4 >500:       34.9% (32.4-37.4) 
Ingle (1246) 36 public sector clinics in 
Free state Province 
2004-07 11,039 Visit 42% (41-43%)  
[6 months since enrolment] 
Larson (604) Public academic hospital in 
Johannesburg 
2007-08 356 1st pre-ART medical 
appointment 
31% (27-36%) [1 year]; 
CD4 200-350: 6% (2-11%) [4 months], 35% (27-44) [1 year]; 
CD4 >350: 14% (10-19%) [9 months], 11% (8-16%) [1 year] 
Kranzer (967) Hospital, PHC in Cape Town 2004-09 419 Repeat CD4 count 46% (41-50%) [study censor date, up to 5 y of follow-up] 
Luseno (1248) Community based trial in 
Gauteng Province 
- 199 Visited referral site 
after HIV test 
46% (39-53%) [study censor date] 
Govindasamy (956) Mobile testing unit in Cape 
Metropolitan Region, 
Western Cape 
2008-09 192 Self-reported access 
to HIV care 
36% (28%-44%) [between 6 and 18 months from HIV 
diagnosis; mean time of 3 months to access care for those 
who did] 
Clouse (959) PHC in Johannesburg (no 
pregnant women) 
2010-11 221 Returned for CD4 test  57% (49%-65%) [1 year] 
Clouse (752) 
 
PHC in Johannesburg 
(pregnant women) 
2010-11 112 Returned for any visits 
after delivery 
49% (40–58%) [study censor date] 
50 (visit after 
delivery) 
received a repeat CD4 
count after delivery 
52% (38.2–66%) [study censor date] 
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Appendix XVIII. Proportion initiated on ART of those eligible in South Africa [modified from 
(551;553)] 
Author Setting Year of the 
study 
N (patient 
eligible for ART) 
Percent (95% CI) initiating ART 
[time] 
Median (IQR) time to initiate 
ART (expressed in days) from 
initial eligibility (i.e. CD4 count 
measure that indicated 
eligibility) 
Lawn (1251) Community Health Centre in 
Gugulethu, Western Cape Province 
2002-05 1,235 75% [study censor date] 34 (28–50). 
April (958) Hospital, PHC in Cape Town 2001-06 2001: ~29a 
2006: ~86%a 
2001: 0% [6 months] 
2006: 68% (57%-78%) [6 months] 
- 
Bassett (841) Semi private hospital in Durban 2006 501 81% [<=3 months last required pre-
ART visit] 
110 (70-119) [To 1st ART 
training]b 
Kaplan (902) PHC for women in Gugulethu,  Western 
Cape Province   
2002-07 2,131 82% (81%-84%) [study censor date] - 
Ingle (1246) 36 public sector clinics in Free state 
Province 
2004-07 22,083 68% (67-68%) [by 2 year since being 
eligible] 
- 
Murphy (1252) General hospital in Durban (Patients 
with TB or OI discharged and referred 
to semi-private hospital) 
2006-07 49 45% [6 months]  83 (34-119) 
Ahonkhai (483) 71 Catholic Bishops 
Conference/Catholic Relief Services HIV 
treatment clinics in 8 different South 
African provinces 
2004-08 11,397 (CD4<200 
cells/μL) 
- 28 (14-53) [from enrolment] 
Bassett (963) Semi private hospital in Durban 2006-08 538 39% (35%-43%) [study censor date,  
median follow-up 12 months] 
- 
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a: the exact number of people eligible for ART was not reported but the % eligible was indicated in a graph and the number of sero-positive in each year reported; b: 3 ART-training visit are scheduled 
one week apart before ART initiation; ART: antiretroviral therapy; CI: confidence interval; IQR: interquartile range; OI: opportunistic infection; PHC: primary healthcare clinic; TB: tuberculosis; 
  
Author Setting Year of the 
study 
N (patient 
eligible for ART) 
Percent (95% CI) initiating ART 
[time] 
Median (IQR) time to initiate 
ART (expressed in days) from 
initial eligibility (i.e. CD4 count 
measure that indicated 
eligibility) 
Kranzer (967) Hospital, PHC in Cape Town 2004-09 219 67% (60%-73%) [6 months since HIV 
test if ART eligibility confirmed 
within 6 months from HIV test] 
 
Pepper (1253) Integrated TB-HIV clinic  in Cape Town 
(TB patients, type of clinic not 
indicated) 
Not 
available 
100 66% (57-75%) [during TB treatment] - 
Clouse (959) PHC in Johannesburg (pregnant women 
excluded) 
2010 589 73% (69%-78%) [3 months] 23 days (12-36) 
Clouse (752) 
 
PHC in Johannesburg (pregnant 
women) 
2010-11 115 81% (73–87%) [ART initiation prior 
to delivery of those with CD4 
staging, median 9.5 weeks between 
ART initiation and delivery] 
27 days (17–41) [from HIV 
testing] 
139 67% (59–74%) [ART initiation prior 
to delivery of all those ART-eligible] 
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Appendix XIX. Median CD4 count at ART initiation in South Africa 
Author Setting Year of the 
study 
N (patients 
initiating 
ART) 
Eligibility criteria to initiate ART Median (IQR) CD4 
cells/μL at ART 
initiation  
Coetzee (477) Public community based programme in 
Khayelitsha 
2001-03 287 WHO stage 3 or 4 and CD4<200 cells/μL 
(eligibility criteria for inclusion in the study) 
43 
Nachega (1254) Private programme (majority of patients 
from SA, with payment from patients) 
1998-2004 2,817 CD4<350 cells/μL on 2 occasions or WHO stage 
4 
171 initiating NVP, 
136 initiating EFV  
Nachega (1255) Private sector programme with multiple 
workplace locations (subsidized by 
employers) 
1999-2004 7,080 WHO stage 3 or 4 and CD4<200 cells/μL ; 
Additional criteria to ensure the patient was 
ready to initiate ART were required (having a 
‘treatment assistant’, home-visit, evidence of 
disclosure, attendance on time for at least 3 
visits over a minimum of 4 months) 
149 (65-227) 
Oijkutu (482) Semi private hospital in Durban 1999-2004 309 WHO stage 4 or CD4<200 cells/μL 65 
Charalambous 
(1256) 
Multiple locations at workplace 2002-05 2,262 WHO stage 4, irrespective of CD4 count; CD4 of 
250-350 and WHO stage 3; CD4<250 cells/μL, 
irrespective of WHO stage. 
158 
Bekker (478) Public clinic in Gugulethu, Western Cape 
Province 
2002-05 1,139 WHO stage 4 or CD4<200 cells/μL 2002/3: 84 (42-139) 
2003/4: 89 (49-149) 
2004/5: 110 (55-172) 
Lawn (Lawn et al. 
2006) 
Community Health Centre in Gugulethu, 
Western Cape Province 
2002-05 1,235 WHO stage 4 or CD4<200 cells/μL 100 (47-160) 
Rosen (964) 
 
Public, partial payment 2005-06 100 CD4<200 cells/μL (Eligibility into the study)^ 97 
Private, no payment 100 84 
NGO, partial 100 60 
NGO, partial 100 104 
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Author Setting Year of 
the study 
N (patients 
initiating 
ART) 
Eligibility criteria to initiate ART Median (IQR) CD4 
cells/μL at ART 
initiation  
Boulle (292)  3 public PHCs in Khayelitscha in Western 
Cape 
2001-07 7,323 WHO stage 4 (excluding extra pulmonary 
disease) or CD4<200 cells/μL 
2001/02: 43 (13-95) 
2003: 72 (26-126) 
2004: 85 (37-141) 
2005: 100 (44-157) 
2006: 109 (52-169) 
2007: 131 (64-191) 
Grimwood (1257) NGO in collaboration with DoH in several 
locations in South Africa 
2003-07 6,469 Not indicated 117 
Barth (498) NGO clinic  co-founded by South Africa DoH in 
rural area of Limpopo province 
- 735 WHO stage 4 and CD4<200 cells/μL 68 (20-140) 
Wang (903) Clinic in mine workers communities in 
Northwest Province 
2004-07 925 WHO stage 4 or CD4<200 cells/μL 111 (41-214) 
Mac Pherson 
(1258) 
Public clinic in Bushbuckbridge district in 
Mpumalanga Province 
2005-07 1,353 WHO stage 4 or CD4<200 cells/μL and 
psychosocial preparedness to undertake ART 
93 (37-148) 
Cornell (601) 8 cohorts from 4 provinces in South Africa 
(Western Cape, Free State, Gauteng and 
KwaZulu-Natal) 
2002-08 44,177 Not indicated Overall:103 (45-164); 
2002/03: 68 
2007: 113 
Ahonkhai (483) 71 Catholic Bishops Conference/ Catholic 
Relief Services HIV treatment clinics in 8 
different South Africa provinces 
2004-08 11,397 
(CD4<200 
cells/μL) 
WHO stage 3 or 4 or CD4<200 cells/μL 101 (43-160) 
Sanne (1207) Public clinic in Johannesburg 2004-08 7,583 Not indicated 87 (31-158) 
Nglazi (1259) Community Health Centre in Gugulethu, 
Western Cape Province 
2002-09 3,162 WHO stage 4 or CD4<200 cells/μL 2002/04: 87 (45-145) 
2007/08: 121 (60-178) 
Kranzer (484) Peri-urban township in Western Cape 2004-09 1,154 Partly with the criteria of WHO stage 4 or 
CD4<200 cells/μL and partly (NIH funded) 
WHO stage 3 or CD4<350 cells/μL 
Overall: 122 (54-190); 
2004: 137 
2006: 279 
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Author Setting Year of 
the study 
N (patients 
initiating 
ART) 
Eligibility criteria to initiate ART Median (IQR) CD4 
cells/μL at ART 
initiation  
Boyles (753) 7 public PHCs and one public hospital in 
Eastern Cape Province 
2005-09 1,805 WHO stage 4 or CD4<200 cells/μL 123 (55-184) 
^ They reported that according to clinic staff not many people with CD4>200 cells/μL are initiated on ART because of clinical conditions; DoH: Department of Health [South Africa]; EFV: efavirenz; IQR: 
interquartile range; NGO: non-governmental organization; NIH: national institutes of health; NVP: nevirapine; PHC: primary healthcare clinic; WHO: World Health Organization;  
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Appendix XX. Retention on ART in South Africa [modified from (1;2)] 
Author Setting Year of the 
study 
N (HIV+ 
who 
initiated 
ART) 
Lost to follow-up 
definition 
Median 
follow-up 
(months) 
Total attrition Retained in care 
Died  Lost to 
follow-up 
Transferre
d to care 
Retained at 
original site 
Coetzee 
(477) 
Public community based 
programme in Khayelitsha 
2001-03 287 >3 months late for a visit 
or medication pickup or 
no visit in past 3 months 
13.9  13.2% 0.3%a 1.0% 82.5% 
Nachega 
(1254) 
Private programme (most 
patients from South Africa, 
with payment from patients) 
1998-2004 2,817 Leaving medical 
insurance fund or AID 
for AIDS program 
24 2.0% 11.2% 0.0% 86.8% 
Oijkutu 
(482) 
Semi private hospital in 
Durban 
1999-2004 309 No clinic visit within 6 
months of end of study 
8.4b 15.9% 7.4% 0.0% 76.7% 
Nachega 
(1255) 
Private sector programme 
with multiple workplace 
locations in South Africa  
(subsidized by employers) 
1999-2004 7,080 Having no VL results 
after ART initiation. 
19.5b 5.4% 25.4% - 69.2% 
Brinkhof 
(493) 
3 free ART Programmes 
(CTAC, Khayelitsha, OPERA) 
2000-05 624c No visit between 6 and 
12 months since ART 
initiation 
12 6% 2% - 92% 
Bekker (478) Public clinic in Gugulethu, 
Western Cape Province 
2002-05 1,139 Missing 2 consecutive 
clinic visits or no visit in 
past 3 months 
12.3b 6.8% 2.9% 10.5% 79.7% 
Lawn (1251) Community Health Centre in 
Gugulethu, Western Cape 
Province 
2002-05 927 >4 weeks late for a 
scheduled clinic or 
pharmacy visit and who 
were neither transfers 
out nor relocations 
 5% 5% 2% 88% 
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Author Setting Year of the 
study 
N (HIV+ 
who 
initiated 
ART) 
Lost to follow-up 
definition 
Median 
follow-up 
(months) 
Total attrition Retained in care 
Died  Lost to 
follow-up 
Transferre
d to care 
Retained at 
original site 
Charalambo
us (1256) 
Multiple locations at 
workplace 
2002-05 2,262 - 18.7b 5.0% 25.1% - 69.9% 
Fairall 
(1260) 
Public clinic in Free State 
Province 
2004-05 3,619 - 6 (3-9, max 
19) 
1 year: 
~10%d 
- - - 
Khan (1261) Public 2004-05 684 Failure to collect ART 36 18.0% 5.3% 3.9% 72.8% 
Reuter 
(1262) 
Public in Lusikisiki 2005 430  12 13.5% 19.3% 4.0% 67.2% 
595 16.8% 2.2% 4.9% 81.0% 
Boulle (291) 43 sites in Western Cape ART 
Programme (Public) 
2001-06 12,587 >90 days since last 
contact 
Maximum 48 
months 
6.5% [At 6 
months]; 
8.4% [At 1 
year]; 
22.5% [At 
4 years] 
4.1% [At 6 
months]; 
6.1% [At 1 
year]; 
1.2% [At 4 
years] 
2.7% [At 6 
months]; 
4.5% [At 1 
year] 
2.5% [At 4 
years] 
87% [At 1 
year] 
74% [At 4 
years] 
Rosen (964) 
 
Public, partial payment 2005-06 100 >3 months late for last 
visit 
12 2.1% 23.9% 0.0% 74.0% 
Private, no payment 100 18.9% 26.1% 0.0% 55.0% 
Rural NGO, partial 100 12.9% 15.1% 0.0% 72.0% 
Peri-urban NGO, partial 100 7.0% 6.0% 0.0% 87.0% 
Boulle (292)  3 public PHCs in 
Khayelitscha in Western 
Cape 
2001-07 7,323 >6 months without a 
clinic visit 
Max 5 years 15.5% 
(13.1-
18.3%) at 5 
years 
23.4% 
(20.5-
26.6%) at 5 
years 
- - 
Cornell 
(1263) 
 
Public clinic in Gugulethu, 
Western Cape Province 
2002-07 2,196 Absent from the clinic 
from >3 months 
Women: 1 
(0.5—1) 
Men: 0.9 
(0.4-1) 
7.% 6.2% 3.2% 83.5% 
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Author Setting Year of the 
study 
N (HIV+ 
who 
initiated 
ART) 
Lost to follow-up 
definition 
Median 
follow-up 
(months) 
Total attrition Retained in care 
Died  Lost to 
follow-up 
Transferre
d to care 
Retained at 
original site 
Kaplan (902) PHC for women in 
Gugulethu, Western Cape 
Province   
2002-07 1,677 No clinic visit ≥ 12 weeks 
(i.e. not having drugs for 
at least 4 weeks) 
36d Pregnant: 
1 year: 5%d 
3 years: 
5%d 
Not 
Pregnant: 
1 year: 8%d  
3 years: 
11%d 
Pregnant: 
1 year: 
16%d 
3 years: 
32%d 
Not 
Pregnant: 
1 year: 7%d  
3 years: 
13%d 
- - 
Grimwood 
(1257) 
Public 2003-07 6,469 - 24 9.0% 11.4% 0.0% 79.6% 
Dahab 
(1264)  
Public - 267 >1 month late for 6 
months visit 
6 6.7% 8.6% 1.1% 83.5% 
Wang (903) Clinic in mine workers 
communities in Northwest 
Province 
2004-07 925 Not returning for a 
scheduled visit or 
medication pick-up 
within first 6 months 
since ART initiation 
- 23.1% [6 
months] 
5.6% [6 
months] 
2.4% [6 
months] 
68.8% [6 
months] 
Mac 
Pherson 
(1258) 
Public clinic in  
Bushbuckbridge district in 
Mpumalanga Province 
2005-07 1,353 >1 day late for 
appointment, 
could not be traced, and 
did not come back 
during study period 
8.6b  9.2%[24 
months] 
2.6%[24 
months] 
4.7%[24 
months] 
83.6%d [24 
months] 
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Author Setting Year of 
the 
study 
N (HIV+ 
who 
initiated 
ART) 
Lost to follow-up 
definition 
Median 
follow-up 
(months) 
Total attrition Retained in care 
Died  Lost to follow-
up 
Transferr
ed to 
care 
Retained at 
original site 
Cornell (601) 8 cohorts from 4 
provinces in South 
Africa (Western Cape, 
Free State, Gauteng 
and KwaZulu-Natal) 
2002-08 44,177 >6 months since last 
contact at the date of 
closure of the cohort 
database 
 At 1 year: 
2002/03: 8.9 
(7.4-10.7) 
2004: 7.2 (6.5-
7.9) 
2005: 7.4 (6.9-
7.9) 
2006: 6.2 (5.8-
6.7) 
2007:5.6 (5.1-
6.0) 
At 1 year: 
2002/03: 1.1 
(0.6-1.9) 
2004: 8.6 (7.9-
9.4) 
2005: 10.3 (9.7-
10.9) 
2006: 13.1 
(12.5-13.7) 
2007: 23.5 
(22.7-24.3) 
- At 1 year: 
2002/03: 90.1 
(88.2-91.7) 
2004: 84.8 
(83.8-85.8) 
2005: 83.1 
(82.3-83.8) 
2006: 81.5 
(80.8-82.1) 
2007: 72.3 
(71.4-73.1) 
Sanne 
(1207) 
Public clinic in 
Johannesburg 
2004-08 7,583 >3 months late for a 
scheduled visit and that 
the tracing team could not 
get information on 
20.3 5.1% [during 
follow-up] 
16.4% [during 
follow-up] 
- At 1 year: 
82.8% (81.9-
83.6%) 
At 4 years: 
74.4% (73.2-
75.6)  
Peltzer 
(1265) 
Three public hospitals 
in Uthukela in 
KwaZulu-Natal 
2007-08 735 Not traceable at 12 
months 
12 months 13.8% [at 12 
months] 
4.0% [at 12 
months] 
7.9% [at 
12 
months] 
75.9% [at 12 
months] 
Nglazi 
(1259) 
Community Health 
Centre in Gugulethu, 
Western Cape 
Province 
2002-09 3,162 ≥12 weeks since last visit  29 (14-46) Overall 10.6%; 
15.2% (13.1-
17.6%) [at 6 
years] 
Overall 18.7%; 
 
Overall 
10.3%; 
21.6% [at 
6 years] 
Overall 61.4%; 
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Author Setting Year of 
the 
study 
N (HIV+ 
who 
initiated 
ART) 
Lost to follow-up 
definition 
Median 
follow-up 
(months) 
Total attrition Retained in care 
Died  Lost to follow-up Transferre
d to care 
Retained at 
original site 
Kranzer 
(484) 
Peri-urban township in 
Western Cape 
2004-09 1,154 >30 days late for ART 
refill at the pharmacy 
17.4 (6-39) 16.9% - - - 
Ahonkhai 
(483) 
71 Catholic Bishops 
Conference/ Catholic 
Relief Services HIV 
treatment clinics in 8 
provinces in South 
Africa 
2004-09 11,397 Not having visits 
involving lab 
measurement between 
40 and 400 days since 
ART initiation 
 9% early 
death 
(within 7 
months); 
17% missed 
laboratory visits and 
did not returned to 
care by 1 year. 
- Retention on 
ART 
63%  
[13 months] 
Boyles (753) 7 public PHCs and one 
public hospital in 
Eastern Cape Province 
2005-09 1,805 No contact for > 6 
months before the end 
of the study period 
13.3 (5.4-
25.0) 
11.1% 6.5% 10.9% 71.5% 
O’ Connor 
(965) 
 
Four PHCs in 
Johannesburg 
(Patients stable on 
ART on average on 
ART for 18 months) 
2007-09 3,361 >6 weeks late for ART 
visit with 3 failed attempt 
to contact them 
telephonically 
6b (2-11) 0.2%e 3.9% 2.9% 92.6% 
Fatti (1266) 38 low caseload 
(median 488 patients) 
clinic and 16 high 
caseload (median 2031 
patients) clinics from 
an NGO in 4 Provinces 
(KwaZulu-Natal, 
Western Cape, Eastern 
Cape, Mapulanga) 
2004-10 40,861 >3 months late for a 
scheduled appointment 
 5.1% (4.9-
5.4%) [12 
months] 
 6.8% (6.5-
7.1%) [24 
months] 
Low caseload: 6.4% 
(5.9-7.0%) [12 
months]; 
11.2% (10.4-12.2%) 
[24 months]; 
High caseload: 8.6% 
(8.3-9.0%) [12 
months]; 14.9% (14.3-
15.4%) [24 months] 
- At 3 6 
months: 
Low caseload: 
78.8% (76.7-
80.8%), 
High caseload: 
73.9% (73.1-
74.7%) 
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Author Setting Year of 
the 
study 
N (HIV+ 
who 
initiated 
ART) 
Lost to follow-up 
definition 
Median 
follow-up 
(months) 
Total attrition Retained in care 
Died  Lost to follow-
up 
Transferr
ed to 
care 
Retained at 
original site 
Barth (498) NGO - 735 Not reported 37.0b 23.3% 12.0% 6.4% 58.4% 
Clouse (959) PHC in Johannesburg 2010-11 299 No clinic attendance > 3 
months since last 
scheduled visit. Patients  
 2.4% (1.1-4.8%) - 10.4 [12 
months] 
67%. 
Among those 
who did not 
transfer: 
80.2% (75.3%- 
84.5%) [6 
months]; 95.3% 
(91.7%-97.6%) 
[6-12 months] 
Clouse (752) PHC in Johannesburg 
(pregnant women) 
2010-11 90f Not returning for at least 
visit after delivery 
- - - - 82.8 % (72.1-
90.6%) 
Mutevedzi 
(1267) 
17 public PHCs in 
KwaZulu-Natal 
Province 
2004-12 4,674 > 180 days since last 
clinic visit 
33  14.5% 11.9% 5.6% 68`% overall. 
61% [5 years] 
a: Transfer rate after 1 y (rate at median follow-up not reported); b: Mean follow-up reported instead of median; c: presenting only data from South Africa; d: Kaplan Meier estimates; e: it includes 
only people who died and were considered lost; f: initiated ART before delivery;-ART: antiretroviral therapy; NGO: non-governmental organization; PHC: primary healthcare clinic;   
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Appendix XXI. Proportion switched to second-line regimen in South Africa 
Source Population Year Follow-up, 
median (IQR) 
Type of analysis (intention to 
treat or on treatment) 
Proportion who switched to 
second-line (if indicated is 
from time since ART 
initiation)* 
Coetzee (477) 287 patients starting ART in a public 
community based programme in Khayelitsha 
2001-03 13.9 Of those initiated on ART 4.2% 
Orrell (307) 929 patients in Nyanga district, near Cape 
Town 
2002-05 6 (3-14). Total 
760 PYs 
Of those on ART  2.2% 
17% (for drug toxicity) 
Innes (495) 1416 patients initiating ART (eligible if CD4 
<250 cells/μL, a WHO stage 4 condition or a 
WHO stage 3 condition and CD4 count <350 
cells/μL) in a multisite workplace programme 
2002-07 - Of those initiated on ART 3 years: 4% 
Barth (498) 735 patients initiated ART in Limpopo  36  Of those initiated on ART 4% 
Hamers (966) 2588 ART naïve patients from 13 clinics: 2 in 
Kenya, 1 in Nigeria, 3 in South Africa, 3 in 
Uganda, 3 in Zambia and 1 in Zimbabwe; 
2007-09  Of those initiated on ART  1 year: 1% 
Fox (499) 23,456 2000-08 15.6 (Range 
across sites: 
13-17), on 
ART 22; 
Total 29,935  
Of those initiated on ART 1 year: 1% 
5 years: 10.1% (9.0%-11.4%) 
Of those who experience VF 
(n=1348) 
62% 
Of those who experience VF 
with ≥6 months of follow-up 
after failure (n=897) 
74% 
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Source Population Year Follow-up, 
median (IQR) 
Type of analysis (intention to 
treat or on treatment) 
Proportion who switched to 
second-line (if indicated is 
from time since ART 
initiation)* 
Johnston 2012 (500) 1668 patients with VF in the Aurum Institute 
ART programme (56 clinics for employees of 
large, mostly mining companies and 81 urban 
and peri-urban private GPs). ART free of charge 
2003-09 Total PYs 
1921.8 
Of those who experienced VF 12 months since VF: 16.9% 
 
ART: antiretroviral treatment; GP: general practitioner; NGP: non-governmental organization; VF: virological failure; 
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Appendix XXII. Research published or presented at an 
international conference 
 
Cambiano, V, Connor, O, Phillips, A, Rodger, A, Lodwick, R, Pharris, A, Lampe, F, Nakagawa, F, 
Smith, C & van de Laar, M. (2013) Antiretroviral therapy for prevention of HIV transmission: 
implications for Europe. Euro.Surveill, 18. (Chapter 4 first part) 
 
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, et al. Health benefits, 
costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded 
treatment coverage: a combined analysis of 12 mathematical models. Lancet Global Health 
2014; 2(1):e23-e34. (Chapter 4 second part) 
 
Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perriens JH, Venter F, Lundgren J & Phillips A 
(2014) Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, 
retention, and eligibility criteria for antiretroviral therapy initiation. AIDS, 28 Suppl 1, S15-S23. 
(Chapter 5) 
 
Cambiano V, Castro H, Chadwick D, Smit E, Geretti AM, Dunn D, Phillips A, on behalf of UK HIV 
Drug Resistance Database & UKCHIC study (2014) Detection of NNRTI Resistance Mutations 
After Interrupting NNRTI-Based Regimens. Abstract 593, Conference on Retroviruses and 
Opportunistic Infections. (Chapter 6) 
 
Cambiano V, Bertagnolio S, Jordan M, Lundgren J, Miners A, Pillay D, Revill P, Venter F, Phillips 
A (2014) Effectiveness of Potential Improvements in the Cascade of HIV Treatment and Care in 
South Africa. Abstract 1066, Conference on Retroviruses and Opportunistic Infections. 
(Chapter 7) 
 
Cambiano V, Ford D, Mabugu T, Napierala Mavedzenge S, Miners A, Mugurungi O, Nakagawa 
F, Revill P, Phillips A (2014) Assessment of the Potential Cost-Effectiveness of HIV Self-Testing 
in Resource Limited Settings. Abstract 1045, Conference on Retroviruses and Opportunistic 
Infections. (Chapter 8)  
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